<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Vaccines for preventing rotavirus diarrhoea: vaccines in use - Bergman, H - 2021 | Cochrane Library</title> <meta content="Vaccines for preventing rotavirus diarrhoea: vaccines in use - Bergman, H - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008521.pub6/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Vaccines for preventing rotavirus diarrhoea: vaccines in use - Bergman, H - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008521.pub6/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD008521.pub6" name="dc.identifier" scheme="DOI"/> <meta content="Vaccines for preventing rotavirus diarrhoea: vaccines in use" name="citation_title"/> <meta content="Hanna Bergman" name="citation_author"/> <meta content="Cochrane" name="citation_author_institution"/> <meta content="hbergman@cochrane.org" name="citation_author_email"/> <meta content="Nicholas Henschke" name="citation_author"/> <meta content="Cochrane" name="citation_author_institution"/> <meta content="Daniel Hungerford" name="citation_author"/> <meta content="Femi Pitan" name="citation_author"/> <meta content="Chevron Corporation" name="citation_author_institution"/> <meta content="Duduzile Ndwandwe" name="citation_author"/> <meta content="South African Medical Research Council " name="citation_author_institution"/> <meta content="Nigel Cunliffe" name="citation_author"/> <meta content="Karla Soares-Weiser" name="citation_author"/> <meta content="Cochrane" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="11" name="citation_issue"/> <meta content="10.1002/14651858.CD008521.pub6" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/11/17" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008521.pub6/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008521.pub6/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008521.pub6/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Child Mortality; Diarrhea [prevention &amp; control]; *Intussusception; *Rotavirus; *Rotavirus Infections [prevention &amp; control]" name="citation_keywords"/> <meta content="" name="citation_fulltext_world_readable"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008521.pub6&amp;doi=10.1002/14651858.CD008521.pub6&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008521.pub6&amp;doi=10.1002/14651858.CD008521.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008521.pub6&amp;doi=10.1002/14651858.CD008521.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008521.pub6&amp;doi=10.1002/14651858.CD008521.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008521.pub6&amp;doi=10.1002/14651858.CD008521.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008521.pub6&amp;doi=10.1002/14651858.CD008521.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008521.pub6&amp;doi=10.1002/14651858.CD008521.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008521.pub6&amp;doi=10.1002/14651858.CD008521.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008521.pub6&amp;doi=10.1002/14651858.CD008521.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008521.pub6&amp;doi=10.1002/14651858.CD008521.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008521.pub6&amp;doi=10.1002/14651858.CD008521.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008521.pub6&amp;doi=10.1002/14651858.CD008521.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008521.pub6&amp;doi=10.1002/14651858.CD008521.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008521.pub6&amp;doi=10.1002/14651858.CD008521.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008521.pub6&amp;doi=10.1002/14651858.CD008521.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008521.pub6&amp;doi=10.1002/14651858.CD008521.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008521.pub6&amp;doi=10.1002/14651858.CD008521.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008521.pub6&amp;doi=10.1002/14651858.CD008521.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008521.pub6&amp;doi=10.1002/14651858.CD008521.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008521.pub6&amp;doi=10.1002/14651858.CD008521.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008521.pub6&amp;doi=10.1002/14651858.CD008521.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008521.pub6&amp;doi=10.1002/14651858.CD008521.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008521.pub6&amp;doi=10.1002/14651858.CD008521.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="zCmos3jT";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD008521\x2epub6\x26doi\x3d10\x2e1002\x2f14651858\x2eCD008521\x2epub6\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008521\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008521\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANS","zh_HANT","th","ms","fa","fr","pl"],languageCode:"en",accessStatus:"open-access",doi:"10.1002/14651858.CD008521.pub6",title:"Vaccines for preventing rotavirus diarrhoea: vaccines in use",firstPublishedDate:"Nov 17, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Infectious Diseases Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=zCmos3jT&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008521.pub6&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008521.pub6';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD008521.pub6/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD008521.pub6/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008521.pub6%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD008521.PUB6" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD008521.pub6/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD008521.PUB6" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD008521.pub6/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD008521.pub6/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>8961 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD008521.pub6" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008521.pub6/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008521.pub6/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008521.pub6/full#CD008521-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008521.pub6/full#CD008521-sec-0264"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008521.pub6/full#CD008521-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008521.pub6/full#CD008521-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008521.pub6/full#CD008521-sec-0023"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008521.pub6/full#CD008521-sec-0024"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008521.pub6/full#CD008521-sec-0050"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008521.pub6/full#CD008521-sec-0243"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008521.pub6/appendices#CD008521-sec-0269"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/table_n/CD008521StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/table_n/CD008521StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008521.pub6/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008521.pub6/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008521.pub6/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008521.pub6/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008521.pub6/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD008521.pub6/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Authors. Cochrane Database of Systematic Reviews published by John Wiley &amp; Sons, Ltd. on behalf of The Cochrane Collaboration." data-creative-commons="true" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Vaccines for preventing rotavirus diarrhoea: vaccines in use</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008521.pub6/information#CD008521-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Hanna Bergman</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008521.pub6/information#CD008521-cr-0005">Nicholas Henschke</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008521.pub6/information#CD008521-cr-0006">Daniel Hungerford</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008521.pub6/information#CD008521-cr-0007">Femi Pitan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008521.pub6/information#CD008521-cr-0008">Duduzile Ndwandwe</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008521.pub6/information#CD008521-cr-0009">Nigel Cunliffe</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008521.pub6/information#CD008521-cr-0010">Karla Soares-Weiser</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/information/en#CD008521-sec-0282">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 17 November 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD008521.pub6">https://doi.org/10.1002/14651858.CD008521.pub6</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD008521-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008521-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008521-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008521-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008521-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/th#CD008521-abs-0007">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008521-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD008521-abs-0001" lang="en"> <section id="CD008521-sec-0001"> <h3 class="title" id="CD008521-sec-0001">Background</h3> <p>Rotavirus is a common cause of diarrhoea, diarrhoea‐related hospital admissions, and diarrhoea‐related deaths worldwide. Rotavirus vaccines prequalified by the World Health Organization (WHO) include Rotarix (GlaxoSmithKline), RotaTeq (Merck), and, more recently, Rotasiil (Serum Institute of India Ltd.), and Rotavac (Bharat Biotech Ltd.). </p> </section> <section id="CD008521-sec-0002"> <h3 class="title" id="CD008521-sec-0002">Objectives</h3> <p>To evaluate rotavirus vaccines prequalified by the WHO for their efficacy and safety in children. </p> </section> <section id="CD008521-sec-0003"> <h3 class="title" id="CD008521-sec-0003">Search methods</h3> <p>On 30 November 2020, we searched PubMed, the Cochrane Infectious Diseases Group Specialized Register, CENTRAL (published in the Cochrane Library), Embase, LILACS, Science Citation Index Expanded, Social Sciences Citation Index, Conference Proceedings Citation Index‐Science, Conference Proceedings Citation Index‐Social Science &amp; Humanities. We also searched the WHO ICTRP, ClinicalTrials.gov, clinical trial reports from manufacturers' websites, and reference lists of included studies, and relevant systematic reviews. </p> </section> <section id="CD008521-sec-0004"> <h3 class="title" id="CD008521-sec-0004">Selection criteria</h3> <p>We selected randomized controlled trials (RCTs) conducted in children that compared rotavirus vaccines prequalified for use by the WHO with either placebo or no intervention. </p> </section> <section id="CD008521-sec-0005"> <h3 class="title" id="CD008521-sec-0005">Data collection and analysis</h3> <p>Two authors independently assessed trial eligibility and assessed risk of bias. One author extracted data and a second author cross‐checked them. We combined dichotomous data using the risk ratio (RR) and 95% confidence interval (CI). We stratified the analyses by under‐five country mortality rate and used GRADE to evaluate evidence certainty. </p> </section> <section id="CD008521-sec-0006"> <h3 class="title" id="CD008521-sec-0006">Main results</h3> <p>Sixty trials met the inclusion criteria and enrolled a total of 228,233 participants. Thirty‐six trials (119,114 participants) assessed Rotarix, 15 trials RotaTeq (88,934 participants), five trials Rotasiil (11,753 participants), and four trials Rotavac (8432 participants). </p> <p><b><i>Rotarix</i> </b> </p> <p><i>Infants vaccinated and followed up for the first year of life</i> </p> <p>In low‐mortality countries, Rotarix prevented 93% of severe rotavirus diarrhoea cases (14,976 participants, 4 trials; high‐certainty evidence), and 52% of severe all‐cause diarrhoea cases (3874 participants, 1 trial; moderate‐certainty evidence).  </p> <p>In medium‐mortality countries, Rotarix prevented 79% of severe rotavirus diarrhoea cases (31,671 participants, 4 trials; high‐certainty evidence), and 36% of severe all‐cause diarrhoea cases (26,479 participants, 2 trials; high‐certainty evidence).  </p> <p>In high‐mortality countries, Rotarix prevented 58% of severe rotavirus diarrhoea cases (15,882 participants, 4 trials; high‐certainty evidence), and 27% of severe all‐cause diarrhoea cases (5639 participants, 2 trials; high‐certainty evidence). </p> <p><i>Children vaccinated and followed up for two years</i> </p> <p>In low‐mortality countries, Rotarix prevented 90% of severe rotavirus diarrhoea cases (18,145 participants, 6 trials; high‐certainty evidence), and 51% of severe all‐cause diarrhoea episodes (6269 participants, 2 trials; moderate‐certainty evidence).   </p> <p>In medium‐mortality countries, Rotarix prevented 77% of severe rotavirus diarrhoea cases (28,834 participants, 3 trials; high‐certainty evidence), and 26% of severe all‐cause diarrhoea cases (23,317 participants, 2 trials; moderate‐certainty evidence).  </p> <p>In high‐mortality countries, Rotarix prevented 35% of severe rotavirus diarrhoea cases (13,768 participants, 2 trials; moderate‐certainty evidence), and 17% of severe all‐cause diarrhoea cases (2764 participants, 1 trial; high‐certainty evidence). </p> <p><b><i>RotaTeq</i> </b> </p> <p><i>Infants vaccinated and followed up for the first year of life</i> </p> <p>In low‐mortality countries, RotaTeq prevented 97% of severe rotavirus diarrhoea cases (5442 participants, 2 trials; high‐certainty evidence).  </p> <p>In medium‐mortality countries, RotaTeq prevented 79% of severe rotavirus diarrhoea cases (3863 participants, 1 trial; low‐certainty evidence).  </p> <p>In high‐mortality countries, RotaTeq prevented 57% of severe rotavirus diarrhoea cases (6775 participants, 2 trials; high‐certainty evidence), but there is probably little or no difference between vaccine and placebo for severe all‐cause diarrhoea (1 trial, 4085 participants; moderate‐certainty evidence).  </p> <p><i>Children vaccinated and followed up for two years</i> </p> <p>In low‐mortality countries, RotaTeq prevented 96% of severe rotavirus diarrhoea cases (5442 participants, 2 trials; high‐certainty evidence).  </p> <p>In medium‐mortality countries, RotaTeq prevented 79% of severe rotavirus diarrhoea cases (3863 participants, 1 trial; low‐certainty evidence).  </p> <p>In high‐mortality countries, RotaTeq prevented 44% of severe rotavirus diarrhoea cases (6744 participants, 2 trials; high‐certainty evidence), and 15% of severe all‐cause diarrhoea cases (5977 participants, 2 trials; high‐certainty evidence).  </p> <p>We did not identify RotaTeq studies reporting on severe all‐cause diarrhoea in low‐ or medium‐mortality countries. </p> <p><b><i>Rotasiil</i> </b> </p> <p>Rotasiil has not been assessed in any RCT in countries with low or medium child mortality.</p> <p><i>Infants vaccinated and followed up for the first year of life</i> </p> <p>In high‐mortality countries, Rotasiil prevented 48% of severe rotavirus diarrhoea cases (11,008 participants, 2 trials; high‐certainty evidence), and resulted in little to no difference in severe all‐cause diarrhoea cases (11,008 participants, 2 trials; high‐certainty evidence). </p> <p><i>Children vaccinated and followed up for two years</i> </p> <p>In high‐mortality countries, Rotasiil prevented 44% of severe rotavirus diarrhoea cases (11,008 participants, 2 trials; high‐certainty evidence), and resulted in little to no difference in severe all‐cause diarrhoea cases (11,008 participants, 2 trials; high‐certainty evidence). </p> <p><b><i>Rotavac</i> </b> </p> <p>Rotavac has not been assessed in any RCT in countries with low or medium child mortality. </p> <p><i>Infants vaccinated and followed up for the first year of life</i> </p> <p>In high‐mortality countries, Rotavac prevented 57% of severe rotavirus diarrhoea cases (6799 participants, 1 trial; moderate‐certainty evidence), and 16% of severe all‐cause diarrhoea cases (6799 participants, 1 trial; moderate‐certainty evidence). </p> <p><i>Children vaccinated and followed up for two years</i> </p> <p>In high‐mortality countries, Rotavac prevented 54% of severe rotavirus diarrhoea cases (6541 participants, 1 trial; moderate‐certainty evidence); no Rotavac studies have reported on severe all‐cause diarrhoea at two‐years follow‐up. </p> <p><b><i>Safety</i> </b> </p> <p>No increased risk of serious adverse events (SAEs) was detected with Rotarix (103,714 participants, 31 trials; high‐certainty evidence), RotaTeq (82,502 participants, 14 trials; moderate to high‐certainty evidence), Rotasiil (11,646 participants, 3 trials; high‐certainty evidence), or Rotavac (8210 participants, 3 trials; moderate‐certainty evidence). </p> <p>Deaths were infrequent and the analysis had insufficient evidence to show an effect on all‐cause mortality. Intussusception was rare.  </p> </section> <section id="CD008521-sec-0007"> <h3 class="title" id="CD008521-sec-0007">Authors' conclusions</h3> <p>Rotarix, RotaTeq, Rotasiil, and Rotavac prevent episodes of rotavirus diarrhoea. The relative effect estimate is smaller in high‐mortality than in low‐mortality countries, but more episodes are prevented in high‐mortality settings as the baseline risk is higher. In high‐mortality countries some results suggest lower efficacy in the second year. We found no increased risk of serious adverse events, including intussusception, from any of the prequalified rotavirus vaccines. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD008521-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008521-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD008521-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD008521-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008521-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008521-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD008521-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD008521-abs-0014">Polski</a> </li> <li class="section-language"> <a class="" href="full/th#CD008521-abs-0008">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008521-abs-0005">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD008521-abs-0006">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD008521-abs-0002" lang="en"> <h3>Are rotavirus vaccines safe and effective in preventing rotavirus diarrhoea in infants and children? </h3> <p><b>What is the aim of this review?</b> </p> <p>The aim of this Cochrane Review was to find out if rotavirus vaccines are effective in preventing diarrhoea and deaths in infants and young children. We also aimed to find out if the rotavirus vaccines are safe. We collected and analysed all relevant studies to answer these questions. </p> <p><b>Key messages</b> </p> <p>Rotarix, RotaTeq, Rotasiil, and Rotavac prevent  the large majority of episodes of rotavirus diarrhoea during the first year of a child's life, when diarrhoea is most dangerous, with a slightly lower efficacy during the second year. We found no increased risk of serious adverse events (moderate‐ to high‐certainty evidence) including intussusception (where the bowel telescopes on itself, and can cause obstruction). </p> <p><b>What was studied in the review?</b> </p> <p>Rotavirus infection is a common cause of diarrhoea in infants and young children, and can cause mild illness, hospitalization, and death. Since 2009, the World Health Organization (WHO) has recommended that a rotavirus vaccine be included in all national infant and child immunization programmes. To date, 96 countries have followed this recommendation. In the years before infants and children started receiving rotavirus vaccine, rotavirus infection resulted in about half a million deaths a year in children aged under five years, mainly in low‐ and middle‐income countries. </p> <p>In this review, we included randomized controlled trials in infants and young children that evaluated rotavirus vaccination with Rotarix (GlaxoSmithKline) or RotaTeq (Merck). These vaccines have been evaluated in several large trials and are approved for use in many countries. We also included trials that evaluated Rotavac (Bharat Biotech Ltd.) and Rotasiil (Serum Institute of India Ltd.), rotavirus vaccines which are currently used in India only. The rotavirus vaccines were compared with placebo or with no vaccine. The included studies did not allow comparisons between the different rotavirus vaccines. </p> <p><b>What are the main results of the review?</b> </p> <p>We found 60 relevant studies with a total of 228,233 participants. The trials took place in several locations worldwide. The vaccines tested were Rotarix (36 trials with 119,114 participants), RotaTeq (15 trials with 88,934 participants), Rotasiil (five trials with 11,753 participants), and Rotavac (four trials with 8432 participants). Fifty‐six studies were funded or co‐funded by vaccine manufacturers, while four were independent of manufacturer funding. </p> <p>In the first two years of life, we found that rotavirus vaccines prevent more than 90% of severe cases of rotavirus diarrhoea in countries with low child mortality rates, more than 75% in countries with medium child mortality rates, and 35% to 58% in countries with high child mortality rates. </p> <p>Rotavirus vaccines probably prevent more than 50% of severe cases of diarrhoea from all causes (such as any viral infection, bacterial infection, or parasitic infection) in countries with low child mortality rates, 26% to 36% in countries with medium child mortality rates, and none to 27% in countries with high child mortality rates. </p> <p>The evidence for countries with low and medium child mortality rates comes from studies of Rotarix and RotaTeq vaccines; these two vaccines have been evaluated in all settings. Rotasiil and Rotavac vaccines have only been assessed in countries with high child mortality rates. </p> <p>We found little or no difference in the number of serious adverse events between those receiving rotavirus vaccines compared with placebo or with no vaccine. </p> <p>Rotavirus vaccines may make little to no difference to the number of deaths or to intussusception cases, compared with placebo or no vaccine, but the certainty of the evidence was limited for these rare outcomes. </p> <p><b>How up‐to‐date is this review?</b> </p> <p>We searched for studies that had been published up to 30 November 2020.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD008521-sec-0264" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD008521-sec-0264"></div> <h3 class="title" id="CD008521-sec-0265">Implications for practice</h3> <section id="CD008521-sec-0265"> <p> <ul id="CD008521-list-0006"> <li> <p>Rotarix, RotaTeq, Rotasiil and Rotavac are efficacious vaccines in preventing rotavirus diarrhoea. Rotarix and RotaTeq have comparable safety and efficacy profiles and have been evaluated in different settings worldwide. The evidence on Rotasiil is currently limited to studies from India and Niger, and evidence on Rotavac to India only. The systematic review data support the global WHO rotavirus vaccine recommendation (<a href="./references#CD008521-bbs2-0169" title="SAGE. Meeting of the immunization Strategic Advisory Group of Experts, April 2009 - conclusions and recommendations. Weekly Epidemiological Record2009;84(23):220-36.">SAGE 2009</a>; <a href="./references#CD008521-bbs2-0170" title="SAGE. Meeting of the immunization Strategic Advisory Group of Experts, April 2012 - conclusions and recommendations. Weekly Epidemiological Record2012;21(87):201-16.">SAGE 2012</a>; <a href="./references#CD008521-bbs2-0187" title="World Health Organization. Rotavirus vaccines WHO position paper – July 2021. Weekly Epidemiological Record2021;96(28):301-20.">WHO 2021b</a>). </p> </li> <li> <p>The data from the included RCTs indicate that Rotarix, RotaTeq, Rotasiil, and Rotavac result in little to no difference in intussusception risk compared to a placebo or to no vaccine and, importantly, a lower risk of intussusception compared to the magnitude observed with the first licensed vaccine (RRV‐TV, RotaShield). However, since the data cannot exclude a smaller risk of intussusception or other rare serious adverse events, routine vaccine introduction should be accompanied by safety surveillance (<a href="./references#CD008521-bbs2-0121" title="ButteryJP , DanchinMH , LeeKJ , CarlinJB , McIntyrePB , ElliottEJ , et al. Intussusception following rotavirus vaccine administration: post-marketing surveillance in the National Immunization Program in Australia. Vaccine2011;29(16):3061-6.">Buttery 2011</a>; <a href="./references#CD008521-bbs2-0140" title="GroomeMJ , TateJE , ArnoldM , ChitnisM , CoxS , De VosC ,  et al. Evaluation of intussusception after oral monovalent Rotavirus vaccination in South Africa. Clinical Infectious Diseases2020;70(8):1606-12.">Groome 2020</a>; <a href="./references#CD008521-bbs2-0157" title="PatelMM , Lopez-ColladaVR , BulhoesMM , De OliveiraLH , MarquezAB , FlanneryB , et al. Intussusception risk and health benefits of rotavirus vaccination in Mexico and Brazil. New England Journal of Medicine2011;364(24):2283-92.">Patel 2011</a>; <a href="./references#CD008521-bbs2-0163" title="ReddySN , NairNP , TateJE , ThiyagarajanV , GiriS , PraharajI , et al. Intussusception after rotavirus vaccine introduction in India. New England Journal of Medicine2020;383(20):1932-40.">Reddy 2020</a>; <a href="./references#CD008521-bbs2-0173" title="ShuiIM , BaggsJ , PatelM , ParasharUD , RettM , BelongiaEA , et al. Risk of intussusception following administration of a pentavalent rotavirus vaccine in US infants. JAMA2012;307(6):598-604.">Shui 2012</a>; <a href="./references#CD008521-bbs2-0184" title="WeintraubES , BaggsJ , DuffyJ , VellozziC , BelongiaEA , IrvingS , et al. Risk of intussusception after monovalent rotavirus vaccination. New England Journal of Medicine2014;370(6):513-9.">Weintraub 2014</a>). </p> </li> </ul> </p> </section> <h3 class="title" id="CD008521-sec-0266">Implications for research</h3> <section id="CD008521-sec-0266"> <p>Placebo‐controlled efficacy trials of Rotarix and RotaTeq have been undertaken in representative populations of low‐, medium‐, and high‐mortality countries and do not require repetition; efficacy or effectiveness trials of Rotavac and Rotasiil outside of India should be considered if these vaccines are introduced globally. Further research would be valuable in the following areas: </p> <p> <ul id="CD008521-list-0007"> <li> <p>Continued post‐introduction studies to examine the impact and effectiveness of rotavirus vaccination, particularly in high‐mortality countries. </p> </li> <li> <p>A greater understanding of the lower vaccine efficacy observed in high‐mortality countries in Africa and Asia compared to low‐mortality countries in the first and second years of life. </p> </li> <li> <p>Studies assessing the impact of malnutrition on rotavirus vaccine performance.</p> </li> <li> <p>Studies to assess the potential benefit of alternative dosage schedules of rotavirus vaccine, especially in high‐mortality countries (e.g. neonatal dosing, additional dosing). </p> </li> <li> <p>Studies to assess risk and severity of rotavirus diarrhoea in older vaccinated children.</p> </li> <li> <p>Continued post‐introduction studies in representative countries should examine vaccine safety with particular respect to intussusception and should analyse the risk/benefit of rotavirus vaccination (<a href="./references#CD008521-bbs2-0157" title="PatelMM , Lopez-ColladaVR , BulhoesMM , De OliveiraLH , MarquezAB , FlanneryB , et al. Intussusception risk and health benefits of rotavirus vaccination in Mexico and Brazil. New England Journal of Medicine2011;364(24):2283-92.">Patel 2011</a>). Given the rarity of the event, data from different countries may need to be pooled (<a href="./references#CD008521-bbs2-0135" title="EscolanoS , FarringtonCP , HillC , Tubert-BitterP . Intussusception after rotavirus vaccination - spontaneous reports. New England Journal of Medicine2011;365(22):2139.">Escolano 2011</a>; <a href="./references#CD008521-bbs2-0136" title="EscolanoS , HillC , Tubert-BitterP . Intussusception risk after RotaTeq vaccination: evaluation from worldwide spontaneous reporting data using a self-controlled case series approach. Vaccine2015;33(8):1017-20.">Escolano 2015</a>), or self‐controlled case series analyses may need to be carried out (<a href="./references#CD008521-bbs2-0124" title="CarlinJB , MacartneyKK , LeeKJ , QuinnHE , ButteryJ , LopertR , et al. Intussusception risk and disease prevention associated with rotavirus vaccines in Australia's National Immunization Program. Clinical Infectious Diseases2013;57:1427-34.">Carlin 2013</a>; <a href="./references#CD008521-bbs2-0176" title="StoweJ , AndrewsN , LadhaniS , MillerE . The risk of intussusception following monovalent rotavirus vaccination in England: a self-controlled case-series evaluation. Vaccine2016;34(32):3684-9.">Stowe 2016</a>; <a href="./references#CD008521-bbs2-0178" title="TateJE , MwendaJM , ArmahG , JaniB , OmoreR , AdemeA , et al. Evaluation of intussusception after monovalent rotavirus vaccination in Africa. New England Journal of Medicine2018;378(16):1521-8.">Tate 2018</a>; <a href="./references#CD008521-bbs2-0190" title="YihWK , LieuTA , KulldorffM , MartinD , McMahill-WalravenCN , PlattR , et al. Intussusception risk after rotavirus vaccination in U.S. infants. New England Journal of Medicine2014;370(6):503-12.">Yih 2014</a>). </p> </li> </ul> </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD008521-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD008521-sec-0008"></div> <div class="table" id="CD008521-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Rotarix compared with placebo for preventing rotavirus diarrhoea in low‐mortality countries</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children<br/><b>Setting:</b> low‐mortality countries<br/><b>Intervention:</b> Rotarix, 2 doses<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Rotarix</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe cases of rotavirus diarrhoea</b><br/>Follow‐up: up to 1 year </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>13 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1 per 1000</b><br/>(0 to 2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.07</b><br/>(0.03 to 0.18) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14,976<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/><b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rotarix reduces severe rotavirus diarrhoea compared with placebo at up to one‐year follow‐up. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe cases of rotavirus diarrhoea</b><br/>Follow‐up: up to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>29 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>3 per 1000</b><br/>(2 to 4) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.10</b><br/>(0.07 to 0.14) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18,145<br/>(6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/><b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rotarix reduces severe rotavirus diarrhoea compared with placebo at up to two years follow‐up. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe cases of all‐cause diarrhoea</b><br/>Follow‐up: up to 1 year </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>94 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>45 per 1000 </b><br/>(35 to 58) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.48</b><br/>(0.37 to 0.61) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3874<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>a</sup> </p> <p><i>due to reporting bias</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rotarix probably reduces severe all‐cause diarrhoea compared with placebo at up to one‐year follow‐up. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe cases of all‐cause diarrhoea</b><br/>Follow‐up: up to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>84 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>41 per 1000 </b><br/>(34 to 51) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.49</b><br/>(0.40 to 0.60) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6269<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>b</sup> </p> <p><i>due to reporting bias</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rotarix probably reduces severe all‐cause diarrhoea compared with placebo at up to two years follow‐up. </p> <p>One additional study reported on <i>episodes </i> of children with severe all‐cause diarrhoea (rate ratio 0.70, 95% CI 0.56 to 0.86; n = 10,519); these data could not be pooled with the studies reporting on number of <i>cases.</i> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause death</b><br/>Follow‐up: 2 months to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.71</b><br/>(0.17 to 2.88) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20,361<br/>(10 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>c</sup> </p> <p><i>due to serious imprecision</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rotarix may result in little to no difference in all‐cause death compared with placebo.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All serious adverse events</b><br/>Follow‐up: 2 months to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>44 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>39 per 1000</b><br/>(32 to 48) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.89</b><br/>(0.72 to 1.10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18,971<br/>(12 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/><b>high</b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rotarix results in little to no difference in serious adverse events compared with placebo. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events: intussusception</b><br/>Follow‐up: 2 months to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1 per 1000</b><br/>(0 to 3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.42</b><br/>(0.52 to 3.87) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20,773<br/>(10 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>d</sup> </p> <p><i>due to serious imprecision</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rotarix may result in little to no difference in intussusception compared with placebo.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the control group risk across studies included in the meta‐analysis. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RCT</b> : randomized controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one level for risk of selective reporting bias. Only one of the four studies reporting on severe rotavirus diarrhoea provided data for this outcome.<br/><sup>b</sup>Downgraded by one level for risk of selective reporting bias. Only three of the six studies reporting on severe rotavirus diarrhoea provided data for this outcome.<br/><sup>c</sup>Downgraded by two levels for serious imprecision. These trials were not powered to detect an effect on mortality.<br/><sup>d</sup>Downgraded by two levels for serious imprecision: very few events with wide 95% CIs that included no effect. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008521-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Rotarix compared with placebo for preventing rotavirus diarrhoea in medium‐mortality countries</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children<br/><b>Setting:</b> medium‐mortality countries<br/><b>Intervention:</b> Rotarix, 2 doses<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Rotarix</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe cases of rotavirus diarrhoea</b><br/>Follow‐up: up to 1 year </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>13 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>3 per 1000</b><br/>(2 to 4) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.21</b><br/>(0.16 to 0.29) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31,671<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/><b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rotarix reduces severe rotavirus diarrhoea compared with placebo at up to one‐year follow‐up. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe cases of rotavirus diarrhoea</b><br/>Follow‐up: up to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>25 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 1000</b><br/>(4 to 7) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.23</b><br/>(0.17 to 0.29) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23,834</p> <p>(3 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/><b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rotarix reduces severe rotavirus diarrhoea compared with placebo at up to two years follow‐up. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe cases of all‐cause diarrhoea</b><br/>Follow‐up: up to 1 year </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>38 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>25 per 1000 </b><br/>(20 to 30) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.64</b> (0.52 to 0.79) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26,479<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rotarix reduces severe all‐cause diarrhoea compared with placebo at up to one‐year follow‐up. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe cases of all‐cause diarrhoea</b><br/>Follow‐up: up to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>78 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>58 per 1000 </b><br/>(39 to 85) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.74</b><br/>(0.50 to 1.09) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23,317<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a,b</sup> </p> <p><i>due to serious inconsistency</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rotarix may reduce severe all‐cause diarrhoea compared with placebo at up to two years follow‐up. </p> <p>Serious inconsistency (I<sup>2</sup> = 92%) in the pooled data: <a href="./references#CD008521-bbs2-0016" title="GlaxoSmithKline[113808-075]. Efficacy, immunogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals' oral live attenuated liquid Human Rotavirus (HRV) vaccine (444563), in healthy infants. www.gsk-studyregister.com/study/4036 (accessed 12 December 2018). LiRC , HuangT , LiY , LuoD , TaoJ , FuB , et al. Human rotavirus vaccine (RIX4414) efficacy in the first two years of life: a randomized, placebo-controlled trial in China. Human Vaccines and Immunotherapeutics2014;10(1):11-8. LiRC , HuangT , LiY , WangLH , TaoJ , FuB , et al. Immunogenicity and reactogenicity of the human rotavirus vaccine, RIX4414 oral suspension, when co-administered with routine childhood vaccines in Chinese infants. Human Vaccines and Immunotherapeutics2016;12(3):785-93. NCT01171963. Efficacy, immunogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals' oral live attenuated liquid human rotavirus (HRV) vaccine (444563), in healthy infants. clinicaltrials.gov/show/NCT01171963 (first received 29 July 2010). ">RIX Li 2014‐CHN</a>: RR 0.91 (0.75 to 1.09), n = 3148; <a href="./references#CD008521-bbs2-0026" title="Costa ClemensSA , et al. Operational organization of a large scale phase III clinical trial of rotavirus vaccine in multiple sites and countries in Latin America. In: International Congress of Pediatrics (ICP); 2004 August 15-20; Cancun, Mexico. 2004. [Not available for review]De VosB , et al. Rotarix™: an effective way to prevent rotavirus diarrhoea and vomiting. In: 9th Congress of the Asian Pan Pacific Society of Paediatric Gastroenterology, Hepatology and Nutrition &amp; 27th Annual Congress of the Malaysian Paediatric Association; 2005 June 16-19; Kuala Lumpur, Malaysia. 2005. [Not available for review]BaayM , BollaertsK , StruchinerC , VerstraetenT . Background rates of disease in Latin American children from a rotavirus vaccine study. Human Vaccines and Immunotherapeutics2017;13(8):1916-20. GlaxoSmithKline[444563-023-pt1]. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants (efficacy data from visit 1 to visit 4). www.gsk-studyregister.com/study/6791 (accessed 12 December 2018). GlaxoSmithKline[444563-023-pt2]. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants (2nd year efficacy from visit 4 to visit 6). www.gsk-studyregister.com/study/6791 (accessed 12 December 2018). GlaxoSmithKline[444563-023-pt3]. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants (safety for the period between visit 1 and visit 3). www.gsk-studyregister.com/study/6791 (accessed 12 December 2018). JustinoMC , AraújoEC , Van DoornLJ , OliveiraCS , GabbayYB , MascarenhasJD , et al. Oral live attenuated human rotavirus vaccine (Rotarix) offers sustained high protection against severe G9P[8] rotavirus gastroenteritis during the first two years of life in Brazilian children. Memorias do Instituto Oswaldo Cruz2012;107(7):846-53. LinharesAC , VelazquezFR , Perez-SchaelI , Saez-LlorensX , AbateH , EspinozaF , et al. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet2008;371(9619):1181-9. LopezP , LinharesA , Pérez-SchaelI , Ruiz-PalaciosG , Costa ClemensS , SanchezN . Early protection against severe rotavirus gastroenteritis - RIX4414 experience in Latin America. In: 24th Annual Meeting of European Society for Paediatric Infectious Diseases (ESPID); 2006 May 03-05; Basel, Switzerland. 2006. [Not available for review]MaciasM , LopezP , VelazquezFR , VergaraRF , SalmeronJ , TavaresJL . The rotavirus vaccine RIX4414 (Rotarix) is not associated with intussusception in one year old infants. In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2005 December 16-19; Washington DC, USA. 2005. [Not available for review]NCT00139347. A multi-country &amp; multi-center study to assess the efficacy, immunogenicity &amp; safety of two doses of GSK Biologicals' oral live attenuated HRV vaccine given concomitantly with routine EPI vaccinations including OPV in healthy infants. clinicaltrials.gov/ct2/show/NCT00139347 (first received 31 August 2005). [Trial registration document (no data for review)]NCT00140673. Placebo-controlled, multi-country &amp; multi-center study to assess the efficacy, safety &amp; immunogenicity of 2 doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants. clinicaltrials.gov/ct2/show/NCT00140673 (first received 1 September 2005). [Trial registration document (no data for review)]Perez-SchaelI , LinharesAC , VesikariT . Two doses of the human attenuated rotavirus vaccine RIX4414 (Rotarix) show heterotypic protection in Latin America and Europe. In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2005 December 16-19; Washington DC, USA. 2005. [Not available for review]PikeM . New rotavirus vaccine is effective and appears to have no increased risk of intussusception. Clinical Research Abstracts For Pediatricians2006;149(1):143. Ruiz-PalaciosG , AranzaC , VelazquezFR , RichardsonV , NandiE , MaciasM . Two doses of the human-attenuated monovalent G1P[8] rotavirus vaccine, Rotarix show high efficacy in Mexican children against severe rotavirus gastroenteritis and severe overall gastroenteritis. In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2005 December 16-19; Washington DC, USA. 2005. [Not available for review]Ruiz-PalaciosGM , Perez-SchaelI , VelazquezFR , AbateH , BreuerT , ClemensSC , et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. New England Journal of Medicine2006;354(1):11-22. VelázquezFR , AbatH , Costa ClemensSA , EspinozaF , GillardP , LinharesAC , et al. The human monovalent G1P[8] rotavirus vaccine, Rotarix is highly efficacious and provides crossprotection against G1 and non-G1 serotypes. In: 23rd Annual meeting of European Society for Paediatric Infectious Diseases (ESPID); 2005 May 18-20; Valencia, Spain. 2005. VelázquezRF , AbateH , BouckenoogheA . RIX4414, the human G1P[8] rotavirus vaccine is highly efficacious during the second year of life. In: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2006 September 27-30; San Francisco, USA. 2006. [Not available for review]VesikariT , O’RyanM , AbateH , Costa ClemensSA , EspinozaF , GillardP . Overcoming the safety hurdle: the rotavirus vaccine RIX4414 is not associated with intussusception. In: 23rd Annual Meeting of European Society for Paediatric Infectious Diseases (ESPID); 2005 May 18-20; Valencia, Spain. 2005. [Not available for review]">RIX Ruiz‐Palac 06‐LA/EU</a>: RR 0.61 (0.55 to 0.69), n = 20,169. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause death</b><br/>Follow‐up: 2 months to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 1000</b><br/>(1 to 3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.27</b><br/>(0.89 to 1.81) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77,043<br/>(9 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>c</sup> </p> <p><i>due to imprecision</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rotarix probably results in little to no difference in all‐cause death compared with placebo. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All serious adverse events</b><br/>Follow‐up: 2 months to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>45 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>38 per 1000</b><br/>(34 to 43) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.85</b><br/>(0.76 to 0.95) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77,069<br/>(9 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/><b>high</b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rotarix reduces serious adverse events compared with placebo.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events: intussusception</b><br/>Follow‐up: 2 months to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.72</b> (0.39 to 1.32) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75,540<br/>(6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>d</sup> </p> <p><i>due to imprecision</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rotarix may result in little to no difference in intussusception compared with placebo.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the control group risk across studies included in the meta‐analysis. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded by two levels for serious inconsistency in the pooled data: I<sup>2</sup> = 92%.<br/><sup>b</sup>Although the 95% CI included both no effect and appreciable benefit, we did not downgrade for imprecision since it arose due to inconsistency between two precise estimates which was accounted for by downgrading for inconsistency.<br/><sup>c</sup>Downgraded by one level for imprecision. The 95% CI was wide and included both no effect and appreciable harm.<br/><sup>d</sup>Downgraded by two levels for serious imprecision: very few events with wide 95% CIs that included no effect. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008521-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Rotarix compared with placebo for preventing rotavirus diarrhoea in high‐mortality countries</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children<br/><b>Settings:</b> high‐mortality countries<br/><b>Intervention:</b> Rotarix, 2 doses<br/><b>Comparison:</b> placebo or no intervention </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty</b> of the evidence<br/>(GRADE) </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Placebo or no intervention</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Rotarix</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe cases of rotavirus diarrhoea</b><br/>Follow‐up: up to 1 year </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>40 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>17 per 1000</b><br/>(11 to 25) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.42</b><br/>(0.28 to 0.61) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15,822**<br/>(5 comparisons from 4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/><b>high</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rotarix reduces severe rotavirus diarrhoea compared with placebo or no intervention at up to one‐year follow‐up. </p> <p>Sensitivity analysis excluding the cluster‐RCT (<a href="./references#CD008521-bbs2-0038" title="ZamanK , SackDA , NeuzilKM , YunusM , MoultonLH , SugimotoJD , et al. Effectiveness of a live oral human rotavirus vaccine after programmatic introduction in Bangladesh: a cluster-randomized trial. PLOS Medicine2017;14(4):e1002282. ">RIX Zaman 2017‐BGD</a>) that contributed data to this outcome showed no important change in the effect estimate or 95% CI (RR 0.37, 95% CI 0.23 to 0.60, n = 6114, 3 RCTs with 4 comparisons). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe cases of rotavirus diarrhoea</b><br/>Follow‐up: up to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>43 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>28 per 1000</b><br/>(22 to 35) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.65 </b><br/>(0.51 to 0.83) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13,768**<br/>(3 comparisons from 2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>c</sup> </p> <p><i>due to risk of bias</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rotarix probably reduces severe rotavirus diarrhoea compared with placebo or no intervention at up to two years follow‐up. </p> <p>Sensitivity analysis excluding the cluster‐RCT (<a href="./references#CD008521-bbs2-0038" title="ZamanK , SackDA , NeuzilKM , YunusM , MoultonLH , SugimotoJD , et al. Effectiveness of a live oral human rotavirus vaccine after programmatic introduction in Bangladesh: a cluster-randomized trial. PLOS Medicine2017;14(4):e1002282. ">RIX Zaman 2017‐BGD</a>) that contributed data to this outcome showed no important change in the effect estimate or 95% CI (RR 0.58, 95% CI 0.42 to 0.79, n = 2764, 1 RCT with 2 comparisons). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe cases of all‐cause diarrhoea</b><br/>Follow‐up: up to 1 year </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>176 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>129 per 1000</b><br/>(99 to 167) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.73 </b><br/>(0.56 to 0.95) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5639<br/>(3 comparisons from 2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/><b>high</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rotarix reduces severe all‐cause diarrhoea compared with placebo or no intervention at up to one‐year follow‐up. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe cases of all‐cause diarrhoea</b><br/>Follow‐up: up to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>233 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>194 per 1000</b><br/>(168 to 224) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.83</b><br/>(0.72 to 0.96) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2764<br/>(2 comparisons from 1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/><b>high</b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rotarix reduces severe all‐cause diarrhoea compared with placebo at up to two years follow‐up. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause death</b><br/>Follow‐up: 2 months to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>20 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>18 per 1000</b><br/>(13 to 25) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.88 </b><br/>(0.63 to 1.21) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8374<br/>(11 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>e</sup> </p> <p><i>due to imprecision</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rotarix probably results in little to no difference in all‐cause death compared with placebo or no intervention. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All serious adverse events</b><br/>Follow‐up: 2 months to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>92 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>83 per 1000</b><br/>(71 to 96) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.90</b><br/>(0.77 to 1.05) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7674<br/>(10 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/><b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rotarix results in little to no difference in serious adverse events compared with placebo or no intervention. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events: intussusception</b><br/>Follow‐up: 2 months to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>not estimable</b>, no events in control group, 1 event in intervention group </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>not estimable</b>, no events in control group, 1 event in intervention group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.49 </b><br/>(0.06 to 36.63) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17,068**<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>f</sup> </p> <p><i>due to serious imprecision</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rotarix may result in little to no difference in intussusception compared with placebo or no intervention. </p> <p>Sensitivity analysis excluding the cluster‐RCT (<a href="./references#CD008521-bbs2-0038" title="ZamanK , SackDA , NeuzilKM , YunusM , MoultonLH , SugimotoJD , et al. Effectiveness of a live oral human rotavirus vaccine after programmatic introduction in Bangladesh: a cluster-randomized trial. PLOS Medicine2017;14(4):e1002282. ">RIX Zaman 2017‐BGD</a>) that contributed data to this outcome showed no change in the effect estimate or 95% CI. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the control group risk across studies included in the meta‐analysis. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p>**Number of participants in this table shows the true number of participants for this outcome; the number of events and the number of participants in the analysis has been adjusted for the included cluster trial <a href="./references#CD008521-bbs2-0038" title="ZamanK , SackDA , NeuzilKM , YunusM , MoultonLH , SugimotoJD , et al. Effectiveness of a live oral human rotavirus vaccine after programmatic introduction in Bangladesh: a cluster-randomized trial. PLOS Medicine2017;14(4):e1002282. ">RIX Zaman 2017‐BGD</a> using a design effect of 2.53.<br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>We did not downgrade for inconsistency as the heterogeneity observed in the pooled data (I<sup>2</sup> = 52%) was due to within‐study heterogeneity (<a href="./references#CD008521-bbs2-0017" title="CunliffeNA , WitteD , NgwiraBM , ToddS , BostockNJ , TurnerAM , et al. Efficacy of human rotavirus vaccine against severe gastroenteritis in Malawian children in the first two years of life: a randomized, double-blind, placebo controlled trial. Vaccine2012;30(Suppl 1):A36-43. MadhiSA , CunliffeNA , SteeleD , WitteD , KirstenM , LouwC , et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. New England Journal of Medicine2010;362(4):289-98. MadhiSA , KirstenM , LouwC , BosP , AspinallS , BouckenoogheA , et al. Efficacy and immunogenicity of two or three dose rotavirus-vaccine regimen in South African children over two consecutive rotavirus seasons: a randomized, double-blind, placebo-controlled trial. Vaccine2012;30(Suppl 1):A44-51. NCT00241644. Multi-center study to assess the efficacy, safety and immunogenicity of 2 or 3 doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations in healthy infants. clinicaltrials.gov/show/NCT00241644 (first received 19 October 2005). NCT00598468. Multi-center study to assess efficacy, safety &amp; immunogenicity of 2 or 3 doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations in healthy infants. clinicaltrials.gov/show/NCT00598468 (first received 19 October 2005). SteeleAD , NeuzilKM , CunliffeNA , MadhiSA , BosP , NgwiraB , et al. Human rotavirus vaccine Rotarix provides protection against diverse circulating rotavirus strains in African infants: a randomized controlled trial. BMC Infectious Diseases2012;12:213. ">RIX Madhi 2010‐AF</a> results split by country).<br/><sup>b</sup>Downgraded by two levels for serious imprecision; wide 95% CIs that included both appreciable benefit and appreciable harm.<br/><sup>c</sup>Downgraded by one for risk of bias: the largest trial contributing data (<a href="./references#CD008521-bbs2-0038" title="ZamanK , SackDA , NeuzilKM , YunusM , MoultonLH , SugimotoJD , et al. Effectiveness of a live oral human rotavirus vaccine after programmatic introduction in Bangladesh: a cluster-randomized trial. PLOS Medicine2017;14(4):e1002282. ">RIX Zaman 2017‐BGD</a>) was a cluster‐RCT where participants, carers and investigators were aware of treatment allocation.<br/><sup>d</sup>We did not downgrade for inconsistency as the heterogeneity observed in the pooled data (I<sup>2</sup> = 75%) was due to within‐study heterogeneity (<a href="./references#CD008521-bbs2-0017" title="CunliffeNA , WitteD , NgwiraBM , ToddS , BostockNJ , TurnerAM , et al. Efficacy of human rotavirus vaccine against severe gastroenteritis in Malawian children in the first two years of life: a randomized, double-blind, placebo controlled trial. Vaccine2012;30(Suppl 1):A36-43. MadhiSA , CunliffeNA , SteeleD , WitteD , KirstenM , LouwC , et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. New England Journal of Medicine2010;362(4):289-98. MadhiSA , KirstenM , LouwC , BosP , AspinallS , BouckenoogheA , et al. Efficacy and immunogenicity of two or three dose rotavirus-vaccine regimen in South African children over two consecutive rotavirus seasons: a randomized, double-blind, placebo-controlled trial. Vaccine2012;30(Suppl 1):A44-51. NCT00241644. Multi-center study to assess the efficacy, safety and immunogenicity of 2 or 3 doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations in healthy infants. clinicaltrials.gov/show/NCT00241644 (first received 19 October 2005). NCT00598468. Multi-center study to assess efficacy, safety &amp; immunogenicity of 2 or 3 doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations in healthy infants. clinicaltrials.gov/show/NCT00598468 (first received 19 October 2005). SteeleAD , NeuzilKM , CunliffeNA , MadhiSA , BosP , NgwiraB , et al. Human rotavirus vaccine Rotarix provides protection against diverse circulating rotavirus strains in African infants: a randomized controlled trial. BMC Infectious Diseases2012;12:213. ">RIX Madhi 2010‐AF</a> results split by country).<br/><sup>e</sup>Downgraded by one level for imprecision; wide 95% CIs that included both appreciable benefit and no effect.<br/><sup>f</sup>Downgraded by two levels for serious imprecision: very few events with wide 95% CIs that included no effect. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008521-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">RotaTeq compared with placebo for preventing rotavirus diarrhoea in low‐mortality countries</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children<br/><b>Settings:</b> low‐mortality countries<br/><b>Intervention:</b> RotaTeq, 3 doses<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty</b> of the evidence<br/>(GRADE) </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>RotaTeq</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe cases of rotavirus diarrhoea</b><br/>Follow‐up: up to 1 year </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>23 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1 per 1000</b><br/>(0 to 3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.03 </b><br/>(0.01 to 0.11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7688<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RotaTeq reduces severe rotavirus diarrhoea compared with placebo at up to one‐year follow‐up. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe cases of rotavirus diarrhoea</b><br/>Follow‐up: up to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>32 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1 per 1000</b><br/>(0 to 4) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.04</b><br/>(0.01 to 0.11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5442<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RotaTeq reduces severe rotavirus diarrhoea compared with placebo at up to two years follow‐up. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe all‐cause diarrhoea</b><br/>Follow‐up: up to 1 year </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We found no studies that reported on this outcome in this setting.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe all‐cause diarrhoea</b><br/>Follow‐up: up to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We found no studies that reported on this outcome in this setting.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause death</b><br/>Follow‐up: 2 months to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1 per 1000</b><br/>(0 to 1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.24</b><br/>(0.69 to 2.22) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72,654<br/>(6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a</sup> </p> <p><i>due to serious imprecision</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RotaTeq may result in little to no difference in all‐cause death compared with placebo.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All serious adverse events</b><br/>Follow‐up: 2 months to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>26 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>24 per 1000</b><br/>(22 to 26) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.92</b><br/>(0.84 to 1.01) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70,690<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/><b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RotaTeq results in little to no difference in serious adverse events compared with placebo. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events: intussusception</b><br/>Follow‐up: 2 months to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.69</b><br/>(0.35 to 1.38) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73,925<br/>(9 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>b</sup> </p> <p><i>due to serious imprecision</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RotaTeq may result in little to no difference in intussusception compared with placebo.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the control group risk across studies included in the meta‐analysis. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by two levels for serious imprecision. These trials were not powered to detect an effect on mortality.<br/><sup>b</sup>Downgraded by two levels for serious imprecision: very few events with wide 95% CIs that included no effect. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008521-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">RotaTeq compared with placebo for preventing rotavirus diarrhoea in medium‐mortality countries</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children<br/><b>Settings:</b> medium‐mortality countries<br/><b>Intervention:</b> RotaTeq, 3 doses<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty</b> of the evidence<br/>(GRADE) </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>RotaTeq</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe cases of rotavirus diarrhoea</b><br/>Follow‐up: up to 1 year </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We found no studies that reported on this outcome in this setting.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe cases of rotavirus diarrhoea</b><br/>Follow‐up: up to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>27 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 1000</b><br/>(3 to 11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.21</b> (0.11 to 0.41) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3863<br/>(1 RCT)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a,b</sup> </p> <p><i>due to risk of bias and indirectness</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RotaTeq may reduce severe rotavirus diarrhoea compared with placebo at up to two years follow‐up. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe all‐cause diarrhoea</b><br/>Follow‐up: up to 1 year </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We found no studies that reported on this outcome in this setting.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe all‐cause diarrhoea</b><br/>Follow‐up: up to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We found no studies that reported on this outcome in this setting.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause death</b><br/>Follow‐up: 2 months to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 4) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.33</b> (0.01 to 8.18) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4088<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>very low</b><sup>a,c,d</sup> </p> <p><i>due to risk of bias, indirectness, and serious imprecision</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effect of RotaTeq on all‐cause death.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All serious adverse events</b><br/>Follow‐up: 2 months to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>58 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>38 per 1000</b><br/>(8 to 185) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.66</b> (0.14 to 3.17) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4082<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a,e</sup> </p> <p><i>due to risk of bias and imprecision</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effect of RotaTeq on serious adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events: intussusception</b><br/>Follow‐up: 2 months to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 5.01</b> (0.24 to 104.29) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4082<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a,e</sup> </p> <p><i>due to risk of bias and serious imprecision</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effect of RotaTeq on intussusception.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the control group risk across studies included in the meta‐analysis. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one level for risk of bias; unclear risk of selection bias.<br/><sup>b</sup>Downgraded by one level for indirectness; single study carried out in China; difficult to apply results to any medium‐mortality settings.<br/><sup>c</sup>Downgraded by one level for indirectness; two studies carried out in China; difficult to apply results to any medium‐mortality settings.<br/><sup>d</sup>Downgraded by two levels for serious imprecision. These trials were not powered to detect an effect on mortality.<br/><sup>e</sup>Downgraded by two levels for serious imprecision: very few events with wide 95% CIs that included no effect. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008521-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">RotaTeq compared with placebo for preventing rotavirus diarrhoea in high‐mortality countries</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children<br/><b>Settings:</b> high‐mortality countries<br/><b>Intervention:</b> RotaTeq, 3 doses<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty</b> of the evidence<br/>(GRADE) </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>RotaTeq</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe cases of rotavirus diarrhoea</b><br/>Follow‐up: up to 1 year </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>28 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>12 per 1000</b><br/>(8 to 18) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.43</b><br/>(0.29 to 0.64) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6775<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/><b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RotaTeq reduces severe rotavirus diarrhoea compared with placebo at up to one‐year follow‐up. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe cases of rotavirus diarrhoea</b><br/>Follow‐up: up to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>59 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>33 per 1000</b><br/>(27 to 51) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.56</b><br/>(0.41 to 0.77) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6744<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/><b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RotaTeq reduces severe rotavirus diarrhoea compared with placebo at up to two years follow‐up. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe cases of all‐cause diarrhoea </b><br/>Follow‐up: up to 1 year </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>77 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>62 per 1000</b><br/>(45 to 85) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.80</b><br/>(0.58 to 1.11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4085<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>a</sup> </p> <p><i>due to imprecision</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RotaTeq probably results in little to no difference in severe all‐cause diarrhoea compared with placebo at up to one‐year follow‐up. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe cases of all‐cause diarrhoea</b><br/>Follow‐up: up to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>130 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>110 per 1000</b><br/>(96 to 128) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.85 </b><br/>(0.74 to 0.99) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5977<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/><b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RotaTeq slightly reduces severe all‐cause diarrhoea compared with placebo at up to two years follow‐up. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause death</b><br/>Follow‐up: 2 months to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>23 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>21 per 1000</b><br/>(16 to 28) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.91</b><br/>(0.68 to 1.23) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7706<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>a</sup> </p> <p><i>due to imprecision</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RotaTeq probably results in little to no difference in all‐cause death compared with placebo. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All serious adverse events</b><br/>Follow‐up: 2 months to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>19 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>19 per 1000</b><br/>(14 to 26) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.99</b><br/>(0.72 to 1.36) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7730<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>b</sup> </p> <p><i>due to imprecision</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RotaTeq probably results in little to no difference in serious adverse events compared with placebo. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events: intussusception</b><br/>Follow‐up: 2 months to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.33</b> (0.01 to 8.16) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7488<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>c</sup> </p> <p><i>due to serious imprecision</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RotaTeq may result in little to no difference in intussusception compared with placebo.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the control group risk across studies included in the meta‐analysis. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one level for imprecision. The 95% CI included both no effect and appreciable benefit.<br/><sup>b</sup>Downgraded by one level for imprecision. The 95% CI included both no effect and appreciable harm.<br/><sup>c</sup>Downgraded by two levels for serious imprecision: very few events with wide 95% CIs that included no effect. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008521-tbl-0007"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Rotasiil compared with placebo for preventing rotavirus diarrhoea in high‐mortality countries</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children </p> <p><b>Settings:</b> high‐mortality countries (Niger, India) </p> <p><b>Intervention:</b> Rotasiil, 3 doses </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Illustrative comparative risks*<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign=""> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign=""> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign=""> <p><b>Certainty of the evidence<br/>(GRADE)<br/> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign=""> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Rotasiil</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Severe cases of rotavirus diarrhoea </b> </p> <p>follow‐up: up to 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>45 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>23 per 1000</b><br/>(15 to 36)  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.52</b><br/>(0.33 to 0.81) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11,008<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/><b>high</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rotasiil reduces severe rotavirus diarrhoea compared with placebo at up to one‐year follow‐up. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Severe cases of rotavirus diarrhoea</b> follow‐up: up to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>76 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>43 per 1000</b><br/>(32 to 56) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.56</b> </p> <p>(0.42 to 0.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11,008<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/><b>high</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rotasiil reduces severe rotavirus diarrhoea compared with placebo at up to two years follow‐up.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Severe cases of all‐cause diarrhoea</b> </p> <p>follow‐up: up to 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>145 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p> <br/> <b>133 per 1000</b><br/>(121 to 146) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.92</b> </p> <p>(0.84 to 1.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11,008<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/><b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rotasiil results in little to no difference in severe all‐cause diarrhoea compared with placebo at up to one‐year follow‐up. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Severe cases of all‐cause diarrhoea</b> </p> <p>follow‐up: up to 2 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>239 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p> <b>225 per 1000</b><br/>(211 to 242) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.94</b> </p> <p>(0.88 to 1.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11,008<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/><b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rotasiil results in little to no difference in severe all‐cause diarrhoea compared with placebo at up to two years follow‐up. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All‐cause death</b> </p> <p>follow‐up: up to 2 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>11 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p> <b>13 per 1000</b><br/>(9 to 18) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.14</b> </p> <p>(0.82 to 1.59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11,586</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>b</sup> </p> <p><i>due to imprecision</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rotasiil probably results in little to no difference in all‐cause death compared with placebo at up to two years follow‐up. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All serious adverse events</b> </p> <p>follow‐up: up to 2 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>264 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p> <b>258 per 1000</b><br/>(242 to 274) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.98</b> </p> <p>(0.92 to 1.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11,646</p> <p>(3 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/><b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rotasiil results in little to no difference in serious adverse events compared with placebo at up to two years follow‐up.<br/>In addition: <a href="./references#CD008521-bbs2-0042" title="CTRI/2009/091/000821. A randomized, double-blind, placebo controlled study to assess the safety and tolerability of RotaVac vaccine (live attenuated bovine-human (UK) reassortant pentavalent rotavirus vaccine). ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=987&amp;EncHid=&amp;modid=&amp;compid=%27,%27987det%27 (first received 15 October 2009). Zade JK,  KulkarniPS ,  Desai SA,  Sabale RN,  Naik SP,  Dhere RM. Bovine rotavirus pentavalent vaccine development in India. Vaccine2014;32(Suppl 1):A124-8. [DOI: 10.1016/j.vaccine.2014.03.003]">SIIL Zade 2014‐INDb</a> reported that "Two SAEs (urinary tract infections and septicaemia) unrelated to study vaccines were reported and both recovered uneventfully". No SAEs were reported among 18 infants and 18 toddlers in <a href="./references#CD008521-bbs2-0041" title="CTRI/2009/091/000821. A randomized, double-blind, placebo controlled study to assess the safety and tolerability of rotaVac vaccine (live attenuated bovine-human (UK) reassortant pentavalent rotavirus vaccine). ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=987&amp;EncHid=&amp;modid=&amp;compid=%27,%27987det%27 (first received 15 October 2009). Zade JK,  KulkarniPS ,  Desai SA,  Sabale RN,  Naik SP,  Dhere RM. Bovine rotavirus pentavalent vaccine development in India. Vaccine2014;32(Suppl 1):A124-8. [DOI: 10.1016/j.vaccine.2014.03.003]">SIIL Zade 2014‐INDa</a>. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events: intussusception</b> </p> <p>follow‐up: up to 2 years</p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>1 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>1 per 1000</b><br/>(0 to 3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.98</b> </p> <p>(0.35 to 2.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11,586</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/><b>low</b><sup>c</sup> </p> <p><i>due to serious imprecision</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rotasiil may result in little to no difference in intussusception compared with placebo at up to two years follow‐up. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the control group risk across studies included in the meta‐analysis. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>There was unexplained statistical heterogeneity in this analysis (I<sup>2</sup> &gt; 50%), however, we did not downgrade for inconsistency since all estimates were in the same direction showing appreciable benefit.<br/><sup>b</sup>Downgraded by one level for imprecision: wide 95% CIs that included no effect as well as appreciable harm.<br/><sup>c</sup>Downgraded by two levels for serious imprecision: very few events with wide 95% CIs that included no effect. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008521-tbl-0008"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Rotavac compared with placebo for preventing rotavirus diarrhoea in high‐mortality countries</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children </p> <p><b>Settings:</b> one high‐mortality country (India) </p> <p><b>Intervention:</b> Rotavac, 3 doses </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty</b> of the evidence<br/>(GRADE) </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Rotavac</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe cases of rotavirus diarrhoea</b> </p> <p>follow‐up: up to 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>31 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>13 per 1000</b><br/>(9 to 19) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.43</b><br/>(0.30 to 0.60) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6799<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>a</sup> </p> <p><i>due to indirectness</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rotavac probably reduces severe rotavirus diarrhoea compared with placebo at up to one‐year follow‐up. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe cases of rotavirus diarrhoea </b><br/>follow‐up: up to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>47 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>21 per 1000</b><br/>(16 to 28) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.46</b><br/>(0.35 to 0.60) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6541<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>a</sup> </p> <p><i>due to indirectness</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rotavac probably reduces severe rotavirus diarrhoea compared with placebo at up to two years follow‐up. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe cases of all‐cause diarrhoea</b> </p> <p>follow‐up: up to 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>93 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>78 per 1000</b><br/>(66 to 91) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.84</b><br/>(0.71 to 0.98) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6799<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>a</sup> </p> <p><i>due to indirectness</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rotavac probably slightly reduces severe all‐cause diarrhoea compared with placebo at up to one‐year follow‐up. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe cases of all‐cause diarrhoea</b> </p> <p>follow‐up: up to 2 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We found no studies that reported on this outcome in this setting.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause death</b> </p> <p>follow‐up: up to 2 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>7 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 1000</b><br/>(3 to 11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.88</b><br/>(0.50 to 1.56) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8155<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>b,c</sup> </p> <p><i>due to indirectness and serious imprecision</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effect of Rotavac on all‐cause death.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All serious adverse events</b> </p> <p>follow‐up: up to 2 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>204 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>189 per 1000</b><br/>(173 to 208) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.93</b><br/>(0.85 to 1.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8210<br/>(3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>b</sup> </p> <p><i>due to indirectness</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rotavac probably results in little to no difference in serious adverse events compared with placebo. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events: intussusception</b> </p> <p>follow‐up: up to 2 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1 per 1000</b><br/>(0 to 5) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.33</b><br/>(0.35 to 5.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8582<br/>(4 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>b,d</sup> </p> <p><i>due to indirectness and serious imprecision</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events were reported in three of the four studies.</p> <p>The evidence is very uncertain about the effect of Rotavac on intussusception.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the control group risk across studies included in the meta‐analysis. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one level for indirectness; single trial conducted in India, so generalization to any high‐mortality country is difficult.<br/><sup>b</sup>Downgraded by one level for indirectness. All trials were conducted in India, so generalization to any high‐mortality country is difficult.<br/><sup>c</sup>Downgraded by two levels for serious imprecision. These trials were not powered to detect an effect on mortality.<br/><sup>d</sup>Downgraded by two levels for serious imprecision: very few events with wide 95% CIs that included no effect. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD008521-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD008521-sec-0009"></div> <section id="CD008521-sec-0010"> <h3 class="title" id="CD008521-sec-0010">Description of the condition</h3> <section id="CD008521-sec-0011"> <h4 class="title">The global impact of rotavirus infection</h4> <p>Rotavirus is the leading known cause of severe gastroenteritis in infants and young children worldwide (<a href="./references#CD008521-bbs2-0154" title="ParasharUD , GlassRI . Public health. Progress toward rotavirus vaccines. Science2006;312(5775):851-2.">Parashar 2006a</a>; <a href="./references#CD008521-bbs2-0182" title="VesikariT . Rotavirus vaccines against diarrhoeal disease. Lancet1997;350(9090):1538-41.">Vesikari 1997</a>; <a href="./references#CD008521-bbs2-0187" title="World Health Organization. Rotavirus vaccines WHO position paper – July 2021. Weekly Epidemiological Record2021;96(28):301-20.">WHO 2021b</a>). While nearly every child experiences at least one rotavirus infection in early childhood regardless of setting, most rotavirus‐associated deaths occur in children in low‐ and middle‐income countries, particularly in sub‐Saharan Africa and in the Indian subcontinent. Prior to the rollout of rotavirus vaccination, rotavirus caused 37% of diarrhoeal deaths (~ 450,000 deaths worldwide in 2008) in children younger than five years. Five countries accounted for more than half of all deaths, and 22% of deaths attributable to rotavirus infection occurred in India (<a href="./references#CD008521-bbs2-0177" title="TateJE , BurtonAH , Boschi-PintoC , SteeleAD , DuqueJ , ParasharUD , WHO-coordinated Global Rotavirus Surveillance Network. 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infectious Diseases2012;12(2):136-41.">Tate 2012</a>). In high‐income countries, where deaths due to rotavirus are rare, rotavirus accounted for 40% to 50% of hospital admissions due to diarrhoeal disease in the pre‐rotavirus vaccine period (<a href="./references#CD008521-bbs2-0149" title="LinharesAC , VelázquezFR , Pérez-SchaelI , Sáez-LlorensX , AbateH , EspinozaF , et al, Human Rotavirus Vaccine Study Group. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet2008;371(9619):1181-9.">Linhares 2008</a>; <a href="./references#CD008521-bbs2-0154" title="ParasharUD , GlassRI . Public health. Progress toward rotavirus vaccines. Science2006;312(5775):851-2.">Parashar 2006a</a>; <a href="./references#CD008521-bbs2-0177" title="TateJE , BurtonAH , Boschi-PintoC , SteeleAD , DuqueJ , ParasharUD , WHO-coordinated Global Rotavirus Surveillance Network. 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infectious Diseases2012;12(2):136-41.">Tate 2012</a>). </p> </section> <section id="CD008521-sec-0012"> <h4 class="title">Epidemiology of rotavirus infection</h4> <p>Rotavirus is transmitted primarily via the faecal‐oral route, with symptoms typically developing one to two days following infection. Rotavirus infection occurs throughout life, and successive rotavirus infections occur during infancy and early childhood. The first rotavirus infection typically results in the most severe disease outcome; subsequent rotavirus infections are associated with milder disease or may be asymptomatic. However, differences in the age of first infection and number of infections required to acquire protection from symptomatic disease vary from one population to another. Rotavirus diarrhoea is particularly associated with severe outcomes between the ages of three and 35 months (<a href="./references#CD008521-bbs2-0155" title="ParasharUD , AlexanderJP , GlassRI , Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention (CDC). Prevention of rotavirus gastroenteritis among infants and children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. Recommendations and Reports2006;55(RR-12):1-13.">Parashar 2006b</a>), with a peak incidence of all episodes occurring between six and 24 months (<a href="./references#CD008521-bbs2-0126" title="Advisory Committee on Immunization Practices. Rotavirus vaccine for the prevention of rotavirus gastroenteritis among children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. Recommendations and Reports1999;48(RR-2):1-20.">CDC‐ASIP 1999</a>; <a href="./references#CD008521-bbs2-0149" title="LinharesAC , VelázquezFR , Pérez-SchaelI , Sáez-LlorensX , AbateH , EspinozaF , et al, Human Rotavirus Vaccine Study Group. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet2008;371(9619):1181-9.">Linhares 2008</a>). The peak incidence of severe rotavirus disease occurs earlier in high‐mortality countries than in low‐mortality countries; an estimated 43% of all rotavirus hospitalizations in children aged under five occur by eight months of age in Africa compared with 27% in Europe (<a href="./references#CD008521-bbs2-0128" title="CrawfordSE , RamaniS , TateJE , ParasharUD , SvenssonL , HagbomM . Rotavirus infection. Nature Reviews Disease Primers2017;3:17083.">Crawford 2017</a>; <a href="./references#CD008521-bbs2-0171" title="SandersonC , ClarkA , TaylorD , BolanosB . Global review of rotavirus morbidity and mortality data by age and region. www.who.int/immunization/sage/meetings/2012/april/Sanderson_et_al_SAGE_April_rotavirus.pdf (accessed 25 October 2018).">Sanderson 2011</a>). Typically, infants in high‐mortality countries experience a greater number of symptomatic episodes (<a href="./references#CD008521-bbs2-0138" title="GladstoneBP , RamaniS , MukhopadhyaI , MuliyilJ , SarkarR , RehmanAM , et al. Protective effect of natural rotavirus infection in an Indian birth cohort. New England Journal of Medicine2011;365(4):337-46.">Gladstone 2011</a>; <a href="./references#CD008521-bbs2-0180" title="VelázquezFR , MatsonDO , CalvaJJ , GuerreroL , MorrowAL , Carter-CampbellS , et al. Rotavirus infection in infants as protection against subsequent infections. New England Journal of Medicine1996;335(14):1022-8.">Velázquez 1996</a>). In temperate countries, rotavirus infections display marked seasonality, with distinct peaks during the winter months and few infections identified outside this period. In contrast, rotavirus infections tend to occur year‐round in many tropical countries, which nevertheless often display peaks of more intense activity and within‐country variation in seasonal patterns (<a href="./references#CD008521-bbs2-0159" title="PatelMM , PitzerVE , AlonsoWJ , VeraD , LopmanB , TateJ , et al. Global seasonality of rotavirus disease. Pediatric Infectious Diseases Journal2013;32(4):e134-47.">Patel 2013</a>) </p> </section> <section id="CD008521-sec-0013"> <h4 class="title">Rotavirus classification</h4> <p>Rotaviruses are double‐stranded (ds) ribonucleic acid (RNA) viruses: genus <i>Rotavirus</i> , family <i>Reoviridae</i> . Each of the 11 dsRNA segments, contained within the core of a triple‐layered viral particle, encodes one or more viral proteins. <i>Rotavirus A,</i> which causes most human disease, is genetically diverse in each of its 11 genome segments (called genotypes), and a nucleotide sequence‐based, complete genome classification system is used. Because of their importance in protective immunity, the outer capsid proteins VP7 and VP4 have been most extensively investigated. Species A rotaviruses are classified into G and P genotypes, based on the sequence diversity of the RNA segments encoding VP7 and VP4, respectively; 32 G genotypes and 47 P genotypes have been described (<a href="./references#CD008521-bbs2-0128" title="CrawfordSE , RamaniS , TateJE , ParasharUD , SvenssonL , HagbomM . Rotavirus infection. Nature Reviews Disease Primers2017;3:17083.">Crawford 2017</a>) (see <a href="#CD008521-fig-0001">Figure 1</a> for details). Rotavirus vaccines are designed to protect against disease caused by the most prevalent strain types; globally, G1P[8], G2P[4], G3P[8], G4P[8], G9P[8] and G12 in combination with P[6] or P[8] account for over 90% of the genotypes that infect humans (<a href="./references#CD008521-bbs2-0117" title="BányaiK , LászlóB , DuqueJ , SteeleAD , NelsonEA , GentschJR , et al. Systematic review of regional and temporal trends in global rotavirus strain diversity in the prerotavirus vaccine era: insights for understanding the impact of rotavirus vaccination programs. Vaccine2012;30(Suppl 1):A122-30.">Bányai 2012</a>). </p> <div class="figure" id="CD008521-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="A simplified diagram of the location of rotavirus structural proteins (source: Graham Cohn, Wikipedia (public domain image)): Rotaviruses are segmented, double‐stranded RNA viruses. The mature, triple‐layered virus particle comprises a core (which contains the viral genome), a middle layer (comprised of viral protein (VP)6, and an outer layer (comprised of VP7 and VP4) as shown in the figure. VP6 defines rotavirus group, and most rotaviruses that infect humans are of group A. The two outer capsid proteins independently induce neutralizing antibodies: VP7, a glycoprotein, defines G‐serotype; and the protease‐sensitive VP4 protein defines P‐serotype. G‐serotype determined by serological methods correlates precisely with G‐genotype obtained through molecular assays, whereas there is an imperfect correlation of P‐serotype and P‐genotype; P‐genotype is thus included in square brackets." data-id="CD008521-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p><b>A simplified diagram of the location of rotavirus structural proteins (source: Graham Cohn, Wikipedia (public domain image)):</b> Rotaviruses are segmented, double‐stranded RNA viruses. The mature, triple‐layered virus particle comprises a core (which contains the viral genome), a middle layer (comprised of viral protein (VP)6, and an outer layer (comprised of VP7 and VP4) as shown in the figure. VP6 defines rotavirus group, and most rotaviruses that infect humans are of group A. The two outer capsid proteins independently induce neutralizing antibodies: VP7, a glycoprotein, defines G‐serotype; and the protease‐sensitive VP4 protein defines P‐serotype. G‐serotype determined by serological methods correlates precisely with G‐genotype obtained through molecular assays, whereas there is an imperfect correlation of P‐serotype and P‐genotype; P‐genotype is thus included in square brackets. </p> </div> </div> </div> </section> </section> <section id="CD008521-sec-0014"> <h3 class="title" id="CD008521-sec-0014">Description of the intervention</h3> <section id="CD008521-sec-0015"> <h4 class="title">Vaccines approved for use</h4> <p>This review evaluates four vaccines that are listed as prequalified by the WHO (<a href="./references#CD008521-bbs2-0186" title="World Health Organization. WHO prequalified vaccines. extranet.who.int/pqweb/vaccines/prequalified-vaccines (accessed 20 June 2021).">WHO 2021a</a>). They include a monovalent rotavirus vaccine (Rotarix, GlaxoSmithKline Biologicals) and a pentavalent rotavirus vaccine (RotaTeq, Merck &amp; Co., Inc.), which have been evaluated in multiple large trials across several continents and are in routine use in many countries. Also included is a further monovalent vaccine (Rotavac, Bharat Biotech Ltd.), and a further pentavalent vaccine (BRV‐PV, Rotasiil, Serum Institute of India Ltd.) which are licensed and used in India. As of April 2020, 107 countries have introduced rotavirus vaccines into their immunization programmes (<a href="./references#CD008521-bbs2-0167" title="ROTA council. Global introduction status. preventrotavirus.org/vaccine-introduction/global-introduction-status/ (accessed 20 June 2021).">ROTA Council 2021</a>). </p> <p>Rotarix is an oral, live‐attenuated, human rotavirus vaccine derived from the most common circulating wild‐type rotavirus strain G1P[8]. Rotarix is based on a rotavirus of human origin and is administered to infants in two oral doses with an interval of at least four weeks between doses. The manufacturer states that the "vaccination course should preferably be given before 16 weeks of age, but must be completed by the age of 24 weeks" (<a href="./references#CD008521-bbs2-0134" title="European Medicines Agency. Summary of Product Characteristics: Rotarix. ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000639/WC500054789.pdf (accessed November 2011).">EMA 2011</a>). As of May 2016, Rotarix had been introduced in national immunization programmes in 63 countries around the world (<a href="./references#CD008521-bbs2-0160" title="PATH. Country National Immunization Program (NIP) introductions of Rotavirus vaccine. www.vaccineresources.org/files/PATH-Country-Introduction-Table-EN-2016.05.01.pdf (accessed 27 July 2018).">PATH 2016</a>). </p> <p>RotaTeq is an oral, live, human‐bovine, reassortant, multivalent rotavirus vaccine developed from an original Wistar calf 3 (WC3) strain of bovine rotavirus. The vaccine contains five live, human‐bovine reassortant rotavirus strains. Four reassortant rotavirus strains each express one of the common human VP7 (G) types including G1, G2, G3, and G4, and the fifth reassortant expresses the common human VP4 (P) type P[8]. The three‐dose liquid vaccine is intended for infants aged between six and 32 weeks, with the first dose given at six to 12 weeks and subsequent doses administered at four‐ to 10‐week intervals; however, the third dose should not be given after 32 weeks of age (<a href="./references#CD008521-bbs2-0151" title="Merck. WHO list of vaccines for purchase by UN agencies as of November 2008. www.who.int/immunization_standards/vaccine_quality/pq_suppliers/en/index.html. Press release (accessed 21 November 2008).">Merck 2008</a>). As of May 2016, RotaTeq had been introduced in national immunization programmes in 22 countries around the world (<a href="./references#CD008521-bbs2-0160" title="PATH. Country National Immunization Program (NIP) introductions of Rotavirus vaccine. www.vaccineresources.org/files/PATH-Country-Introduction-Table-EN-2016.05.01.pdf (accessed 27 July 2018).">PATH 2016</a>). </p> <p>Rotavac is an oral live‐attenuated, monovalent vaccine derived from a naturally‐occurring reassortant G9P[11] strain [116E] isolated from a newborn child in India (<a href="./references#CD008521-bbs2-0188" title="YenC , TateJE , HydeTB , CorteseMM , LopmanBA , JiangB , et al. Rotavirus vaccines: current status and future considerations. Human Vaccines and Immunotherapeutics2014;10(6):1436-48.">Yen 2014</a>). This oral vaccine was developed by Bharat Biotech Ltd. in India and was licensed in India in 2014 (<a href="./references#CD008521-bbs2-0067" title="ChandolaTR , TanejaS , GoyalN , AntonyK , BhatiaK , MoreD , et al. ROTAVAC does not interfere with the immune response to childhood vaccines in Indian infants: a randomized placebo controlled trial. Heliyon2017;3(5):e00302. CTRI/2014/05/004592. A phase III study to evaluate the non-interference in the immune response of rotavac to childhood vaccines and to assess the clinical lot consistency. ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=5870&amp;EncHid=&amp;modid=&amp;compid=%27,%275870det%27 (first received 13 May 2014). ">VAC Chandola 2017‐IND</a>). Three doses are recommended, to be administered at 6, 10, and 14 weeks of age. </p> <p>Rotasiil is an oral, live, human‐bovine, reassortant, multivalent rotavirus vaccine. The vaccine contains five live, human‐bovine reassortant rotavirus strains (G1, G2, G3, G4, and G9). This vaccine was developed by the Serum Institute of India Ltd. and nationally licensed in 2017. Three doses are recommended, to be administered at 6, 10, and 14 weeks of age, at the same time as routine vaccinations under India’s childhood immunization schedule. </p> <p>There are a further two rotavirus vaccines that have been licensed and approved for use in individual countries, but are not yet prequalified by the WHO: Lanzhou lamb rotavirus vaccine (LLR; Lanzhou Institute of Biomedical Products) which is licensed and used in China; and a monovalent vaccine (Rotavin‐M1, POLYVAC) which is licensed and used in Vietnam. </p> </section> <section id="CD008521-sec-0016"> <h4 class="title">Vaccines no longer in use</h4> <p>Several vaccines, including the first licensed rotavirus vaccine (RRV‐TV; RotaShield, Wyeth Laboratories), were developed, tested in trials, and later abandoned or withdrawn from use. These vaccines are included in a separate Cochrane Review (<a href="./references#CD008521-bbs2-0191" title="Soares-WeiserK , GoldbergE , TamimiG , PitanOC , LeiboviciL . Rotavirus vaccine for preventing diarrhoea. Cochrane Database of Systematic Reviews2004, Issue 1. Art. No: CD002848. [DOI: 10.1002/14651858.CD002848.pub2]">Soares‐Weiser 2004</a>). RRV‐TV, a tetravalent rhesus‐human reassortant vaccine, was withdrawn from use in 1999 following reports of intussusception (bowel obstruction which occurs when one segment of bowel becomes enfolded within another segment). Evaluations have since suggested that the risk of developing intussusception was age‐related, with 80% of intussusception cases occurring in infants who were more than 90 days old when the first vaccine dose was administered (<a href="./references#CD008521-bbs2-0174" title="SimonsenL , ViboudC , ElixhauserA , TaylorRJ , KapikianAZ . More on RotaShield and intussusception: the role of age at the time of vaccination. Journal of Infectious Diseases2005;192(Suppl 1):36-43.">Simonsen 2005</a>). Although it is still currently licensed, this vaccine is no longer in clinical use (<a href="./references#CD008521-bbs2-0132" title="DennehyPH , BradyRC , HalperinSA , WardRL , AlveyJC , Fischer FH Jr, et al, North American Human Rotavirus Vaccine Study Group. Comparative evaluation of safety and immunogenicity of two dosages of an oral live attenuated human rotavirus vaccine. Pediatric Infectious Disease Journal2005;24(6):481-8.">Dennehy 2008</a>). </p> </section> </section> <section id="CD008521-sec-0017"> <h3 class="title" id="CD008521-sec-0017">How the intervention might work</h3> <section id="CD008521-sec-0018"> <h4 class="title">Recommendations for rotavirus vaccine use</h4> <p>Vaccination with Rotarix and RotaTeq was first recommended in 2006 in Europe and the Americas, where clinical trials had demonstrated vaccine efficacy of 85% to 100% (<a href="./references#CD008521-bbs2-0026" title="Costa ClemensSA , et al. Operational organization of a large scale phase III clinical trial of rotavirus vaccine in multiple sites and countries in Latin America. In: International Congress of Pediatrics (ICP); 2004 August 15-20; Cancun, Mexico. 2004. [Not available for review]De VosB , et al. Rotarix™: an effective way to prevent rotavirus diarrhoea and vomiting. In: 9th Congress of the Asian Pan Pacific Society of Paediatric Gastroenterology, Hepatology and Nutrition &amp; 27th Annual Congress of the Malaysian Paediatric Association; 2005 June 16-19; Kuala Lumpur, Malaysia. 2005. [Not available for review]BaayM , BollaertsK , StruchinerC , VerstraetenT . Background rates of disease in Latin American children from a rotavirus vaccine study. Human Vaccines and Immunotherapeutics2017;13(8):1916-20. GlaxoSmithKline[444563-023-pt1]. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants (efficacy data from visit 1 to visit 4). www.gsk-studyregister.com/study/6791 (accessed 12 December 2018). GlaxoSmithKline[444563-023-pt2]. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants (2nd year efficacy from visit 4 to visit 6). www.gsk-studyregister.com/study/6791 (accessed 12 December 2018). GlaxoSmithKline[444563-023-pt3]. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants (safety for the period between visit 1 and visit 3). www.gsk-studyregister.com/study/6791 (accessed 12 December 2018). JustinoMC , AraújoEC , Van DoornLJ , OliveiraCS , GabbayYB , MascarenhasJD , et al. Oral live attenuated human rotavirus vaccine (Rotarix) offers sustained high protection against severe G9P[8] rotavirus gastroenteritis during the first two years of life in Brazilian children. Memorias do Instituto Oswaldo Cruz2012;107(7):846-53. LinharesAC , VelazquezFR , Perez-SchaelI , Saez-LlorensX , AbateH , EspinozaF , et al. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet2008;371(9619):1181-9. LopezP , LinharesA , Pérez-SchaelI , Ruiz-PalaciosG , Costa ClemensS , SanchezN . Early protection against severe rotavirus gastroenteritis - RIX4414 experience in Latin America. In: 24th Annual Meeting of European Society for Paediatric Infectious Diseases (ESPID); 2006 May 03-05; Basel, Switzerland. 2006. [Not available for review]MaciasM , LopezP , VelazquezFR , VergaraRF , SalmeronJ , TavaresJL . The rotavirus vaccine RIX4414 (Rotarix) is not associated with intussusception in one year old infants. In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2005 December 16-19; Washington DC, USA. 2005. [Not available for review]NCT00139347. A multi-country &amp; multi-center study to assess the efficacy, immunogenicity &amp; safety of two doses of GSK Biologicals' oral live attenuated HRV vaccine given concomitantly with routine EPI vaccinations including OPV in healthy infants. clinicaltrials.gov/ct2/show/NCT00139347 (first received 31 August 2005). [Trial registration document (no data for review)]NCT00140673. Placebo-controlled, multi-country &amp; multi-center study to assess the efficacy, safety &amp; immunogenicity of 2 doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants. clinicaltrials.gov/ct2/show/NCT00140673 (first received 1 September 2005). [Trial registration document (no data for review)]Perez-SchaelI , LinharesAC , VesikariT . Two doses of the human attenuated rotavirus vaccine RIX4414 (Rotarix) show heterotypic protection in Latin America and Europe. In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2005 December 16-19; Washington DC, USA. 2005. [Not available for review]PikeM . New rotavirus vaccine is effective and appears to have no increased risk of intussusception. Clinical Research Abstracts For Pediatricians2006;149(1):143. Ruiz-PalaciosG , AranzaC , VelazquezFR , RichardsonV , NandiE , MaciasM . Two doses of the human-attenuated monovalent G1P[8] rotavirus vaccine, Rotarix show high efficacy in Mexican children against severe rotavirus gastroenteritis and severe overall gastroenteritis. In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2005 December 16-19; Washington DC, USA. 2005. [Not available for review]Ruiz-PalaciosGM , Perez-SchaelI , VelazquezFR , AbateH , BreuerT , ClemensSC , et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. New England Journal of Medicine2006;354(1):11-22. VelázquezFR , AbatH , Costa ClemensSA , EspinozaF , GillardP , LinharesAC , et al. The human monovalent G1P[8] rotavirus vaccine, Rotarix is highly efficacious and provides crossprotection against G1 and non-G1 serotypes. In: 23rd Annual meeting of European Society for Paediatric Infectious Diseases (ESPID); 2005 May 18-20; Valencia, Spain. 2005. VelázquezRF , AbateH , BouckenoogheA . RIX4414, the human G1P[8] rotavirus vaccine is highly efficacious during the second year of life. In: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2006 September 27-30; San Francisco, USA. 2006. [Not available for review]VesikariT , O’RyanM , AbateH , Costa ClemensSA , EspinozaF , GillardP . Overcoming the safety hurdle: the rotavirus vaccine RIX4414 is not associated with intussusception. In: 23rd Annual Meeting of European Society for Paediatric Infectious Diseases (ESPID); 2005 May 18-20; Valencia, Spain. 2005. [Not available for review]">RIX Ruiz‐Palac 06‐LA/EU</a>; <a href="./references#CD008521-bbs2-0060" title="ChangCC , ChangMH , LinTY , LeeHC , HsiehWS , LeePI . Experience of pentavalent human-bovine reassortant rotavirus vaccine among healthy infants in Taiwan. Journal of the Formosan Medical Association2009;108(4):280-5. ChristieCD , DuncanND , ThameKA , OnoratoMT , SmithHD , MalcolmLG , et al. Pentavalent rotavirus vaccine in developing countries: safety and health care resource utilization. Pediatrics2010;126(6):e1499-506. DennehyPH , GoveiaMG , DallasMJ , HeatonPM . The integrated phase III safety profile of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine. International Journal of Infectious Diseases2007;11(Suppl 2):36-42. [No data available for review]GoveiaMG , DiNubileMJ , DallasMJ , HeatonPM , KuterBJ , REST Study Team. Efficacy of pentavalent human-bovine (WC3) reassortant rotavirus vaccine based on breastfeeding frequency. Pediatric Infectious Disease Journal2008;27(7):656-8. GoveiaMG , RodriguezZM , DallasMJ , ItzlerRF , BoslegoJW , HeatonPM , et al. Safety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infants. Pediatric Infectious Disease Journal2007;26(12):1099-104. [No data available for review]GoveiaMG , SuprunL , ItzlerRF , McFetridgeR , DallasMJ , KuterBJ . Efficacy and safety of pentavalent human-bovine reassortant rotavirus vaccine when administered with greater than 10 weeks between doses. Pediatric Infectious Disease Journal2010;29(3):263-5. GrantL , WattJ , MoultonL , WeatherholtzR , ReidR , SantoshamM , et al. Lack of nonspecific protection against all-cause nonrotavirus gastroenteritis by vaccination with orally administered rotavirus vaccine. Journal of Pediatric Gastroenterology and Nutrition2013;56(6):635-40. GrantLR , WattJP , WeatherholtzRC , MoultonLH , ReidR , SantoshamM , et al. Efficacy of a pentavalent human-bovine reassortant rotavirus vaccine against rotavirus gastroenteritis among American Indian children. Pediatric Infectious Disease Journal2012;31(2):184-8. ItzlerR , KochG , MatsonDO , GotheforsL , Van DammeP , DinubileMJ , et al. Robustness of the healthcare utilization results from the Rotavirus Efficacy and Safety Trial (REST) evaluating the human-bovine (WC3) reassortant pentavalent rotavirus vaccine (RV5). BMC Pediatrics2010;10:42. Merck[PN-006]. Safety and efficacy of pentavalent (G1, G2, G3, G4, and P1) human-bovine reassortant rotavirus vaccine in healthy infants NCT00090233 (PN 006). clinicalstudyresults.org/drugdetails/?indication_id=523&amp;sort=c.company_name&amp;page=1&amp;drug_id=1144 (accessed prior to 19 October 2021). [No data available for review]NCT00090233. Safety and efficacy of pentavalent (G1, G2, G3, G4, and P1) human-bovine reassortant rotavirus vaccine in healthy infants. clinicaltrials.gov/ct2/show/record/NCT00090233 (first received 27 August 2004). [Trial registration document]RodriguezZM , GoveiaMG , StekJE , DallasMJ , BoslegoJW , DiNubileMJ , et al. Concomitant use of an oral live pentavalent human-bovine reassortant rotavirus vaccine with licensed parenteral pediatric vaccines in the United States. Pediatric Infectious Disease Journal2007;26(3):221-7. VesikariT ,  KarvonenA ,  FerranteSA ,  KuterBJ ,  CiarletM . Sustained efficacy of the pentavalent rotavirus vaccine, RV5, up to 3.1 years following the last dose of vaccine. Pediatric Infectious Disease Journal2010;29(10):957-63. VesikariT , ItzlerR , KarvonenA , KorhonenT , Van DammeP , BehreU , et al. RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe. Vaccine2009;28(2):345-51. VesikariT , ItzlerR , MatsonDO , SantoshamM , ChristieCD , CoiaM , et al. Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across three regions (11 countries). International Journal of Infectious Diseases2007;11(Suppl 2):29-35. VesikariT , KarvonenA , FerranteSA , CiarletM . Efficacy of the pentavalent rotavirus vaccine, RotaTeq(R), in Finnish infants up to 3 years of age: the Finnish Extension Study. European Journal of Pediatrics2010;169(11):1379-86. VesikariT , MatsonDO , DennehyP , Van DammeP , SantoshamM , RodriguezZ , et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. New England Journal of Medicine2006;354(1):23-33. ">TEQ Vesikari 2006b‐INT</a>). In April 2009, following clinical trials of Rotarix and RotaTeq in low‐ and middle‐income countries in Africa and Asia, the WHO Strategic Advisory Group of Experts (SAGE) on Immunization recommended "the inclusion of rotavirus vaccination of infants into all national immunization programmes", with a stronger recommendation for countries where "diarrhoeal deaths account for ≥ 10% of mortality among children aged &lt; 5 years" (<a href="./references#CD008521-bbs2-0169" title="SAGE. Meeting of the immunization Strategic Advisory Group of Experts, April 2009 - conclusions and recommendations. Weekly Epidemiological Record2009;84(23):220-36.">SAGE 2009</a>). Due to an age‐related risk of intussusception identified with RRV‐TV (<a href="./references#CD008521-bbs2-0153" title="MurphyTV , GargiulloPM , MassoudiMS , NelsonDB , JumaanAO , OkoroCA , et al. Intussusception among infants given an oral rotavirus vaccine. New England Journal of Medicine2001;344(8):564-72.">Murphy 2001</a>), SAGE recommended administering the first dose of Rotarix or RotaTeq to infants of six to 15 weeks of age, with the last dose administered before 32 weeks of age (<a href="./references#CD008521-bbs2-0169" title="SAGE. Meeting of the immunization Strategic Advisory Group of Experts, April 2009 - conclusions and recommendations. Weekly Epidemiological Record2009;84(23):220-36.">SAGE 2009</a>). In April 2012, SAGE relaxed the age‐restricted recommendation and advised to vaccinate "as soon as possible after the age of six weeks" because "the current age restrictions for the first dose (&lt; 15 weeks) and last dose (&lt; 32 weeks) are preventing vaccination of many vulnerable children" (<a href="./references#CD008521-bbs2-0158" title="PatelMM , ClarkAD , SandersonCF , TateJ , ParasharUD . Removing the age restrictions for rotavirus vaccination: a benefit-risk modeling analysis. PLOS Medicine2012;9(10):e1001330.">Patel 2012</a>; <a href="./references#CD008521-bbs2-0170" title="SAGE. Meeting of the immunization Strategic Advisory Group of Experts, April 2012 - conclusions and recommendations. Weekly Epidemiological Record2012;21(87):201-16.">SAGE 2012</a>). Rotavac and Rotasiil, which have been prequalified for use by the WHO, are nationally licensed in India and were recommended for use by SAGE in 2020 (<a href="./references#CD008521-bbs2-0185" title="World Health Organization. Meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization 5 -7 October 2020. www.who.int/docs/default-source/mca-documents/stage/2-4-nov-2020-meeting/stage-2-4-nov-2020-sage-oct-2020-meeting_short-summary_.pdf?sfvrsn=1ca0e652_5 (accessed 20 May 2021).">WHO 2020</a>). </p> </section> <section id="CD008521-sec-0019"> <h4 class="title">Performance of oral rotavirus vaccines by setting</h4> <p>Many orally administered vaccines, including rotavirus vaccines, have demonstrated lower immunogenicity and efficacy in low‐ and middle‐income countries in Africa and Asia compared to high‐income countries in North America, South America, and Europe (<a href="./references#CD008521-bbs2-0148" title="LevineMM . Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine. BMC Biology2010;8:129.">Levine 2010</a>). A systematic review demonstrated a correlation between lower vaccine efficacy against severe rotavirus diarrhoea, and high child mortality rates (<a href="./references#CD008521-bbs2-0137" title="Fischer WalkerC , BlackR . Rotavirus vaccine and diarrhea mortality: quantifying regional variation in effect size. BMC Public Health2011;11(Suppl 3):S16.">Fischer Walker 2011</a>). The reasons for reduced oral vaccine efficacy in countries with higher child mortality rates are unknown; factors may include interference by maternal antibody, environmental enteropathy, co‐administration with oral poliovirus vaccine, histoblood group antigen, diverse rotavirus strain types, micronutrient deficiencies, and altered gut microbiota (<a href="./references#CD008521-bbs2-0130" title="CzerkinskyC , HolmgrenJ . Vaccines against enteric infections for the developing world. Philosophical Transactions of the Royal Society of London2015;370(1671):pii: 20150142.">Czerkinsky 2015</a>; <a href="./references#CD008521-bbs2-0156" title="ParkerEPK , RamaniS , LopmanBA , ChurchJA ,  Iturriza-Gómara M, PrendergastAJ , et al. Causes of impaired oral vaccine efficacy in developing countries. Future Microbiology2018;13(1):97-118.">Parker 2018</a>). </p> </section> <section id="CD008521-sec-0020"> <h4 class="title">Outcomes of interest</h4> <p>The safety and efficacy of the licensed vaccines for the prevention of rotavirus gastroenteritis in infants have been assessed in several randomized controlled trials (RCTs) worldwide. The goal of this review is to systematically assess these trials and to evaluate vaccine efficacy against severe rotavirus diarrhoea and severe all‐cause diarrhoea, within the first year of life and up to two years of age. We also examine the occurrence of deaths and serious adverse events, including intussusception, to provide decision makers, clinicians, and caregivers with the relevant information to aid decisions about vaccine use. </p> </section> </section> <section id="CD008521-sec-0021"> <h3 class="title" id="CD008521-sec-0021">Why it is important to do this review</h3> <section id="CD008521-sec-0022"> <h4 class="title">Development of Cochrane systematic rotavirus vaccine reviews</h4> <p>The original Cochrane Review of rotavirus vaccines (<a href="./references#CD008521-bbs2-0191" title="Soares-WeiserK , GoldbergE , TamimiG , PitanOC , LeiboviciL . Rotavirus vaccine for preventing diarrhoea. Cochrane Database of Systematic Reviews2004, Issue 1. Art. No: CD002848. [DOI: 10.1002/14651858.CD002848.pub2]">Soares‐Weiser 2004</a>) examined vaccines in use and other vaccines, including those that were no longer in use or were in development. <a href="./references#CD008521-bbs2-0191" title="Soares-WeiserK , GoldbergE , TamimiG , PitanOC , LeiboviciL . Rotavirus vaccine for preventing diarrhoea. Cochrane Database of Systematic Reviews2004, Issue 1. Art. No: CD002848. [DOI: 10.1002/14651858.CD002848.pub2]">Soares‐Weiser 2004</a> concluded that more trials were needed before routine vaccine use could be recommended. An update in 2009 included a new search, revised inclusion criteria (only vaccines in use in children), and updated review methods and new authors. The review was updated again in 2010 with nine new studies (<a href="./references#CD008521-bbs2-0192" title="Soares-WeiserK , MacLehoseH , Ben-AharonI , GoldbergE , PitanF , CunliffeN . Vaccines for preventing rotavirus diarrhoea: vaccines in use. Cochrane Database of Systematic Reviews2010, Issue 5. Art. No: CD008521. [DOI: 10.1002/14651858.CD008521]">Soares‐Weiser 2010</a>). The 2010 version of the review concluded that Rotarix and RotaTeq are both effective vaccines for the prevention of rotavirus diarrhoea. Another update in February 2012 added a further nine new studies, GRADE ‘Summary of findings' tables and, again, new authors joined the team (<a href="./references#CD008521-bbs2-0193" title="Soares-Weiser K,  MacLehoseH ,  BergmanH ,  Ben-AharonI ,  NagpalS ,  GoldbergE ,  et al. Vaccines for preventing rotavirus diarrhoea: vaccines in use. Cochrane Database of Systematic Reviews2012, Issue 2. Art. No: CD008521. [DOI: 10.1002/14651858.CD008521.pub2]">Soares‐Weiser 2012a</a>). The November 2012 update included a new search, and major restructuring of analyses, including re‐evaluating primary outcomes in consultation with the WHO to reflect the observation that vaccine efficacy profiles are different in countries with different mortality rates (<a href="./references#CD008521-bbs2-0194" title="Soares-WeiserK , MacLehoseH , BergmanH , Ben-AharonI , NagpalS , GoldbergE , et al. Vaccines for preventing rotavirus diarrhoea: vaccines in use. Cochrane Database of Systematic Reviews2012, Issue 11. Art. No: CD008521. [DOI: 10.1002/14651858.CD008521.pub3]">Soares‐Weiser 2012b</a>). The previous update published in 2019 (<a href="./references#CD008521-bbs2-0195" title="Soares-WeiserK , BergmanH , HenschkeN , PitanF , CunliffeN . Vaccines for preventing rotavirus diarrhoea: vaccines in use. Cochrane Database of Systematic Reviews2019, Issue 10. Art. No: CD008521. [DOI: 10.1002/14651858.CD008521.pub4]">Soares‐Weiser 2019</a>) added a further 10 Rotarix and RotaTeq studies to the review and, for the first time, four studies of Rotavac. This update added another five studies of a new vaccine Rotasiil, that has been prequalified by the WHO since the previous version of the review (<a href="#CD008521-tbl-0009">Table 1</a>). </p> <div class="table" id="CD008521-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Prespecified changes for review update</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Protocol section</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Appraisal points</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Address here </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Background and research question</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>• Review and update background section, including supporting references to take account of any changes that may have occurred. This should include updating any new information and current policy debates on the topic. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Authors plan to update the Background section with any new relevant background information and references, but this will not have changed much since October 2019. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Inclusion criteria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>• Review current PICO(s) and amend in light of new knowledge.<br/>• Identify any changes in usual care standards.<br/>• Check for standardized core outcome sets, such as those developed in collaboration with the core outcome measures in effectiveness trials (COMET) initiative (<a href="http://www.comet-initiative.org/" target="_blank">www.comet-initiative.org</a>) or by guideline groups since the original review.<br/>• Check for any relevant patient reported outcomes to include subsequent to the original review.<br/>• Consider any new studies with less risk of bias that might warrant a stricter study design inclusion criteria (where the older version, when there was a dearth of evidence, included observational or quasi‐randomized comparisons). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Authors plan to amend the types of outcome measures list: </p> <p>1) remove immunogenicity outcomes because there is plenty of high‐certainty efficacy data, also for the new vaccines, and therefore no need to include immunogenicity outcomes for the objective of this review.  </p> <p>2) include 2<sup>nd</sup> year of life as a time point for primary efficacy outcomes (in addition to first year of life and up to two years).  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Methods</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>• Appraise and update the methods pending relevant methodological advancements or developments. For example, if there are new tools for assessing the risk of bias of individual studies or appraising the quality of a body of evidence (e.g. GRADE). </p> <p>• Update or include a summary of findings table, which is recommended for all systematic reviews, because it improves the clarity, understanding, and interpretation of the findings of a systematic review, and rapidly reduces the amount of time readers require to find key information. </p> <p>• Any new subanalysis needed.</p> <p>• Any substantive change in the review structure.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1) Authors plan to update the country mortality stratification using the 2019 UNICEF report on levels and trends in child mortality <a href="https://reliefweb.int/sites/reliefweb.int/files/resources/UN-IGME-Child-Mortality-Report-2019.pdf" target="_blank">https://reliefweb.int/sites/reliefweb.int/files/resources/UN-IGME-Child-Mortality-Report-2019.pdf</a>. Data and summary of findings tables will be stratified based on country under‐5 mortality: low‐mortality countries are those in the lowest quartile of under‐5 child mortality rates, medium‐mortality countries are those in the second quartile, and high‐mortality countries are those in the highest two quartiles. </p> <p>2) Authors plan to carry out subgroup analyses for virus P‐types (in addition to G‐types that have been assessed in the current review). </p> <p>3) Authors plan to use vaccine brand names (Rotarix, Rotasiil, RotaTeq, Rotavac with abbreviations rix, siil, teq, vac) since the previous way of naming the vaccines, based on number of strains, is no longer possible because the new vaccines have the same number of strains (one or five) as the old. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Submitted by the author team, and approved by the CIDG Editors 23 November 2020.</p> </div> </div> </section> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD008521-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD008521-sec-0023"></div> <p>To evaluate rotavirus vaccines prequalified by the WHO (Rotarix, RotaTeq, Rotasiil, and Rotavac) for their efficacy and safety in children. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD008521-sec-0024" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD008521-sec-0024"></div> <section id="CD008521-sec-0025"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD008521-sec-0026"> <h4 class="title">Types of studies</h4> <p>Randomized controlled trials (RCTs).</p> </section> <section id="CD008521-sec-0027"> <h4 class="title">Types of participants</h4> <p>Children (age as defined in the trials).</p> </section> <section id="CD008521-sec-0028"> <h4 class="title">Types of interventions</h4> <section id="CD008521-sec-0029"> <h5 class="title">Intervention</h5> <p>Rotavirus vaccines approved by the WHO vaccine prequalification programme (<a href="./references#CD008521-bbs2-0131" title="DellepianeN , WoodD . Twenty-five years of the WHO vaccines prequalification programme (1987-2012): lessons learned and future perspectives. Vaccine2015;33(1):52-61.">Dellepiane 2015</a>; <a href="./references#CD008521-bbs2-0186" title="World Health Organization. WHO prequalified vaccines. extranet.who.int/pqweb/vaccines/prequalified-vaccines (accessed 20 June 2021).">WHO 2021a</a>). </p> </section> <section id="CD008521-sec-0030"> <h5 class="title">Control</h5> <p>Placebo, no vaccination, or other vaccine.</p> </section> </section> <section id="CD008521-sec-0031"> <h4 class="title">Types of outcome measures</h4> <section id="CD008521-sec-0032"> <h5 class="title">Primary outcomes</h5> <p>We selected our primary outcome measures in consultation with the WHO, and stratified them according to low‐, medium‐, or high‐mortality rate, based on country under‐five mortality rates taken from the UNICEF report on levels and trends in child mortality (<a href="./references#CD008521-bbs2-0179" title="United Nations Inter-agency Group for Child Mortality Estimation (UN IGME). Levels &amp; trends in child mortality: report 2019, estimates developed by the United Nations Inter-agency Group for child mortality estimation. Available from unicef.org/reports/levels-and-trends-child-mortality-report-2019 (accessed prior to 12 October 2021).">UNICEF 2019</a>). Efficacy outcomes were collected for up to one year and up to two years follow‐up. In addition, the severe rotavirus diarrhoea outcome was collected for the second year of life. </p> <p> <ul id="CD008521-list-0001"> <li> <p>Rotavirus diarrhoea: severe (as defined in trial report)</p> </li> <li> <p>All‐cause diarrhoea: severe</p> </li> <li> <p>All‐cause death</p> </li> <li> <p>Serious adverse events (that are fatal, life‐threatening, or result in hospitalization)</p> </li> <li> <p>Intussusception</p> </li> </ul> </p> </section> <section id="CD008521-sec-0033"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD008521-list-0002"> <li> <p>Rotavirus diarrhoea: of any severity</p> </li> <li> <p>All‐cause diarrhoea (as defined in trial report)</p> </li> <li> <p>Rotavirus diarrhoea: requiring hospitalization</p> </li> <li> <p>All‐cause diarrhoea: requiring hospitalization</p> </li> <li> <p>Emergency department visit</p> </li> <li> <p>Hospital admission: all‐cause</p> </li> <li> <p>Reactogenicity (capacity to produce an adverse reaction, such as fever, diarrhoea, and vomiting) </p> </li> <li> <p>Adverse events that require discontinuation of vaccination schedule</p> </li> <li> <p>Dropouts</p> </li> </ul> </p> </section> </section> </section> <section id="CD008521-sec-0034"> <h3 class="title">Search methods for identification of studies</h3> <p>We attempted to identify all relevant trials regardless of language or publication status (published, unpublished, in press, and ongoing). </p> <section id="CD008521-sec-0035"> <h4 class="title">Electronic searches</h4> <p>For this review update, Dr Vittoria Lutje (Information Specialist, Cochrane Infectious Diseases Group) searched the following databases using the search terms and strategy described in Appendix 10. </p> <p> <ul id="CD008521-list-0003"> <li> <p>Cochrane Infectious Diseases Group Specialized Register (30 November 2020)</p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL), published in the Cochrane Library (2020, Issue 11) </p> </li> <li> <p>MEDLINE (via PubMed; 1966 to 30 November 2020)</p> </li> <li> <p>Embase (1974 to 30 November 2020)</p> </li> <li> <p>LILACS (1982 to 30 November 2020)</p> </li> <li> <p>Science Citation Index Expanded (SCI‐EXPANDED), Social Sciences Citation Index (SSCI), Conference Proceedings Citation Index‐Science (CPCI‐S), Conference Proceedings Citation Index‐Social Science &amp; Humanities (CPCI‐SSH), all via Web of Science, 1990‐30 November 2020. </p> </li> </ul> </p> </section> <section id="CD008521-sec-0036"> <h4 class="title">Searching other resources</h4> <p>We also searched the WHO International Clinical Trials Registry Platform (ICTRP) and the Clinicaltrials.gov Clinical Study Register (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>). </p> <p>We searched manufacturers' websites for clinical trial reports. We also checked the reference lists of relevant systematic reviews and included studies. </p> </section> </section> <section id="CD008521-sec-0037"> <h3 class="title" id="CD008521-sec-0037">Data collection and analysis</h3> <section id="CD008521-sec-0038"> <h4 class="title">Selection of studies</h4> <p>For this review update, we uploaded and screened references in <a href="https://www.evidencepartners.com/products/distillersr-systematic-review-software/" target="_blank">DistillerSR</a> online. Two review authors independently screened each title and abstract identified in the search. We retrieved full texts for potentially relevant references and two review authors again screened them independently, resolving disagreements by recourse to a third review author. We tabulated the excluded studies along with the reason for excluding them in the <a href="./references#CD008521-sec-0289" title="">Characteristics of excluded studies</a> tables. We ensured that data from each trial were entered only once in our review. In previous versions of this review, we had screened references in an EndNote database. </p> </section> <section id="CD008521-sec-0039"> <h4 class="title">Data extraction and management</h4> <p>We created Microsoft Excel forms for data collection, which were piloted and then revised after the review author team's discussion. For previous versions of this review, we had used Microsoft Word or Excel data collection forms. </p> <p>One review author extracted data and another review author cross‐checked them. All outcomes were dichotomous, and we extracted the total number of participants and the number of participants who experienced the event. We cross‐checked the extracted data to identify errors, resolving disagreements by referring to the trial report or by consulting a third review author. One review author entered data into Review Manager 5 for previous versions of this review (<a href="./references#CD008521-bbs2-0164" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">RevMan 2014</a>), or RevMan Web for this review update version (<a href="./references#CD008521-bbs2-0165" title="The Cochrane CollaborationReview Manager Web (RevMan Web). Version 3.11.1. The Cochrane Collaboration, 26 October 2021. Available at revman.cochrane.org.">RevMan Web 2021</a>). </p> <p>The use and mentioning of trade names in this review represents no endorsement of or advertisement for any product. The use of trade names was unavoidable as no generic names were identified for some of the vaccines evaluated here. </p> </section> <section id="CD008521-sec-0040"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors independently assessed the risks of bias of each trial, using the Cochrane Risk of bias tool (<a href="./references#CD008521-bbs2-0143" title="HigginsJP , AltmanDG , SterneJAC , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Cochrane, 2017. Available from www.training.cochrane.org/handbook/archive/v5.2.">Higgins 2017</a>). Based on the guidance of the Cochrane Risk of bias tool (<a href="./references#CD008521-bbs2-0143" title="HigginsJP , AltmanDG , SterneJAC , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Cochrane, 2017. Available from www.training.cochrane.org/handbook/archive/v5.2.">Higgins 2017</a>), we created a form to make judgements on the risk of bias for the rotavirus diarrhoea outcome measure in six domains: sequence generation; allocation concealment; blinding (of participants, personnel, and outcome assessors); incomplete outcome data; selective outcome reporting; and other potential sources of bias. We categorized these judgements as ‘low', ‘high', or ‘unclear' risk of bias. We resolved disagreements through discussion with a third review author. </p> <p>For the 2012 published version of this review, we asked for help from Dr Ana Maria Restrepo at the WHO Initiative for Vaccine Research, who contacted the vaccine manufacturers GlaxoSmithKline (Rotarix) and Merck (RotaTeq), who were involved in designing and funding most of the included trials. We provided them with an Excel spreadsheet with specific details of each trial that would impact on the assessment of risk of bias. We received details from Merck (RotaTeq) (see <a href="./references#CD008521-sec-0288" title="">Characteristics of included studies</a> for details). For the 2019 review update, we matched most of the previously‐included Rotarix studies to the full clinical trial reports available on the manufacturer's website (<a href="https://www.gsk-clinicalstudyregister.com/" target="_blank">www.gsk-clinicalstudyregister.com</a>). More details were available in these trial reports than in the published studies, that were helpful in assessing the risks of bias for these studies. </p> </section> <section id="CD008521-sec-0041"> <h4 class="title">Measures of treatment effect</h4> <p>We analysed dichotomous data of cases by calculating the risk ratio (RR) for each trial (expressed using blue squares in forest plots) with the uncertainty in each result expressed using 95% confidence intervals (CIs). For dichotomous data of events that could occur more than once in one participant, we calculated the rate ratio (expressed using red squares in forest plots) on the logarithmic scale using the generic inverse variance method (see <a href="#CD008521-sec-0046">Data synthesis</a> for more details). For outcomes that included cluster‐RCTs we calculated risk ratios (expressed using red squares in forest plots) using the generic inverse variance method (see <a href="#CD008521-sec-0042">Unit of analysis issues</a> for more details). </p> </section> <section id="CD008521-sec-0042"> <h4 class="title">Unit of analysis issues</h4> <p>When trials had multiple treatment arms and we considered it suitable, we grouped the trial arms. We excluded irrelevant trial arms. </p> <p>We pooled cluster‐RCT data that had been adjusted for clustering with data from trials that randomly assigned individuals (individual‐RCTs). For outcomes that included cluster‐RCTs, we pooled risk ratios on the logarithmic scale with their standard errors using the generic inverse variance method (16.3.3. in <a href="./references#CD008521-bbs2-0142" title="HigginsJP , DeeksJJ , AltmanDG , editor(s). Chapter 16: Special topics in statistics. In: Higgins JP, Green S, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.2.">Higgins 2011</a>). When the results of a cluster‐RCT had not been adjusted for clustering, we imputed the clustering effect (intra‐cluster correlation coefficient (ICC)) from another study, and performed sensitivity analyses excluding these studies. </p> </section> <section id="CD008521-sec-0043"> <h4 class="title">Dealing with missing data</h4> <p>We undertook a complete‐case analysis (the number analysed) and an intention‐to‐treat analysis when data were available. </p> </section> <section id="CD008521-sec-0044"> <h4 class="title">Assessment of heterogeneity</h4> <p>We initially assessed heterogeneity in the results of the trials by inspecting the graphical presentations and by calculating the Chi<sup>2</sup> test of heterogeneity. However, we were aware of the fact that the Chi<sup>2</sup> test has a poor ability to detect statistically significant heterogeneity among studies. We therefore also quantified the impact of heterogeneity in the meta‐analysis using a measure of the degree of inconsistency in the studies' results (<a href="./references#CD008521-bbs2-0141" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency is preferable to testing for heterogeneity in meta-analysis. BMJ2003;327(7414):557-60.">Higgins 2003</a>). This measure (the I<sup>2</sup> statistic) describes the percentage of total variation across studies that are due to heterogeneity rather than to the play of chance (<a href="./references#CD008521-bbs2-0141" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency is preferable to testing for heterogeneity in meta-analysis. BMJ2003;327(7414):557-60.">Higgins 2003</a>). The I<sup>2</sup> statistic values lie between 0% and 100%, and a simplified categorization of heterogeneity could be low, moderate, and high for I<sup>2</sup> statistic values of 25%, 50%, and 75% respectively (<a href="./references#CD008521-bbs2-0141" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency is preferable to testing for heterogeneity in meta-analysis. BMJ2003;327(7414):557-60.">Higgins 2003</a>). </p> </section> <section id="CD008521-sec-0045"> <h4 class="title">Assessment of reporting biases</h4> <p>If 10 or more studies were included in an outcome, we examined a funnel plot for the primary outcome (severe rotavirus diarrhoea), estimating the precision of trials (plotting the RR against the standard error (SE) of the log of RR) to estimate potential asymmetry. </p> </section> <section id="CD008521-sec-0046"> <h4 class="title">Data synthesis</h4> <p>We stratified all analyses by the type of vaccine, Rotarix, RotaTeq, Rotasiil, or Rotavac. Subsequently, we grouped all outcomes in the meta‐analyses according to the time point when the outcome was measured or the number of rotavirus seasons, or both, as follows: less than two months; up to one year (one rotavirus season); up to two years (up to two rotavirus seasons); and up to three years (three rotavirus seasons). For severe rotavirus diarrhoea, we also reported on cases during the second year of life (or during the second rotavirus season). If data were available for more than one time point, we used the number of completely vaccinated children for each time point in the trial. </p> <p>For the current update, we stratified each primary outcome (rotavirus diarrhoea, all‐cause diarrhoea, all‐cause death, all serious adverse events, and intussusception) and selected secondary efficacy outcomes (rotavirus diarrhoea and all‐cause diarrhoea of any severity, and all‐cause hospitalization) by country under‐five mortality rates taken from the UNICEF report on levels and trends in child mortality (<a href="./references#CD008521-bbs2-0179" title="United Nations Inter-agency Group for Child Mortality Estimation (UN IGME). Levels &amp; trends in child mortality: report 2019, estimates developed by the United Nations Inter-agency Group for child mortality estimation. Available from unicef.org/reports/levels-and-trends-child-mortality-report-2019 (accessed prior to 12 October 2021).">UNICEF 2019</a>), as follows: </p> <p> <ul id="CD008521-list-0004"> <li> <p>Low‐mortality countries: those in the lowest quartile of under‐five child mortality rates  </p> </li> <li> <p>Medium‐mortality countries: those in the second quartile of under‐five child mortality rates  </p> </li> <li> <p>High‐mortality countries: those in the highest two quartiles of under‐five child mortality rates </p> </li> </ul> </p> <p>We used a random‐effects model for all meta‐analyses.</p> <p>We included separate analyses for cases of diarrhoea (e.g. a child who has diarrhoea regardless of the number of episodes) and episodes (i.e. one child can experience more than one episode), where data permitted. We combined episodes using the rate ratio in the logarithmic scale and SE, with the uncertainty in each result being expressed using a 95% CI (9.4.8. in <a href="./references#CD008521-bbs2-0142" title="HigginsJP , DeeksJJ , AltmanDG , editor(s). Chapter 16: Special topics in statistics. In: Higgins JP, Green S, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.2.">Higgins 2011</a>). </p> </section> <section id="CD008521-sec-0047"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>In addition to stratifying the results by country‐based low‐, medium‐, or high‐mortality, we planned to perform subgroup analyses to assess the impact of the following possible sources of heterogeneity for any of the included vaccines: vaccine protection against specific rotavirus serotypes; and vaccination of special groups, including immunocompromised (such as HIV‐infected) children and children with malnutrition. In previous versions of this review (<a href="./references#CD008521-bbs2-0192" title="Soares-WeiserK , MacLehoseH , Ben-AharonI , GoldbergE , PitanF , CunliffeN . Vaccines for preventing rotavirus diarrhoea: vaccines in use. Cochrane Database of Systematic Reviews2010, Issue 5. Art. No: CD008521. [DOI: 10.1002/14651858.CD008521]">Soares‐Weiser 2010</a>; <a href="./references#CD008521-bbs2-0193" title="Soares-Weiser K,  MacLehoseH ,  BergmanH ,  Ben-AharonI ,  NagpalS ,  GoldbergE ,  et al. Vaccines for preventing rotavirus diarrhoea: vaccines in use. Cochrane Database of Systematic Reviews2012, Issue 2. Art. No: CD008521. [DOI: 10.1002/14651858.CD008521.pub2]">Soares‐Weiser 2012a</a>), we also analysed vaccine effect according to each study's country income, use of other childhood vaccines, number of doses administered, source of funding, and whether infants were born prematurely or were breast‐ or formula‐fed. These subgroup analyses did not show any differences, and were not presented in subsequent updates of this review; they can be found in <a href="./references#CD008521-bbs2-0192" title="Soares-WeiserK , MacLehoseH , Ben-AharonI , GoldbergE , PitanF , CunliffeN . Vaccines for preventing rotavirus diarrhoea: vaccines in use. Cochrane Database of Systematic Reviews2010, Issue 5. Art. No: CD008521. [DOI: 10.1002/14651858.CD008521]">Soares‐Weiser 2010</a> and <a href="./references#CD008521-bbs2-0193" title="Soares-Weiser K,  MacLehoseH ,  BergmanH ,  Ben-AharonI ,  NagpalS ,  GoldbergE ,  et al. Vaccines for preventing rotavirus diarrhoea: vaccines in use. Cochrane Database of Systematic Reviews2012, Issue 2. Art. No: CD008521. [DOI: 10.1002/14651858.CD008521.pub2]">Soares‐Weiser 2012a</a>. </p> <p>To get a more stable estimate for intussusception, which is a very rare event, we also included a post hoc subgroup analysis where we analysed the risk of intussusception with any vaccine compared with placebo by country mortality setting and overall (<a href="#CD008521-tbl-0010">Table 2</a>).  </p> <div class="table" id="CD008521-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Post hoc subgroup analysis: Intussusception combining all vaccines</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Setting</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Illustrative comparable risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Number of participants</b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>RR (95% CI)</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Assumed risk</b> <br/><b>Placebo</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Corresponding risk </b> <br/><b>Rotavirus vaccine</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Low‐mortality countries</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 per 10,000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 per 10,000<br/>(3 to 9) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>94,698 <br/>(19 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.87 (0.50 to 1.54)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>1 fewer per 10,000<br/>(from 3 fewer to 3 more) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Medium‐mortality countries</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 per 10,000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 per 10,000<br/>(3 to 8) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>79,622<br/>(8 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.77 (0.43 to 1.40)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>1 fewer per 10,000<br/>(from 3 fewer to 2 more) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>High‐mortality countries</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 per 10,000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 per 10,000<br/>(3 to 15) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>38,316<br/>(16 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>1.04 (0.49 to 2.25)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>0 fewer per 10,000<br/>(from 3 fewer to 8 more) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>All settings</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 per 10,000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 per 10,000<br/>(4 to 7) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>212,636<br/>(43 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.87 (0.61 to 1.25)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>1 fewer per 10,000<br/>(from 2 fewer to 1 more) </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>*The basis for the <b>assumed risk</b> is the control group risk across studies included in the meta‐analysis. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RCT</b> : randomized controlled trial; <b>RR:</b> risk ratio </p> </div> </div> </section> <section id="CD008521-sec-0048"> <h4 class="title">Sensitivity analysis</h4> <p>We conducted sensitivity analyses excluding cluster‐randomized studies.</p> <p>We also planned to conduct sensitivity analyses for the primary outcomes according to allocation concealment (high, low, and unclear risk of bias) for outcomes in which data could not be pooled because of significant heterogeneity (I<sup>2</sup> statistic &gt; 75%). </p> </section> <section id="CD008521-sec-0049"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We interpreted the findings of this review using the GRADE approach (<a href="./references#CD008521-bbs2-0172" title="SchünemannHJ , OxmanAD , VistGE , HigginsJP , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Cochrane, 2017. Available from training.cochrane.org/handbook/archive/v5.2.">Schünemann 2017</a>), and we used GRADE profiler (<a href="./references#CD008521-bbs2-0139" title="McMaster University (developed by Evidence Prime)GRADEpro GDT. Version accessed before 09 October 2018. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. Available at gradepro.org.">GRADE 2004</a>) to import data from RevMan 5 (<a href="./references#CD008521-bbs2-0164" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">RevMan 2014</a>) to create summary of findings tables. These tables provide outcome‐specific information concerning the overall certainty of evidence from each included study in the comparison, the magnitude of effect of the interventions examined, and the sum of available data on all outcomes we rated as important to patient care and decision making, and is reflected as follows: high certainty ("vaccine prevents...."); moderate certainty ("vaccine probably prevents..."); low certainty ("vaccine may prevent...."); and very low certainty ("we do not know whether or not the vaccine prevents...."). </p> <p>We selected primary outcomes, all stratified by vaccine and high or low country mortality, for inclusion in the summary of findings tables: severe rotavirus diarrhoea at up to one year and up to two years follow‐up; severe all‐cause diarrhoea at up to one year and up to two years follow‐up; all‐cause death; serious adverse events; and intussusception. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD008521-sec-0050" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD008521-sec-0050"></div> <section id="CD008521-sec-0051"> <h3 class="title">Description of studies</h3> <section id="CD008521-sec-0052"> <h4 class="title">Results of the search</h4> <p>The update search in November 2020 identified 300 records after de‐duplication and an additional five studies that were retrieved from the excluded studies list. We screened 305 records and considered 282 to be irrelevant. We reviewed the full text of 23 studies. We excluded 18 studies for this update. Together with the previously 31 excluded studies, there are now 49 excluded studies in this review. The current update of the review includes 60 independent trials (see <a href="./references#CD008521-sec-0288" title="">Characteristics of included studies</a>), five of which are new to this update (<a href="./references#CD008521-bbs2-0039" title="ColdironME , GuindoO , MakarimiR , SoumanaI , Matar SeckA , GarbaS , et al. Safety of a heat-stable rotavirus vaccine among children in Niger: data from a phase 3, randomized, double-blind, placebo-controlled trial. Vaccine2018;36(25):3674-80. IsanakaS , DjiboA , GraisRF . Heat-stable oral rotavirus vaccine. New England Journal of Medicine2017;377(3):302. IsanakaS , GuindoO , LangendorfC , GraisR , ROSE Trial Study Team. Efficacy and safety of a low-cost, heat-stable oral roatvirus vaccine agains severe rotavirus gastroenteritis in Niger. American Journal of Tropical Medicine and Hygiene2017;95(Suppl 5):242. IsanakaS , GuindoO , LangendorfC , Matar SeckA , PlikaytisBD , Sayinzoga-MakombeN , et al. Efficacy of a low-cost, heat-stable oral Rotavirus vaccine in Niger. New England Journal of Medicine2017;376(12):1121-30. IsanakaS , LangendorfC , McNealMM , MeyerN , PlikaytisB , GarbaS , et al. Rotavirus vaccine efficacy up to 2 years of age and against diverse circulating rotavirus strains in Niger: a randomized controlled clinical trial (unpublished manuscript received via email correspondence from Rebecca Grais to Nicholas Henschke on 19 August 2020). data on file. NCT02145000. Efficacy and safety of a pentavalent Rotavirus vaccine (BRV-PV) against severe rotavirus gastroenteritis in Niger (ROSE). clinicaltrials.gov/ct2/show/NCT02145000 (first received 20 May 2014). ">SIIL Isanaka 2017‐NER</a>; <a href="./references#CD008521-bbs2-0040" title="CTRI/2013/05/003667. A clinical trial to study the effect and safety of Rotavirus vaccine against severe Rotavirus gastroenteritis in healthy Indian Infants. www.ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=5518&amp;EncHid=&amp;modid=&amp;compid=%27,%275518det%27 (first received 23 May 2013). KulkarniPS , DesaiS , TewariT , KawadeA , GoyalN , GargBS , et al. A randomized phase III clinical trial to assess the efficacy of a bovine-human reassortant pentavalent rotavirus vaccine in Indian infants. Vaccine2017;35(45):6228-37. NCT02133690. A clinical trial to study the effect and safety of Rotavirus vaccine against severe rotavirus gastroenteritis in healthy Indian infants. clinicaltrials.gov/ct2/show/NCT02133690 (first received 6 May 2014). ">SIIL Kulkarni 2017‐IND</a>; <a href="./references#CD008521-bbs2-0041" title="CTRI/2009/091/000821. A randomized, double-blind, placebo controlled study to assess the safety and tolerability of rotaVac vaccine (live attenuated bovine-human (UK) reassortant pentavalent rotavirus vaccine). ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=987&amp;EncHid=&amp;modid=&amp;compid=%27,%27987det%27 (first received 15 October 2009). Zade JK,  KulkarniPS ,  Desai SA,  Sabale RN,  Naik SP,  Dhere RM. Bovine rotavirus pentavalent vaccine development in India. Vaccine2014;32(Suppl 1):A124-8. [DOI: 10.1016/j.vaccine.2014.03.003]">SIIL Zade 2014‐INDa</a>; <a href="./references#CD008521-bbs2-0042" title="CTRI/2009/091/000821. A randomized, double-blind, placebo controlled study to assess the safety and tolerability of RotaVac vaccine (live attenuated bovine-human (UK) reassortant pentavalent rotavirus vaccine). ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=987&amp;EncHid=&amp;modid=&amp;compid=%27,%27987det%27 (first received 15 October 2009). Zade JK,  KulkarniPS ,  Desai SA,  Sabale RN,  Naik SP,  Dhere RM. Bovine rotavirus pentavalent vaccine development in India. Vaccine2014;32(Suppl 1):A124-8. [DOI: 10.1016/j.vaccine.2014.03.003]">SIIL Zade 2014‐INDb</a>; <a href="./references#CD008521-bbs2-0043" title="CTRI/2010/091/003064. A randomized, double-blind, placebo controlled study to assess safety and tolerability of RotaVac vaccine (live attenuated bovine-human (UK) reassortant pentavalent rotavirus vaccine). ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=2458&amp;EncHid=&amp;modid=&amp;compid=%27,%272458det%27 (first received 4 January 2011). Zade JK,  KulkarniPS ,  Desai SA,  Sabale RN,  Naik SP,  Dhere RM. Bovine rotavirus pentavalent vaccine development in India. Vaccine2014;32(Suppl 1):A124-8. [DOI: 10.1016/j.vaccine.2014.03.003]">SIIL Zade 2014‐INDc</a>). </p> </section> <section id="CD008521-sec-0053"> <h4 class="title">Included studies</h4> <p>The 60 included trials enrolled about 228,233 participants (approximate number, as some trials provided only the number evaluable), and each trial compared a rotavirus vaccine with a placebo or no intervention. The vaccines tested were Rotarix (36 trials reported in 171 publications or reports; 119,114 participants), RotaTeq (15 trials reported in 60 publications or reports; 88,934 participants), Rotasiil (five trials reported in 11 publications or reports; 11,753 participants), and Rotavac (four trials reported in 13 publications or reports; 8432 participants). </p> <p>The trials were conducted in Africa, Asia, Europe, and the Americas, and the location can be identified in the study reference: AF, Africa; AS, Asia; EU, Europe; INT, several international locations; LA, Latin America; NA, North America; or country three‐letter acronym according to ISO 3166‐1 Alpha‐3 (e.g. BGD for Bangladesh) from <a href="http://www.all-acronyms.com/special/countries_acronyms_and_abbreviations" target="_blank">www.all-acronyms.com/special/countries_acronyms_and_abbreviations</a>, if the study was conducted in a single country. </p> <section id="CD008521-sec-0054"> <h5 class="title">1. Rotarix</h5> <p>The 36 Rotarix trials were published between 1998 and 2017. Five of the trials are unpublished and were located on the GlaxoSmithKline website through <a href="http://www.clinicalstudyresults.org" target="_blank">clinicalstudyresults.org</a> or <a href="http://clinicaltrials.gov" target="_blank">clinicaltrials.gov</a>. One trial (<a href="./references#CD008521-bbs2-0017" title="CunliffeNA , WitteD , NgwiraBM , ToddS , BostockNJ , TurnerAM , et al. Efficacy of human rotavirus vaccine against severe gastroenteritis in Malawian children in the first two years of life: a randomized, double-blind, placebo controlled trial. Vaccine2012;30(Suppl 1):A36-43. MadhiSA , CunliffeNA , SteeleD , WitteD , KirstenM , LouwC , et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. New England Journal of Medicine2010;362(4):289-98. MadhiSA , KirstenM , LouwC , BosP , AspinallS , BouckenoogheA , et al. Efficacy and immunogenicity of two or three dose rotavirus-vaccine regimen in South African children over two consecutive rotavirus seasons: a randomized, double-blind, placebo-controlled trial. Vaccine2012;30(Suppl 1):A44-51. NCT00241644. Multi-center study to assess the efficacy, safety and immunogenicity of 2 or 3 doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations in healthy infants. clinicaltrials.gov/show/NCT00241644 (first received 19 October 2005). NCT00598468. Multi-center study to assess efficacy, safety &amp; immunogenicity of 2 or 3 doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations in healthy infants. clinicaltrials.gov/show/NCT00598468 (first received 19 October 2005). SteeleAD , NeuzilKM , CunliffeNA , MadhiSA , BosP , NgwiraB , et al. Human rotavirus vaccine Rotarix provides protection against diverse circulating rotavirus strains in African infants: a randomized controlled trial. BMC Infectious Diseases2012;12:213. ">RIX Madhi 2010‐AF</a>) provided country‐specific data for efficacy outcomes but not for safety outcomes, and was consequently split into <a href="./references#CD008521-bbs2-0018" title="CunliffeNA , WitteD , NgwiraBM , ToddS , BostockNJ , TurnerAM , et al. Efficacy of human rotavirus vaccine against severe gastroenteritis in Malawian children in the first two years of life: a randomized, double-blind, placebo controlled trial. Vaccine2012;30(Suppl 1):A36-43. MadhiSA , CunliffeNA , SteeleD , WitteD , KirstenM , LouwC , et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. New England Journal of Medicine2010;362(4):289-98. NCT00241644. Multi-center study to assess the efficacy, safety and immunogenicity of 2 or 3 doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations in healthy infants. clinicaltrials.gov/show/NCT00241644 (first received 19 October 2005). NCT00598468. Multi-center study to assess efficacy, safety &amp; immunogenicity of 2 or 3 doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations in healthy infants. clinicaltrials.gov/show/NCT00598468 (first received 19 October 2005). SteeleAD , NeuzilKM , CunliffeNA , MadhiSA , BosP , NgwiraB , et al. Human rotavirus vaccine Rotarix provides protection against diverse circulating rotavirus strains in African infants: a randomized controlled trial. BMC Infectious Diseases2012;12:213. ">RIX Madhi 2010‐MWI</a> and <a href="./references#CD008521-bbs2-0019" title="MadhiSA , CunliffeNA , SteeleD , WitteD , KirstenM , LouwC , et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. New England Journal of Medicine2010;362(4):289-98. MadhiSA , KirstenM , LouwC , BosP , AspinallS , BouckenoogheA , et al. Efficacy and immunogenicity of two or three dose rotavirus-vaccine regimen in South African children over two consecutive rotavirus seasons: a randomized, double-blind, placebo-controlled trial. Vaccine2012;30(Suppl 1):A44-51. NCT00241644. Multi-center study to assess the efficacy, safety and immunogenicity of 2 or 3 doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations in healthy infants. clinicaltrials.gov/show/NCT00241644 (first received 19 October 2005). NCT00598468. Multi-center study to assess efficacy, safety &amp; immunogenicity of 2 or 3 doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations in healthy infants. clinicaltrials.gov/show/NCT00598468 (first received 19 October 2005). SteeleAD , NeuzilKM , CunliffeNA , MadhiSA , BosP , NgwiraB , et al. Human rotavirus vaccine Rotarix provides protection against diverse circulating rotavirus strains in African infants: a randomized controlled trial. BMC Infectious Diseases2012;12:213. ">RIX Madhi 2010‐ZAF</a> for the Malawi‐ and South Africa‐specific data. Twenty‐five trials enrolled around 500 participants or fewer, three trials enrolled around 1000 participants, seven trials enrolled between 2155 and 12,318 participants, and one large trial enrolled 63,225 participants. Most children were aged between one and three months at the time of the first vaccination. </p> <section id="CD008521-sec-0055"> <h6 class="title">Population</h6> <p>Most trials included healthy infants. Two trials included HIV‐infected or ‐exposed infants (<a href="./references#CD008521-bbs2-0017" title="CunliffeNA , WitteD , NgwiraBM , ToddS , BostockNJ , TurnerAM , et al. Efficacy of human rotavirus vaccine against severe gastroenteritis in Malawian children in the first two years of life: a randomized, double-blind, placebo controlled trial. Vaccine2012;30(Suppl 1):A36-43. MadhiSA , CunliffeNA , SteeleD , WitteD , KirstenM , LouwC , et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. New England Journal of Medicine2010;362(4):289-98. MadhiSA , KirstenM , LouwC , BosP , AspinallS , BouckenoogheA , et al. Efficacy and immunogenicity of two or three dose rotavirus-vaccine regimen in South African children over two consecutive rotavirus seasons: a randomized, double-blind, placebo-controlled trial. Vaccine2012;30(Suppl 1):A44-51. NCT00241644. Multi-center study to assess the efficacy, safety and immunogenicity of 2 or 3 doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations in healthy infants. clinicaltrials.gov/show/NCT00241644 (first received 19 October 2005). NCT00598468. Multi-center study to assess efficacy, safety &amp; immunogenicity of 2 or 3 doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations in healthy infants. clinicaltrials.gov/show/NCT00598468 (first received 19 October 2005). SteeleAD , NeuzilKM , CunliffeNA , MadhiSA , BosP , NgwiraB , et al. Human rotavirus vaccine Rotarix provides protection against diverse circulating rotavirus strains in African infants: a randomized controlled trial. BMC Infectious Diseases2012;12:213. ">RIX Madhi 2010‐AF</a>; <a href="./references#CD008521-bbs2-0029" title="EUCTR2015-001484-39. A phase II study to assess the safety and immunogenicity of GlaxoSmithKline Biologicals rotavirus vaccine, RIX4414 when administered to HIV infected infants in South Africa. www.clinicaltrialsregister.eu/ctr-search/trial/2015-001484-39/results (first received 11 June 2015). GlaxoSmithKline[444563-022]. A phase II, double-blind, randomized, placebo-controlled study to assess the safety, reactogenicity and immunogenicity of three doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine. www.gsk-studyregister.com/study/6790 (accessed 12 December 2018). ISRCTN11877362. A phase II, double-blind, randomised, placebo-controlled study to assess the safety, reactogenicity and immunogenicity of three doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine (RIX4414 at 106.5 CCID50) administered to human immunodeficiency virus (HIV) infected infants at 6, 10 and 14 weeks of age in South Africa. www.controlled-trials.com/ISRCTN11877362 (first received 25 November 2005). NCT00263666. A study of safety, reactogenicity and immunogenicity of HRV vaccine in HIV infected infants in South Africa. clinicaltrials.gov/ct2/show/results/NCT00263666 (first received on 9 December 2005). SteeleAD ,  MadhiSA ,  LouwCE ,  BosP ,  TumboJM ,  WernerCM ,  et al. Safety, reactogenicity, and immunogenicity of human rotavirus vaccine RIX4414 in human immunodeficiency virus-positive infants in South Africa. Pediatric Infectious Diseases Journal2011;30(2):125-30. ">RIX Steele 2010a‐ZAF</a>), one trial included premature infants (<a href="./references#CD008521-bbs2-0022" title="GlaxoSmithKline[106481-054]. Phase IIIb, double blind, randomised, placebo-controlled, multi-country/centre, study to assess safety, reactogenicity &amp; immunogenicity of 2 doses of GSK Biologicals' oral live attenuated Human Rotavirus (HRV) vaccine in pre-term infants. www.gsk-studyregister.com/study/3064 (accessed 12 December 2018). NCT00420745. Phase IIIb, double blind, randomised, placebo-controlled, multi-country/centre, study to assess safety, reactogenicity &amp; immunogenicity of 2 doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine in pre-term infants. clinicaltrials.gov/show/NCT00420745 (first received 11 January 2007). OmenacaF , SarlangueJ , SzenbornL , NogueiraM , SuryakiranPV , SmolenovIV , et al. Safety, reactogenicity and immunogenicity of the human rotavirus vaccine in preterm European infants: a randomized phase IIIb study. Pediatric Infectious Disease Journal2012;31(5):487-93. ">RIX Omenaca 2012‐EU</a>), and one trial included children aged two to six years (<a href="./references#CD008521-bbs2-0014" title="GlaxoSmithKline[113552-073]. Reactogenicity and safety of a single dose of GlaxoSmithKline (GSK) Biologicals' human rotavirus (HRV) vaccine (444563) in healthy children. www.gsk-studyregister.com/study/3957 (accessed 12 December 2018). LiRC , LiYP , MoZJ , LuoD , HuangT , KongJL , et al. Reactogenicity and safety of a liquid human rotavirus vaccine (RIX4414) in healthy adults, children and infants in China: randomized, double-blind, placebo-controlled phase I studies. Human Vaccines and Immunotherapeutics2013;9(8):1638-42. NCT01086436. Study to evaluate the safety of Rotarix in Chinese children. clinicaltrials.gov/ct2/show/NCT01086436 (first received on 15 March 2010). ">RIX Li 2013a‐CHN</a>). </p> </section> <section id="CD008521-sec-0056"> <h6 class="title">Outcome measures</h6> <p>Each trial reported on one or more of the outcome measures specified for this review (see <a href="./appendices#CD008521-sec-0270">Appendix 1</a>). We included data on participants requiring medical visits, as this was reported in some trials and is a similar outcome measure to participants requiring hospitalization. </p> <p>Twenty‐three trials were safety studies, reporting mainly safety outcomes (e.g. serious adverse events and reactogenicity). Eleven of these trials also reported efficacy outcomes (e.g. rotavirus diarrhoea) with a follow‐up of up to two months. Two trials reported on efficacy or effectiveness but not safety (<a href="./references#CD008521-bbs2-0005" title='ColgateER , HaqueR , DicksonDM , CarmolliMP , MychaleckyjJC , NayakU , et al. Delayed dosing of oral rotavirus vaccine demonstrates decreased risk of rotavirus gastroenteritis associated with serum zinc: a randomized controlled trial. Clinical Infectious Diseases2016;63(5):634-41. KirkpatrickBD , ColgateER , MychaleckyjJC , HaqueR , DicksonDM , CarmolliMP , et al. The "Performance of Rotavirus and Oral Polio Vaccines in Developing Countries" (PROVIDE) study: description of methods of an interventional study designed to explore complex biologic problems. American Journal of Tropical Medicine and Hygiene2015;92(4):744-51. LeeB , DicksonDM , DeCampAC , ColgateER , DiehlSA , UddinMI , et al. Histo-blood group antigen phenotype determines susceptibility to genotype-specific rotavirus infections and impacts measures of rotavirus vaccine efficacy. Journal of Infectious Diseases2018;217(9):1399-407. LeeB , DiehlSA , ColgateER , DicksonDM , UddinMI , SharminS , et al. Lewis antigen and secretor status mediate susceptibility to p-genotype specific rotavirus infections but do not affect rotavirus vaccine performance among infants in Bangladesh. American Journal of Tropical Medicine and Hygiene2017;97:226. NCT01375647. Exploration of the biologic basis for underperformance of oral polio and rotavirus vaccines in Bangladesh PROVIDE. clinicaltrials.gov/show/NCT01375647 (first received 17 June 2011). RogawskiET , Platts-MillsJA , ColgateER , HaqueR , ZamanK , PetriWA , et al. Quantifying the impact of natural immunity on rotavirus vaccine efficacy estimates: a clinical trial in Dhaka, Bangladesh (PROVIDE) and a simulation study. Journal of Infectious Diseases2018;217(6):861-8. '>RIX Colgate 2016‐BGD</a>; <a href="./references#CD008521-bbs2-0038" title="ZamanK , SackDA , NeuzilKM , YunusM , MoultonLH , SugimotoJD , et al. Effectiveness of a live oral human rotavirus vaccine after programmatic introduction in Bangladesh: a cluster-randomized trial. PLOS Medicine2017;14(4):e1002282. ">RIX Zaman 2017‐BGD</a>). The trials varied in the length of follow‐up, but in general the trials that specified efficacy outcome measures had longer follow‐up times (<a href="./appendices#CD008521-sec-0270">Appendix 1</a>). </p> <p>As shown in <a href="./appendices#CD008521-sec-0271">Appendix 2</a>, rotavirus diarrhoea (of any severity) was the most common efficacy outcome reported (by 23 trials); 14 trials reported on severe rotavirus diarrhoea, and 10 reported on rotavirus diarrhoea requiring hospitalization. Data on all‐cause diarrhoea were provided by 17 trials, and severe all‐cause diarrhoea by nine trials. Most reported all‐cause death and dropouts, but other efficacy outcomes were reported by few trials. </p> <p>For safety outcomes (<a href="./appendices#CD008521-sec-0272">Appendix 3</a>), 29 trials reported on reactogenicity, all but four trials reported on serious adverse events, and 24 reported on adverse events leading to discontinuation of the intervention. </p> </section> <section id="CD008521-sec-0057"> <h6 class="title">Location</h6> <p>Early trials were conducted in North America and Europe, but since 2005 trials have also been conducted in Asia (Bangladesh, China, India, Japan, Philippines, South Korea, Singapore, Thailand, Vietnam; 17 trials), Latin America (Argentina, Brazil, Chile, Colombia, Dominican Republic, Honduras, Mexico, Nicaragua, Panama, Peru, Venezuela; six trials), and Africa (South Africa, Malawi; four trials); see <a href="./appendices#CD008521-sec-0273">Appendix 4</a>. Most trials had multiple sites, often in several countries; <a href="./references#CD008521-bbs2-0034" title="VesikariT , et al. Human rotavirus vaccine Rotarix is highly efficacious in Europe. In: 24th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); 2006 June 15-18; Basel, Switzerland. 2006. [Not available for review]VesikariT , et al. Rotarix, an oral human Rotavirus vaccine, is highly immunogenic in healthy infants from 6 European countries. In: 24th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); 2006 June 15-18; Basel, Switzerland. 2006. [Not available for review]GlaxoSmithKline[102247-036]. A phase IIIb, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants in co-administration with specific childhood vaccinations [This summary presents results from the first efficacy period] [102247-036]. www.gsk-studyregister.com/study/2669 (accessed 12 December 2018). GlaxoSmithKline[102247-036-Annex]. A phase IIIb, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants in co-administration with specific childhood vaccinations [This summary presents results for the second and combined efficacy periods]. www.gsk-studyregister.com/study/2669 (accessed 12 December 2018). GlaxoSmithKline[102247-036-Yr3]. A phase IIIb, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants in co-administration with specific childhood vaccinations [A phase IIIb open study to assess the long-term efficacy and safety of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine approximately three years after vaccination in healthy infants aged 6-12 weeks at the time of first vaccination in the Rota-036 study (eTrack No.102247) in Finland]. www.gsk-studyregister.com/study/2669 (accessed 12 December 2018). NCT00140686. A multi-country &amp; multi-center study to assess the efficacy, safety &amp; immunogenicity of 2 doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants in co-administration with specific childhood vaccines. clinicaltrials.gov/ct2/show/record/NCT00140686 (first received 1 September 2005). [Trial registration document]NCT00420316. To assess long-term efficacy &amp; safety of subjects approximately 3 years after priming with 2 doses of GlaxoSmithKline (GSK) Biologicals' oral live attenuated human rotavirus (HRV) vaccine (Rotarix) in the primary vaccination study (102247). clinicaltrials.gov/show/NCT00420316 (first received 11 January 2007). SchusterV , OttoW , CohenR . RotarixTM an oral human Rotavirus vaccine, is highly immunogenic when co-administered with a Streptococcus pneumoniae conjugate vaccine (PrevenarTM) in healthy infants from France and Germany. In: 24th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); 2006 June 15-18; Basel, Switzerland. 2006. [Not available for review]TejedorJC , Diez-DelegadoJ , AristeguiJ . Rotarix (RIX4414), an oral Human Rotavirus vaccine, is highly immunogenic when co-administered with a Neisseria meningitides Serogroup C vaccine (MeningitecTM) in healthy infants from Spain. In: 24th Annual Meeting Meeting of the European Society for Paediatric Infectious Diseases (ESPID); 2006 June 15-18; Basel, Switzerland. 2006. [Not available for review]VesikariT ,  KarvonenA ,  PrymulaR ,  SchusterV ,  TejedorJC ,  ThollotF ,  et al. Immunogenicity and safety of the human rotavirus vaccine Rotarix co-administered with routine infant vaccines following the vaccination schedules in Europe. Vaccine2010;28(32):5272-9. VesikariT , KarvonenA , FerranteSA , KuterBJ , CiarletM . Sustained efficacy of the pentavalent rotavirus vaccine, RV5, up to 3.1 years following the last dose of vaccine. Pediatric Infectious Disease Journal2010;29(10):957-63. VesikariT , KarvonenA , PrymulaR , SchusterV , TejedorJC , CohenR , et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet2007;370(9601):1757-63. VesikariT , PrymulaR , SchusterV , TejedorJC , CohenR , BouckenoogheA , et al. Efficacy and immunogenicity of live-attenuated human rotavirus vaccine in breast-fed and formula-fed European infants. Pediatric Infectious Disease Journal2012;31(5):509-13. VesikariT , PrymulaR , SchusterV . Early protection against Rotavirus, Rotarix, experience in an European setting. In: 12th International Congress for Infectious Diseases; 2006 June 15-18; Lisbon, Portugal. 2006. [Not available for review]VesikariT , PrymulaR , SchusterV . Rotarix (RIX4414), an oral human rotavirus vaccine, is highly immunogenic when co-administered with diphteria-tetanus-pertussis (DTPA)-combined vaccines in healthy infants from Europe. In: 24th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); 2006 June 15-18; Basel, Switzerland. 2006. [Not available for review]">RIX Vesikari 2007a‐EU</a> included 98 sites in six European countries. </p> </section> <section id="CD008521-sec-0058"> <h6 class="title">Country mortality rate</h6> <p>Fourteen trials were conducted in countries with low‐mortality rates, ten trials in medium‐mortality countries, and 12 trials were conducted in countries with high‐mortality rates; see <a href="./appendices#CD008521-sec-0273">Appendix 4</a>. For <a href="./references#CD008521-bbs2-0017" title="CunliffeNA , WitteD , NgwiraBM , ToddS , BostockNJ , TurnerAM , et al. Efficacy of human rotavirus vaccine against severe gastroenteritis in Malawian children in the first two years of life: a randomized, double-blind, placebo controlled trial. Vaccine2012;30(Suppl 1):A36-43. MadhiSA , CunliffeNA , SteeleD , WitteD , KirstenM , LouwC , et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. New England Journal of Medicine2010;362(4):289-98. MadhiSA , KirstenM , LouwC , BosP , AspinallS , BouckenoogheA , et al. Efficacy and immunogenicity of two or three dose rotavirus-vaccine regimen in South African children over two consecutive rotavirus seasons: a randomized, double-blind, placebo-controlled trial. Vaccine2012;30(Suppl 1):A44-51. NCT00241644. Multi-center study to assess the efficacy, safety and immunogenicity of 2 or 3 doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations in healthy infants. clinicaltrials.gov/show/NCT00241644 (first received 19 October 2005). NCT00598468. Multi-center study to assess efficacy, safety &amp; immunogenicity of 2 or 3 doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations in healthy infants. clinicaltrials.gov/show/NCT00598468 (first received 19 October 2005). SteeleAD , NeuzilKM , CunliffeNA , MadhiSA , BosP , NgwiraB , et al. Human rotavirus vaccine Rotarix provides protection against diverse circulating rotavirus strains in African infants: a randomized controlled trial. BMC Infectious Diseases2012;12:213. ">RIX Madhi 2010‐AF</a>, available data were split between countries into <a href="./references#CD008521-bbs2-0018" title="CunliffeNA , WitteD , NgwiraBM , ToddS , BostockNJ , TurnerAM , et al. Efficacy of human rotavirus vaccine against severe gastroenteritis in Malawian children in the first two years of life: a randomized, double-blind, placebo controlled trial. Vaccine2012;30(Suppl 1):A36-43. MadhiSA , CunliffeNA , SteeleD , WitteD , KirstenM , LouwC , et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. New England Journal of Medicine2010;362(4):289-98. NCT00241644. Multi-center study to assess the efficacy, safety and immunogenicity of 2 or 3 doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations in healthy infants. clinicaltrials.gov/show/NCT00241644 (first received 19 October 2005). NCT00598468. Multi-center study to assess efficacy, safety &amp; immunogenicity of 2 or 3 doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations in healthy infants. clinicaltrials.gov/show/NCT00598468 (first received 19 October 2005). SteeleAD , NeuzilKM , CunliffeNA , MadhiSA , BosP , NgwiraB , et al. Human rotavirus vaccine Rotarix provides protection against diverse circulating rotavirus strains in African infants: a randomized controlled trial. BMC Infectious Diseases2012;12:213. ">RIX Madhi 2010‐MWI</a> and <a href="./references#CD008521-bbs2-0019" title="MadhiSA , CunliffeNA , SteeleD , WitteD , KirstenM , LouwC , et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. New England Journal of Medicine2010;362(4):289-98. MadhiSA , KirstenM , LouwC , BosP , AspinallS , BouckenoogheA , et al. Efficacy and immunogenicity of two or three dose rotavirus-vaccine regimen in South African children over two consecutive rotavirus seasons: a randomized, double-blind, placebo-controlled trial. Vaccine2012;30(Suppl 1):A44-51. NCT00241644. Multi-center study to assess the efficacy, safety and immunogenicity of 2 or 3 doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations in healthy infants. clinicaltrials.gov/show/NCT00241644 (first received 19 October 2005). NCT00598468. Multi-center study to assess efficacy, safety &amp; immunogenicity of 2 or 3 doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations in healthy infants. clinicaltrials.gov/show/NCT00598468 (first received 19 October 2005). SteeleAD , NeuzilKM , CunliffeNA , MadhiSA , BosP , NgwiraB , et al. Human rotavirus vaccine Rotarix provides protection against diverse circulating rotavirus strains in African infants: a randomized controlled trial. BMC Infectious Diseases2012;12:213. ">RIX Madhi 2010‐ZAF</a>. Three trials were conducted in several countries with both low and medium, or medium and high mortality: <a href="./references#CD008521-bbs2-0026" title="Costa ClemensSA , et al. Operational organization of a large scale phase III clinical trial of rotavirus vaccine in multiple sites and countries in Latin America. In: International Congress of Pediatrics (ICP); 2004 August 15-20; Cancun, Mexico. 2004. [Not available for review]De VosB , et al. Rotarix™: an effective way to prevent rotavirus diarrhoea and vomiting. In: 9th Congress of the Asian Pan Pacific Society of Paediatric Gastroenterology, Hepatology and Nutrition &amp; 27th Annual Congress of the Malaysian Paediatric Association; 2005 June 16-19; Kuala Lumpur, Malaysia. 2005. [Not available for review]BaayM , BollaertsK , StruchinerC , VerstraetenT . Background rates of disease in Latin American children from a rotavirus vaccine study. Human Vaccines and Immunotherapeutics2017;13(8):1916-20. GlaxoSmithKline[444563-023-pt1]. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants (efficacy data from visit 1 to visit 4). www.gsk-studyregister.com/study/6791 (accessed 12 December 2018). GlaxoSmithKline[444563-023-pt2]. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants (2nd year efficacy from visit 4 to visit 6). www.gsk-studyregister.com/study/6791 (accessed 12 December 2018). GlaxoSmithKline[444563-023-pt3]. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants (safety for the period between visit 1 and visit 3). www.gsk-studyregister.com/study/6791 (accessed 12 December 2018). JustinoMC , AraújoEC , Van DoornLJ , OliveiraCS , GabbayYB , MascarenhasJD , et al. Oral live attenuated human rotavirus vaccine (Rotarix) offers sustained high protection against severe G9P[8] rotavirus gastroenteritis during the first two years of life in Brazilian children. Memorias do Instituto Oswaldo Cruz2012;107(7):846-53. LinharesAC , VelazquezFR , Perez-SchaelI , Saez-LlorensX , AbateH , EspinozaF , et al. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet2008;371(9619):1181-9. LopezP , LinharesA , Pérez-SchaelI , Ruiz-PalaciosG , Costa ClemensS , SanchezN . Early protection against severe rotavirus gastroenteritis - RIX4414 experience in Latin America. In: 24th Annual Meeting of European Society for Paediatric Infectious Diseases (ESPID); 2006 May 03-05; Basel, Switzerland. 2006. [Not available for review]MaciasM , LopezP , VelazquezFR , VergaraRF , SalmeronJ , TavaresJL . The rotavirus vaccine RIX4414 (Rotarix) is not associated with intussusception in one year old infants. In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2005 December 16-19; Washington DC, USA. 2005. [Not available for review]NCT00139347. A multi-country &amp; multi-center study to assess the efficacy, immunogenicity &amp; safety of two doses of GSK Biologicals' oral live attenuated HRV vaccine given concomitantly with routine EPI vaccinations including OPV in healthy infants. clinicaltrials.gov/ct2/show/NCT00139347 (first received 31 August 2005). [Trial registration document (no data for review)]NCT00140673. Placebo-controlled, multi-country &amp; multi-center study to assess the efficacy, safety &amp; immunogenicity of 2 doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants. clinicaltrials.gov/ct2/show/NCT00140673 (first received 1 September 2005). [Trial registration document (no data for review)]Perez-SchaelI , LinharesAC , VesikariT . Two doses of the human attenuated rotavirus vaccine RIX4414 (Rotarix) show heterotypic protection in Latin America and Europe. In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2005 December 16-19; Washington DC, USA. 2005. [Not available for review]PikeM . New rotavirus vaccine is effective and appears to have no increased risk of intussusception. Clinical Research Abstracts For Pediatricians2006;149(1):143. Ruiz-PalaciosG , AranzaC , VelazquezFR , RichardsonV , NandiE , MaciasM . Two doses of the human-attenuated monovalent G1P[8] rotavirus vaccine, Rotarix show high efficacy in Mexican children against severe rotavirus gastroenteritis and severe overall gastroenteritis. In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2005 December 16-19; Washington DC, USA. 2005. [Not available for review]Ruiz-PalaciosGM , Perez-SchaelI , VelazquezFR , AbateH , BreuerT , ClemensSC , et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. New England Journal of Medicine2006;354(1):11-22. VelázquezFR , AbatH , Costa ClemensSA , EspinozaF , GillardP , LinharesAC , et al. The human monovalent G1P[8] rotavirus vaccine, Rotarix is highly efficacious and provides crossprotection against G1 and non-G1 serotypes. In: 23rd Annual meeting of European Society for Paediatric Infectious Diseases (ESPID); 2005 May 18-20; Valencia, Spain. 2005. VelázquezRF , AbateH , BouckenoogheA . RIX4414, the human G1P[8] rotavirus vaccine is highly efficacious during the second year of life. In: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2006 September 27-30; San Francisco, USA. 2006. [Not available for review]VesikariT , O’RyanM , AbateH , Costa ClemensSA , EspinozaF , GillardP . Overcoming the safety hurdle: the rotavirus vaccine RIX4414 is not associated with intussusception. In: 23rd Annual Meeting of European Society for Paediatric Infectious Diseases (ESPID); 2005 May 18-20; Valencia, Spain. 2005. [Not available for review]">RIX Ruiz‐Palac 06‐LA/EU</a> was conducted mainly in medium‐mortality countries in Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Panama, Peru), but also in low‐mortality Finland, and in four high‐mortality countries (Dominican Republic, Honduras, Nicaragua, Venezuela), and was placed in the medium‐mortality group. <a href="./references#CD008521-bbs2-0027" title="Ruiz-PalaciosG , GuerreroL , LinharesAC , et al. Efficacy of an oral human rotavirus (HRV) vaccine in preventing diarrhoea due to G1 and non-G1 rotavirus [Presentation]. In: 3rd World Congress of Pediatric Infectious Diseases; 2002 November 19-23; Santiago, Chile. 2002. [Not available for review]Ruiz-PalaciosG , GuerreroML , LinharesAC , et al. Two-year efficacy of GlaxoSmithKline Biologicals' live attenuated rotavirus vaccine in Latin American children [poster]. In: 24th International Congress of Pediatrics; 2004 August 15-20; Cancun, Mexico. 2004. [Not available for review]SalinasB , Perez-SchaelI , Ruiz-PalaciosG , et al. Early protection by GlaxoSmithKline Biologicals' live attenuated rotavirus vaccine in Latin American children [poster]. In: 24th International Congress of Pediatrics; 2004 August 15-20; Cancun, Mexico. 2004. [Not available for review]SalinasB , TomatMA , YarzabalJP , et al. Efficacy of the rotavirus vaccine (RIX4414) among infants in Carabobo State, Venezuela [poster]. In: Asocación Venezolana para el Avance de la Cienca (AsoVAC); 2004; Venezuela. 2004. [Not available for review]AraujoEC , ClemensSA , OliveiraCS , JustinoMC , RubioP , GabbayYB , et al. Safety, immunogenicity, and protective efficacy of two doses of RIX4414 live attenuated human rotavirus vaccine in healthy infants. Jornal de Pediatria2007;83(3):217-24. De VosB , HardtK , LinharesAC , Ruiz-PalaciosG , GuerreroL , SalinasB . Efficacy of two doses of a human monovalent rotavirus vaccine, Rotarix™ in preventing gastro-enteritis due to G1 and Non-G1 rotavirus in Brazil, Mexico and Venezuela [presentation]. In: 8th International Symposium on Double-Stranded RNA Viruses; 2003 September 13-18; Lucca, Italy. 2003. [Not available for review]De VosB , VesikariT , LinharesAC , SalinasB , Perez-SchaelI , Ruiz-PalaciosGM , et al. A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis. Pediatric Infectious Disease Journal2004;23(10 Suppl):179-82. GlaxoSmithKline[444563-006]. A phase IIb, double-blind, randomized, placebo-controlled study to assess the efficacy, immunogenicity, reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals' live attenuated human rotavirus (HRV) vaccine at different virus concentrations (104.7, 105.2 and 105.8 foci forming units [ffu]) in healthy infants (approximately 2 months of age at first dose) following a 0, 2 month schedule and previously uninfected with HRV, when administered concurrently with DTPw-HBV and Hib vaccines. www.gsk-studyregister.com/study/6784 (accessed 12 December 2018). GlaxoSmithKline[444563-006-Annex]. A phase IIb, double-blind, randomized, placebo-controlled study to assess the efficacy, immunogenicity, reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals' live attenuated human rotavirus (HRV) vaccine at different virus concentrations (104.7, 105.2 and 105.8 foci forming units [ffu]) in healthy infants (approximately 2 months of age at first dose) following a 0, 2 month schedule and previously uninfected with HRV, when administered concurrently with DTPw-HBV and Hib vaccines [This summary presents results for the second and combined efficacy periods and results from the 3-Dose subset. Results from the first efficacy period are presented in 444563/006 (Rota-006) summary]. www.gsk-studyregister.com/study/6784 (accessed 12 December 2018). LinharesA , Perez-SchaelI , Ruiz-PalaciosM , PernambucoE , JacquetJ , De VosB . Immunogenicity and reactogenicity of an oral human rotavirus (HRV) vaccine in Latin American infants [poster]. In: 3rd World Congress of Pediatric Infectious Diseases; 2002 November 19-23; Santiago, Chile. 2002. [Not available for review]LinharesAC , Ruiz-PalaciosGM , GuerreroML , SalinasB , Perez-SchaelI , ClemensSA , et al. A short report on highlights of world-wide development of RIX4414: a Latin American experience. Vaccine2006;24(18):3784-5. LinharesAC , VerstraetenT , Wolleswinkel-Van den BoschJ , ClemensR , BreuerT . Rotavirus serotype G9 is associated with more-severe disease in Latin America. Clinical Infectious Diseases2006;43(3):312-4. [Not available for review]NCT00385320. To assess the efficacy, immuno &amp; safety of 2 doses of GSK HRV vaccine at different virus concentrations in healthy infants aged 2 months &amp; previously uninfected with HRV, concurrently given with DTPw-HBV, Hib. clinicaltrials.gov/show/NCT00385320 (first received 9 October 2006). Perez-SchaelI , SalinasB , LinharesA , GuerreroM , Ruiz-PalaciosG , ClemensS , et al. Protective efficacy of an oral human rotavirus (HRV) vaccine in Latin American infants [poster]. In: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy ( ICAAC); San Diego, 27-30 September 2002. 2002:18, LB-23. [Not available for review]Perez-SchaelI , SalinasB , TomatM , LinharesAC , GuerreroML , Ruiz-PalaciosGM , et al. Efficacy of the human rotavirus vaccine RIX4414 in malnourished children. Journal of Infectious Diseases2007;196(4):537-40. Ruiz-PalaciosGM , GuerreroML , Bautista-MarquezA , Ortega-GallegosH , Tuz-DzibF , Reyes-GonzalezL , et al. Dose response and efficacy of a live, attenuated human rotavirus vaccine in Mexican infants. Pediatrics2007;120(2):e253-61. [Not available for review]Ruiz-PalaciosGM . Impact of maternal antibodies on the immune response to an oral human rotavirus (HRV) vaccine in Mexican infants [presentation]. In: 3rd World Congress of Pediatric Infectious Diseases; 2002 November 19-23; Santiago, Chile. 2002. [Not available for review]SalinasB , Perez SchaelI , LinharesAC , Ruiz PalaciosGM , GuerreroML , YarzabalJP , et al. Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: a randomized, placebo-controlled trial in Latin American infants. Pediatric Infectious Disease Journal2005;24(9):807-16. ">RIX Salinas 2005‐LA</a> was mainly conducted in medium‐mortality Brazil and Mexico but also in high‐mortality Venezuela and was placed in the medium‐mortality group. Finally, <a href="./references#CD008521-bbs2-0031" title="GlaxoSmithKline[444563-024]. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, immunogenicity and safety of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations including OPV in healthy infants. www.gsk-studyregister.com/study/6792 (accessed 12 December 2018). Gonzalez AyalaS , RiveraL , Rivera-MedinaDM , LopezP , ValenciaA , De LeónT , et al. Co-administration with rotavirus vaccine rix4414 (Rotarix™) does not interfere with the immunogenicity of oral polio vaccine (OPV) [poster]. In: World Society for Pediatric Infectious Diseases (WSPID); 2007 November 15-18; Bangkok, Thailand. 2007. [Not available for review]TregnaghiMW , AbateHJ , ValenciaA , LopezP , Da SilveiraTR , RiveraL , et al. Human rotavirus vaccine is highly efficacious when coadministered with routine expanded program of immunization vaccines including oral poliovirus vaccine in Latin America. Pediatric Infectious Disease Journal2011;30(6):e103-e8. ">RIX Tregnaghi 2011‐LA</a> was also mainly conducted in medium‐mortality countries (Argentina, Brazil, Colombia, Panama) but also in high‐mortality Dominican Republic and Honduras and was placed in the medium‐mortality group. </p> </section> <section id="CD008521-sec-0059"> <h6 class="title">Vaccine schedule</h6> <p>The trials varied in the vaccine dose and schedule (see <a href="./appendices#CD008521-sec-0274">Appendix 5</a>). Most trials gave two doses of the vaccine with virus concentration of more than 10<sup>6</sup> plaque‐forming units (PFUs). Older trials, conducted between 1998 and 2005, tended to include slightly lower PFUs or a range of PFUs for comparison. </p> <p>Rotarix was given as two doses in all but five trials: one trial conducted in partnership with GlaxoSmithKline and PATH Rotavirus Vaccine Program tested two and three doses of the vaccine (<a href="./references#CD008521-bbs2-0017" title="CunliffeNA , WitteD , NgwiraBM , ToddS , BostockNJ , TurnerAM , et al. Efficacy of human rotavirus vaccine against severe gastroenteritis in Malawian children in the first two years of life: a randomized, double-blind, placebo controlled trial. Vaccine2012;30(Suppl 1):A36-43. MadhiSA , CunliffeNA , SteeleD , WitteD , KirstenM , LouwC , et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. New England Journal of Medicine2010;362(4):289-98. MadhiSA , KirstenM , LouwC , BosP , AspinallS , BouckenoogheA , et al. Efficacy and immunogenicity of two or three dose rotavirus-vaccine regimen in South African children over two consecutive rotavirus seasons: a randomized, double-blind, placebo-controlled trial. Vaccine2012;30(Suppl 1):A44-51. NCT00241644. Multi-center study to assess the efficacy, safety and immunogenicity of 2 or 3 doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations in healthy infants. clinicaltrials.gov/show/NCT00241644 (first received 19 October 2005). NCT00598468. Multi-center study to assess efficacy, safety &amp; immunogenicity of 2 or 3 doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations in healthy infants. clinicaltrials.gov/show/NCT00598468 (first received 19 October 2005). SteeleAD , NeuzilKM , CunliffeNA , MadhiSA , BosP , NgwiraB , et al. Human rotavirus vaccine Rotarix provides protection against diverse circulating rotavirus strains in African infants: a randomized controlled trial. BMC Infectious Diseases2012;12:213. ">RIX Madhi 2010‐AF</a>); another trial conducted by GlaxoSmithKline in which the poliovirus vaccine was co‐administered with Rotarix, tested two or three vaccine doses to investigate differences in immune response (<a href="./references#CD008521-bbs2-0030" title="GlaxoSmithKline[444563-013]. A phase II, double-blind before the 2002 rotavirus season and single blind with respect to OPV after, randomised, placebo-controlled study of the safety, reactogenicity and immunogenicity of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine (RIX4414 at 105 ffu) co-administered with either oral polio vaccine (OPV) or inactivated polio vaccine (IPV) in healthy infants (approximately 5-10 weeks old) in South Africa. www.gsk-studyregister.com/study/6786 (accessed 12 December 2018). ISRCTN37373664. A double blind, randomised placebo controlled study of the safety, reactogenicity and immunogenicity of two doses of orally administered human rotavirus vaccine (RIX4414) in healthy infants in South Africa. controlled-trials.com/ISRCTN37373664 (first received 25 November 2005). NCT00383903. A study of the safety, reactogenicity and immunogenicity of 2 or 3 doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants (approximately 5-10 weeks old) in South Africa. clinicaltrials.gov/show/NCT00383903 (first received 3 October 2006). SteeleAD ,  ReyndersJ ,  ScholtzF ,  BosP ,  De BeerMC ,  TumboJ ,  et al. Comparison of 2 different regimens for reactogenicity, safety, and immunogenicity of the live attenuated oral rotavirus vaccine RIX4414 coadministered with oral polio vaccine in South African infants. Journal of Infectious Diseases2010;202(Suppl):S93-100. ">RIX Steele 2010b‐ZAF</a>); a third study tested three vaccine doses in HIV‐positive infants (<a href="./references#CD008521-bbs2-0029" title="EUCTR2015-001484-39. A phase II study to assess the safety and immunogenicity of GlaxoSmithKline Biologicals rotavirus vaccine, RIX4414 when administered to HIV infected infants in South Africa. www.clinicaltrialsregister.eu/ctr-search/trial/2015-001484-39/results (first received 11 June 2015). GlaxoSmithKline[444563-022]. A phase II, double-blind, randomized, placebo-controlled study to assess the safety, reactogenicity and immunogenicity of three doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine. www.gsk-studyregister.com/study/6790 (accessed 12 December 2018). ISRCTN11877362. A phase II, double-blind, randomised, placebo-controlled study to assess the safety, reactogenicity and immunogenicity of three doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine (RIX4414 at 106.5 CCID50) administered to human immunodeficiency virus (HIV) infected infants at 6, 10 and 14 weeks of age in South Africa. www.controlled-trials.com/ISRCTN11877362 (first received 25 November 2005). NCT00263666. A study of safety, reactogenicity and immunogenicity of HRV vaccine in HIV infected infants in South Africa. clinicaltrials.gov/ct2/show/results/NCT00263666 (first received on 9 December 2005). SteeleAD ,  MadhiSA ,  LouwCE ,  BosP ,  TumboJM ,  WernerCM ,  et al. Safety, reactogenicity, and immunogenicity of human rotavirus vaccine RIX4414 in human immunodeficiency virus-positive infants in South Africa. Pediatric Infectious Diseases Journal2011;30(2):125-30. ">RIX Steele 2010a‐ZAF</a>); a fourth study tested three vaccine doses in healthy infants (<a href="./references#CD008521-bbs2-0007" title="GlaxoSmithKline[444563-021]. A phase II, double-blind, randomized, placebo-controlled clinical study to assess the immunogenicity and reactogenicity of three doses of a modified vaccine formulation versus GlaxoSmithKline (GSK) Biologicals’ live attenuated human rotavirus (HRV) vaccine when orally administered to healthy infants at 2, 4 and 6 months of age. www.gsk-studyregister.com/study/6789 (accessed 12 December 2018). ">RIX GSK[021] 2007‐PAN</a>); a fifth study, that included children aged two to six years, administered one dose only (<a href="./references#CD008521-bbs2-0014" title="GlaxoSmithKline[113552-073]. Reactogenicity and safety of a single dose of GlaxoSmithKline (GSK) Biologicals' human rotavirus (HRV) vaccine (444563) in healthy children. www.gsk-studyregister.com/study/3957 (accessed 12 December 2018). LiRC , LiYP , MoZJ , LuoD , HuangT , KongJL , et al. Reactogenicity and safety of a liquid human rotavirus vaccine (RIX4414) in healthy adults, children and infants in China: randomized, double-blind, placebo-controlled phase I studies. Human Vaccines and Immunotherapeutics2013;9(8):1638-42. NCT01086436. Study to evaluate the safety of Rotarix in Chinese children. clinicaltrials.gov/ct2/show/NCT01086436 (first received on 15 March 2010). ">RIX Li 2013a‐CHN</a>). </p> <p>Some trials compared more than one intervention arm: different PFU virus concentrations (<a href="./references#CD008521-bbs2-0032" title="GlaxoSmithKline[444563-003]. A phase II, double-blind, randomized, placebo-controlled, dose-escalating, stepwise study to assess safety, reactogenicity and immunogenicity of GlaxoSmithKline Biologicals’ live attenuated human rotavirus (HRV) vaccine in healthy infants previously uninfected with human rotavirus. www.gsk-studyregister.com/study/6781 (accessed 12 December 2018). VesikariT , KarvonenA , KorhonenT , EspoM , LebacqE , ForsterJ , et al. Safety and immunogenicity of RIX4414 live attenuated human rotavirus vaccine in adults, toddlers and previously uninfected infants. Vaccine2004;22(21-2):2836-42. ">RIX Vesikari 2004a‐FIN</a>; <a href="./references#CD008521-bbs2-0006" title="DennehyPH , BradyRC , HalperinSA , WardRL , AlveyJC , Fischer FH Jr, et al. Comparative evaluation of safety and immunogenicity of two dosages of an oral live attenuated human rotavirus vaccine. Pediatric Infectious Disease Journal2005;24(6):481-8. DennehyPH . A short report on the highlights of world-wide development of RIX4414: a North American experience comparative evaluation of safety and immunogenicity of two dosages of an oral live attenuated human rotavirus vaccine (RIX4414) in infants in the United States and Canada. Vaccine2006;24(18):3780-1. GlaxoSmithKline[444563-005]. A phase II, double-blind, randomized, placebo-controlled study of two doses of GlaxoSmithKline Biologicals’ live attenuated human rotavirus (HRV) vaccine at different virus concentrations (10 5.2 and 10 6.4 ffu) in healthy infants (approximately 2 months of age at first dose) following a 0, 2 month schedule and previously uninfected with human rotavirus. www.gsk-studyregister.com/study/6783 (accessed 12 December 2018). NCT00729001. Study of two doses of GSK Biologicals' live attenuated HRV vaccine (two different formulations) in healthy infants. clinicaltrials.gov/ct2/show/NCT00729001 (accessed 6 August 2008). ">RIX Dennehy 2005‐NA</a>; <a href="./references#CD008521-bbs2-0023" title="EmmanuelB , et al. Immunogenicity of an acellular pertussis combination vaccine co-administered with a novel rotavirus vaccine in Singaporean infants. Asian Congress on Pediatric Infectious Diseases (ACPID); 2-4 September 2004; Kota Kinabula, Malaysia2004. [Not available for review]PhuaKB , et al. Immunogenicity and reactogenicity of two doses of an oral human rotavirus (HRV) vaccine at different concentrations in healthy infants from Singapore. In: 11th Asia Pacific Congress of Pediatrics and the 3rd Asia Pacific Congress of Pediatric Nursing; 2003; Bangkok, Thailand. 2003. [Not available for review]PhuaKB , et al. Intussusception in children: a seven-year experience in Singapore. In: 24th International Congress of Pediatrics (ICP); 2004 August 15-20; Cancun, Mexico. 2004. [Not available for review]VesikariT , et al. High efficacy of two doses of Rotarix™ (RIX4414) against rotavirus disease in Europe, Latin-America and Asia. In: Asian Congress on Pediatric Infectious Diseases (ACPID); 2006 March 07-10; Cebu, Philippines. 2006. [Not available for review]De VosB , GillardP , CheuvartB . RIX4414 vaccine efficacy against rotavirus gastroenteritis due to G2P[4] strain. In: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2006 September 27-30; San Francisco, USA. 2006. [Not available for review]De VosB , VesikariT , LinharesAC , SalinasB , Perez-SchaelI , Ruiz-PalaciosGM , et al. A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis. Pediatric Infectious Disease Journal2004;23(10 Suppl):179-82. [No data for review]EmmanuelS , PhuaKB , GohP , QuakSH , DattaSK , HanHH , et al. Immunogenicity of an acellular pertussis combination vaccine co-administered with a novel rotavirus vaccine in Singaporean infants. In: 23rd Annual Meeting of European Society for Paediatric Infectious Diseases (ESPID); 2005 May 18-20; Valencia, Spain. 2005. [Not available for review]GlaxoSmithKline[444563-007]. A phase IIb, double-blind, randomized, placebo-controlled study to assess the efficacy, immunogenicity, reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine at different viral concentrations (104.7, 105.2 and 106.1 foci forming units (ffu)) in healthy infants previously uninfected with human rotavirus and approximately three months of age, when administered concurrently with DTPa-IPV/Hib and HBV vaccines. www.gsk-studyregister.com/study/6785 (accessed 12 December 2018). NCT00429481. A study to assess the efficacy, immunogenicity and safety of 2 doses of oral live attenuated human rotavirus vaccine (Rotarix) at different viral concentrations in healthy infants. clinicaltrials.gov/ct2/show/record/NCT00429481 (first received 31 January 2007). PhuaKB , EmmanuelSC , GohP , QuakSH , LeeBW , HanHH , et al. A rotavirus vaccine for prophylaxis of infant rotavirus gastroenteritis: the Asian experience. Annals of the Academy of Medicine, Singapore2006;35(1):38-44. PhuaKB , QuakSH , EmmanuelS , GohPS , HanHH , HardtK , et al. A short report on highlights of worldwide development of RIX4414: a Singaporean experience. Vaccine2006;24(18):3782-3. PhuaKB , QuakSH , EmmanuelS , GohPSC , HanHH , HardtK , et al. Highlights of world-wide development: a Singapore experience. In: 3rd International Conference on Vaccines for Enteric Diseases (VED) 28-30 April 2004; Montego Bay, Jamaica. 2004. [Not available for review]PhuaKB , QuakSH , LeeBW , EmmanuelSC , GohP , HanHH , et al. Evaluation of RIX4414, a live, attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled phase 2 trial involving 2464 Singaporean infants. Journal of Infectious Diseases2005;192(Suppl 1):6-16. PhuaKB , QuakSH , LimFS , GohP , TeohYL , DattaSK , et al. Immunogenicity, reactogenicity and safety of a diphtheria-tetanus-acellular pertussis-inactivated polio and Haemophilus influenzae type b combination vaccine in a placebo-controlled rotavirus vaccine study. Annals of the Academy of Medicine, Singapore2008;37(7):546-53. VesikariT . RIX4414: a new attenuated human rotavirus vaccine. In: 23rd Annual Meeting of European Society for Paediatric Infectious Diseases (ESPID); 2005 May 18-20; Valencia, Spain. 2005. [Not available for review]">RIX Phua 2005‐SGP</a>; <a href="./references#CD008521-bbs2-0027" title="Ruiz-PalaciosG , GuerreroL , LinharesAC , et al. Efficacy of an oral human rotavirus (HRV) vaccine in preventing diarrhoea due to G1 and non-G1 rotavirus [Presentation]. In: 3rd World Congress of Pediatric Infectious Diseases; 2002 November 19-23; Santiago, Chile. 2002. [Not available for review]Ruiz-PalaciosG , GuerreroML , LinharesAC , et al. Two-year efficacy of GlaxoSmithKline Biologicals' live attenuated rotavirus vaccine in Latin American children [poster]. In: 24th International Congress of Pediatrics; 2004 August 15-20; Cancun, Mexico. 2004. [Not available for review]SalinasB , Perez-SchaelI , Ruiz-PalaciosG , et al. Early protection by GlaxoSmithKline Biologicals' live attenuated rotavirus vaccine in Latin American children [poster]. In: 24th International Congress of Pediatrics; 2004 August 15-20; Cancun, Mexico. 2004. [Not available for review]SalinasB , TomatMA , YarzabalJP , et al. Efficacy of the rotavirus vaccine (RIX4414) among infants in Carabobo State, Venezuela [poster]. In: Asocación Venezolana para el Avance de la Cienca (AsoVAC); 2004; Venezuela. 2004. [Not available for review]AraujoEC , ClemensSA , OliveiraCS , JustinoMC , RubioP , GabbayYB , et al. Safety, immunogenicity, and protective efficacy of two doses of RIX4414 live attenuated human rotavirus vaccine in healthy infants. Jornal de Pediatria2007;83(3):217-24. De VosB , HardtK , LinharesAC , Ruiz-PalaciosG , GuerreroL , SalinasB . Efficacy of two doses of a human monovalent rotavirus vaccine, Rotarix™ in preventing gastro-enteritis due to G1 and Non-G1 rotavirus in Brazil, Mexico and Venezuela [presentation]. In: 8th International Symposium on Double-Stranded RNA Viruses; 2003 September 13-18; Lucca, Italy. 2003. [Not available for review]De VosB , VesikariT , LinharesAC , SalinasB , Perez-SchaelI , Ruiz-PalaciosGM , et al. A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis. Pediatric Infectious Disease Journal2004;23(10 Suppl):179-82. GlaxoSmithKline[444563-006]. A phase IIb, double-blind, randomized, placebo-controlled study to assess the efficacy, immunogenicity, reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals' live attenuated human rotavirus (HRV) vaccine at different virus concentrations (104.7, 105.2 and 105.8 foci forming units [ffu]) in healthy infants (approximately 2 months of age at first dose) following a 0, 2 month schedule and previously uninfected with HRV, when administered concurrently with DTPw-HBV and Hib vaccines. www.gsk-studyregister.com/study/6784 (accessed 12 December 2018). GlaxoSmithKline[444563-006-Annex]. A phase IIb, double-blind, randomized, placebo-controlled study to assess the efficacy, immunogenicity, reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals' live attenuated human rotavirus (HRV) vaccine at different virus concentrations (104.7, 105.2 and 105.8 foci forming units [ffu]) in healthy infants (approximately 2 months of age at first dose) following a 0, 2 month schedule and previously uninfected with HRV, when administered concurrently with DTPw-HBV and Hib vaccines [This summary presents results for the second and combined efficacy periods and results from the 3-Dose subset. Results from the first efficacy period are presented in 444563/006 (Rota-006) summary]. www.gsk-studyregister.com/study/6784 (accessed 12 December 2018). LinharesA , Perez-SchaelI , Ruiz-PalaciosM , PernambucoE , JacquetJ , De VosB . Immunogenicity and reactogenicity of an oral human rotavirus (HRV) vaccine in Latin American infants [poster]. In: 3rd World Congress of Pediatric Infectious Diseases; 2002 November 19-23; Santiago, Chile. 2002. [Not available for review]LinharesAC , Ruiz-PalaciosGM , GuerreroML , SalinasB , Perez-SchaelI , ClemensSA , et al. A short report on highlights of world-wide development of RIX4414: a Latin American experience. Vaccine2006;24(18):3784-5. LinharesAC , VerstraetenT , Wolleswinkel-Van den BoschJ , ClemensR , BreuerT . Rotavirus serotype G9 is associated with more-severe disease in Latin America. Clinical Infectious Diseases2006;43(3):312-4. [Not available for review]NCT00385320. To assess the efficacy, immuno &amp; safety of 2 doses of GSK HRV vaccine at different virus concentrations in healthy infants aged 2 months &amp; previously uninfected with HRV, concurrently given with DTPw-HBV, Hib. clinicaltrials.gov/show/NCT00385320 (first received 9 October 2006). Perez-SchaelI , SalinasB , LinharesA , GuerreroM , Ruiz-PalaciosG , ClemensS , et al. Protective efficacy of an oral human rotavirus (HRV) vaccine in Latin American infants [poster]. In: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy ( ICAAC); San Diego, 27-30 September 2002. 2002:18, LB-23. [Not available for review]Perez-SchaelI , SalinasB , TomatM , LinharesAC , GuerreroML , Ruiz-PalaciosGM , et al. Efficacy of the human rotavirus vaccine RIX4414 in malnourished children. Journal of Infectious Diseases2007;196(4):537-40. Ruiz-PalaciosGM , GuerreroML , Bautista-MarquezA , Ortega-GallegosH , Tuz-DzibF , Reyes-GonzalezL , et al. Dose response and efficacy of a live, attenuated human rotavirus vaccine in Mexican infants. Pediatrics2007;120(2):e253-61. [Not available for review]Ruiz-PalaciosGM . Impact of maternal antibodies on the immune response to an oral human rotavirus (HRV) vaccine in Mexican infants [presentation]. In: 3rd World Congress of Pediatric Infectious Diseases; 2002 November 19-23; Santiago, Chile. 2002. [Not available for review]SalinasB , Perez SchaelI , LinharesAC , Ruiz PalaciosGM , GuerreroML , YarzabalJP , et al. Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: a randomized, placebo-controlled trial in Latin American infants. Pediatric Infectious Disease Journal2005;24(9):807-16. ">RIX Salinas 2005‐LA</a>; <a href="./references#CD008521-bbs2-0036" title="WardRL , KirkwoodCD , SanderDS , SmithVE , ShaoM , BeanJA , et al. Reductions in cross-neutralizing antibody responses in infants after attenuation of the human rotavirus vaccine candidate 89-12. Journal of Infectious Diseases2006;194(12):1729-36. ">RIX Ward 2006‐USA</a>); different formulations (<a href="./references#CD008521-bbs2-0007" title="GlaxoSmithKline[444563-021]. A phase II, double-blind, randomized, placebo-controlled clinical study to assess the immunogenicity and reactogenicity of three doses of a modified vaccine formulation versus GlaxoSmithKline (GSK) Biologicals’ live attenuated human rotavirus (HRV) vaccine when orally administered to healthy infants at 2, 4 and 6 months of age. www.gsk-studyregister.com/study/6789 (accessed 12 December 2018). ">RIX GSK[021] 2007‐PAN</a>; <a href="./references#CD008521-bbs2-0008" title="GlaxoSmithKline[444563-033]. A phase III, randomized, double-blind and placebo-controlled study to assess the clinical consistency of three production lots of GSK Biologicals’ HRV vaccine in terms of immunogenicity and safety when given to healthy infants at 2 and 4 months of age. www.gsk-studyregister.com/study/6794 (accessed 12 December 2018). LópezP , Galan HerreraJF , CervantesY , Costa ClemensSA , AguirreF , YarzabalJP . Three consecutive production lots of the human monovalent RIX4414 G1P(8) rotavirus vaccine, Rotarix™ induce a consistent immune response in Latin American infants [poster]. In: 4th World Congress of The World Society for Pediatric Infectious Diseases; 2005 September 01-04; Warsaw, Poland. 2005. [Not available for review]NCT00757770. Assessment of clinical consistency of three production lots of GSK Biologicals' HRV vaccine. clinicaltrials.gov/ct2/show/NCT00757770 (first received 23 September 2008). ">RIX GSK[033] 2007‐LA</a>; <a href="./references#CD008521-bbs2-0010" title="GlaxoSmithKline[101555]. A phase II, double-blind, randomized, placebo-controlled study to compare the immunogenicity, reactogenicity and safety of 2 different formulations of GlaxoSmithKline (GSK) Biologicals’ live attenuated human rotavirus (HRV) vaccine given as a two-dose primary vaccination in healthy infants previously uninfected with HRV. www.gsk-studyregister.com/study/2632 (accessed 12 December 2018). ">RIX GSK[101555] 2008‐PHL</a>; <a href="./references#CD008521-bbs2-0012" title="GlaxoSmithKline[103477-039]. A phase IIIb, partially blind, randomized, placebo-controlled study to asses the effect on immunogenicity of administration of vaccine without buffering agent and to assess heat stability in terms of immunogenicity, reactogenicity and safety of GlaxoSmithKline Biologicals’ oral live attenuated human rotavirus (HRV) vaccine following a 0, 2 month schedule, in healthy infants previously uninfected with human rotavirus. www.gsk-studyregister.com/study/2713 (accessed 12 December 2018). KerdpanichA , ChokephaibulkitK , WatanaveeradejV , VanpraparN , HutagalungY , HanHH , et al. Exposure to elevated temperature of 37°C for 7 days does not affect immunogenicity and reactogenicity of RIX4414 [poster]. In: dsRNA Virus Meeting; 2006 October 21-26; Cape Town, South Africa. 2006. [Not available for review]KerdpanichA , ChokephaibulkitK , WatanaveeradejV , VanpraparN , SimasathienS , PhavichitrN , et al. Immunogenicity of a human rotavirus vaccine (RIX4414) after storage at 37 degrees C for seven days. Human Vaccine2011;7(1):74-80. KerdpanichA , ChokephaibulkitK , WatanaveeradejV , VanpraparN , SimasathienS , PhavichitrN , et al. Immunogenicity of a live-attenuated human rotavirus RIX4414 vaccine with or without buffering agent. Human Vaccines2010;6(3):254-62. NCT00169455. Assess the effect on immunogenicity of administration of vaccine without buffering agent &amp; assess heat stability in terms of immunogenicity, reactogenicity &amp; safety of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine following a 0, 2 m schedule, in healthy infants previously uninfected with human rotavirus. clinicaltrials.gov/show/NCT00169455 (first received 15 September 2005). ">RIX Kerdpanich 2010‐THA</a>; <a href="./references#CD008521-bbs2-0035" title="VesikariT , et al. Immunogenicity of liquid formulation of the oral live attenuated human rotavirus vaccine (Rotarix™) [poster]. Sociedad Latinoamericana de Infectología Pediátrica (SLIPE). San Jose, Costa Rica 8-11 May 2007. [Not available for review]GlaxoSmithKline[104480-048]. A phase II, double-blind, randomized, placebo controlled study to compare the immunogenicity, reactogenicity and safety of two different formulations of GlaxoSmithKline (GSK) Biologicals’ live attenuated human rotavirus (HRV) vaccine given as a two-dose primary vaccination in healthy infants previously uninfected with HRV. www.gsk-studyregister.com/study/2783 (accessed 12 December 2018). NCT00137930. Compare the immunogenicity, reactogenicity &amp; safety of 2 different formulations of GSK Biologicals’ live attenuated human rotavirus (HRV) vaccine given as a two-dose primary vaccination in healthy infants previously uninfected with HRV. clinicaltrials.gov/ct2/show/record/NCT00137930 (first received 30 August 2005). VesikariT , KarvonenA , BouckenoogheA , SuryakiranPV , SmolenovI , HanHH . Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 oral suspension (liquid formulation) in Finnish infants. Vaccine2011;29(11):2079-84. ">RIX Vesikari 2011‐FIN</a>); co‐administration of other vaccine (<a href="./references#CD008521-bbs2-0028" title="GlaxoSmithKline[444563-014]. A phase II, double-blind before the 2002 rotavirus season and single blind with respect to OPV after, randomised, placebo-controlled study of the safety, reactogenicity and immunogenicity of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine (RIX4414 at 105 ffu) co-administered with either oral polio vaccine (OPV) or inactivated polio vaccine (IPV) in healthy infants (approximately 5-10 weeks old) in South Africa. www.gsk-studyregister.com/study/6787 (accessed 12 December 2018). ISRCTN86632774. A phase II, double blind randomised, placebo controlled study to assess the safety reactogenicity and immunogenicity of three doses of GSK Biologicals (South Africa). controlled-trials.com/ISRCTN86632774 (first received 25 November 2005). NCT00346892. Reactogenicity &amp; immunogenicity study of two doses of GSK Biologicals’ oral live attenuated HRV vaccine co-administered with either OPV or IPV in healthy infants (approximately 5-10 weeks old) in South Africa. clinicaltrials.gov/show/NCT00346892 (first received 30 June 2006). SteeleAD ,  De VosB ,  TumboJ ,  ReyndersJ ,  ScholtzF ,  BosP ,  et al. Co-administration study in South African infants of a live-attenuated oral human rotavirus vaccine (RIX4414) and poliovirus vaccines. Vaccine2010 ;28(39):6542-8. SteeleAD , TumboJ , ArmahG , ReyndersJ , ScholtzF , BosP , et al. Immunogenicity and reactogenicity of a new live attenuated oral rotavirus vaccine (RIX4414) when administered concurrently with poliovirus vaccines in African infants. In: 24th International Congress of Pediatrics; 2004 August 15-20; Cancun, Mexico. 2004. [Not available for review]SteeleAD , TumboJM , ArmahGE , ReyndersJ , ScholtzF , BosP , et al. Concomitant administration of a live-attenuated oral rotavirus vaccine (RIX4414) with poliovirus vaccines in African infants. In: 23rd Annual Meeting of the European Society for Pediatric Infectious Diseases - ESPID; 2005 May 18-20; Valencia, Spain. 2005. [Not available for review]">RIX Steele 2008‐ZAF</a>; <a href="./references#CD008521-bbs2-0037" title="GlaxoSmithKline[103992-045]. A phase II, randomised, double-blind, placebo-controlled study to evaluate the immunogenicity, reactogenicity and safety of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine (RIX4414 at 106.5 CCID50) when given concomitantly with OPV versus when given alone (HRV vaccine dose given 15 days after the OPV dose) in healthy infants in Bangladesh. www.gsk-studyregister.com/study/2748 (accessed 12 December 2018). NCT00139334. Evaluate immunogenicity, reactogenicity &amp; safety of 2 doses of GSK Biologicals’ oral live attenuated HRV vaccine (RIX4414 at 106.5 CCID50) when given concomitantly with OPV versus given alone (HRV vaccine dose given 15 days after the OPV dose) in healthy infants in Bangladesh. clinicaltrials.gov/show/NCT00139334 (first received 31 August 2005). ZamanK , SackDA , YunusM , ArifeenSE , PodderG , AzimT , et al, Bangladesh Rotavirus Vaccine study group. Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age. Vaccine2009;27(9):1333-9. ">RIX Zaman 2009‐BGD</a>; <a href="./references#CD008521-bbs2-0021" title="GlaxoSmithKline[104021-DTPw CSL-HBVGOD-005]. A phase III, partially blind, randomized study to evaluate the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ Tritanrix™-HepB and GSK Biologicals Kft’s DTPw-HBV vaccines as compared to concomitant administration of Commonwealth Serum Laboratory’s (CSL’s) DTPw (Triple Antigen™) and GSK Biologicals’ HBV (Engerix™-B), when co-administered with GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine, to healthy infants at 3, 4½ and 6 months of age, after a birth dose of hepatitis B vaccine. www.gsk-studyregister.com/study/2753 (accessed 12 December 2018). NCT00158756. Assess immunogenicity &amp; reactogenicity of 2 formulations of GSK's DTPw-HBV vaccines vs concomitant admn of CSL's DTPw &amp; GSK's HBV vaccine, co-admnd with GSK's rotavirus vaccine, to infants at 3, 4½ &amp; 6 mths, after birth dose of HBV vaccine. clinicaltrials.gov/show/NCT00158756 (first received 12 September 2005). TatochenkoVK , RomanenkoVV , KharitSM , SmolenovI , LeFevreI , De ClercqN , et al. Co-administration of a human rotavirus vaccine Rix4414 with DTPw-HBv vaccines: immunogenicity and reactogenicity in healthy infants. In: 13th International Congress on Infectious Diseases; June 19–22. 2008; Kuala Lumpur, Malaysia. 2008. ">RIX NCT00158756‐RUS</a>; <a href="./references#CD008521-bbs2-0016" title="GlaxoSmithKline[113808-075]. Efficacy, immunogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals' oral live attenuated liquid Human Rotavirus (HRV) vaccine (444563), in healthy infants. www.gsk-studyregister.com/study/4036 (accessed 12 December 2018). LiRC , HuangT , LiY , LuoD , TaoJ , FuB , et al. Human rotavirus vaccine (RIX4414) efficacy in the first two years of life: a randomized, placebo-controlled trial in China. Human Vaccines and Immunotherapeutics2014;10(1):11-8. LiRC , HuangT , LiY , WangLH , TaoJ , FuB , et al. Immunogenicity and reactogenicity of the human rotavirus vaccine, RIX4414 oral suspension, when co-administered with routine childhood vaccines in Chinese infants. Human Vaccines and Immunotherapeutics2016;12(3):785-93. NCT01171963. Efficacy, immunogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals' oral live attenuated liquid human rotavirus (HRV) vaccine (444563), in healthy infants. clinicaltrials.gov/show/NCT01171963 (first received 29 July 2010). ">RIX Li 2014‐CHN</a>); and different intervals between doses (<a href="./references#CD008521-bbs2-0001" title="AnhDD , CarlosCC , ThiemDV , HutagalungY , GatchalianS , BockHL , et al. Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 (Rotarix) oral suspension (liquid formulation) when co-administered with expanded program on immunization (EPI) vaccines in Vietnam and the Philippines in 2006-2007. Vaccine2011;29(11):2029-36. GlaxoSmithKline[109216-063]. A phase II, randomized, double-blind, placebo-controlled study to evaluate the immunogenicity, reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) liquid vaccine, when given to healthy infants, in Philippines. www.gsk-studyregister.com/study/3204 (accessed 12 December 2018). NCT00432380. Immunogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals' oral live attenuated human rotavirus (HRV) liquid vaccine (GSK 357941A) in healthy infants. clinicaltrials.gov/show/NCT00432380 (first received 7 February 2007). ">RIX Anh 2011‐PHL</a>; <a href="./references#CD008521-bbs2-0002" title="AnhDD , CarlosCC , ThiemDV , HutagalungY , GatchalianS , BockHL , et al. Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 (Rotarix) oral suspension (liquid formulation) when co-administered with expanded program on immunization (EPI) vaccines in Vietnam and the Philippines in 2006-2007. Vaccine2011;29(11):2029-36. AnhDD , ThiemVD , HutagalungY , BockHL , SuryakiranP , DelemA , et al. Immunogenicity, reactogenicity and safety of the oral live attenuated human rotavirus vaccine RIX4414 (Rotarix™) oral suspension (liquid formulation) in Vietnamese Infants. In: 13th International Congress on Infectious Diseases Abstracts, Poster Presentations; June 19–22, 2008; Kuala Lumpur, Malaysia. 2008. GlaxoSmithKline[105722-051]. A phase II, randomized, double-blind, placebo-controlled study to evaluate the immunogenicity, reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) liquid vaccine, when given to healthy infants, in Vietnam. www.gsk-studyregister.com/study/3012 (accessed 12 December 2018). NCT00345956. A placebo-controlled study to evaluate the immunogenicity, reactogenicity and safety of two doses of GSK Bio oral live attenuated human rotavirus (HRV) liquid vaccine, when given to healthy infants, in Vietnam. clinicaltrials.gov/show/NCT00345956 (first received 29 June 2006). ">RIX Anh 2011‐VNM</a>). </p> </section> <section id="CD008521-sec-0060"> <h6 class="title">Infant vaccination status</h6> <p>All but four trial reports referred to vaccination with other infant vaccines (see <a href="./appendices#CD008521-sec-0274">Appendix 5</a>). Most trials co‐administered other routine infant vaccines, such as diphtheria‐tetanus‐acellular pertussis (DTaP), <i>Haemophilus influenzae</i> type b (HiB), inactivated polio vaccine (IPV), and hepatitis B vaccine (HBV). Some trials also co‐administered oral polio vaccine (OPV). Other trials imposed a two‐week separation between other infant vaccines and rotavirus vaccine or placebo, or specified other vaccines as not allowed. </p> </section> <section id="CD008521-sec-0061"> <h6 class="title">Methods for collecting adverse event data</h6> <p>Fifteen of the 36 trials did not provide details of how adverse event data were collected. Out of the trials that did report the method of collecting adverse event data, 13 trials used passive methods (e.g. diary cards), two used an active method ("active surveillance system"), and five used both passive and active methods (e.g. diary card plus regular telephone calls to parents); see <a href="./appendices#CD008521-sec-0275">Appendix 6</a>. </p> </section> <section id="CD008521-sec-0062"> <h6 class="title">Source of funding</h6> <p>Most trials were supported by GlaxoSmithKline Biologicals, three of which were in partnership with PATH Rotavirus Vaccine Program (<a href="./references#CD008521-bbs2-0016" title="GlaxoSmithKline[113808-075]. Efficacy, immunogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals' oral live attenuated liquid Human Rotavirus (HRV) vaccine (444563), in healthy infants. www.gsk-studyregister.com/study/4036 (accessed 12 December 2018). LiRC , HuangT , LiY , LuoD , TaoJ , FuB , et al. Human rotavirus vaccine (RIX4414) efficacy in the first two years of life: a randomized, placebo-controlled trial in China. Human Vaccines and Immunotherapeutics2014;10(1):11-8. LiRC , HuangT , LiY , WangLH , TaoJ , FuB , et al. Immunogenicity and reactogenicity of the human rotavirus vaccine, RIX4414 oral suspension, when co-administered with routine childhood vaccines in Chinese infants. Human Vaccines and Immunotherapeutics2016;12(3):785-93. NCT01171963. Efficacy, immunogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals' oral live attenuated liquid human rotavirus (HRV) vaccine (444563), in healthy infants. clinicaltrials.gov/show/NCT01171963 (first received 29 July 2010). ">RIX Li 2014‐CHN</a>; <a href="./references#CD008521-bbs2-0017" title="CunliffeNA , WitteD , NgwiraBM , ToddS , BostockNJ , TurnerAM , et al. Efficacy of human rotavirus vaccine against severe gastroenteritis in Malawian children in the first two years of life: a randomized, double-blind, placebo controlled trial. Vaccine2012;30(Suppl 1):A36-43. MadhiSA , CunliffeNA , SteeleD , WitteD , KirstenM , LouwC , et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. New England Journal of Medicine2010;362(4):289-98. MadhiSA , KirstenM , LouwC , BosP , AspinallS , BouckenoogheA , et al. Efficacy and immunogenicity of two or three dose rotavirus-vaccine regimen in South African children over two consecutive rotavirus seasons: a randomized, double-blind, placebo-controlled trial. Vaccine2012;30(Suppl 1):A44-51. NCT00241644. Multi-center study to assess the efficacy, safety and immunogenicity of 2 or 3 doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations in healthy infants. clinicaltrials.gov/show/NCT00241644 (first received 19 October 2005). NCT00598468. Multi-center study to assess efficacy, safety &amp; immunogenicity of 2 or 3 doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations in healthy infants. clinicaltrials.gov/show/NCT00598468 (first received 19 October 2005). SteeleAD , NeuzilKM , CunliffeNA , MadhiSA , BosP , NgwiraB , et al. Human rotavirus vaccine Rotarix provides protection against diverse circulating rotavirus strains in African infants: a randomized controlled trial. BMC Infectious Diseases2012;12:213. ">RIX Madhi 2010‐AF</a>; <a href="./references#CD008521-bbs2-0037" title="GlaxoSmithKline[103992-045]. A phase II, randomised, double-blind, placebo-controlled study to evaluate the immunogenicity, reactogenicity and safety of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine (RIX4414 at 106.5 CCID50) when given concomitantly with OPV versus when given alone (HRV vaccine dose given 15 days after the OPV dose) in healthy infants in Bangladesh. www.gsk-studyregister.com/study/2748 (accessed 12 December 2018). NCT00139334. Evaluate immunogenicity, reactogenicity &amp; safety of 2 doses of GSK Biologicals’ oral live attenuated HRV vaccine (RIX4414 at 106.5 CCID50) when given concomitantly with OPV versus given alone (HRV vaccine dose given 15 days after the OPV dose) in healthy infants in Bangladesh. clinicaltrials.gov/show/NCT00139334 (first received 31 August 2005). ZamanK , SackDA , YunusM , ArifeenSE , PodderG , AzimT , et al, Bangladesh Rotavirus Vaccine study group. Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age. Vaccine2009;27(9):1333-9. ">RIX Zaman 2009‐BGD</a>), and another two in partnership with RAPID trials and the WHO (<a href="./references#CD008521-bbs2-0028" title="GlaxoSmithKline[444563-014]. A phase II, double-blind before the 2002 rotavirus season and single blind with respect to OPV after, randomised, placebo-controlled study of the safety, reactogenicity and immunogenicity of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine (RIX4414 at 105 ffu) co-administered with either oral polio vaccine (OPV) or inactivated polio vaccine (IPV) in healthy infants (approximately 5-10 weeks old) in South Africa. www.gsk-studyregister.com/study/6787 (accessed 12 December 2018). ISRCTN86632774. A phase II, double blind randomised, placebo controlled study to assess the safety reactogenicity and immunogenicity of three doses of GSK Biologicals (South Africa). controlled-trials.com/ISRCTN86632774 (first received 25 November 2005). NCT00346892. Reactogenicity &amp; immunogenicity study of two doses of GSK Biologicals’ oral live attenuated HRV vaccine co-administered with either OPV or IPV in healthy infants (approximately 5-10 weeks old) in South Africa. clinicaltrials.gov/show/NCT00346892 (first received 30 June 2006). SteeleAD ,  De VosB ,  TumboJ ,  ReyndersJ ,  ScholtzF ,  BosP ,  et al. Co-administration study in South African infants of a live-attenuated oral human rotavirus vaccine (RIX4414) and poliovirus vaccines. Vaccine2010 ;28(39):6542-8. SteeleAD , TumboJ , ArmahG , ReyndersJ , ScholtzF , BosP , et al. Immunogenicity and reactogenicity of a new live attenuated oral rotavirus vaccine (RIX4414) when administered concurrently with poliovirus vaccines in African infants. In: 24th International Congress of Pediatrics; 2004 August 15-20; Cancun, Mexico. 2004. [Not available for review]SteeleAD , TumboJM , ArmahGE , ReyndersJ , ScholtzF , BosP , et al. Concomitant administration of a live-attenuated oral rotavirus vaccine (RIX4414) with poliovirus vaccines in African infants. In: 23rd Annual Meeting of the European Society for Pediatric Infectious Diseases - ESPID; 2005 May 18-20; Valencia, Spain. 2005. [Not available for review]">RIX Steele 2008‐ZAF</a>; <a href="./references#CD008521-bbs2-0029" title="EUCTR2015-001484-39. A phase II study to assess the safety and immunogenicity of GlaxoSmithKline Biologicals rotavirus vaccine, RIX4414 when administered to HIV infected infants in South Africa. www.clinicaltrialsregister.eu/ctr-search/trial/2015-001484-39/results (first received 11 June 2015). GlaxoSmithKline[444563-022]. A phase II, double-blind, randomized, placebo-controlled study to assess the safety, reactogenicity and immunogenicity of three doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine. www.gsk-studyregister.com/study/6790 (accessed 12 December 2018). ISRCTN11877362. A phase II, double-blind, randomised, placebo-controlled study to assess the safety, reactogenicity and immunogenicity of three doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine (RIX4414 at 106.5 CCID50) administered to human immunodeficiency virus (HIV) infected infants at 6, 10 and 14 weeks of age in South Africa. www.controlled-trials.com/ISRCTN11877362 (first received 25 November 2005). NCT00263666. A study of safety, reactogenicity and immunogenicity of HRV vaccine in HIV infected infants in South Africa. clinicaltrials.gov/ct2/show/results/NCT00263666 (first received on 9 December 2005). SteeleAD ,  MadhiSA ,  LouwCE ,  BosP ,  TumboJM ,  WernerCM ,  et al. Safety, reactogenicity, and immunogenicity of human rotavirus vaccine RIX4414 in human immunodeficiency virus-positive infants in South Africa. Pediatric Infectious Diseases Journal2011;30(2):125-30. ">RIX Steele 2010a‐ZAF</a>). One trial was funded by The Bill and Melinda Gates Foundation (<a href="./references#CD008521-bbs2-0005" title='ColgateER , HaqueR , DicksonDM , CarmolliMP , MychaleckyjJC , NayakU , et al. Delayed dosing of oral rotavirus vaccine demonstrates decreased risk of rotavirus gastroenteritis associated with serum zinc: a randomized controlled trial. Clinical Infectious Diseases2016;63(5):634-41. KirkpatrickBD , ColgateER , MychaleckyjJC , HaqueR , DicksonDM , CarmolliMP , et al. The "Performance of Rotavirus and Oral Polio Vaccines in Developing Countries" (PROVIDE) study: description of methods of an interventional study designed to explore complex biologic problems. American Journal of Tropical Medicine and Hygiene2015;92(4):744-51. LeeB , DicksonDM , DeCampAC , ColgateER , DiehlSA , UddinMI , et al. Histo-blood group antigen phenotype determines susceptibility to genotype-specific rotavirus infections and impacts measures of rotavirus vaccine efficacy. Journal of Infectious Diseases2018;217(9):1399-407. LeeB , DiehlSA , ColgateER , DicksonDM , UddinMI , SharminS , et al. Lewis antigen and secretor status mediate susceptibility to p-genotype specific rotavirus infections but do not affect rotavirus vaccine performance among infants in Bangladesh. American Journal of Tropical Medicine and Hygiene2017;97:226. NCT01375647. Exploration of the biologic basis for underperformance of oral polio and rotavirus vaccines in Bangladesh PROVIDE. clinicaltrials.gov/show/NCT01375647 (first received 17 June 2011). RogawskiET , Platts-MillsJA , ColgateER , HaqueR , ZamanK , PetriWA , et al. Quantifying the impact of natural immunity on rotavirus vaccine efficacy estimates: a clinical trial in Dhaka, Bangladesh (PROVIDE) and a simulation study. Journal of Infectious Diseases2018;217(6):861-8. '>RIX Colgate 2016‐BGD</a>) and one by GAVI and PATH (<a href="./references#CD008521-bbs2-0038" title="ZamanK , SackDA , NeuzilKM , YunusM , MoultonLH , SugimotoJD , et al. Effectiveness of a live oral human rotavirus vaccine after programmatic introduction in Bangladesh: a cluster-randomized trial. PLOS Medicine2017;14(4):e1002282. ">RIX Zaman 2017‐BGD</a>). Three trials were sponsored by Avant Immunotherapeutics (formerly Virus Research Institute, Inc.) (<a href="./references#CD008521-bbs2-0003" title="BernsteinDI , SmithVE , SherwoodJR , SchiffGM , SanderDS , DeFeudisD , et al. Safety and immunogenicity of live, attenuated human rotavirus vaccine 89-12. Vaccine1998;16(4):381-7. ">RIX Bernstein 1998‐USA</a>; <a href="./references#CD008521-bbs2-0004" title="BernsteinDI , SackDA , ReisingerK , RothsteinE , WardRL . Second-year follow-up evaluation of live, attenuated human rotavirus vaccine 89-12 in healthy infants. Journal of Infectious Diseases2002;186(10):1487-9. BernsteinDI , SackDA , RothsteinE , ReisingerK , SmithVE , O'SullivanD , et al. Efficacy of live, attenuated, human rotavirus vaccine 89-12 in infants: a randomised placebo-controlled trial. Lancet1999;354(9175):287-90. ">RIX Bernstein 1999‐USA</a>; <a href="./references#CD008521-bbs2-0036" title="WardRL , KirkwoodCD , SanderDS , SmithVE , ShaoM , BeanJA , et al. Reductions in cross-neutralizing antibody responses in infants after attenuation of the human rotavirus vaccine candidate 89-12. Journal of Infectious Diseases2006;194(12):1729-36. ">RIX Ward 2006‐USA</a>). </p> </section> </section> <section id="CD008521-sec-0063"> <h5 class="title">2. RotaTeq</h5> <p>We identified 15 trials of RotaTeq vaccine. The earliest was reported in 2003 and the most recent in 2017. One of the trials is unpublished and was accessed via <a href="http://www.clinicalstudyresults.org" target="_blank">clinicalstudyresults.org</a>. Two trials (<a href="./references#CD008521-bbs2-0044" title="ArmahGE ,  SowSO ,  BreimanRF ,  DallasMJ ,  TapiaMD ,  FeikinDR ,  et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet2010;376(9741):606-14. ArmahGE , BreimanRF , TapiaMD , DallasMJ , NeuzilKM , BinkaFN , et al. Immunogenicity of the pentavalent rotavirus vaccine in African infants. Vaccine2012;30(Suppl 1):A86-93. BreimanRF , ZamanK , ArmahG , SowSO , AnhDD , VictorJC , et al. Analyses of health outcomes from the 5 sites participating in the Africa and Asia clinical efficacy trials of the oral pentavalent rotavirus vaccine. Vaccine2012;30(Suppl 1):A24-9. GruberJF , HilleDA , LiuGF , KaplanSS , NelsonM , GoveiaMG , et al. Heterogeneity of rotavirus vaccine efficacy among infants in developing countries. Pediatric Infectious Disease Journal2017;36(1):72-8. HeylenE , ZellerM , CiarletM , LawrenceJ , SteeleD , Van RanstM , et al. Comparative analysis of pentavalent rotavirus vaccine strains and G8 rotaviruses identified during vaccine trial in Africa. Science Reports2015;5:14658. NCT00362648. Efficacy, safety, and immunogenicity of RotaTeqTM among infants in Asia and Africa. clinicaltrials.gov/ct2/show/record/NCT00362648 (first received 10 August 2006). TapiaMD , ArmahG , BreimanRF , DallasMJ , LewisKD , SowSO , et al. Secondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africa. Vaccine2012;30(Suppl 1):A79-85. ">TEQ Armah 2010‐AF</a> and <a href="./references#CD008521-bbs2-0061" title="BreimanRF , ZamanK , ArmahG , SowSO , AnhDD , VictorJC , et al. Analyses of health outcomes from the 5 sites participating in the Africa and Asia clinical efficacy trials of the oral pentavalent rotavirus vaccine. Vaccine2012;30(Suppl 1):A24-9. GruberJF , HilleDA , LiuGF , KaplanSS , NelsonM , GoveiaMG , et al. Heterogeneity of rotavirus vaccine efficacy among infants in developing countries. Pediatric Infectious Disease Journal2017;36(1):72-8. NCT00362648. Efficacy, safety, and immunogenicity of RotaTeqTM among infants in Asia and Africa. clinicaltrials.gov/ct2/show/record/NCT00362648 (first received 8 August 2006). ShinS , AnhDD , ZamanK , YunusM , Mai leTP , ThiemVD , et al. Immunogenicity of the pentavalent rotavirus vaccine among infants in two developing countries in Asia, Bangladesh and Vietnam. Vaccine2012;30(Suppl 1):A106-13. ZamanK ,  DangDA ,  VictorJC ,  ShinS ,  YunusM ,  DallasMJ ,  et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet2010;376(9741):615-23. ">TEQ Zaman 2010‐AS</a>) provided country‐specific data for some outcomes but not for all outcomes, and were consequently split into <a href="./references#CD008521-bbs2-0045" title="ArmahGE ,  SowSO ,  BreimanRF ,  DallasMJ ,  TapiaMD ,  FeikinDR ,  et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet2010;376(9741):606-14. TapiaMD , ArmahG , BreimanRF , DallasMJ , LewisKD , SowSO , et al. Secondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africa. Vaccine2012;30(Suppl 1):A79-85. ">TEQ Armah 2010‐GHA</a>; <a href="./references#CD008521-bbs2-0046" title="ArmahGE ,  SowSO ,  BreimanRF ,  DallasMJ ,  TapiaMD ,  FeikinDR ,  et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet2010;376(9741):606-14. FeikinDR , LasersonKF , OjwandoJ , NyambaneG , SsempijjaV , AudiA , et al. Efficacy of pentavalent rotavirus vaccine in a high HIV prevalence population in Kenya. Vaccine2012;30(Suppl 1):A52-60. LasersonKF , NyakundiD , FeikinDR , NyambaneG , CookE , OyiekoJ , et al. Safety of the pentavalent rotavirus vaccine (PRV), RotaTeq((R)), in Kenya, including among HIV-infected and HIV-exposed infants. Vaccine2012;30(Suppl 1):A61-70. TapiaMD , ArmahG , BreimanRF , DallasMJ , LewisKD , SowSO , et al. Secondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africa. Vaccine2012;30(Suppl 1):A79-85. ">TEQ Armah 2010‐KEN</a>; and <a href="./references#CD008521-bbs2-0047" title="ArmahGE ,  SowSO ,  BreimanRF ,  DallasMJ ,  TapiaMD ,  FeikinDR ,  et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet2010;376(9741):606-14. SowSO , TapiaM , HaidaraFC , CiarletM , DialloF , KodioM , et al. Efficacy of the oral pentavalent rotavirus vaccine in Mali. Vaccine2012;30(Suppl 1):A71-8. TapiaMD , ArmahG , BreimanRF , DallasMJ , LewisKD , SowSO , et al. Secondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africa. Vaccine2012;30(Suppl 1):A79-85. ">TEQ Armah 2010‐MLI</a> for the Ghana‐, Kenya‐, and Mali‐specific data, and <a href="./references#CD008521-bbs2-0062" title="FellerAJ , ZamanK , LewisKD , HossainI , YunusM , SackDA . Malnutrition levels among vaccinated and unvaccinated children between 2 and 3 years of age following enrollment in a randomized clinical trial with the pentavalent rotavirus vaccine (PRV) in Bangladesh. Vaccine2012;30(Suppl 1):A101-5. ZamanK ,  DangDA ,  VictorJC ,  ShinS ,  YunusM ,  DallasMJ ,  et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet2010;376(9741):615-23. ZamanK , YunusM , ArifeenSE , AzimT , FaruqueAS , HuqE , et al. Methodology and lessons-learned from the efficacy clinical trial of the pentavalent rotavirus vaccine in Bangladesh. Vaccine2012;30(Suppl 1):A94-100. ">TEQ Zaman 2010‐BGD</a> and <a href="./references#CD008521-bbs2-0063" title="ZamanK ,  DangDA ,  VictorJC ,  ShinS ,  YunusM ,  DallasMJ ,  et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet2010;376(9741):615-23. ">TEQ Zaman 2010‐VNM</a> for the Bangladesh‐ and Vietnam‐specific data. Overall, 88,934 participants were included in the trials; the largest trial included 70,301 participants (<a href="./references#CD008521-bbs2-0060" title="ChangCC , ChangMH , LinTY , LeeHC , HsiehWS , LeePI . Experience of pentavalent human-bovine reassortant rotavirus vaccine among healthy infants in Taiwan. Journal of the Formosan Medical Association2009;108(4):280-5. ChristieCD , DuncanND , ThameKA , OnoratoMT , SmithHD , MalcolmLG , et al. Pentavalent rotavirus vaccine in developing countries: safety and health care resource utilization. Pediatrics2010;126(6):e1499-506. DennehyPH , GoveiaMG , DallasMJ , HeatonPM . The integrated phase III safety profile of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine. International Journal of Infectious Diseases2007;11(Suppl 2):36-42. [No data available for review]GoveiaMG , DiNubileMJ , DallasMJ , HeatonPM , KuterBJ , REST Study Team. Efficacy of pentavalent human-bovine (WC3) reassortant rotavirus vaccine based on breastfeeding frequency. Pediatric Infectious Disease Journal2008;27(7):656-8. GoveiaMG , RodriguezZM , DallasMJ , ItzlerRF , BoslegoJW , HeatonPM , et al. Safety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infants. Pediatric Infectious Disease Journal2007;26(12):1099-104. [No data available for review]GoveiaMG , SuprunL , ItzlerRF , McFetridgeR , DallasMJ , KuterBJ . Efficacy and safety of pentavalent human-bovine reassortant rotavirus vaccine when administered with greater than 10 weeks between doses. Pediatric Infectious Disease Journal2010;29(3):263-5. GrantL , WattJ , MoultonL , WeatherholtzR , ReidR , SantoshamM , et al. Lack of nonspecific protection against all-cause nonrotavirus gastroenteritis by vaccination with orally administered rotavirus vaccine. Journal of Pediatric Gastroenterology and Nutrition2013;56(6):635-40. GrantLR , WattJP , WeatherholtzRC , MoultonLH , ReidR , SantoshamM , et al. Efficacy of a pentavalent human-bovine reassortant rotavirus vaccine against rotavirus gastroenteritis among American Indian children. Pediatric Infectious Disease Journal2012;31(2):184-8. ItzlerR , KochG , MatsonDO , GotheforsL , Van DammeP , DinubileMJ , et al. Robustness of the healthcare utilization results from the Rotavirus Efficacy and Safety Trial (REST) evaluating the human-bovine (WC3) reassortant pentavalent rotavirus vaccine (RV5). BMC Pediatrics2010;10:42. Merck[PN-006]. Safety and efficacy of pentavalent (G1, G2, G3, G4, and P1) human-bovine reassortant rotavirus vaccine in healthy infants NCT00090233 (PN 006). clinicalstudyresults.org/drugdetails/?indication_id=523&amp;sort=c.company_name&amp;page=1&amp;drug_id=1144 (accessed prior to 19 October 2021). [No data available for review]NCT00090233. Safety and efficacy of pentavalent (G1, G2, G3, G4, and P1) human-bovine reassortant rotavirus vaccine in healthy infants. clinicaltrials.gov/ct2/show/record/NCT00090233 (first received 27 August 2004). [Trial registration document]RodriguezZM , GoveiaMG , StekJE , DallasMJ , BoslegoJW , DiNubileMJ , et al. Concomitant use of an oral live pentavalent human-bovine reassortant rotavirus vaccine with licensed parenteral pediatric vaccines in the United States. Pediatric Infectious Disease Journal2007;26(3):221-7. VesikariT ,  KarvonenA ,  FerranteSA ,  KuterBJ ,  CiarletM . Sustained efficacy of the pentavalent rotavirus vaccine, RV5, up to 3.1 years following the last dose of vaccine. Pediatric Infectious Disease Journal2010;29(10):957-63. VesikariT , ItzlerR , KarvonenA , KorhonenT , Van DammeP , BehreU , et al. RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe. Vaccine2009;28(2):345-51. VesikariT , ItzlerR , MatsonDO , SantoshamM , ChristieCD , CoiaM , et al. Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across three regions (11 countries). International Journal of Infectious Diseases2007;11(Suppl 2):29-35. VesikariT , KarvonenA , FerranteSA , CiarletM . Efficacy of the pentavalent rotavirus vaccine, RotaTeq(R), in Finnish infants up to 3 years of age: the Finnish Extension Study. European Journal of Pediatrics2010;169(11):1379-86. VesikariT , MatsonDO , DennehyP , Van DammeP , SantoshamM , RodriguezZ , et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. New England Journal of Medicine2006;354(1):23-33. ">TEQ Vesikari 2006b‐INT</a>) and the smallest included 48 participants (<a href="./references#CD008521-bbs2-0055" title="LawrenceJ , HeS , HilleD , ShenC , KuterB , SchodelF , et al. A study of RotaTeqTM (pentavalent rotavirus vaccine) in Chinese healthy adults, children and infants. International Journal of Infectious Diseases2012;16(1):e307. NCT00953056. A study of V260 in healthy Chinese adults, children and infants. clinicaltrials.gov/ct2/show/study/NCT00953056 (first received 4 August 2009). ">TEQ Lawrence 2012‐CHN</a>). For the 2012 update of this review, we received new information from Merck (<a href="./references#CD008521-bbs2-0152" title="Merck &amp; Co, Inc. Quality details for 9 RV5 included trials (correspondence). On file 12 March 2012.">Merck 2012</a>) for some of the trials on the outcomes, serious adverse events, intussusception, and deaths. We have incorporated the new information into the analyses and have indicated this in the <a href="./references#CD008521-sec-0288" title="">Characteristics of included studies</a> section. </p> <section id="CD008521-sec-0064"> <h6 class="title">Population</h6> <p>Most trials included healthy infants. One trial included both healthy and HIV‐infected infants (<a href="./references#CD008521-bbs2-0046" title="ArmahGE ,  SowSO ,  BreimanRF ,  DallasMJ ,  TapiaMD ,  FeikinDR ,  et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet2010;376(9741):606-14. FeikinDR , LasersonKF , OjwandoJ , NyambaneG , SsempijjaV , AudiA , et al. Efficacy of pentavalent rotavirus vaccine in a high HIV prevalence population in Kenya. Vaccine2012;30(Suppl 1):A52-60. LasersonKF , NyakundiD , FeikinDR , NyambaneG , CookE , OyiekoJ , et al. Safety of the pentavalent rotavirus vaccine (PRV), RotaTeq((R)), in Kenya, including among HIV-infected and HIV-exposed infants. Vaccine2012;30(Suppl 1):A61-70. TapiaMD , ArmahG , BreimanRF , DallasMJ , LewisKD , SowSO , et al. Secondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africa. Vaccine2012;30(Suppl 1):A79-85. ">TEQ Armah 2010‐KEN</a>), another trial included HIV‐exposed but uninfected and HIV‐infected infants (<a href="./references#CD008521-bbs2-0056" title="LevinMJ , LindseyJC , KaplanSS , SchimanaW , LawrenceJ , McNealMM , et al. Safety and immunogenicity of a live attenuated pentavalent rotavirus vaccine in HIV-exposed infants with or without HIV infection in Africa. AIDS2017;31(1):49-59. NCT00880698. Safety and immunogenicity of a live, attenuated rotavirus (RotaTeqTM) in HIV-1 infected and uninfected children born to HIV-1-infected mothers. clinicaltrials.gov/ct2/show/study/NCT00880698 (first received 14 April 2009). UpretyP , LindseyJ , LevinM , Rainwater-LovettK , ZiemniakC , KaplanS , et al. Enhanced inflammation and rotavirus vaccine responses in perinatal HIV-1 infection. In: Topics in Antiviral Medicine; 23rd Conference on Retroviruses and Opportunistic Infections, CROI; 2016, USA. Vol. 24(E-1). 2016:347. ">TEQ Levin 2017‐AF</a>), and one trial included prematurely‐born infants as well as those born at normal gestation (<a href="./references#CD008521-bbs2-0060" title="ChangCC , ChangMH , LinTY , LeeHC , HsiehWS , LeePI . Experience of pentavalent human-bovine reassortant rotavirus vaccine among healthy infants in Taiwan. Journal of the Formosan Medical Association2009;108(4):280-5. ChristieCD , DuncanND , ThameKA , OnoratoMT , SmithHD , MalcolmLG , et al. Pentavalent rotavirus vaccine in developing countries: safety and health care resource utilization. Pediatrics2010;126(6):e1499-506. DennehyPH , GoveiaMG , DallasMJ , HeatonPM . The integrated phase III safety profile of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine. International Journal of Infectious Diseases2007;11(Suppl 2):36-42. [No data available for review]GoveiaMG , DiNubileMJ , DallasMJ , HeatonPM , KuterBJ , REST Study Team. Efficacy of pentavalent human-bovine (WC3) reassortant rotavirus vaccine based on breastfeeding frequency. Pediatric Infectious Disease Journal2008;27(7):656-8. GoveiaMG , RodriguezZM , DallasMJ , ItzlerRF , BoslegoJW , HeatonPM , et al. Safety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infants. Pediatric Infectious Disease Journal2007;26(12):1099-104. [No data available for review]GoveiaMG , SuprunL , ItzlerRF , McFetridgeR , DallasMJ , KuterBJ . Efficacy and safety of pentavalent human-bovine reassortant rotavirus vaccine when administered with greater than 10 weeks between doses. Pediatric Infectious Disease Journal2010;29(3):263-5. GrantL , WattJ , MoultonL , WeatherholtzR , ReidR , SantoshamM , et al. Lack of nonspecific protection against all-cause nonrotavirus gastroenteritis by vaccination with orally administered rotavirus vaccine. Journal of Pediatric Gastroenterology and Nutrition2013;56(6):635-40. GrantLR , WattJP , WeatherholtzRC , MoultonLH , ReidR , SantoshamM , et al. Efficacy of a pentavalent human-bovine reassortant rotavirus vaccine against rotavirus gastroenteritis among American Indian children. Pediatric Infectious Disease Journal2012;31(2):184-8. ItzlerR , KochG , MatsonDO , GotheforsL , Van DammeP , DinubileMJ , et al. Robustness of the healthcare utilization results from the Rotavirus Efficacy and Safety Trial (REST) evaluating the human-bovine (WC3) reassortant pentavalent rotavirus vaccine (RV5). BMC Pediatrics2010;10:42. Merck[PN-006]. Safety and efficacy of pentavalent (G1, G2, G3, G4, and P1) human-bovine reassortant rotavirus vaccine in healthy infants NCT00090233 (PN 006). clinicalstudyresults.org/drugdetails/?indication_id=523&amp;sort=c.company_name&amp;page=1&amp;drug_id=1144 (accessed prior to 19 October 2021). [No data available for review]NCT00090233. Safety and efficacy of pentavalent (G1, G2, G3, G4, and P1) human-bovine reassortant rotavirus vaccine in healthy infants. clinicaltrials.gov/ct2/show/record/NCT00090233 (first received 27 August 2004). [Trial registration document]RodriguezZM , GoveiaMG , StekJE , DallasMJ , BoslegoJW , DiNubileMJ , et al. Concomitant use of an oral live pentavalent human-bovine reassortant rotavirus vaccine with licensed parenteral pediatric vaccines in the United States. Pediatric Infectious Disease Journal2007;26(3):221-7. VesikariT ,  KarvonenA ,  FerranteSA ,  KuterBJ ,  CiarletM . Sustained efficacy of the pentavalent rotavirus vaccine, RV5, up to 3.1 years following the last dose of vaccine. Pediatric Infectious Disease Journal2010;29(10):957-63. VesikariT , ItzlerR , KarvonenA , KorhonenT , Van DammeP , BehreU , et al. RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe. Vaccine2009;28(2):345-51. VesikariT , ItzlerR , MatsonDO , SantoshamM , ChristieCD , CoiaM , et al. Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across three regions (11 countries). International Journal of Infectious Diseases2007;11(Suppl 2):29-35. VesikariT , KarvonenA , FerranteSA , CiarletM . Efficacy of the pentavalent rotavirus vaccine, RotaTeq(R), in Finnish infants up to 3 years of age: the Finnish Extension Study. European Journal of Pediatrics2010;169(11):1379-86. VesikariT , MatsonDO , DennehyP , Van DammeP , SantoshamM , RodriguezZ , et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. New England Journal of Medicine2006;354(1):23-33. ">TEQ Vesikari 2006b‐INT</a>). All but two trials enrolled children aged between one month and three months; the children in <a href="./references#CD008521-bbs2-0059" title="VesikariT , ClarkHF , OffitP , SchodelF , DallasM , HeatonP , et al. The effect of dose and composition of a pentavalent rotavirus reassortant vaccine [RotaTeq (R)] in safety, efficacy, and immunogenicity in healthy infants. Pediatric Research2003;53(4 Suppl):307A. VesikariT , ClarkHF , OffitPA , DallasMJ , DiStefanoDJ , GoveiaMG , et al. Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants. Vaccine2006;24(22):4821-9. ">TEQ Vesikari 2006a‐FIN</a> were aged between three months and six months, and there was a child cohort (2‐ to 6‐year‐old children) in addition to an infant cohort in <a href="./references#CD008521-bbs2-0055" title="LawrenceJ , HeS , HilleD , ShenC , KuterB , SchodelF , et al. A study of RotaTeqTM (pentavalent rotavirus vaccine) in Chinese healthy adults, children and infants. International Journal of Infectious Diseases2012;16(1):e307. NCT00953056. A study of V260 in healthy Chinese adults, children and infants. clinicaltrials.gov/ct2/show/study/NCT00953056 (first received 4 August 2009). ">TEQ Lawrence 2012‐CHN</a>. </p> </section> <section id="CD008521-sec-0065"> <h6 class="title">Outcome measures</h6> <p>Six trials were safety studies (<a href="./appendices#CD008521-sec-0270">Appendix 1</a>), reporting safety outcomes (e.g. serious adverse events and reactogenicity). The other nine trials reported one or more efficacy and safety outcomes (<a href="./appendices#CD008521-sec-0270">Appendix 1</a>). The trials varied in the length of follow‐up (<a href="./appendices#CD008521-sec-0270">Appendix 1</a>), but in general the trials that specified efficacy outcome measures had longer follow‐up times (up to three years). Similar to the Rotarix trials, we included data on participants requiring medical visits, as this was reported in some trials and is a similar outcome measure to participants requiring hospitalization. </p> <p>As shown in <a href="./appendices#CD008521-sec-0271">Appendix 2</a>, rotavirus diarrhoea, severe cases and cases of any severity, were the most common efficacy outcomes reported (by eight trials); only one of these reported rotavirus diarrhoea requiring hospitalization. Three trials provided data on severe cases of all‐cause diarrhoea; two also presented data on cases with any severity. Eleven trials reported all‐cause death, and 13 of the 15 trials reported dropouts. </p> <p>For safety outcomes, all trials reported on serious adverse events and reactogenicity, and 13 trials reported on adverse events leading to discontinuation of the intervention; see <a href="./appendices#CD008521-sec-0272">Appendix 3</a>. </p> </section> <section id="CD008521-sec-0066"> <h6 class="title">Location</h6> <p>Half of the trials were conducted in low‐mortality countries in North America and Europe. Six trials, including the smallest and the largest trials, were conducted in other regions: <a href="./references#CD008521-bbs2-0044" title="ArmahGE ,  SowSO ,  BreimanRF ,  DallasMJ ,  TapiaMD ,  FeikinDR ,  et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet2010;376(9741):606-14. ArmahGE , BreimanRF , TapiaMD , DallasMJ , NeuzilKM , BinkaFN , et al. Immunogenicity of the pentavalent rotavirus vaccine in African infants. Vaccine2012;30(Suppl 1):A86-93. BreimanRF , ZamanK , ArmahG , SowSO , AnhDD , VictorJC , et al. Analyses of health outcomes from the 5 sites participating in the Africa and Asia clinical efficacy trials of the oral pentavalent rotavirus vaccine. Vaccine2012;30(Suppl 1):A24-9. GruberJF , HilleDA , LiuGF , KaplanSS , NelsonM , GoveiaMG , et al. Heterogeneity of rotavirus vaccine efficacy among infants in developing countries. Pediatric Infectious Disease Journal2017;36(1):72-8. HeylenE , ZellerM , CiarletM , LawrenceJ , SteeleD , Van RanstM , et al. Comparative analysis of pentavalent rotavirus vaccine strains and G8 rotaviruses identified during vaccine trial in Africa. Science Reports2015;5:14658. NCT00362648. Efficacy, safety, and immunogenicity of RotaTeqTM among infants in Asia and Africa. clinicaltrials.gov/ct2/show/record/NCT00362648 (first received 10 August 2006). TapiaMD , ArmahG , BreimanRF , DallasMJ , LewisKD , SowSO , et al. Secondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africa. Vaccine2012;30(Suppl 1):A79-85. ">TEQ Armah 2010‐AF</a> was conducted in Ghana, Kenya and Mali; <a href="./references#CD008521-bbs2-0056" title="LevinMJ , LindseyJC , KaplanSS , SchimanaW , LawrenceJ , McNealMM , et al. Safety and immunogenicity of a live attenuated pentavalent rotavirus vaccine in HIV-exposed infants with or without HIV infection in Africa. AIDS2017;31(1):49-59. NCT00880698. Safety and immunogenicity of a live, attenuated rotavirus (RotaTeqTM) in HIV-1 infected and uninfected children born to HIV-1-infected mothers. clinicaltrials.gov/ct2/show/study/NCT00880698 (first received 14 April 2009). UpretyP , LindseyJ , LevinM , Rainwater-LovettK , ZiemniakC , KaplanS , et al. Enhanced inflammation and rotavirus vaccine responses in perinatal HIV-1 infection. In: Topics in Antiviral Medicine; 23rd Conference on Retroviruses and Opportunistic Infections, CROI; 2016, USA. Vol. 24(E-1). 2016:347. ">TEQ Levin 2017‐AF</a> was conducted in Botswana, Tanzania, Zambia and Zimbabwe, <a href="./references#CD008521-bbs2-0052" title="CTRI/2012/07/002820. A study to evaluate safety of Rotavirus vaccine in healthy adult volunteers followed by safety, tolerability and immunogenicity evaluation in healthy infants. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=4929&amp;EncHid=&amp;userName=CTRI/2012/07/002820 (first received 23 July 2012). DhingraMS , KunduR , GuptaM , KanungoS , GangulyN , SinghMP , et al. Evaluation of safety and immunogenicity of a live attenuated tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus vaccine (BRV-TV) in healthy Indian adults and infants. Vaccine2014;32(Suppl 1):A117-23. ">TEQ Dhingra 2014‐IND</a> was conducted in India, <a href="./references#CD008521-bbs2-0054" title="KimDS , LeeTJ , KangJH , KimJH , LeeJH , MaSH , et al. Immunogenicity and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy infants in Korea. Pediatric Infectious Disease Journal2008;27(2):177-8. Merck[PN-013]. Immunogenicity and safety of RotaTeq® in healthy infants in Korea - NCT00166517 (PN 013). clinicalstudyresults.org/drugdetails/?indication_id=523&amp;sort=c.company_name&amp;page=1&amp;drug_id=2148 (accessed prior to 19 October 2021). NCT00166517. Immunogenicity and safety of V260 in healthy infants in Korea. clinicaltrials.gov/show/NCT00166517 (first received 14 September 2005). [Trial registration document (no data for review)]">TEQ Kim 2008‐KOR</a> was conducted in South Korea; <a href="./references#CD008521-bbs2-0053" title="IwataS , NakataS , UkaeS , KoizumiY , MoritaY , KurokiH , et al. Efficacy and safety of pentavalent rotavirus vaccine in Japan: a randomized, double-blind, placebo-controlled, multicenter trial. Human Vaccines and Immunotherapeutics2013;9(8):1626-33. NCT00718237. A phase III randomized, placebo-controlled clinical trial to study the efficacy and safety of V260 in healthy infants in Japan. clinicaltrials.gov/ct2/show/record/NCT00718237 (first received 16 July 2008). ">TEQ Iwata 2013‐JPN</a> was conducted in Japan; <a href="./references#CD008521-bbs2-0055" title="LawrenceJ , HeS , HilleD , ShenC , KuterB , SchodelF , et al. A study of RotaTeqTM (pentavalent rotavirus vaccine) in Chinese healthy adults, children and infants. International Journal of Infectious Diseases2012;16(1):e307. NCT00953056. A study of V260 in healthy Chinese adults, children and infants. clinicaltrials.gov/ct2/show/study/NCT00953056 (first received 4 August 2009). ">TEQ Lawrence 2012‐CHN</a> and <a href="./references#CD008521-bbs2-0058" title="MoZ , MoY , LiM , TaoJ , YangX , KongJ , et al. Efficacy and safety of a pentavalent live human-bovine reassortant rotavirus vaccine (RV5) in healthy Chinese infants: a randomized, double-blind, placebo-controlled trial. Vaccine2017;35(43):5897-904. NCT02062385. Efficacy, safety, and immunogenicity of V260 in healthy Chinese infants (V260-024). clinicaltrials.gov/show/NCT02062385 (first received 13 February 2014). ">TEQ Mo 2017‐CHN</a> were conducted in China; <a href="./references#CD008521-bbs2-0060" title="ChangCC , ChangMH , LinTY , LeeHC , HsiehWS , LeePI . Experience of pentavalent human-bovine reassortant rotavirus vaccine among healthy infants in Taiwan. Journal of the Formosan Medical Association2009;108(4):280-5. ChristieCD , DuncanND , ThameKA , OnoratoMT , SmithHD , MalcolmLG , et al. Pentavalent rotavirus vaccine in developing countries: safety and health care resource utilization. Pediatrics2010;126(6):e1499-506. DennehyPH , GoveiaMG , DallasMJ , HeatonPM . The integrated phase III safety profile of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine. International Journal of Infectious Diseases2007;11(Suppl 2):36-42. [No data available for review]GoveiaMG , DiNubileMJ , DallasMJ , HeatonPM , KuterBJ , REST Study Team. Efficacy of pentavalent human-bovine (WC3) reassortant rotavirus vaccine based on breastfeeding frequency. Pediatric Infectious Disease Journal2008;27(7):656-8. GoveiaMG , RodriguezZM , DallasMJ , ItzlerRF , BoslegoJW , HeatonPM , et al. Safety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infants. Pediatric Infectious Disease Journal2007;26(12):1099-104. [No data available for review]GoveiaMG , SuprunL , ItzlerRF , McFetridgeR , DallasMJ , KuterBJ . Efficacy and safety of pentavalent human-bovine reassortant rotavirus vaccine when administered with greater than 10 weeks between doses. Pediatric Infectious Disease Journal2010;29(3):263-5. GrantL , WattJ , MoultonL , WeatherholtzR , ReidR , SantoshamM , et al. Lack of nonspecific protection against all-cause nonrotavirus gastroenteritis by vaccination with orally administered rotavirus vaccine. Journal of Pediatric Gastroenterology and Nutrition2013;56(6):635-40. GrantLR , WattJP , WeatherholtzRC , MoultonLH , ReidR , SantoshamM , et al. Efficacy of a pentavalent human-bovine reassortant rotavirus vaccine against rotavirus gastroenteritis among American Indian children. Pediatric Infectious Disease Journal2012;31(2):184-8. ItzlerR , KochG , MatsonDO , GotheforsL , Van DammeP , DinubileMJ , et al. Robustness of the healthcare utilization results from the Rotavirus Efficacy and Safety Trial (REST) evaluating the human-bovine (WC3) reassortant pentavalent rotavirus vaccine (RV5). BMC Pediatrics2010;10:42. Merck[PN-006]. Safety and efficacy of pentavalent (G1, G2, G3, G4, and P1) human-bovine reassortant rotavirus vaccine in healthy infants NCT00090233 (PN 006). clinicalstudyresults.org/drugdetails/?indication_id=523&amp;sort=c.company_name&amp;page=1&amp;drug_id=1144 (accessed prior to 19 October 2021). [No data available for review]NCT00090233. Safety and efficacy of pentavalent (G1, G2, G3, G4, and P1) human-bovine reassortant rotavirus vaccine in healthy infants. clinicaltrials.gov/ct2/show/record/NCT00090233 (first received 27 August 2004). [Trial registration document]RodriguezZM , GoveiaMG , StekJE , DallasMJ , BoslegoJW , DiNubileMJ , et al. Concomitant use of an oral live pentavalent human-bovine reassortant rotavirus vaccine with licensed parenteral pediatric vaccines in the United States. Pediatric Infectious Disease Journal2007;26(3):221-7. VesikariT ,  KarvonenA ,  FerranteSA ,  KuterBJ ,  CiarletM . Sustained efficacy of the pentavalent rotavirus vaccine, RV5, up to 3.1 years following the last dose of vaccine. Pediatric Infectious Disease Journal2010;29(10):957-63. VesikariT , ItzlerR , KarvonenA , KorhonenT , Van DammeP , BehreU , et al. RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe. Vaccine2009;28(2):345-51. VesikariT , ItzlerR , MatsonDO , SantoshamM , ChristieCD , CoiaM , et al. Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across three regions (11 countries). International Journal of Infectious Diseases2007;11(Suppl 2):29-35. VesikariT , KarvonenA , FerranteSA , CiarletM . Efficacy of the pentavalent rotavirus vaccine, RotaTeq(R), in Finnish infants up to 3 years of age: the Finnish Extension Study. European Journal of Pediatrics2010;169(11):1379-86. VesikariT , MatsonDO , DennehyP , Van DammeP , SantoshamM , RodriguezZ , et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. New England Journal of Medicine2006;354(1):23-33. ">TEQ Vesikari 2006b‐INT</a> was conducted in 12 countries in Asia, the Caribbean, Europe, Latin America, North America; and <a href="./references#CD008521-bbs2-0061" title="BreimanRF , ZamanK , ArmahG , SowSO , AnhDD , VictorJC , et al. Analyses of health outcomes from the 5 sites participating in the Africa and Asia clinical efficacy trials of the oral pentavalent rotavirus vaccine. Vaccine2012;30(Suppl 1):A24-9. GruberJF , HilleDA , LiuGF , KaplanSS , NelsonM , GoveiaMG , et al. Heterogeneity of rotavirus vaccine efficacy among infants in developing countries. Pediatric Infectious Disease Journal2017;36(1):72-8. NCT00362648. Efficacy, safety, and immunogenicity of RotaTeqTM among infants in Asia and Africa. clinicaltrials.gov/ct2/show/record/NCT00362648 (first received 8 August 2006). ShinS , AnhDD , ZamanK , YunusM , Mai leTP , ThiemVD , et al. Immunogenicity of the pentavalent rotavirus vaccine among infants in two developing countries in Asia, Bangladesh and Vietnam. Vaccine2012;30(Suppl 1):A106-13. ZamanK ,  DangDA ,  VictorJC ,  ShinS ,  YunusM ,  DallasMJ ,  et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet2010;376(9741):615-23. ">TEQ Zaman 2010‐AS</a> was conducted in Bangladesh and Vietnam. Each trial had multiple sites, ranging from three (<a href="./references#CD008521-bbs2-0059" title="VesikariT , ClarkHF , OffitP , SchodelF , DallasM , HeatonP , et al. The effect of dose and composition of a pentavalent rotavirus reassortant vaccine [RotaTeq (R)] in safety, efficacy, and immunogenicity in healthy infants. Pediatric Research2003;53(4 Suppl):307A. VesikariT , ClarkHF , OffitPA , DallasMJ , DiStefanoDJ , GoveiaMG , et al. Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants. Vaccine2006;24(22):4821-9. ">TEQ Vesikari 2006a‐FIN</a>) to 356 sites (<a href="./references#CD008521-bbs2-0060" title="ChangCC , ChangMH , LinTY , LeeHC , HsiehWS , LeePI . Experience of pentavalent human-bovine reassortant rotavirus vaccine among healthy infants in Taiwan. Journal of the Formosan Medical Association2009;108(4):280-5. ChristieCD , DuncanND , ThameKA , OnoratoMT , SmithHD , MalcolmLG , et al. Pentavalent rotavirus vaccine in developing countries: safety and health care resource utilization. Pediatrics2010;126(6):e1499-506. DennehyPH , GoveiaMG , DallasMJ , HeatonPM . The integrated phase III safety profile of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine. International Journal of Infectious Diseases2007;11(Suppl 2):36-42. [No data available for review]GoveiaMG , DiNubileMJ , DallasMJ , HeatonPM , KuterBJ , REST Study Team. Efficacy of pentavalent human-bovine (WC3) reassortant rotavirus vaccine based on breastfeeding frequency. Pediatric Infectious Disease Journal2008;27(7):656-8. GoveiaMG , RodriguezZM , DallasMJ , ItzlerRF , BoslegoJW , HeatonPM , et al. Safety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infants. Pediatric Infectious Disease Journal2007;26(12):1099-104. [No data available for review]GoveiaMG , SuprunL , ItzlerRF , McFetridgeR , DallasMJ , KuterBJ . Efficacy and safety of pentavalent human-bovine reassortant rotavirus vaccine when administered with greater than 10 weeks between doses. Pediatric Infectious Disease Journal2010;29(3):263-5. GrantL , WattJ , MoultonL , WeatherholtzR , ReidR , SantoshamM , et al. Lack of nonspecific protection against all-cause nonrotavirus gastroenteritis by vaccination with orally administered rotavirus vaccine. Journal of Pediatric Gastroenterology and Nutrition2013;56(6):635-40. GrantLR , WattJP , WeatherholtzRC , MoultonLH , ReidR , SantoshamM , et al. Efficacy of a pentavalent human-bovine reassortant rotavirus vaccine against rotavirus gastroenteritis among American Indian children. Pediatric Infectious Disease Journal2012;31(2):184-8. ItzlerR , KochG , MatsonDO , GotheforsL , Van DammeP , DinubileMJ , et al. Robustness of the healthcare utilization results from the Rotavirus Efficacy and Safety Trial (REST) evaluating the human-bovine (WC3) reassortant pentavalent rotavirus vaccine (RV5). BMC Pediatrics2010;10:42. Merck[PN-006]. Safety and efficacy of pentavalent (G1, G2, G3, G4, and P1) human-bovine reassortant rotavirus vaccine in healthy infants NCT00090233 (PN 006). clinicalstudyresults.org/drugdetails/?indication_id=523&amp;sort=c.company_name&amp;page=1&amp;drug_id=1144 (accessed prior to 19 October 2021). [No data available for review]NCT00090233. Safety and efficacy of pentavalent (G1, G2, G3, G4, and P1) human-bovine reassortant rotavirus vaccine in healthy infants. clinicaltrials.gov/ct2/show/record/NCT00090233 (first received 27 August 2004). [Trial registration document]RodriguezZM , GoveiaMG , StekJE , DallasMJ , BoslegoJW , DiNubileMJ , et al. Concomitant use of an oral live pentavalent human-bovine reassortant rotavirus vaccine with licensed parenteral pediatric vaccines in the United States. Pediatric Infectious Disease Journal2007;26(3):221-7. VesikariT ,  KarvonenA ,  FerranteSA ,  KuterBJ ,  CiarletM . Sustained efficacy of the pentavalent rotavirus vaccine, RV5, up to 3.1 years following the last dose of vaccine. Pediatric Infectious Disease Journal2010;29(10):957-63. VesikariT , ItzlerR , KarvonenA , KorhonenT , Van DammeP , BehreU , et al. RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe. Vaccine2009;28(2):345-51. VesikariT , ItzlerR , MatsonDO , SantoshamM , ChristieCD , CoiaM , et al. Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across three regions (11 countries). International Journal of Infectious Diseases2007;11(Suppl 2):29-35. VesikariT , KarvonenA , FerranteSA , CiarletM . Efficacy of the pentavalent rotavirus vaccine, RotaTeq(R), in Finnish infants up to 3 years of age: the Finnish Extension Study. European Journal of Pediatrics2010;169(11):1379-86. VesikariT , MatsonDO , DennehyP , Van DammeP , SantoshamM , RodriguezZ , et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. New England Journal of Medicine2006;354(1):23-33. ">TEQ Vesikari 2006b‐INT</a>); see <a href="./appendices#CD008521-sec-0273">Appendix 4</a>. </p> </section> <section id="CD008521-sec-0067"> <h6 class="title">Country mortality rate</h6> <p>Nine trials were conducted in countries with low‐mortality rates, two trials were conducted in medium‐mortality countries, and four trials in high‐mortality countries; see <a href="./appendices#CD008521-sec-0273">Appendix 4</a>. <a href="./references#CD008521-bbs2-0044" title="ArmahGE ,  SowSO ,  BreimanRF ,  DallasMJ ,  TapiaMD ,  FeikinDR ,  et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet2010;376(9741):606-14. ArmahGE , BreimanRF , TapiaMD , DallasMJ , NeuzilKM , BinkaFN , et al. Immunogenicity of the pentavalent rotavirus vaccine in African infants. Vaccine2012;30(Suppl 1):A86-93. BreimanRF , ZamanK , ArmahG , SowSO , AnhDD , VictorJC , et al. Analyses of health outcomes from the 5 sites participating in the Africa and Asia clinical efficacy trials of the oral pentavalent rotavirus vaccine. Vaccine2012;30(Suppl 1):A24-9. GruberJF , HilleDA , LiuGF , KaplanSS , NelsonM , GoveiaMG , et al. Heterogeneity of rotavirus vaccine efficacy among infants in developing countries. Pediatric Infectious Disease Journal2017;36(1):72-8. HeylenE , ZellerM , CiarletM , LawrenceJ , SteeleD , Van RanstM , et al. Comparative analysis of pentavalent rotavirus vaccine strains and G8 rotaviruses identified during vaccine trial in Africa. Science Reports2015;5:14658. NCT00362648. Efficacy, safety, and immunogenicity of RotaTeqTM among infants in Asia and Africa. clinicaltrials.gov/ct2/show/record/NCT00362648 (first received 10 August 2006). TapiaMD , ArmahG , BreimanRF , DallasMJ , LewisKD , SowSO , et al. Secondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africa. Vaccine2012;30(Suppl 1):A79-85. ">TEQ Armah 2010‐AF</a> was conducted in three high‐mortality countries, Ghana, Kenya, and Mali and, when available, the data were split into <a href="./references#CD008521-bbs2-0045" title="ArmahGE ,  SowSO ,  BreimanRF ,  DallasMJ ,  TapiaMD ,  FeikinDR ,  et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet2010;376(9741):606-14. TapiaMD , ArmahG , BreimanRF , DallasMJ , LewisKD , SowSO , et al. Secondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africa. Vaccine2012;30(Suppl 1):A79-85. ">TEQ Armah 2010‐GHA</a>, <a href="./references#CD008521-bbs2-0046" title="ArmahGE ,  SowSO ,  BreimanRF ,  DallasMJ ,  TapiaMD ,  FeikinDR ,  et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet2010;376(9741):606-14. FeikinDR , LasersonKF , OjwandoJ , NyambaneG , SsempijjaV , AudiA , et al. Efficacy of pentavalent rotavirus vaccine in a high HIV prevalence population in Kenya. Vaccine2012;30(Suppl 1):A52-60. LasersonKF , NyakundiD , FeikinDR , NyambaneG , CookE , OyiekoJ , et al. Safety of the pentavalent rotavirus vaccine (PRV), RotaTeq((R)), in Kenya, including among HIV-infected and HIV-exposed infants. Vaccine2012;30(Suppl 1):A61-70. TapiaMD , ArmahG , BreimanRF , DallasMJ , LewisKD , SowSO , et al. Secondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africa. Vaccine2012;30(Suppl 1):A79-85. ">TEQ Armah 2010‐KEN</a> and <a href="./references#CD008521-bbs2-0047" title="ArmahGE ,  SowSO ,  BreimanRF ,  DallasMJ ,  TapiaMD ,  FeikinDR ,  et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet2010;376(9741):606-14. SowSO , TapiaM , HaidaraFC , CiarletM , DialloF , KodioM , et al. Efficacy of the oral pentavalent rotavirus vaccine in Mali. Vaccine2012;30(Suppl 1):A71-8. TapiaMD , ArmahG , BreimanRF , DallasMJ , LewisKD , SowSO , et al. Secondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africa. Vaccine2012;30(Suppl 1):A79-85. ">TEQ Armah 2010‐MLI</a>. <a href="./references#CD008521-bbs2-0061" title="BreimanRF , ZamanK , ArmahG , SowSO , AnhDD , VictorJC , et al. Analyses of health outcomes from the 5 sites participating in the Africa and Asia clinical efficacy trials of the oral pentavalent rotavirus vaccine. Vaccine2012;30(Suppl 1):A24-9. GruberJF , HilleDA , LiuGF , KaplanSS , NelsonM , GoveiaMG , et al. Heterogeneity of rotavirus vaccine efficacy among infants in developing countries. Pediatric Infectious Disease Journal2017;36(1):72-8. NCT00362648. Efficacy, safety, and immunogenicity of RotaTeqTM among infants in Asia and Africa. clinicaltrials.gov/ct2/show/record/NCT00362648 (first received 8 August 2006). ShinS , AnhDD , ZamanK , YunusM , Mai leTP , ThiemVD , et al. Immunogenicity of the pentavalent rotavirus vaccine among infants in two developing countries in Asia, Bangladesh and Vietnam. Vaccine2012;30(Suppl 1):A106-13. ZamanK ,  DangDA ,  VictorJC ,  ShinS ,  YunusM ,  DallasMJ ,  et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet2010;376(9741):615-23. ">TEQ Zaman 2010‐AS</a> was conducted in high‐mortality Bangladesh and Vietnam and, when available, the data were split into <a href="./references#CD008521-bbs2-0062" title="FellerAJ , ZamanK , LewisKD , HossainI , YunusM , SackDA . Malnutrition levels among vaccinated and unvaccinated children between 2 and 3 years of age following enrollment in a randomized clinical trial with the pentavalent rotavirus vaccine (PRV) in Bangladesh. Vaccine2012;30(Suppl 1):A101-5. ZamanK ,  DangDA ,  VictorJC ,  ShinS ,  YunusM ,  DallasMJ ,  et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet2010;376(9741):615-23. ZamanK , YunusM , ArifeenSE , AzimT , FaruqueAS , HuqE , et al. Methodology and lessons-learned from the efficacy clinical trial of the pentavalent rotavirus vaccine in Bangladesh. Vaccine2012;30(Suppl 1):A94-100. ">TEQ Zaman 2010‐BGD</a> and <a href="./references#CD008521-bbs2-0063" title="ZamanK ,  DangDA ,  VictorJC ,  ShinS ,  YunusM ,  DallasMJ ,  et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet2010;376(9741):615-23. ">TEQ Zaman 2010‐VNM</a>. <a href="./references#CD008521-bbs2-0060" title="ChangCC , ChangMH , LinTY , LeeHC , HsiehWS , LeePI . Experience of pentavalent human-bovine reassortant rotavirus vaccine among healthy infants in Taiwan. Journal of the Formosan Medical Association2009;108(4):280-5. ChristieCD , DuncanND , ThameKA , OnoratoMT , SmithHD , MalcolmLG , et al. Pentavalent rotavirus vaccine in developing countries: safety and health care resource utilization. Pediatrics2010;126(6):e1499-506. DennehyPH , GoveiaMG , DallasMJ , HeatonPM . The integrated phase III safety profile of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine. International Journal of Infectious Diseases2007;11(Suppl 2):36-42. [No data available for review]GoveiaMG , DiNubileMJ , DallasMJ , HeatonPM , KuterBJ , REST Study Team. Efficacy of pentavalent human-bovine (WC3) reassortant rotavirus vaccine based on breastfeeding frequency. Pediatric Infectious Disease Journal2008;27(7):656-8. GoveiaMG , RodriguezZM , DallasMJ , ItzlerRF , BoslegoJW , HeatonPM , et al. Safety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infants. Pediatric Infectious Disease Journal2007;26(12):1099-104. [No data available for review]GoveiaMG , SuprunL , ItzlerRF , McFetridgeR , DallasMJ , KuterBJ . Efficacy and safety of pentavalent human-bovine reassortant rotavirus vaccine when administered with greater than 10 weeks between doses. Pediatric Infectious Disease Journal2010;29(3):263-5. GrantL , WattJ , MoultonL , WeatherholtzR , ReidR , SantoshamM , et al. Lack of nonspecific protection against all-cause nonrotavirus gastroenteritis by vaccination with orally administered rotavirus vaccine. Journal of Pediatric Gastroenterology and Nutrition2013;56(6):635-40. GrantLR , WattJP , WeatherholtzRC , MoultonLH , ReidR , SantoshamM , et al. Efficacy of a pentavalent human-bovine reassortant rotavirus vaccine against rotavirus gastroenteritis among American Indian children. Pediatric Infectious Disease Journal2012;31(2):184-8. ItzlerR , KochG , MatsonDO , GotheforsL , Van DammeP , DinubileMJ , et al. Robustness of the healthcare utilization results from the Rotavirus Efficacy and Safety Trial (REST) evaluating the human-bovine (WC3) reassortant pentavalent rotavirus vaccine (RV5). BMC Pediatrics2010;10:42. Merck[PN-006]. Safety and efficacy of pentavalent (G1, G2, G3, G4, and P1) human-bovine reassortant rotavirus vaccine in healthy infants NCT00090233 (PN 006). clinicalstudyresults.org/drugdetails/?indication_id=523&amp;sort=c.company_name&amp;page=1&amp;drug_id=1144 (accessed prior to 19 October 2021). [No data available for review]NCT00090233. Safety and efficacy of pentavalent (G1, G2, G3, G4, and P1) human-bovine reassortant rotavirus vaccine in healthy infants. clinicaltrials.gov/ct2/show/record/NCT00090233 (first received 27 August 2004). [Trial registration document]RodriguezZM , GoveiaMG , StekJE , DallasMJ , BoslegoJW , DiNubileMJ , et al. Concomitant use of an oral live pentavalent human-bovine reassortant rotavirus vaccine with licensed parenteral pediatric vaccines in the United States. Pediatric Infectious Disease Journal2007;26(3):221-7. VesikariT ,  KarvonenA ,  FerranteSA ,  KuterBJ ,  CiarletM . Sustained efficacy of the pentavalent rotavirus vaccine, RV5, up to 3.1 years following the last dose of vaccine. Pediatric Infectious Disease Journal2010;29(10):957-63. VesikariT , ItzlerR , KarvonenA , KorhonenT , Van DammeP , BehreU , et al. RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe. Vaccine2009;28(2):345-51. VesikariT , ItzlerR , MatsonDO , SantoshamM , ChristieCD , CoiaM , et al. Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across three regions (11 countries). International Journal of Infectious Diseases2007;11(Suppl 2):29-35. VesikariT , KarvonenA , FerranteSA , CiarletM . Efficacy of the pentavalent rotavirus vaccine, RotaTeq(R), in Finnish infants up to 3 years of age: the Finnish Extension Study. European Journal of Pediatrics2010;169(11):1379-86. VesikariT , MatsonDO , DennehyP , Van DammeP , SantoshamM , RodriguezZ , et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. New England Journal of Medicine2006;354(1):23-33. ">TEQ Vesikari 2006b‐INT</a> was conducted mainly in European and American low‐mortality countries (Belgium, Finland, Germany, Italy, Puerto Rico, Sweden, Taiwan, USA), but also in medium‐mortality countries (Costa Rica, Jamaica, Mexico) and high‐mortality Guatemala, and was placed in the low‐mortality group. </p> </section> <section id="CD008521-sec-0068"> <h6 class="title">Vaccine schedule</h6> <p>Each trial used three doses of RotaTeq vaccine, with intervals between doses of four and 10 weeks (see <a href="./appendices#CD008521-sec-0274">Appendix 5</a>). All but two trials had one vaccine and one placebo arm; <a href="./references#CD008521-bbs2-0059" title="VesikariT , ClarkHF , OffitP , SchodelF , DallasM , HeatonP , et al. The effect of dose and composition of a pentavalent rotavirus reassortant vaccine [RotaTeq (R)] in safety, efficacy, and immunogenicity in healthy infants. Pediatric Research2003;53(4 Suppl):307A. VesikariT , ClarkHF , OffitPA , DallasMJ , DiStefanoDJ , GoveiaMG , et al. Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants. Vaccine2006;24(22):4821-9. ">TEQ Vesikari 2006a‐FIN</a> included three vaccine arms in which there were different RotaTeq components (G1‐4, P1A, G1‐4, and P1A), and <a href="./references#CD008521-bbs2-0052" title="CTRI/2012/07/002820. A study to evaluate safety of Rotavirus vaccine in healthy adult volunteers followed by safety, tolerability and immunogenicity evaluation in healthy infants. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=4929&amp;EncHid=&amp;userName=CTRI/2012/07/002820 (first received 23 July 2012). DhingraMS , KunduR , GuptaM , KanungoS , GangulyN , SinghMP , et al. Evaluation of safety and immunogenicity of a live attenuated tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus vaccine (BRV-TV) in healthy Indian adults and infants. Vaccine2014;32(Suppl 1):A117-23. ">TEQ Dhingra 2014‐IND</a> included a RotaTeq arm, a placebo arm, and three arms with different concentrations of BRV‐TV vaccine. </p> </section> <section id="CD008521-sec-0069"> <h6 class="title">Infant vaccination status</h6> <p>Most trials did not restrict the use of other childhood vaccines (see <a href="./appendices#CD008521-sec-0274">Appendix 5</a>). Two trials co‐administered HBV, diphtheria‐tetanus‐pertussis (DTP), poliovirus, and Hib vaccines with RotaTeq (<a href="./references#CD008521-bbs2-0049" title="CiarletM , HeS , LaiS , PetreczM , YuanG , LiuGF , et al. Concomitant use of the 3-dose oral pentavalent rotavirus vaccine with a 3-dose primary vaccination course of a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b vaccine: immunogenicity and reactogenicity. Pediatric Infectious Disease Journal2009;28(3):177-81. Merck[PN-010]. Safety and immunogenicity of concomitant use of RotaTeq™ and INFANRIX™ hexa in healthy infants NCT00258154 (PN 010) [Merck &amp; Co. Inc. Study Synopsis]. clinicalstudyresults.org/drugdetails/?indication_id=1101&amp;sort=c.company_name&amp;page=1&amp;drug_id=2823 (accessed prior to 19 October 2021). NCT00258154. Safety and immunogenicity of concomitant use of V260 and INFANRIX(Tm) hexa in healthy infants. clinicaltrials.gov/show/NCT00258154 (first received 24 November 2005). [Trial registration document (no data for review)]">TEQ Ciarlet 2009‐EU</a>; <a href="./references#CD008521-bbs2-0052" title="CTRI/2012/07/002820. A study to evaluate safety of Rotavirus vaccine in healthy adult volunteers followed by safety, tolerability and immunogenicity evaluation in healthy infants. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=4929&amp;EncHid=&amp;userName=CTRI/2012/07/002820 (first received 23 July 2012). DhingraMS , KunduR , GuptaM , KanungoS , GangulyN , SinghMP , et al. Evaluation of safety and immunogenicity of a live attenuated tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus vaccine (BRV-TV) in healthy Indian adults and infants. Vaccine2014;32(Suppl 1):A117-23. ">TEQ Dhingra 2014‐IND</a>). One trial randomized participants to either concomitant or staggered administration of other childhood vaccines (OPV, DTaP) with RotaTeq or placebo (<a href="./references#CD008521-bbs2-0058" title="MoZ , MoY , LiM , TaoJ , YangX , KongJ , et al. Efficacy and safety of a pentavalent live human-bovine reassortant rotavirus vaccine (RV5) in healthy Chinese infants: a randomized, double-blind, placebo-controlled trial. Vaccine2017;35(43):5897-904. NCT02062385. Efficacy, safety, and immunogenicity of V260 in healthy Chinese infants (V260-024). clinicaltrials.gov/show/NCT02062385 (first received 13 February 2014). ">TEQ Mo 2017‐CHN</a>). Three trials allowed the use of OPV, in addition to other licensed childhood vaccines (<a href="./references#CD008521-bbs2-0044" title="ArmahGE ,  SowSO ,  BreimanRF ,  DallasMJ ,  TapiaMD ,  FeikinDR ,  et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet2010;376(9741):606-14. ArmahGE , BreimanRF , TapiaMD , DallasMJ , NeuzilKM , BinkaFN , et al. Immunogenicity of the pentavalent rotavirus vaccine in African infants. Vaccine2012;30(Suppl 1):A86-93. BreimanRF , ZamanK , ArmahG , SowSO , AnhDD , VictorJC , et al. Analyses of health outcomes from the 5 sites participating in the Africa and Asia clinical efficacy trials of the oral pentavalent rotavirus vaccine. Vaccine2012;30(Suppl 1):A24-9. GruberJF , HilleDA , LiuGF , KaplanSS , NelsonM , GoveiaMG , et al. Heterogeneity of rotavirus vaccine efficacy among infants in developing countries. Pediatric Infectious Disease Journal2017;36(1):72-8. HeylenE , ZellerM , CiarletM , LawrenceJ , SteeleD , Van RanstM , et al. Comparative analysis of pentavalent rotavirus vaccine strains and G8 rotaviruses identified during vaccine trial in Africa. Science Reports2015;5:14658. NCT00362648. Efficacy, safety, and immunogenicity of RotaTeqTM among infants in Asia and Africa. clinicaltrials.gov/ct2/show/record/NCT00362648 (first received 10 August 2006). TapiaMD , ArmahG , BreimanRF , DallasMJ , LewisKD , SowSO , et al. Secondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africa. Vaccine2012;30(Suppl 1):A79-85. ">TEQ Armah 2010‐AF</a>; <a href="./references#CD008521-bbs2-0058" title="MoZ , MoY , LiM , TaoJ , YangX , KongJ , et al. Efficacy and safety of a pentavalent live human-bovine reassortant rotavirus vaccine (RV5) in healthy Chinese infants: a randomized, double-blind, placebo-controlled trial. Vaccine2017;35(43):5897-904. NCT02062385. Efficacy, safety, and immunogenicity of V260 in healthy Chinese infants (V260-024). clinicaltrials.gov/show/NCT02062385 (first received 13 February 2014). ">TEQ Mo 2017‐CHN</a>; <a href="./references#CD008521-bbs2-0061" title="BreimanRF , ZamanK , ArmahG , SowSO , AnhDD , VictorJC , et al. Analyses of health outcomes from the 5 sites participating in the Africa and Asia clinical efficacy trials of the oral pentavalent rotavirus vaccine. Vaccine2012;30(Suppl 1):A24-9. GruberJF , HilleDA , LiuGF , KaplanSS , NelsonM , GoveiaMG , et al. Heterogeneity of rotavirus vaccine efficacy among infants in developing countries. Pediatric Infectious Disease Journal2017;36(1):72-8. NCT00362648. Efficacy, safety, and immunogenicity of RotaTeqTM among infants in Asia and Africa. clinicaltrials.gov/ct2/show/record/NCT00362648 (first received 8 August 2006). ShinS , AnhDD , ZamanK , YunusM , Mai leTP , ThiemVD , et al. Immunogenicity of the pentavalent rotavirus vaccine among infants in two developing countries in Asia, Bangladesh and Vietnam. Vaccine2012;30(Suppl 1):A106-13. ZamanK ,  DangDA ,  VictorJC ,  ShinS ,  YunusM ,  DallasMJ ,  et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet2010;376(9741):615-23. ">TEQ Zaman 2010‐AS</a>). Three trials did not allow the use of other vaccines (<a href="./references#CD008521-bbs2-0050" title="ClarkHF , BurkeCJ , VolkinDB , OffitP , WardRL , BreseeJS , et al. Safety, immunogenicity and efficacy in healthy infants of G1 and G2 human reassortant rotavirus vaccine in a new stabilizer/buffer liquid formulation. Pediatric Infectious Disease Journal2003;22(10):914-20. ">TEQ Clark 2003‐USA</a>; <a href="./references#CD008521-bbs2-0051" title="ClarkH , WhiteC , OffitP , StinsonD , EidenJ , WeaverS , et al. Preliminary evaluation of safety and efficacy of quadrivalent human-bovine reassortant rotavirus vaccine [abstract]. Pediatric Research1995;37:172A. [No data for review]ClarkHF , BernsteinDI , DennehyPH , OffitP , PichicheroM , TreanorJ , et al. Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants. Journal of Pediatrics2004;144(2):184-90. ClarkHF , OffitPA , EllisRW , EidenJJ , KrahD , ShawAR , et al. The development of multivalent bovine rotavirus (strain WC3) reassortant vaccine for infants. Journal of Infectious Diseases1996;174(Suppl 1):73-80. [No data for review]WardRL , BernsteinDI , SmithVE , SanderDS , ShawA , EidenJJ , et al. Rotavirus immunoglobulin a responses stimulated by each of 3 doses of a quadrivalent human/bovine reassortant rotavirus vaccine. Journal of Infectious Diseases2004;189(12):2290-3. ">TEQ Clark 2004‐USA</a>; <a href="./references#CD008521-bbs2-0055" title="LawrenceJ , HeS , HilleD , ShenC , KuterB , SchodelF , et al. A study of RotaTeqTM (pentavalent rotavirus vaccine) in Chinese healthy adults, children and infants. International Journal of Infectious Diseases2012;16(1):e307. NCT00953056. A study of V260 in healthy Chinese adults, children and infants. clinicaltrials.gov/ct2/show/study/NCT00953056 (first received 4 August 2009). ">TEQ Lawrence 2012‐CHN</a>), and one trial did not mention their use (<a href="./references#CD008521-bbs2-0053" title="IwataS , NakataS , UkaeS , KoizumiY , MoritaY , KurokiH , et al. Efficacy and safety of pentavalent rotavirus vaccine in Japan: a randomized, double-blind, placebo-controlled, multicenter trial. Human Vaccines and Immunotherapeutics2013;9(8):1626-33. NCT00718237. A phase III randomized, placebo-controlled clinical trial to study the efficacy and safety of V260 in healthy infants in Japan. clinicaltrials.gov/ct2/show/record/NCT00718237 (first received 16 July 2008). ">TEQ Iwata 2013‐JPN</a>). </p> </section> <section id="CD008521-sec-0070"> <h6 class="title">Methods for collecting adverse event data</h6> <p>As shown in <a href="./appendices#CD008521-sec-0275">Appendix 6</a>, seven trials used a combination of passive methods (e.g. diary cards for parents) and active methods (directly contacting parents) to collect adverse event data. The other trials used passive methods only (diary cards, three trials), active methods only ("active surveillance", three trials), or the information was not provided (two trials). </p> </section> <section id="CD008521-sec-0071"> <h6 class="title">Source of funding</h6> <p>All but one trial was funded by Merck &amp; Co., Inc. Two of those trials also received funding and were run by PATH (GAVI Alliance grant) (<a href="./references#CD008521-bbs2-0044" title="ArmahGE ,  SowSO ,  BreimanRF ,  DallasMJ ,  TapiaMD ,  FeikinDR ,  et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet2010;376(9741):606-14. ArmahGE , BreimanRF , TapiaMD , DallasMJ , NeuzilKM , BinkaFN , et al. Immunogenicity of the pentavalent rotavirus vaccine in African infants. Vaccine2012;30(Suppl 1):A86-93. BreimanRF , ZamanK , ArmahG , SowSO , AnhDD , VictorJC , et al. Analyses of health outcomes from the 5 sites participating in the Africa and Asia clinical efficacy trials of the oral pentavalent rotavirus vaccine. Vaccine2012;30(Suppl 1):A24-9. GruberJF , HilleDA , LiuGF , KaplanSS , NelsonM , GoveiaMG , et al. Heterogeneity of rotavirus vaccine efficacy among infants in developing countries. Pediatric Infectious Disease Journal2017;36(1):72-8. HeylenE , ZellerM , CiarletM , LawrenceJ , SteeleD , Van RanstM , et al. Comparative analysis of pentavalent rotavirus vaccine strains and G8 rotaviruses identified during vaccine trial in Africa. Science Reports2015;5:14658. NCT00362648. Efficacy, safety, and immunogenicity of RotaTeqTM among infants in Asia and Africa. clinicaltrials.gov/ct2/show/record/NCT00362648 (first received 10 August 2006). TapiaMD , ArmahG , BreimanRF , DallasMJ , LewisKD , SowSO , et al. Secondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africa. Vaccine2012;30(Suppl 1):A79-85. ">TEQ Armah 2010‐AF</a>; <a href="./references#CD008521-bbs2-0061" title="BreimanRF , ZamanK , ArmahG , SowSO , AnhDD , VictorJC , et al. Analyses of health outcomes from the 5 sites participating in the Africa and Asia clinical efficacy trials of the oral pentavalent rotavirus vaccine. Vaccine2012;30(Suppl 1):A24-9. GruberJF , HilleDA , LiuGF , KaplanSS , NelsonM , GoveiaMG , et al. Heterogeneity of rotavirus vaccine efficacy among infants in developing countries. Pediatric Infectious Disease Journal2017;36(1):72-8. NCT00362648. Efficacy, safety, and immunogenicity of RotaTeqTM among infants in Asia and Africa. clinicaltrials.gov/ct2/show/record/NCT00362648 (first received 8 August 2006). ShinS , AnhDD , ZamanK , YunusM , Mai leTP , ThiemVD , et al. Immunogenicity of the pentavalent rotavirus vaccine among infants in two developing countries in Asia, Bangladesh and Vietnam. Vaccine2012;30(Suppl 1):A106-13. ZamanK ,  DangDA ,  VictorJC ,  ShinS ,  YunusM ,  DallasMJ ,  et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet2010;376(9741):615-23. ">TEQ Zaman 2010‐AS</a>), and one trial also received funding from the International Maternal, Pediatric, and Adolescent AIDS Clinical Trial Network (IMPAACT) through the National Institute of Health (<a href="./references#CD008521-bbs2-0056" title="LevinMJ , LindseyJC , KaplanSS , SchimanaW , LawrenceJ , McNealMM , et al. Safety and immunogenicity of a live attenuated pentavalent rotavirus vaccine in HIV-exposed infants with or without HIV infection in Africa. AIDS2017;31(1):49-59. NCT00880698. Safety and immunogenicity of a live, attenuated rotavirus (RotaTeqTM) in HIV-1 infected and uninfected children born to HIV-1-infected mothers. clinicaltrials.gov/ct2/show/study/NCT00880698 (first received 14 April 2009). UpretyP , LindseyJ , LevinM , Rainwater-LovettK , ZiemniakC , KaplanS , et al. Enhanced inflammation and rotavirus vaccine responses in perinatal HIV-1 infection. In: Topics in Antiviral Medicine; 23rd Conference on Retroviruses and Opportunistic Infections, CROI; 2016, USA. Vol. 24(E-1). 2016:347. ">TEQ Levin 2017‐AF</a>). One trial was funded by Shantha Biotechnics Ltd (<a href="./references#CD008521-bbs2-0052" title="CTRI/2012/07/002820. A study to evaluate safety of Rotavirus vaccine in healthy adult volunteers followed by safety, tolerability and immunogenicity evaluation in healthy infants. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=4929&amp;EncHid=&amp;userName=CTRI/2012/07/002820 (first received 23 July 2012). DhingraMS , KunduR , GuptaM , KanungoS , GangulyN , SinghMP , et al. Evaluation of safety and immunogenicity of a live attenuated tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus vaccine (BRV-TV) in healthy Indian adults and infants. Vaccine2014;32(Suppl 1):A117-23. ">TEQ Dhingra 2014‐IND</a>). </p> </section> </section> <section id="CD008521-sec-0072"> <h5 class="title">3. Rotasiil</h5> <p>We identified five trials of Rotasiil vaccine. The earliest was reported in 2014 and the most recent in 2017. Overall, 11,753 participants were included in the trials; the largest trial included 7505 participants (<a href="./references#CD008521-bbs2-0040" title="CTRI/2013/05/003667. A clinical trial to study the effect and safety of Rotavirus vaccine against severe Rotavirus gastroenteritis in healthy Indian Infants. www.ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=5518&amp;EncHid=&amp;modid=&amp;compid=%27,%275518det%27 (first received 23 May 2013). KulkarniPS , DesaiS , TewariT , KawadeA , GoyalN , GargBS , et al. A randomized phase III clinical trial to assess the efficacy of a bovine-human reassortant pentavalent rotavirus vaccine in Indian infants. Vaccine2017;35(45):6228-37. NCT02133690. A clinical trial to study the effect and safety of Rotavirus vaccine against severe rotavirus gastroenteritis in healthy Indian infants. clinicaltrials.gov/ct2/show/NCT02133690 (first received 6 May 2014). ">SIIL Kulkarni 2017‐IND</a>) and the smallest included 36 participants (<a href="./references#CD008521-bbs2-0041" title="CTRI/2009/091/000821. A randomized, double-blind, placebo controlled study to assess the safety and tolerability of rotaVac vaccine (live attenuated bovine-human (UK) reassortant pentavalent rotavirus vaccine). ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=987&amp;EncHid=&amp;modid=&amp;compid=%27,%27987det%27 (first received 15 October 2009). Zade JK,  KulkarniPS ,  Desai SA,  Sabale RN,  Naik SP,  Dhere RM. Bovine rotavirus pentavalent vaccine development in India. Vaccine2014;32(Suppl 1):A124-8. [DOI: 10.1016/j.vaccine.2014.03.003]">SIIL Zade 2014‐INDa</a>). </p> <section id="CD008521-sec-0073"> <h6 class="title">Population</h6> <p>All trials included healthy infants. Trials enrolled infants aged between six weeks and ten weeks. <a href="./references#CD008521-bbs2-0041" title="CTRI/2009/091/000821. A randomized, double-blind, placebo controlled study to assess the safety and tolerability of rotaVac vaccine (live attenuated bovine-human (UK) reassortant pentavalent rotavirus vaccine). ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=987&amp;EncHid=&amp;modid=&amp;compid=%27,%27987det%27 (first received 15 October 2009). Zade JK,  KulkarniPS ,  Desai SA,  Sabale RN,  Naik SP,  Dhere RM. Bovine rotavirus pentavalent vaccine development in India. Vaccine2014;32(Suppl 1):A124-8. [DOI: 10.1016/j.vaccine.2014.03.003]">SIIL Zade 2014‐INDa</a> also enrolled 18 toddlers (age not specified) and 18 adults (not included in the review). </p> </section> <section id="CD008521-sec-0074"> <h6 class="title">Outcome measures</h6> <p>Three trials were safety studies (<a href="./appendices#CD008521-sec-0270">Appendix 1</a>) reporting safety outcomes and immunogenicity outcomes. They reported on follow‐up results for up to one month after the last vaccine dose. The other two trials (<a href="./references#CD008521-bbs2-0039" title="ColdironME , GuindoO , MakarimiR , SoumanaI , Matar SeckA , GarbaS , et al. Safety of a heat-stable rotavirus vaccine among children in Niger: data from a phase 3, randomized, double-blind, placebo-controlled trial. Vaccine2018;36(25):3674-80. IsanakaS , DjiboA , GraisRF . Heat-stable oral rotavirus vaccine. New England Journal of Medicine2017;377(3):302. IsanakaS , GuindoO , LangendorfC , GraisR , ROSE Trial Study Team. Efficacy and safety of a low-cost, heat-stable oral roatvirus vaccine agains severe rotavirus gastroenteritis in Niger. American Journal of Tropical Medicine and Hygiene2017;95(Suppl 5):242. IsanakaS , GuindoO , LangendorfC , Matar SeckA , PlikaytisBD , Sayinzoga-MakombeN , et al. Efficacy of a low-cost, heat-stable oral Rotavirus vaccine in Niger. New England Journal of Medicine2017;376(12):1121-30. IsanakaS , LangendorfC , McNealMM , MeyerN , PlikaytisB , GarbaS , et al. Rotavirus vaccine efficacy up to 2 years of age and against diverse circulating rotavirus strains in Niger: a randomized controlled clinical trial (unpublished manuscript received via email correspondence from Rebecca Grais to Nicholas Henschke on 19 August 2020). data on file. NCT02145000. Efficacy and safety of a pentavalent Rotavirus vaccine (BRV-PV) against severe rotavirus gastroenteritis in Niger (ROSE). clinicaltrials.gov/ct2/show/NCT02145000 (first received 20 May 2014). ">SIIL Isanaka 2017‐NER</a>; <a href="./references#CD008521-bbs2-0040" title="CTRI/2013/05/003667. A clinical trial to study the effect and safety of Rotavirus vaccine against severe Rotavirus gastroenteritis in healthy Indian Infants. www.ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=5518&amp;EncHid=&amp;modid=&amp;compid=%27,%275518det%27 (first received 23 May 2013). KulkarniPS , DesaiS , TewariT , KawadeA , GoyalN , GargBS , et al. A randomized phase III clinical trial to assess the efficacy of a bovine-human reassortant pentavalent rotavirus vaccine in Indian infants. Vaccine2017;35(45):6228-37. NCT02133690. A clinical trial to study the effect and safety of Rotavirus vaccine against severe rotavirus gastroenteritis in healthy Indian infants. clinicaltrials.gov/ct2/show/NCT02133690 (first received 6 May 2014). ">SIIL Kulkarni 2017‐IND</a>) reported on efficacy, safety, and immunogenicity outcomes until the infants were two years of age. </p> <p>For safety outcomes, all trials reported on serious adverse events and four reported on reactogenicity. </p> </section> <section id="CD008521-sec-0075"> <h6 class="title">Location</h6> <p>Four trials were conducted in India, three of them in Pune and one trial in six sites in Pune, Kolkata, Sewagram, Delhi, Manipal, and Jammu (<a href="./references#CD008521-bbs2-0040" title="CTRI/2013/05/003667. A clinical trial to study the effect and safety of Rotavirus vaccine against severe Rotavirus gastroenteritis in healthy Indian Infants. www.ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=5518&amp;EncHid=&amp;modid=&amp;compid=%27,%275518det%27 (first received 23 May 2013). KulkarniPS , DesaiS , TewariT , KawadeA , GoyalN , GargBS , et al. A randomized phase III clinical trial to assess the efficacy of a bovine-human reassortant pentavalent rotavirus vaccine in Indian infants. Vaccine2017;35(45):6228-37. NCT02133690. A clinical trial to study the effect and safety of Rotavirus vaccine against severe rotavirus gastroenteritis in healthy Indian infants. clinicaltrials.gov/ct2/show/NCT02133690 (first received 6 May 2014). ">SIIL Kulkarni 2017‐IND</a>). One trial (<a href="./references#CD008521-bbs2-0039" title="ColdironME , GuindoO , MakarimiR , SoumanaI , Matar SeckA , GarbaS , et al. Safety of a heat-stable rotavirus vaccine among children in Niger: data from a phase 3, randomized, double-blind, placebo-controlled trial. Vaccine2018;36(25):3674-80. IsanakaS , DjiboA , GraisRF . Heat-stable oral rotavirus vaccine. New England Journal of Medicine2017;377(3):302. IsanakaS , GuindoO , LangendorfC , GraisR , ROSE Trial Study Team. Efficacy and safety of a low-cost, heat-stable oral roatvirus vaccine agains severe rotavirus gastroenteritis in Niger. American Journal of Tropical Medicine and Hygiene2017;95(Suppl 5):242. IsanakaS , GuindoO , LangendorfC , Matar SeckA , PlikaytisBD , Sayinzoga-MakombeN , et al. Efficacy of a low-cost, heat-stable oral Rotavirus vaccine in Niger. New England Journal of Medicine2017;376(12):1121-30. IsanakaS , LangendorfC , McNealMM , MeyerN , PlikaytisB , GarbaS , et al. Rotavirus vaccine efficacy up to 2 years of age and against diverse circulating rotavirus strains in Niger: a randomized controlled clinical trial (unpublished manuscript received via email correspondence from Rebecca Grais to Nicholas Henschke on 19 August 2020). data on file. NCT02145000. Efficacy and safety of a pentavalent Rotavirus vaccine (BRV-PV) against severe rotavirus gastroenteritis in Niger (ROSE). clinicaltrials.gov/ct2/show/NCT02145000 (first received 20 May 2014). ">SIIL Isanaka 2017‐NER</a>) was conducted in Niger (one site in Madarounfa). </p> </section> <section id="CD008521-sec-0076"> <h6 class="title">Country mortality rate</h6> <p>All trials were conducted in countries with high‐mortality rates (India and Niger).</p> </section> <section id="CD008521-sec-0077"> <h6 class="title">Vaccine schedule</h6> <p>Four trials used three doses of Rotasiil vaccine with an interval of four weeks between the doses. One trial (<a href="./references#CD008521-bbs2-0041" title="CTRI/2009/091/000821. A randomized, double-blind, placebo controlled study to assess the safety and tolerability of rotaVac vaccine (live attenuated bovine-human (UK) reassortant pentavalent rotavirus vaccine). ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=987&amp;EncHid=&amp;modid=&amp;compid=%27,%27987det%27 (first received 15 October 2009). Zade JK,  KulkarniPS ,  Desai SA,  Sabale RN,  Naik SP,  Dhere RM. Bovine rotavirus pentavalent vaccine development in India. Vaccine2014;32(Suppl 1):A124-8. [DOI: 10.1016/j.vaccine.2014.03.003]">SIIL Zade 2014‐INDa</a>) administered one dose. All five trials had one vaccine and one placebo arm. </p> </section> <section id="CD008521-sec-0078"> <h6 class="title">Infant vaccination status</h6> <p>Two trials co‐administered other routine childhood vaccines (OPV, DTP, HBV and Hib) with Rotasiil (<a href="./references#CD008521-bbs2-0039" title="ColdironME , GuindoO , MakarimiR , SoumanaI , Matar SeckA , GarbaS , et al. Safety of a heat-stable rotavirus vaccine among children in Niger: data from a phase 3, randomized, double-blind, placebo-controlled trial. Vaccine2018;36(25):3674-80. IsanakaS , DjiboA , GraisRF . Heat-stable oral rotavirus vaccine. New England Journal of Medicine2017;377(3):302. IsanakaS , GuindoO , LangendorfC , GraisR , ROSE Trial Study Team. Efficacy and safety of a low-cost, heat-stable oral roatvirus vaccine agains severe rotavirus gastroenteritis in Niger. American Journal of Tropical Medicine and Hygiene2017;95(Suppl 5):242. IsanakaS , GuindoO , LangendorfC , Matar SeckA , PlikaytisBD , Sayinzoga-MakombeN , et al. Efficacy of a low-cost, heat-stable oral Rotavirus vaccine in Niger. New England Journal of Medicine2017;376(12):1121-30. IsanakaS , LangendorfC , McNealMM , MeyerN , PlikaytisB , GarbaS , et al. Rotavirus vaccine efficacy up to 2 years of age and against diverse circulating rotavirus strains in Niger: a randomized controlled clinical trial (unpublished manuscript received via email correspondence from Rebecca Grais to Nicholas Henschke on 19 August 2020). data on file. NCT02145000. Efficacy and safety of a pentavalent Rotavirus vaccine (BRV-PV) against severe rotavirus gastroenteritis in Niger (ROSE). clinicaltrials.gov/ct2/show/NCT02145000 (first received 20 May 2014). ">SIIL Isanaka 2017‐NER</a>; <a href="./references#CD008521-bbs2-0040" title="CTRI/2013/05/003667. A clinical trial to study the effect and safety of Rotavirus vaccine against severe Rotavirus gastroenteritis in healthy Indian Infants. www.ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=5518&amp;EncHid=&amp;modid=&amp;compid=%27,%275518det%27 (first received 23 May 2013). KulkarniPS , DesaiS , TewariT , KawadeA , GoyalN , GargBS , et al. A randomized phase III clinical trial to assess the efficacy of a bovine-human reassortant pentavalent rotavirus vaccine in Indian infants. Vaccine2017;35(45):6228-37. NCT02133690. A clinical trial to study the effect and safety of Rotavirus vaccine against severe rotavirus gastroenteritis in healthy Indian infants. clinicaltrials.gov/ct2/show/NCT02133690 (first received 6 May 2014). ">SIIL Kulkarni 2017‐IND</a>). One trial separated the use of other routine childhood vaccines from Rotasiil administration by at least one week (<a href="./references#CD008521-bbs2-0043" title="CTRI/2010/091/003064. A randomized, double-blind, placebo controlled study to assess safety and tolerability of RotaVac vaccine (live attenuated bovine-human (UK) reassortant pentavalent rotavirus vaccine). ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=2458&amp;EncHid=&amp;modid=&amp;compid=%27,%272458det%27 (first received 4 January 2011). Zade JK,  KulkarniPS ,  Desai SA,  Sabale RN,  Naik SP,  Dhere RM. Bovine rotavirus pentavalent vaccine development in India. Vaccine2014;32(Suppl 1):A124-8. [DOI: 10.1016/j.vaccine.2014.03.003]">SIIL Zade 2014‐INDc</a>). Two studies did not report on vaccination with other childhood vaccines (<a href="./references#CD008521-bbs2-0041" title="CTRI/2009/091/000821. A randomized, double-blind, placebo controlled study to assess the safety and tolerability of rotaVac vaccine (live attenuated bovine-human (UK) reassortant pentavalent rotavirus vaccine). ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=987&amp;EncHid=&amp;modid=&amp;compid=%27,%27987det%27 (first received 15 October 2009). Zade JK,  KulkarniPS ,  Desai SA,  Sabale RN,  Naik SP,  Dhere RM. Bovine rotavirus pentavalent vaccine development in India. Vaccine2014;32(Suppl 1):A124-8. [DOI: 10.1016/j.vaccine.2014.03.003]">SIIL Zade 2014‐INDa</a>; <a href="./references#CD008521-bbs2-0042" title="CTRI/2009/091/000821. A randomized, double-blind, placebo controlled study to assess the safety and tolerability of RotaVac vaccine (live attenuated bovine-human (UK) reassortant pentavalent rotavirus vaccine). ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=987&amp;EncHid=&amp;modid=&amp;compid=%27,%27987det%27 (first received 15 October 2009). Zade JK,  KulkarniPS ,  Desai SA,  Sabale RN,  Naik SP,  Dhere RM. Bovine rotavirus pentavalent vaccine development in India. Vaccine2014;32(Suppl 1):A124-8. [DOI: 10.1016/j.vaccine.2014.03.003]">SIIL Zade 2014‐INDb</a>). </p> </section> <section id="CD008521-sec-0079"> <h6 class="title">Methods for collecting adverse event data</h6> <p>Two trials used a combination of passive methods (e.g. diary cards for parents) and active methods (home visits) to collect adverse event data (<a href="./references#CD008521-bbs2-0039" title="ColdironME , GuindoO , MakarimiR , SoumanaI , Matar SeckA , GarbaS , et al. Safety of a heat-stable rotavirus vaccine among children in Niger: data from a phase 3, randomized, double-blind, placebo-controlled trial. Vaccine2018;36(25):3674-80. IsanakaS , DjiboA , GraisRF . Heat-stable oral rotavirus vaccine. New England Journal of Medicine2017;377(3):302. IsanakaS , GuindoO , LangendorfC , GraisR , ROSE Trial Study Team. Efficacy and safety of a low-cost, heat-stable oral roatvirus vaccine agains severe rotavirus gastroenteritis in Niger. American Journal of Tropical Medicine and Hygiene2017;95(Suppl 5):242. IsanakaS , GuindoO , LangendorfC , Matar SeckA , PlikaytisBD , Sayinzoga-MakombeN , et al. Efficacy of a low-cost, heat-stable oral Rotavirus vaccine in Niger. New England Journal of Medicine2017;376(12):1121-30. IsanakaS , LangendorfC , McNealMM , MeyerN , PlikaytisB , GarbaS , et al. Rotavirus vaccine efficacy up to 2 years of age and against diverse circulating rotavirus strains in Niger: a randomized controlled clinical trial (unpublished manuscript received via email correspondence from Rebecca Grais to Nicholas Henschke on 19 August 2020). data on file. NCT02145000. Efficacy and safety of a pentavalent Rotavirus vaccine (BRV-PV) against severe rotavirus gastroenteritis in Niger (ROSE). clinicaltrials.gov/ct2/show/NCT02145000 (first received 20 May 2014). ">SIIL Isanaka 2017‐NER</a>; <a href="./references#CD008521-bbs2-0040" title="CTRI/2013/05/003667. A clinical trial to study the effect and safety of Rotavirus vaccine against severe Rotavirus gastroenteritis in healthy Indian Infants. www.ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=5518&amp;EncHid=&amp;modid=&amp;compid=%27,%275518det%27 (first received 23 May 2013). KulkarniPS , DesaiS , TewariT , KawadeA , GoyalN , GargBS , et al. A randomized phase III clinical trial to assess the efficacy of a bovine-human reassortant pentavalent rotavirus vaccine in Indian infants. Vaccine2017;35(45):6228-37. NCT02133690. A clinical trial to study the effect and safety of Rotavirus vaccine against severe rotavirus gastroenteritis in healthy Indian infants. clinicaltrials.gov/ct2/show/NCT02133690 (first received 6 May 2014). ">SIIL Kulkarni 2017‐IND</a>). The remaining three trials did not provide information on methods for collecting adverse event data. </p> </section> <section id="CD008521-sec-0080"> <h6 class="title">Source of funding</h6> <p>The four trials conducted in India were funded by the Serum Institute of India, and one of them was also co‐funded by PATH (<a href="./references#CD008521-bbs2-0040" title="CTRI/2013/05/003667. A clinical trial to study the effect and safety of Rotavirus vaccine against severe Rotavirus gastroenteritis in healthy Indian Infants. www.ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=5518&amp;EncHid=&amp;modid=&amp;compid=%27,%275518det%27 (first received 23 May 2013). KulkarniPS , DesaiS , TewariT , KawadeA , GoyalN , GargBS , et al. A randomized phase III clinical trial to assess the efficacy of a bovine-human reassortant pentavalent rotavirus vaccine in Indian infants. Vaccine2017;35(45):6228-37. NCT02133690. A clinical trial to study the effect and safety of Rotavirus vaccine against severe rotavirus gastroenteritis in healthy Indian infants. clinicaltrials.gov/ct2/show/NCT02133690 (first received 6 May 2014). ">SIIL Kulkarni 2017‐IND</a>). The study conducted in Niger (<a href="./references#CD008521-bbs2-0039" title="ColdironME , GuindoO , MakarimiR , SoumanaI , Matar SeckA , GarbaS , et al. Safety of a heat-stable rotavirus vaccine among children in Niger: data from a phase 3, randomized, double-blind, placebo-controlled trial. Vaccine2018;36(25):3674-80. IsanakaS , DjiboA , GraisRF . Heat-stable oral rotavirus vaccine. New England Journal of Medicine2017;377(3):302. IsanakaS , GuindoO , LangendorfC , GraisR , ROSE Trial Study Team. Efficacy and safety of a low-cost, heat-stable oral roatvirus vaccine agains severe rotavirus gastroenteritis in Niger. American Journal of Tropical Medicine and Hygiene2017;95(Suppl 5):242. IsanakaS , GuindoO , LangendorfC , Matar SeckA , PlikaytisBD , Sayinzoga-MakombeN , et al. Efficacy of a low-cost, heat-stable oral Rotavirus vaccine in Niger. New England Journal of Medicine2017;376(12):1121-30. IsanakaS , LangendorfC , McNealMM , MeyerN , PlikaytisB , GarbaS , et al. Rotavirus vaccine efficacy up to 2 years of age and against diverse circulating rotavirus strains in Niger: a randomized controlled clinical trial (unpublished manuscript received via email correspondence from Rebecca Grais to Nicholas Henschke on 19 August 2020). data on file. NCT02145000. Efficacy and safety of a pentavalent Rotavirus vaccine (BRV-PV) against severe rotavirus gastroenteritis in Niger (ROSE). clinicaltrials.gov/ct2/show/NCT02145000 (first received 20 May 2014). ">SIIL Isanaka 2017‐NER</a>) was funded by Médecins sans Frontières and the Kavli Foundation, and the Serum Institute of India donated vaccine and placebo. </p> </section> </section> <section id="CD008521-sec-0081"> <h5 class="title">4. Rotavac</h5> <p>We identified four trials of Rotavac vaccine. The earliest was reported in 2006 and the most recent in 2017. Overall, 8432 participants were included in the trials; the largest trial included 6799 participants (<a href="./references#CD008521-bbs2-0066" title="BhandariN , Rongsen-ChandolaT , BavdekarA , JohnJ , AntonyK , TanejaS , et al. Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian children in the second year of life. Vaccine2014;32(Suppl 1):A110-6. BhandariN , Rongsen-ChandolaT , BavdekarA , JohnJ , AntonyK , TanejaS , et al. Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo-controlled trial. Lancet2014;383(9935):2136-43. CTRI/2010/091/000102. A phase III clinical trial to evaluate the protective efficacy of three doses of oral rotavirus vaccine (ORV) 116E. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=1317 (first received 22 November 2010). JohnJ , KawadeA , Rongsen-ChandolaT , BavdekarA , BhandariN , TanejaS , et al. Active surveillance for intussusception in a phase III efficacy trial of an oral monovalent rotavirus vaccine in India. Vaccine2014;32(Suppl 1):A104-9. JohnTJ . Why was there no vaccine-associated intussusception in Indian rotavirus vaccine trial?Indian Pediatrics2015;52(10):906. NCT01305109. A phase III, randomized, double blind, placebo controlled trial to evaluate the protective efficacy of three doses of oral rotavirus vaccine (ORV) 116E, against severe rotavirus gastroenteritis in infants. clinicaltrials.gov/show/NCT01305109 (first received 28 February 2011). ">VAC Bhandari 2014‐IND</a>) and the smallest included 90 participants (<a href="./references#CD008521-bbs2-0064" title="BhandariN , SharmaP , GlassRI , RayP , GreenbergH , TanejaS , et al. Safety and immunogenicity of two live attenuated human rotavirus vaccine candidates, 116E and I321, in infants: results of a randomised controlled trial. Vaccine2006;24(31):5817-23. ISRCTN57452882. A double-blind randomised placebo controlled dose escalating phase Ib/IIa study to evaluate the safety and immunogenicity of live attenuated rotavirus vaccine 116E in healthy non-malnourished infants eight to 20 weeks of age. isrctn.com/ISRCTN57452882 (first received 26 July 2006). NCT00280111. Safety and immunogenicity study of live attenuated Indian rotavirus vaccine candidate strains 116E and I321 in infants. clinicaltrials.gov/ct2/show/NCT00280111 (first received 20 January 2006). ">VAC Bhandari 2006‐IND</a>). </p> <section id="CD008521-sec-0082"> <h6 class="title">Population</h6> <p>All trials included healthy infants. Trials enrolled infants aged between six weeks and nine weeks. </p> </section> <section id="CD008521-sec-0083"> <h6 class="title">Outcome measures</h6> <p>Three trials were safety studies (<a href="./appendices#CD008521-sec-0270">Appendix 1</a>) reporting safety outcomes. They reported on follow‐up results for one to 12 months after the last vaccine dose. The other trial (<a href="./references#CD008521-bbs2-0066" title="BhandariN , Rongsen-ChandolaT , BavdekarA , JohnJ , AntonyK , TanejaS , et al. Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian children in the second year of life. Vaccine2014;32(Suppl 1):A110-6. BhandariN , Rongsen-ChandolaT , BavdekarA , JohnJ , AntonyK , TanejaS , et al. Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo-controlled trial. Lancet2014;383(9935):2136-43. CTRI/2010/091/000102. A phase III clinical trial to evaluate the protective efficacy of three doses of oral rotavirus vaccine (ORV) 116E. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=1317 (first received 22 November 2010). JohnJ , KawadeA , Rongsen-ChandolaT , BavdekarA , BhandariN , TanejaS , et al. Active surveillance for intussusception in a phase III efficacy trial of an oral monovalent rotavirus vaccine in India. Vaccine2014;32(Suppl 1):A104-9. JohnTJ . Why was there no vaccine-associated intussusception in Indian rotavirus vaccine trial?Indian Pediatrics2015;52(10):906. NCT01305109. A phase III, randomized, double blind, placebo controlled trial to evaluate the protective efficacy of three doses of oral rotavirus vaccine (ORV) 116E, against severe rotavirus gastroenteritis in infants. clinicaltrials.gov/show/NCT01305109 (first received 28 February 2011). ">VAC Bhandari 2014‐IND</a>) reported on efficacy, safety, and immunogenicity outcomes until the infants were two years of age. </p> <p>As shown in <a href="./appendices#CD008521-sec-0271">Appendix 2</a>, <a href="./references#CD008521-bbs2-0066" title="BhandariN , Rongsen-ChandolaT , BavdekarA , JohnJ , AntonyK , TanejaS , et al. Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian children in the second year of life. Vaccine2014;32(Suppl 1):A110-6. BhandariN , Rongsen-ChandolaT , BavdekarA , JohnJ , AntonyK , TanejaS , et al. Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo-controlled trial. Lancet2014;383(9935):2136-43. CTRI/2010/091/000102. A phase III clinical trial to evaluate the protective efficacy of three doses of oral rotavirus vaccine (ORV) 116E. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=1317 (first received 22 November 2010). JohnJ , KawadeA , Rongsen-ChandolaT , BavdekarA , BhandariN , TanejaS , et al. Active surveillance for intussusception in a phase III efficacy trial of an oral monovalent rotavirus vaccine in India. Vaccine2014;32(Suppl 1):A104-9. JohnTJ . Why was there no vaccine-associated intussusception in Indian rotavirus vaccine trial?Indian Pediatrics2015;52(10):906. NCT01305109. A phase III, randomized, double blind, placebo controlled trial to evaluate the protective efficacy of three doses of oral rotavirus vaccine (ORV) 116E, against severe rotavirus gastroenteritis in infants. clinicaltrials.gov/show/NCT01305109 (first received 28 February 2011). ">VAC Bhandari 2014‐IND</a> reported on rotavirus diarrhoea (severe cases, cases of any severity, and cases requiring medical attention). The same trial also provided data on severe cases of all‐cause diarrhoea. Two trials reported all‐cause death, and three of the four trials reported dropouts. </p> <p>For safety outcomes, all trials reported on serious adverse events and two reported on reactogenicity. </p> </section> <section id="CD008521-sec-0084"> <h6 class="title">Location</h6> <p>All trials were conducted in India, one at three sites in the cities of Delhi, Pune, and Vellore (<a href="./references#CD008521-bbs2-0066" title="BhandariN , Rongsen-ChandolaT , BavdekarA , JohnJ , AntonyK , TanejaS , et al. Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian children in the second year of life. Vaccine2014;32(Suppl 1):A110-6. BhandariN , Rongsen-ChandolaT , BavdekarA , JohnJ , AntonyK , TanejaS , et al. Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo-controlled trial. Lancet2014;383(9935):2136-43. CTRI/2010/091/000102. A phase III clinical trial to evaluate the protective efficacy of three doses of oral rotavirus vaccine (ORV) 116E. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=1317 (first received 22 November 2010). JohnJ , KawadeA , Rongsen-ChandolaT , BavdekarA , BhandariN , TanejaS , et al. Active surveillance for intussusception in a phase III efficacy trial of an oral monovalent rotavirus vaccine in India. Vaccine2014;32(Suppl 1):A104-9. JohnTJ . Why was there no vaccine-associated intussusception in Indian rotavirus vaccine trial?Indian Pediatrics2015;52(10):906. NCT01305109. A phase III, randomized, double blind, placebo controlled trial to evaluate the protective efficacy of three doses of oral rotavirus vaccine (ORV) 116E, against severe rotavirus gastroenteritis in infants. clinicaltrials.gov/show/NCT01305109 (first received 28 February 2011). ">VAC Bhandari 2014‐IND</a>), and the remaining three studies at one site in Delhi. </p> </section> <section id="CD008521-sec-0085"> <h6 class="title">Country mortality rate</h6> <p>All trials were conducted in India, a country with a high‐mortality rate.</p> </section> <section id="CD008521-sec-0086"> <h6 class="title">Vaccine schedule</h6> <p>Most trials used three doses of Rotavac vaccine, with intervals between doses of four to eight weeks (see <a href="./appendices#CD008521-sec-0274">Appendix 5</a>). One trial (<a href="./references#CD008521-bbs2-0064" title="BhandariN , SharmaP , GlassRI , RayP , GreenbergH , TanejaS , et al. Safety and immunogenicity of two live attenuated human rotavirus vaccine candidates, 116E and I321, in infants: results of a randomised controlled trial. Vaccine2006;24(31):5817-23. ISRCTN57452882. A double-blind randomised placebo controlled dose escalating phase Ib/IIa study to evaluate the safety and immunogenicity of live attenuated rotavirus vaccine 116E in healthy non-malnourished infants eight to 20 weeks of age. isrctn.com/ISRCTN57452882 (first received 26 July 2006). NCT00280111. Safety and immunogenicity study of live attenuated Indian rotavirus vaccine candidate strains 116E and I321 in infants. clinicaltrials.gov/ct2/show/NCT00280111 (first received 20 January 2006). ">VAC Bhandari 2006‐IND</a>) administered one dose. One trial had one vaccine and one placebo arm (<a href="./references#CD008521-bbs2-0066" title="BhandariN , Rongsen-ChandolaT , BavdekarA , JohnJ , AntonyK , TanejaS , et al. Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian children in the second year of life. Vaccine2014;32(Suppl 1):A110-6. BhandariN , Rongsen-ChandolaT , BavdekarA , JohnJ , AntonyK , TanejaS , et al. Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo-controlled trial. Lancet2014;383(9935):2136-43. CTRI/2010/091/000102. A phase III clinical trial to evaluate the protective efficacy of three doses of oral rotavirus vaccine (ORV) 116E. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=1317 (first received 22 November 2010). JohnJ , KawadeA , Rongsen-ChandolaT , BavdekarA , BhandariN , TanejaS , et al. Active surveillance for intussusception in a phase III efficacy trial of an oral monovalent rotavirus vaccine in India. Vaccine2014;32(Suppl 1):A104-9. JohnTJ . Why was there no vaccine-associated intussusception in Indian rotavirus vaccine trial?Indian Pediatrics2015;52(10):906. NCT01305109. A phase III, randomized, double blind, placebo controlled trial to evaluate the protective efficacy of three doses of oral rotavirus vaccine (ORV) 116E, against severe rotavirus gastroenteritis in infants. clinicaltrials.gov/show/NCT01305109 (first received 28 February 2011). ">VAC Bhandari 2014‐IND</a>). <a href="./references#CD008521-bbs2-0064" title="BhandariN , SharmaP , GlassRI , RayP , GreenbergH , TanejaS , et al. Safety and immunogenicity of two live attenuated human rotavirus vaccine candidates, 116E and I321, in infants: results of a randomised controlled trial. Vaccine2006;24(31):5817-23. ISRCTN57452882. A double-blind randomised placebo controlled dose escalating phase Ib/IIa study to evaluate the safety and immunogenicity of live attenuated rotavirus vaccine 116E in healthy non-malnourished infants eight to 20 weeks of age. isrctn.com/ISRCTN57452882 (first received 26 July 2006). NCT00280111. Safety and immunogenicity study of live attenuated Indian rotavirus vaccine candidate strains 116E and I321 in infants. clinicaltrials.gov/ct2/show/NCT00280111 (first received 20 January 2006). ">VAC Bhandari 2006‐IND</a> included an additional vaccine arm for a rotavirus vaccine candidate (I321) that we did not include for analysis in this review. <a href="./references#CD008521-bbs2-0065" title="BhandariN , SharmaP , TanejaS , KumarT , Rongsen-ChandolaT , AppaiahgariMB , et al. A dose-escalation safety and immunogenicity study of live attenuated oral rotavirus vaccine 116E in infants: a randomized, double-blind, placebo-controlled trial. Journal of Infectious Diseases2009;200(3):421-9. ISRCTN57452882. A double-blind randomised placebo controlled dose escalating phase Ib/IIa study to evaluate the safety and immunogenicity of live attenuated rotavirus vaccine 116E in healthy non-malnourished infants eight to 20 weeks of age. isrctn.com/ISRCTN57452882 (first received 26 July 2006). NCT00439660. Dose escalation study to evaluate oral rotavirus vaccine 116E live attenuated in healthy infants 8 to 20 weeks old. clinicaltrials.gov/ct2/show/NCT00439660 (first received 26 February 2007). ">VAC Bhandari 2009‐IND</a> randomized participants to high‐ (1 x 10<sup>5</sup> ffu) and low‐dose (1 x 10<sup>4</sup> ffu) vaccine arms which we combined in this review. <a href="./references#CD008521-bbs2-0067" title="ChandolaTR , TanejaS , GoyalN , AntonyK , BhatiaK , MoreD , et al. ROTAVAC does not interfere with the immune response to childhood vaccines in Indian infants: a randomized placebo controlled trial. Heliyon2017;3(5):e00302. CTRI/2014/05/004592. A phase III study to evaluate the non-interference in the immune response of rotavac to childhood vaccines and to assess the clinical lot consistency. ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=5870&amp;EncHid=&amp;modid=&amp;compid=%27,%275870det%27 (first received 13 May 2014). ">VAC Chandola 2017‐IND</a> randomized participants to three vaccine production lots as well as to placebo. We combined the different production lot arms in our analyses. </p> </section> <section id="CD008521-sec-0087"> <h6 class="title">Infant vaccination status</h6> <p>Two trials separated the use of other routine childhood vaccines from Rotavac administration by at least two weeks (<a href="./references#CD008521-bbs2-0064" title="BhandariN , SharmaP , GlassRI , RayP , GreenbergH , TanejaS , et al. Safety and immunogenicity of two live attenuated human rotavirus vaccine candidates, 116E and I321, in infants: results of a randomised controlled trial. Vaccine2006;24(31):5817-23. ISRCTN57452882. A double-blind randomised placebo controlled dose escalating phase Ib/IIa study to evaluate the safety and immunogenicity of live attenuated rotavirus vaccine 116E in healthy non-malnourished infants eight to 20 weeks of age. isrctn.com/ISRCTN57452882 (first received 26 July 2006). NCT00280111. Safety and immunogenicity study of live attenuated Indian rotavirus vaccine candidate strains 116E and I321 in infants. clinicaltrials.gov/ct2/show/NCT00280111 (first received 20 January 2006). ">VAC Bhandari 2006‐IND</a>; <a href="./references#CD008521-bbs2-0065" title="BhandariN , SharmaP , TanejaS , KumarT , Rongsen-ChandolaT , AppaiahgariMB , et al. A dose-escalation safety and immunogenicity study of live attenuated oral rotavirus vaccine 116E in infants: a randomized, double-blind, placebo-controlled trial. Journal of Infectious Diseases2009;200(3):421-9. ISRCTN57452882. A double-blind randomised placebo controlled dose escalating phase Ib/IIa study to evaluate the safety and immunogenicity of live attenuated rotavirus vaccine 116E in healthy non-malnourished infants eight to 20 weeks of age. isrctn.com/ISRCTN57452882 (first received 26 July 2006). NCT00439660. Dose escalation study to evaluate oral rotavirus vaccine 116E live attenuated in healthy infants 8 to 20 weeks old. clinicaltrials.gov/ct2/show/NCT00439660 (first received 26 February 2007). ">VAC Bhandari 2009‐IND</a>). Two trials co‐administered other routine childhood vaccines (OPV, DTP, HBV and Hib) with Rotavac (<a href="./references#CD008521-bbs2-0066" title="BhandariN , Rongsen-ChandolaT , BavdekarA , JohnJ , AntonyK , TanejaS , et al. Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian children in the second year of life. Vaccine2014;32(Suppl 1):A110-6. BhandariN , Rongsen-ChandolaT , BavdekarA , JohnJ , AntonyK , TanejaS , et al. Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo-controlled trial. Lancet2014;383(9935):2136-43. CTRI/2010/091/000102. A phase III clinical trial to evaluate the protective efficacy of three doses of oral rotavirus vaccine (ORV) 116E. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=1317 (first received 22 November 2010). JohnJ , KawadeA , Rongsen-ChandolaT , BavdekarA , BhandariN , TanejaS , et al. Active surveillance for intussusception in a phase III efficacy trial of an oral monovalent rotavirus vaccine in India. Vaccine2014;32(Suppl 1):A104-9. JohnTJ . Why was there no vaccine-associated intussusception in Indian rotavirus vaccine trial?Indian Pediatrics2015;52(10):906. NCT01305109. A phase III, randomized, double blind, placebo controlled trial to evaluate the protective efficacy of three doses of oral rotavirus vaccine (ORV) 116E, against severe rotavirus gastroenteritis in infants. clinicaltrials.gov/show/NCT01305109 (first received 28 February 2011). ">VAC Bhandari 2014‐IND</a>; <a href="./references#CD008521-bbs2-0067" title="ChandolaTR , TanejaS , GoyalN , AntonyK , BhatiaK , MoreD , et al. ROTAVAC does not interfere with the immune response to childhood vaccines in Indian infants: a randomized placebo controlled trial. Heliyon2017;3(5):e00302. CTRI/2014/05/004592. A phase III study to evaluate the non-interference in the immune response of rotavac to childhood vaccines and to assess the clinical lot consistency. ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=5870&amp;EncHid=&amp;modid=&amp;compid=%27,%275870det%27 (first received 13 May 2014). ">VAC Chandola 2017‐IND</a>). </p> </section> <section id="CD008521-sec-0088"> <h6 class="title">Methods for collecting adverse event data</h6> <p>As shown in <a href="./appendices#CD008521-sec-0275">Appendix 6</a>, three trials used a combination of passive methods (e.g. diary cards for parents) and active methods (directly contacting parents) to collect adverse event data. The other trial (<a href="./references#CD008521-bbs2-0067" title="ChandolaTR , TanejaS , GoyalN , AntonyK , BhatiaK , MoreD , et al. ROTAVAC does not interfere with the immune response to childhood vaccines in Indian infants: a randomized placebo controlled trial. Heliyon2017;3(5):e00302. CTRI/2014/05/004592. A phase III study to evaluate the non-interference in the immune response of rotavac to childhood vaccines and to assess the clinical lot consistency. ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=5870&amp;EncHid=&amp;modid=&amp;compid=%27,%275870det%27 (first received 13 May 2014). ">VAC Chandola 2017‐IND</a>) used active methods only (directly contacting parents). </p> </section> <section id="CD008521-sec-0089"> <h6 class="title">Source of funding</h6> <p>One trial was funded by Bharat Biotech (<a href="./references#CD008521-bbs2-0064" title="BhandariN , SharmaP , GlassRI , RayP , GreenbergH , TanejaS , et al. Safety and immunogenicity of two live attenuated human rotavirus vaccine candidates, 116E and I321, in infants: results of a randomised controlled trial. Vaccine2006;24(31):5817-23. ISRCTN57452882. A double-blind randomised placebo controlled dose escalating phase Ib/IIa study to evaluate the safety and immunogenicity of live attenuated rotavirus vaccine 116E in healthy non-malnourished infants eight to 20 weeks of age. isrctn.com/ISRCTN57452882 (first received 26 July 2006). NCT00280111. Safety and immunogenicity study of live attenuated Indian rotavirus vaccine candidate strains 116E and I321 in infants. clinicaltrials.gov/ct2/show/NCT00280111 (first received 20 January 2006). ">VAC Bhandari 2006‐IND</a>), one trial was co‐funded by Bharat Biotech (<a href="./references#CD008521-bbs2-0065" title="BhandariN , SharmaP , TanejaS , KumarT , Rongsen-ChandolaT , AppaiahgariMB , et al. A dose-escalation safety and immunogenicity study of live attenuated oral rotavirus vaccine 116E in infants: a randomized, double-blind, placebo-controlled trial. Journal of Infectious Diseases2009;200(3):421-9. ISRCTN57452882. A double-blind randomised placebo controlled dose escalating phase Ib/IIa study to evaluate the safety and immunogenicity of live attenuated rotavirus vaccine 116E in healthy non-malnourished infants eight to 20 weeks of age. isrctn.com/ISRCTN57452882 (first received 26 July 2006). NCT00439660. Dose escalation study to evaluate oral rotavirus vaccine 116E live attenuated in healthy infants 8 to 20 weeks old. clinicaltrials.gov/ct2/show/NCT00439660 (first received 26 February 2007). ">VAC Bhandari 2009‐IND</a>) and the other two trials were funded by PATH, the Government of India, and other not‐for‐profit organisations (<a href="./references#CD008521-bbs2-0066" title="BhandariN , Rongsen-ChandolaT , BavdekarA , JohnJ , AntonyK , TanejaS , et al. Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian children in the second year of life. Vaccine2014;32(Suppl 1):A110-6. BhandariN , Rongsen-ChandolaT , BavdekarA , JohnJ , AntonyK , TanejaS , et al. Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo-controlled trial. Lancet2014;383(9935):2136-43. CTRI/2010/091/000102. A phase III clinical trial to evaluate the protective efficacy of three doses of oral rotavirus vaccine (ORV) 116E. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=1317 (first received 22 November 2010). JohnJ , KawadeA , Rongsen-ChandolaT , BavdekarA , BhandariN , TanejaS , et al. Active surveillance for intussusception in a phase III efficacy trial of an oral monovalent rotavirus vaccine in India. Vaccine2014;32(Suppl 1):A104-9. JohnTJ . Why was there no vaccine-associated intussusception in Indian rotavirus vaccine trial?Indian Pediatrics2015;52(10):906. NCT01305109. A phase III, randomized, double blind, placebo controlled trial to evaluate the protective efficacy of three doses of oral rotavirus vaccine (ORV) 116E, against severe rotavirus gastroenteritis in infants. clinicaltrials.gov/show/NCT01305109 (first received 28 February 2011). ">VAC Bhandari 2014‐IND</a>; <a href="./references#CD008521-bbs2-0067" title="ChandolaTR , TanejaS , GoyalN , AntonyK , BhatiaK , MoreD , et al. ROTAVAC does not interfere with the immune response to childhood vaccines in Indian infants: a randomized placebo controlled trial. Heliyon2017;3(5):e00302. CTRI/2014/05/004592. A phase III study to evaluate the non-interference in the immune response of rotavac to childhood vaccines and to assess the clinical lot consistency. ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=5870&amp;EncHid=&amp;modid=&amp;compid=%27,%275870det%27 (first received 13 May 2014). ">VAC Chandola 2017‐IND</a>). </p> </section> </section> <section id="CD008521-sec-0090"> <h5 class="title">5. Studies awaiting classification</h5> <p>There are no studies awaiting classification.</p> </section> <section id="CD008521-sec-0091"> <h5 class="title">6. Ongoing studies</h5> <p>We did not identify any relevant ongoing trials.</p> </section> </section> <section id="CD008521-sec-0092"> <h4 class="title">Excluded studies</h4> <p>There are 49 excluded studies (<a href="#CD008521-fig-0002">Figure 2</a>). Eighteen of these excluded studies are new to this update. We excluded 31 studies because they reported on comparisons not relevant to this review, nine because they reported on irrelevant outcomes, six because they reported on unlicensed vaccines in development, two because they reported on licensed vaccines that have not been prequalified by the WHO, and one because it reported on a withdrawn rotavirus vaccine. </p> <div class="figure" id="CD008521-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="original image" data-id="CD008521-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-FIG-02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> <p>We moved five excluded studies from the list in the previously published version of this review to the included studies list because they now qualify for inclusion. </p> <p>We removed 42 excluded studies from the list in the previously published version of this review because the list had become very long and these studies clearly did not qualify for inclusion: 22 were observational studies, 11 were trial registration records without outcome results of irrelevant trials, six were not primary research studies, and three did not assess a rotavirus vaccine. These references can be found in the previously published version of this review (<a href="./references#CD008521-bbs2-0195" title="Soares-WeiserK , BergmanH , HenschkeN , PitanF , CunliffeN . Vaccines for preventing rotavirus diarrhoea: vaccines in use. Cochrane Database of Systematic Reviews2019, Issue 10. Art. No: CD008521. [DOI: 10.1002/14651858.CD008521.pub4]">Soares‐Weiser 2019</a>). </p> </section> </section> <section id="CD008521-sec-0093"> <h3 class="title">Risk of bias in included studies</h3> <p>Risk of bias was assessed for each trial, with a focus on the rotavirus diarrhoea outcome measure. Overall pictorial summaries of the risk of bias assessments are shown in <a href="#CD008521-fig-0003">Figure 3</a> and <a href="#CD008521-fig-0004">Figure 4</a>. </p> <div class="figure" id="CD008521-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD008521-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD008521-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study." data-id="CD008521-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. </p> </div> </div> </div> <p>Detailed clinical study reports of most of the GlaxoSmithKline‐sponsored studies (27 of the 36 Rotarix trials) have been published online (<a href="http://gsk-clinicalstudyregister.com" target="_blank">gsk-clinicalstudyregister.com</a>). Full details of blinding, participant selection, and attrition are available from these reports and, for the 2019 update of this review, we could subsequently update risks of bias for these studies, where previously there was no information available. </p> <p>Based on unpublished information provided by Merck, many of the RotaTeq trials' risks of bias were upgraded for the 2012 version of this review. Details of the unpublished information are indicated in the risk of bias tables in the <a href="./references#CD008521-sec-0288" title="">Characteristics of included studies</a> section. </p> <section id="CD008521-sec-0094"> <h4 class="title">Allocation</h4> <p>Of the 60 RCTs analysed in this review, 53 (88%) reported an adequate generation of allocation sequence, while the method of assignment was unclear in the remaining studies due to insufficient reporting. We considered the methods used to conceal allocation to be adequate in 51 trials (85%), and unclear in the remaining studies, again, due to insufficient reporting. </p> </section> <section id="CD008521-sec-0095"> <h4 class="title">Blinding</h4> <p>Information about blinding of participants, care providers, and outcome assessors was provided and we considered blinding to be adequate in 46 studies (77%), unclear in ten studies due to insufficient reporting, and at high risk of bias in four studies: <a href="./references#CD008521-bbs2-0005" title='ColgateER , HaqueR , DicksonDM , CarmolliMP , MychaleckyjJC , NayakU , et al. Delayed dosing of oral rotavirus vaccine demonstrates decreased risk of rotavirus gastroenteritis associated with serum zinc: a randomized controlled trial. Clinical Infectious Diseases2016;63(5):634-41. KirkpatrickBD , ColgateER , MychaleckyjJC , HaqueR , DicksonDM , CarmolliMP , et al. The "Performance of Rotavirus and Oral Polio Vaccines in Developing Countries" (PROVIDE) study: description of methods of an interventional study designed to explore complex biologic problems. American Journal of Tropical Medicine and Hygiene2015;92(4):744-51. LeeB , DicksonDM , DeCampAC , ColgateER , DiehlSA , UddinMI , et al. Histo-blood group antigen phenotype determines susceptibility to genotype-specific rotavirus infections and impacts measures of rotavirus vaccine efficacy. Journal of Infectious Diseases2018;217(9):1399-407. LeeB , DiehlSA , ColgateER , DicksonDM , UddinMI , SharminS , et al. Lewis antigen and secretor status mediate susceptibility to p-genotype specific rotavirus infections but do not affect rotavirus vaccine performance among infants in Bangladesh. American Journal of Tropical Medicine and Hygiene2017;97:226. NCT01375647. Exploration of the biologic basis for underperformance of oral polio and rotavirus vaccines in Bangladesh PROVIDE. clinicaltrials.gov/show/NCT01375647 (first received 17 June 2011). RogawskiET , Platts-MillsJA , ColgateER , HaqueR , ZamanK , PetriWA , et al. Quantifying the impact of natural immunity on rotavirus vaccine efficacy estimates: a clinical trial in Dhaka, Bangladesh (PROVIDE) and a simulation study. Journal of Infectious Diseases2018;217(6):861-8. '>RIX Colgate 2016‐BGD</a> did not include a placebo arm and compared vaccine to no intervention, <a href="./references#CD008521-bbs2-0012" title="GlaxoSmithKline[103477-039]. A phase IIIb, partially blind, randomized, placebo-controlled study to asses the effect on immunogenicity of administration of vaccine without buffering agent and to assess heat stability in terms of immunogenicity, reactogenicity and safety of GlaxoSmithKline Biologicals’ oral live attenuated human rotavirus (HRV) vaccine following a 0, 2 month schedule, in healthy infants previously uninfected with human rotavirus. www.gsk-studyregister.com/study/2713 (accessed 12 December 2018). KerdpanichA , ChokephaibulkitK , WatanaveeradejV , VanpraparN , HutagalungY , HanHH , et al. Exposure to elevated temperature of 37°C for 7 days does not affect immunogenicity and reactogenicity of RIX4414 [poster]. In: dsRNA Virus Meeting; 2006 October 21-26; Cape Town, South Africa. 2006. [Not available for review]KerdpanichA , ChokephaibulkitK , WatanaveeradejV , VanpraparN , SimasathienS , PhavichitrN , et al. Immunogenicity of a human rotavirus vaccine (RIX4414) after storage at 37 degrees C for seven days. Human Vaccine2011;7(1):74-80. KerdpanichA , ChokephaibulkitK , WatanaveeradejV , VanpraparN , SimasathienS , PhavichitrN , et al. Immunogenicity of a live-attenuated human rotavirus RIX4414 vaccine with or without buffering agent. Human Vaccines2010;6(3):254-62. NCT00169455. Assess the effect on immunogenicity of administration of vaccine without buffering agent &amp; assess heat stability in terms of immunogenicity, reactogenicity &amp; safety of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine following a 0, 2 m schedule, in healthy infants previously uninfected with human rotavirus. clinicaltrials.gov/show/NCT00169455 (first received 15 September 2005). ">RIX Kerdpanich 2010‐THA</a> and <a href="./references#CD008521-bbs2-0052" title="CTRI/2012/07/002820. A study to evaluate safety of Rotavirus vaccine in healthy adult volunteers followed by safety, tolerability and immunogenicity evaluation in healthy infants. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=4929&amp;EncHid=&amp;userName=CTRI/2012/07/002820 (first received 23 July 2012). DhingraMS , KunduR , GuptaM , KanungoS , GangulyN , SinghMP , et al. Evaluation of safety and immunogenicity of a live attenuated tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus vaccine (BRV-TV) in healthy Indian adults and infants. Vaccine2014;32(Suppl 1):A117-23. ">TEQ Dhingra 2014‐IND</a> were single‐blind studies, and <a href="./references#CD008521-bbs2-0038" title="ZamanK , SackDA , NeuzilKM , YunusM , MoultonLH , SugimotoJD , et al. Effectiveness of a live oral human rotavirus vaccine after programmatic introduction in Bangladesh: a cluster-randomized trial. PLOS Medicine2017;14(4):e1002282. ">RIX Zaman 2017‐BGD</a> was an open‐label trial. </p> </section> <section id="CD008521-sec-0096"> <h4 class="title">Incomplete outcome data</h4> <p>Incomplete outcome data were adequately addressed, or there were very little or no missing data in 48 studies (80%). In 11 studies, attrition bias was considered unclear, mainly due to insufficient reporting. In one study (<a href="./references#CD008521-bbs2-0054" title="KimDS , LeeTJ , KangJH , KimJH , LeeJH , MaSH , et al. Immunogenicity and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy infants in Korea. Pediatric Infectious Disease Journal2008;27(2):177-8. Merck[PN-013]. Immunogenicity and safety of RotaTeq® in healthy infants in Korea - NCT00166517 (PN 013). clinicalstudyresults.org/drugdetails/?indication_id=523&amp;sort=c.company_name&amp;page=1&amp;drug_id=2148 (accessed prior to 19 October 2021). NCT00166517. Immunogenicity and safety of V260 in healthy infants in Korea. clinicaltrials.gov/show/NCT00166517 (first received 14 September 2005). [Trial registration document (no data for review)]">TEQ Kim 2008‐KOR</a>), the risk of attrition bias was assessed as high because the reasons for missing data were related to the outcome. </p> </section> <section id="CD008521-sec-0097"> <h4 class="title">Selective reporting</h4> <p>Forty‐two (70%) trials were free from selective reporting bias, nine were not, and the remaining nine trials were unclear mainly due to insufficient information. High‐risk assessments of reporting bias were due to incomplete reporting of more than one important outcome (<a href="./references#CD008521-bbs2-0051" title="ClarkH , WhiteC , OffitP , StinsonD , EidenJ , WeaverS , et al. Preliminary evaluation of safety and efficacy of quadrivalent human-bovine reassortant rotavirus vaccine [abstract]. Pediatric Research1995;37:172A. [No data for review]ClarkHF , BernsteinDI , DennehyPH , OffitP , PichicheroM , TreanorJ , et al. Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants. Journal of Pediatrics2004;144(2):184-90. ClarkHF , OffitPA , EllisRW , EidenJJ , KrahD , ShawAR , et al. The development of multivalent bovine rotavirus (strain WC3) reassortant vaccine for infants. Journal of Infectious Diseases1996;174(Suppl 1):73-80. [No data for review]WardRL , BernsteinDI , SmithVE , SanderDS , ShawA , EidenJJ , et al. Rotavirus immunoglobulin a responses stimulated by each of 3 doses of a quadrivalent human/bovine reassortant rotavirus vaccine. Journal of Infectious Diseases2004;189(12):2290-3. ">TEQ Clark 2004‐USA</a>; <a href="./references#CD008521-bbs2-0059" title="VesikariT , ClarkHF , OffitP , SchodelF , DallasM , HeatonP , et al. The effect of dose and composition of a pentavalent rotavirus reassortant vaccine [RotaTeq (R)] in safety, efficacy, and immunogenicity in healthy infants. Pediatric Research2003;53(4 Suppl):307A. VesikariT , ClarkHF , OffitPA , DallasMJ , DiStefanoDJ , GoveiaMG , et al. Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants. Vaccine2006;24(22):4821-9. ">TEQ Vesikari 2006a‐FIN</a>), key expected outcomes were not included (<a href="./references#CD008521-bbs2-0026" title="Costa ClemensSA , et al. Operational organization of a large scale phase III clinical trial of rotavirus vaccine in multiple sites and countries in Latin America. In: International Congress of Pediatrics (ICP); 2004 August 15-20; Cancun, Mexico. 2004. [Not available for review]De VosB , et al. Rotarix™: an effective way to prevent rotavirus diarrhoea and vomiting. In: 9th Congress of the Asian Pan Pacific Society of Paediatric Gastroenterology, Hepatology and Nutrition &amp; 27th Annual Congress of the Malaysian Paediatric Association; 2005 June 16-19; Kuala Lumpur, Malaysia. 2005. [Not available for review]BaayM , BollaertsK , StruchinerC , VerstraetenT . Background rates of disease in Latin American children from a rotavirus vaccine study. Human Vaccines and Immunotherapeutics2017;13(8):1916-20. GlaxoSmithKline[444563-023-pt1]. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants (efficacy data from visit 1 to visit 4). www.gsk-studyregister.com/study/6791 (accessed 12 December 2018). GlaxoSmithKline[444563-023-pt2]. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants (2nd year efficacy from visit 4 to visit 6). www.gsk-studyregister.com/study/6791 (accessed 12 December 2018). GlaxoSmithKline[444563-023-pt3]. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants (safety for the period between visit 1 and visit 3). www.gsk-studyregister.com/study/6791 (accessed 12 December 2018). JustinoMC , AraújoEC , Van DoornLJ , OliveiraCS , GabbayYB , MascarenhasJD , et al. Oral live attenuated human rotavirus vaccine (Rotarix) offers sustained high protection against severe G9P[8] rotavirus gastroenteritis during the first two years of life in Brazilian children. Memorias do Instituto Oswaldo Cruz2012;107(7):846-53. LinharesAC , VelazquezFR , Perez-SchaelI , Saez-LlorensX , AbateH , EspinozaF , et al. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet2008;371(9619):1181-9. LopezP , LinharesA , Pérez-SchaelI , Ruiz-PalaciosG , Costa ClemensS , SanchezN . Early protection against severe rotavirus gastroenteritis - RIX4414 experience in Latin America. In: 24th Annual Meeting of European Society for Paediatric Infectious Diseases (ESPID); 2006 May 03-05; Basel, Switzerland. 2006. [Not available for review]MaciasM , LopezP , VelazquezFR , VergaraRF , SalmeronJ , TavaresJL . The rotavirus vaccine RIX4414 (Rotarix) is not associated with intussusception in one year old infants. In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2005 December 16-19; Washington DC, USA. 2005. [Not available for review]NCT00139347. A multi-country &amp; multi-center study to assess the efficacy, immunogenicity &amp; safety of two doses of GSK Biologicals' oral live attenuated HRV vaccine given concomitantly with routine EPI vaccinations including OPV in healthy infants. clinicaltrials.gov/ct2/show/NCT00139347 (first received 31 August 2005). [Trial registration document (no data for review)]NCT00140673. Placebo-controlled, multi-country &amp; multi-center study to assess the efficacy, safety &amp; immunogenicity of 2 doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants. clinicaltrials.gov/ct2/show/NCT00140673 (first received 1 September 2005). [Trial registration document (no data for review)]Perez-SchaelI , LinharesAC , VesikariT . Two doses of the human attenuated rotavirus vaccine RIX4414 (Rotarix) show heterotypic protection in Latin America and Europe. In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2005 December 16-19; Washington DC, USA. 2005. [Not available for review]PikeM . New rotavirus vaccine is effective and appears to have no increased risk of intussusception. Clinical Research Abstracts For Pediatricians2006;149(1):143. Ruiz-PalaciosG , AranzaC , VelazquezFR , RichardsonV , NandiE , MaciasM . Two doses of the human-attenuated monovalent G1P[8] rotavirus vaccine, Rotarix show high efficacy in Mexican children against severe rotavirus gastroenteritis and severe overall gastroenteritis. In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2005 December 16-19; Washington DC, USA. 2005. [Not available for review]Ruiz-PalaciosGM , Perez-SchaelI , VelazquezFR , AbateH , BreuerT , ClemensSC , et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. New England Journal of Medicine2006;354(1):11-22. VelázquezFR , AbatH , Costa ClemensSA , EspinozaF , GillardP , LinharesAC , et al. The human monovalent G1P[8] rotavirus vaccine, Rotarix is highly efficacious and provides crossprotection against G1 and non-G1 serotypes. In: 23rd Annual meeting of European Society for Paediatric Infectious Diseases (ESPID); 2005 May 18-20; Valencia, Spain. 2005. VelázquezRF , AbateH , BouckenoogheA . RIX4414, the human G1P[8] rotavirus vaccine is highly efficacious during the second year of life. In: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2006 September 27-30; San Francisco, USA. 2006. [Not available for review]VesikariT , O’RyanM , AbateH , Costa ClemensSA , EspinozaF , GillardP . Overcoming the safety hurdle: the rotavirus vaccine RIX4414 is not associated with intussusception. In: 23rd Annual Meeting of European Society for Paediatric Infectious Diseases (ESPID); 2005 May 18-20; Valencia, Spain. 2005. [Not available for review]">RIX Ruiz‐Palac 06‐LA/EU</a>; <a href="./references#CD008521-bbs2-0038" title="ZamanK , SackDA , NeuzilKM , YunusM , MoultonLH , SugimotoJD , et al. Effectiveness of a live oral human rotavirus vaccine after programmatic introduction in Bangladesh: a cluster-randomized trial. PLOS Medicine2017;14(4):e1002282. ">RIX Zaman 2017‐BGD</a>; <a href="./references#CD008521-bbs2-0054" title="KimDS , LeeTJ , KangJH , KimJH , LeeJH , MaSH , et al. Immunogenicity and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy infants in Korea. Pediatric Infectious Disease Journal2008;27(2):177-8. Merck[PN-013]. Immunogenicity and safety of RotaTeq® in healthy infants in Korea - NCT00166517 (PN 013). clinicalstudyresults.org/drugdetails/?indication_id=523&amp;sort=c.company_name&amp;page=1&amp;drug_id=2148 (accessed prior to 19 October 2021). NCT00166517. Immunogenicity and safety of V260 in healthy infants in Korea. clinicaltrials.gov/show/NCT00166517 (first received 14 September 2005). [Trial registration document (no data for review)]">TEQ Kim 2008‐KOR</a>), or important prespecified outcomes were not reported (<a href="./references#CD008521-bbs2-0027" title="Ruiz-PalaciosG , GuerreroL , LinharesAC , et al. Efficacy of an oral human rotavirus (HRV) vaccine in preventing diarrhoea due to G1 and non-G1 rotavirus [Presentation]. In: 3rd World Congress of Pediatric Infectious Diseases; 2002 November 19-23; Santiago, Chile. 2002. [Not available for review]Ruiz-PalaciosG , GuerreroML , LinharesAC , et al. Two-year efficacy of GlaxoSmithKline Biologicals' live attenuated rotavirus vaccine in Latin American children [poster]. In: 24th International Congress of Pediatrics; 2004 August 15-20; Cancun, Mexico. 2004. [Not available for review]SalinasB , Perez-SchaelI , Ruiz-PalaciosG , et al. Early protection by GlaxoSmithKline Biologicals' live attenuated rotavirus vaccine in Latin American children [poster]. In: 24th International Congress of Pediatrics; 2004 August 15-20; Cancun, Mexico. 2004. [Not available for review]SalinasB , TomatMA , YarzabalJP , et al. Efficacy of the rotavirus vaccine (RIX4414) among infants in Carabobo State, Venezuela [poster]. In: Asocación Venezolana para el Avance de la Cienca (AsoVAC); 2004; Venezuela. 2004. [Not available for review]AraujoEC , ClemensSA , OliveiraCS , JustinoMC , RubioP , GabbayYB , et al. Safety, immunogenicity, and protective efficacy of two doses of RIX4414 live attenuated human rotavirus vaccine in healthy infants. Jornal de Pediatria2007;83(3):217-24. De VosB , HardtK , LinharesAC , Ruiz-PalaciosG , GuerreroL , SalinasB . Efficacy of two doses of a human monovalent rotavirus vaccine, Rotarix™ in preventing gastro-enteritis due to G1 and Non-G1 rotavirus in Brazil, Mexico and Venezuela [presentation]. In: 8th International Symposium on Double-Stranded RNA Viruses; 2003 September 13-18; Lucca, Italy. 2003. [Not available for review]De VosB , VesikariT , LinharesAC , SalinasB , Perez-SchaelI , Ruiz-PalaciosGM , et al. A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis. Pediatric Infectious Disease Journal2004;23(10 Suppl):179-82. GlaxoSmithKline[444563-006]. A phase IIb, double-blind, randomized, placebo-controlled study to assess the efficacy, immunogenicity, reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals' live attenuated human rotavirus (HRV) vaccine at different virus concentrations (104.7, 105.2 and 105.8 foci forming units [ffu]) in healthy infants (approximately 2 months of age at first dose) following a 0, 2 month schedule and previously uninfected with HRV, when administered concurrently with DTPw-HBV and Hib vaccines. www.gsk-studyregister.com/study/6784 (accessed 12 December 2018). GlaxoSmithKline[444563-006-Annex]. A phase IIb, double-blind, randomized, placebo-controlled study to assess the efficacy, immunogenicity, reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals' live attenuated human rotavirus (HRV) vaccine at different virus concentrations (104.7, 105.2 and 105.8 foci forming units [ffu]) in healthy infants (approximately 2 months of age at first dose) following a 0, 2 month schedule and previously uninfected with HRV, when administered concurrently with DTPw-HBV and Hib vaccines [This summary presents results for the second and combined efficacy periods and results from the 3-Dose subset. Results from the first efficacy period are presented in 444563/006 (Rota-006) summary]. www.gsk-studyregister.com/study/6784 (accessed 12 December 2018). LinharesA , Perez-SchaelI , Ruiz-PalaciosM , PernambucoE , JacquetJ , De VosB . Immunogenicity and reactogenicity of an oral human rotavirus (HRV) vaccine in Latin American infants [poster]. In: 3rd World Congress of Pediatric Infectious Diseases; 2002 November 19-23; Santiago, Chile. 2002. [Not available for review]LinharesAC , Ruiz-PalaciosGM , GuerreroML , SalinasB , Perez-SchaelI , ClemensSA , et al. A short report on highlights of world-wide development of RIX4414: a Latin American experience. Vaccine2006;24(18):3784-5. LinharesAC , VerstraetenT , Wolleswinkel-Van den BoschJ , ClemensR , BreuerT . Rotavirus serotype G9 is associated with more-severe disease in Latin America. Clinical Infectious Diseases2006;43(3):312-4. [Not available for review]NCT00385320. To assess the efficacy, immuno &amp; safety of 2 doses of GSK HRV vaccine at different virus concentrations in healthy infants aged 2 months &amp; previously uninfected with HRV, concurrently given with DTPw-HBV, Hib. clinicaltrials.gov/show/NCT00385320 (first received 9 October 2006). Perez-SchaelI , SalinasB , LinharesA , GuerreroM , Ruiz-PalaciosG , ClemensS , et al. Protective efficacy of an oral human rotavirus (HRV) vaccine in Latin American infants [poster]. In: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy ( ICAAC); San Diego, 27-30 September 2002. 2002:18, LB-23. [Not available for review]Perez-SchaelI , SalinasB , TomatM , LinharesAC , GuerreroML , Ruiz-PalaciosGM , et al. Efficacy of the human rotavirus vaccine RIX4414 in malnourished children. Journal of Infectious Diseases2007;196(4):537-40. Ruiz-PalaciosGM , GuerreroML , Bautista-MarquezA , Ortega-GallegosH , Tuz-DzibF , Reyes-GonzalezL , et al. Dose response and efficacy of a live, attenuated human rotavirus vaccine in Mexican infants. Pediatrics2007;120(2):e253-61. [Not available for review]Ruiz-PalaciosGM . Impact of maternal antibodies on the immune response to an oral human rotavirus (HRV) vaccine in Mexican infants [presentation]. In: 3rd World Congress of Pediatric Infectious Diseases; 2002 November 19-23; Santiago, Chile. 2002. [Not available for review]SalinasB , Perez SchaelI , LinharesAC , Ruiz PalaciosGM , GuerreroML , YarzabalJP , et al. Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: a randomized, placebo-controlled trial in Latin American infants. Pediatric Infectious Disease Journal2005;24(9):807-16. ">RIX Salinas 2005‐LA</a>; <a href="./references#CD008521-bbs2-0048" title="BlockSL , VesikariT , GoveiaMG , RiversSB , AdeyiBA , DallasMJ , et al. Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life. Pediatrics2007;119(1):11-8. Merck[PN-007]. Study of the efficacy, safety, and immunogenicity of RotaTeq™ at expiry potency NCT00092443 (PN 007). www.clinicalstudyresults.org/drugdetails/?indication_id=523&amp;sort=c.company_name&amp;page=1&amp;drug_id=900 (accessed prior to 19 October 2021). NCT00092443. Study of the efficacy, safety, and immunogenicity of V260 at expiry. clinicaltrials.gov/ct2/show/NCT00092443 (first received 27 September 2004). [Trial registration document]">TEQ Block 2007‐EU/USA</a>; <a href="./references#CD008521-bbs2-0049" title="CiarletM , HeS , LaiS , PetreczM , YuanG , LiuGF , et al. Concomitant use of the 3-dose oral pentavalent rotavirus vaccine with a 3-dose primary vaccination course of a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b vaccine: immunogenicity and reactogenicity. Pediatric Infectious Disease Journal2009;28(3):177-81. Merck[PN-010]. Safety and immunogenicity of concomitant use of RotaTeq™ and INFANRIX™ hexa in healthy infants NCT00258154 (PN 010) [Merck &amp; Co. Inc. Study Synopsis]. clinicalstudyresults.org/drugdetails/?indication_id=1101&amp;sort=c.company_name&amp;page=1&amp;drug_id=2823 (accessed prior to 19 October 2021). NCT00258154. Safety and immunogenicity of concomitant use of V260 and INFANRIX(Tm) hexa in healthy infants. clinicaltrials.gov/show/NCT00258154 (first received 24 November 2005). [Trial registration document (no data for review)]">TEQ Ciarlet 2009‐EU</a>; <a href="./references#CD008521-bbs2-0050" title="ClarkHF , BurkeCJ , VolkinDB , OffitP , WardRL , BreseeJS , et al. Safety, immunogenicity and efficacy in healthy infants of G1 and G2 human reassortant rotavirus vaccine in a new stabilizer/buffer liquid formulation. Pediatric Infectious Disease Journal2003;22(10):914-20. ">TEQ Clark 2003‐USA</a>). </p> </section> <section id="CD008521-sec-0098"> <h4 class="title">Other potential sources of bias</h4> <p>No other bias was apparent in 33 trials (55%). Other bias was unclear in the remaining 27 trials (45%), mainly due to limited reporting where other bias could not be ruled out. </p> </section> </section> <section id="CD008521-sec-0099"> <h3 class="title" id="CD008521-sec-0099">Effects of interventions</h3> <p>See: <a href="./full#CD008521-tbl-0001"><b>Summary of findings 1</b> Rotarix compared with placebo for preventing rotavirus diarrhoea in low‐mortality countries</a>; <a href="./full#CD008521-tbl-0002"><b>Summary of findings 2</b> Rotarix compared with placebo for preventing rotavirus diarrhoea in medium‐mortality countries</a>; <a href="./full#CD008521-tbl-0003"><b>Summary of findings 3</b> Rotarix compared with placebo for preventing rotavirus diarrhoea in high‐mortality countries</a>; <a href="./full#CD008521-tbl-0004"><b>Summary of findings 4</b> RotaTeq compared with placebo for preventing rotavirus diarrhoea in low‐mortality countries</a>; <a href="./full#CD008521-tbl-0005"><b>Summary of findings 5</b> RotaTeq compared with placebo for preventing rotavirus diarrhoea in medium‐mortality countries</a>; <a href="./full#CD008521-tbl-0006"><b>Summary of findings 6</b> RotaTeq compared with placebo for preventing rotavirus diarrhoea in high‐mortality countries</a>; <a href="./full#CD008521-tbl-0007"><b>Summary of findings 7</b> Rotasiil compared with placebo for preventing rotavirus diarrhoea in high‐mortality countries</a>; <a href="./full#CD008521-tbl-0008"><b>Summary of findings 8</b> Rotavac compared with placebo for preventing rotavirus diarrhoea in high‐mortality countries</a> </p> <section id="CD008521-sec-0100"> <h4 class="title">1. Rotarix</h4> <section id="CD008521-sec-0101"> <h5 class="title">1.1. Primary outcomes</h5> <p>Summary of findings of primary outcomes according to country mortality rate are presented in <a href="./full#CD008521-tbl-0001">summary of findings Table 1</a> (Rotarix, low‐mortality countries), <a href="./full#CD008521-tbl-0002">summary of findings Table 2</a> (Rotarix, medium‐mortality countries), and in <a href="./full#CD008521-tbl-0003">summary of findings Table 3</a> (Rotarix, high‐mortality countries). </p> <section id="CD008521-sec-0102"> <h6 class="title">1.1.1. Rotavirus diarrhoea: severe</h6> <p>Fourteen trials provided data on the efficacy of Rotarix to prevent severe rotavirus diarrhoea in children; see <a href="./references#CD008521-fig-0005" title="">Analysis 1.1</a> for up to one‐year follow‐up, <a href="./references#CD008521-fig-0006" title="">Analysis 1.2</a> for second year of life data, and <a href="./references#CD008521-fig-0007" title="">Analysis 1.3</a> for two years follow‐up. Trials were performed in low‐mortality countries (<a href="./references#CD008521-bbs2-0004" title="BernsteinDI , SackDA , ReisingerK , RothsteinE , WardRL . Second-year follow-up evaluation of live, attenuated human rotavirus vaccine 89-12 in healthy infants. Journal of Infectious Diseases2002;186(10):1487-9. BernsteinDI , SackDA , RothsteinE , ReisingerK , SmithVE , O'SullivanD , et al. Efficacy of live, attenuated, human rotavirus vaccine 89-12 in infants: a randomised placebo-controlled trial. Lancet1999;354(9175):287-90. ">RIX Bernstein 1999‐USA</a>; <a href="./references#CD008521-bbs2-0011" title="GlaxoSmithKline[107625 (Rota-056)]. Efficacy, safety, reactogenicity and immunogenicity study of the lyophilised formulation of Rotarix vaccine in healthy Japanese infants. www.gsk-studyregister.com/study/3131 (accessed 12 December 2018). KawamuraN , TokoedaY , MoriS , OhshimaM , OkahataH , UedaD , et al. Efficacy of human rotavirus vaccine RIX4414 in Japanese infants from 2 weeks post dose 2 up to data lock point. In: 28th Meeting of European Society for Paediatric Infectious Diseases (ESPID); 2010 May 04-08; Nice, France. 2010. KawamuraN , TokoedaY , OshimaM , OkahataH , TsutsumiH , Van DoornLJ , et al. Efficacy, safety and immunogenicity of RIX4414 in Japanese infants during the first two years of life. Vaccine2011;29(37):6335-41. NCT00480324. Efficacy, safety, reactogenicity and immunogenicity study of the lyophilised formulation of Rotarix vaccine in healthy Japanese infants. clinicaltrials.gov/show/NCT00480324 (first received 17 November 2010). ">RIX Kawamura 2011‐JPN</a>; <a href="./references#CD008521-bbs2-0023" title="EmmanuelB , et al. Immunogenicity of an acellular pertussis combination vaccine co-administered with a novel rotavirus vaccine in Singaporean infants. Asian Congress on Pediatric Infectious Diseases (ACPID); 2-4 September 2004; Kota Kinabula, Malaysia2004. [Not available for review]PhuaKB , et al. Immunogenicity and reactogenicity of two doses of an oral human rotavirus (HRV) vaccine at different concentrations in healthy infants from Singapore. In: 11th Asia Pacific Congress of Pediatrics and the 3rd Asia Pacific Congress of Pediatric Nursing; 2003; Bangkok, Thailand. 2003. [Not available for review]PhuaKB , et al. Intussusception in children: a seven-year experience in Singapore. In: 24th International Congress of Pediatrics (ICP); 2004 August 15-20; Cancun, Mexico. 2004. [Not available for review]VesikariT , et al. High efficacy of two doses of Rotarix™ (RIX4414) against rotavirus disease in Europe, Latin-America and Asia. In: Asian Congress on Pediatric Infectious Diseases (ACPID); 2006 March 07-10; Cebu, Philippines. 2006. [Not available for review]De VosB , GillardP , CheuvartB . RIX4414 vaccine efficacy against rotavirus gastroenteritis due to G2P[4] strain. In: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2006 September 27-30; San Francisco, USA. 2006. [Not available for review]De VosB , VesikariT , LinharesAC , SalinasB , Perez-SchaelI , Ruiz-PalaciosGM , et al. A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis. Pediatric Infectious Disease Journal2004;23(10 Suppl):179-82. [No data for review]EmmanuelS , PhuaKB , GohP , QuakSH , DattaSK , HanHH , et al. Immunogenicity of an acellular pertussis combination vaccine co-administered with a novel rotavirus vaccine in Singaporean infants. In: 23rd Annual Meeting of European Society for Paediatric Infectious Diseases (ESPID); 2005 May 18-20; Valencia, Spain. 2005. [Not available for review]GlaxoSmithKline[444563-007]. A phase IIb, double-blind, randomized, placebo-controlled study to assess the efficacy, immunogenicity, reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine at different viral concentrations (104.7, 105.2 and 106.1 foci forming units (ffu)) in healthy infants previously uninfected with human rotavirus and approximately three months of age, when administered concurrently with DTPa-IPV/Hib and HBV vaccines. www.gsk-studyregister.com/study/6785 (accessed 12 December 2018). NCT00429481. A study to assess the efficacy, immunogenicity and safety of 2 doses of oral live attenuated human rotavirus vaccine (Rotarix) at different viral concentrations in healthy infants. clinicaltrials.gov/ct2/show/record/NCT00429481 (first received 31 January 2007). PhuaKB , EmmanuelSC , GohP , QuakSH , LeeBW , HanHH , et al. A rotavirus vaccine for prophylaxis of infant rotavirus gastroenteritis: the Asian experience. Annals of the Academy of Medicine, Singapore2006;35(1):38-44. PhuaKB , QuakSH , EmmanuelS , GohPS , HanHH , HardtK , et al. A short report on highlights of worldwide development of RIX4414: a Singaporean experience. Vaccine2006;24(18):3782-3. PhuaKB , QuakSH , EmmanuelS , GohPSC , HanHH , HardtK , et al. Highlights of world-wide development: a Singapore experience. In: 3rd International Conference on Vaccines for Enteric Diseases (VED) 28-30 April 2004; Montego Bay, Jamaica. 2004. [Not available for review]PhuaKB , QuakSH , LeeBW , EmmanuelSC , GohP , HanHH , et al. Evaluation of RIX4414, a live, attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled phase 2 trial involving 2464 Singaporean infants. Journal of Infectious Diseases2005;192(Suppl 1):6-16. PhuaKB , QuakSH , LimFS , GohP , TeohYL , DattaSK , et al. Immunogenicity, reactogenicity and safety of a diphtheria-tetanus-acellular pertussis-inactivated polio and Haemophilus influenzae type b combination vaccine in a placebo-controlled rotavirus vaccine study. Annals of the Academy of Medicine, Singapore2008;37(7):546-53. VesikariT . RIX4414: a new attenuated human rotavirus vaccine. In: 23rd Annual Meeting of European Society for Paediatric Infectious Diseases (ESPID); 2005 May 18-20; Valencia, Spain. 2005. [Not available for review]">RIX Phua 2005‐SGP</a>; <a href="./references#CD008521-bbs2-0024" title="LauYL , NelsonEA , PoonKH , ChanPK , ChiuS , SungR , et al. Efficacy, safety and immunogenicity of a human rotavirus vaccine (RIX4414) in Hong Kong children up to three years of age: a randomized, controlled trial. Vaccine2013;31(18):2253-9. NCT00197210. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy and safety of two doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine in healthy infants. clinicaltrials.gov/show/NCT00197210 (first received 20 September 2005). NCT00329745. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy and safety of two doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine in healthy infants. clinicaltrials.gov/show/NCT00329745 (first received 25 May 2006). PhuaKB , LimFS , LauYL , NelsonEA , HuangLM , QuakSH , et al. Rotavirus vaccine RIX4414 efficacy sustained during the third year of life: a randomized clinical trial in an Asian population. Vaccine2012;30(30):4552-7. PhuaKB , LimFS , LauYL , NelsonEA , HuangLM , QuakSH , et al. Safety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: randomised, double-blind, controlled study. Vaccine2009;27(43):5936-41. PhuaKB , LimFS , QuakSH , LeeBW , TeohYL , SuryakiranPV , et al. Efficacy, immunogenicity and safety of a human rotavirus vaccine RIX4414 in Singaporean infants. Annals of the Academy of Medicine, Singapore2016;45(2):44-50. ">RIX Phua 2009‐AS</a>; <a href="./references#CD008521-bbs2-0033" title="De VosB , VesikariT , LinharesAC , SalinasB , Perez-SchaelI , Ruiz-PalaciosGM , et al. A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis. Pediatric Infectious Disease Journal2004;23(10 Suppl):179-82. GlaxoSmithKline[444563-004]. A phase IIb, double-blind, randomized, placebo-controlled study to assess the efficacy, immunogenicity, reactogenicity and safety of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants approximately 2 months of age and previously uninfected with HRV [Results for the first efficacy period (starting from 2 weeks after dose 2 until the end of the first RV season following vaccination)]. www.gsk-studyregister.com/study/6782 (accessed 12 December 2018). GlaxoSmithKline[444563-004-Annex]. A phase IIb, double-blind, randomized, placebo-controlled study to assess the efficacy, immunogenicity, reactogenicity and safety of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants approximately 2 months of age and previously uninfected with HRV [This summary presents results for the second efficacy period (from the end of the first rotavirus season post-vaccination until the end of the second rotavirus season) and for the two consecutive rotavirus seasons]. www.gsk-studyregister.com/study/6782 (accessed 12 December 2018). NCT00425737. A study to assess the efficacy, immunogenicity and safety of two doses of oral live attenuated human rotavirus (HRV) vaccine (Rotarix) in healthy infants. clinicaltrials.gov/show/NCT00425737 (first received 23 January 2007). VesikariT , KarvonenA , EspoM , KorhonenT , DelemA , De VosB . Efficacy evaluation of an oral human rotavirus (HRV) vaccine in previously uninfected Finnish infants. In: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 September 27-30; San Diego, California. 2002. [Not available for review]VesikariT , KarvonenA , PuustinenL , ZengSQ , SzakalED , DelemA , et al. Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants. Pediatric Infectious Disease Journal2004;23(10):937-43. ">RIX Vesikari 2004b‐FIN</a>; <a href="./references#CD008521-bbs2-0034" title="VesikariT , et al. Human rotavirus vaccine Rotarix is highly efficacious in Europe. In: 24th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); 2006 June 15-18; Basel, Switzerland. 2006. [Not available for review]VesikariT , et al. Rotarix, an oral human Rotavirus vaccine, is highly immunogenic in healthy infants from 6 European countries. In: 24th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); 2006 June 15-18; Basel, Switzerland. 2006. [Not available for review]GlaxoSmithKline[102247-036]. A phase IIIb, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants in co-administration with specific childhood vaccinations [This summary presents results from the first efficacy period] [102247-036]. www.gsk-studyregister.com/study/2669 (accessed 12 December 2018). GlaxoSmithKline[102247-036-Annex]. A phase IIIb, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants in co-administration with specific childhood vaccinations [This summary presents results for the second and combined efficacy periods]. www.gsk-studyregister.com/study/2669 (accessed 12 December 2018). GlaxoSmithKline[102247-036-Yr3]. A phase IIIb, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants in co-administration with specific childhood vaccinations [A phase IIIb open study to assess the long-term efficacy and safety of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine approximately three years after vaccination in healthy infants aged 6-12 weeks at the time of first vaccination in the Rota-036 study (eTrack No.102247) in Finland]. www.gsk-studyregister.com/study/2669 (accessed 12 December 2018). NCT00140686. A multi-country &amp; multi-center study to assess the efficacy, safety &amp; immunogenicity of 2 doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants in co-administration with specific childhood vaccines. clinicaltrials.gov/ct2/show/record/NCT00140686 (first received 1 September 2005). [Trial registration document]NCT00420316. To assess long-term efficacy &amp; safety of subjects approximately 3 years after priming with 2 doses of GlaxoSmithKline (GSK) Biologicals' oral live attenuated human rotavirus (HRV) vaccine (Rotarix) in the primary vaccination study (102247). clinicaltrials.gov/show/NCT00420316 (first received 11 January 2007). SchusterV , OttoW , CohenR . RotarixTM an oral human Rotavirus vaccine, is highly immunogenic when co-administered with a Streptococcus pneumoniae conjugate vaccine (PrevenarTM) in healthy infants from France and Germany. In: 24th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); 2006 June 15-18; Basel, Switzerland. 2006. [Not available for review]TejedorJC , Diez-DelegadoJ , AristeguiJ . Rotarix (RIX4414), an oral Human Rotavirus vaccine, is highly immunogenic when co-administered with a Neisseria meningitides Serogroup C vaccine (MeningitecTM) in healthy infants from Spain. In: 24th Annual Meeting Meeting of the European Society for Paediatric Infectious Diseases (ESPID); 2006 June 15-18; Basel, Switzerland. 2006. [Not available for review]VesikariT ,  KarvonenA ,  PrymulaR ,  SchusterV ,  TejedorJC ,  ThollotF ,  et al. Immunogenicity and safety of the human rotavirus vaccine Rotarix co-administered with routine infant vaccines following the vaccination schedules in Europe. Vaccine2010;28(32):5272-9. VesikariT , KarvonenA , FerranteSA , KuterBJ , CiarletM . Sustained efficacy of the pentavalent rotavirus vaccine, RV5, up to 3.1 years following the last dose of vaccine. Pediatric Infectious Disease Journal2010;29(10):957-63. VesikariT , KarvonenA , PrymulaR , SchusterV , TejedorJC , CohenR , et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet2007;370(9601):1757-63. VesikariT , PrymulaR , SchusterV , TejedorJC , CohenR , BouckenoogheA , et al. Efficacy and immunogenicity of live-attenuated human rotavirus vaccine in breast-fed and formula-fed European infants. Pediatric Infectious Disease Journal2012;31(5):509-13. VesikariT , PrymulaR , SchusterV . Early protection against Rotavirus, Rotarix, experience in an European setting. In: 12th International Congress for Infectious Diseases; 2006 June 15-18; Lisbon, Portugal. 2006. [Not available for review]VesikariT , PrymulaR , SchusterV . Rotarix (RIX4414), an oral human rotavirus vaccine, is highly immunogenic when co-administered with diphteria-tetanus-pertussis (DTPA)-combined vaccines in healthy infants from Europe. In: 24th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); 2006 June 15-18; Basel, Switzerland. 2006. [Not available for review]">RIX Vesikari 2007a‐EU</a>), medium‐mortality countries ( <a href="./references#CD008521-bbs2-0016" title="GlaxoSmithKline[113808-075]. Efficacy, immunogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals' oral live attenuated liquid Human Rotavirus (HRV) vaccine (444563), in healthy infants. www.gsk-studyregister.com/study/4036 (accessed 12 December 2018). LiRC , HuangT , LiY , LuoD , TaoJ , FuB , et al. Human rotavirus vaccine (RIX4414) efficacy in the first two years of life: a randomized, placebo-controlled trial in China. Human Vaccines and Immunotherapeutics2014;10(1):11-8. LiRC , HuangT , LiY , WangLH , TaoJ , FuB , et al. Immunogenicity and reactogenicity of the human rotavirus vaccine, RIX4414 oral suspension, when co-administered with routine childhood vaccines in Chinese infants. Human Vaccines and Immunotherapeutics2016;12(3):785-93. NCT01171963. Efficacy, immunogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals' oral live attenuated liquid human rotavirus (HRV) vaccine (444563), in healthy infants. clinicaltrials.gov/show/NCT01171963 (first received 29 July 2010). ">RIX Li 2014‐CHN</a>; <a href="./references#CD008521-bbs2-0026" title="Costa ClemensSA , et al. Operational organization of a large scale phase III clinical trial of rotavirus vaccine in multiple sites and countries in Latin America. In: International Congress of Pediatrics (ICP); 2004 August 15-20; Cancun, Mexico. 2004. [Not available for review]De VosB , et al. Rotarix™: an effective way to prevent rotavirus diarrhoea and vomiting. In: 9th Congress of the Asian Pan Pacific Society of Paediatric Gastroenterology, Hepatology and Nutrition &amp; 27th Annual Congress of the Malaysian Paediatric Association; 2005 June 16-19; Kuala Lumpur, Malaysia. 2005. [Not available for review]BaayM , BollaertsK , StruchinerC , VerstraetenT . Background rates of disease in Latin American children from a rotavirus vaccine study. Human Vaccines and Immunotherapeutics2017;13(8):1916-20. GlaxoSmithKline[444563-023-pt1]. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants (efficacy data from visit 1 to visit 4). www.gsk-studyregister.com/study/6791 (accessed 12 December 2018). GlaxoSmithKline[444563-023-pt2]. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants (2nd year efficacy from visit 4 to visit 6). www.gsk-studyregister.com/study/6791 (accessed 12 December 2018). GlaxoSmithKline[444563-023-pt3]. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants (safety for the period between visit 1 and visit 3). www.gsk-studyregister.com/study/6791 (accessed 12 December 2018). JustinoMC , AraújoEC , Van DoornLJ , OliveiraCS , GabbayYB , MascarenhasJD , et al. Oral live attenuated human rotavirus vaccine (Rotarix) offers sustained high protection against severe G9P[8] rotavirus gastroenteritis during the first two years of life in Brazilian children. Memorias do Instituto Oswaldo Cruz2012;107(7):846-53. LinharesAC , VelazquezFR , Perez-SchaelI , Saez-LlorensX , AbateH , EspinozaF , et al. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet2008;371(9619):1181-9. LopezP , LinharesA , Pérez-SchaelI , Ruiz-PalaciosG , Costa ClemensS , SanchezN . Early protection against severe rotavirus gastroenteritis - RIX4414 experience in Latin America. In: 24th Annual Meeting of European Society for Paediatric Infectious Diseases (ESPID); 2006 May 03-05; Basel, Switzerland. 2006. [Not available for review]MaciasM , LopezP , VelazquezFR , VergaraRF , SalmeronJ , TavaresJL . The rotavirus vaccine RIX4414 (Rotarix) is not associated with intussusception in one year old infants. In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2005 December 16-19; Washington DC, USA. 2005. [Not available for review]NCT00139347. A multi-country &amp; multi-center study to assess the efficacy, immunogenicity &amp; safety of two doses of GSK Biologicals' oral live attenuated HRV vaccine given concomitantly with routine EPI vaccinations including OPV in healthy infants. clinicaltrials.gov/ct2/show/NCT00139347 (first received 31 August 2005). [Trial registration document (no data for review)]NCT00140673. Placebo-controlled, multi-country &amp; multi-center study to assess the efficacy, safety &amp; immunogenicity of 2 doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants. clinicaltrials.gov/ct2/show/NCT00140673 (first received 1 September 2005). [Trial registration document (no data for review)]Perez-SchaelI , LinharesAC , VesikariT . Two doses of the human attenuated rotavirus vaccine RIX4414 (Rotarix) show heterotypic protection in Latin America and Europe. In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2005 December 16-19; Washington DC, USA. 2005. [Not available for review]PikeM . New rotavirus vaccine is effective and appears to have no increased risk of intussusception. Clinical Research Abstracts For Pediatricians2006;149(1):143. Ruiz-PalaciosG , AranzaC , VelazquezFR , RichardsonV , NandiE , MaciasM . Two doses of the human-attenuated monovalent G1P[8] rotavirus vaccine, Rotarix show high efficacy in Mexican children against severe rotavirus gastroenteritis and severe overall gastroenteritis. In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2005 December 16-19; Washington DC, USA. 2005. [Not available for review]Ruiz-PalaciosGM , Perez-SchaelI , VelazquezFR , AbateH , BreuerT , ClemensSC , et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. New England Journal of Medicine2006;354(1):11-22. VelázquezFR , AbatH , Costa ClemensSA , EspinozaF , GillardP , LinharesAC , et al. The human monovalent G1P[8] rotavirus vaccine, Rotarix is highly efficacious and provides crossprotection against G1 and non-G1 serotypes. In: 23rd Annual meeting of European Society for Paediatric Infectious Diseases (ESPID); 2005 May 18-20; Valencia, Spain. 2005. VelázquezRF , AbateH , BouckenoogheA . RIX4414, the human G1P[8] rotavirus vaccine is highly efficacious during the second year of life. In: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2006 September 27-30; San Francisco, USA. 2006. [Not available for review]VesikariT , O’RyanM , AbateH , Costa ClemensSA , EspinozaF , GillardP . Overcoming the safety hurdle: the rotavirus vaccine RIX4414 is not associated with intussusception. In: 23rd Annual Meeting of European Society for Paediatric Infectious Diseases (ESPID); 2005 May 18-20; Valencia, Spain. 2005. [Not available for review]">RIX Ruiz‐Palac 06‐LA/EU</a>; <a href="./references#CD008521-bbs2-0027" title="Ruiz-PalaciosG , GuerreroL , LinharesAC , et al. Efficacy of an oral human rotavirus (HRV) vaccine in preventing diarrhoea due to G1 and non-G1 rotavirus [Presentation]. In: 3rd World Congress of Pediatric Infectious Diseases; 2002 November 19-23; Santiago, Chile. 2002. [Not available for review]Ruiz-PalaciosG , GuerreroML , LinharesAC , et al. Two-year efficacy of GlaxoSmithKline Biologicals' live attenuated rotavirus vaccine in Latin American children [poster]. In: 24th International Congress of Pediatrics; 2004 August 15-20; Cancun, Mexico. 2004. [Not available for review]SalinasB , Perez-SchaelI , Ruiz-PalaciosG , et al. Early protection by GlaxoSmithKline Biologicals' live attenuated rotavirus vaccine in Latin American children [poster]. In: 24th International Congress of Pediatrics; 2004 August 15-20; Cancun, Mexico. 2004. [Not available for review]SalinasB , TomatMA , YarzabalJP , et al. Efficacy of the rotavirus vaccine (RIX4414) among infants in Carabobo State, Venezuela [poster]. In: Asocación Venezolana para el Avance de la Cienca (AsoVAC); 2004; Venezuela. 2004. [Not available for review]AraujoEC , ClemensSA , OliveiraCS , JustinoMC , RubioP , GabbayYB , et al. Safety, immunogenicity, and protective efficacy of two doses of RIX4414 live attenuated human rotavirus vaccine in healthy infants. Jornal de Pediatria2007;83(3):217-24. De VosB , HardtK , LinharesAC , Ruiz-PalaciosG , GuerreroL , SalinasB . Efficacy of two doses of a human monovalent rotavirus vaccine, Rotarix™ in preventing gastro-enteritis due to G1 and Non-G1 rotavirus in Brazil, Mexico and Venezuela [presentation]. In: 8th International Symposium on Double-Stranded RNA Viruses; 2003 September 13-18; Lucca, Italy. 2003. [Not available for review]De VosB , VesikariT , LinharesAC , SalinasB , Perez-SchaelI , Ruiz-PalaciosGM , et al. A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis. Pediatric Infectious Disease Journal2004;23(10 Suppl):179-82. GlaxoSmithKline[444563-006]. A phase IIb, double-blind, randomized, placebo-controlled study to assess the efficacy, immunogenicity, reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals' live attenuated human rotavirus (HRV) vaccine at different virus concentrations (104.7, 105.2 and 105.8 foci forming units [ffu]) in healthy infants (approximately 2 months of age at first dose) following a 0, 2 month schedule and previously uninfected with HRV, when administered concurrently with DTPw-HBV and Hib vaccines. www.gsk-studyregister.com/study/6784 (accessed 12 December 2018). GlaxoSmithKline[444563-006-Annex]. A phase IIb, double-blind, randomized, placebo-controlled study to assess the efficacy, immunogenicity, reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals' live attenuated human rotavirus (HRV) vaccine at different virus concentrations (104.7, 105.2 and 105.8 foci forming units [ffu]) in healthy infants (approximately 2 months of age at first dose) following a 0, 2 month schedule and previously uninfected with HRV, when administered concurrently with DTPw-HBV and Hib vaccines [This summary presents results for the second and combined efficacy periods and results from the 3-Dose subset. Results from the first efficacy period are presented in 444563/006 (Rota-006) summary]. www.gsk-studyregister.com/study/6784 (accessed 12 December 2018). LinharesA , Perez-SchaelI , Ruiz-PalaciosM , PernambucoE , JacquetJ , De VosB . Immunogenicity and reactogenicity of an oral human rotavirus (HRV) vaccine in Latin American infants [poster]. In: 3rd World Congress of Pediatric Infectious Diseases; 2002 November 19-23; Santiago, Chile. 2002. [Not available for review]LinharesAC , Ruiz-PalaciosGM , GuerreroML , SalinasB , Perez-SchaelI , ClemensSA , et al. A short report on highlights of world-wide development of RIX4414: a Latin American experience. Vaccine2006;24(18):3784-5. LinharesAC , VerstraetenT , Wolleswinkel-Van den BoschJ , ClemensR , BreuerT . Rotavirus serotype G9 is associated with more-severe disease in Latin America. Clinical Infectious Diseases2006;43(3):312-4. [Not available for review]NCT00385320. To assess the efficacy, immuno &amp; safety of 2 doses of GSK HRV vaccine at different virus concentrations in healthy infants aged 2 months &amp; previously uninfected with HRV, concurrently given with DTPw-HBV, Hib. clinicaltrials.gov/show/NCT00385320 (first received 9 October 2006). Perez-SchaelI , SalinasB , LinharesA , GuerreroM , Ruiz-PalaciosG , ClemensS , et al. Protective efficacy of an oral human rotavirus (HRV) vaccine in Latin American infants [poster]. In: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy ( ICAAC); San Diego, 27-30 September 2002. 2002:18, LB-23. [Not available for review]Perez-SchaelI , SalinasB , TomatM , LinharesAC , GuerreroML , Ruiz-PalaciosGM , et al. Efficacy of the human rotavirus vaccine RIX4414 in malnourished children. Journal of Infectious Diseases2007;196(4):537-40. Ruiz-PalaciosGM , GuerreroML , Bautista-MarquezA , Ortega-GallegosH , Tuz-DzibF , Reyes-GonzalezL , et al. Dose response and efficacy of a live, attenuated human rotavirus vaccine in Mexican infants. Pediatrics2007;120(2):e253-61. [Not available for review]Ruiz-PalaciosGM . Impact of maternal antibodies on the immune response to an oral human rotavirus (HRV) vaccine in Mexican infants [presentation]. In: 3rd World Congress of Pediatric Infectious Diseases; 2002 November 19-23; Santiago, Chile. 2002. [Not available for review]SalinasB , Perez SchaelI , LinharesAC , Ruiz PalaciosGM , GuerreroML , YarzabalJP , et al. Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: a randomized, placebo-controlled trial in Latin American infants. Pediatric Infectious Disease Journal2005;24(9):807-16. ">RIX Salinas 2005‐LA</a>; <a href="./references#CD008521-bbs2-0031" title="GlaxoSmithKline[444563-024]. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, immunogenicity and safety of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations including OPV in healthy infants. www.gsk-studyregister.com/study/6792 (accessed 12 December 2018). Gonzalez AyalaS , RiveraL , Rivera-MedinaDM , LopezP , ValenciaA , De LeónT , et al. Co-administration with rotavirus vaccine rix4414 (Rotarix™) does not interfere with the immunogenicity of oral polio vaccine (OPV) [poster]. In: World Society for Pediatric Infectious Diseases (WSPID); 2007 November 15-18; Bangkok, Thailand. 2007. [Not available for review]TregnaghiMW , AbateHJ , ValenciaA , LopezP , Da SilveiraTR , RiveraL , et al. Human rotavirus vaccine is highly efficacious when coadministered with routine expanded program of immunization vaccines including oral poliovirus vaccine in Latin America. Pediatric Infectious Disease Journal2011;30(6):e103-e8. ">RIX Tregnaghi 2011‐LA</a>), and high‐mortality countries (<a href="./references#CD008521-bbs2-0005" title='ColgateER , HaqueR , DicksonDM , CarmolliMP , MychaleckyjJC , NayakU , et al. Delayed dosing of oral rotavirus vaccine demonstrates decreased risk of rotavirus gastroenteritis associated with serum zinc: a randomized controlled trial. Clinical Infectious Diseases2016;63(5):634-41. KirkpatrickBD , ColgateER , MychaleckyjJC , HaqueR , DicksonDM , CarmolliMP , et al. The "Performance of Rotavirus and Oral Polio Vaccines in Developing Countries" (PROVIDE) study: description of methods of an interventional study designed to explore complex biologic problems. American Journal of Tropical Medicine and Hygiene2015;92(4):744-51. LeeB , DicksonDM , DeCampAC , ColgateER , DiehlSA , UddinMI , et al. Histo-blood group antigen phenotype determines susceptibility to genotype-specific rotavirus infections and impacts measures of rotavirus vaccine efficacy. Journal of Infectious Diseases2018;217(9):1399-407. LeeB , DiehlSA , ColgateER , DicksonDM , UddinMI , SharminS , et al. Lewis antigen and secretor status mediate susceptibility to p-genotype specific rotavirus infections but do not affect rotavirus vaccine performance among infants in Bangladesh. American Journal of Tropical Medicine and Hygiene2017;97:226. NCT01375647. Exploration of the biologic basis for underperformance of oral polio and rotavirus vaccines in Bangladesh PROVIDE. clinicaltrials.gov/show/NCT01375647 (first received 17 June 2011). RogawskiET , Platts-MillsJA , ColgateER , HaqueR , ZamanK , PetriWA , et al. Quantifying the impact of natural immunity on rotavirus vaccine efficacy estimates: a clinical trial in Dhaka, Bangladesh (PROVIDE) and a simulation study. Journal of Infectious Diseases2018;217(6):861-8. '>RIX Colgate 2016‐BGD</a>; <a href="./references#CD008521-bbs2-0018" title="CunliffeNA , WitteD , NgwiraBM , ToddS , BostockNJ , TurnerAM , et al. Efficacy of human rotavirus vaccine against severe gastroenteritis in Malawian children in the first two years of life: a randomized, double-blind, placebo controlled trial. Vaccine2012;30(Suppl 1):A36-43. MadhiSA , CunliffeNA , SteeleD , WitteD , KirstenM , LouwC , et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. New England Journal of Medicine2010;362(4):289-98. NCT00241644. Multi-center study to assess the efficacy, safety and immunogenicity of 2 or 3 doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations in healthy infants. clinicaltrials.gov/show/NCT00241644 (first received 19 October 2005). NCT00598468. Multi-center study to assess efficacy, safety &amp; immunogenicity of 2 or 3 doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations in healthy infants. clinicaltrials.gov/show/NCT00598468 (first received 19 October 2005). SteeleAD , NeuzilKM , CunliffeNA , MadhiSA , BosP , NgwiraB , et al. Human rotavirus vaccine Rotarix provides protection against diverse circulating rotavirus strains in African infants: a randomized controlled trial. BMC Infectious Diseases2012;12:213. ">RIX Madhi 2010‐MWI</a>; <a href="./references#CD008521-bbs2-0019" title="MadhiSA , CunliffeNA , SteeleD , WitteD , KirstenM , LouwC , et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. New England Journal of Medicine2010;362(4):289-98. MadhiSA , KirstenM , LouwC , BosP , AspinallS , BouckenoogheA , et al. Efficacy and immunogenicity of two or three dose rotavirus-vaccine regimen in South African children over two consecutive rotavirus seasons: a randomized, double-blind, placebo-controlled trial. Vaccine2012;30(Suppl 1):A44-51. NCT00241644. Multi-center study to assess the efficacy, safety and immunogenicity of 2 or 3 doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations in healthy infants. clinicaltrials.gov/show/NCT00241644 (first received 19 October 2005). NCT00598468. Multi-center study to assess efficacy, safety &amp; immunogenicity of 2 or 3 doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations in healthy infants. clinicaltrials.gov/show/NCT00598468 (first received 19 October 2005). SteeleAD , NeuzilKM , CunliffeNA , MadhiSA , BosP , NgwiraB , et al. Human rotavirus vaccine Rotarix provides protection against diverse circulating rotavirus strains in African infants: a randomized controlled trial. BMC Infectious Diseases2012;12:213. ">RIX Madhi 2010‐ZAF</a>; <a href="./references#CD008521-bbs2-0030" title="GlaxoSmithKline[444563-013]. A phase II, double-blind before the 2002 rotavirus season and single blind with respect to OPV after, randomised, placebo-controlled study of the safety, reactogenicity and immunogenicity of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine (RIX4414 at 105 ffu) co-administered with either oral polio vaccine (OPV) or inactivated polio vaccine (IPV) in healthy infants (approximately 5-10 weeks old) in South Africa. www.gsk-studyregister.com/study/6786 (accessed 12 December 2018). ISRCTN37373664. A double blind, randomised placebo controlled study of the safety, reactogenicity and immunogenicity of two doses of orally administered human rotavirus vaccine (RIX4414) in healthy infants in South Africa. controlled-trials.com/ISRCTN37373664 (first received 25 November 2005). NCT00383903. A study of the safety, reactogenicity and immunogenicity of 2 or 3 doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants (approximately 5-10 weeks old) in South Africa. clinicaltrials.gov/show/NCT00383903 (first received 3 October 2006). SteeleAD ,  ReyndersJ ,  ScholtzF ,  BosP ,  De BeerMC ,  TumboJ ,  et al. Comparison of 2 different regimens for reactogenicity, safety, and immunogenicity of the live attenuated oral rotavirus vaccine RIX4414 coadministered with oral polio vaccine in South African infants. Journal of Infectious Diseases2010;202(Suppl):S93-100. ">RIX Steele 2010b‐ZAF</a>; <a href="./references#CD008521-bbs2-0038" title="ZamanK , SackDA , NeuzilKM , YunusM , MoultonLH , SugimotoJD , et al. Effectiveness of a live oral human rotavirus vaccine after programmatic introduction in Bangladesh: a cluster-randomized trial. PLOS Medicine2017;14(4):e1002282. ">RIX Zaman 2017‐BGD</a>). Data below are grouped accordingly. </p> <section id="CD008521-sec-0103"> <p><b>Low‐mortality countries</b></p> <p>Rotarix reduced severe rotavirus diarrhoea cases by 93% after one year (RR 0.07, 95% CI 0.03 to 0.18; 14,976 participants, 4 trials), by 87% in the second year of life (RR 0.13, 95% CI 0.08 to 0.20; 14,808 participants, 4 trials), and by 90% after two years (RR 0.10, 95% CI 0.07 to 0.14; 18,145 participants, 6 trials). After three years, the pooled estimate from two studies showed an effect in favour of Rotarix compared to placebo, but the 95% CIs were very wide (RR 0.10, 95% CI 0.01 to 1.52; 12,109 participants, <a href="./references#CD008521-bbs2-0024" title="LauYL , NelsonEA , PoonKH , ChanPK , ChiuS , SungR , et al. Efficacy, safety and immunogenicity of a human rotavirus vaccine (RIX4414) in Hong Kong children up to three years of age: a randomized, controlled trial. Vaccine2013;31(18):2253-9. NCT00197210. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy and safety of two doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine in healthy infants. clinicaltrials.gov/show/NCT00197210 (first received 20 September 2005). NCT00329745. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy and safety of two doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine in healthy infants. clinicaltrials.gov/show/NCT00329745 (first received 25 May 2006). PhuaKB , LimFS , LauYL , NelsonEA , HuangLM , QuakSH , et al. Rotavirus vaccine RIX4414 efficacy sustained during the third year of life: a randomized clinical trial in an Asian population. Vaccine2012;30(30):4552-7. PhuaKB , LimFS , LauYL , NelsonEA , HuangLM , QuakSH , et al. Safety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: randomised, double-blind, controlled study. Vaccine2009;27(43):5936-41. PhuaKB , LimFS , QuakSH , LeeBW , TeohYL , SuryakiranPV , et al. Efficacy, immunogenicity and safety of a human rotavirus vaccine RIX4414 in Singaporean infants. Annals of the Academy of Medicine, Singapore2016;45(2):44-50. ">RIX Phua 2009‐AS</a> and <a href="./references#CD008521-bbs2-0034" title="VesikariT , et al. Human rotavirus vaccine Rotarix is highly efficacious in Europe. In: 24th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); 2006 June 15-18; Basel, Switzerland. 2006. [Not available for review]VesikariT , et al. Rotarix, an oral human Rotavirus vaccine, is highly immunogenic in healthy infants from 6 European countries. In: 24th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); 2006 June 15-18; Basel, Switzerland. 2006. [Not available for review]GlaxoSmithKline[102247-036]. A phase IIIb, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants in co-administration with specific childhood vaccinations [This summary presents results from the first efficacy period] [102247-036]. www.gsk-studyregister.com/study/2669 (accessed 12 December 2018). GlaxoSmithKline[102247-036-Annex]. A phase IIIb, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants in co-administration with specific childhood vaccinations [This summary presents results for the second and combined efficacy periods]. www.gsk-studyregister.com/study/2669 (accessed 12 December 2018). GlaxoSmithKline[102247-036-Yr3]. A phase IIIb, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants in co-administration with specific childhood vaccinations [A phase IIIb open study to assess the long-term efficacy and safety of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine approximately three years after vaccination in healthy infants aged 6-12 weeks at the time of first vaccination in the Rota-036 study (eTrack No.102247) in Finland]. www.gsk-studyregister.com/study/2669 (accessed 12 December 2018). NCT00140686. A multi-country &amp; multi-center study to assess the efficacy, safety &amp; immunogenicity of 2 doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants in co-administration with specific childhood vaccines. clinicaltrials.gov/ct2/show/record/NCT00140686 (first received 1 September 2005). [Trial registration document]NCT00420316. To assess long-term efficacy &amp; safety of subjects approximately 3 years after priming with 2 doses of GlaxoSmithKline (GSK) Biologicals' oral live attenuated human rotavirus (HRV) vaccine (Rotarix) in the primary vaccination study (102247). clinicaltrials.gov/show/NCT00420316 (first received 11 January 2007). SchusterV , OttoW , CohenR . RotarixTM an oral human Rotavirus vaccine, is highly immunogenic when co-administered with a Streptococcus pneumoniae conjugate vaccine (PrevenarTM) in healthy infants from France and Germany. In: 24th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); 2006 June 15-18; Basel, Switzerland. 2006. [Not available for review]TejedorJC , Diez-DelegadoJ , AristeguiJ . Rotarix (RIX4414), an oral Human Rotavirus vaccine, is highly immunogenic when co-administered with a Neisseria meningitides Serogroup C vaccine (MeningitecTM) in healthy infants from Spain. In: 24th Annual Meeting Meeting of the European Society for Paediatric Infectious Diseases (ESPID); 2006 June 15-18; Basel, Switzerland. 2006. [Not available for review]VesikariT ,  KarvonenA ,  PrymulaR ,  SchusterV ,  TejedorJC ,  ThollotF ,  et al. Immunogenicity and safety of the human rotavirus vaccine Rotarix co-administered with routine infant vaccines following the vaccination schedules in Europe. Vaccine2010;28(32):5272-9. VesikariT , KarvonenA , FerranteSA , KuterBJ , CiarletM . Sustained efficacy of the pentavalent rotavirus vaccine, RV5, up to 3.1 years following the last dose of vaccine. Pediatric Infectious Disease Journal2010;29(10):957-63. VesikariT , KarvonenA , PrymulaR , SchusterV , TejedorJC , CohenR , et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet2007;370(9601):1757-63. VesikariT , PrymulaR , SchusterV , TejedorJC , CohenR , BouckenoogheA , et al. Efficacy and immunogenicity of live-attenuated human rotavirus vaccine in breast-fed and formula-fed European infants. Pediatric Infectious Disease Journal2012;31(5):509-13. VesikariT , PrymulaR , SchusterV . Early protection against Rotavirus, Rotarix, experience in an European setting. In: 12th International Congress for Infectious Diseases; 2006 June 15-18; Lisbon, Portugal. 2006. [Not available for review]VesikariT , PrymulaR , SchusterV . Rotarix (RIX4414), an oral human rotavirus vaccine, is highly immunogenic when co-administered with diphteria-tetanus-pertussis (DTPA)-combined vaccines in healthy infants from Europe. In: 24th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); 2006 June 15-18; Basel, Switzerland. 2006. [Not available for review]">RIX Vesikari 2007a‐EU</a>; data not shown). Pooled results showed statistical heterogeneity at three years follow‐up (I<sup>2</sup> = 69%, data not shown). </p> </section> <section id="CD008521-sec-0104"> <p><b>Medium‐mortality countries</b></p> <p>Rotarix reduced severe rotavirus diarrhoea cases by 79% during the first year of follow‐up (RR 0.21, 95% CI 0.16 to 0.29; 31,671 participants, 4 trials), by 76% in the second year of life (RR 0.24, 95% CI 0.17 to 0.35; 17,733 participants, 3 trials), and by 78% after two years (RR 0.23, 95% CI 0.17 to 0.29; 23,834 participants, 3 trials).  </p> </section> <section id="CD008521-sec-0105"> <p><b>High‐mortality countries</b></p> <p>Rotarix reduced severe rotavirus diarrhoea cases by 58% during the first year of follow‐up (RR 0.42, 95% CI 0.28 to 0.61; 9951 participants, 5 comparisons from 4 trials), made little or no difference in the second year of life (RR 0.82, 95% CI 0.52 to 1.29; 6049 participants, 3 comparisons from 2 trials), and reduced severe rotavirus diarrhoea cases by 35% after two years (RR 0.65, 95% CI 0.51 to 0.83; 7113 participants, 3 comparisons from 2 trials). Pooled results showed statistical heterogeneity at one‐year follow‐up (I<sup>2</sup> = 52%, <a href="./references#CD008521-fig-0005" title="">Analysis 1.1</a>). </p> </section> </section> <section id="CD008521-sec-0106"> <h6 class="title">1.1.2. All‐cause diarrhoea: severe</h6> <p>Severe all‐cause diarrhoea was reported as cases in seven trials (<a href="./references#CD008521-bbs2-0005" title='ColgateER , HaqueR , DicksonDM , CarmolliMP , MychaleckyjJC , NayakU , et al. Delayed dosing of oral rotavirus vaccine demonstrates decreased risk of rotavirus gastroenteritis associated with serum zinc: a randomized controlled trial. Clinical Infectious Diseases2016;63(5):634-41. KirkpatrickBD , ColgateER , MychaleckyjJC , HaqueR , DicksonDM , CarmolliMP , et al. The "Performance of Rotavirus and Oral Polio Vaccines in Developing Countries" (PROVIDE) study: description of methods of an interventional study designed to explore complex biologic problems. American Journal of Tropical Medicine and Hygiene2015;92(4):744-51. LeeB , DicksonDM , DeCampAC , ColgateER , DiehlSA , UddinMI , et al. Histo-blood group antigen phenotype determines susceptibility to genotype-specific rotavirus infections and impacts measures of rotavirus vaccine efficacy. Journal of Infectious Diseases2018;217(9):1399-407. LeeB , DiehlSA , ColgateER , DicksonDM , UddinMI , SharminS , et al. Lewis antigen and secretor status mediate susceptibility to p-genotype specific rotavirus infections but do not affect rotavirus vaccine performance among infants in Bangladesh. American Journal of Tropical Medicine and Hygiene2017;97:226. NCT01375647. Exploration of the biologic basis for underperformance of oral polio and rotavirus vaccines in Bangladesh PROVIDE. clinicaltrials.gov/show/NCT01375647 (first received 17 June 2011). RogawskiET , Platts-MillsJA , ColgateER , HaqueR , ZamanK , PetriWA , et al. Quantifying the impact of natural immunity on rotavirus vaccine efficacy estimates: a clinical trial in Dhaka, Bangladesh (PROVIDE) and a simulation study. Journal of Infectious Diseases2018;217(6):861-8. '>RIX Colgate 2016‐BGD</a>; <a href="./references#CD008521-bbs2-0016" title="GlaxoSmithKline[113808-075]. Efficacy, immunogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals' oral live attenuated liquid Human Rotavirus (HRV) vaccine (444563), in healthy infants. www.gsk-studyregister.com/study/4036 (accessed 12 December 2018). LiRC , HuangT , LiY , LuoD , TaoJ , FuB , et al. Human rotavirus vaccine (RIX4414) efficacy in the first two years of life: a randomized, placebo-controlled trial in China. Human Vaccines and Immunotherapeutics2014;10(1):11-8. LiRC , HuangT , LiY , WangLH , TaoJ , FuB , et al. Immunogenicity and reactogenicity of the human rotavirus vaccine, RIX4414 oral suspension, when co-administered with routine childhood vaccines in Chinese infants. Human Vaccines and Immunotherapeutics2016;12(3):785-93. NCT01171963. Efficacy, immunogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals' oral live attenuated liquid human rotavirus (HRV) vaccine (444563), in healthy infants. clinicaltrials.gov/show/NCT01171963 (first received 29 July 2010). ">RIX Li 2014‐CHN</a>; <a href="./references#CD008521-bbs2-0017" title="CunliffeNA , WitteD , NgwiraBM , ToddS , BostockNJ , TurnerAM , et al. Efficacy of human rotavirus vaccine against severe gastroenteritis in Malawian children in the first two years of life: a randomized, double-blind, placebo controlled trial. Vaccine2012;30(Suppl 1):A36-43. MadhiSA , CunliffeNA , SteeleD , WitteD , KirstenM , LouwC , et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. New England Journal of Medicine2010;362(4):289-98. MadhiSA , KirstenM , LouwC , BosP , AspinallS , BouckenoogheA , et al. Efficacy and immunogenicity of two or three dose rotavirus-vaccine regimen in South African children over two consecutive rotavirus seasons: a randomized, double-blind, placebo-controlled trial. Vaccine2012;30(Suppl 1):A44-51. NCT00241644. Multi-center study to assess the efficacy, safety and immunogenicity of 2 or 3 doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations in healthy infants. clinicaltrials.gov/show/NCT00241644 (first received 19 October 2005). NCT00598468. Multi-center study to assess efficacy, safety &amp; immunogenicity of 2 or 3 doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations in healthy infants. clinicaltrials.gov/show/NCT00598468 (first received 19 October 2005). SteeleAD , NeuzilKM , CunliffeNA , MadhiSA , BosP , NgwiraB , et al. Human rotavirus vaccine Rotarix provides protection against diverse circulating rotavirus strains in African infants: a randomized controlled trial. BMC Infectious Diseases2012;12:213. ">RIX Madhi 2010‐AF</a>; <a href="./references#CD008521-bbs2-0023" title="EmmanuelB , et al. Immunogenicity of an acellular pertussis combination vaccine co-administered with a novel rotavirus vaccine in Singaporean infants. Asian Congress on Pediatric Infectious Diseases (ACPID); 2-4 September 2004; Kota Kinabula, Malaysia2004. [Not available for review]PhuaKB , et al. Immunogenicity and reactogenicity of two doses of an oral human rotavirus (HRV) vaccine at different concentrations in healthy infants from Singapore. In: 11th Asia Pacific Congress of Pediatrics and the 3rd Asia Pacific Congress of Pediatric Nursing; 2003; Bangkok, Thailand. 2003. [Not available for review]PhuaKB , et al. Intussusception in children: a seven-year experience in Singapore. In: 24th International Congress of Pediatrics (ICP); 2004 August 15-20; Cancun, Mexico. 2004. [Not available for review]VesikariT , et al. High efficacy of two doses of Rotarix™ (RIX4414) against rotavirus disease in Europe, Latin-America and Asia. In: Asian Congress on Pediatric Infectious Diseases (ACPID); 2006 March 07-10; Cebu, Philippines. 2006. [Not available for review]De VosB , GillardP , CheuvartB . RIX4414 vaccine efficacy against rotavirus gastroenteritis due to G2P[4] strain. In: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2006 September 27-30; San Francisco, USA. 2006. [Not available for review]De VosB , VesikariT , LinharesAC , SalinasB , Perez-SchaelI , Ruiz-PalaciosGM , et al. A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis. Pediatric Infectious Disease Journal2004;23(10 Suppl):179-82. [No data for review]EmmanuelS , PhuaKB , GohP , QuakSH , DattaSK , HanHH , et al. Immunogenicity of an acellular pertussis combination vaccine co-administered with a novel rotavirus vaccine in Singaporean infants. In: 23rd Annual Meeting of European Society for Paediatric Infectious Diseases (ESPID); 2005 May 18-20; Valencia, Spain. 2005. [Not available for review]GlaxoSmithKline[444563-007]. A phase IIb, double-blind, randomized, placebo-controlled study to assess the efficacy, immunogenicity, reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine at different viral concentrations (104.7, 105.2 and 106.1 foci forming units (ffu)) in healthy infants previously uninfected with human rotavirus and approximately three months of age, when administered concurrently with DTPa-IPV/Hib and HBV vaccines. www.gsk-studyregister.com/study/6785 (accessed 12 December 2018). NCT00429481. A study to assess the efficacy, immunogenicity and safety of 2 doses of oral live attenuated human rotavirus vaccine (Rotarix) at different viral concentrations in healthy infants. clinicaltrials.gov/ct2/show/record/NCT00429481 (first received 31 January 2007). PhuaKB , EmmanuelSC , GohP , QuakSH , LeeBW , HanHH , et al. A rotavirus vaccine for prophylaxis of infant rotavirus gastroenteritis: the Asian experience. Annals of the Academy of Medicine, Singapore2006;35(1):38-44. PhuaKB , QuakSH , EmmanuelS , GohPS , HanHH , HardtK , et al. A short report on highlights of worldwide development of RIX4414: a Singaporean experience. Vaccine2006;24(18):3782-3. PhuaKB , QuakSH , EmmanuelS , GohPSC , HanHH , HardtK , et al. Highlights of world-wide development: a Singapore experience. In: 3rd International Conference on Vaccines for Enteric Diseases (VED) 28-30 April 2004; Montego Bay, Jamaica. 2004. [Not available for review]PhuaKB , QuakSH , LeeBW , EmmanuelSC , GohP , HanHH , et al. Evaluation of RIX4414, a live, attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled phase 2 trial involving 2464 Singaporean infants. Journal of Infectious Diseases2005;192(Suppl 1):6-16. PhuaKB , QuakSH , LimFS , GohP , TeohYL , DattaSK , et al. Immunogenicity, reactogenicity and safety of a diphtheria-tetanus-acellular pertussis-inactivated polio and Haemophilus influenzae type b combination vaccine in a placebo-controlled rotavirus vaccine study. Annals of the Academy of Medicine, Singapore2008;37(7):546-53. VesikariT . RIX4414: a new attenuated human rotavirus vaccine. In: 23rd Annual Meeting of European Society for Paediatric Infectious Diseases (ESPID); 2005 May 18-20; Valencia, Spain. 2005. [Not available for review]">RIX Phua 2005‐SGP</a>; <a href="./references#CD008521-bbs2-0026" title="Costa ClemensSA , et al. Operational organization of a large scale phase III clinical trial of rotavirus vaccine in multiple sites and countries in Latin America. In: International Congress of Pediatrics (ICP); 2004 August 15-20; Cancun, Mexico. 2004. [Not available for review]De VosB , et al. Rotarix™: an effective way to prevent rotavirus diarrhoea and vomiting. In: 9th Congress of the Asian Pan Pacific Society of Paediatric Gastroenterology, Hepatology and Nutrition &amp; 27th Annual Congress of the Malaysian Paediatric Association; 2005 June 16-19; Kuala Lumpur, Malaysia. 2005. [Not available for review]BaayM , BollaertsK , StruchinerC , VerstraetenT . Background rates of disease in Latin American children from a rotavirus vaccine study. Human Vaccines and Immunotherapeutics2017;13(8):1916-20. GlaxoSmithKline[444563-023-pt1]. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants (efficacy data from visit 1 to visit 4). www.gsk-studyregister.com/study/6791 (accessed 12 December 2018). GlaxoSmithKline[444563-023-pt2]. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants (2nd year efficacy from visit 4 to visit 6). www.gsk-studyregister.com/study/6791 (accessed 12 December 2018). GlaxoSmithKline[444563-023-pt3]. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants (safety for the period between visit 1 and visit 3). www.gsk-studyregister.com/study/6791 (accessed 12 December 2018). JustinoMC , AraújoEC , Van DoornLJ , OliveiraCS , GabbayYB , MascarenhasJD , et al. Oral live attenuated human rotavirus vaccine (Rotarix) offers sustained high protection against severe G9P[8] rotavirus gastroenteritis during the first two years of life in Brazilian children. Memorias do Instituto Oswaldo Cruz2012;107(7):846-53. LinharesAC , VelazquezFR , Perez-SchaelI , Saez-LlorensX , AbateH , EspinozaF , et al. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet2008;371(9619):1181-9. LopezP , LinharesA , Pérez-SchaelI , Ruiz-PalaciosG , Costa ClemensS , SanchezN . Early protection against severe rotavirus gastroenteritis - RIX4414 experience in Latin America. In: 24th Annual Meeting of European Society for Paediatric Infectious Diseases (ESPID); 2006 May 03-05; Basel, Switzerland. 2006. [Not available for review]MaciasM , LopezP , VelazquezFR , VergaraRF , SalmeronJ , TavaresJL . The rotavirus vaccine RIX4414 (Rotarix) is not associated with intussusception in one year old infants. In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2005 December 16-19; Washington DC, USA. 2005. [Not available for review]NCT00139347. A multi-country &amp; multi-center study to assess the efficacy, immunogenicity &amp; safety of two doses of GSK Biologicals' oral live attenuated HRV vaccine given concomitantly with routine EPI vaccinations including OPV in healthy infants. clinicaltrials.gov/ct2/show/NCT00139347 (first received 31 August 2005). [Trial registration document (no data for review)]NCT00140673. Placebo-controlled, multi-country &amp; multi-center study to assess the efficacy, safety &amp; immunogenicity of 2 doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants. clinicaltrials.gov/ct2/show/NCT00140673 (first received 1 September 2005). [Trial registration document (no data for review)]Perez-SchaelI , LinharesAC , VesikariT . Two doses of the human attenuated rotavirus vaccine RIX4414 (Rotarix) show heterotypic protection in Latin America and Europe. In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2005 December 16-19; Washington DC, USA. 2005. [Not available for review]PikeM . New rotavirus vaccine is effective and appears to have no increased risk of intussusception. Clinical Research Abstracts For Pediatricians2006;149(1):143. Ruiz-PalaciosG , AranzaC , VelazquezFR , RichardsonV , NandiE , MaciasM . Two doses of the human-attenuated monovalent G1P[8] rotavirus vaccine, Rotarix show high efficacy in Mexican children against severe rotavirus gastroenteritis and severe overall gastroenteritis. In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2005 December 16-19; Washington DC, USA. 2005. [Not available for review]Ruiz-PalaciosGM , Perez-SchaelI , VelazquezFR , AbateH , BreuerT , ClemensSC , et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. New England Journal of Medicine2006;354(1):11-22. VelázquezFR , AbatH , Costa ClemensSA , EspinozaF , GillardP , LinharesAC , et al. The human monovalent G1P[8] rotavirus vaccine, Rotarix is highly efficacious and provides crossprotection against G1 and non-G1 serotypes. In: 23rd Annual meeting of European Society for Paediatric Infectious Diseases (ESPID); 2005 May 18-20; Valencia, Spain. 2005. VelázquezRF , AbateH , BouckenoogheA . RIX4414, the human G1P[8] rotavirus vaccine is highly efficacious during the second year of life. In: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2006 September 27-30; San Francisco, USA. 2006. [Not available for review]VesikariT , O’RyanM , AbateH , Costa ClemensSA , EspinozaF , GillardP . Overcoming the safety hurdle: the rotavirus vaccine RIX4414 is not associated with intussusception. In: 23rd Annual Meeting of European Society for Paediatric Infectious Diseases (ESPID); 2005 May 18-20; Valencia, Spain. 2005. [Not available for review]">RIX Ruiz‐Palac 06‐LA/EU</a>; <a href="./references#CD008521-bbs2-0031" title="GlaxoSmithKline[444563-024]. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, immunogenicity and safety of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations including OPV in healthy infants. www.gsk-studyregister.com/study/6792 (accessed 12 December 2018). Gonzalez AyalaS , RiveraL , Rivera-MedinaDM , LopezP , ValenciaA , De LeónT , et al. Co-administration with rotavirus vaccine rix4414 (Rotarix™) does not interfere with the immunogenicity of oral polio vaccine (OPV) [poster]. In: World Society for Pediatric Infectious Diseases (WSPID); 2007 November 15-18; Bangkok, Thailand. 2007. [Not available for review]TregnaghiMW , AbateHJ , ValenciaA , LopezP , Da SilveiraTR , RiveraL , et al. Human rotavirus vaccine is highly efficacious when coadministered with routine expanded program of immunization vaccines including oral poliovirus vaccine in Latin America. Pediatric Infectious Disease Journal2011;30(6):e103-e8. ">RIX Tregnaghi 2011‐LA</a>; <a href="./references#CD008521-bbs2-0034" title="VesikariT , et al. Human rotavirus vaccine Rotarix is highly efficacious in Europe. In: 24th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); 2006 June 15-18; Basel, Switzerland. 2006. [Not available for review]VesikariT , et al. Rotarix, an oral human Rotavirus vaccine, is highly immunogenic in healthy infants from 6 European countries. In: 24th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); 2006 June 15-18; Basel, Switzerland. 2006. [Not available for review]GlaxoSmithKline[102247-036]. A phase IIIb, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants in co-administration with specific childhood vaccinations [This summary presents results from the first efficacy period] [102247-036]. www.gsk-studyregister.com/study/2669 (accessed 12 December 2018). GlaxoSmithKline[102247-036-Annex]. A phase IIIb, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants in co-administration with specific childhood vaccinations [This summary presents results for the second and combined efficacy periods]. www.gsk-studyregister.com/study/2669 (accessed 12 December 2018). GlaxoSmithKline[102247-036-Yr3]. A phase IIIb, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants in co-administration with specific childhood vaccinations [A phase IIIb open study to assess the long-term efficacy and safety of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine approximately three years after vaccination in healthy infants aged 6-12 weeks at the time of first vaccination in the Rota-036 study (eTrack No.102247) in Finland]. www.gsk-studyregister.com/study/2669 (accessed 12 December 2018). NCT00140686. A multi-country &amp; multi-center study to assess the efficacy, safety &amp; immunogenicity of 2 doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants in co-administration with specific childhood vaccines. clinicaltrials.gov/ct2/show/record/NCT00140686 (first received 1 September 2005). [Trial registration document]NCT00420316. To assess long-term efficacy &amp; safety of subjects approximately 3 years after priming with 2 doses of GlaxoSmithKline (GSK) Biologicals' oral live attenuated human rotavirus (HRV) vaccine (Rotarix) in the primary vaccination study (102247). clinicaltrials.gov/show/NCT00420316 (first received 11 January 2007). SchusterV , OttoW , CohenR . RotarixTM an oral human Rotavirus vaccine, is highly immunogenic when co-administered with a Streptococcus pneumoniae conjugate vaccine (PrevenarTM) in healthy infants from France and Germany. In: 24th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); 2006 June 15-18; Basel, Switzerland. 2006. [Not available for review]TejedorJC , Diez-DelegadoJ , AristeguiJ . Rotarix (RIX4414), an oral Human Rotavirus vaccine, is highly immunogenic when co-administered with a Neisseria meningitides Serogroup C vaccine (MeningitecTM) in healthy infants from Spain. In: 24th Annual Meeting Meeting of the European Society for Paediatric Infectious Diseases (ESPID); 2006 June 15-18; Basel, Switzerland. 2006. [Not available for review]VesikariT ,  KarvonenA ,  PrymulaR ,  SchusterV ,  TejedorJC ,  ThollotF ,  et al. Immunogenicity and safety of the human rotavirus vaccine Rotarix co-administered with routine infant vaccines following the vaccination schedules in Europe. Vaccine2010;28(32):5272-9. VesikariT , KarvonenA , FerranteSA , KuterBJ , CiarletM . Sustained efficacy of the pentavalent rotavirus vaccine, RV5, up to 3.1 years following the last dose of vaccine. Pediatric Infectious Disease Journal2010;29(10):957-63. VesikariT , KarvonenA , PrymulaR , SchusterV , TejedorJC , CohenR , et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet2007;370(9601):1757-63. VesikariT , PrymulaR , SchusterV , TejedorJC , CohenR , BouckenoogheA , et al. Efficacy and immunogenicity of live-attenuated human rotavirus vaccine in breast-fed and formula-fed European infants. Pediatric Infectious Disease Journal2012;31(5):509-13. VesikariT , PrymulaR , SchusterV . Early protection against Rotavirus, Rotarix, experience in an European setting. In: 12th International Congress for Infectious Diseases; 2006 June 15-18; Lisbon, Portugal. 2006. [Not available for review]VesikariT , PrymulaR , SchusterV . Rotarix (RIX4414), an oral human rotavirus vaccine, is highly immunogenic when co-administered with diphteria-tetanus-pertussis (DTPA)-combined vaccines in healthy infants from Europe. In: 24th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); 2006 June 15-18; Basel, Switzerland. 2006. [Not available for review]">RIX Vesikari 2007a‐EU</a>) and as episodes in two trials (<a href="./references#CD008521-bbs2-0024" title="LauYL , NelsonEA , PoonKH , ChanPK , ChiuS , SungR , et al. Efficacy, safety and immunogenicity of a human rotavirus vaccine (RIX4414) in Hong Kong children up to three years of age: a randomized, controlled trial. Vaccine2013;31(18):2253-9. NCT00197210. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy and safety of two doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine in healthy infants. clinicaltrials.gov/show/NCT00197210 (first received 20 September 2005). NCT00329745. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy and safety of two doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine in healthy infants. clinicaltrials.gov/show/NCT00329745 (first received 25 May 2006). PhuaKB , LimFS , LauYL , NelsonEA , HuangLM , QuakSH , et al. Rotavirus vaccine RIX4414 efficacy sustained during the third year of life: a randomized clinical trial in an Asian population. Vaccine2012;30(30):4552-7. PhuaKB , LimFS , LauYL , NelsonEA , HuangLM , QuakSH , et al. Safety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: randomised, double-blind, controlled study. Vaccine2009;27(43):5936-41. PhuaKB , LimFS , QuakSH , LeeBW , TeohYL , SuryakiranPV , et al. Efficacy, immunogenicity and safety of a human rotavirus vaccine RIX4414 in Singaporean infants. Annals of the Academy of Medicine, Singapore2016;45(2):44-50. ">RIX Phua 2009‐AS</a>; <a href="./references#CD008521-bbs2-0026" title="Costa ClemensSA , et al. Operational organization of a large scale phase III clinical trial of rotavirus vaccine in multiple sites and countries in Latin America. In: International Congress of Pediatrics (ICP); 2004 August 15-20; Cancun, Mexico. 2004. [Not available for review]De VosB , et al. Rotarix™: an effective way to prevent rotavirus diarrhoea and vomiting. In: 9th Congress of the Asian Pan Pacific Society of Paediatric Gastroenterology, Hepatology and Nutrition &amp; 27th Annual Congress of the Malaysian Paediatric Association; 2005 June 16-19; Kuala Lumpur, Malaysia. 2005. [Not available for review]BaayM , BollaertsK , StruchinerC , VerstraetenT . Background rates of disease in Latin American children from a rotavirus vaccine study. Human Vaccines and Immunotherapeutics2017;13(8):1916-20. GlaxoSmithKline[444563-023-pt1]. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants (efficacy data from visit 1 to visit 4). www.gsk-studyregister.com/study/6791 (accessed 12 December 2018). GlaxoSmithKline[444563-023-pt2]. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants (2nd year efficacy from visit 4 to visit 6). www.gsk-studyregister.com/study/6791 (accessed 12 December 2018). GlaxoSmithKline[444563-023-pt3]. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants (safety for the period between visit 1 and visit 3). www.gsk-studyregister.com/study/6791 (accessed 12 December 2018). JustinoMC , AraújoEC , Van DoornLJ , OliveiraCS , GabbayYB , MascarenhasJD , et al. Oral live attenuated human rotavirus vaccine (Rotarix) offers sustained high protection against severe G9P[8] rotavirus gastroenteritis during the first two years of life in Brazilian children. Memorias do Instituto Oswaldo Cruz2012;107(7):846-53. LinharesAC , VelazquezFR , Perez-SchaelI , Saez-LlorensX , AbateH , EspinozaF , et al. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet2008;371(9619):1181-9. LopezP , LinharesA , Pérez-SchaelI , Ruiz-PalaciosG , Costa ClemensS , SanchezN . Early protection against severe rotavirus gastroenteritis - RIX4414 experience in Latin America. In: 24th Annual Meeting of European Society for Paediatric Infectious Diseases (ESPID); 2006 May 03-05; Basel, Switzerland. 2006. [Not available for review]MaciasM , LopezP , VelazquezFR , VergaraRF , SalmeronJ , TavaresJL . The rotavirus vaccine RIX4414 (Rotarix) is not associated with intussusception in one year old infants. In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2005 December 16-19; Washington DC, USA. 2005. [Not available for review]NCT00139347. A multi-country &amp; multi-center study to assess the efficacy, immunogenicity &amp; safety of two doses of GSK Biologicals' oral live attenuated HRV vaccine given concomitantly with routine EPI vaccinations including OPV in healthy infants. clinicaltrials.gov/ct2/show/NCT00139347 (first received 31 August 2005). [Trial registration document (no data for review)]NCT00140673. Placebo-controlled, multi-country &amp; multi-center study to assess the efficacy, safety &amp; immunogenicity of 2 doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants. clinicaltrials.gov/ct2/show/NCT00140673 (first received 1 September 2005). [Trial registration document (no data for review)]Perez-SchaelI , LinharesAC , VesikariT . Two doses of the human attenuated rotavirus vaccine RIX4414 (Rotarix) show heterotypic protection in Latin America and Europe. In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2005 December 16-19; Washington DC, USA. 2005. [Not available for review]PikeM . New rotavirus vaccine is effective and appears to have no increased risk of intussusception. Clinical Research Abstracts For Pediatricians2006;149(1):143. Ruiz-PalaciosG , AranzaC , VelazquezFR , RichardsonV , NandiE , MaciasM . Two doses of the human-attenuated monovalent G1P[8] rotavirus vaccine, Rotarix show high efficacy in Mexican children against severe rotavirus gastroenteritis and severe overall gastroenteritis. In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2005 December 16-19; Washington DC, USA. 2005. [Not available for review]Ruiz-PalaciosGM , Perez-SchaelI , VelazquezFR , AbateH , BreuerT , ClemensSC , et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. New England Journal of Medicine2006;354(1):11-22. VelázquezFR , AbatH , Costa ClemensSA , EspinozaF , GillardP , LinharesAC , et al. The human monovalent G1P[8] rotavirus vaccine, Rotarix is highly efficacious and provides crossprotection against G1 and non-G1 serotypes. In: 23rd Annual meeting of European Society for Paediatric Infectious Diseases (ESPID); 2005 May 18-20; Valencia, Spain. 2005. VelázquezRF , AbateH , BouckenoogheA . RIX4414, the human G1P[8] rotavirus vaccine is highly efficacious during the second year of life. In: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2006 September 27-30; San Francisco, USA. 2006. [Not available for review]VesikariT , O’RyanM , AbateH , Costa ClemensSA , EspinozaF , GillardP . Overcoming the safety hurdle: the rotavirus vaccine RIX4414 is not associated with intussusception. In: 23rd Annual Meeting of European Society for Paediatric Infectious Diseases (ESPID); 2005 May 18-20; Valencia, Spain. 2005. [Not available for review]">RIX Ruiz‐Palac 06‐LA/EU</a>). We have reported these data separately. Trials were performed in low‐mortality countries (<a href="./references#CD008521-bbs2-0023" title="EmmanuelB , et al. Immunogenicity of an acellular pertussis combination vaccine co-administered with a novel rotavirus vaccine in Singaporean infants. Asian Congress on Pediatric Infectious Diseases (ACPID); 2-4 September 2004; Kota Kinabula, Malaysia2004. [Not available for review]PhuaKB , et al. Immunogenicity and reactogenicity of two doses of an oral human rotavirus (HRV) vaccine at different concentrations in healthy infants from Singapore. In: 11th Asia Pacific Congress of Pediatrics and the 3rd Asia Pacific Congress of Pediatric Nursing; 2003; Bangkok, Thailand. 2003. [Not available for review]PhuaKB , et al. Intussusception in children: a seven-year experience in Singapore. In: 24th International Congress of Pediatrics (ICP); 2004 August 15-20; Cancun, Mexico. 2004. [Not available for review]VesikariT , et al. High efficacy of two doses of Rotarix™ (RIX4414) against rotavirus disease in Europe, Latin-America and Asia. In: Asian Congress on Pediatric Infectious Diseases (ACPID); 2006 March 07-10; Cebu, Philippines. 2006. [Not available for review]De VosB , GillardP , CheuvartB . RIX4414 vaccine efficacy against rotavirus gastroenteritis due to G2P[4] strain. In: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2006 September 27-30; San Francisco, USA. 2006. [Not available for review]De VosB , VesikariT , LinharesAC , SalinasB , Perez-SchaelI , Ruiz-PalaciosGM , et al. A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis. Pediatric Infectious Disease Journal2004;23(10 Suppl):179-82. [No data for review]EmmanuelS , PhuaKB , GohP , QuakSH , DattaSK , HanHH , et al. Immunogenicity of an acellular pertussis combination vaccine co-administered with a novel rotavirus vaccine in Singaporean infants. In: 23rd Annual Meeting of European Society for Paediatric Infectious Diseases (ESPID); 2005 May 18-20; Valencia, Spain. 2005. [Not available for review]GlaxoSmithKline[444563-007]. A phase IIb, double-blind, randomized, placebo-controlled study to assess the efficacy, immunogenicity, reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine at different viral concentrations (104.7, 105.2 and 106.1 foci forming units (ffu)) in healthy infants previously uninfected with human rotavirus and approximately three months of age, when administered concurrently with DTPa-IPV/Hib and HBV vaccines. www.gsk-studyregister.com/study/6785 (accessed 12 December 2018). NCT00429481. A study to assess the efficacy, immunogenicity and safety of 2 doses of oral live attenuated human rotavirus vaccine (Rotarix) at different viral concentrations in healthy infants. clinicaltrials.gov/ct2/show/record/NCT00429481 (first received 31 January 2007). PhuaKB , EmmanuelSC , GohP , QuakSH , LeeBW , HanHH , et al. A rotavirus vaccine for prophylaxis of infant rotavirus gastroenteritis: the Asian experience. Annals of the Academy of Medicine, Singapore2006;35(1):38-44. PhuaKB , QuakSH , EmmanuelS , GohPS , HanHH , HardtK , et al. A short report on highlights of worldwide development of RIX4414: a Singaporean experience. Vaccine2006;24(18):3782-3. PhuaKB , QuakSH , EmmanuelS , GohPSC , HanHH , HardtK , et al. Highlights of world-wide development: a Singapore experience. In: 3rd International Conference on Vaccines for Enteric Diseases (VED) 28-30 April 2004; Montego Bay, Jamaica. 2004. [Not available for review]PhuaKB , QuakSH , LeeBW , EmmanuelSC , GohP , HanHH , et al. Evaluation of RIX4414, a live, attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled phase 2 trial involving 2464 Singaporean infants. Journal of Infectious Diseases2005;192(Suppl 1):6-16. PhuaKB , QuakSH , LimFS , GohP , TeohYL , DattaSK , et al. Immunogenicity, reactogenicity and safety of a diphtheria-tetanus-acellular pertussis-inactivated polio and Haemophilus influenzae type b combination vaccine in a placebo-controlled rotavirus vaccine study. Annals of the Academy of Medicine, Singapore2008;37(7):546-53. VesikariT . RIX4414: a new attenuated human rotavirus vaccine. In: 23rd Annual Meeting of European Society for Paediatric Infectious Diseases (ESPID); 2005 May 18-20; Valencia, Spain. 2005. [Not available for review]">RIX Phua 2005‐SGP</a>; <a href="./references#CD008521-bbs2-0024" title="LauYL , NelsonEA , PoonKH , ChanPK , ChiuS , SungR , et al. Efficacy, safety and immunogenicity of a human rotavirus vaccine (RIX4414) in Hong Kong children up to three years of age: a randomized, controlled trial. Vaccine2013;31(18):2253-9. NCT00197210. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy and safety of two doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine in healthy infants. clinicaltrials.gov/show/NCT00197210 (first received 20 September 2005). NCT00329745. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy and safety of two doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine in healthy infants. clinicaltrials.gov/show/NCT00329745 (first received 25 May 2006). PhuaKB , LimFS , LauYL , NelsonEA , HuangLM , QuakSH , et al. Rotavirus vaccine RIX4414 efficacy sustained during the third year of life: a randomized clinical trial in an Asian population. Vaccine2012;30(30):4552-7. PhuaKB , LimFS , LauYL , NelsonEA , HuangLM , QuakSH , et al. Safety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: randomised, double-blind, controlled study. Vaccine2009;27(43):5936-41. PhuaKB , LimFS , QuakSH , LeeBW , TeohYL , SuryakiranPV , et al. Efficacy, immunogenicity and safety of a human rotavirus vaccine RIX4414 in Singaporean infants. Annals of the Academy of Medicine, Singapore2016;45(2):44-50. ">RIX Phua 2009‐AS</a>; <a href="./references#CD008521-bbs2-0034" title="VesikariT , et al. Human rotavirus vaccine Rotarix is highly efficacious in Europe. In: 24th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); 2006 June 15-18; Basel, Switzerland. 2006. [Not available for review]VesikariT , et al. Rotarix, an oral human Rotavirus vaccine, is highly immunogenic in healthy infants from 6 European countries. In: 24th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); 2006 June 15-18; Basel, Switzerland. 2006. [Not available for review]GlaxoSmithKline[102247-036]. A phase IIIb, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants in co-administration with specific childhood vaccinations [This summary presents results from the first efficacy period] [102247-036]. www.gsk-studyregister.com/study/2669 (accessed 12 December 2018). GlaxoSmithKline[102247-036-Annex]. A phase IIIb, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants in co-administration with specific childhood vaccinations [This summary presents results for the second and combined efficacy periods]. www.gsk-studyregister.com/study/2669 (accessed 12 December 2018). GlaxoSmithKline[102247-036-Yr3]. A phase IIIb, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants in co-administration with specific childhood vaccinations [A phase IIIb open study to assess the long-term efficacy and safety of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine approximately three years after vaccination in healthy infants aged 6-12 weeks at the time of first vaccination in the Rota-036 study (eTrack No.102247) in Finland]. www.gsk-studyregister.com/study/2669 (accessed 12 December 2018). NCT00140686. A multi-country &amp; multi-center study to assess the efficacy, safety &amp; immunogenicity of 2 doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants in co-administration with specific childhood vaccines. clinicaltrials.gov/ct2/show/record/NCT00140686 (first received 1 September 2005). [Trial registration document]NCT00420316. To assess long-term efficacy &amp; safety of subjects approximately 3 years after priming with 2 doses of GlaxoSmithKline (GSK) Biologicals' oral live attenuated human rotavirus (HRV) vaccine (Rotarix) in the primary vaccination study (102247). clinicaltrials.gov/show/NCT00420316 (first received 11 January 2007). SchusterV , OttoW , CohenR . RotarixTM an oral human Rotavirus vaccine, is highly immunogenic when co-administered with a Streptococcus pneumoniae conjugate vaccine (PrevenarTM) in healthy infants from France and Germany. In: 24th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); 2006 June 15-18; Basel, Switzerland. 2006. [Not available for review]TejedorJC , Diez-DelegadoJ , AristeguiJ . Rotarix (RIX4414), an oral Human Rotavirus vaccine, is highly immunogenic when co-administered with a Neisseria meningitides Serogroup C vaccine (MeningitecTM) in healthy infants from Spain. In: 24th Annual Meeting Meeting of the European Society for Paediatric Infectious Diseases (ESPID); 2006 June 15-18; Basel, Switzerland. 2006. [Not available for review]VesikariT ,  KarvonenA ,  PrymulaR ,  SchusterV ,  TejedorJC ,  ThollotF ,  et al. Immunogenicity and safety of the human rotavirus vaccine Rotarix co-administered with routine infant vaccines following the vaccination schedules in Europe. Vaccine2010;28(32):5272-9. VesikariT , KarvonenA , FerranteSA , KuterBJ , CiarletM . Sustained efficacy of the pentavalent rotavirus vaccine, RV5, up to 3.1 years following the last dose of vaccine. Pediatric Infectious Disease Journal2010;29(10):957-63. VesikariT , KarvonenA , PrymulaR , SchusterV , TejedorJC , CohenR , et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet2007;370(9601):1757-63. VesikariT , PrymulaR , SchusterV , TejedorJC , CohenR , BouckenoogheA , et al. Efficacy and immunogenicity of live-attenuated human rotavirus vaccine in breast-fed and formula-fed European infants. Pediatric Infectious Disease Journal2012;31(5):509-13. VesikariT , PrymulaR , SchusterV . Early protection against Rotavirus, Rotarix, experience in an European setting. In: 12th International Congress for Infectious Diseases; 2006 June 15-18; Lisbon, Portugal. 2006. [Not available for review]VesikariT , PrymulaR , SchusterV . Rotarix (RIX4414), an oral human rotavirus vaccine, is highly immunogenic when co-administered with diphteria-tetanus-pertussis (DTPA)-combined vaccines in healthy infants from Europe. In: 24th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); 2006 June 15-18; Basel, Switzerland. 2006. [Not available for review]">RIX Vesikari 2007a‐EU</a>), medium‐mortality countries (<a href="./references#CD008521-bbs2-0016" title="GlaxoSmithKline[113808-075]. Efficacy, immunogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals' oral live attenuated liquid Human Rotavirus (HRV) vaccine (444563), in healthy infants. www.gsk-studyregister.com/study/4036 (accessed 12 December 2018). LiRC , HuangT , LiY , LuoD , TaoJ , FuB , et al. Human rotavirus vaccine (RIX4414) efficacy in the first two years of life: a randomized, placebo-controlled trial in China. Human Vaccines and Immunotherapeutics2014;10(1):11-8. LiRC , HuangT , LiY , WangLH , TaoJ , FuB , et al. Immunogenicity and reactogenicity of the human rotavirus vaccine, RIX4414 oral suspension, when co-administered with routine childhood vaccines in Chinese infants. Human Vaccines and Immunotherapeutics2016;12(3):785-93. NCT01171963. Efficacy, immunogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals' oral live attenuated liquid human rotavirus (HRV) vaccine (444563), in healthy infants. clinicaltrials.gov/show/NCT01171963 (first received 29 July 2010). ">RIX Li 2014‐CHN</a>; <a href="./references#CD008521-bbs2-0026" title="Costa ClemensSA , et al. Operational organization of a large scale phase III clinical trial of rotavirus vaccine in multiple sites and countries in Latin America. In: International Congress of Pediatrics (ICP); 2004 August 15-20; Cancun, Mexico. 2004. [Not available for review]De VosB , et al. Rotarix™: an effective way to prevent rotavirus diarrhoea and vomiting. In: 9th Congress of the Asian Pan Pacific Society of Paediatric Gastroenterology, Hepatology and Nutrition &amp; 27th Annual Congress of the Malaysian Paediatric Association; 2005 June 16-19; Kuala Lumpur, Malaysia. 2005. [Not available for review]BaayM , BollaertsK , StruchinerC , VerstraetenT . Background rates of disease in Latin American children from a rotavirus vaccine study. Human Vaccines and Immunotherapeutics2017;13(8):1916-20. GlaxoSmithKline[444563-023-pt1]. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants (efficacy data from visit 1 to visit 4). www.gsk-studyregister.com/study/6791 (accessed 12 December 2018). GlaxoSmithKline[444563-023-pt2]. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants (2nd year efficacy from visit 4 to visit 6). www.gsk-studyregister.com/study/6791 (accessed 12 December 2018). GlaxoSmithKline[444563-023-pt3]. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants (safety for the period between visit 1 and visit 3). www.gsk-studyregister.com/study/6791 (accessed 12 December 2018). JustinoMC , AraújoEC , Van DoornLJ , OliveiraCS , GabbayYB , MascarenhasJD , et al. Oral live attenuated human rotavirus vaccine (Rotarix) offers sustained high protection against severe G9P[8] rotavirus gastroenteritis during the first two years of life in Brazilian children. Memorias do Instituto Oswaldo Cruz2012;107(7):846-53. LinharesAC , VelazquezFR , Perez-SchaelI , Saez-LlorensX , AbateH , EspinozaF , et al. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet2008;371(9619):1181-9. LopezP , LinharesA , Pérez-SchaelI , Ruiz-PalaciosG , Costa ClemensS , SanchezN . Early protection against severe rotavirus gastroenteritis - RIX4414 experience in Latin America. In: 24th Annual Meeting of European Society for Paediatric Infectious Diseases (ESPID); 2006 May 03-05; Basel, Switzerland. 2006. [Not available for review]MaciasM , LopezP , VelazquezFR , VergaraRF , SalmeronJ , TavaresJL . The rotavirus vaccine RIX4414 (Rotarix) is not associated with intussusception in one year old infants. In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2005 December 16-19; Washington DC, USA. 2005. [Not available for review]NCT00139347. A multi-country &amp; multi-center study to assess the efficacy, immunogenicity &amp; safety of two doses of GSK Biologicals' oral live attenuated HRV vaccine given concomitantly with routine EPI vaccinations including OPV in healthy infants. clinicaltrials.gov/ct2/show/NCT00139347 (first received 31 August 2005). [Trial registration document (no data for review)]NCT00140673. Placebo-controlled, multi-country &amp; multi-center study to assess the efficacy, safety &amp; immunogenicity of 2 doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants. clinicaltrials.gov/ct2/show/NCT00140673 (first received 1 September 2005). [Trial registration document (no data for review)]Perez-SchaelI , LinharesAC , VesikariT . Two doses of the human attenuated rotavirus vaccine RIX4414 (Rotarix) show heterotypic protection in Latin America and Europe. In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2005 December 16-19; Washington DC, USA. 2005. [Not available for review]PikeM . New rotavirus vaccine is effective and appears to have no increased risk of intussusception. Clinical Research Abstracts For Pediatricians2006;149(1):143. Ruiz-PalaciosG , AranzaC , VelazquezFR , RichardsonV , NandiE , MaciasM . Two doses of the human-attenuated monovalent G1P[8] rotavirus vaccine, Rotarix show high efficacy in Mexican children against severe rotavirus gastroenteritis and severe overall gastroenteritis. In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2005 December 16-19; Washington DC, USA. 2005. [Not available for review]Ruiz-PalaciosGM , Perez-SchaelI , VelazquezFR , AbateH , BreuerT , ClemensSC , et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. New England Journal of Medicine2006;354(1):11-22. VelázquezFR , AbatH , Costa ClemensSA , EspinozaF , GillardP , LinharesAC , et al. The human monovalent G1P[8] rotavirus vaccine, Rotarix is highly efficacious and provides crossprotection against G1 and non-G1 serotypes. In: 23rd Annual meeting of European Society for Paediatric Infectious Diseases (ESPID); 2005 May 18-20; Valencia, Spain. 2005. VelázquezRF , AbateH , BouckenoogheA . RIX4414, the human G1P[8] rotavirus vaccine is highly efficacious during the second year of life. In: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2006 September 27-30; San Francisco, USA. 2006. [Not available for review]VesikariT , O’RyanM , AbateH , Costa ClemensSA , EspinozaF , GillardP . Overcoming the safety hurdle: the rotavirus vaccine RIX4414 is not associated with intussusception. In: 23rd Annual Meeting of European Society for Paediatric Infectious Diseases (ESPID); 2005 May 18-20; Valencia, Spain. 2005. [Not available for review]">RIX Ruiz‐Palac 06‐LA/EU</a>; <a href="./references#CD008521-bbs2-0031" title="GlaxoSmithKline[444563-024]. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, immunogenicity and safety of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations including OPV in healthy infants. www.gsk-studyregister.com/study/6792 (accessed 12 December 2018). Gonzalez AyalaS , RiveraL , Rivera-MedinaDM , LopezP , ValenciaA , De LeónT , et al. Co-administration with rotavirus vaccine rix4414 (Rotarix™) does not interfere with the immunogenicity of oral polio vaccine (OPV) [poster]. In: World Society for Pediatric Infectious Diseases (WSPID); 2007 November 15-18; Bangkok, Thailand. 2007. [Not available for review]TregnaghiMW , AbateHJ , ValenciaA , LopezP , Da SilveiraTR , RiveraL , et al. Human rotavirus vaccine is highly efficacious when coadministered with routine expanded program of immunization vaccines including oral poliovirus vaccine in Latin America. Pediatric Infectious Disease Journal2011;30(6):e103-e8. ">RIX Tregnaghi 2011‐LA</a>), and in high‐mortality countries (<a href="./references#CD008521-bbs2-0005" title='ColgateER , HaqueR , DicksonDM , CarmolliMP , MychaleckyjJC , NayakU , et al. Delayed dosing of oral rotavirus vaccine demonstrates decreased risk of rotavirus gastroenteritis associated with serum zinc: a randomized controlled trial. Clinical Infectious Diseases2016;63(5):634-41. KirkpatrickBD , ColgateER , MychaleckyjJC , HaqueR , DicksonDM , CarmolliMP , et al. The "Performance of Rotavirus and Oral Polio Vaccines in Developing Countries" (PROVIDE) study: description of methods of an interventional study designed to explore complex biologic problems. American Journal of Tropical Medicine and Hygiene2015;92(4):744-51. LeeB , DicksonDM , DeCampAC , ColgateER , DiehlSA , UddinMI , et al. Histo-blood group antigen phenotype determines susceptibility to genotype-specific rotavirus infections and impacts measures of rotavirus vaccine efficacy. Journal of Infectious Diseases2018;217(9):1399-407. LeeB , DiehlSA , ColgateER , DicksonDM , UddinMI , SharminS , et al. Lewis antigen and secretor status mediate susceptibility to p-genotype specific rotavirus infections but do not affect rotavirus vaccine performance among infants in Bangladesh. American Journal of Tropical Medicine and Hygiene2017;97:226. NCT01375647. Exploration of the biologic basis for underperformance of oral polio and rotavirus vaccines in Bangladesh PROVIDE. clinicaltrials.gov/show/NCT01375647 (first received 17 June 2011). RogawskiET , Platts-MillsJA , ColgateER , HaqueR , ZamanK , PetriWA , et al. Quantifying the impact of natural immunity on rotavirus vaccine efficacy estimates: a clinical trial in Dhaka, Bangladesh (PROVIDE) and a simulation study. Journal of Infectious Diseases2018;217(6):861-8. '>RIX Colgate 2016‐BGD</a>; <a href="./references#CD008521-bbs2-0018" title="CunliffeNA , WitteD , NgwiraBM , ToddS , BostockNJ , TurnerAM , et al. Efficacy of human rotavirus vaccine against severe gastroenteritis in Malawian children in the first two years of life: a randomized, double-blind, placebo controlled trial. Vaccine2012;30(Suppl 1):A36-43. MadhiSA , CunliffeNA , SteeleD , WitteD , KirstenM , LouwC , et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. New England Journal of Medicine2010;362(4):289-98. NCT00241644. Multi-center study to assess the efficacy, safety and immunogenicity of 2 or 3 doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations in healthy infants. clinicaltrials.gov/show/NCT00241644 (first received 19 October 2005). NCT00598468. Multi-center study to assess efficacy, safety &amp; immunogenicity of 2 or 3 doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations in healthy infants. clinicaltrials.gov/show/NCT00598468 (first received 19 October 2005). SteeleAD , NeuzilKM , CunliffeNA , MadhiSA , BosP , NgwiraB , et al. Human rotavirus vaccine Rotarix provides protection against diverse circulating rotavirus strains in African infants: a randomized controlled trial. BMC Infectious Diseases2012;12:213. ">RIX Madhi 2010‐MWI</a>; <a href="./references#CD008521-bbs2-0019" title="MadhiSA , CunliffeNA , SteeleD , WitteD , KirstenM , LouwC , et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. New England Journal of Medicine2010;362(4):289-98. MadhiSA , KirstenM , LouwC , BosP , AspinallS , BouckenoogheA , et al. Efficacy and immunogenicity of two or three dose rotavirus-vaccine regimen in South African children over two consecutive rotavirus seasons: a randomized, double-blind, placebo-controlled trial. Vaccine2012;30(Suppl 1):A44-51. NCT00241644. Multi-center study to assess the efficacy, safety and immunogenicity of 2 or 3 doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations in healthy infants. clinicaltrials.gov/show/NCT00241644 (first received 19 October 2005). NCT00598468. Multi-center study to assess efficacy, safety &amp; immunogenicity of 2 or 3 doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations in healthy infants. clinicaltrials.gov/show/NCT00598468 (first received 19 October 2005). SteeleAD , NeuzilKM , CunliffeNA , MadhiSA , BosP , NgwiraB , et al. Human rotavirus vaccine Rotarix provides protection against diverse circulating rotavirus strains in African infants: a randomized controlled trial. BMC Infectious Diseases2012;12:213. ">RIX Madhi 2010‐ZAF</a>). </p> <section id="CD008521-sec-0107"> <p><b>Low‐mortality countries</b></p> <p>Rotarix reduced the number of severe cases of all‐cause diarrhoea by 52% at one year (RR 0.48, 95% CI 0.37 to 0.61; 3874 participants, 1 trial; <a href="./references#CD008521-fig-0008" title="">Analysis 1.4</a>), and by 51% at two years (RR 0.49, 95% CI 0.40 to 0.60; 6269 participants, 2 trials; <a href="./references#CD008521-fig-0009" title="">Analysis 1.5</a>). Rotarix reduced the rate of severe episodes of all‐cause diarrhoea by 30% at two years (rate ratio 0.70, 95% CI 0.56 to 0.86; 39,091 participants, 1 trial; <a href="./references#CD008521-fig-0011" title="">Analysis 1.7</a>). One trial reported on severe all‐cause diarrhoea after three years follow‐up (<a href="./references#CD008521-bbs2-0024" title="LauYL , NelsonEA , PoonKH , ChanPK , ChiuS , SungR , et al. Efficacy, safety and immunogenicity of a human rotavirus vaccine (RIX4414) in Hong Kong children up to three years of age: a randomized, controlled trial. Vaccine2013;31(18):2253-9. NCT00197210. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy and safety of two doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine in healthy infants. clinicaltrials.gov/show/NCT00197210 (first received 20 September 2005). NCT00329745. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy and safety of two doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine in healthy infants. clinicaltrials.gov/show/NCT00329745 (first received 25 May 2006). PhuaKB , LimFS , LauYL , NelsonEA , HuangLM , QuakSH , et al. Rotavirus vaccine RIX4414 efficacy sustained during the third year of life: a randomized clinical trial in an Asian population. Vaccine2012;30(30):4552-7. PhuaKB , LimFS , LauYL , NelsonEA , HuangLM , QuakSH , et al. Safety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: randomised, double-blind, controlled study. Vaccine2009;27(43):5936-41. PhuaKB , LimFS , QuakSH , LeeBW , TeohYL , SuryakiranPV , et al. Efficacy, immunogenicity and safety of a human rotavirus vaccine RIX4414 in Singaporean infants. Annals of the Academy of Medicine, Singapore2016;45(2):44-50. ">RIX Phua 2009‐AS</a>); Rotarix reduced the number of severe cases by 27% (RR 0.73, 95% CI 0.61 to 0.88; 10,519 participants; data not shown). </p> </section> <section id="CD008521-sec-0108"> <p><b>Medium‐mortality countries</b></p> <p>Rotarix reduced the number of severe cases of all‐cause diarrhoea by 36% at one year (RR 0.64, 95% CI 0.52 to 0.79; 26,479 participants, 2 trials; <a href="./references#CD008521-fig-0008" title="">Analysis 1.4</a>), and by 26% at two years (RR 0.74, 95% CI 0.50 to 1.09; 23,317 participants, 2 trials; <a href="./references#CD008521-fig-0009" title="">Analysis 1.5</a>). Pooled results showed statistical heterogeneity at both one year (I<sup>2</sup> = 46%) and two years follow‐up (I<sup>2</sup> = 92%). Rotarix reduced the rate of severe episodes of all‐cause diarrhoea by 40% at one year (rate ratio 0.60, 95% CI 0.50 to 0.72; 17,867 participants, 1 trial; <a href="./references#CD008521-fig-0010" title="">Analysis 1.6</a>), and by 39% at two years (rate ratio 0.61, 95% CI 0.53 to 0.70; 39,091 participants, 1 trial; <a href="./references#CD008521-fig-0011" title="">Analysis 1.7</a>).  </p> </section> <section id="CD008521-sec-0109"> <p><b>High‐mortality countries</b></p> <p>Rotarix reduced the number of severe cases of all‐cause diarrhoea by 27% at one‐year follow‐up (RR 0.73, 95% CI 0.56 to 0.95; 5639 participants, 3 comparisons from 2 trials; <a href="./references#CD008521-fig-0008" title="">Analysis 1.4</a>), and by 17% at two years follow‐up (RR 0.83, 95% CI 0.72 to 0.96; 2764 participants, 2 comparisons from 1 trial; <a href="./references#CD008521-fig-0009" title="">Analysis 1.5</a>). Pooled results showed statistical heterogeneity at one‐year follow‐up (I<sup>2</sup> = 75%). </p> </section> </section> <section id="CD008521-sec-0110"> <h6 class="title">1.1.3. All‐cause death</h6> <p>Thirty trials reported on all‐cause death, either as the number of deaths (<a href="./references#CD008521-bbs2-0004" title="BernsteinDI , SackDA , ReisingerK , RothsteinE , WardRL . Second-year follow-up evaluation of live, attenuated human rotavirus vaccine 89-12 in healthy infants. Journal of Infectious Diseases2002;186(10):1487-9. BernsteinDI , SackDA , RothsteinE , ReisingerK , SmithVE , O'SullivanD , et al. Efficacy of live, attenuated, human rotavirus vaccine 89-12 in infants: a randomised placebo-controlled trial. Lancet1999;354(9175):287-90. ">RIX Bernstein 1999‐USA</a>; <a href="./references#CD008521-bbs2-0013" title="GlaxoSmithKline[112269-068]. Immunogenicity, reactogenicity and safety study to evaluate two doses of the lyophilised formulation of the human rotavirus (HRV) vaccine when administered to healthy Korean infants previously uninfected with HRV. www.gsk-studyregister.com/study/3589 (accessed 12 December 2018). KimJS , BaeCW , LeeKY , ParkMS , ChoiYY , KimKN , et al. Immunogenicity, reactogenicity and safety of a human rotavirus vaccine (RIX4414) in Korean infants: a randomized, double-blind, placebo-controlled, phase IV study. Human Vaccines and Immunotherapeutics2012;8(6):806-12. NCT00969228. Study to evaluate immunogenicity, reactogenicity and safety of Rotarix™ vaccine in Korean infants. clinicaltrials.gov/ct2/show/NCT00969228 (first received 1 September 2009). ">RIX Kim 2012‐KOR</a>; <a href="./references#CD008521-bbs2-0015" title="GlaxoSmithKline[113518-074]. Reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated liquid human rotavirus (HRV) vaccine 444563, in healthy infants. www.gsk-studyregister.com/study/3947 (accessed 12 December 2018). LiRC , LiYP , MoZJ , LuoD , HuangT , KongJL , et al. Reactogenicity and safety of a liquid human rotavirus vaccine (RIX4414) in healthy adults, children and infants in China: randomized, double-blind, placebo-controlled phase I studies. Human Vaccines and Immunotherapeutics2013;9(8):1638-42. NCT01107587. Study to assess the safety of GSK Biologicals' liquid human rotavirus vaccine in healthy infants. clinicaltrials.gov/ct2/show/NCT01107587 (first received 20 April 2010). ">RIX Li 2013b‐CHN</a>; <a href="./references#CD008521-bbs2-0016" title="GlaxoSmithKline[113808-075]. Efficacy, immunogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals' oral live attenuated liquid Human Rotavirus (HRV) vaccine (444563), in healthy infants. www.gsk-studyregister.com/study/4036 (accessed 12 December 2018). LiRC , HuangT , LiY , LuoD , TaoJ , FuB , et al. Human rotavirus vaccine (RIX4414) efficacy in the first two years of life: a randomized, placebo-controlled trial in China. Human Vaccines and Immunotherapeutics2014;10(1):11-8. LiRC , HuangT , LiY , WangLH , TaoJ , FuB , et al. Immunogenicity and reactogenicity of the human rotavirus vaccine, RIX4414 oral suspension, when co-administered with routine childhood vaccines in Chinese infants. Human Vaccines and Immunotherapeutics2016;12(3):785-93. NCT01171963. Efficacy, immunogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals' oral live attenuated liquid human rotavirus (HRV) vaccine (444563), in healthy infants. clinicaltrials.gov/show/NCT01171963 (first received 29 July 2010). ">RIX Li 2014‐CHN</a>; <a href="./references#CD008521-bbs2-0017" title="CunliffeNA , WitteD , NgwiraBM , ToddS , BostockNJ , TurnerAM , et al. Efficacy of human rotavirus vaccine against severe gastroenteritis in Malawian children in the first two years of life: a randomized, double-blind, placebo controlled trial. Vaccine2012;30(Suppl 1):A36-43. MadhiSA , CunliffeNA , SteeleD , WitteD , KirstenM , LouwC , et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. New England Journal of Medicine2010;362(4):289-98. MadhiSA , KirstenM , LouwC , BosP , AspinallS , BouckenoogheA , et al. Efficacy and immunogenicity of two or three dose rotavirus-vaccine regimen in South African children over two consecutive rotavirus seasons: a randomized, double-blind, placebo-controlled trial. Vaccine2012;30(Suppl 1):A44-51. NCT00241644. Multi-center study to assess the efficacy, safety and immunogenicity of 2 or 3 doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations in healthy infants. clinicaltrials.gov/show/NCT00241644 (first received 19 October 2005). NCT00598468. Multi-center study to assess efficacy, safety &amp; immunogenicity of 2 or 3 doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations in healthy infants. clinicaltrials.gov/show/NCT00598468 (first received 19 October 2005). SteeleAD , NeuzilKM , CunliffeNA , MadhiSA , BosP , NgwiraB , et al. Human rotavirus vaccine Rotarix provides protection against diverse circulating rotavirus strains in African infants: a randomized controlled trial. BMC Infectious Diseases2012;12:213. ">RIX Madhi 2010‐AF</a>; <a href="./references#CD008521-bbs2-0021" title="GlaxoSmithKline[104021-DTPw CSL-HBVGOD-005]. A phase III, partially blind, randomized study to evaluate the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ Tritanrix™-HepB and GSK Biologicals Kft’s DTPw-HBV vaccines as compared to concomitant administration of Commonwealth Serum Laboratory’s (CSL’s) DTPw (Triple Antigen™) and GSK Biologicals’ HBV (Engerix™-B), when co-administered with GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine, to healthy infants at 3, 4½ and 6 months of age, after a birth dose of hepatitis B vaccine. www.gsk-studyregister.com/study/2753 (accessed 12 December 2018). NCT00158756. Assess immunogenicity &amp; reactogenicity of 2 formulations of GSK's DTPw-HBV vaccines vs concomitant admn of CSL's DTPw &amp; GSK's HBV vaccine, co-admnd with GSK's rotavirus vaccine, to infants at 3, 4½ &amp; 6 mths, after birth dose of HBV vaccine. clinicaltrials.gov/show/NCT00158756 (first received 12 September 2005). TatochenkoVK , RomanenkoVV , KharitSM , SmolenovI , LeFevreI , De ClercqN , et al. Co-administration of a human rotavirus vaccine Rix4414 with DTPw-HBv vaccines: immunogenicity and reactogenicity in healthy infants. In: 13th International Congress on Infectious Diseases; June 19–22. 2008; Kuala Lumpur, Malaysia. 2008. ">RIX NCT00158756‐RUS</a>; <a href="./references#CD008521-bbs2-0023" title="EmmanuelB , et al. Immunogenicity of an acellular pertussis combination vaccine co-administered with a novel rotavirus vaccine in Singaporean infants. Asian Congress on Pediatric Infectious Diseases (ACPID); 2-4 September 2004; Kota Kinabula, Malaysia2004. [Not available for review]PhuaKB , et al. Immunogenicity and reactogenicity of two doses of an oral human rotavirus (HRV) vaccine at different concentrations in healthy infants from Singapore. In: 11th Asia Pacific Congress of Pediatrics and the 3rd Asia Pacific Congress of Pediatric Nursing; 2003; Bangkok, Thailand. 2003. [Not available for review]PhuaKB , et al. Intussusception in children: a seven-year experience in Singapore. In: 24th International Congress of Pediatrics (ICP); 2004 August 15-20; Cancun, Mexico. 2004. [Not available for review]VesikariT , et al. High efficacy of two doses of Rotarix™ (RIX4414) against rotavirus disease in Europe, Latin-America and Asia. In: Asian Congress on Pediatric Infectious Diseases (ACPID); 2006 March 07-10; Cebu, Philippines. 2006. [Not available for review]De VosB , GillardP , CheuvartB . RIX4414 vaccine efficacy against rotavirus gastroenteritis due to G2P[4] strain. In: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2006 September 27-30; San Francisco, USA. 2006. [Not available for review]De VosB , VesikariT , LinharesAC , SalinasB , Perez-SchaelI , Ruiz-PalaciosGM , et al. A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis. Pediatric Infectious Disease Journal2004;23(10 Suppl):179-82. [No data for review]EmmanuelS , PhuaKB , GohP , QuakSH , DattaSK , HanHH , et al. Immunogenicity of an acellular pertussis combination vaccine co-administered with a novel rotavirus vaccine in Singaporean infants. In: 23rd Annual Meeting of European Society for Paediatric Infectious Diseases (ESPID); 2005 May 18-20; Valencia, Spain. 2005. [Not available for review]GlaxoSmithKline[444563-007]. A phase IIb, double-blind, randomized, placebo-controlled study to assess the efficacy, immunogenicity, reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine at different viral concentrations (104.7, 105.2 and 106.1 foci forming units (ffu)) in healthy infants previously uninfected with human rotavirus and approximately three months of age, when administered concurrently with DTPa-IPV/Hib and HBV vaccines. www.gsk-studyregister.com/study/6785 (accessed 12 December 2018). NCT00429481. A study to assess the efficacy, immunogenicity and safety of 2 doses of oral live attenuated human rotavirus vaccine (Rotarix) at different viral concentrations in healthy infants. clinicaltrials.gov/ct2/show/record/NCT00429481 (first received 31 January 2007). PhuaKB , EmmanuelSC , GohP , QuakSH , LeeBW , HanHH , et al. A rotavirus vaccine for prophylaxis of infant rotavirus gastroenteritis: the Asian experience. Annals of the Academy of Medicine, Singapore2006;35(1):38-44. PhuaKB , QuakSH , EmmanuelS , GohPS , HanHH , HardtK , et al. A short report on highlights of worldwide development of RIX4414: a Singaporean experience. Vaccine2006;24(18):3782-3. PhuaKB , QuakSH , EmmanuelS , GohPSC , HanHH , HardtK , et al. Highlights of world-wide development: a Singapore experience. In: 3rd International Conference on Vaccines for Enteric Diseases (VED) 28-30 April 2004; Montego Bay, Jamaica. 2004. [Not available for review]PhuaKB , QuakSH , LeeBW , EmmanuelSC , GohP , HanHH , et al. Evaluation of RIX4414, a live, attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled phase 2 trial involving 2464 Singaporean infants. Journal of Infectious Diseases2005;192(Suppl 1):6-16. PhuaKB , QuakSH , LimFS , GohP , TeohYL , DattaSK , et al. Immunogenicity, reactogenicity and safety of a diphtheria-tetanus-acellular pertussis-inactivated polio and Haemophilus influenzae type b combination vaccine in a placebo-controlled rotavirus vaccine study. Annals of the Academy of Medicine, Singapore2008;37(7):546-53. VesikariT . RIX4414: a new attenuated human rotavirus vaccine. In: 23rd Annual Meeting of European Society for Paediatric Infectious Diseases (ESPID); 2005 May 18-20; Valencia, Spain. 2005. [Not available for review]">RIX Phua 2005‐SGP</a>; <a href="./references#CD008521-bbs2-0024" title="LauYL , NelsonEA , PoonKH , ChanPK , ChiuS , SungR , et al. Efficacy, safety and immunogenicity of a human rotavirus vaccine (RIX4414) in Hong Kong children up to three years of age: a randomized, controlled trial. Vaccine2013;31(18):2253-9. NCT00197210. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy and safety of two doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine in healthy infants. clinicaltrials.gov/show/NCT00197210 (first received 20 September 2005). NCT00329745. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy and safety of two doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine in healthy infants. clinicaltrials.gov/show/NCT00329745 (first received 25 May 2006). PhuaKB , LimFS , LauYL , NelsonEA , HuangLM , QuakSH , et al. Rotavirus vaccine RIX4414 efficacy sustained during the third year of life: a randomized clinical trial in an Asian population. Vaccine2012;30(30):4552-7. PhuaKB , LimFS , LauYL , NelsonEA , HuangLM , QuakSH , et al. Safety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: randomised, double-blind, controlled study. Vaccine2009;27(43):5936-41. PhuaKB , LimFS , QuakSH , LeeBW , TeohYL , SuryakiranPV , et al. Efficacy, immunogenicity and safety of a human rotavirus vaccine RIX4414 in Singaporean infants. Annals of the Academy of Medicine, Singapore2016;45(2):44-50. ">RIX Phua 2009‐AS</a>; <a href="./references#CD008521-bbs2-0029" title="EUCTR2015-001484-39. A phase II study to assess the safety and immunogenicity of GlaxoSmithKline Biologicals rotavirus vaccine, RIX4414 when administered to HIV infected infants in South Africa. www.clinicaltrialsregister.eu/ctr-search/trial/2015-001484-39/results (first received 11 June 2015). GlaxoSmithKline[444563-022]. A phase II, double-blind, randomized, placebo-controlled study to assess the safety, reactogenicity and immunogenicity of three doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine. www.gsk-studyregister.com/study/6790 (accessed 12 December 2018). ISRCTN11877362. A phase II, double-blind, randomised, placebo-controlled study to assess the safety, reactogenicity and immunogenicity of three doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine (RIX4414 at 106.5 CCID50) administered to human immunodeficiency virus (HIV) infected infants at 6, 10 and 14 weeks of age in South Africa. www.controlled-trials.com/ISRCTN11877362 (first received 25 November 2005). NCT00263666. A study of safety, reactogenicity and immunogenicity of HRV vaccine in HIV infected infants in South Africa. clinicaltrials.gov/ct2/show/results/NCT00263666 (first received on 9 December 2005). SteeleAD ,  MadhiSA ,  LouwCE ,  BosP ,  TumboJM ,  WernerCM ,  et al. Safety, reactogenicity, and immunogenicity of human rotavirus vaccine RIX4414 in human immunodeficiency virus-positive infants in South Africa. Pediatric Infectious Diseases Journal2011;30(2):125-30. ">RIX Steele 2010a‐ZAF</a>; <a href="./references#CD008521-bbs2-0034" title="VesikariT , et al. Human rotavirus vaccine Rotarix is highly efficacious in Europe. In: 24th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); 2006 June 15-18; Basel, Switzerland. 2006. [Not available for review]VesikariT , et al. Rotarix, an oral human Rotavirus vaccine, is highly immunogenic in healthy infants from 6 European countries. In: 24th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); 2006 June 15-18; Basel, Switzerland. 2006. [Not available for review]GlaxoSmithKline[102247-036]. A phase IIIb, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants in co-administration with specific childhood vaccinations [This summary presents results from the first efficacy period] [102247-036]. www.gsk-studyregister.com/study/2669 (accessed 12 December 2018). GlaxoSmithKline[102247-036-Annex]. A phase IIIb, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants in co-administration with specific childhood vaccinations [This summary presents results for the second and combined efficacy periods]. www.gsk-studyregister.com/study/2669 (accessed 12 December 2018). GlaxoSmithKline[102247-036-Yr3]. A phase IIIb, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants in co-administration with specific childhood vaccinations [A phase IIIb open study to assess the long-term efficacy and safety of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine approximately three years after vaccination in healthy infants aged 6-12 weeks at the time of first vaccination in the Rota-036 study (eTrack No.102247) in Finland]. www.gsk-studyregister.com/study/2669 (accessed 12 December 2018). NCT00140686. A multi-country &amp; multi-center study to assess the efficacy, safety &amp; immunogenicity of 2 doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants in co-administration with specific childhood vaccines. clinicaltrials.gov/ct2/show/record/NCT00140686 (first received 1 September 2005). [Trial registration document]NCT00420316. To assess long-term efficacy &amp; safety of subjects approximately 3 years after priming with 2 doses of GlaxoSmithKline (GSK) Biologicals' oral live attenuated human rotavirus (HRV) vaccine (Rotarix) in the primary vaccination study (102247). clinicaltrials.gov/show/NCT00420316 (first received 11 January 2007). SchusterV , OttoW , CohenR . RotarixTM an oral human Rotavirus vaccine, is highly immunogenic when co-administered with a Streptococcus pneumoniae conjugate vaccine (PrevenarTM) in healthy infants from France and Germany. In: 24th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); 2006 June 15-18; Basel, Switzerland. 2006. [Not available for review]TejedorJC , Diez-DelegadoJ , AristeguiJ . Rotarix (RIX4414), an oral Human Rotavirus vaccine, is highly immunogenic when co-administered with a Neisseria meningitides Serogroup C vaccine (MeningitecTM) in healthy infants from Spain. In: 24th Annual Meeting Meeting of the European Society for Paediatric Infectious Diseases (ESPID); 2006 June 15-18; Basel, Switzerland. 2006. [Not available for review]VesikariT ,  KarvonenA ,  PrymulaR ,  SchusterV ,  TejedorJC ,  ThollotF ,  et al. Immunogenicity and safety of the human rotavirus vaccine Rotarix co-administered with routine infant vaccines following the vaccination schedules in Europe. Vaccine2010;28(32):5272-9. VesikariT , KarvonenA , FerranteSA , KuterBJ , CiarletM . Sustained efficacy of the pentavalent rotavirus vaccine, RV5, up to 3.1 years following the last dose of vaccine. Pediatric Infectious Disease Journal2010;29(10):957-63. VesikariT , KarvonenA , PrymulaR , SchusterV , TejedorJC , CohenR , et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet2007;370(9601):1757-63. VesikariT , PrymulaR , SchusterV , TejedorJC , CohenR , BouckenoogheA , et al. Efficacy and immunogenicity of live-attenuated human rotavirus vaccine in breast-fed and formula-fed European infants. Pediatric Infectious Disease Journal2012;31(5):509-13. VesikariT , PrymulaR , SchusterV . Early protection against Rotavirus, Rotarix, experience in an European setting. In: 12th International Congress for Infectious Diseases; 2006 June 15-18; Lisbon, Portugal. 2006. [Not available for review]VesikariT , PrymulaR , SchusterV . Rotarix (RIX4414), an oral human rotavirus vaccine, is highly immunogenic when co-administered with diphteria-tetanus-pertussis (DTPA)-combined vaccines in healthy infants from Europe. In: 24th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); 2006 June 15-18; Basel, Switzerland. 2006. [Not available for review]">RIX Vesikari 2007a‐EU</a>) or as the number of fatal serious adverse events (<a href="./references#CD008521-bbs2-0001" title="AnhDD , CarlosCC , ThiemDV , HutagalungY , GatchalianS , BockHL , et al. Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 (Rotarix) oral suspension (liquid formulation) when co-administered with expanded program on immunization (EPI) vaccines in Vietnam and the Philippines in 2006-2007. Vaccine2011;29(11):2029-36. GlaxoSmithKline[109216-063]. A phase II, randomized, double-blind, placebo-controlled study to evaluate the immunogenicity, reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) liquid vaccine, when given to healthy infants, in Philippines. www.gsk-studyregister.com/study/3204 (accessed 12 December 2018). NCT00432380. Immunogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals' oral live attenuated human rotavirus (HRV) liquid vaccine (GSK 357941A) in healthy infants. clinicaltrials.gov/show/NCT00432380 (first received 7 February 2007). ">RIX Anh 2011‐PHL</a>; <a href="./references#CD008521-bbs2-0002" title="AnhDD , CarlosCC , ThiemDV , HutagalungY , GatchalianS , BockHL , et al. Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 (Rotarix) oral suspension (liquid formulation) when co-administered with expanded program on immunization (EPI) vaccines in Vietnam and the Philippines in 2006-2007. Vaccine2011;29(11):2029-36. AnhDD , ThiemVD , HutagalungY , BockHL , SuryakiranP , DelemA , et al. Immunogenicity, reactogenicity and safety of the oral live attenuated human rotavirus vaccine RIX4414 (Rotarix™) oral suspension (liquid formulation) in Vietnamese Infants. In: 13th International Congress on Infectious Diseases Abstracts, Poster Presentations; June 19–22, 2008; Kuala Lumpur, Malaysia. 2008. GlaxoSmithKline[105722-051]. A phase II, randomized, double-blind, placebo-controlled study to evaluate the immunogenicity, reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) liquid vaccine, when given to healthy infants, in Vietnam. www.gsk-studyregister.com/study/3012 (accessed 12 December 2018). NCT00345956. A placebo-controlled study to evaluate the immunogenicity, reactogenicity and safety of two doses of GSK Bio oral live attenuated human rotavirus (HRV) liquid vaccine, when given to healthy infants, in Vietnam. clinicaltrials.gov/show/NCT00345956 (first received 29 June 2006). ">RIX Anh 2011‐VNM</a>; <a href="./references#CD008521-bbs2-0007" title="GlaxoSmithKline[444563-021]. A phase II, double-blind, randomized, placebo-controlled clinical study to assess the immunogenicity and reactogenicity of three doses of a modified vaccine formulation versus GlaxoSmithKline (GSK) Biologicals’ live attenuated human rotavirus (HRV) vaccine when orally administered to healthy infants at 2, 4 and 6 months of age. www.gsk-studyregister.com/study/6789 (accessed 12 December 2018). ">RIX GSK[021] 2007‐PAN</a>; <a href="./references#CD008521-bbs2-0008" title="GlaxoSmithKline[444563-033]. A phase III, randomized, double-blind and placebo-controlled study to assess the clinical consistency of three production lots of GSK Biologicals’ HRV vaccine in terms of immunogenicity and safety when given to healthy infants at 2 and 4 months of age. www.gsk-studyregister.com/study/6794 (accessed 12 December 2018). LópezP , Galan HerreraJF , CervantesY , Costa ClemensSA , AguirreF , YarzabalJP . Three consecutive production lots of the human monovalent RIX4414 G1P(8) rotavirus vaccine, Rotarix™ induce a consistent immune response in Latin American infants [poster]. In: 4th World Congress of The World Society for Pediatric Infectious Diseases; 2005 September 01-04; Warsaw, Poland. 2005. [Not available for review]NCT00757770. Assessment of clinical consistency of three production lots of GSK Biologicals' HRV vaccine. clinicaltrials.gov/ct2/show/NCT00757770 (first received 23 September 2008). ">RIX GSK[033] 2007‐LA</a>; <a href="./references#CD008521-bbs2-0009" title="GlaxoSmithKline[103478-041]. A phase IIIb, double-blind, randomized, placebo-controlled, multicentre study to assess the immunogenicity, safety and reactogenicity of 2 doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants (6-12 weeks of age at first dose) previously uninfected with human rotavirus. www.gsk-studyregister.com/study/2714 (accessed 12 December 2018). NCT00134732. Assess the immunogenicity, safety &amp; reactogenicity of 2 doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants (6-12 weeks of age at first dose) previously uninfected with human rotavirus. clinicaltrials.gov/ct2/show/record/NCT00134732 (first received 25 August 2005). ">RIX GSK[041] 2007‐KOR</a>; <a href="./references#CD008521-bbs2-0010" title="GlaxoSmithKline[101555]. A phase II, double-blind, randomized, placebo-controlled study to compare the immunogenicity, reactogenicity and safety of 2 different formulations of GlaxoSmithKline (GSK) Biologicals’ live attenuated human rotavirus (HRV) vaccine given as a two-dose primary vaccination in healthy infants previously uninfected with HRV. www.gsk-studyregister.com/study/2632 (accessed 12 December 2018). ">RIX GSK[101555] 2008‐PHL</a>; <a href="./references#CD008521-bbs2-0011" title="GlaxoSmithKline[107625 (Rota-056)]. Efficacy, safety, reactogenicity and immunogenicity study of the lyophilised formulation of Rotarix vaccine in healthy Japanese infants. www.gsk-studyregister.com/study/3131 (accessed 12 December 2018). KawamuraN , TokoedaY , MoriS , OhshimaM , OkahataH , UedaD , et al. Efficacy of human rotavirus vaccine RIX4414 in Japanese infants from 2 weeks post dose 2 up to data lock point. In: 28th Meeting of European Society for Paediatric Infectious Diseases (ESPID); 2010 May 04-08; Nice, France. 2010. KawamuraN , TokoedaY , OshimaM , OkahataH , TsutsumiH , Van DoornLJ , et al. Efficacy, safety and immunogenicity of RIX4414 in Japanese infants during the first two years of life. Vaccine2011;29(37):6335-41. NCT00480324. Efficacy, safety, reactogenicity and immunogenicity study of the lyophilised formulation of Rotarix vaccine in healthy Japanese infants. clinicaltrials.gov/show/NCT00480324 (first received 17 November 2010). ">RIX Kawamura 2011‐JPN</a>; <a href="./references#CD008521-bbs2-0012" title="GlaxoSmithKline[103477-039]. A phase IIIb, partially blind, randomized, placebo-controlled study to asses the effect on immunogenicity of administration of vaccine without buffering agent and to assess heat stability in terms of immunogenicity, reactogenicity and safety of GlaxoSmithKline Biologicals’ oral live attenuated human rotavirus (HRV) vaccine following a 0, 2 month schedule, in healthy infants previously uninfected with human rotavirus. www.gsk-studyregister.com/study/2713 (accessed 12 December 2018). KerdpanichA , ChokephaibulkitK , WatanaveeradejV , VanpraparN , HutagalungY , HanHH , et al. Exposure to elevated temperature of 37°C for 7 days does not affect immunogenicity and reactogenicity of RIX4414 [poster]. In: dsRNA Virus Meeting; 2006 October 21-26; Cape Town, South Africa. 2006. [Not available for review]KerdpanichA , ChokephaibulkitK , WatanaveeradejV , VanpraparN , SimasathienS , PhavichitrN , et al. Immunogenicity of a human rotavirus vaccine (RIX4414) after storage at 37 degrees C for seven days. Human Vaccine2011;7(1):74-80. KerdpanichA , ChokephaibulkitK , WatanaveeradejV , VanpraparN , SimasathienS , PhavichitrN , et al. Immunogenicity of a live-attenuated human rotavirus RIX4414 vaccine with or without buffering agent. Human Vaccines2010;6(3):254-62. NCT00169455. Assess the effect on immunogenicity of administration of vaccine without buffering agent &amp; assess heat stability in terms of immunogenicity, reactogenicity &amp; safety of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine following a 0, 2 m schedule, in healthy infants previously uninfected with human rotavirus. clinicaltrials.gov/show/NCT00169455 (first received 15 September 2005). ">RIX Kerdpanich 2010‐THA</a>; <a href="./references#CD008521-bbs2-0020" title="GlaxoSmithKline[103792-044]. A phase IIIb, randomised, multicentre double-blind, placebo-controlled study of the immunogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine (RIX4414) as primary dosing in healthy infants in India of approximately 8 weeks of age at the first dose. www.gsk-studyregister.com/study/2723 (accessed 12 December 2018). NarangA , BoseA , PanditAN , DuttaP , KangG , BhattacharyaSK , et al. Immunogenicity, reactogenicity and safety of human rotavirus vaccine (RIX4414) in Indian infants. Human Vaccines2009;5(6):414-9. NCT00289172. A multicenter study of the immunogenicity &amp; safety of 2 doses of GSK Biologicals’ oral live attenuated human rotavirus vaccine (RIX4414) as primary dosing of healthy infants in India aged approximately 8 wks at the time of the first dose. clinicaltrials.gov/ct2/show/record/NCT00289172 (first received 9 February 2006). ">RIX Narang 2009‐IND</a>; <a href="./references#CD008521-bbs2-0022" title="GlaxoSmithKline[106481-054]. Phase IIIb, double blind, randomised, placebo-controlled, multi-country/centre, study to assess safety, reactogenicity &amp; immunogenicity of 2 doses of GSK Biologicals' oral live attenuated Human Rotavirus (HRV) vaccine in pre-term infants. www.gsk-studyregister.com/study/3064 (accessed 12 December 2018). NCT00420745. Phase IIIb, double blind, randomised, placebo-controlled, multi-country/centre, study to assess safety, reactogenicity &amp; immunogenicity of 2 doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine in pre-term infants. clinicaltrials.gov/show/NCT00420745 (first received 11 January 2007). OmenacaF , SarlangueJ , SzenbornL , NogueiraM , SuryakiranPV , SmolenovIV , et al. Safety, reactogenicity and immunogenicity of the human rotavirus vaccine in preterm European infants: a randomized phase IIIb study. Pediatric Infectious Disease Journal2012;31(5):487-93. ">RIX Omenaca 2012‐EU</a>; <a href="./references#CD008521-bbs2-0025" title="EUCTR2015-001542-29. Immunization of infants 6-14 weeks of age, with GlaxoSmithKline Biologicals Rotavirus vaccine to explore the existence of transmission of rotavirus vaccine strain between twins in a family. clinicaltrialsregister.eu/ctr-search/trial/2015-001542-29/results (first received 22 June 2015). NCT00396630. A Phase IIIb, randomized, double-blind, placebo-controlled study to explore the existence of horizontal transmission of the RIX4414 vaccine strain between twins within a family. clinicaltrials.gov/show/NCT00396630 (first received 7 November 2006). RiveraL ,  PeñaLM ,  StainierI ,  GillardP ,  CheuvartB ,  SmolenovI , et al. Horizontal transmission of a human rotavirus vaccine strain - a randomized, placebo-controlled study in twins. Vaccine2011;29(51):9508-13. ">RIX Rivera 2011‐DOM</a>; <a href="./references#CD008521-bbs2-0026" title="Costa ClemensSA , et al. Operational organization of a large scale phase III clinical trial of rotavirus vaccine in multiple sites and countries in Latin America. In: International Congress of Pediatrics (ICP); 2004 August 15-20; Cancun, Mexico. 2004. [Not available for review]De VosB , et al. Rotarix™: an effective way to prevent rotavirus diarrhoea and vomiting. In: 9th Congress of the Asian Pan Pacific Society of Paediatric Gastroenterology, Hepatology and Nutrition &amp; 27th Annual Congress of the Malaysian Paediatric Association; 2005 June 16-19; Kuala Lumpur, Malaysia. 2005. [Not available for review]BaayM , BollaertsK , StruchinerC , VerstraetenT . Background rates of disease in Latin American children from a rotavirus vaccine study. Human Vaccines and Immunotherapeutics2017;13(8):1916-20. GlaxoSmithKline[444563-023-pt1]. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants (efficacy data from visit 1 to visit 4). www.gsk-studyregister.com/study/6791 (accessed 12 December 2018). GlaxoSmithKline[444563-023-pt2]. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants (2nd year efficacy from visit 4 to visit 6). www.gsk-studyregister.com/study/6791 (accessed 12 December 2018). GlaxoSmithKline[444563-023-pt3]. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants (safety for the period between visit 1 and visit 3). www.gsk-studyregister.com/study/6791 (accessed 12 December 2018). JustinoMC , AraújoEC , Van DoornLJ , OliveiraCS , GabbayYB , MascarenhasJD , et al. Oral live attenuated human rotavirus vaccine (Rotarix) offers sustained high protection against severe G9P[8] rotavirus gastroenteritis during the first two years of life in Brazilian children. Memorias do Instituto Oswaldo Cruz2012;107(7):846-53. LinharesAC , VelazquezFR , Perez-SchaelI , Saez-LlorensX , AbateH , EspinozaF , et al. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet2008;371(9619):1181-9. LopezP , LinharesA , Pérez-SchaelI , Ruiz-PalaciosG , Costa ClemensS , SanchezN . Early protection against severe rotavirus gastroenteritis - RIX4414 experience in Latin America. In: 24th Annual Meeting of European Society for Paediatric Infectious Diseases (ESPID); 2006 May 03-05; Basel, Switzerland. 2006. [Not available for review]MaciasM , LopezP , VelazquezFR , VergaraRF , SalmeronJ , TavaresJL . The rotavirus vaccine RIX4414 (Rotarix) is not associated with intussusception in one year old infants. In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2005 December 16-19; Washington DC, USA. 2005. [Not available for review]NCT00139347. A multi-country &amp; multi-center study to assess the efficacy, immunogenicity &amp; safety of two doses of GSK Biologicals' oral live attenuated HRV vaccine given concomitantly with routine EPI vaccinations including OPV in healthy infants. clinicaltrials.gov/ct2/show/NCT00139347 (first received 31 August 2005). [Trial registration document (no data for review)]NCT00140673. Placebo-controlled, multi-country &amp; multi-center study to assess the efficacy, safety &amp; immunogenicity of 2 doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants. clinicaltrials.gov/ct2/show/NCT00140673 (first received 1 September 2005). [Trial registration document (no data for review)]Perez-SchaelI , LinharesAC , VesikariT . Two doses of the human attenuated rotavirus vaccine RIX4414 (Rotarix) show heterotypic protection in Latin America and Europe. In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2005 December 16-19; Washington DC, USA. 2005. [Not available for review]PikeM . New rotavirus vaccine is effective and appears to have no increased risk of intussusception. Clinical Research Abstracts For Pediatricians2006;149(1):143. Ruiz-PalaciosG , AranzaC , VelazquezFR , RichardsonV , NandiE , MaciasM . Two doses of the human-attenuated monovalent G1P[8] rotavirus vaccine, Rotarix show high efficacy in Mexican children against severe rotavirus gastroenteritis and severe overall gastroenteritis. In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2005 December 16-19; Washington DC, USA. 2005. [Not available for review]Ruiz-PalaciosGM , Perez-SchaelI , VelazquezFR , AbateH , BreuerT , ClemensSC , et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. New England Journal of Medicine2006;354(1):11-22. VelázquezFR , AbatH , Costa ClemensSA , EspinozaF , GillardP , LinharesAC , et al. The human monovalent G1P[8] rotavirus vaccine, Rotarix is highly efficacious and provides crossprotection against G1 and non-G1 serotypes. In: 23rd Annual meeting of European Society for Paediatric Infectious Diseases (ESPID); 2005 May 18-20; Valencia, Spain. 2005. VelázquezRF , AbateH , BouckenoogheA . RIX4414, the human G1P[8] rotavirus vaccine is highly efficacious during the second year of life. In: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2006 September 27-30; San Francisco, USA. 2006. [Not available for review]VesikariT , O’RyanM , AbateH , Costa ClemensSA , EspinozaF , GillardP . Overcoming the safety hurdle: the rotavirus vaccine RIX4414 is not associated with intussusception. In: 23rd Annual Meeting of European Society for Paediatric Infectious Diseases (ESPID); 2005 May 18-20; Valencia, Spain. 2005. [Not available for review]">RIX Ruiz‐Palac 06‐LA/EU</a>; <a href="./references#CD008521-bbs2-0027" title="Ruiz-PalaciosG , GuerreroL , LinharesAC , et al. Efficacy of an oral human rotavirus (HRV) vaccine in preventing diarrhoea due to G1 and non-G1 rotavirus [Presentation]. In: 3rd World Congress of Pediatric Infectious Diseases; 2002 November 19-23; Santiago, Chile. 2002. [Not available for review]Ruiz-PalaciosG , GuerreroML , LinharesAC , et al. Two-year efficacy of GlaxoSmithKline Biologicals' live attenuated rotavirus vaccine in Latin American children [poster]. In: 24th International Congress of Pediatrics; 2004 August 15-20; Cancun, Mexico. 2004. [Not available for review]SalinasB , Perez-SchaelI , Ruiz-PalaciosG , et al. Early protection by GlaxoSmithKline Biologicals' live attenuated rotavirus vaccine in Latin American children [poster]. In: 24th International Congress of Pediatrics; 2004 August 15-20; Cancun, Mexico. 2004. [Not available for review]SalinasB , TomatMA , YarzabalJP , et al. Efficacy of the rotavirus vaccine (RIX4414) among infants in Carabobo State, Venezuela [poster]. In: Asocación Venezolana para el Avance de la Cienca (AsoVAC); 2004; Venezuela. 2004. [Not available for review]AraujoEC , ClemensSA , OliveiraCS , JustinoMC , RubioP , GabbayYB , et al. Safety, immunogenicity, and protective efficacy of two doses of RIX4414 live attenuated human rotavirus vaccine in healthy infants. Jornal de Pediatria2007;83(3):217-24. De VosB , HardtK , LinharesAC , Ruiz-PalaciosG , GuerreroL , SalinasB . Efficacy of two doses of a human monovalent rotavirus vaccine, Rotarix™ in preventing gastro-enteritis due to G1 and Non-G1 rotavirus in Brazil, Mexico and Venezuela [presentation]. In: 8th International Symposium on Double-Stranded RNA Viruses; 2003 September 13-18; Lucca, Italy. 2003. [Not available for review]De VosB , VesikariT , LinharesAC , SalinasB , Perez-SchaelI , Ruiz-PalaciosGM , et al. A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis. Pediatric Infectious Disease Journal2004;23(10 Suppl):179-82. GlaxoSmithKline[444563-006]. A phase IIb, double-blind, randomized, placebo-controlled study to assess the efficacy, immunogenicity, reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals' live attenuated human rotavirus (HRV) vaccine at different virus concentrations (104.7, 105.2 and 105.8 foci forming units [ffu]) in healthy infants (approximately 2 months of age at first dose) following a 0, 2 month schedule and previously uninfected with HRV, when administered concurrently with DTPw-HBV and Hib vaccines. www.gsk-studyregister.com/study/6784 (accessed 12 December 2018). GlaxoSmithKline[444563-006-Annex]. A phase IIb, double-blind, randomized, placebo-controlled study to assess the efficacy, immunogenicity, reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals' live attenuated human rotavirus (HRV) vaccine at different virus concentrations (104.7, 105.2 and 105.8 foci forming units [ffu]) in healthy infants (approximately 2 months of age at first dose) following a 0, 2 month schedule and previously uninfected with HRV, when administered concurrently with DTPw-HBV and Hib vaccines [This summary presents results for the second and combined efficacy periods and results from the 3-Dose subset. Results from the first efficacy period are presented in 444563/006 (Rota-006) summary]. www.gsk-studyregister.com/study/6784 (accessed 12 December 2018). LinharesA , Perez-SchaelI , Ruiz-PalaciosM , PernambucoE , JacquetJ , De VosB . Immunogenicity and reactogenicity of an oral human rotavirus (HRV) vaccine in Latin American infants [poster]. In: 3rd World Congress of Pediatric Infectious Diseases; 2002 November 19-23; Santiago, Chile. 2002. [Not available for review]LinharesAC , Ruiz-PalaciosGM , GuerreroML , SalinasB , Perez-SchaelI , ClemensSA , et al. A short report on highlights of world-wide development of RIX4414: a Latin American experience. Vaccine2006;24(18):3784-5. LinharesAC , VerstraetenT , Wolleswinkel-Van den BoschJ , ClemensR , BreuerT . Rotavirus serotype G9 is associated with more-severe disease in Latin America. Clinical Infectious Diseases2006;43(3):312-4. [Not available for review]NCT00385320. To assess the efficacy, immuno &amp; safety of 2 doses of GSK HRV vaccine at different virus concentrations in healthy infants aged 2 months &amp; previously uninfected with HRV, concurrently given with DTPw-HBV, Hib. clinicaltrials.gov/show/NCT00385320 (first received 9 October 2006). Perez-SchaelI , SalinasB , LinharesA , GuerreroM , Ruiz-PalaciosG , ClemensS , et al. Protective efficacy of an oral human rotavirus (HRV) vaccine in Latin American infants [poster]. In: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy ( ICAAC); San Diego, 27-30 September 2002. 2002:18, LB-23. [Not available for review]Perez-SchaelI , SalinasB , TomatM , LinharesAC , GuerreroML , Ruiz-PalaciosGM , et al. Efficacy of the human rotavirus vaccine RIX4414 in malnourished children. Journal of Infectious Diseases2007;196(4):537-40. Ruiz-PalaciosGM , GuerreroML , Bautista-MarquezA , Ortega-GallegosH , Tuz-DzibF , Reyes-GonzalezL , et al. Dose response and efficacy of a live, attenuated human rotavirus vaccine in Mexican infants. Pediatrics2007;120(2):e253-61. [Not available for review]Ruiz-PalaciosGM . Impact of maternal antibodies on the immune response to an oral human rotavirus (HRV) vaccine in Mexican infants [presentation]. In: 3rd World Congress of Pediatric Infectious Diseases; 2002 November 19-23; Santiago, Chile. 2002. [Not available for review]SalinasB , Perez SchaelI , LinharesAC , Ruiz PalaciosGM , GuerreroML , YarzabalJP , et al. Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: a randomized, placebo-controlled trial in Latin American infants. Pediatric Infectious Disease Journal2005;24(9):807-16. ">RIX Salinas 2005‐LA</a>; <a href="./references#CD008521-bbs2-0028" title="GlaxoSmithKline[444563-014]. A phase II, double-blind before the 2002 rotavirus season and single blind with respect to OPV after, randomised, placebo-controlled study of the safety, reactogenicity and immunogenicity of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine (RIX4414 at 105 ffu) co-administered with either oral polio vaccine (OPV) or inactivated polio vaccine (IPV) in healthy infants (approximately 5-10 weeks old) in South Africa. www.gsk-studyregister.com/study/6787 (accessed 12 December 2018). ISRCTN86632774. A phase II, double blind randomised, placebo controlled study to assess the safety reactogenicity and immunogenicity of three doses of GSK Biologicals (South Africa). controlled-trials.com/ISRCTN86632774 (first received 25 November 2005). NCT00346892. Reactogenicity &amp; immunogenicity study of two doses of GSK Biologicals’ oral live attenuated HRV vaccine co-administered with either OPV or IPV in healthy infants (approximately 5-10 weeks old) in South Africa. clinicaltrials.gov/show/NCT00346892 (first received 30 June 2006). SteeleAD ,  De VosB ,  TumboJ ,  ReyndersJ ,  ScholtzF ,  BosP ,  et al. Co-administration study in South African infants of a live-attenuated oral human rotavirus vaccine (RIX4414) and poliovirus vaccines. Vaccine2010 ;28(39):6542-8. SteeleAD , TumboJ , ArmahG , ReyndersJ , ScholtzF , BosP , et al. Immunogenicity and reactogenicity of a new live attenuated oral rotavirus vaccine (RIX4414) when administered concurrently with poliovirus vaccines in African infants. In: 24th International Congress of Pediatrics; 2004 August 15-20; Cancun, Mexico. 2004. [Not available for review]SteeleAD , TumboJM , ArmahGE , ReyndersJ , ScholtzF , BosP , et al. Concomitant administration of a live-attenuated oral rotavirus vaccine (RIX4414) with poliovirus vaccines in African infants. In: 23rd Annual Meeting of the European Society for Pediatric Infectious Diseases - ESPID; 2005 May 18-20; Valencia, Spain. 2005. [Not available for review]">RIX Steele 2008‐ZAF</a>; <a href="./references#CD008521-bbs2-0030" title="GlaxoSmithKline[444563-013]. A phase II, double-blind before the 2002 rotavirus season and single blind with respect to OPV after, randomised, placebo-controlled study of the safety, reactogenicity and immunogenicity of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine (RIX4414 at 105 ffu) co-administered with either oral polio vaccine (OPV) or inactivated polio vaccine (IPV) in healthy infants (approximately 5-10 weeks old) in South Africa. www.gsk-studyregister.com/study/6786 (accessed 12 December 2018). ISRCTN37373664. A double blind, randomised placebo controlled study of the safety, reactogenicity and immunogenicity of two doses of orally administered human rotavirus vaccine (RIX4414) in healthy infants in South Africa. controlled-trials.com/ISRCTN37373664 (first received 25 November 2005). NCT00383903. A study of the safety, reactogenicity and immunogenicity of 2 or 3 doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants (approximately 5-10 weeks old) in South Africa. clinicaltrials.gov/show/NCT00383903 (first received 3 October 2006). SteeleAD ,  ReyndersJ ,  ScholtzF ,  BosP ,  De BeerMC ,  TumboJ ,  et al. Comparison of 2 different regimens for reactogenicity, safety, and immunogenicity of the live attenuated oral rotavirus vaccine RIX4414 coadministered with oral polio vaccine in South African infants. Journal of Infectious Diseases2010;202(Suppl):S93-100. ">RIX Steele 2010b‐ZAF</a>; <a href="./references#CD008521-bbs2-0031" title="GlaxoSmithKline[444563-024]. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, immunogenicity and safety of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations including OPV in healthy infants. www.gsk-studyregister.com/study/6792 (accessed 12 December 2018). Gonzalez AyalaS , RiveraL , Rivera-MedinaDM , LopezP , ValenciaA , De LeónT , et al. Co-administration with rotavirus vaccine rix4414 (Rotarix™) does not interfere with the immunogenicity of oral polio vaccine (OPV) [poster]. In: World Society for Pediatric Infectious Diseases (WSPID); 2007 November 15-18; Bangkok, Thailand. 2007. [Not available for review]TregnaghiMW , AbateHJ , ValenciaA , LopezP , Da SilveiraTR , RiveraL , et al. Human rotavirus vaccine is highly efficacious when coadministered with routine expanded program of immunization vaccines including oral poliovirus vaccine in Latin America. Pediatric Infectious Disease Journal2011;30(6):e103-e8. ">RIX Tregnaghi 2011‐LA</a>; <a href="./references#CD008521-bbs2-0033" title="De VosB , VesikariT , LinharesAC , SalinasB , Perez-SchaelI , Ruiz-PalaciosGM , et al. A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis. Pediatric Infectious Disease Journal2004;23(10 Suppl):179-82. GlaxoSmithKline[444563-004]. A phase IIb, double-blind, randomized, placebo-controlled study to assess the efficacy, immunogenicity, reactogenicity and safety of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants approximately 2 months of age and previously uninfected with HRV [Results for the first efficacy period (starting from 2 weeks after dose 2 until the end of the first RV season following vaccination)]. www.gsk-studyregister.com/study/6782 (accessed 12 December 2018). GlaxoSmithKline[444563-004-Annex]. A phase IIb, double-blind, randomized, placebo-controlled study to assess the efficacy, immunogenicity, reactogenicity and safety of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants approximately 2 months of age and previously uninfected with HRV [This summary presents results for the second efficacy period (from the end of the first rotavirus season post-vaccination until the end of the second rotavirus season) and for the two consecutive rotavirus seasons]. www.gsk-studyregister.com/study/6782 (accessed 12 December 2018). NCT00425737. A study to assess the efficacy, immunogenicity and safety of two doses of oral live attenuated human rotavirus (HRV) vaccine (Rotarix) in healthy infants. clinicaltrials.gov/show/NCT00425737 (first received 23 January 2007). VesikariT , KarvonenA , EspoM , KorhonenT , DelemA , De VosB . Efficacy evaluation of an oral human rotavirus (HRV) vaccine in previously uninfected Finnish infants. In: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 September 27-30; San Diego, California. 2002. [Not available for review]VesikariT , KarvonenA , PuustinenL , ZengSQ , SzakalED , DelemA , et al. Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants. Pediatric Infectious Disease Journal2004;23(10):937-43. ">RIX Vesikari 2004b‐FIN</a>; <a href="./references#CD008521-bbs2-0035" title="VesikariT , et al. Immunogenicity of liquid formulation of the oral live attenuated human rotavirus vaccine (Rotarix™) [poster]. Sociedad Latinoamericana de Infectología Pediátrica (SLIPE). San Jose, Costa Rica 8-11 May 2007. [Not available for review]GlaxoSmithKline[104480-048]. A phase II, double-blind, randomized, placebo controlled study to compare the immunogenicity, reactogenicity and safety of two different formulations of GlaxoSmithKline (GSK) Biologicals’ live attenuated human rotavirus (HRV) vaccine given as a two-dose primary vaccination in healthy infants previously uninfected with HRV. www.gsk-studyregister.com/study/2783 (accessed 12 December 2018). NCT00137930. Compare the immunogenicity, reactogenicity &amp; safety of 2 different formulations of GSK Biologicals’ live attenuated human rotavirus (HRV) vaccine given as a two-dose primary vaccination in healthy infants previously uninfected with HRV. clinicaltrials.gov/ct2/show/record/NCT00137930 (first received 30 August 2005). VesikariT , KarvonenA , BouckenoogheA , SuryakiranPV , SmolenovI , HanHH . Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 oral suspension (liquid formulation) in Finnish infants. Vaccine2011;29(11):2079-84. ">RIX Vesikari 2011‐FIN</a>; <a href="./references#CD008521-bbs2-0037" title="GlaxoSmithKline[103992-045]. A phase II, randomised, double-blind, placebo-controlled study to evaluate the immunogenicity, reactogenicity and safety of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine (RIX4414 at 106.5 CCID50) when given concomitantly with OPV versus when given alone (HRV vaccine dose given 15 days after the OPV dose) in healthy infants in Bangladesh. www.gsk-studyregister.com/study/2748 (accessed 12 December 2018). NCT00139334. Evaluate immunogenicity, reactogenicity &amp; safety of 2 doses of GSK Biologicals’ oral live attenuated HRV vaccine (RIX4414 at 106.5 CCID50) when given concomitantly with OPV versus given alone (HRV vaccine dose given 15 days after the OPV dose) in healthy infants in Bangladesh. clinicaltrials.gov/show/NCT00139334 (first received 31 August 2005). ZamanK , SackDA , YunusM , ArifeenSE , PodderG , AzimT , et al, Bangladesh Rotavirus Vaccine study group. Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age. Vaccine2009;27(9):1333-9. ">RIX Zaman 2009‐BGD</a>). We pooled the number of deaths and fatal serious adverse events; see <a href="./references#CD008521-fig-0012" title="">Analysis 1.8</a>. We present details of causes of death for each trial in <a href="./appendices#CD008521-sec-0276">Appendix 7</a>. Ten trials were performed in low‐mortality countries, nine trials in medium‐mortality countries, and 11 trials in high‐mortality countries. </p> <section id="CD008521-sec-0111"> <p><b>Low‐mortality countries</b></p> <p>There was little or no difference in all‐cause death between infants and children that received Rotarix or placebo (RR 0.71, 95% CI 0.17 to 2.88; 20,361 participants, 10 trials; <a href="./references#CD008521-fig-0012" title="">Analysis 1.8</a>). Five deaths occurred among 12,018 participants in the Rotarix arms and four deaths occurred among 8343 participants in the placebo arms. This corresponds to a risk difference of 14 fewer deaths with Rotarix per 100,000 with the 95% CI indicating from 40 fewer to 90 more per 100,000 (data not shown). </p> </section> <section id="CD008521-sec-0112"> <p><b>Medium‐mortality countries</b></p> <p>There was little or no difference in all‐cause death between infants and children that received Rotarix or placebo (RR 1.27, 95% CI 0.89 to 1.81; 77,043 participants, 10 trials; <a href="./references#CD008521-fig-0012" title="">Analysis 1.8</a>). Seventy‐seven deaths occurred among 40,821 participants in the Rotarix arms and 53 deaths occurred among 36,222 participants in the placebo arms. This corresponds to a risk difference of 40 more deaths with Rotarix per 100,000 with the 95% CI indicating from 16 fewer to 119 more per 100,000 (data not shown). </p> </section> <section id="CD008521-sec-0113"> <p><b>High‐mortality countries</b></p> <p>There was no little or no difference in all‐cause death between the two arms (RR 0.88, 95% CI 0.63 to 1.21; 8374 participants, 8 trials). Ninety‐eight deaths occurred among 5519 participants in the Rotarix arms and 58 deaths occurred among 2855 participants in the placebo arms. This corresponds to a risk difference of 244 fewer deaths with Rotarix per 100,000 with the 95% CI indicating from 752 fewer to 427 more per 100,000 (data not shown). </p> </section> </section> <section id="CD008521-sec-0114"> <h6 class="title">1.1.4. All serious adverse events</h6> <p>The total number of serious adverse events was reported in 31 trials, performed in low‐mortality countries (<a href="./references#CD008521-bbs2-0003" title="BernsteinDI , SmithVE , SherwoodJR , SchiffGM , SanderDS , DeFeudisD , et al. Safety and immunogenicity of live, attenuated human rotavirus vaccine 89-12. Vaccine1998;16(4):381-7. ">RIX Bernstein 1998‐USA</a>; <a href="./references#CD008521-bbs2-0006" title="DennehyPH , BradyRC , HalperinSA , WardRL , AlveyJC , Fischer FH Jr, et al. Comparative evaluation of safety and immunogenicity of two dosages of an oral live attenuated human rotavirus vaccine. Pediatric Infectious Disease Journal2005;24(6):481-8. DennehyPH . A short report on the highlights of world-wide development of RIX4414: a North American experience comparative evaluation of safety and immunogenicity of two dosages of an oral live attenuated human rotavirus vaccine (RIX4414) in infants in the United States and Canada. Vaccine2006;24(18):3780-1. GlaxoSmithKline[444563-005]. A phase II, double-blind, randomized, placebo-controlled study of two doses of GlaxoSmithKline Biologicals’ live attenuated human rotavirus (HRV) vaccine at different virus concentrations (10 5.2 and 10 6.4 ffu) in healthy infants (approximately 2 months of age at first dose) following a 0, 2 month schedule and previously uninfected with human rotavirus. www.gsk-studyregister.com/study/6783 (accessed 12 December 2018). NCT00729001. Study of two doses of GSK Biologicals' live attenuated HRV vaccine (two different formulations) in healthy infants. clinicaltrials.gov/ct2/show/NCT00729001 (accessed 6 August 2008). ">RIX Dennehy 2005‐NA</a>; <a href="./references#CD008521-bbs2-0009" title="GlaxoSmithKline[103478-041]. A phase IIIb, double-blind, randomized, placebo-controlled, multicentre study to assess the immunogenicity, safety and reactogenicity of 2 doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants (6-12 weeks of age at first dose) previously uninfected with human rotavirus. www.gsk-studyregister.com/study/2714 (accessed 12 December 2018). NCT00134732. Assess the immunogenicity, safety &amp; reactogenicity of 2 doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants (6-12 weeks of age at first dose) previously uninfected with human rotavirus. clinicaltrials.gov/ct2/show/record/NCT00134732 (first received 25 August 2005). ">RIX GSK[041] 2007‐KOR</a>; <a href="./references#CD008521-bbs2-0011" title="GlaxoSmithKline[107625 (Rota-056)]. Efficacy, safety, reactogenicity and immunogenicity study of the lyophilised formulation of Rotarix vaccine in healthy Japanese infants. www.gsk-studyregister.com/study/3131 (accessed 12 December 2018). KawamuraN , TokoedaY , MoriS , OhshimaM , OkahataH , UedaD , et al. Efficacy of human rotavirus vaccine RIX4414 in Japanese infants from 2 weeks post dose 2 up to data lock point. In: 28th Meeting of European Society for Paediatric Infectious Diseases (ESPID); 2010 May 04-08; Nice, France. 2010. KawamuraN , TokoedaY , OshimaM , OkahataH , TsutsumiH , Van DoornLJ , et al. Efficacy, safety and immunogenicity of RIX4414 in Japanese infants during the first two years of life. Vaccine2011;29(37):6335-41. NCT00480324. Efficacy, safety, reactogenicity and immunogenicity study of the lyophilised formulation of Rotarix vaccine in healthy Japanese infants. clinicaltrials.gov/show/NCT00480324 (first received 17 November 2010). ">RIX Kawamura 2011‐JPN</a>; <a href="./references#CD008521-bbs2-0013" title="GlaxoSmithKline[112269-068]. Immunogenicity, reactogenicity and safety study to evaluate two doses of the lyophilised formulation of the human rotavirus (HRV) vaccine when administered to healthy Korean infants previously uninfected with HRV. www.gsk-studyregister.com/study/3589 (accessed 12 December 2018). KimJS , BaeCW , LeeKY , ParkMS , ChoiYY , KimKN , et al. Immunogenicity, reactogenicity and safety of a human rotavirus vaccine (RIX4414) in Korean infants: a randomized, double-blind, placebo-controlled, phase IV study. Human Vaccines and Immunotherapeutics2012;8(6):806-12. NCT00969228. Study to evaluate immunogenicity, reactogenicity and safety of Rotarix™ vaccine in Korean infants. clinicaltrials.gov/ct2/show/NCT00969228 (first received 1 September 2009). ">RIX Kim 2012‐KOR</a>; <a href="./references#CD008521-bbs2-0022" title="GlaxoSmithKline[106481-054]. Phase IIIb, double blind, randomised, placebo-controlled, multi-country/centre, study to assess safety, reactogenicity &amp; immunogenicity of 2 doses of GSK Biologicals' oral live attenuated Human Rotavirus (HRV) vaccine in pre-term infants. www.gsk-studyregister.com/study/3064 (accessed 12 December 2018). NCT00420745. Phase IIIb, double blind, randomised, placebo-controlled, multi-country/centre, study to assess safety, reactogenicity &amp; immunogenicity of 2 doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine in pre-term infants. clinicaltrials.gov/show/NCT00420745 (first received 11 January 2007). OmenacaF , SarlangueJ , SzenbornL , NogueiraM , SuryakiranPV , SmolenovIV , et al. Safety, reactogenicity and immunogenicity of the human rotavirus vaccine in preterm European infants: a randomized phase IIIb study. Pediatric Infectious Disease Journal2012;31(5):487-93. ">RIX Omenaca 2012‐EU</a>; <a href="./references#CD008521-bbs2-0023" title="EmmanuelB , et al. Immunogenicity of an acellular pertussis combination vaccine co-administered with a novel rotavirus vaccine in Singaporean infants. Asian Congress on Pediatric Infectious Diseases (ACPID); 2-4 September 2004; Kota Kinabula, Malaysia2004. [Not available for review]PhuaKB , et al. Immunogenicity and reactogenicity of two doses of an oral human rotavirus (HRV) vaccine at different concentrations in healthy infants from Singapore. In: 11th Asia Pacific Congress of Pediatrics and the 3rd Asia Pacific Congress of Pediatric Nursing; 2003; Bangkok, Thailand. 2003. [Not available for review]PhuaKB , et al. Intussusception in children: a seven-year experience in Singapore. In: 24th International Congress of Pediatrics (ICP); 2004 August 15-20; Cancun, Mexico. 2004. [Not available for review]VesikariT , et al. High efficacy of two doses of Rotarix™ (RIX4414) against rotavirus disease in Europe, Latin-America and Asia. In: Asian Congress on Pediatric Infectious Diseases (ACPID); 2006 March 07-10; Cebu, Philippines. 2006. [Not available for review]De VosB , GillardP , CheuvartB . RIX4414 vaccine efficacy against rotavirus gastroenteritis due to G2P[4] strain. In: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2006 September 27-30; San Francisco, USA. 2006. [Not available for review]De VosB , VesikariT , LinharesAC , SalinasB , Perez-SchaelI , Ruiz-PalaciosGM , et al. A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis. Pediatric Infectious Disease Journal2004;23(10 Suppl):179-82. [No data for review]EmmanuelS , PhuaKB , GohP , QuakSH , DattaSK , HanHH , et al. Immunogenicity of an acellular pertussis combination vaccine co-administered with a novel rotavirus vaccine in Singaporean infants. In: 23rd Annual Meeting of European Society for Paediatric Infectious Diseases (ESPID); 2005 May 18-20; Valencia, Spain. 2005. [Not available for review]GlaxoSmithKline[444563-007]. A phase IIb, double-blind, randomized, placebo-controlled study to assess the efficacy, immunogenicity, reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine at different viral concentrations (104.7, 105.2 and 106.1 foci forming units (ffu)) in healthy infants previously uninfected with human rotavirus and approximately three months of age, when administered concurrently with DTPa-IPV/Hib and HBV vaccines. www.gsk-studyregister.com/study/6785 (accessed 12 December 2018). NCT00429481. A study to assess the efficacy, immunogenicity and safety of 2 doses of oral live attenuated human rotavirus vaccine (Rotarix) at different viral concentrations in healthy infants. clinicaltrials.gov/ct2/show/record/NCT00429481 (first received 31 January 2007). PhuaKB , EmmanuelSC , GohP , QuakSH , LeeBW , HanHH , et al. A rotavirus vaccine for prophylaxis of infant rotavirus gastroenteritis: the Asian experience. Annals of the Academy of Medicine, Singapore2006;35(1):38-44. PhuaKB , QuakSH , EmmanuelS , GohPS , HanHH , HardtK , et al. A short report on highlights of worldwide development of RIX4414: a Singaporean experience. Vaccine2006;24(18):3782-3. PhuaKB , QuakSH , EmmanuelS , GohPSC , HanHH , HardtK , et al. Highlights of world-wide development: a Singapore experience. In: 3rd International Conference on Vaccines for Enteric Diseases (VED) 28-30 April 2004; Montego Bay, Jamaica. 2004. [Not available for review]PhuaKB , QuakSH , LeeBW , EmmanuelSC , GohP , HanHH , et al. Evaluation of RIX4414, a live, attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled phase 2 trial involving 2464 Singaporean infants. Journal of Infectious Diseases2005;192(Suppl 1):6-16. PhuaKB , QuakSH , LimFS , GohP , TeohYL , DattaSK , et al. Immunogenicity, reactogenicity and safety of a diphtheria-tetanus-acellular pertussis-inactivated polio and Haemophilus influenzae type b combination vaccine in a placebo-controlled rotavirus vaccine study. Annals of the Academy of Medicine, Singapore2008;37(7):546-53. VesikariT . RIX4414: a new attenuated human rotavirus vaccine. In: 23rd Annual Meeting of European Society for Paediatric Infectious Diseases (ESPID); 2005 May 18-20; Valencia, Spain. 2005. [Not available for review]">RIX Phua 2005‐SGP</a>; <a href="./references#CD008521-bbs2-0024" title="LauYL , NelsonEA , PoonKH , ChanPK , ChiuS , SungR , et al. Efficacy, safety and immunogenicity of a human rotavirus vaccine (RIX4414) in Hong Kong children up to three years of age: a randomized, controlled trial. Vaccine2013;31(18):2253-9. NCT00197210. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy and safety of two doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine in healthy infants. clinicaltrials.gov/show/NCT00197210 (first received 20 September 2005). NCT00329745. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy and safety of two doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine in healthy infants. clinicaltrials.gov/show/NCT00329745 (first received 25 May 2006). PhuaKB , LimFS , LauYL , NelsonEA , HuangLM , QuakSH , et al. Rotavirus vaccine RIX4414 efficacy sustained during the third year of life: a randomized clinical trial in an Asian population. Vaccine2012;30(30):4552-7. PhuaKB , LimFS , LauYL , NelsonEA , HuangLM , QuakSH , et al. Safety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: randomised, double-blind, controlled study. Vaccine2009;27(43):5936-41. PhuaKB , LimFS , QuakSH , LeeBW , TeohYL , SuryakiranPV , et al. Efficacy, immunogenicity and safety of a human rotavirus vaccine RIX4414 in Singaporean infants. Annals of the Academy of Medicine, Singapore2016;45(2):44-50. ">RIX Phua 2009‐AS</a>; <a href="./references#CD008521-bbs2-0032" title="GlaxoSmithKline[444563-003]. A phase II, double-blind, randomized, placebo-controlled, dose-escalating, stepwise study to assess safety, reactogenicity and immunogenicity of GlaxoSmithKline Biologicals’ live attenuated human rotavirus (HRV) vaccine in healthy infants previously uninfected with human rotavirus. www.gsk-studyregister.com/study/6781 (accessed 12 December 2018). VesikariT , KarvonenA , KorhonenT , EspoM , LebacqE , ForsterJ , et al. Safety and immunogenicity of RIX4414 live attenuated human rotavirus vaccine in adults, toddlers and previously uninfected infants. Vaccine2004;22(21-2):2836-42. ">RIX Vesikari 2004a‐FIN</a>; <a href="./references#CD008521-bbs2-0033" title="De VosB , VesikariT , LinharesAC , SalinasB , Perez-SchaelI , Ruiz-PalaciosGM , et al. A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis. Pediatric Infectious Disease Journal2004;23(10 Suppl):179-82. GlaxoSmithKline[444563-004]. A phase IIb, double-blind, randomized, placebo-controlled study to assess the efficacy, immunogenicity, reactogenicity and safety of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants approximately 2 months of age and previously uninfected with HRV [Results for the first efficacy period (starting from 2 weeks after dose 2 until the end of the first RV season following vaccination)]. www.gsk-studyregister.com/study/6782 (accessed 12 December 2018). GlaxoSmithKline[444563-004-Annex]. A phase IIb, double-blind, randomized, placebo-controlled study to assess the efficacy, immunogenicity, reactogenicity and safety of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants approximately 2 months of age and previously uninfected with HRV [This summary presents results for the second efficacy period (from the end of the first rotavirus season post-vaccination until the end of the second rotavirus season) and for the two consecutive rotavirus seasons]. www.gsk-studyregister.com/study/6782 (accessed 12 December 2018). NCT00425737. A study to assess the efficacy, immunogenicity and safety of two doses of oral live attenuated human rotavirus (HRV) vaccine (Rotarix) in healthy infants. clinicaltrials.gov/show/NCT00425737 (first received 23 January 2007). VesikariT , KarvonenA , EspoM , KorhonenT , DelemA , De VosB . Efficacy evaluation of an oral human rotavirus (HRV) vaccine in previously uninfected Finnish infants. In: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 September 27-30; San Diego, California. 2002. [Not available for review]VesikariT , KarvonenA , PuustinenL , ZengSQ , SzakalED , DelemA , et al. Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants. Pediatric Infectious Disease Journal2004;23(10):937-43. ">RIX Vesikari 2004b‐FIN</a>; <a href="./references#CD008521-bbs2-0034" title="VesikariT , et al. Human rotavirus vaccine Rotarix is highly efficacious in Europe. In: 24th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); 2006 June 15-18; Basel, Switzerland. 2006. [Not available for review]VesikariT , et al. Rotarix, an oral human Rotavirus vaccine, is highly immunogenic in healthy infants from 6 European countries. In: 24th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); 2006 June 15-18; Basel, Switzerland. 2006. [Not available for review]GlaxoSmithKline[102247-036]. A phase IIIb, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants in co-administration with specific childhood vaccinations [This summary presents results from the first efficacy period] [102247-036]. www.gsk-studyregister.com/study/2669 (accessed 12 December 2018). GlaxoSmithKline[102247-036-Annex]. A phase IIIb, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants in co-administration with specific childhood vaccinations [This summary presents results for the second and combined efficacy periods]. www.gsk-studyregister.com/study/2669 (accessed 12 December 2018). GlaxoSmithKline[102247-036-Yr3]. A phase IIIb, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants in co-administration with specific childhood vaccinations [A phase IIIb open study to assess the long-term efficacy and safety of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine approximately three years after vaccination in healthy infants aged 6-12 weeks at the time of first vaccination in the Rota-036 study (eTrack No.102247) in Finland]. www.gsk-studyregister.com/study/2669 (accessed 12 December 2018). NCT00140686. A multi-country &amp; multi-center study to assess the efficacy, safety &amp; immunogenicity of 2 doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants in co-administration with specific childhood vaccines. clinicaltrials.gov/ct2/show/record/NCT00140686 (first received 1 September 2005). [Trial registration document]NCT00420316. To assess long-term efficacy &amp; safety of subjects approximately 3 years after priming with 2 doses of GlaxoSmithKline (GSK) Biologicals' oral live attenuated human rotavirus (HRV) vaccine (Rotarix) in the primary vaccination study (102247). clinicaltrials.gov/show/NCT00420316 (first received 11 January 2007). SchusterV , OttoW , CohenR . RotarixTM an oral human Rotavirus vaccine, is highly immunogenic when co-administered with a Streptococcus pneumoniae conjugate vaccine (PrevenarTM) in healthy infants from France and Germany. In: 24th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); 2006 June 15-18; Basel, Switzerland. 2006. [Not available for review]TejedorJC , Diez-DelegadoJ , AristeguiJ . Rotarix (RIX4414), an oral Human Rotavirus vaccine, is highly immunogenic when co-administered with a Neisseria meningitides Serogroup C vaccine (MeningitecTM) in healthy infants from Spain. In: 24th Annual Meeting Meeting of the European Society for Paediatric Infectious Diseases (ESPID); 2006 June 15-18; Basel, Switzerland. 2006. [Not available for review]VesikariT ,  KarvonenA ,  PrymulaR ,  SchusterV ,  TejedorJC ,  ThollotF ,  et al. Immunogenicity and safety of the human rotavirus vaccine Rotarix co-administered with routine infant vaccines following the vaccination schedules in Europe. Vaccine2010;28(32):5272-9. VesikariT , KarvonenA , FerranteSA , KuterBJ , CiarletM . Sustained efficacy of the pentavalent rotavirus vaccine, RV5, up to 3.1 years following the last dose of vaccine. Pediatric Infectious Disease Journal2010;29(10):957-63. VesikariT , KarvonenA , PrymulaR , SchusterV , TejedorJC , CohenR , et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet2007;370(9601):1757-63. VesikariT , PrymulaR , SchusterV , TejedorJC , CohenR , BouckenoogheA , et al. Efficacy and immunogenicity of live-attenuated human rotavirus vaccine in breast-fed and formula-fed European infants. Pediatric Infectious Disease Journal2012;31(5):509-13. VesikariT , PrymulaR , SchusterV . Early protection against Rotavirus, Rotarix, experience in an European setting. In: 12th International Congress for Infectious Diseases; 2006 June 15-18; Lisbon, Portugal. 2006. [Not available for review]VesikariT , PrymulaR , SchusterV . Rotarix (RIX4414), an oral human rotavirus vaccine, is highly immunogenic when co-administered with diphteria-tetanus-pertussis (DTPA)-combined vaccines in healthy infants from Europe. In: 24th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); 2006 June 15-18; Basel, Switzerland. 2006. [Not available for review]">RIX Vesikari 2007a‐EU</a>; <a href="./references#CD008521-bbs2-0035" title="VesikariT , et al. Immunogenicity of liquid formulation of the oral live attenuated human rotavirus vaccine (Rotarix™) [poster]. Sociedad Latinoamericana de Infectología Pediátrica (SLIPE). San Jose, Costa Rica 8-11 May 2007. [Not available for review]GlaxoSmithKline[104480-048]. A phase II, double-blind, randomized, placebo controlled study to compare the immunogenicity, reactogenicity and safety of two different formulations of GlaxoSmithKline (GSK) Biologicals’ live attenuated human rotavirus (HRV) vaccine given as a two-dose primary vaccination in healthy infants previously uninfected with HRV. www.gsk-studyregister.com/study/2783 (accessed 12 December 2018). NCT00137930. Compare the immunogenicity, reactogenicity &amp; safety of 2 different formulations of GSK Biologicals’ live attenuated human rotavirus (HRV) vaccine given as a two-dose primary vaccination in healthy infants previously uninfected with HRV. clinicaltrials.gov/ct2/show/record/NCT00137930 (first received 30 August 2005). VesikariT , KarvonenA , BouckenoogheA , SuryakiranPV , SmolenovI , HanHH . Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 oral suspension (liquid formulation) in Finnish infants. Vaccine2011;29(11):2079-84. ">RIX Vesikari 2011‐FIN</a>), medium‐mortality countries (<a href="./references#CD008521-bbs2-0007" title="GlaxoSmithKline[444563-021]. A phase II, double-blind, randomized, placebo-controlled clinical study to assess the immunogenicity and reactogenicity of three doses of a modified vaccine formulation versus GlaxoSmithKline (GSK) Biologicals’ live attenuated human rotavirus (HRV) vaccine when orally administered to healthy infants at 2, 4 and 6 months of age. www.gsk-studyregister.com/study/6789 (accessed 12 December 2018). ">RIX GSK[021] 2007‐PAN</a>; <a href="./references#CD008521-bbs2-0008" title="GlaxoSmithKline[444563-033]. A phase III, randomized, double-blind and placebo-controlled study to assess the clinical consistency of three production lots of GSK Biologicals’ HRV vaccine in terms of immunogenicity and safety when given to healthy infants at 2 and 4 months of age. www.gsk-studyregister.com/study/6794 (accessed 12 December 2018). LópezP , Galan HerreraJF , CervantesY , Costa ClemensSA , AguirreF , YarzabalJP . Three consecutive production lots of the human monovalent RIX4414 G1P(8) rotavirus vaccine, Rotarix™ induce a consistent immune response in Latin American infants [poster]. In: 4th World Congress of The World Society for Pediatric Infectious Diseases; 2005 September 01-04; Warsaw, Poland. 2005. [Not available for review]NCT00757770. Assessment of clinical consistency of three production lots of GSK Biologicals' HRV vaccine. clinicaltrials.gov/ct2/show/NCT00757770 (first received 23 September 2008). ">RIX GSK[033] 2007‐LA</a>; <a href="./references#CD008521-bbs2-0012" title="GlaxoSmithKline[103477-039]. A phase IIIb, partially blind, randomized, placebo-controlled study to asses the effect on immunogenicity of administration of vaccine without buffering agent and to assess heat stability in terms of immunogenicity, reactogenicity and safety of GlaxoSmithKline Biologicals’ oral live attenuated human rotavirus (HRV) vaccine following a 0, 2 month schedule, in healthy infants previously uninfected with human rotavirus. www.gsk-studyregister.com/study/2713 (accessed 12 December 2018). KerdpanichA , ChokephaibulkitK , WatanaveeradejV , VanpraparN , HutagalungY , HanHH , et al. Exposure to elevated temperature of 37°C for 7 days does not affect immunogenicity and reactogenicity of RIX4414 [poster]. In: dsRNA Virus Meeting; 2006 October 21-26; Cape Town, South Africa. 2006. [Not available for review]KerdpanichA , ChokephaibulkitK , WatanaveeradejV , VanpraparN , SimasathienS , PhavichitrN , et al. Immunogenicity of a human rotavirus vaccine (RIX4414) after storage at 37 degrees C for seven days. Human Vaccine2011;7(1):74-80. KerdpanichA , ChokephaibulkitK , WatanaveeradejV , VanpraparN , SimasathienS , PhavichitrN , et al. Immunogenicity of a live-attenuated human rotavirus RIX4414 vaccine with or without buffering agent. Human Vaccines2010;6(3):254-62. NCT00169455. Assess the effect on immunogenicity of administration of vaccine without buffering agent &amp; assess heat stability in terms of immunogenicity, reactogenicity &amp; safety of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine following a 0, 2 m schedule, in healthy infants previously uninfected with human rotavirus. clinicaltrials.gov/show/NCT00169455 (first received 15 September 2005). ">RIX Kerdpanich 2010‐THA</a>; <a href="./references#CD008521-bbs2-0015" title="GlaxoSmithKline[113518-074]. Reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated liquid human rotavirus (HRV) vaccine 444563, in healthy infants. www.gsk-studyregister.com/study/3947 (accessed 12 December 2018). LiRC , LiYP , MoZJ , LuoD , HuangT , KongJL , et al. Reactogenicity and safety of a liquid human rotavirus vaccine (RIX4414) in healthy adults, children and infants in China: randomized, double-blind, placebo-controlled phase I studies. Human Vaccines and Immunotherapeutics2013;9(8):1638-42. NCT01107587. Study to assess the safety of GSK Biologicals' liquid human rotavirus vaccine in healthy infants. clinicaltrials.gov/ct2/show/NCT01107587 (first received 20 April 2010). ">RIX Li 2013b‐CHN</a>; <a href="./references#CD008521-bbs2-0016" title="GlaxoSmithKline[113808-075]. Efficacy, immunogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals' oral live attenuated liquid Human Rotavirus (HRV) vaccine (444563), in healthy infants. www.gsk-studyregister.com/study/4036 (accessed 12 December 2018). LiRC , HuangT , LiY , LuoD , TaoJ , FuB , et al. Human rotavirus vaccine (RIX4414) efficacy in the first two years of life: a randomized, placebo-controlled trial in China. Human Vaccines and Immunotherapeutics2014;10(1):11-8. LiRC , HuangT , LiY , WangLH , TaoJ , FuB , et al. Immunogenicity and reactogenicity of the human rotavirus vaccine, RIX4414 oral suspension, when co-administered with routine childhood vaccines in Chinese infants. Human Vaccines and Immunotherapeutics2016;12(3):785-93. NCT01171963. Efficacy, immunogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals' oral live attenuated liquid human rotavirus (HRV) vaccine (444563), in healthy infants. clinicaltrials.gov/show/NCT01171963 (first received 29 July 2010). ">RIX Li 2014‐CHN</a>; <a href="./references#CD008521-bbs2-0021" title="GlaxoSmithKline[104021-DTPw CSL-HBVGOD-005]. A phase III, partially blind, randomized study to evaluate the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ Tritanrix™-HepB and GSK Biologicals Kft’s DTPw-HBV vaccines as compared to concomitant administration of Commonwealth Serum Laboratory’s (CSL’s) DTPw (Triple Antigen™) and GSK Biologicals’ HBV (Engerix™-B), when co-administered with GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine, to healthy infants at 3, 4½ and 6 months of age, after a birth dose of hepatitis B vaccine. www.gsk-studyregister.com/study/2753 (accessed 12 December 2018). NCT00158756. Assess immunogenicity &amp; reactogenicity of 2 formulations of GSK's DTPw-HBV vaccines vs concomitant admn of CSL's DTPw &amp; GSK's HBV vaccine, co-admnd with GSK's rotavirus vaccine, to infants at 3, 4½ &amp; 6 mths, after birth dose of HBV vaccine. clinicaltrials.gov/show/NCT00158756 (first received 12 September 2005). TatochenkoVK , RomanenkoVV , KharitSM , SmolenovI , LeFevreI , De ClercqN , et al. Co-administration of a human rotavirus vaccine Rix4414 with DTPw-HBv vaccines: immunogenicity and reactogenicity in healthy infants. In: 13th International Congress on Infectious Diseases; June 19–22. 2008; Kuala Lumpur, Malaysia. 2008. ">RIX NCT00158756‐RUS</a>; <a href="./references#CD008521-bbs2-0026" title="Costa ClemensSA , et al. Operational organization of a large scale phase III clinical trial of rotavirus vaccine in multiple sites and countries in Latin America. In: International Congress of Pediatrics (ICP); 2004 August 15-20; Cancun, Mexico. 2004. [Not available for review]De VosB , et al. Rotarix™: an effective way to prevent rotavirus diarrhoea and vomiting. In: 9th Congress of the Asian Pan Pacific Society of Paediatric Gastroenterology, Hepatology and Nutrition &amp; 27th Annual Congress of the Malaysian Paediatric Association; 2005 June 16-19; Kuala Lumpur, Malaysia. 2005. [Not available for review]BaayM , BollaertsK , StruchinerC , VerstraetenT . Background rates of disease in Latin American children from a rotavirus vaccine study. Human Vaccines and Immunotherapeutics2017;13(8):1916-20. GlaxoSmithKline[444563-023-pt1]. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants (efficacy data from visit 1 to visit 4). www.gsk-studyregister.com/study/6791 (accessed 12 December 2018). GlaxoSmithKline[444563-023-pt2]. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants (2nd year efficacy from visit 4 to visit 6). www.gsk-studyregister.com/study/6791 (accessed 12 December 2018). GlaxoSmithKline[444563-023-pt3]. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants (safety for the period between visit 1 and visit 3). www.gsk-studyregister.com/study/6791 (accessed 12 December 2018). JustinoMC , AraújoEC , Van DoornLJ , OliveiraCS , GabbayYB , MascarenhasJD , et al. Oral live attenuated human rotavirus vaccine (Rotarix) offers sustained high protection against severe G9P[8] rotavirus gastroenteritis during the first two years of life in Brazilian children. Memorias do Instituto Oswaldo Cruz2012;107(7):846-53. LinharesAC , VelazquezFR , Perez-SchaelI , Saez-LlorensX , AbateH , EspinozaF , et al. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet2008;371(9619):1181-9. LopezP , LinharesA , Pérez-SchaelI , Ruiz-PalaciosG , Costa ClemensS , SanchezN . Early protection against severe rotavirus gastroenteritis - RIX4414 experience in Latin America. In: 24th Annual Meeting of European Society for Paediatric Infectious Diseases (ESPID); 2006 May 03-05; Basel, Switzerland. 2006. [Not available for review]MaciasM , LopezP , VelazquezFR , VergaraRF , SalmeronJ , TavaresJL . The rotavirus vaccine RIX4414 (Rotarix) is not associated with intussusception in one year old infants. In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2005 December 16-19; Washington DC, USA. 2005. [Not available for review]NCT00139347. A multi-country &amp; multi-center study to assess the efficacy, immunogenicity &amp; safety of two doses of GSK Biologicals' oral live attenuated HRV vaccine given concomitantly with routine EPI vaccinations including OPV in healthy infants. clinicaltrials.gov/ct2/show/NCT00139347 (first received 31 August 2005). [Trial registration document (no data for review)]NCT00140673. Placebo-controlled, multi-country &amp; multi-center study to assess the efficacy, safety &amp; immunogenicity of 2 doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants. clinicaltrials.gov/ct2/show/NCT00140673 (first received 1 September 2005). [Trial registration document (no data for review)]Perez-SchaelI , LinharesAC , VesikariT . Two doses of the human attenuated rotavirus vaccine RIX4414 (Rotarix) show heterotypic protection in Latin America and Europe. In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2005 December 16-19; Washington DC, USA. 2005. [Not available for review]PikeM . New rotavirus vaccine is effective and appears to have no increased risk of intussusception. Clinical Research Abstracts For Pediatricians2006;149(1):143. Ruiz-PalaciosG , AranzaC , VelazquezFR , RichardsonV , NandiE , MaciasM . Two doses of the human-attenuated monovalent G1P[8] rotavirus vaccine, Rotarix show high efficacy in Mexican children against severe rotavirus gastroenteritis and severe overall gastroenteritis. In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2005 December 16-19; Washington DC, USA. 2005. [Not available for review]Ruiz-PalaciosGM , Perez-SchaelI , VelazquezFR , AbateH , BreuerT , ClemensSC , et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. New England Journal of Medicine2006;354(1):11-22. VelázquezFR , AbatH , Costa ClemensSA , EspinozaF , GillardP , LinharesAC , et al. The human monovalent G1P[8] rotavirus vaccine, Rotarix is highly efficacious and provides crossprotection against G1 and non-G1 serotypes. In: 23rd Annual meeting of European Society for Paediatric Infectious Diseases (ESPID); 2005 May 18-20; Valencia, Spain. 2005. VelázquezRF , AbateH , BouckenoogheA . RIX4414, the human G1P[8] rotavirus vaccine is highly efficacious during the second year of life. In: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2006 September 27-30; San Francisco, USA. 2006. [Not available for review]VesikariT , O’RyanM , AbateH , Costa ClemensSA , EspinozaF , GillardP . Overcoming the safety hurdle: the rotavirus vaccine RIX4414 is not associated with intussusception. In: 23rd Annual Meeting of European Society for Paediatric Infectious Diseases (ESPID); 2005 May 18-20; Valencia, Spain. 2005. [Not available for review]">RIX Ruiz‐Palac 06‐LA/EU</a>; <a href="./references#CD008521-bbs2-0027" title="Ruiz-PalaciosG , GuerreroL , LinharesAC , et al. Efficacy of an oral human rotavirus (HRV) vaccine in preventing diarrhoea due to G1 and non-G1 rotavirus [Presentation]. In: 3rd World Congress of Pediatric Infectious Diseases; 2002 November 19-23; Santiago, Chile. 2002. [Not available for review]Ruiz-PalaciosG , GuerreroML , LinharesAC , et al. Two-year efficacy of GlaxoSmithKline Biologicals' live attenuated rotavirus vaccine in Latin American children [poster]. In: 24th International Congress of Pediatrics; 2004 August 15-20; Cancun, Mexico. 2004. [Not available for review]SalinasB , Perez-SchaelI , Ruiz-PalaciosG , et al. Early protection by GlaxoSmithKline Biologicals' live attenuated rotavirus vaccine in Latin American children [poster]. In: 24th International Congress of Pediatrics; 2004 August 15-20; Cancun, Mexico. 2004. [Not available for review]SalinasB , TomatMA , YarzabalJP , et al. Efficacy of the rotavirus vaccine (RIX4414) among infants in Carabobo State, Venezuela [poster]. In: Asocación Venezolana para el Avance de la Cienca (AsoVAC); 2004; Venezuela. 2004. [Not available for review]AraujoEC , ClemensSA , OliveiraCS , JustinoMC , RubioP , GabbayYB , et al. Safety, immunogenicity, and protective efficacy of two doses of RIX4414 live attenuated human rotavirus vaccine in healthy infants. Jornal de Pediatria2007;83(3):217-24. De VosB , HardtK , LinharesAC , Ruiz-PalaciosG , GuerreroL , SalinasB . Efficacy of two doses of a human monovalent rotavirus vaccine, Rotarix™ in preventing gastro-enteritis due to G1 and Non-G1 rotavirus in Brazil, Mexico and Venezuela [presentation]. In: 8th International Symposium on Double-Stranded RNA Viruses; 2003 September 13-18; Lucca, Italy. 2003. [Not available for review]De VosB , VesikariT , LinharesAC , SalinasB , Perez-SchaelI , Ruiz-PalaciosGM , et al. A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis. Pediatric Infectious Disease Journal2004;23(10 Suppl):179-82. GlaxoSmithKline[444563-006]. A phase IIb, double-blind, randomized, placebo-controlled study to assess the efficacy, immunogenicity, reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals' live attenuated human rotavirus (HRV) vaccine at different virus concentrations (104.7, 105.2 and 105.8 foci forming units [ffu]) in healthy infants (approximately 2 months of age at first dose) following a 0, 2 month schedule and previously uninfected with HRV, when administered concurrently with DTPw-HBV and Hib vaccines. www.gsk-studyregister.com/study/6784 (accessed 12 December 2018). GlaxoSmithKline[444563-006-Annex]. A phase IIb, double-blind, randomized, placebo-controlled study to assess the efficacy, immunogenicity, reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals' live attenuated human rotavirus (HRV) vaccine at different virus concentrations (104.7, 105.2 and 105.8 foci forming units [ffu]) in healthy infants (approximately 2 months of age at first dose) following a 0, 2 month schedule and previously uninfected with HRV, when administered concurrently with DTPw-HBV and Hib vaccines [This summary presents results for the second and combined efficacy periods and results from the 3-Dose subset. Results from the first efficacy period are presented in 444563/006 (Rota-006) summary]. www.gsk-studyregister.com/study/6784 (accessed 12 December 2018). LinharesA , Perez-SchaelI , Ruiz-PalaciosM , PernambucoE , JacquetJ , De VosB . Immunogenicity and reactogenicity of an oral human rotavirus (HRV) vaccine in Latin American infants [poster]. In: 3rd World Congress of Pediatric Infectious Diseases; 2002 November 19-23; Santiago, Chile. 2002. [Not available for review]LinharesAC , Ruiz-PalaciosGM , GuerreroML , SalinasB , Perez-SchaelI , ClemensSA , et al. A short report on highlights of world-wide development of RIX4414: a Latin American experience. Vaccine2006;24(18):3784-5. LinharesAC , VerstraetenT , Wolleswinkel-Van den BoschJ , ClemensR , BreuerT . Rotavirus serotype G9 is associated with more-severe disease in Latin America. Clinical Infectious Diseases2006;43(3):312-4. [Not available for review]NCT00385320. To assess the efficacy, immuno &amp; safety of 2 doses of GSK HRV vaccine at different virus concentrations in healthy infants aged 2 months &amp; previously uninfected with HRV, concurrently given with DTPw-HBV, Hib. clinicaltrials.gov/show/NCT00385320 (first received 9 October 2006). Perez-SchaelI , SalinasB , LinharesA , GuerreroM , Ruiz-PalaciosG , ClemensS , et al. Protective efficacy of an oral human rotavirus (HRV) vaccine in Latin American infants [poster]. In: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy ( ICAAC); San Diego, 27-30 September 2002. 2002:18, LB-23. [Not available for review]Perez-SchaelI , SalinasB , TomatM , LinharesAC , GuerreroML , Ruiz-PalaciosGM , et al. Efficacy of the human rotavirus vaccine RIX4414 in malnourished children. Journal of Infectious Diseases2007;196(4):537-40. Ruiz-PalaciosGM , GuerreroML , Bautista-MarquezA , Ortega-GallegosH , Tuz-DzibF , Reyes-GonzalezL , et al. Dose response and efficacy of a live, attenuated human rotavirus vaccine in Mexican infants. Pediatrics2007;120(2):e253-61. [Not available for review]Ruiz-PalaciosGM . Impact of maternal antibodies on the immune response to an oral human rotavirus (HRV) vaccine in Mexican infants [presentation]. In: 3rd World Congress of Pediatric Infectious Diseases; 2002 November 19-23; Santiago, Chile. 2002. [Not available for review]SalinasB , Perez SchaelI , LinharesAC , Ruiz PalaciosGM , GuerreroML , YarzabalJP , et al. Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: a randomized, placebo-controlled trial in Latin American infants. Pediatric Infectious Disease Journal2005;24(9):807-16. ">RIX Salinas 2005‐LA</a>; <a href="./references#CD008521-bbs2-0031" title="GlaxoSmithKline[444563-024]. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, immunogenicity and safety of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations including OPV in healthy infants. www.gsk-studyregister.com/study/6792 (accessed 12 December 2018). Gonzalez AyalaS , RiveraL , Rivera-MedinaDM , LopezP , ValenciaA , De LeónT , et al. Co-administration with rotavirus vaccine rix4414 (Rotarix™) does not interfere with the immunogenicity of oral polio vaccine (OPV) [poster]. In: World Society for Pediatric Infectious Diseases (WSPID); 2007 November 15-18; Bangkok, Thailand. 2007. [Not available for review]TregnaghiMW , AbateHJ , ValenciaA , LopezP , Da SilveiraTR , RiveraL , et al. Human rotavirus vaccine is highly efficacious when coadministered with routine expanded program of immunization vaccines including oral poliovirus vaccine in Latin America. Pediatric Infectious Disease Journal2011;30(6):e103-e8. ">RIX Tregnaghi 2011‐LA</a>), and in high‐mortality countries (<a href="./references#CD008521-bbs2-0001" title="AnhDD , CarlosCC , ThiemDV , HutagalungY , GatchalianS , BockHL , et al. Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 (Rotarix) oral suspension (liquid formulation) when co-administered with expanded program on immunization (EPI) vaccines in Vietnam and the Philippines in 2006-2007. Vaccine2011;29(11):2029-36. GlaxoSmithKline[109216-063]. A phase II, randomized, double-blind, placebo-controlled study to evaluate the immunogenicity, reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) liquid vaccine, when given to healthy infants, in Philippines. www.gsk-studyregister.com/study/3204 (accessed 12 December 2018). NCT00432380. Immunogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals' oral live attenuated human rotavirus (HRV) liquid vaccine (GSK 357941A) in healthy infants. clinicaltrials.gov/show/NCT00432380 (first received 7 February 2007). ">RIX Anh 2011‐PHL</a>; <a href="./references#CD008521-bbs2-0002" title="AnhDD , CarlosCC , ThiemDV , HutagalungY , GatchalianS , BockHL , et al. Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 (Rotarix) oral suspension (liquid formulation) when co-administered with expanded program on immunization (EPI) vaccines in Vietnam and the Philippines in 2006-2007. Vaccine2011;29(11):2029-36. AnhDD , ThiemVD , HutagalungY , BockHL , SuryakiranP , DelemA , et al. Immunogenicity, reactogenicity and safety of the oral live attenuated human rotavirus vaccine RIX4414 (Rotarix™) oral suspension (liquid formulation) in Vietnamese Infants. In: 13th International Congress on Infectious Diseases Abstracts, Poster Presentations; June 19–22, 2008; Kuala Lumpur, Malaysia. 2008. GlaxoSmithKline[105722-051]. A phase II, randomized, double-blind, placebo-controlled study to evaluate the immunogenicity, reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) liquid vaccine, when given to healthy infants, in Vietnam. www.gsk-studyregister.com/study/3012 (accessed 12 December 2018). NCT00345956. A placebo-controlled study to evaluate the immunogenicity, reactogenicity and safety of two doses of GSK Bio oral live attenuated human rotavirus (HRV) liquid vaccine, when given to healthy infants, in Vietnam. clinicaltrials.gov/show/NCT00345956 (first received 29 June 2006). ">RIX Anh 2011‐VNM</a>;  <a href="./references#CD008521-bbs2-0010" title="GlaxoSmithKline[101555]. A phase II, double-blind, randomized, placebo-controlled study to compare the immunogenicity, reactogenicity and safety of 2 different formulations of GlaxoSmithKline (GSK) Biologicals’ live attenuated human rotavirus (HRV) vaccine given as a two-dose primary vaccination in healthy infants previously uninfected with HRV. www.gsk-studyregister.com/study/2632 (accessed 12 December 2018). ">RIX GSK[101555] 2008‐PHL</a>; <a href="./references#CD008521-bbs2-0017" title="CunliffeNA , WitteD , NgwiraBM , ToddS , BostockNJ , TurnerAM , et al. Efficacy of human rotavirus vaccine against severe gastroenteritis in Malawian children in the first two years of life: a randomized, double-blind, placebo controlled trial. Vaccine2012;30(Suppl 1):A36-43. MadhiSA , CunliffeNA , SteeleD , WitteD , KirstenM , LouwC , et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. New England Journal of Medicine2010;362(4):289-98. MadhiSA , KirstenM , LouwC , BosP , AspinallS , BouckenoogheA , et al. Efficacy and immunogenicity of two or three dose rotavirus-vaccine regimen in South African children over two consecutive rotavirus seasons: a randomized, double-blind, placebo-controlled trial. Vaccine2012;30(Suppl 1):A44-51. NCT00241644. Multi-center study to assess the efficacy, safety and immunogenicity of 2 or 3 doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations in healthy infants. clinicaltrials.gov/show/NCT00241644 (first received 19 October 2005). NCT00598468. Multi-center study to assess efficacy, safety &amp; immunogenicity of 2 or 3 doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations in healthy infants. clinicaltrials.gov/show/NCT00598468 (first received 19 October 2005). SteeleAD , NeuzilKM , CunliffeNA , MadhiSA , BosP , NgwiraB , et al. Human rotavirus vaccine Rotarix provides protection against diverse circulating rotavirus strains in African infants: a randomized controlled trial. BMC Infectious Diseases2012;12:213. ">RIX Madhi 2010‐AF</a>; <a href="./references#CD008521-bbs2-0020" title="GlaxoSmithKline[103792-044]. A phase IIIb, randomised, multicentre double-blind, placebo-controlled study of the immunogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine (RIX4414) as primary dosing in healthy infants in India of approximately 8 weeks of age at the first dose. www.gsk-studyregister.com/study/2723 (accessed 12 December 2018). NarangA , BoseA , PanditAN , DuttaP , KangG , BhattacharyaSK , et al. Immunogenicity, reactogenicity and safety of human rotavirus vaccine (RIX4414) in Indian infants. Human Vaccines2009;5(6):414-9. NCT00289172. A multicenter study of the immunogenicity &amp; safety of 2 doses of GSK Biologicals’ oral live attenuated human rotavirus vaccine (RIX4414) as primary dosing of healthy infants in India aged approximately 8 wks at the time of the first dose. clinicaltrials.gov/ct2/show/record/NCT00289172 (first received 9 February 2006). ">RIX Narang 2009‐IND</a>; <a href="./references#CD008521-bbs2-0025" title="EUCTR2015-001542-29. Immunization of infants 6-14 weeks of age, with GlaxoSmithKline Biologicals Rotavirus vaccine to explore the existence of transmission of rotavirus vaccine strain between twins in a family. clinicaltrialsregister.eu/ctr-search/trial/2015-001542-29/results (first received 22 June 2015). NCT00396630. A Phase IIIb, randomized, double-blind, placebo-controlled study to explore the existence of horizontal transmission of the RIX4414 vaccine strain between twins within a family. clinicaltrials.gov/show/NCT00396630 (first received 7 November 2006). RiveraL ,  PeñaLM ,  StainierI ,  GillardP ,  CheuvartB ,  SmolenovI , et al. Horizontal transmission of a human rotavirus vaccine strain - a randomized, placebo-controlled study in twins. Vaccine2011;29(51):9508-13. ">RIX Rivera 2011‐DOM</a>; <a href="./references#CD008521-bbs2-0028" title="GlaxoSmithKline[444563-014]. A phase II, double-blind before the 2002 rotavirus season and single blind with respect to OPV after, randomised, placebo-controlled study of the safety, reactogenicity and immunogenicity of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine (RIX4414 at 105 ffu) co-administered with either oral polio vaccine (OPV) or inactivated polio vaccine (IPV) in healthy infants (approximately 5-10 weeks old) in South Africa. www.gsk-studyregister.com/study/6787 (accessed 12 December 2018). ISRCTN86632774. A phase II, double blind randomised, placebo controlled study to assess the safety reactogenicity and immunogenicity of three doses of GSK Biologicals (South Africa). controlled-trials.com/ISRCTN86632774 (first received 25 November 2005). NCT00346892. Reactogenicity &amp; immunogenicity study of two doses of GSK Biologicals’ oral live attenuated HRV vaccine co-administered with either OPV or IPV in healthy infants (approximately 5-10 weeks old) in South Africa. clinicaltrials.gov/show/NCT00346892 (first received 30 June 2006). SteeleAD ,  De VosB ,  TumboJ ,  ReyndersJ ,  ScholtzF ,  BosP ,  et al. Co-administration study in South African infants of a live-attenuated oral human rotavirus vaccine (RIX4414) and poliovirus vaccines. Vaccine2010 ;28(39):6542-8. SteeleAD , TumboJ , ArmahG , ReyndersJ , ScholtzF , BosP , et al. Immunogenicity and reactogenicity of a new live attenuated oral rotavirus vaccine (RIX4414) when administered concurrently with poliovirus vaccines in African infants. In: 24th International Congress of Pediatrics; 2004 August 15-20; Cancun, Mexico. 2004. [Not available for review]SteeleAD , TumboJM , ArmahGE , ReyndersJ , ScholtzF , BosP , et al. Concomitant administration of a live-attenuated oral rotavirus vaccine (RIX4414) with poliovirus vaccines in African infants. In: 23rd Annual Meeting of the European Society for Pediatric Infectious Diseases - ESPID; 2005 May 18-20; Valencia, Spain. 2005. [Not available for review]">RIX Steele 2008‐ZAF</a>; <a href="./references#CD008521-bbs2-0029" title="EUCTR2015-001484-39. A phase II study to assess the safety and immunogenicity of GlaxoSmithKline Biologicals rotavirus vaccine, RIX4414 when administered to HIV infected infants in South Africa. www.clinicaltrialsregister.eu/ctr-search/trial/2015-001484-39/results (first received 11 June 2015). GlaxoSmithKline[444563-022]. A phase II, double-blind, randomized, placebo-controlled study to assess the safety, reactogenicity and immunogenicity of three doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine. www.gsk-studyregister.com/study/6790 (accessed 12 December 2018). ISRCTN11877362. A phase II, double-blind, randomised, placebo-controlled study to assess the safety, reactogenicity and immunogenicity of three doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine (RIX4414 at 106.5 CCID50) administered to human immunodeficiency virus (HIV) infected infants at 6, 10 and 14 weeks of age in South Africa. www.controlled-trials.com/ISRCTN11877362 (first received 25 November 2005). NCT00263666. A study of safety, reactogenicity and immunogenicity of HRV vaccine in HIV infected infants in South Africa. clinicaltrials.gov/ct2/show/results/NCT00263666 (first received on 9 December 2005). SteeleAD ,  MadhiSA ,  LouwCE ,  BosP ,  TumboJM ,  WernerCM ,  et al. Safety, reactogenicity, and immunogenicity of human rotavirus vaccine RIX4414 in human immunodeficiency virus-positive infants in South Africa. Pediatric Infectious Diseases Journal2011;30(2):125-30. ">RIX Steele 2010a‐ZAF</a>; <a href="./references#CD008521-bbs2-0030" title="GlaxoSmithKline[444563-013]. A phase II, double-blind before the 2002 rotavirus season and single blind with respect to OPV after, randomised, placebo-controlled study of the safety, reactogenicity and immunogenicity of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine (RIX4414 at 105 ffu) co-administered with either oral polio vaccine (OPV) or inactivated polio vaccine (IPV) in healthy infants (approximately 5-10 weeks old) in South Africa. www.gsk-studyregister.com/study/6786 (accessed 12 December 2018). ISRCTN37373664. A double blind, randomised placebo controlled study of the safety, reactogenicity and immunogenicity of two doses of orally administered human rotavirus vaccine (RIX4414) in healthy infants in South Africa. controlled-trials.com/ISRCTN37373664 (first received 25 November 2005). NCT00383903. A study of the safety, reactogenicity and immunogenicity of 2 or 3 doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants (approximately 5-10 weeks old) in South Africa. clinicaltrials.gov/show/NCT00383903 (first received 3 October 2006). SteeleAD ,  ReyndersJ ,  ScholtzF ,  BosP ,  De BeerMC ,  TumboJ ,  et al. Comparison of 2 different regimens for reactogenicity, safety, and immunogenicity of the live attenuated oral rotavirus vaccine RIX4414 coadministered with oral polio vaccine in South African infants. Journal of Infectious Diseases2010;202(Suppl):S93-100. ">RIX Steele 2010b‐ZAF</a>; <a href="./references#CD008521-bbs2-0037" title="GlaxoSmithKline[103992-045]. A phase II, randomised, double-blind, placebo-controlled study to evaluate the immunogenicity, reactogenicity and safety of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine (RIX4414 at 106.5 CCID50) when given concomitantly with OPV versus when given alone (HRV vaccine dose given 15 days after the OPV dose) in healthy infants in Bangladesh. www.gsk-studyregister.com/study/2748 (accessed 12 December 2018). NCT00139334. Evaluate immunogenicity, reactogenicity &amp; safety of 2 doses of GSK Biologicals’ oral live attenuated HRV vaccine (RIX4414 at 106.5 CCID50) when given concomitantly with OPV versus given alone (HRV vaccine dose given 15 days after the OPV dose) in healthy infants in Bangladesh. clinicaltrials.gov/show/NCT00139334 (first received 31 August 2005). ZamanK , SackDA , YunusM , ArifeenSE , PodderG , AzimT , et al, Bangladesh Rotavirus Vaccine study group. Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age. Vaccine2009;27(9):1333-9. ">RIX Zaman 2009‐BGD</a>); see <a href="./references#CD008521-fig-0013" title="">Analysis 1.9</a>. </p> <section id="CD008521-sec-0115"> <p><b>Low‐mortality countries</b></p> <p>There was little or no difference between children allocated to Rotarix compared with placebo in the risk of serious adverse events (RR 0.89, 95% CI 0.72 to 1.10; 18,971 participants, 12 trials).  </p> </section> <section id="CD008521-sec-0116"> <p><b>Medium‐mortality countries</b></p> <p>Fewer children allocated to Rotarix had serious adverse events compared with placebo (RR 0.85, 95% CI 0.76 to 0.95; 77,069 participants, 9 trials). In addition, in one trial (<a href="./references#CD008521-bbs2-0014" title="GlaxoSmithKline[113552-073]. Reactogenicity and safety of a single dose of GlaxoSmithKline (GSK) Biologicals' human rotavirus (HRV) vaccine (444563) in healthy children. www.gsk-studyregister.com/study/3957 (accessed 12 December 2018). LiRC , LiYP , MoZJ , LuoD , HuangT , KongJL , et al. Reactogenicity and safety of a liquid human rotavirus vaccine (RIX4414) in healthy adults, children and infants in China: randomized, double-blind, placebo-controlled phase I studies. Human Vaccines and Immunotherapeutics2013;9(8):1638-42. NCT01086436. Study to evaluate the safety of Rotarix in Chinese children. clinicaltrials.gov/ct2/show/NCT01086436 (first received on 15 March 2010). ">RIX Li 2013a‐CHN</a>) that vaccinated 25 older children (aged two to six years) with one‐dose Rotarix, there were no serious adverse events reported. </p> </section> <section id="CD008521-sec-0117"> <p><b>High‐mortality countries</b></p> <p>There was little or no difference in the number of serious adverse events between the two arms (RR 0.90, 95% CI 0.77 to 1.05; 7674 participants, 10 trials). </p> </section> </section> <section id="CD008521-sec-0118"> <h6 class="title">1.1.5. Serious adverse events: intussusception</h6> <p>Twenty‐one trials reported on intussusception, and 11 of these reported that no cases of intussusception had occurred. Trials were performed in low‐mortality countries (<a href="./references#CD008521-bbs2-0006" title="DennehyPH , BradyRC , HalperinSA , WardRL , AlveyJC , Fischer FH Jr, et al. Comparative evaluation of safety and immunogenicity of two dosages of an oral live attenuated human rotavirus vaccine. Pediatric Infectious Disease Journal2005;24(6):481-8. DennehyPH . A short report on the highlights of world-wide development of RIX4414: a North American experience comparative evaluation of safety and immunogenicity of two dosages of an oral live attenuated human rotavirus vaccine (RIX4414) in infants in the United States and Canada. Vaccine2006;24(18):3780-1. GlaxoSmithKline[444563-005]. A phase II, double-blind, randomized, placebo-controlled study of two doses of GlaxoSmithKline Biologicals’ live attenuated human rotavirus (HRV) vaccine at different virus concentrations (10 5.2 and 10 6.4 ffu) in healthy infants (approximately 2 months of age at first dose) following a 0, 2 month schedule and previously uninfected with human rotavirus. www.gsk-studyregister.com/study/6783 (accessed 12 December 2018). NCT00729001. Study of two doses of GSK Biologicals' live attenuated HRV vaccine (two different formulations) in healthy infants. clinicaltrials.gov/ct2/show/NCT00729001 (accessed 6 August 2008). ">RIX Dennehy 2005‐NA</a>; <a href="./references#CD008521-bbs2-0009" title="GlaxoSmithKline[103478-041]. A phase IIIb, double-blind, randomized, placebo-controlled, multicentre study to assess the immunogenicity, safety and reactogenicity of 2 doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants (6-12 weeks of age at first dose) previously uninfected with human rotavirus. www.gsk-studyregister.com/study/2714 (accessed 12 December 2018). NCT00134732. Assess the immunogenicity, safety &amp; reactogenicity of 2 doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants (6-12 weeks of age at first dose) previously uninfected with human rotavirus. clinicaltrials.gov/ct2/show/record/NCT00134732 (first received 25 August 2005). ">RIX GSK[041] 2007‐KOR</a>; <a href="./references#CD008521-bbs2-0011" title="GlaxoSmithKline[107625 (Rota-056)]. Efficacy, safety, reactogenicity and immunogenicity study of the lyophilised formulation of Rotarix vaccine in healthy Japanese infants. www.gsk-studyregister.com/study/3131 (accessed 12 December 2018). KawamuraN , TokoedaY , MoriS , OhshimaM , OkahataH , UedaD , et al. Efficacy of human rotavirus vaccine RIX4414 in Japanese infants from 2 weeks post dose 2 up to data lock point. In: 28th Meeting of European Society for Paediatric Infectious Diseases (ESPID); 2010 May 04-08; Nice, France. 2010. KawamuraN , TokoedaY , OshimaM , OkahataH , TsutsumiH , Van DoornLJ , et al. Efficacy, safety and immunogenicity of RIX4414 in Japanese infants during the first two years of life. Vaccine2011;29(37):6335-41. NCT00480324. Efficacy, safety, reactogenicity and immunogenicity study of the lyophilised formulation of Rotarix vaccine in healthy Japanese infants. clinicaltrials.gov/show/NCT00480324 (first received 17 November 2010). ">RIX Kawamura 2011‐JPN</a>; <a href="./references#CD008521-bbs2-0013" title="GlaxoSmithKline[112269-068]. Immunogenicity, reactogenicity and safety study to evaluate two doses of the lyophilised formulation of the human rotavirus (HRV) vaccine when administered to healthy Korean infants previously uninfected with HRV. www.gsk-studyregister.com/study/3589 (accessed 12 December 2018). KimJS , BaeCW , LeeKY , ParkMS , ChoiYY , KimKN , et al. Immunogenicity, reactogenicity and safety of a human rotavirus vaccine (RIX4414) in Korean infants: a randomized, double-blind, placebo-controlled, phase IV study. Human Vaccines and Immunotherapeutics2012;8(6):806-12. NCT00969228. Study to evaluate immunogenicity, reactogenicity and safety of Rotarix™ vaccine in Korean infants. clinicaltrials.gov/ct2/show/NCT00969228 (first received 1 September 2009). ">RIX Kim 2012‐KOR</a>; <a href="./references#CD008521-bbs2-0023" title="EmmanuelB , et al. Immunogenicity of an acellular pertussis combination vaccine co-administered with a novel rotavirus vaccine in Singaporean infants. Asian Congress on Pediatric Infectious Diseases (ACPID); 2-4 September 2004; Kota Kinabula, Malaysia2004. [Not available for review]PhuaKB , et al. Immunogenicity and reactogenicity of two doses of an oral human rotavirus (HRV) vaccine at different concentrations in healthy infants from Singapore. In: 11th Asia Pacific Congress of Pediatrics and the 3rd Asia Pacific Congress of Pediatric Nursing; 2003; Bangkok, Thailand. 2003. [Not available for review]PhuaKB , et al. Intussusception in children: a seven-year experience in Singapore. In: 24th International Congress of Pediatrics (ICP); 2004 August 15-20; Cancun, Mexico. 2004. [Not available for review]VesikariT , et al. High efficacy of two doses of Rotarix™ (RIX4414) against rotavirus disease in Europe, Latin-America and Asia. In: Asian Congress on Pediatric Infectious Diseases (ACPID); 2006 March 07-10; Cebu, Philippines. 2006. [Not available for review]De VosB , GillardP , CheuvartB . RIX4414 vaccine efficacy against rotavirus gastroenteritis due to G2P[4] strain. In: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2006 September 27-30; San Francisco, USA. 2006. [Not available for review]De VosB , VesikariT , LinharesAC , SalinasB , Perez-SchaelI , Ruiz-PalaciosGM , et al. A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis. Pediatric Infectious Disease Journal2004;23(10 Suppl):179-82. [No data for review]EmmanuelS , PhuaKB , GohP , QuakSH , DattaSK , HanHH , et al. Immunogenicity of an acellular pertussis combination vaccine co-administered with a novel rotavirus vaccine in Singaporean infants. In: 23rd Annual Meeting of European Society for Paediatric Infectious Diseases (ESPID); 2005 May 18-20; Valencia, Spain. 2005. [Not available for review]GlaxoSmithKline[444563-007]. A phase IIb, double-blind, randomized, placebo-controlled study to assess the efficacy, immunogenicity, reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine at different viral concentrations (104.7, 105.2 and 106.1 foci forming units (ffu)) in healthy infants previously uninfected with human rotavirus and approximately three months of age, when administered concurrently with DTPa-IPV/Hib and HBV vaccines. www.gsk-studyregister.com/study/6785 (accessed 12 December 2018). NCT00429481. A study to assess the efficacy, immunogenicity and safety of 2 doses of oral live attenuated human rotavirus vaccine (Rotarix) at different viral concentrations in healthy infants. clinicaltrials.gov/ct2/show/record/NCT00429481 (first received 31 January 2007). PhuaKB , EmmanuelSC , GohP , QuakSH , LeeBW , HanHH , et al. A rotavirus vaccine for prophylaxis of infant rotavirus gastroenteritis: the Asian experience. Annals of the Academy of Medicine, Singapore2006;35(1):38-44. PhuaKB , QuakSH , EmmanuelS , GohPS , HanHH , HardtK , et al. A short report on highlights of worldwide development of RIX4414: a Singaporean experience. Vaccine2006;24(18):3782-3. PhuaKB , QuakSH , EmmanuelS , GohPSC , HanHH , HardtK , et al. Highlights of world-wide development: a Singapore experience. In: 3rd International Conference on Vaccines for Enteric Diseases (VED) 28-30 April 2004; Montego Bay, Jamaica. 2004. [Not available for review]PhuaKB , QuakSH , LeeBW , EmmanuelSC , GohP , HanHH , et al. Evaluation of RIX4414, a live, attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled phase 2 trial involving 2464 Singaporean infants. Journal of Infectious Diseases2005;192(Suppl 1):6-16. PhuaKB , QuakSH , LimFS , GohP , TeohYL , DattaSK , et al. Immunogenicity, reactogenicity and safety of a diphtheria-tetanus-acellular pertussis-inactivated polio and Haemophilus influenzae type b combination vaccine in a placebo-controlled rotavirus vaccine study. Annals of the Academy of Medicine, Singapore2008;37(7):546-53. VesikariT . RIX4414: a new attenuated human rotavirus vaccine. In: 23rd Annual Meeting of European Society for Paediatric Infectious Diseases (ESPID); 2005 May 18-20; Valencia, Spain. 2005. [Not available for review]">RIX Phua 2005‐SGP</a>; <a href="./references#CD008521-bbs2-0024" title="LauYL , NelsonEA , PoonKH , ChanPK , ChiuS , SungR , et al. Efficacy, safety and immunogenicity of a human rotavirus vaccine (RIX4414) in Hong Kong children up to three years of age: a randomized, controlled trial. Vaccine2013;31(18):2253-9. NCT00197210. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy and safety of two doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine in healthy infants. clinicaltrials.gov/show/NCT00197210 (first received 20 September 2005). NCT00329745. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy and safety of two doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine in healthy infants. clinicaltrials.gov/show/NCT00329745 (first received 25 May 2006). PhuaKB , LimFS , LauYL , NelsonEA , HuangLM , QuakSH , et al. Rotavirus vaccine RIX4414 efficacy sustained during the third year of life: a randomized clinical trial in an Asian population. Vaccine2012;30(30):4552-7. PhuaKB , LimFS , LauYL , NelsonEA , HuangLM , QuakSH , et al. Safety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: randomised, double-blind, controlled study. Vaccine2009;27(43):5936-41. PhuaKB , LimFS , QuakSH , LeeBW , TeohYL , SuryakiranPV , et al. Efficacy, immunogenicity and safety of a human rotavirus vaccine RIX4414 in Singaporean infants. Annals of the Academy of Medicine, Singapore2016;45(2):44-50. ">RIX Phua 2009‐AS</a>;<a href="./references#CD008521-bbs2-0033" title="De VosB , VesikariT , LinharesAC , SalinasB , Perez-SchaelI , Ruiz-PalaciosGM , et al. A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis. Pediatric Infectious Disease Journal2004;23(10 Suppl):179-82. GlaxoSmithKline[444563-004]. A phase IIb, double-blind, randomized, placebo-controlled study to assess the efficacy, immunogenicity, reactogenicity and safety of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants approximately 2 months of age and previously uninfected with HRV [Results for the first efficacy period (starting from 2 weeks after dose 2 until the end of the first RV season following vaccination)]. www.gsk-studyregister.com/study/6782 (accessed 12 December 2018). GlaxoSmithKline[444563-004-Annex]. A phase IIb, double-blind, randomized, placebo-controlled study to assess the efficacy, immunogenicity, reactogenicity and safety of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants approximately 2 months of age and previously uninfected with HRV [This summary presents results for the second efficacy period (from the end of the first rotavirus season post-vaccination until the end of the second rotavirus season) and for the two consecutive rotavirus seasons]. www.gsk-studyregister.com/study/6782 (accessed 12 December 2018). NCT00425737. A study to assess the efficacy, immunogenicity and safety of two doses of oral live attenuated human rotavirus (HRV) vaccine (Rotarix) in healthy infants. clinicaltrials.gov/show/NCT00425737 (first received 23 January 2007). VesikariT , KarvonenA , EspoM , KorhonenT , DelemA , De VosB . Efficacy evaluation of an oral human rotavirus (HRV) vaccine in previously uninfected Finnish infants. In: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 September 27-30; San Diego, California. 2002. [Not available for review]VesikariT , KarvonenA , PuustinenL , ZengSQ , SzakalED , DelemA , et al. Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants. Pediatric Infectious Disease Journal2004;23(10):937-43. ">RIX Vesikari 2004b‐FIN</a>; <a href="./references#CD008521-bbs2-0034" title="VesikariT , et al. Human rotavirus vaccine Rotarix is highly efficacious in Europe. In: 24th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); 2006 June 15-18; Basel, Switzerland. 2006. [Not available for review]VesikariT , et al. Rotarix, an oral human Rotavirus vaccine, is highly immunogenic in healthy infants from 6 European countries. In: 24th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); 2006 June 15-18; Basel, Switzerland. 2006. [Not available for review]GlaxoSmithKline[102247-036]. A phase IIIb, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants in co-administration with specific childhood vaccinations [This summary presents results from the first efficacy period] [102247-036]. www.gsk-studyregister.com/study/2669 (accessed 12 December 2018). GlaxoSmithKline[102247-036-Annex]. A phase IIIb, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants in co-administration with specific childhood vaccinations [This summary presents results for the second and combined efficacy periods]. www.gsk-studyregister.com/study/2669 (accessed 12 December 2018). GlaxoSmithKline[102247-036-Yr3]. A phase IIIb, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants in co-administration with specific childhood vaccinations [A phase IIIb open study to assess the long-term efficacy and safety of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine approximately three years after vaccination in healthy infants aged 6-12 weeks at the time of first vaccination in the Rota-036 study (eTrack No.102247) in Finland]. www.gsk-studyregister.com/study/2669 (accessed 12 December 2018). NCT00140686. A multi-country &amp; multi-center study to assess the efficacy, safety &amp; immunogenicity of 2 doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants in co-administration with specific childhood vaccines. clinicaltrials.gov/ct2/show/record/NCT00140686 (first received 1 September 2005). [Trial registration document]NCT00420316. To assess long-term efficacy &amp; safety of subjects approximately 3 years after priming with 2 doses of GlaxoSmithKline (GSK) Biologicals' oral live attenuated human rotavirus (HRV) vaccine (Rotarix) in the primary vaccination study (102247). clinicaltrials.gov/show/NCT00420316 (first received 11 January 2007). SchusterV , OttoW , CohenR . RotarixTM an oral human Rotavirus vaccine, is highly immunogenic when co-administered with a Streptococcus pneumoniae conjugate vaccine (PrevenarTM) in healthy infants from France and Germany. In: 24th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); 2006 June 15-18; Basel, Switzerland. 2006. [Not available for review]TejedorJC , Diez-DelegadoJ , AristeguiJ . Rotarix (RIX4414), an oral Human Rotavirus vaccine, is highly immunogenic when co-administered with a Neisseria meningitides Serogroup C vaccine (MeningitecTM) in healthy infants from Spain. In: 24th Annual Meeting Meeting of the European Society for Paediatric Infectious Diseases (ESPID); 2006 June 15-18; Basel, Switzerland. 2006. [Not available for review]VesikariT ,  KarvonenA ,  PrymulaR ,  SchusterV ,  TejedorJC ,  ThollotF ,  et al. Immunogenicity and safety of the human rotavirus vaccine Rotarix co-administered with routine infant vaccines following the vaccination schedules in Europe. Vaccine2010;28(32):5272-9. VesikariT , KarvonenA , FerranteSA , KuterBJ , CiarletM . Sustained efficacy of the pentavalent rotavirus vaccine, RV5, up to 3.1 years following the last dose of vaccine. Pediatric Infectious Disease Journal2010;29(10):957-63. VesikariT , KarvonenA , PrymulaR , SchusterV , TejedorJC , CohenR , et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet2007;370(9601):1757-63. VesikariT , PrymulaR , SchusterV , TejedorJC , CohenR , BouckenoogheA , et al. Efficacy and immunogenicity of live-attenuated human rotavirus vaccine in breast-fed and formula-fed European infants. Pediatric Infectious Disease Journal2012;31(5):509-13. VesikariT , PrymulaR , SchusterV . Early protection against Rotavirus, Rotarix, experience in an European setting. In: 12th International Congress for Infectious Diseases; 2006 June 15-18; Lisbon, Portugal. 2006. [Not available for review]VesikariT , PrymulaR , SchusterV . Rotarix (RIX4414), an oral human rotavirus vaccine, is highly immunogenic when co-administered with diphteria-tetanus-pertussis (DTPA)-combined vaccines in healthy infants from Europe. In: 24th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); 2006 June 15-18; Basel, Switzerland. 2006. [Not available for review]">RIX Vesikari 2007a‐EU</a>; <a href="./references#CD008521-bbs2-0035" title="VesikariT , et al. Immunogenicity of liquid formulation of the oral live attenuated human rotavirus vaccine (Rotarix™) [poster]. Sociedad Latinoamericana de Infectología Pediátrica (SLIPE). San Jose, Costa Rica 8-11 May 2007. [Not available for review]GlaxoSmithKline[104480-048]. A phase II, double-blind, randomized, placebo controlled study to compare the immunogenicity, reactogenicity and safety of two different formulations of GlaxoSmithKline (GSK) Biologicals’ live attenuated human rotavirus (HRV) vaccine given as a two-dose primary vaccination in healthy infants previously uninfected with HRV. www.gsk-studyregister.com/study/2783 (accessed 12 December 2018). NCT00137930. Compare the immunogenicity, reactogenicity &amp; safety of 2 different formulations of GSK Biologicals’ live attenuated human rotavirus (HRV) vaccine given as a two-dose primary vaccination in healthy infants previously uninfected with HRV. clinicaltrials.gov/ct2/show/record/NCT00137930 (first received 30 August 2005). VesikariT , KarvonenA , BouckenoogheA , SuryakiranPV , SmolenovI , HanHH . Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 oral suspension (liquid formulation) in Finnish infants. Vaccine2011;29(11):2079-84. ">RIX Vesikari 2011‐FIN</a>), in medium‐mortality countries (<a href="./references#CD008521-bbs2-0026" title="Costa ClemensSA , et al. Operational organization of a large scale phase III clinical trial of rotavirus vaccine in multiple sites and countries in Latin America. In: International Congress of Pediatrics (ICP); 2004 August 15-20; Cancun, Mexico. 2004. [Not available for review]De VosB , et al. Rotarix™: an effective way to prevent rotavirus diarrhoea and vomiting. In: 9th Congress of the Asian Pan Pacific Society of Paediatric Gastroenterology, Hepatology and Nutrition &amp; 27th Annual Congress of the Malaysian Paediatric Association; 2005 June 16-19; Kuala Lumpur, Malaysia. 2005. [Not available for review]BaayM , BollaertsK , StruchinerC , VerstraetenT . Background rates of disease in Latin American children from a rotavirus vaccine study. Human Vaccines and Immunotherapeutics2017;13(8):1916-20. GlaxoSmithKline[444563-023-pt1]. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants (efficacy data from visit 1 to visit 4). www.gsk-studyregister.com/study/6791 (accessed 12 December 2018). GlaxoSmithKline[444563-023-pt2]. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants (2nd year efficacy from visit 4 to visit 6). www.gsk-studyregister.com/study/6791 (accessed 12 December 2018). GlaxoSmithKline[444563-023-pt3]. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants (safety for the period between visit 1 and visit 3). www.gsk-studyregister.com/study/6791 (accessed 12 December 2018). JustinoMC , AraújoEC , Van DoornLJ , OliveiraCS , GabbayYB , MascarenhasJD , et al. Oral live attenuated human rotavirus vaccine (Rotarix) offers sustained high protection against severe G9P[8] rotavirus gastroenteritis during the first two years of life in Brazilian children. Memorias do Instituto Oswaldo Cruz2012;107(7):846-53. LinharesAC , VelazquezFR , Perez-SchaelI , Saez-LlorensX , AbateH , EspinozaF , et al. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet2008;371(9619):1181-9. LopezP , LinharesA , Pérez-SchaelI , Ruiz-PalaciosG , Costa ClemensS , SanchezN . Early protection against severe rotavirus gastroenteritis - RIX4414 experience in Latin America. In: 24th Annual Meeting of European Society for Paediatric Infectious Diseases (ESPID); 2006 May 03-05; Basel, Switzerland. 2006. [Not available for review]MaciasM , LopezP , VelazquezFR , VergaraRF , SalmeronJ , TavaresJL . The rotavirus vaccine RIX4414 (Rotarix) is not associated with intussusception in one year old infants. In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2005 December 16-19; Washington DC, USA. 2005. [Not available for review]NCT00139347. A multi-country &amp; multi-center study to assess the efficacy, immunogenicity &amp; safety of two doses of GSK Biologicals' oral live attenuated HRV vaccine given concomitantly with routine EPI vaccinations including OPV in healthy infants. clinicaltrials.gov/ct2/show/NCT00139347 (first received 31 August 2005). [Trial registration document (no data for review)]NCT00140673. Placebo-controlled, multi-country &amp; multi-center study to assess the efficacy, safety &amp; immunogenicity of 2 doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants. clinicaltrials.gov/ct2/show/NCT00140673 (first received 1 September 2005). [Trial registration document (no data for review)]Perez-SchaelI , LinharesAC , VesikariT . Two doses of the human attenuated rotavirus vaccine RIX4414 (Rotarix) show heterotypic protection in Latin America and Europe. In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2005 December 16-19; Washington DC, USA. 2005. [Not available for review]PikeM . New rotavirus vaccine is effective and appears to have no increased risk of intussusception. Clinical Research Abstracts For Pediatricians2006;149(1):143. Ruiz-PalaciosG , AranzaC , VelazquezFR , RichardsonV , NandiE , MaciasM . Two doses of the human-attenuated monovalent G1P[8] rotavirus vaccine, Rotarix show high efficacy in Mexican children against severe rotavirus gastroenteritis and severe overall gastroenteritis. In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2005 December 16-19; Washington DC, USA. 2005. [Not available for review]Ruiz-PalaciosGM , Perez-SchaelI , VelazquezFR , AbateH , BreuerT , ClemensSC , et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. New England Journal of Medicine2006;354(1):11-22. VelázquezFR , AbatH , Costa ClemensSA , EspinozaF , GillardP , LinharesAC , et al. The human monovalent G1P[8] rotavirus vaccine, Rotarix is highly efficacious and provides crossprotection against G1 and non-G1 serotypes. In: 23rd Annual meeting of European Society for Paediatric Infectious Diseases (ESPID); 2005 May 18-20; Valencia, Spain. 2005. VelázquezRF , AbateH , BouckenoogheA . RIX4414, the human G1P[8] rotavirus vaccine is highly efficacious during the second year of life. In: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2006 September 27-30; San Francisco, USA. 2006. [Not available for review]VesikariT , O’RyanM , AbateH , Costa ClemensSA , EspinozaF , GillardP . Overcoming the safety hurdle: the rotavirus vaccine RIX4414 is not associated with intussusception. In: 23rd Annual Meeting of European Society for Paediatric Infectious Diseases (ESPID); 2005 May 18-20; Valencia, Spain. 2005. [Not available for review]">RIX Ruiz‐Palac 06‐LA/EU</a>; <a href="./references#CD008521-bbs2-0027" title="Ruiz-PalaciosG , GuerreroL , LinharesAC , et al. Efficacy of an oral human rotavirus (HRV) vaccine in preventing diarrhoea due to G1 and non-G1 rotavirus [Presentation]. In: 3rd World Congress of Pediatric Infectious Diseases; 2002 November 19-23; Santiago, Chile. 2002. [Not available for review]Ruiz-PalaciosG , GuerreroML , LinharesAC , et al. Two-year efficacy of GlaxoSmithKline Biologicals' live attenuated rotavirus vaccine in Latin American children [poster]. In: 24th International Congress of Pediatrics; 2004 August 15-20; Cancun, Mexico. 2004. [Not available for review]SalinasB , Perez-SchaelI , Ruiz-PalaciosG , et al. Early protection by GlaxoSmithKline Biologicals' live attenuated rotavirus vaccine in Latin American children [poster]. In: 24th International Congress of Pediatrics; 2004 August 15-20; Cancun, Mexico. 2004. [Not available for review]SalinasB , TomatMA , YarzabalJP , et al. Efficacy of the rotavirus vaccine (RIX4414) among infants in Carabobo State, Venezuela [poster]. In: Asocación Venezolana para el Avance de la Cienca (AsoVAC); 2004; Venezuela. 2004. [Not available for review]AraujoEC , ClemensSA , OliveiraCS , JustinoMC , RubioP , GabbayYB , et al. Safety, immunogenicity, and protective efficacy of two doses of RIX4414 live attenuated human rotavirus vaccine in healthy infants. Jornal de Pediatria2007;83(3):217-24. De VosB , HardtK , LinharesAC , Ruiz-PalaciosG , GuerreroL , SalinasB . Efficacy of two doses of a human monovalent rotavirus vaccine, Rotarix™ in preventing gastro-enteritis due to G1 and Non-G1 rotavirus in Brazil, Mexico and Venezuela [presentation]. In: 8th International Symposium on Double-Stranded RNA Viruses; 2003 September 13-18; Lucca, Italy. 2003. [Not available for review]De VosB , VesikariT , LinharesAC , SalinasB , Perez-SchaelI , Ruiz-PalaciosGM , et al. A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis. Pediatric Infectious Disease Journal2004;23(10 Suppl):179-82. GlaxoSmithKline[444563-006]. A phase IIb, double-blind, randomized, placebo-controlled study to assess the efficacy, immunogenicity, reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals' live attenuated human rotavirus (HRV) vaccine at different virus concentrations (104.7, 105.2 and 105.8 foci forming units [ffu]) in healthy infants (approximately 2 months of age at first dose) following a 0, 2 month schedule and previously uninfected with HRV, when administered concurrently with DTPw-HBV and Hib vaccines. www.gsk-studyregister.com/study/6784 (accessed 12 December 2018). GlaxoSmithKline[444563-006-Annex]. A phase IIb, double-blind, randomized, placebo-controlled study to assess the efficacy, immunogenicity, reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals' live attenuated human rotavirus (HRV) vaccine at different virus concentrations (104.7, 105.2 and 105.8 foci forming units [ffu]) in healthy infants (approximately 2 months of age at first dose) following a 0, 2 month schedule and previously uninfected with HRV, when administered concurrently with DTPw-HBV and Hib vaccines [This summary presents results for the second and combined efficacy periods and results from the 3-Dose subset. Results from the first efficacy period are presented in 444563/006 (Rota-006) summary]. www.gsk-studyregister.com/study/6784 (accessed 12 December 2018). LinharesA , Perez-SchaelI , Ruiz-PalaciosM , PernambucoE , JacquetJ , De VosB . Immunogenicity and reactogenicity of an oral human rotavirus (HRV) vaccine in Latin American infants [poster]. In: 3rd World Congress of Pediatric Infectious Diseases; 2002 November 19-23; Santiago, Chile. 2002. [Not available for review]LinharesAC , Ruiz-PalaciosGM , GuerreroML , SalinasB , Perez-SchaelI , ClemensSA , et al. A short report on highlights of world-wide development of RIX4414: a Latin American experience. Vaccine2006;24(18):3784-5. LinharesAC , VerstraetenT , Wolleswinkel-Van den BoschJ , ClemensR , BreuerT . Rotavirus serotype G9 is associated with more-severe disease in Latin America. Clinical Infectious Diseases2006;43(3):312-4. [Not available for review]NCT00385320. To assess the efficacy, immuno &amp; safety of 2 doses of GSK HRV vaccine at different virus concentrations in healthy infants aged 2 months &amp; previously uninfected with HRV, concurrently given with DTPw-HBV, Hib. clinicaltrials.gov/show/NCT00385320 (first received 9 October 2006). Perez-SchaelI , SalinasB , LinharesA , GuerreroM , Ruiz-PalaciosG , ClemensS , et al. Protective efficacy of an oral human rotavirus (HRV) vaccine in Latin American infants [poster]. In: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy ( ICAAC); San Diego, 27-30 September 2002. 2002:18, LB-23. [Not available for review]Perez-SchaelI , SalinasB , TomatM , LinharesAC , GuerreroML , Ruiz-PalaciosGM , et al. Efficacy of the human rotavirus vaccine RIX4414 in malnourished children. Journal of Infectious Diseases2007;196(4):537-40. Ruiz-PalaciosGM , GuerreroML , Bautista-MarquezA , Ortega-GallegosH , Tuz-DzibF , Reyes-GonzalezL , et al. Dose response and efficacy of a live, attenuated human rotavirus vaccine in Mexican infants. Pediatrics2007;120(2):e253-61. [Not available for review]Ruiz-PalaciosGM . Impact of maternal antibodies on the immune response to an oral human rotavirus (HRV) vaccine in Mexican infants [presentation]. In: 3rd World Congress of Pediatric Infectious Diseases; 2002 November 19-23; Santiago, Chile. 2002. [Not available for review]SalinasB , Perez SchaelI , LinharesAC , Ruiz PalaciosGM , GuerreroML , YarzabalJP , et al. Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: a randomized, placebo-controlled trial in Latin American infants. Pediatric Infectious Disease Journal2005;24(9):807-16. ">RIX Salinas 2005‐LA</a>; <a href="./references#CD008521-bbs2-0031" title="GlaxoSmithKline[444563-024]. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, immunogenicity and safety of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations including OPV in healthy infants. www.gsk-studyregister.com/study/6792 (accessed 12 December 2018). Gonzalez AyalaS , RiveraL , Rivera-MedinaDM , LopezP , ValenciaA , De LeónT , et al. Co-administration with rotavirus vaccine rix4414 (Rotarix™) does not interfere with the immunogenicity of oral polio vaccine (OPV) [poster]. In: World Society for Pediatric Infectious Diseases (WSPID); 2007 November 15-18; Bangkok, Thailand. 2007. [Not available for review]TregnaghiMW , AbateHJ , ValenciaA , LopezP , Da SilveiraTR , RiveraL , et al. Human rotavirus vaccine is highly efficacious when coadministered with routine expanded program of immunization vaccines including oral poliovirus vaccine in Latin America. Pediatric Infectious Disease Journal2011;30(6):e103-e8. ">RIX Tregnaghi 2011‐LA</a>), and in high‐mortality countries (<a href="./references#CD008521-bbs2-0017" title="CunliffeNA , WitteD , NgwiraBM , ToddS , BostockNJ , TurnerAM , et al. Efficacy of human rotavirus vaccine against severe gastroenteritis in Malawian children in the first two years of life: a randomized, double-blind, placebo controlled trial. Vaccine2012;30(Suppl 1):A36-43. MadhiSA , CunliffeNA , SteeleD , WitteD , KirstenM , LouwC , et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. New England Journal of Medicine2010;362(4):289-98. MadhiSA , KirstenM , LouwC , BosP , AspinallS , BouckenoogheA , et al. Efficacy and immunogenicity of two or three dose rotavirus-vaccine regimen in South African children over two consecutive rotavirus seasons: a randomized, double-blind, placebo-controlled trial. Vaccine2012;30(Suppl 1):A44-51. NCT00241644. Multi-center study to assess the efficacy, safety and immunogenicity of 2 or 3 doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations in healthy infants. clinicaltrials.gov/show/NCT00241644 (first received 19 October 2005). NCT00598468. Multi-center study to assess efficacy, safety &amp; immunogenicity of 2 or 3 doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations in healthy infants. clinicaltrials.gov/show/NCT00598468 (first received 19 October 2005). SteeleAD , NeuzilKM , CunliffeNA , MadhiSA , BosP , NgwiraB , et al. Human rotavirus vaccine Rotarix provides protection against diverse circulating rotavirus strains in African infants: a randomized controlled trial. BMC Infectious Diseases2012;12:213. ">RIX Madhi 2010‐AF</a>; <a href="./references#CD008521-bbs2-0025" title="EUCTR2015-001542-29. Immunization of infants 6-14 weeks of age, with GlaxoSmithKline Biologicals Rotavirus vaccine to explore the existence of transmission of rotavirus vaccine strain between twins in a family. clinicaltrialsregister.eu/ctr-search/trial/2015-001542-29/results (first received 22 June 2015). NCT00396630. A Phase IIIb, randomized, double-blind, placebo-controlled study to explore the existence of horizontal transmission of the RIX4414 vaccine strain between twins within a family. clinicaltrials.gov/show/NCT00396630 (first received 7 November 2006). RiveraL ,  PeñaLM ,  StainierI ,  GillardP ,  CheuvartB ,  SmolenovI , et al. Horizontal transmission of a human rotavirus vaccine strain - a randomized, placebo-controlled study in twins. Vaccine2011;29(51):9508-13. ">RIX Rivera 2011‐DOM</a>; <a href="./references#CD008521-bbs2-0028" title="GlaxoSmithKline[444563-014]. A phase II, double-blind before the 2002 rotavirus season and single blind with respect to OPV after, randomised, placebo-controlled study of the safety, reactogenicity and immunogenicity of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine (RIX4414 at 105 ffu) co-administered with either oral polio vaccine (OPV) or inactivated polio vaccine (IPV) in healthy infants (approximately 5-10 weeks old) in South Africa. www.gsk-studyregister.com/study/6787 (accessed 12 December 2018). ISRCTN86632774. A phase II, double blind randomised, placebo controlled study to assess the safety reactogenicity and immunogenicity of three doses of GSK Biologicals (South Africa). controlled-trials.com/ISRCTN86632774 (first received 25 November 2005). NCT00346892. Reactogenicity &amp; immunogenicity study of two doses of GSK Biologicals’ oral live attenuated HRV vaccine co-administered with either OPV or IPV in healthy infants (approximately 5-10 weeks old) in South Africa. clinicaltrials.gov/show/NCT00346892 (first received 30 June 2006). SteeleAD ,  De VosB ,  TumboJ ,  ReyndersJ ,  ScholtzF ,  BosP ,  et al. Co-administration study in South African infants of a live-attenuated oral human rotavirus vaccine (RIX4414) and poliovirus vaccines. Vaccine2010 ;28(39):6542-8. SteeleAD , TumboJ , ArmahG , ReyndersJ , ScholtzF , BosP , et al. Immunogenicity and reactogenicity of a new live attenuated oral rotavirus vaccine (RIX4414) when administered concurrently with poliovirus vaccines in African infants. In: 24th International Congress of Pediatrics; 2004 August 15-20; Cancun, Mexico. 2004. [Not available for review]SteeleAD , TumboJM , ArmahGE , ReyndersJ , ScholtzF , BosP , et al. Concomitant administration of a live-attenuated oral rotavirus vaccine (RIX4414) with poliovirus vaccines in African infants. In: 23rd Annual Meeting of the European Society for Pediatric Infectious Diseases - ESPID; 2005 May 18-20; Valencia, Spain. 2005. [Not available for review]">RIX Steele 2008‐ZAF</a>; <a href="./references#CD008521-bbs2-0030" title="GlaxoSmithKline[444563-013]. A phase II, double-blind before the 2002 rotavirus season and single blind with respect to OPV after, randomised, placebo-controlled study of the safety, reactogenicity and immunogenicity of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine (RIX4414 at 105 ffu) co-administered with either oral polio vaccine (OPV) or inactivated polio vaccine (IPV) in healthy infants (approximately 5-10 weeks old) in South Africa. www.gsk-studyregister.com/study/6786 (accessed 12 December 2018). ISRCTN37373664. A double blind, randomised placebo controlled study of the safety, reactogenicity and immunogenicity of two doses of orally administered human rotavirus vaccine (RIX4414) in healthy infants in South Africa. controlled-trials.com/ISRCTN37373664 (first received 25 November 2005). NCT00383903. A study of the safety, reactogenicity and immunogenicity of 2 or 3 doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants (approximately 5-10 weeks old) in South Africa. clinicaltrials.gov/show/NCT00383903 (first received 3 October 2006). SteeleAD ,  ReyndersJ ,  ScholtzF ,  BosP ,  De BeerMC ,  TumboJ ,  et al. Comparison of 2 different regimens for reactogenicity, safety, and immunogenicity of the live attenuated oral rotavirus vaccine RIX4414 coadministered with oral polio vaccine in South African infants. Journal of Infectious Diseases2010;202(Suppl):S93-100. ">RIX Steele 2010b‐ZAF</a>; <a href="./references#CD008521-bbs2-0038" title="ZamanK , SackDA , NeuzilKM , YunusM , MoultonLH , SugimotoJD , et al. Effectiveness of a live oral human rotavirus vaccine after programmatic introduction in Bangladesh: a cluster-randomized trial. PLOS Medicine2017;14(4):e1002282. ">RIX Zaman 2017‐BGD</a>); see <a href="./references#CD008521-fig-0014" title="">Analysis 1.10</a>. </p> <section id="CD008521-sec-0119"> <p><b>Low‐mortality countries</b></p> <p>Eleven cases of intussusception were reported in a total of 12,399 children in the Rotarix arm compared with six cases of intussusception in 8374 children of the placebo arm. Pooled results showed no increased risk for intussusception in children receiving Rotarix when compared to placebo (RR 1.42, 95% CI 0.52 to 3.87; 20,773 participants, 10 trials). </p> </section> <section id="CD008521-sec-0120"> <p><b>Medium‐mortality countries</b></p> <p>Twenty cases of intussusception were reported in a total of 39,519 children in the Rotarix arm compared with 23 cases of intussusception in 36,021 children of the placebo arm. Pooled results showed no increased risk for intussusception in children receiving Rotarix when compared to placebo (RR 0.72, 95% CI 0.39 to 1.32; 75,540 participants, 6 trials). </p> </section> <section id="CD008521-sec-0121"> <p><b>High‐mortality countries</b></p> <p>One case of intussusception was reported in a total of 6384 children in the Rotarix arm compared with no cases of intussusception in 4276 children in the placebo or no‐intervention arm. Pooled results showed no increased risk for intussusception in children receiving Rotarix when compared to placebo (RR 1.49, 95% CI 0.06 to 36.63; 10,660 participants, 5 trials).  </p> </section> </section> </section> <section id="CD008521-sec-0122"> <h5 class="title">1.2. Secondary outcomes</h5> <section id="CD008521-sec-0123"> <h6 class="title">1.2.1 Serious adverse events: Kawasaki disease</h6> <p>Three trials reported four cases of Kawasaki disease among 7701 children allocated to Rotarix compared to no cases in 5416 children allocated to placebo (<a href="./references#CD008521-bbs2-0023" title="EmmanuelB , et al. Immunogenicity of an acellular pertussis combination vaccine co-administered with a novel rotavirus vaccine in Singaporean infants. Asian Congress on Pediatric Infectious Diseases (ACPID); 2-4 September 2004; Kota Kinabula, Malaysia2004. [Not available for review]PhuaKB , et al. Immunogenicity and reactogenicity of two doses of an oral human rotavirus (HRV) vaccine at different concentrations in healthy infants from Singapore. In: 11th Asia Pacific Congress of Pediatrics and the 3rd Asia Pacific Congress of Pediatric Nursing; 2003; Bangkok, Thailand. 2003. [Not available for review]PhuaKB , et al. Intussusception in children: a seven-year experience in Singapore. In: 24th International Congress of Pediatrics (ICP); 2004 August 15-20; Cancun, Mexico. 2004. [Not available for review]VesikariT , et al. High efficacy of two doses of Rotarix™ (RIX4414) against rotavirus disease in Europe, Latin-America and Asia. In: Asian Congress on Pediatric Infectious Diseases (ACPID); 2006 March 07-10; Cebu, Philippines. 2006. [Not available for review]De VosB , GillardP , CheuvartB . RIX4414 vaccine efficacy against rotavirus gastroenteritis due to G2P[4] strain. In: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2006 September 27-30; San Francisco, USA. 2006. [Not available for review]De VosB , VesikariT , LinharesAC , SalinasB , Perez-SchaelI , Ruiz-PalaciosGM , et al. A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis. Pediatric Infectious Disease Journal2004;23(10 Suppl):179-82. [No data for review]EmmanuelS , PhuaKB , GohP , QuakSH , DattaSK , HanHH , et al. Immunogenicity of an acellular pertussis combination vaccine co-administered with a novel rotavirus vaccine in Singaporean infants. In: 23rd Annual Meeting of European Society for Paediatric Infectious Diseases (ESPID); 2005 May 18-20; Valencia, Spain. 2005. [Not available for review]GlaxoSmithKline[444563-007]. A phase IIb, double-blind, randomized, placebo-controlled study to assess the efficacy, immunogenicity, reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine at different viral concentrations (104.7, 105.2 and 106.1 foci forming units (ffu)) in healthy infants previously uninfected with human rotavirus and approximately three months of age, when administered concurrently with DTPa-IPV/Hib and HBV vaccines. www.gsk-studyregister.com/study/6785 (accessed 12 December 2018). NCT00429481. A study to assess the efficacy, immunogenicity and safety of 2 doses of oral live attenuated human rotavirus vaccine (Rotarix) at different viral concentrations in healthy infants. clinicaltrials.gov/ct2/show/record/NCT00429481 (first received 31 January 2007). PhuaKB , EmmanuelSC , GohP , QuakSH , LeeBW , HanHH , et al. A rotavirus vaccine for prophylaxis of infant rotavirus gastroenteritis: the Asian experience. Annals of the Academy of Medicine, Singapore2006;35(1):38-44. PhuaKB , QuakSH , EmmanuelS , GohPS , HanHH , HardtK , et al. A short report on highlights of worldwide development of RIX4414: a Singaporean experience. Vaccine2006;24(18):3782-3. PhuaKB , QuakSH , EmmanuelS , GohPSC , HanHH , HardtK , et al. Highlights of world-wide development: a Singapore experience. In: 3rd International Conference on Vaccines for Enteric Diseases (VED) 28-30 April 2004; Montego Bay, Jamaica. 2004. [Not available for review]PhuaKB , QuakSH , LeeBW , EmmanuelSC , GohP , HanHH , et al. Evaluation of RIX4414, a live, attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled phase 2 trial involving 2464 Singaporean infants. Journal of Infectious Diseases2005;192(Suppl 1):6-16. PhuaKB , QuakSH , LimFS , GohP , TeohYL , DattaSK , et al. Immunogenicity, reactogenicity and safety of a diphtheria-tetanus-acellular pertussis-inactivated polio and Haemophilus influenzae type b combination vaccine in a placebo-controlled rotavirus vaccine study. Annals of the Academy of Medicine, Singapore2008;37(7):546-53. VesikariT . RIX4414: a new attenuated human rotavirus vaccine. In: 23rd Annual Meeting of European Society for Paediatric Infectious Diseases (ESPID); 2005 May 18-20; Valencia, Spain. 2005. [Not available for review]">RIX Phua 2005‐SGP</a>; <a href="./references#CD008521-bbs2-0024" title="LauYL , NelsonEA , PoonKH , ChanPK , ChiuS , SungR , et al. Efficacy, safety and immunogenicity of a human rotavirus vaccine (RIX4414) in Hong Kong children up to three years of age: a randomized, controlled trial. Vaccine2013;31(18):2253-9. NCT00197210. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy and safety of two doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine in healthy infants. clinicaltrials.gov/show/NCT00197210 (first received 20 September 2005). NCT00329745. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy and safety of two doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine in healthy infants. clinicaltrials.gov/show/NCT00329745 (first received 25 May 2006). PhuaKB , LimFS , LauYL , NelsonEA , HuangLM , QuakSH , et al. Rotavirus vaccine RIX4414 efficacy sustained during the third year of life: a randomized clinical trial in an Asian population. Vaccine2012;30(30):4552-7. PhuaKB , LimFS , LauYL , NelsonEA , HuangLM , QuakSH , et al. Safety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: randomised, double-blind, controlled study. Vaccine2009;27(43):5936-41. PhuaKB , LimFS , QuakSH , LeeBW , TeohYL , SuryakiranPV , et al. Efficacy, immunogenicity and safety of a human rotavirus vaccine RIX4414 in Singaporean infants. Annals of the Academy of Medicine, Singapore2016;45(2):44-50. ">RIX Phua 2009‐AS</a>; <a href="./references#CD008521-bbs2-0027" title="Ruiz-PalaciosG , GuerreroL , LinharesAC , et al. Efficacy of an oral human rotavirus (HRV) vaccine in preventing diarrhoea due to G1 and non-G1 rotavirus [Presentation]. In: 3rd World Congress of Pediatric Infectious Diseases; 2002 November 19-23; Santiago, Chile. 2002. [Not available for review]Ruiz-PalaciosG , GuerreroML , LinharesAC , et al. Two-year efficacy of GlaxoSmithKline Biologicals' live attenuated rotavirus vaccine in Latin American children [poster]. In: 24th International Congress of Pediatrics; 2004 August 15-20; Cancun, Mexico. 2004. [Not available for review]SalinasB , Perez-SchaelI , Ruiz-PalaciosG , et al. Early protection by GlaxoSmithKline Biologicals' live attenuated rotavirus vaccine in Latin American children [poster]. In: 24th International Congress of Pediatrics; 2004 August 15-20; Cancun, Mexico. 2004. [Not available for review]SalinasB , TomatMA , YarzabalJP , et al. Efficacy of the rotavirus vaccine (RIX4414) among infants in Carabobo State, Venezuela [poster]. In: Asocación Venezolana para el Avance de la Cienca (AsoVAC); 2004; Venezuela. 2004. [Not available for review]AraujoEC , ClemensSA , OliveiraCS , JustinoMC , RubioP , GabbayYB , et al. Safety, immunogenicity, and protective efficacy of two doses of RIX4414 live attenuated human rotavirus vaccine in healthy infants. Jornal de Pediatria2007;83(3):217-24. De VosB , HardtK , LinharesAC , Ruiz-PalaciosG , GuerreroL , SalinasB . Efficacy of two doses of a human monovalent rotavirus vaccine, Rotarix™ in preventing gastro-enteritis due to G1 and Non-G1 rotavirus in Brazil, Mexico and Venezuela [presentation]. In: 8th International Symposium on Double-Stranded RNA Viruses; 2003 September 13-18; Lucca, Italy. 2003. [Not available for review]De VosB , VesikariT , LinharesAC , SalinasB , Perez-SchaelI , Ruiz-PalaciosGM , et al. A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis. Pediatric Infectious Disease Journal2004;23(10 Suppl):179-82. GlaxoSmithKline[444563-006]. A phase IIb, double-blind, randomized, placebo-controlled study to assess the efficacy, immunogenicity, reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals' live attenuated human rotavirus (HRV) vaccine at different virus concentrations (104.7, 105.2 and 105.8 foci forming units [ffu]) in healthy infants (approximately 2 months of age at first dose) following a 0, 2 month schedule and previously uninfected with HRV, when administered concurrently with DTPw-HBV and Hib vaccines. www.gsk-studyregister.com/study/6784 (accessed 12 December 2018). GlaxoSmithKline[444563-006-Annex]. A phase IIb, double-blind, randomized, placebo-controlled study to assess the efficacy, immunogenicity, reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals' live attenuated human rotavirus (HRV) vaccine at different virus concentrations (104.7, 105.2 and 105.8 foci forming units [ffu]) in healthy infants (approximately 2 months of age at first dose) following a 0, 2 month schedule and previously uninfected with HRV, when administered concurrently with DTPw-HBV and Hib vaccines [This summary presents results for the second and combined efficacy periods and results from the 3-Dose subset. Results from the first efficacy period are presented in 444563/006 (Rota-006) summary]. www.gsk-studyregister.com/study/6784 (accessed 12 December 2018). LinharesA , Perez-SchaelI , Ruiz-PalaciosM , PernambucoE , JacquetJ , De VosB . Immunogenicity and reactogenicity of an oral human rotavirus (HRV) vaccine in Latin American infants [poster]. In: 3rd World Congress of Pediatric Infectious Diseases; 2002 November 19-23; Santiago, Chile. 2002. [Not available for review]LinharesAC , Ruiz-PalaciosGM , GuerreroML , SalinasB , Perez-SchaelI , ClemensSA , et al. A short report on highlights of world-wide development of RIX4414: a Latin American experience. Vaccine2006;24(18):3784-5. LinharesAC , VerstraetenT , Wolleswinkel-Van den BoschJ , ClemensR , BreuerT . Rotavirus serotype G9 is associated with more-severe disease in Latin America. Clinical Infectious Diseases2006;43(3):312-4. [Not available for review]NCT00385320. To assess the efficacy, immuno &amp; safety of 2 doses of GSK HRV vaccine at different virus concentrations in healthy infants aged 2 months &amp; previously uninfected with HRV, concurrently given with DTPw-HBV, Hib. clinicaltrials.gov/show/NCT00385320 (first received 9 October 2006). Perez-SchaelI , SalinasB , LinharesA , GuerreroM , Ruiz-PalaciosG , ClemensS , et al. Protective efficacy of an oral human rotavirus (HRV) vaccine in Latin American infants [poster]. In: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy ( ICAAC); San Diego, 27-30 September 2002. 2002:18, LB-23. [Not available for review]Perez-SchaelI , SalinasB , TomatM , LinharesAC , GuerreroML , Ruiz-PalaciosGM , et al. Efficacy of the human rotavirus vaccine RIX4414 in malnourished children. Journal of Infectious Diseases2007;196(4):537-40. Ruiz-PalaciosGM , GuerreroML , Bautista-MarquezA , Ortega-GallegosH , Tuz-DzibF , Reyes-GonzalezL , et al. Dose response and efficacy of a live, attenuated human rotavirus vaccine in Mexican infants. Pediatrics2007;120(2):e253-61. [Not available for review]Ruiz-PalaciosGM . Impact of maternal antibodies on the immune response to an oral human rotavirus (HRV) vaccine in Mexican infants [presentation]. In: 3rd World Congress of Pediatric Infectious Diseases; 2002 November 19-23; Santiago, Chile. 2002. [Not available for review]SalinasB , Perez SchaelI , LinharesAC , Ruiz PalaciosGM , GuerreroML , YarzabalJP , et al. Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: a randomized, placebo-controlled trial in Latin American infants. Pediatric Infectious Disease Journal2005;24(9):807-16. ">RIX Salinas 2005‐LA</a>). We did not observe a statistically significant difference between the intervention and placebo groups (RR 1.75, 95% CI 0.29 to 10.73; 13,117 participants, 3 trials; <a href="./references#CD008521-fig-0015" title="">Analysis 1.11</a>). </p> </section> <section id="CD008521-sec-0124"> <h6 class="title">1.2.2. Serious adverse events requiring hospitalization</h6> <p>Two trials reported serious adverse events requiring hospitalization (<a href="./references#CD008521-bbs2-0026" title="Costa ClemensSA , et al. Operational organization of a large scale phase III clinical trial of rotavirus vaccine in multiple sites and countries in Latin America. In: International Congress of Pediatrics (ICP); 2004 August 15-20; Cancun, Mexico. 2004. [Not available for review]De VosB , et al. Rotarix™: an effective way to prevent rotavirus diarrhoea and vomiting. In: 9th Congress of the Asian Pan Pacific Society of Paediatric Gastroenterology, Hepatology and Nutrition &amp; 27th Annual Congress of the Malaysian Paediatric Association; 2005 June 16-19; Kuala Lumpur, Malaysia. 2005. [Not available for review]BaayM , BollaertsK , StruchinerC , VerstraetenT . Background rates of disease in Latin American children from a rotavirus vaccine study. Human Vaccines and Immunotherapeutics2017;13(8):1916-20. GlaxoSmithKline[444563-023-pt1]. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants (efficacy data from visit 1 to visit 4). www.gsk-studyregister.com/study/6791 (accessed 12 December 2018). GlaxoSmithKline[444563-023-pt2]. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants (2nd year efficacy from visit 4 to visit 6). www.gsk-studyregister.com/study/6791 (accessed 12 December 2018). GlaxoSmithKline[444563-023-pt3]. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants (safety for the period between visit 1 and visit 3). www.gsk-studyregister.com/study/6791 (accessed 12 December 2018). JustinoMC , AraújoEC , Van DoornLJ , OliveiraCS , GabbayYB , MascarenhasJD , et al. Oral live attenuated human rotavirus vaccine (Rotarix) offers sustained high protection against severe G9P[8] rotavirus gastroenteritis during the first two years of life in Brazilian children. Memorias do Instituto Oswaldo Cruz2012;107(7):846-53. LinharesAC , VelazquezFR , Perez-SchaelI , Saez-LlorensX , AbateH , EspinozaF , et al. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet2008;371(9619):1181-9. LopezP , LinharesA , Pérez-SchaelI , Ruiz-PalaciosG , Costa ClemensS , SanchezN . Early protection against severe rotavirus gastroenteritis - RIX4414 experience in Latin America. In: 24th Annual Meeting of European Society for Paediatric Infectious Diseases (ESPID); 2006 May 03-05; Basel, Switzerland. 2006. [Not available for review]MaciasM , LopezP , VelazquezFR , VergaraRF , SalmeronJ , TavaresJL . The rotavirus vaccine RIX4414 (Rotarix) is not associated with intussusception in one year old infants. In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2005 December 16-19; Washington DC, USA. 2005. [Not available for review]NCT00139347. A multi-country &amp; multi-center study to assess the efficacy, immunogenicity &amp; safety of two doses of GSK Biologicals' oral live attenuated HRV vaccine given concomitantly with routine EPI vaccinations including OPV in healthy infants. clinicaltrials.gov/ct2/show/NCT00139347 (first received 31 August 2005). [Trial registration document (no data for review)]NCT00140673. Placebo-controlled, multi-country &amp; multi-center study to assess the efficacy, safety &amp; immunogenicity of 2 doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants. clinicaltrials.gov/ct2/show/NCT00140673 (first received 1 September 2005). [Trial registration document (no data for review)]Perez-SchaelI , LinharesAC , VesikariT . Two doses of the human attenuated rotavirus vaccine RIX4414 (Rotarix) show heterotypic protection in Latin America and Europe. In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2005 December 16-19; Washington DC, USA. 2005. [Not available for review]PikeM . New rotavirus vaccine is effective and appears to have no increased risk of intussusception. Clinical Research Abstracts For Pediatricians2006;149(1):143. Ruiz-PalaciosG , AranzaC , VelazquezFR , RichardsonV , NandiE , MaciasM . Two doses of the human-attenuated monovalent G1P[8] rotavirus vaccine, Rotarix show high efficacy in Mexican children against severe rotavirus gastroenteritis and severe overall gastroenteritis. In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2005 December 16-19; Washington DC, USA. 2005. [Not available for review]Ruiz-PalaciosGM , Perez-SchaelI , VelazquezFR , AbateH , BreuerT , ClemensSC , et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. New England Journal of Medicine2006;354(1):11-22. VelázquezFR , AbatH , Costa ClemensSA , EspinozaF , GillardP , LinharesAC , et al. The human monovalent G1P[8] rotavirus vaccine, Rotarix is highly efficacious and provides crossprotection against G1 and non-G1 serotypes. In: 23rd Annual meeting of European Society for Paediatric Infectious Diseases (ESPID); 2005 May 18-20; Valencia, Spain. 2005. VelázquezRF , AbateH , BouckenoogheA . RIX4414, the human G1P[8] rotavirus vaccine is highly efficacious during the second year of life. In: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2006 September 27-30; San Francisco, USA. 2006. [Not available for review]VesikariT , O’RyanM , AbateH , Costa ClemensSA , EspinozaF , GillardP . Overcoming the safety hurdle: the rotavirus vaccine RIX4414 is not associated with intussusception. In: 23rd Annual Meeting of European Society for Paediatric Infectious Diseases (ESPID); 2005 May 18-20; Valencia, Spain. 2005. [Not available for review]">RIX Ruiz‐Palac 06‐LA/EU</a>; <a href="./references#CD008521-bbs2-0028" title="GlaxoSmithKline[444563-014]. A phase II, double-blind before the 2002 rotavirus season and single blind with respect to OPV after, randomised, placebo-controlled study of the safety, reactogenicity and immunogenicity of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine (RIX4414 at 105 ffu) co-administered with either oral polio vaccine (OPV) or inactivated polio vaccine (IPV) in healthy infants (approximately 5-10 weeks old) in South Africa. www.gsk-studyregister.com/study/6787 (accessed 12 December 2018). ISRCTN86632774. A phase II, double blind randomised, placebo controlled study to assess the safety reactogenicity and immunogenicity of three doses of GSK Biologicals (South Africa). controlled-trials.com/ISRCTN86632774 (first received 25 November 2005). NCT00346892. Reactogenicity &amp; immunogenicity study of two doses of GSK Biologicals’ oral live attenuated HRV vaccine co-administered with either OPV or IPV in healthy infants (approximately 5-10 weeks old) in South Africa. clinicaltrials.gov/show/NCT00346892 (first received 30 June 2006). SteeleAD ,  De VosB ,  TumboJ ,  ReyndersJ ,  ScholtzF ,  BosP ,  et al. Co-administration study in South African infants of a live-attenuated oral human rotavirus vaccine (RIX4414) and poliovirus vaccines. Vaccine2010 ;28(39):6542-8. SteeleAD , TumboJ , ArmahG , ReyndersJ , ScholtzF , BosP , et al. Immunogenicity and reactogenicity of a new live attenuated oral rotavirus vaccine (RIX4414) when administered concurrently with poliovirus vaccines in African infants. In: 24th International Congress of Pediatrics; 2004 August 15-20; Cancun, Mexico. 2004. [Not available for review]SteeleAD , TumboJM , ArmahGE , ReyndersJ , ScholtzF , BosP , et al. Concomitant administration of a live-attenuated oral rotavirus vaccine (RIX4414) with poliovirus vaccines in African infants. In: 23rd Annual Meeting of the European Society for Pediatric Infectious Diseases - ESPID; 2005 May 18-20; Valencia, Spain. 2005. [Not available for review]">RIX Steele 2008‐ZAF</a>) and found fewer events in the Rotarix group than the placebo group (RR 0.88, 95% CI 0.81 to 0.96; 63,675 participants, 2 trials; <a href="./references#CD008521-fig-0016" title="">Analysis 1.12</a>). </p> </section> <section id="CD008521-sec-0125"> <h6 class="title">1.2.3 Rotavirus diarrhoea of any severity</h6> <p>Eighteen trials provided data for the efficacy of Rotarix to prevent rotavirus diarrhoea of any severity in children; see <a href="./references#CD008521-fig-0017" title="">Analysis 1.13</a> for two‐month safety trial follow‐up, <a href="./references#CD008521-fig-0018" title="">Analysis 1.14</a> for one‐year follow‐up and <a href="./references#CD008521-fig-0020" title="">Analysis 1.16</a> for two‐year follow‐up. Trials were performed in low‐mortality countries ( <a href="./references#CD008521-bbs2-0004" title="BernsteinDI , SackDA , ReisingerK , RothsteinE , WardRL . Second-year follow-up evaluation of live, attenuated human rotavirus vaccine 89-12 in healthy infants. Journal of Infectious Diseases2002;186(10):1487-9. BernsteinDI , SackDA , RothsteinE , ReisingerK , SmithVE , O'SullivanD , et al. Efficacy of live, attenuated, human rotavirus vaccine 89-12 in infants: a randomised placebo-controlled trial. Lancet1999;354(9175):287-90. ">RIX Bernstein 1999‐USA</a>; <a href="./references#CD008521-bbs2-0009" title="GlaxoSmithKline[103478-041]. A phase IIIb, double-blind, randomized, placebo-controlled, multicentre study to assess the immunogenicity, safety and reactogenicity of 2 doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants (6-12 weeks of age at first dose) previously uninfected with human rotavirus. www.gsk-studyregister.com/study/2714 (accessed 12 December 2018). NCT00134732. Assess the immunogenicity, safety &amp; reactogenicity of 2 doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants (6-12 weeks of age at first dose) previously uninfected with human rotavirus. clinicaltrials.gov/ct2/show/record/NCT00134732 (first received 25 August 2005). ">RIX GSK[041] 2007‐KOR</a>; <a href="./references#CD008521-bbs2-0022" title="GlaxoSmithKline[106481-054]. Phase IIIb, double blind, randomised, placebo-controlled, multi-country/centre, study to assess safety, reactogenicity &amp; immunogenicity of 2 doses of GSK Biologicals' oral live attenuated Human Rotavirus (HRV) vaccine in pre-term infants. www.gsk-studyregister.com/study/3064 (accessed 12 December 2018). NCT00420745. Phase IIIb, double blind, randomised, placebo-controlled, multi-country/centre, study to assess safety, reactogenicity &amp; immunogenicity of 2 doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine in pre-term infants. clinicaltrials.gov/show/NCT00420745 (first received 11 January 2007). OmenacaF , SarlangueJ , SzenbornL , NogueiraM , SuryakiranPV , SmolenovIV , et al. Safety, reactogenicity and immunogenicity of the human rotavirus vaccine in preterm European infants: a randomized phase IIIb study. Pediatric Infectious Disease Journal2012;31(5):487-93. ">RIX Omenaca 2012‐EU</a>; <a href="./references#CD008521-bbs2-0023" title="EmmanuelB , et al. Immunogenicity of an acellular pertussis combination vaccine co-administered with a novel rotavirus vaccine in Singaporean infants. Asian Congress on Pediatric Infectious Diseases (ACPID); 2-4 September 2004; Kota Kinabula, Malaysia2004. [Not available for review]PhuaKB , et al. Immunogenicity and reactogenicity of two doses of an oral human rotavirus (HRV) vaccine at different concentrations in healthy infants from Singapore. In: 11th Asia Pacific Congress of Pediatrics and the 3rd Asia Pacific Congress of Pediatric Nursing; 2003; Bangkok, Thailand. 2003. [Not available for review]PhuaKB , et al. Intussusception in children: a seven-year experience in Singapore. In: 24th International Congress of Pediatrics (ICP); 2004 August 15-20; Cancun, Mexico. 2004. [Not available for review]VesikariT , et al. High efficacy of two doses of Rotarix™ (RIX4414) against rotavirus disease in Europe, Latin-America and Asia. In: Asian Congress on Pediatric Infectious Diseases (ACPID); 2006 March 07-10; Cebu, Philippines. 2006. [Not available for review]De VosB , GillardP , CheuvartB . RIX4414 vaccine efficacy against rotavirus gastroenteritis due to G2P[4] strain. In: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2006 September 27-30; San Francisco, USA. 2006. [Not available for review]De VosB , VesikariT , LinharesAC , SalinasB , Perez-SchaelI , Ruiz-PalaciosGM , et al. A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis. Pediatric Infectious Disease Journal2004;23(10 Suppl):179-82. [No data for review]EmmanuelS , PhuaKB , GohP , QuakSH , DattaSK , HanHH , et al. Immunogenicity of an acellular pertussis combination vaccine co-administered with a novel rotavirus vaccine in Singaporean infants. In: 23rd Annual Meeting of European Society for Paediatric Infectious Diseases (ESPID); 2005 May 18-20; Valencia, Spain. 2005. [Not available for review]GlaxoSmithKline[444563-007]. A phase IIb, double-blind, randomized, placebo-controlled study to assess the efficacy, immunogenicity, reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine at different viral concentrations (104.7, 105.2 and 106.1 foci forming units (ffu)) in healthy infants previously uninfected with human rotavirus and approximately three months of age, when administered concurrently with DTPa-IPV/Hib and HBV vaccines. www.gsk-studyregister.com/study/6785 (accessed 12 December 2018). NCT00429481. A study to assess the efficacy, immunogenicity and safety of 2 doses of oral live attenuated human rotavirus vaccine (Rotarix) at different viral concentrations in healthy infants. clinicaltrials.gov/ct2/show/record/NCT00429481 (first received 31 January 2007). PhuaKB , EmmanuelSC , GohP , QuakSH , LeeBW , HanHH , et al. A rotavirus vaccine for prophylaxis of infant rotavirus gastroenteritis: the Asian experience. Annals of the Academy of Medicine, Singapore2006;35(1):38-44. PhuaKB , QuakSH , EmmanuelS , GohPS , HanHH , HardtK , et al. A short report on highlights of worldwide development of RIX4414: a Singaporean experience. Vaccine2006;24(18):3782-3. PhuaKB , QuakSH , EmmanuelS , GohPSC , HanHH , HardtK , et al. Highlights of world-wide development: a Singapore experience. In: 3rd International Conference on Vaccines for Enteric Diseases (VED) 28-30 April 2004; Montego Bay, Jamaica. 2004. [Not available for review]PhuaKB , QuakSH , LeeBW , EmmanuelSC , GohP , HanHH , et al. Evaluation of RIX4414, a live, attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled phase 2 trial involving 2464 Singaporean infants. Journal of Infectious Diseases2005;192(Suppl 1):6-16. PhuaKB , QuakSH , LimFS , GohP , TeohYL , DattaSK , et al. Immunogenicity, reactogenicity and safety of a diphtheria-tetanus-acellular pertussis-inactivated polio and Haemophilus influenzae type b combination vaccine in a placebo-controlled rotavirus vaccine study. Annals of the Academy of Medicine, Singapore2008;37(7):546-53. VesikariT . RIX4414: a new attenuated human rotavirus vaccine. In: 23rd Annual Meeting of European Society for Paediatric Infectious Diseases (ESPID); 2005 May 18-20; Valencia, Spain. 2005. [Not available for review]">RIX Phua 2005‐SGP</a>; <a href="./references#CD008521-bbs2-0033" title="De VosB , VesikariT , LinharesAC , SalinasB , Perez-SchaelI , Ruiz-PalaciosGM , et al. A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis. Pediatric Infectious Disease Journal2004;23(10 Suppl):179-82. GlaxoSmithKline[444563-004]. A phase IIb, double-blind, randomized, placebo-controlled study to assess the efficacy, immunogenicity, reactogenicity and safety of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants approximately 2 months of age and previously uninfected with HRV [Results for the first efficacy period (starting from 2 weeks after dose 2 until the end of the first RV season following vaccination)]. www.gsk-studyregister.com/study/6782 (accessed 12 December 2018). GlaxoSmithKline[444563-004-Annex]. A phase IIb, double-blind, randomized, placebo-controlled study to assess the efficacy, immunogenicity, reactogenicity and safety of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants approximately 2 months of age and previously uninfected with HRV [This summary presents results for the second efficacy period (from the end of the first rotavirus season post-vaccination until the end of the second rotavirus season) and for the two consecutive rotavirus seasons]. www.gsk-studyregister.com/study/6782 (accessed 12 December 2018). NCT00425737. A study to assess the efficacy, immunogenicity and safety of two doses of oral live attenuated human rotavirus (HRV) vaccine (Rotarix) in healthy infants. clinicaltrials.gov/show/NCT00425737 (first received 23 January 2007). VesikariT , KarvonenA , EspoM , KorhonenT , DelemA , De VosB . Efficacy evaluation of an oral human rotavirus (HRV) vaccine in previously uninfected Finnish infants. In: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 September 27-30; San Diego, California. 2002. [Not available for review]VesikariT , KarvonenA , PuustinenL , ZengSQ , SzakalED , DelemA , et al. Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants. Pediatric Infectious Disease Journal2004;23(10):937-43. ">RIX Vesikari 2004b‐FIN</a>; <a href="./references#CD008521-bbs2-0034" title="VesikariT , et al. Human rotavirus vaccine Rotarix is highly efficacious in Europe. In: 24th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); 2006 June 15-18; Basel, Switzerland. 2006. [Not available for review]VesikariT , et al. Rotarix, an oral human Rotavirus vaccine, is highly immunogenic in healthy infants from 6 European countries. In: 24th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); 2006 June 15-18; Basel, Switzerland. 2006. [Not available for review]GlaxoSmithKline[102247-036]. A phase IIIb, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants in co-administration with specific childhood vaccinations [This summary presents results from the first efficacy period] [102247-036]. www.gsk-studyregister.com/study/2669 (accessed 12 December 2018). GlaxoSmithKline[102247-036-Annex]. A phase IIIb, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants in co-administration with specific childhood vaccinations [This summary presents results for the second and combined efficacy periods]. www.gsk-studyregister.com/study/2669 (accessed 12 December 2018). GlaxoSmithKline[102247-036-Yr3]. A phase IIIb, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants in co-administration with specific childhood vaccinations [A phase IIIb open study to assess the long-term efficacy and safety of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine approximately three years after vaccination in healthy infants aged 6-12 weeks at the time of first vaccination in the Rota-036 study (eTrack No.102247) in Finland]. www.gsk-studyregister.com/study/2669 (accessed 12 December 2018). NCT00140686. A multi-country &amp; multi-center study to assess the efficacy, safety &amp; immunogenicity of 2 doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants in co-administration with specific childhood vaccines. clinicaltrials.gov/ct2/show/record/NCT00140686 (first received 1 September 2005). [Trial registration document]NCT00420316. To assess long-term efficacy &amp; safety of subjects approximately 3 years after priming with 2 doses of GlaxoSmithKline (GSK) Biologicals' oral live attenuated human rotavirus (HRV) vaccine (Rotarix) in the primary vaccination study (102247). clinicaltrials.gov/show/NCT00420316 (first received 11 January 2007). SchusterV , OttoW , CohenR . RotarixTM an oral human Rotavirus vaccine, is highly immunogenic when co-administered with a Streptococcus pneumoniae conjugate vaccine (PrevenarTM) in healthy infants from France and Germany. In: 24th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); 2006 June 15-18; Basel, Switzerland. 2006. [Not available for review]TejedorJC , Diez-DelegadoJ , AristeguiJ . Rotarix (RIX4414), an oral Human Rotavirus vaccine, is highly immunogenic when co-administered with a Neisseria meningitides Serogroup C vaccine (MeningitecTM) in healthy infants from Spain. In: 24th Annual Meeting Meeting of the European Society for Paediatric Infectious Diseases (ESPID); 2006 June 15-18; Basel, Switzerland. 2006. [Not available for review]VesikariT ,  KarvonenA ,  PrymulaR ,  SchusterV ,  TejedorJC ,  ThollotF ,  et al. Immunogenicity and safety of the human rotavirus vaccine Rotarix co-administered with routine infant vaccines following the vaccination schedules in Europe. Vaccine2010;28(32):5272-9. VesikariT , KarvonenA , FerranteSA , KuterBJ , CiarletM . Sustained efficacy of the pentavalent rotavirus vaccine, RV5, up to 3.1 years following the last dose of vaccine. Pediatric Infectious Disease Journal2010;29(10):957-63. VesikariT , KarvonenA , PrymulaR , SchusterV , TejedorJC , CohenR , et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet2007;370(9601):1757-63. VesikariT , PrymulaR , SchusterV , TejedorJC , CohenR , BouckenoogheA , et al. Efficacy and immunogenicity of live-attenuated human rotavirus vaccine in breast-fed and formula-fed European infants. Pediatric Infectious Disease Journal2012;31(5):509-13. VesikariT , PrymulaR , SchusterV . Early protection against Rotavirus, Rotarix, experience in an European setting. In: 12th International Congress for Infectious Diseases; 2006 June 15-18; Lisbon, Portugal. 2006. [Not available for review]VesikariT , PrymulaR , SchusterV . Rotarix (RIX4414), an oral human rotavirus vaccine, is highly immunogenic when co-administered with diphteria-tetanus-pertussis (DTPA)-combined vaccines in healthy infants from Europe. In: 24th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); 2006 June 15-18; Basel, Switzerland. 2006. [Not available for review]">RIX Vesikari 2007a‐EU</a>; <a href="./references#CD008521-bbs2-0035" title="VesikariT , et al. Immunogenicity of liquid formulation of the oral live attenuated human rotavirus vaccine (Rotarix™) [poster]. Sociedad Latinoamericana de Infectología Pediátrica (SLIPE). San Jose, Costa Rica 8-11 May 2007. [Not available for review]GlaxoSmithKline[104480-048]. A phase II, double-blind, randomized, placebo controlled study to compare the immunogenicity, reactogenicity and safety of two different formulations of GlaxoSmithKline (GSK) Biologicals’ live attenuated human rotavirus (HRV) vaccine given as a two-dose primary vaccination in healthy infants previously uninfected with HRV. www.gsk-studyregister.com/study/2783 (accessed 12 December 2018). NCT00137930. Compare the immunogenicity, reactogenicity &amp; safety of 2 different formulations of GSK Biologicals’ live attenuated human rotavirus (HRV) vaccine given as a two-dose primary vaccination in healthy infants previously uninfected with HRV. clinicaltrials.gov/ct2/show/record/NCT00137930 (first received 30 August 2005). VesikariT , KarvonenA , BouckenoogheA , SuryakiranPV , SmolenovI , HanHH . Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 oral suspension (liquid formulation) in Finnish infants. Vaccine2011;29(11):2079-84. ">RIX Vesikari 2011‐FIN</a>), medium‐mortality countries (<a href="./references#CD008521-bbs2-0012" title="GlaxoSmithKline[103477-039]. A phase IIIb, partially blind, randomized, placebo-controlled study to asses the effect on immunogenicity of administration of vaccine without buffering agent and to assess heat stability in terms of immunogenicity, reactogenicity and safety of GlaxoSmithKline Biologicals’ oral live attenuated human rotavirus (HRV) vaccine following a 0, 2 month schedule, in healthy infants previously uninfected with human rotavirus. www.gsk-studyregister.com/study/2713 (accessed 12 December 2018). KerdpanichA , ChokephaibulkitK , WatanaveeradejV , VanpraparN , HutagalungY , HanHH , et al. Exposure to elevated temperature of 37°C for 7 days does not affect immunogenicity and reactogenicity of RIX4414 [poster]. In: dsRNA Virus Meeting; 2006 October 21-26; Cape Town, South Africa. 2006. [Not available for review]KerdpanichA , ChokephaibulkitK , WatanaveeradejV , VanpraparN , SimasathienS , PhavichitrN , et al. Immunogenicity of a human rotavirus vaccine (RIX4414) after storage at 37 degrees C for seven days. Human Vaccine2011;7(1):74-80. KerdpanichA , ChokephaibulkitK , WatanaveeradejV , VanpraparN , SimasathienS , PhavichitrN , et al. Immunogenicity of a live-attenuated human rotavirus RIX4414 vaccine with or without buffering agent. Human Vaccines2010;6(3):254-62. NCT00169455. Assess the effect on immunogenicity of administration of vaccine without buffering agent &amp; assess heat stability in terms of immunogenicity, reactogenicity &amp; safety of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine following a 0, 2 m schedule, in healthy infants previously uninfected with human rotavirus. clinicaltrials.gov/show/NCT00169455 (first received 15 September 2005). ">RIX Kerdpanich 2010‐THA</a>; <a href="./references#CD008521-bbs2-0027" title="Ruiz-PalaciosG , GuerreroL , LinharesAC , et al. Efficacy of an oral human rotavirus (HRV) vaccine in preventing diarrhoea due to G1 and non-G1 rotavirus [Presentation]. In: 3rd World Congress of Pediatric Infectious Diseases; 2002 November 19-23; Santiago, Chile. 2002. [Not available for review]Ruiz-PalaciosG , GuerreroML , LinharesAC , et al. Two-year efficacy of GlaxoSmithKline Biologicals' live attenuated rotavirus vaccine in Latin American children [poster]. In: 24th International Congress of Pediatrics; 2004 August 15-20; Cancun, Mexico. 2004. [Not available for review]SalinasB , Perez-SchaelI , Ruiz-PalaciosG , et al. Early protection by GlaxoSmithKline Biologicals' live attenuated rotavirus vaccine in Latin American children [poster]. In: 24th International Congress of Pediatrics; 2004 August 15-20; Cancun, Mexico. 2004. [Not available for review]SalinasB , TomatMA , YarzabalJP , et al. Efficacy of the rotavirus vaccine (RIX4414) among infants in Carabobo State, Venezuela [poster]. In: Asocación Venezolana para el Avance de la Cienca (AsoVAC); 2004; Venezuela. 2004. [Not available for review]AraujoEC , ClemensSA , OliveiraCS , JustinoMC , RubioP , GabbayYB , et al. Safety, immunogenicity, and protective efficacy of two doses of RIX4414 live attenuated human rotavirus vaccine in healthy infants. Jornal de Pediatria2007;83(3):217-24. De VosB , HardtK , LinharesAC , Ruiz-PalaciosG , GuerreroL , SalinasB . Efficacy of two doses of a human monovalent rotavirus vaccine, Rotarix™ in preventing gastro-enteritis due to G1 and Non-G1 rotavirus in Brazil, Mexico and Venezuela [presentation]. In: 8th International Symposium on Double-Stranded RNA Viruses; 2003 September 13-18; Lucca, Italy. 2003. [Not available for review]De VosB , VesikariT , LinharesAC , SalinasB , Perez-SchaelI , Ruiz-PalaciosGM , et al. A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis. Pediatric Infectious Disease Journal2004;23(10 Suppl):179-82. GlaxoSmithKline[444563-006]. A phase IIb, double-blind, randomized, placebo-controlled study to assess the efficacy, immunogenicity, reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals' live attenuated human rotavirus (HRV) vaccine at different virus concentrations (104.7, 105.2 and 105.8 foci forming units [ffu]) in healthy infants (approximately 2 months of age at first dose) following a 0, 2 month schedule and previously uninfected with HRV, when administered concurrently with DTPw-HBV and Hib vaccines. www.gsk-studyregister.com/study/6784 (accessed 12 December 2018). GlaxoSmithKline[444563-006-Annex]. A phase IIb, double-blind, randomized, placebo-controlled study to assess the efficacy, immunogenicity, reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals' live attenuated human rotavirus (HRV) vaccine at different virus concentrations (104.7, 105.2 and 105.8 foci forming units [ffu]) in healthy infants (approximately 2 months of age at first dose) following a 0, 2 month schedule and previously uninfected with HRV, when administered concurrently with DTPw-HBV and Hib vaccines [This summary presents results for the second and combined efficacy periods and results from the 3-Dose subset. Results from the first efficacy period are presented in 444563/006 (Rota-006) summary]. www.gsk-studyregister.com/study/6784 (accessed 12 December 2018). LinharesA , Perez-SchaelI , Ruiz-PalaciosM , PernambucoE , JacquetJ , De VosB . Immunogenicity and reactogenicity of an oral human rotavirus (HRV) vaccine in Latin American infants [poster]. In: 3rd World Congress of Pediatric Infectious Diseases; 2002 November 19-23; Santiago, Chile. 2002. [Not available for review]LinharesAC , Ruiz-PalaciosGM , GuerreroML , SalinasB , Perez-SchaelI , ClemensSA , et al. A short report on highlights of world-wide development of RIX4414: a Latin American experience. Vaccine2006;24(18):3784-5. LinharesAC , VerstraetenT , Wolleswinkel-Van den BoschJ , ClemensR , BreuerT . Rotavirus serotype G9 is associated with more-severe disease in Latin America. Clinical Infectious Diseases2006;43(3):312-4. [Not available for review]NCT00385320. To assess the efficacy, immuno &amp; safety of 2 doses of GSK HRV vaccine at different virus concentrations in healthy infants aged 2 months &amp; previously uninfected with HRV, concurrently given with DTPw-HBV, Hib. clinicaltrials.gov/show/NCT00385320 (first received 9 October 2006). Perez-SchaelI , SalinasB , LinharesA , GuerreroM , Ruiz-PalaciosG , ClemensS , et al. Protective efficacy of an oral human rotavirus (HRV) vaccine in Latin American infants [poster]. In: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy ( ICAAC); San Diego, 27-30 September 2002. 2002:18, LB-23. [Not available for review]Perez-SchaelI , SalinasB , TomatM , LinharesAC , GuerreroML , Ruiz-PalaciosGM , et al. Efficacy of the human rotavirus vaccine RIX4414 in malnourished children. Journal of Infectious Diseases2007;196(4):537-40. Ruiz-PalaciosGM , GuerreroML , Bautista-MarquezA , Ortega-GallegosH , Tuz-DzibF , Reyes-GonzalezL , et al. Dose response and efficacy of a live, attenuated human rotavirus vaccine in Mexican infants. Pediatrics2007;120(2):e253-61. [Not available for review]Ruiz-PalaciosGM . Impact of maternal antibodies on the immune response to an oral human rotavirus (HRV) vaccine in Mexican infants [presentation]. In: 3rd World Congress of Pediatric Infectious Diseases; 2002 November 19-23; Santiago, Chile. 2002. [Not available for review]SalinasB , Perez SchaelI , LinharesAC , Ruiz PalaciosGM , GuerreroML , YarzabalJP , et al. Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: a randomized, placebo-controlled trial in Latin American infants. Pediatric Infectious Disease Journal2005;24(9):807-16. ">RIX Salinas 2005‐LA</a>), and in high‐mortality countries (<a href="./references#CD008521-bbs2-0001" title="AnhDD , CarlosCC , ThiemDV , HutagalungY , GatchalianS , BockHL , et al. Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 (Rotarix) oral suspension (liquid formulation) when co-administered with expanded program on immunization (EPI) vaccines in Vietnam and the Philippines in 2006-2007. Vaccine2011;29(11):2029-36. GlaxoSmithKline[109216-063]. A phase II, randomized, double-blind, placebo-controlled study to evaluate the immunogenicity, reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) liquid vaccine, when given to healthy infants, in Philippines. www.gsk-studyregister.com/study/3204 (accessed 12 December 2018). NCT00432380. Immunogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals' oral live attenuated human rotavirus (HRV) liquid vaccine (GSK 357941A) in healthy infants. clinicaltrials.gov/show/NCT00432380 (first received 7 February 2007). ">RIX Anh 2011‐PHL</a>; <a href="./references#CD008521-bbs2-0002" title="AnhDD , CarlosCC , ThiemDV , HutagalungY , GatchalianS , BockHL , et al. Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 (Rotarix) oral suspension (liquid formulation) when co-administered with expanded program on immunization (EPI) vaccines in Vietnam and the Philippines in 2006-2007. Vaccine2011;29(11):2029-36. AnhDD , ThiemVD , HutagalungY , BockHL , SuryakiranP , DelemA , et al. Immunogenicity, reactogenicity and safety of the oral live attenuated human rotavirus vaccine RIX4414 (Rotarix™) oral suspension (liquid formulation) in Vietnamese Infants. In: 13th International Congress on Infectious Diseases Abstracts, Poster Presentations; June 19–22, 2008; Kuala Lumpur, Malaysia. 2008. GlaxoSmithKline[105722-051]. A phase II, randomized, double-blind, placebo-controlled study to evaluate the immunogenicity, reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) liquid vaccine, when given to healthy infants, in Vietnam. www.gsk-studyregister.com/study/3012 (accessed 12 December 2018). NCT00345956. A placebo-controlled study to evaluate the immunogenicity, reactogenicity and safety of two doses of GSK Bio oral live attenuated human rotavirus (HRV) liquid vaccine, when given to healthy infants, in Vietnam. clinicaltrials.gov/show/NCT00345956 (first received 29 June 2006). ">RIX Anh 2011‐VNM</a>; <a href="./references#CD008521-bbs2-0010" title="GlaxoSmithKline[101555]. A phase II, double-blind, randomized, placebo-controlled study to compare the immunogenicity, reactogenicity and safety of 2 different formulations of GlaxoSmithKline (GSK) Biologicals’ live attenuated human rotavirus (HRV) vaccine given as a two-dose primary vaccination in healthy infants previously uninfected with HRV. www.gsk-studyregister.com/study/2632 (accessed 12 December 2018). ">RIX GSK[101555] 2008‐PHL</a>; <a href="./references#CD008521-bbs2-0018" title="CunliffeNA , WitteD , NgwiraBM , ToddS , BostockNJ , TurnerAM , et al. Efficacy of human rotavirus vaccine against severe gastroenteritis in Malawian children in the first two years of life: a randomized, double-blind, placebo controlled trial. Vaccine2012;30(Suppl 1):A36-43. MadhiSA , CunliffeNA , SteeleD , WitteD , KirstenM , LouwC , et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. New England Journal of Medicine2010;362(4):289-98. NCT00241644. Multi-center study to assess the efficacy, safety and immunogenicity of 2 or 3 doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations in healthy infants. clinicaltrials.gov/show/NCT00241644 (first received 19 October 2005). NCT00598468. Multi-center study to assess efficacy, safety &amp; immunogenicity of 2 or 3 doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations in healthy infants. clinicaltrials.gov/show/NCT00598468 (first received 19 October 2005). SteeleAD , NeuzilKM , CunliffeNA , MadhiSA , BosP , NgwiraB , et al. Human rotavirus vaccine Rotarix provides protection against diverse circulating rotavirus strains in African infants: a randomized controlled trial. BMC Infectious Diseases2012;12:213. ">RIX Madhi 2010‐MWI</a>; <a href="./references#CD008521-bbs2-0019" title="MadhiSA , CunliffeNA , SteeleD , WitteD , KirstenM , LouwC , et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. New England Journal of Medicine2010;362(4):289-98. MadhiSA , KirstenM , LouwC , BosP , AspinallS , BouckenoogheA , et al. Efficacy and immunogenicity of two or three dose rotavirus-vaccine regimen in South African children over two consecutive rotavirus seasons: a randomized, double-blind, placebo-controlled trial. Vaccine2012;30(Suppl 1):A44-51. NCT00241644. Multi-center study to assess the efficacy, safety and immunogenicity of 2 or 3 doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations in healthy infants. clinicaltrials.gov/show/NCT00241644 (first received 19 October 2005). NCT00598468. Multi-center study to assess efficacy, safety &amp; immunogenicity of 2 or 3 doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations in healthy infants. clinicaltrials.gov/show/NCT00598468 (first received 19 October 2005). SteeleAD , NeuzilKM , CunliffeNA , MadhiSA , BosP , NgwiraB , et al. Human rotavirus vaccine Rotarix provides protection against diverse circulating rotavirus strains in African infants: a randomized controlled trial. BMC Infectious Diseases2012;12:213. ">RIX Madhi 2010‐ZAF</a>; <a href="./references#CD008521-bbs2-0020" title="GlaxoSmithKline[103792-044]. A phase IIIb, randomised, multicentre double-blind, placebo-controlled study of the immunogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine (RIX4414) as primary dosing in healthy infants in India of approximately 8 weeks of age at the first dose. www.gsk-studyregister.com/study/2723 (accessed 12 December 2018). NarangA , BoseA , PanditAN , DuttaP , KangG , BhattacharyaSK , et al. Immunogenicity, reactogenicity and safety of human rotavirus vaccine (RIX4414) in Indian infants. Human Vaccines2009;5(6):414-9. NCT00289172. A multicenter study of the immunogenicity &amp; safety of 2 doses of GSK Biologicals’ oral live attenuated human rotavirus vaccine (RIX4414) as primary dosing of healthy infants in India aged approximately 8 wks at the time of the first dose. clinicaltrials.gov/ct2/show/record/NCT00289172 (first received 9 February 2006). ">RIX Narang 2009‐IND</a>; <a href="./references#CD008521-bbs2-0025" title="EUCTR2015-001542-29. Immunization of infants 6-14 weeks of age, with GlaxoSmithKline Biologicals Rotavirus vaccine to explore the existence of transmission of rotavirus vaccine strain between twins in a family. clinicaltrialsregister.eu/ctr-search/trial/2015-001542-29/results (first received 22 June 2015). NCT00396630. A Phase IIIb, randomized, double-blind, placebo-controlled study to explore the existence of horizontal transmission of the RIX4414 vaccine strain between twins within a family. clinicaltrials.gov/show/NCT00396630 (first received 7 November 2006). RiveraL ,  PeñaLM ,  StainierI ,  GillardP ,  CheuvartB ,  SmolenovI , et al. Horizontal transmission of a human rotavirus vaccine strain - a randomized, placebo-controlled study in twins. Vaccine2011;29(51):9508-13. ">RIX Rivera 2011‐DOM</a>; <a href="./references#CD008521-bbs2-0029" title="EUCTR2015-001484-39. A phase II study to assess the safety and immunogenicity of GlaxoSmithKline Biologicals rotavirus vaccine, RIX4414 when administered to HIV infected infants in South Africa. www.clinicaltrialsregister.eu/ctr-search/trial/2015-001484-39/results (first received 11 June 2015). GlaxoSmithKline[444563-022]. A phase II, double-blind, randomized, placebo-controlled study to assess the safety, reactogenicity and immunogenicity of three doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine. www.gsk-studyregister.com/study/6790 (accessed 12 December 2018). ISRCTN11877362. A phase II, double-blind, randomised, placebo-controlled study to assess the safety, reactogenicity and immunogenicity of three doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine (RIX4414 at 106.5 CCID50) administered to human immunodeficiency virus (HIV) infected infants at 6, 10 and 14 weeks of age in South Africa. www.controlled-trials.com/ISRCTN11877362 (first received 25 November 2005). NCT00263666. A study of safety, reactogenicity and immunogenicity of HRV vaccine in HIV infected infants in South Africa. clinicaltrials.gov/ct2/show/results/NCT00263666 (first received on 9 December 2005). SteeleAD ,  MadhiSA ,  LouwCE ,  BosP ,  TumboJM ,  WernerCM ,  et al. Safety, reactogenicity, and immunogenicity of human rotavirus vaccine RIX4414 in human immunodeficiency virus-positive infants in South Africa. Pediatric Infectious Diseases Journal2011;30(2):125-30. ">RIX Steele 2010a‐ZAF</a>; <a href="./references#CD008521-bbs2-0030" title="GlaxoSmithKline[444563-013]. A phase II, double-blind before the 2002 rotavirus season and single blind with respect to OPV after, randomised, placebo-controlled study of the safety, reactogenicity and immunogenicity of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine (RIX4414 at 105 ffu) co-administered with either oral polio vaccine (OPV) or inactivated polio vaccine (IPV) in healthy infants (approximately 5-10 weeks old) in South Africa. www.gsk-studyregister.com/study/6786 (accessed 12 December 2018). ISRCTN37373664. A double blind, randomised placebo controlled study of the safety, reactogenicity and immunogenicity of two doses of orally administered human rotavirus vaccine (RIX4414) in healthy infants in South Africa. controlled-trials.com/ISRCTN37373664 (first received 25 November 2005). NCT00383903. A study of the safety, reactogenicity and immunogenicity of 2 or 3 doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants (approximately 5-10 weeks old) in South Africa. clinicaltrials.gov/show/NCT00383903 (first received 3 October 2006). SteeleAD ,  ReyndersJ ,  ScholtzF ,  BosP ,  De BeerMC ,  TumboJ ,  et al. Comparison of 2 different regimens for reactogenicity, safety, and immunogenicity of the live attenuated oral rotavirus vaccine RIX4414 coadministered with oral polio vaccine in South African infants. Journal of Infectious Diseases2010;202(Suppl):S93-100. ">RIX Steele 2010b‐ZAF</a>; <a href="./references#CD008521-bbs2-0037" title="GlaxoSmithKline[103992-045]. A phase II, randomised, double-blind, placebo-controlled study to evaluate the immunogenicity, reactogenicity and safety of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine (RIX4414 at 106.5 CCID50) when given concomitantly with OPV versus when given alone (HRV vaccine dose given 15 days after the OPV dose) in healthy infants in Bangladesh. www.gsk-studyregister.com/study/2748 (accessed 12 December 2018). NCT00139334. Evaluate immunogenicity, reactogenicity &amp; safety of 2 doses of GSK Biologicals’ oral live attenuated HRV vaccine (RIX4414 at 106.5 CCID50) when given concomitantly with OPV versus given alone (HRV vaccine dose given 15 days after the OPV dose) in healthy infants in Bangladesh. clinicaltrials.gov/show/NCT00139334 (first received 31 August 2005). ZamanK , SackDA , YunusM , ArifeenSE , PodderG , AzimT , et al, Bangladesh Rotavirus Vaccine study group. Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age. Vaccine2009;27(9):1333-9. ">RIX Zaman 2009‐BGD</a>). Data below are grouped accordingly. </p> <section id="CD008521-sec-0126"> <p><b>Low‐mortality countries</b></p> <p><b>Safety trials (up to two months follow‐up):</b> Rotarix was not superior to placebo in the prevention of rotavirus diarrhoea in the trials assessing outcomes up to two months after vaccination (RR 0.88, 95% CI 0.23 to 3.32; 2061 participants, 4 trials). These trials, although reporting cases of rotavirus diarrhoea, were not designed to measure efficacy. </p> <p><b>Efficacy trials (one to three years follow‐up):</b> Rotarix reduced rotavirus diarrhoea by 85% at up to one year (RR 0.15, 95% CI 0.10 to 0.24; 4457 participants, 3 trials) and 78% at up to two years of follow‐up (RR 0.22, 95% CI 0.18 to 0.27; 6878 participants, 4 trials). At the third year of follow‐up, there were very few reported cases of rotavirus diarrhoea of any severity. Based on a single trial (<a href="./references#CD008521-bbs2-0034" title="VesikariT , et al. Human rotavirus vaccine Rotarix is highly efficacious in Europe. In: 24th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); 2006 June 15-18; Basel, Switzerland. 2006. [Not available for review]VesikariT , et al. Rotarix, an oral human Rotavirus vaccine, is highly immunogenic in healthy infants from 6 European countries. In: 24th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); 2006 June 15-18; Basel, Switzerland. 2006. [Not available for review]GlaxoSmithKline[102247-036]. A phase IIIb, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants in co-administration with specific childhood vaccinations [This summary presents results from the first efficacy period] [102247-036]. www.gsk-studyregister.com/study/2669 (accessed 12 December 2018). GlaxoSmithKline[102247-036-Annex]. A phase IIIb, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants in co-administration with specific childhood vaccinations [This summary presents results for the second and combined efficacy periods]. www.gsk-studyregister.com/study/2669 (accessed 12 December 2018). GlaxoSmithKline[102247-036-Yr3]. A phase IIIb, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants in co-administration with specific childhood vaccinations [A phase IIIb open study to assess the long-term efficacy and safety of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine approximately three years after vaccination in healthy infants aged 6-12 weeks at the time of first vaccination in the Rota-036 study (eTrack No.102247) in Finland]. www.gsk-studyregister.com/study/2669 (accessed 12 December 2018). NCT00140686. A multi-country &amp; multi-center study to assess the efficacy, safety &amp; immunogenicity of 2 doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants in co-administration with specific childhood vaccines. clinicaltrials.gov/ct2/show/record/NCT00140686 (first received 1 September 2005). [Trial registration document]NCT00420316. To assess long-term efficacy &amp; safety of subjects approximately 3 years after priming with 2 doses of GlaxoSmithKline (GSK) Biologicals' oral live attenuated human rotavirus (HRV) vaccine (Rotarix) in the primary vaccination study (102247). clinicaltrials.gov/show/NCT00420316 (first received 11 January 2007). SchusterV , OttoW , CohenR . RotarixTM an oral human Rotavirus vaccine, is highly immunogenic when co-administered with a Streptococcus pneumoniae conjugate vaccine (PrevenarTM) in healthy infants from France and Germany. In: 24th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); 2006 June 15-18; Basel, Switzerland. 2006. [Not available for review]TejedorJC , Diez-DelegadoJ , AristeguiJ . Rotarix (RIX4414), an oral Human Rotavirus vaccine, is highly immunogenic when co-administered with a Neisseria meningitides Serogroup C vaccine (MeningitecTM) in healthy infants from Spain. In: 24th Annual Meeting Meeting of the European Society for Paediatric Infectious Diseases (ESPID); 2006 June 15-18; Basel, Switzerland. 2006. [Not available for review]VesikariT ,  KarvonenA ,  PrymulaR ,  SchusterV ,  TejedorJC ,  ThollotF ,  et al. Immunogenicity and safety of the human rotavirus vaccine Rotarix co-administered with routine infant vaccines following the vaccination schedules in Europe. Vaccine2010;28(32):5272-9. VesikariT , KarvonenA , FerranteSA , KuterBJ , CiarletM . Sustained efficacy of the pentavalent rotavirus vaccine, RV5, up to 3.1 years following the last dose of vaccine. Pediatric Infectious Disease Journal2010;29(10):957-63. VesikariT , KarvonenA , PrymulaR , SchusterV , TejedorJC , CohenR , et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet2007;370(9601):1757-63. VesikariT , PrymulaR , SchusterV , TejedorJC , CohenR , BouckenoogheA , et al. Efficacy and immunogenicity of live-attenuated human rotavirus vaccine in breast-fed and formula-fed European infants. Pediatric Infectious Disease Journal2012;31(5):509-13. VesikariT , PrymulaR , SchusterV . Early protection against Rotavirus, Rotarix, experience in an European setting. In: 12th International Congress for Infectious Diseases; 2006 June 15-18; Lisbon, Portugal. 2006. [Not available for review]VesikariT , PrymulaR , SchusterV . Rotarix (RIX4414), an oral human rotavirus vaccine, is highly immunogenic when co-administered with diphteria-tetanus-pertussis (DTPA)-combined vaccines in healthy infants from Europe. In: 24th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); 2006 June 15-18; Basel, Switzerland. 2006. [Not available for review]">RIX Vesikari 2007a‐EU</a>, 1590 participants), there was no difference between Rotarix and placebo groups (data not shown). </p> </section> <section id="CD008521-sec-0127"> <p><b>Medium‐mortality countries</b></p> <p><b>Safety trials (up to two months follow‐up):</b> Rotarix was not superior to placebo in the prevention of rotavirus diarrhoea in the trials assessing outcomes up to two months after vaccination (RR 1.21, 95% CI 0.07 to 22.23; 444 participants, 1 trial). This trial, although reporting cases of rotavirus diarrhoea, was not designed to measure efficacy. </p> <p><b>Efficacy trials (one to two years follow‐up):</b> Rotarix reduced rotavirus diarrhoea by 66% at up to one year (RR 0.34, 95% CI 0.26 to 0.44; 5192 participants, 2 trials) and 54% at up to two years of follow‐up (RR 0.46, 95% CI 0.35 to 0.59; 3665 participants, 2 trials).  </p> </section> <section id="CD008521-sec-0128"> <p><b>High‐mortality countries</b></p> <p><b>Safety trials (up to two months follow‐up):</b> Three trials found no difference in the Rotarix group compared to placebo when outcomes were assessed up to two months after vaccination (RR 1.21, 95% CI 0.65 to 2.22; 1789 participants, 7 trials). </p> <p><b>Efficacy trials (one to two years follow‐up):</b> Rotarix reduced rotavirus diarrhoea by 49% during the first year of follow‐up (RR 0.51, 95% CI 0.39 to 0.68; 9951 participants, 5 comparisons from 4 trials), and by 45% at up to two years follow‐up (RR 0.55, 95% CI 0.32 to 0.93; 5600 participants, 2 trials). Pooled results showed statistical heterogeneity at one‐year follow‐up (I<sup>2</sup> = 70%, <a href="./references#CD008521-fig-0018" title="">Analysis 1.14</a>) and at up to two years follow‐up (I<sup>2</sup> = 77%, <a href="./references#CD008521-fig-0020" title="">Analysis 1.16</a>). </p> </section> </section> <section id="CD008521-sec-0129"> <h6 class="title">1.2.4. All‐cause diarrhoea: of any severity</h6> <p>This outcome was reported as cases in five trials from low‐mortality countries (<a href="./references#CD008521-bbs2-0013" title="GlaxoSmithKline[112269-068]. Immunogenicity, reactogenicity and safety study to evaluate two doses of the lyophilised formulation of the human rotavirus (HRV) vaccine when administered to healthy Korean infants previously uninfected with HRV. www.gsk-studyregister.com/study/3589 (accessed 12 December 2018). KimJS , BaeCW , LeeKY , ParkMS , ChoiYY , KimKN , et al. Immunogenicity, reactogenicity and safety of a human rotavirus vaccine (RIX4414) in Korean infants: a randomized, double-blind, placebo-controlled, phase IV study. Human Vaccines and Immunotherapeutics2012;8(6):806-12. NCT00969228. Study to evaluate immunogenicity, reactogenicity and safety of Rotarix™ vaccine in Korean infants. clinicaltrials.gov/ct2/show/NCT00969228 (first received 1 September 2009). ">RIX Kim 2012‐KOR</a>; <a href="./references#CD008521-bbs2-0022" title="GlaxoSmithKline[106481-054]. Phase IIIb, double blind, randomised, placebo-controlled, multi-country/centre, study to assess safety, reactogenicity &amp; immunogenicity of 2 doses of GSK Biologicals' oral live attenuated Human Rotavirus (HRV) vaccine in pre-term infants. www.gsk-studyregister.com/study/3064 (accessed 12 December 2018). NCT00420745. Phase IIIb, double blind, randomised, placebo-controlled, multi-country/centre, study to assess safety, reactogenicity &amp; immunogenicity of 2 doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine in pre-term infants. clinicaltrials.gov/show/NCT00420745 (first received 11 January 2007). OmenacaF , SarlangueJ , SzenbornL , NogueiraM , SuryakiranPV , SmolenovIV , et al. Safety, reactogenicity and immunogenicity of the human rotavirus vaccine in preterm European infants: a randomized phase IIIb study. Pediatric Infectious Disease Journal2012;31(5):487-93. ">RIX Omenaca 2012‐EU</a>; <a href="./references#CD008521-bbs2-0023" title="EmmanuelB , et al. Immunogenicity of an acellular pertussis combination vaccine co-administered with a novel rotavirus vaccine in Singaporean infants. Asian Congress on Pediatric Infectious Diseases (ACPID); 2-4 September 2004; Kota Kinabula, Malaysia2004. [Not available for review]PhuaKB , et al. Immunogenicity and reactogenicity of two doses of an oral human rotavirus (HRV) vaccine at different concentrations in healthy infants from Singapore. In: 11th Asia Pacific Congress of Pediatrics and the 3rd Asia Pacific Congress of Pediatric Nursing; 2003; Bangkok, Thailand. 2003. [Not available for review]PhuaKB , et al. Intussusception in children: a seven-year experience in Singapore. In: 24th International Congress of Pediatrics (ICP); 2004 August 15-20; Cancun, Mexico. 2004. [Not available for review]VesikariT , et al. High efficacy of two doses of Rotarix™ (RIX4414) against rotavirus disease in Europe, Latin-America and Asia. In: Asian Congress on Pediatric Infectious Diseases (ACPID); 2006 March 07-10; Cebu, Philippines. 2006. [Not available for review]De VosB , GillardP , CheuvartB . RIX4414 vaccine efficacy against rotavirus gastroenteritis due to G2P[4] strain. In: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2006 September 27-30; San Francisco, USA. 2006. [Not available for review]De VosB , VesikariT , LinharesAC , SalinasB , Perez-SchaelI , Ruiz-PalaciosGM , et al. A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis. Pediatric Infectious Disease Journal2004;23(10 Suppl):179-82. [No data for review]EmmanuelS , PhuaKB , GohP , QuakSH , DattaSK , HanHH , et al. Immunogenicity of an acellular pertussis combination vaccine co-administered with a novel rotavirus vaccine in Singaporean infants. In: 23rd Annual Meeting of European Society for Paediatric Infectious Diseases (ESPID); 2005 May 18-20; Valencia, Spain. 2005. [Not available for review]GlaxoSmithKline[444563-007]. A phase IIb, double-blind, randomized, placebo-controlled study to assess the efficacy, immunogenicity, reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine at different viral concentrations (104.7, 105.2 and 106.1 foci forming units (ffu)) in healthy infants previously uninfected with human rotavirus and approximately three months of age, when administered concurrently with DTPa-IPV/Hib and HBV vaccines. www.gsk-studyregister.com/study/6785 (accessed 12 December 2018). NCT00429481. A study to assess the efficacy, immunogenicity and safety of 2 doses of oral live attenuated human rotavirus vaccine (Rotarix) at different viral concentrations in healthy infants. clinicaltrials.gov/ct2/show/record/NCT00429481 (first received 31 January 2007). PhuaKB , EmmanuelSC , GohP , QuakSH , LeeBW , HanHH , et al. A rotavirus vaccine for prophylaxis of infant rotavirus gastroenteritis: the Asian experience. Annals of the Academy of Medicine, Singapore2006;35(1):38-44. PhuaKB , QuakSH , EmmanuelS , GohPS , HanHH , HardtK , et al. A short report on highlights of worldwide development of RIX4414: a Singaporean experience. Vaccine2006;24(18):3782-3. PhuaKB , QuakSH , EmmanuelS , GohPSC , HanHH , HardtK , et al. Highlights of world-wide development: a Singapore experience. In: 3rd International Conference on Vaccines for Enteric Diseases (VED) 28-30 April 2004; Montego Bay, Jamaica. 2004. [Not available for review]PhuaKB , QuakSH , LeeBW , EmmanuelSC , GohP , HanHH , et al. Evaluation of RIX4414, a live, attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled phase 2 trial involving 2464 Singaporean infants. Journal of Infectious Diseases2005;192(Suppl 1):6-16. PhuaKB , QuakSH , LimFS , GohP , TeohYL , DattaSK , et al. Immunogenicity, reactogenicity and safety of a diphtheria-tetanus-acellular pertussis-inactivated polio and Haemophilus influenzae type b combination vaccine in a placebo-controlled rotavirus vaccine study. Annals of the Academy of Medicine, Singapore2008;37(7):546-53. VesikariT . RIX4414: a new attenuated human rotavirus vaccine. In: 23rd Annual Meeting of European Society for Paediatric Infectious Diseases (ESPID); 2005 May 18-20; Valencia, Spain. 2005. [Not available for review]">RIX Phua 2005‐SGP</a>; <a href="./references#CD008521-bbs2-0033" title="De VosB , VesikariT , LinharesAC , SalinasB , Perez-SchaelI , Ruiz-PalaciosGM , et al. A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis. Pediatric Infectious Disease Journal2004;23(10 Suppl):179-82. GlaxoSmithKline[444563-004]. A phase IIb, double-blind, randomized, placebo-controlled study to assess the efficacy, immunogenicity, reactogenicity and safety of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants approximately 2 months of age and previously uninfected with HRV [Results for the first efficacy period (starting from 2 weeks after dose 2 until the end of the first RV season following vaccination)]. www.gsk-studyregister.com/study/6782 (accessed 12 December 2018). GlaxoSmithKline[444563-004-Annex]. A phase IIb, double-blind, randomized, placebo-controlled study to assess the efficacy, immunogenicity, reactogenicity and safety of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants approximately 2 months of age and previously uninfected with HRV [This summary presents results for the second efficacy period (from the end of the first rotavirus season post-vaccination until the end of the second rotavirus season) and for the two consecutive rotavirus seasons]. www.gsk-studyregister.com/study/6782 (accessed 12 December 2018). NCT00425737. A study to assess the efficacy, immunogenicity and safety of two doses of oral live attenuated human rotavirus (HRV) vaccine (Rotarix) in healthy infants. clinicaltrials.gov/show/NCT00425737 (first received 23 January 2007). VesikariT , KarvonenA , EspoM , KorhonenT , DelemA , De VosB . Efficacy evaluation of an oral human rotavirus (HRV) vaccine in previously uninfected Finnish infants. In: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 September 27-30; San Diego, California. 2002. [Not available for review]VesikariT , KarvonenA , PuustinenL , ZengSQ , SzakalED , DelemA , et al. Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants. Pediatric Infectious Disease Journal2004;23(10):937-43. ">RIX Vesikari 2004b‐FIN</a>; <a href="./references#CD008521-bbs2-0035" title="VesikariT , et al. Immunogenicity of liquid formulation of the oral live attenuated human rotavirus vaccine (Rotarix™) [poster]. Sociedad Latinoamericana de Infectología Pediátrica (SLIPE). San Jose, Costa Rica 8-11 May 2007. [Not available for review]GlaxoSmithKline[104480-048]. A phase II, double-blind, randomized, placebo controlled study to compare the immunogenicity, reactogenicity and safety of two different formulations of GlaxoSmithKline (GSK) Biologicals’ live attenuated human rotavirus (HRV) vaccine given as a two-dose primary vaccination in healthy infants previously uninfected with HRV. www.gsk-studyregister.com/study/2783 (accessed 12 December 2018). NCT00137930. Compare the immunogenicity, reactogenicity &amp; safety of 2 different formulations of GSK Biologicals’ live attenuated human rotavirus (HRV) vaccine given as a two-dose primary vaccination in healthy infants previously uninfected with HRV. clinicaltrials.gov/ct2/show/record/NCT00137930 (first received 30 August 2005). VesikariT , KarvonenA , BouckenoogheA , SuryakiranPV , SmolenovI , HanHH . Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 oral suspension (liquid formulation) in Finnish infants. Vaccine2011;29(11):2079-84. ">RIX Vesikari 2011‐FIN</a>), in four trials from medium‐mortality countries (<a href="./references#CD008521-bbs2-0012" title="GlaxoSmithKline[103477-039]. A phase IIIb, partially blind, randomized, placebo-controlled study to asses the effect on immunogenicity of administration of vaccine without buffering agent and to assess heat stability in terms of immunogenicity, reactogenicity and safety of GlaxoSmithKline Biologicals’ oral live attenuated human rotavirus (HRV) vaccine following a 0, 2 month schedule, in healthy infants previously uninfected with human rotavirus. www.gsk-studyregister.com/study/2713 (accessed 12 December 2018). KerdpanichA , ChokephaibulkitK , WatanaveeradejV , VanpraparN , HutagalungY , HanHH , et al. Exposure to elevated temperature of 37°C for 7 days does not affect immunogenicity and reactogenicity of RIX4414 [poster]. In: dsRNA Virus Meeting; 2006 October 21-26; Cape Town, South Africa. 2006. [Not available for review]KerdpanichA , ChokephaibulkitK , WatanaveeradejV , VanpraparN , SimasathienS , PhavichitrN , et al. Immunogenicity of a human rotavirus vaccine (RIX4414) after storage at 37 degrees C for seven days. Human Vaccine2011;7(1):74-80. KerdpanichA , ChokephaibulkitK , WatanaveeradejV , VanpraparN , SimasathienS , PhavichitrN , et al. Immunogenicity of a live-attenuated human rotavirus RIX4414 vaccine with or without buffering agent. Human Vaccines2010;6(3):254-62. NCT00169455. Assess the effect on immunogenicity of administration of vaccine without buffering agent &amp; assess heat stability in terms of immunogenicity, reactogenicity &amp; safety of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine following a 0, 2 m schedule, in healthy infants previously uninfected with human rotavirus. clinicaltrials.gov/show/NCT00169455 (first received 15 September 2005). ">RIX Kerdpanich 2010‐THA</a>; <a href="./references#CD008521-bbs2-0016" title="GlaxoSmithKline[113808-075]. Efficacy, immunogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals' oral live attenuated liquid Human Rotavirus (HRV) vaccine (444563), in healthy infants. www.gsk-studyregister.com/study/4036 (accessed 12 December 2018). LiRC , HuangT , LiY , LuoD , TaoJ , FuB , et al. Human rotavirus vaccine (RIX4414) efficacy in the first two years of life: a randomized, placebo-controlled trial in China. Human Vaccines and Immunotherapeutics2014;10(1):11-8. LiRC , HuangT , LiY , WangLH , TaoJ , FuB , et al. Immunogenicity and reactogenicity of the human rotavirus vaccine, RIX4414 oral suspension, when co-administered with routine childhood vaccines in Chinese infants. Human Vaccines and Immunotherapeutics2016;12(3):785-93. NCT01171963. Efficacy, immunogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals' oral live attenuated liquid human rotavirus (HRV) vaccine (444563), in healthy infants. clinicaltrials.gov/show/NCT01171963 (first received 29 July 2010). ">RIX Li 2014‐CHN</a>; <a href="./references#CD008521-bbs2-0025" title="EUCTR2015-001542-29. Immunization of infants 6-14 weeks of age, with GlaxoSmithKline Biologicals Rotavirus vaccine to explore the existence of transmission of rotavirus vaccine strain between twins in a family. clinicaltrialsregister.eu/ctr-search/trial/2015-001542-29/results (first received 22 June 2015). NCT00396630. A Phase IIIb, randomized, double-blind, placebo-controlled study to explore the existence of horizontal transmission of the RIX4414 vaccine strain between twins within a family. clinicaltrials.gov/show/NCT00396630 (first received 7 November 2006). RiveraL ,  PeñaLM ,  StainierI ,  GillardP ,  CheuvartB ,  SmolenovI , et al. Horizontal transmission of a human rotavirus vaccine strain - a randomized, placebo-controlled study in twins. Vaccine2011;29(51):9508-13. ">RIX Rivera 2011‐DOM</a>; <a href="./references#CD008521-bbs2-0027" title="Ruiz-PalaciosG , GuerreroL , LinharesAC , et al. Efficacy of an oral human rotavirus (HRV) vaccine in preventing diarrhoea due to G1 and non-G1 rotavirus [Presentation]. In: 3rd World Congress of Pediatric Infectious Diseases; 2002 November 19-23; Santiago, Chile. 2002. [Not available for review]Ruiz-PalaciosG , GuerreroML , LinharesAC , et al. Two-year efficacy of GlaxoSmithKline Biologicals' live attenuated rotavirus vaccine in Latin American children [poster]. In: 24th International Congress of Pediatrics; 2004 August 15-20; Cancun, Mexico. 2004. [Not available for review]SalinasB , Perez-SchaelI , Ruiz-PalaciosG , et al. Early protection by GlaxoSmithKline Biologicals' live attenuated rotavirus vaccine in Latin American children [poster]. In: 24th International Congress of Pediatrics; 2004 August 15-20; Cancun, Mexico. 2004. [Not available for review]SalinasB , TomatMA , YarzabalJP , et al. Efficacy of the rotavirus vaccine (RIX4414) among infants in Carabobo State, Venezuela [poster]. In: Asocación Venezolana para el Avance de la Cienca (AsoVAC); 2004; Venezuela. 2004. [Not available for review]AraujoEC , ClemensSA , OliveiraCS , JustinoMC , RubioP , GabbayYB , et al. Safety, immunogenicity, and protective efficacy of two doses of RIX4414 live attenuated human rotavirus vaccine in healthy infants. Jornal de Pediatria2007;83(3):217-24. De VosB , HardtK , LinharesAC , Ruiz-PalaciosG , GuerreroL , SalinasB . Efficacy of two doses of a human monovalent rotavirus vaccine, Rotarix™ in preventing gastro-enteritis due to G1 and Non-G1 rotavirus in Brazil, Mexico and Venezuela [presentation]. In: 8th International Symposium on Double-Stranded RNA Viruses; 2003 September 13-18; Lucca, Italy. 2003. [Not available for review]De VosB , VesikariT , LinharesAC , SalinasB , Perez-SchaelI , Ruiz-PalaciosGM , et al. A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis. Pediatric Infectious Disease Journal2004;23(10 Suppl):179-82. GlaxoSmithKline[444563-006]. A phase IIb, double-blind, randomized, placebo-controlled study to assess the efficacy, immunogenicity, reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals' live attenuated human rotavirus (HRV) vaccine at different virus concentrations (104.7, 105.2 and 105.8 foci forming units [ffu]) in healthy infants (approximately 2 months of age at first dose) following a 0, 2 month schedule and previously uninfected with HRV, when administered concurrently with DTPw-HBV and Hib vaccines. www.gsk-studyregister.com/study/6784 (accessed 12 December 2018). GlaxoSmithKline[444563-006-Annex]. A phase IIb, double-blind, randomized, placebo-controlled study to assess the efficacy, immunogenicity, reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals' live attenuated human rotavirus (HRV) vaccine at different virus concentrations (104.7, 105.2 and 105.8 foci forming units [ffu]) in healthy infants (approximately 2 months of age at first dose) following a 0, 2 month schedule and previously uninfected with HRV, when administered concurrently with DTPw-HBV and Hib vaccines [This summary presents results for the second and combined efficacy periods and results from the 3-Dose subset. Results from the first efficacy period are presented in 444563/006 (Rota-006) summary]. www.gsk-studyregister.com/study/6784 (accessed 12 December 2018). LinharesA , Perez-SchaelI , Ruiz-PalaciosM , PernambucoE , JacquetJ , De VosB . Immunogenicity and reactogenicity of an oral human rotavirus (HRV) vaccine in Latin American infants [poster]. In: 3rd World Congress of Pediatric Infectious Diseases; 2002 November 19-23; Santiago, Chile. 2002. [Not available for review]LinharesAC , Ruiz-PalaciosGM , GuerreroML , SalinasB , Perez-SchaelI , ClemensSA , et al. A short report on highlights of world-wide development of RIX4414: a Latin American experience. Vaccine2006;24(18):3784-5. LinharesAC , VerstraetenT , Wolleswinkel-Van den BoschJ , ClemensR , BreuerT . Rotavirus serotype G9 is associated with more-severe disease in Latin America. Clinical Infectious Diseases2006;43(3):312-4. [Not available for review]NCT00385320. To assess the efficacy, immuno &amp; safety of 2 doses of GSK HRV vaccine at different virus concentrations in healthy infants aged 2 months &amp; previously uninfected with HRV, concurrently given with DTPw-HBV, Hib. clinicaltrials.gov/show/NCT00385320 (first received 9 October 2006). Perez-SchaelI , SalinasB , LinharesA , GuerreroM , Ruiz-PalaciosG , ClemensS , et al. Protective efficacy of an oral human rotavirus (HRV) vaccine in Latin American infants [poster]. In: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy ( ICAAC); San Diego, 27-30 September 2002. 2002:18, LB-23. [Not available for review]Perez-SchaelI , SalinasB , TomatM , LinharesAC , GuerreroML , Ruiz-PalaciosGM , et al. Efficacy of the human rotavirus vaccine RIX4414 in malnourished children. Journal of Infectious Diseases2007;196(4):537-40. Ruiz-PalaciosGM , GuerreroML , Bautista-MarquezA , Ortega-GallegosH , Tuz-DzibF , Reyes-GonzalezL , et al. Dose response and efficacy of a live, attenuated human rotavirus vaccine in Mexican infants. Pediatrics2007;120(2):e253-61. [Not available for review]Ruiz-PalaciosGM . Impact of maternal antibodies on the immune response to an oral human rotavirus (HRV) vaccine in Mexican infants [presentation]. In: 3rd World Congress of Pediatric Infectious Diseases; 2002 November 19-23; Santiago, Chile. 2002. [Not available for review]SalinasB , Perez SchaelI , LinharesAC , Ruiz PalaciosGM , GuerreroML , YarzabalJP , et al. Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: a randomized, placebo-controlled trial in Latin American infants. Pediatric Infectious Disease Journal2005;24(9):807-16. ">RIX Salinas 2005‐LA</a>), and in four trials from high‐mortality countries (<a href="./references#CD008521-bbs2-0001" title="AnhDD , CarlosCC , ThiemDV , HutagalungY , GatchalianS , BockHL , et al. Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 (Rotarix) oral suspension (liquid formulation) when co-administered with expanded program on immunization (EPI) vaccines in Vietnam and the Philippines in 2006-2007. Vaccine2011;29(11):2029-36. GlaxoSmithKline[109216-063]. A phase II, randomized, double-blind, placebo-controlled study to evaluate the immunogenicity, reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) liquid vaccine, when given to healthy infants, in Philippines. www.gsk-studyregister.com/study/3204 (accessed 12 December 2018). NCT00432380. Immunogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals' oral live attenuated human rotavirus (HRV) liquid vaccine (GSK 357941A) in healthy infants. clinicaltrials.gov/show/NCT00432380 (first received 7 February 2007). ">RIX Anh 2011‐PHL</a>; <a href="./references#CD008521-bbs2-0002" title="AnhDD , CarlosCC , ThiemDV , HutagalungY , GatchalianS , BockHL , et al. Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 (Rotarix) oral suspension (liquid formulation) when co-administered with expanded program on immunization (EPI) vaccines in Vietnam and the Philippines in 2006-2007. Vaccine2011;29(11):2029-36. AnhDD , ThiemVD , HutagalungY , BockHL , SuryakiranP , DelemA , et al. Immunogenicity, reactogenicity and safety of the oral live attenuated human rotavirus vaccine RIX4414 (Rotarix™) oral suspension (liquid formulation) in Vietnamese Infants. In: 13th International Congress on Infectious Diseases Abstracts, Poster Presentations; June 19–22, 2008; Kuala Lumpur, Malaysia. 2008. GlaxoSmithKline[105722-051]. A phase II, randomized, double-blind, placebo-controlled study to evaluate the immunogenicity, reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) liquid vaccine, when given to healthy infants, in Vietnam. www.gsk-studyregister.com/study/3012 (accessed 12 December 2018). NCT00345956. A placebo-controlled study to evaluate the immunogenicity, reactogenicity and safety of two doses of GSK Bio oral live attenuated human rotavirus (HRV) liquid vaccine, when given to healthy infants, in Vietnam. clinicaltrials.gov/show/NCT00345956 (first received 29 June 2006). ">RIX Anh 2011‐VNM</a>; <a href="./references#CD008521-bbs2-0005" title='ColgateER , HaqueR , DicksonDM , CarmolliMP , MychaleckyjJC , NayakU , et al. Delayed dosing of oral rotavirus vaccine demonstrates decreased risk of rotavirus gastroenteritis associated with serum zinc: a randomized controlled trial. Clinical Infectious Diseases2016;63(5):634-41. KirkpatrickBD , ColgateER , MychaleckyjJC , HaqueR , DicksonDM , CarmolliMP , et al. The "Performance of Rotavirus and Oral Polio Vaccines in Developing Countries" (PROVIDE) study: description of methods of an interventional study designed to explore complex biologic problems. American Journal of Tropical Medicine and Hygiene2015;92(4):744-51. LeeB , DicksonDM , DeCampAC , ColgateER , DiehlSA , UddinMI , et al. Histo-blood group antigen phenotype determines susceptibility to genotype-specific rotavirus infections and impacts measures of rotavirus vaccine efficacy. Journal of Infectious Diseases2018;217(9):1399-407. LeeB , DiehlSA , ColgateER , DicksonDM , UddinMI , SharminS , et al. Lewis antigen and secretor status mediate susceptibility to p-genotype specific rotavirus infections but do not affect rotavirus vaccine performance among infants in Bangladesh. American Journal of Tropical Medicine and Hygiene2017;97:226. NCT01375647. Exploration of the biologic basis for underperformance of oral polio and rotavirus vaccines in Bangladesh PROVIDE. clinicaltrials.gov/show/NCT01375647 (first received 17 June 2011). RogawskiET , Platts-MillsJA , ColgateER , HaqueR , ZamanK , PetriWA , et al. Quantifying the impact of natural immunity on rotavirus vaccine efficacy estimates: a clinical trial in Dhaka, Bangladesh (PROVIDE) and a simulation study. Journal of Infectious Diseases2018;217(6):861-8. '>RIX Colgate 2016‐BGD</a>; <a href="./references#CD008521-bbs2-0029" title="EUCTR2015-001484-39. A phase II study to assess the safety and immunogenicity of GlaxoSmithKline Biologicals rotavirus vaccine, RIX4414 when administered to HIV infected infants in South Africa. www.clinicaltrialsregister.eu/ctr-search/trial/2015-001484-39/results (first received 11 June 2015). GlaxoSmithKline[444563-022]. A phase II, double-blind, randomized, placebo-controlled study to assess the safety, reactogenicity and immunogenicity of three doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine. www.gsk-studyregister.com/study/6790 (accessed 12 December 2018). ISRCTN11877362. A phase II, double-blind, randomised, placebo-controlled study to assess the safety, reactogenicity and immunogenicity of three doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine (RIX4414 at 106.5 CCID50) administered to human immunodeficiency virus (HIV) infected infants at 6, 10 and 14 weeks of age in South Africa. www.controlled-trials.com/ISRCTN11877362 (first received 25 November 2005). NCT00263666. A study of safety, reactogenicity and immunogenicity of HRV vaccine in HIV infected infants in South Africa. clinicaltrials.gov/ct2/show/results/NCT00263666 (first received on 9 December 2005). SteeleAD ,  MadhiSA ,  LouwCE ,  BosP ,  TumboJM ,  WernerCM ,  et al. Safety, reactogenicity, and immunogenicity of human rotavirus vaccine RIX4414 in human immunodeficiency virus-positive infants in South Africa. Pediatric Infectious Diseases Journal2011;30(2):125-30. ">RIX Steele 2010a‐ZAF</a>). All‐cause diarrhoea of any severity was reported as episodes in one trial from low‐mortality countries (<a href="./references#CD008521-bbs2-0033" title="De VosB , VesikariT , LinharesAC , SalinasB , Perez-SchaelI , Ruiz-PalaciosGM , et al. A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis. Pediatric Infectious Disease Journal2004;23(10 Suppl):179-82. GlaxoSmithKline[444563-004]. A phase IIb, double-blind, randomized, placebo-controlled study to assess the efficacy, immunogenicity, reactogenicity and safety of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants approximately 2 months of age and previously uninfected with HRV [Results for the first efficacy period (starting from 2 weeks after dose 2 until the end of the first RV season following vaccination)]. www.gsk-studyregister.com/study/6782 (accessed 12 December 2018). GlaxoSmithKline[444563-004-Annex]. A phase IIb, double-blind, randomized, placebo-controlled study to assess the efficacy, immunogenicity, reactogenicity and safety of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants approximately 2 months of age and previously uninfected with HRV [This summary presents results for the second efficacy period (from the end of the first rotavirus season post-vaccination until the end of the second rotavirus season) and for the two consecutive rotavirus seasons]. www.gsk-studyregister.com/study/6782 (accessed 12 December 2018). NCT00425737. A study to assess the efficacy, immunogenicity and safety of two doses of oral live attenuated human rotavirus (HRV) vaccine (Rotarix) in healthy infants. clinicaltrials.gov/show/NCT00425737 (first received 23 January 2007). VesikariT , KarvonenA , EspoM , KorhonenT , DelemA , De VosB . Efficacy evaluation of an oral human rotavirus (HRV) vaccine in previously uninfected Finnish infants. In: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 September 27-30; San Diego, California. 2002. [Not available for review]VesikariT , KarvonenA , PuustinenL , ZengSQ , SzakalED , DelemA , et al. Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants. Pediatric Infectious Disease Journal2004;23(10):937-43. ">RIX Vesikari 2004b‐FIN</a>) and in two trials from medium‐mortality countries (<a href="./references#CD008521-bbs2-0025" title="EUCTR2015-001542-29. Immunization of infants 6-14 weeks of age, with GlaxoSmithKline Biologicals Rotavirus vaccine to explore the existence of transmission of rotavirus vaccine strain between twins in a family. clinicaltrialsregister.eu/ctr-search/trial/2015-001542-29/results (first received 22 June 2015). NCT00396630. A Phase IIIb, randomized, double-blind, placebo-controlled study to explore the existence of horizontal transmission of the RIX4414 vaccine strain between twins within a family. clinicaltrials.gov/show/NCT00396630 (first received 7 November 2006). RiveraL ,  PeñaLM ,  StainierI ,  GillardP ,  CheuvartB ,  SmolenovI , et al. Horizontal transmission of a human rotavirus vaccine strain - a randomized, placebo-controlled study in twins. Vaccine2011;29(51):9508-13. ">RIX Rivera 2011‐DOM</a>; <a href="./references#CD008521-bbs2-0027" title="Ruiz-PalaciosG , GuerreroL , LinharesAC , et al. Efficacy of an oral human rotavirus (HRV) vaccine in preventing diarrhoea due to G1 and non-G1 rotavirus [Presentation]. In: 3rd World Congress of Pediatric Infectious Diseases; 2002 November 19-23; Santiago, Chile. 2002. [Not available for review]Ruiz-PalaciosG , GuerreroML , LinharesAC , et al. Two-year efficacy of GlaxoSmithKline Biologicals' live attenuated rotavirus vaccine in Latin American children [poster]. In: 24th International Congress of Pediatrics; 2004 August 15-20; Cancun, Mexico. 2004. [Not available for review]SalinasB , Perez-SchaelI , Ruiz-PalaciosG , et al. Early protection by GlaxoSmithKline Biologicals' live attenuated rotavirus vaccine in Latin American children [poster]. In: 24th International Congress of Pediatrics; 2004 August 15-20; Cancun, Mexico. 2004. [Not available for review]SalinasB , TomatMA , YarzabalJP , et al. Efficacy of the rotavirus vaccine (RIX4414) among infants in Carabobo State, Venezuela [poster]. In: Asocación Venezolana para el Avance de la Cienca (AsoVAC); 2004; Venezuela. 2004. [Not available for review]AraujoEC , ClemensSA , OliveiraCS , JustinoMC , RubioP , GabbayYB , et al. Safety, immunogenicity, and protective efficacy of two doses of RIX4414 live attenuated human rotavirus vaccine in healthy infants. Jornal de Pediatria2007;83(3):217-24. De VosB , HardtK , LinharesAC , Ruiz-PalaciosG , GuerreroL , SalinasB . Efficacy of two doses of a human monovalent rotavirus vaccine, Rotarix™ in preventing gastro-enteritis due to G1 and Non-G1 rotavirus in Brazil, Mexico and Venezuela [presentation]. In: 8th International Symposium on Double-Stranded RNA Viruses; 2003 September 13-18; Lucca, Italy. 2003. [Not available for review]De VosB , VesikariT , LinharesAC , SalinasB , Perez-SchaelI , Ruiz-PalaciosGM , et al. A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis. Pediatric Infectious Disease Journal2004;23(10 Suppl):179-82. GlaxoSmithKline[444563-006]. A phase IIb, double-blind, randomized, placebo-controlled study to assess the efficacy, immunogenicity, reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals' live attenuated human rotavirus (HRV) vaccine at different virus concentrations (104.7, 105.2 and 105.8 foci forming units [ffu]) in healthy infants (approximately 2 months of age at first dose) following a 0, 2 month schedule and previously uninfected with HRV, when administered concurrently with DTPw-HBV and Hib vaccines. www.gsk-studyregister.com/study/6784 (accessed 12 December 2018). GlaxoSmithKline[444563-006-Annex]. A phase IIb, double-blind, randomized, placebo-controlled study to assess the efficacy, immunogenicity, reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals' live attenuated human rotavirus (HRV) vaccine at different virus concentrations (104.7, 105.2 and 105.8 foci forming units [ffu]) in healthy infants (approximately 2 months of age at first dose) following a 0, 2 month schedule and previously uninfected with HRV, when administered concurrently with DTPw-HBV and Hib vaccines [This summary presents results for the second and combined efficacy periods and results from the 3-Dose subset. Results from the first efficacy period are presented in 444563/006 (Rota-006) summary]. www.gsk-studyregister.com/study/6784 (accessed 12 December 2018). LinharesA , Perez-SchaelI , Ruiz-PalaciosM , PernambucoE , JacquetJ , De VosB . Immunogenicity and reactogenicity of an oral human rotavirus (HRV) vaccine in Latin American infants [poster]. In: 3rd World Congress of Pediatric Infectious Diseases; 2002 November 19-23; Santiago, Chile. 2002. [Not available for review]LinharesAC , Ruiz-PalaciosGM , GuerreroML , SalinasB , Perez-SchaelI , ClemensSA , et al. A short report on highlights of world-wide development of RIX4414: a Latin American experience. Vaccine2006;24(18):3784-5. LinharesAC , VerstraetenT , Wolleswinkel-Van den BoschJ , ClemensR , BreuerT . Rotavirus serotype G9 is associated with more-severe disease in Latin America. Clinical Infectious Diseases2006;43(3):312-4. [Not available for review]NCT00385320. To assess the efficacy, immuno &amp; safety of 2 doses of GSK HRV vaccine at different virus concentrations in healthy infants aged 2 months &amp; previously uninfected with HRV, concurrently given with DTPw-HBV, Hib. clinicaltrials.gov/show/NCT00385320 (first received 9 October 2006). Perez-SchaelI , SalinasB , LinharesA , GuerreroM , Ruiz-PalaciosG , ClemensS , et al. Protective efficacy of an oral human rotavirus (HRV) vaccine in Latin American infants [poster]. In: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy ( ICAAC); San Diego, 27-30 September 2002. 2002:18, LB-23. [Not available for review]Perez-SchaelI , SalinasB , TomatM , LinharesAC , GuerreroML , Ruiz-PalaciosGM , et al. Efficacy of the human rotavirus vaccine RIX4414 in malnourished children. Journal of Infectious Diseases2007;196(4):537-40. Ruiz-PalaciosGM , GuerreroML , Bautista-MarquezA , Ortega-GallegosH , Tuz-DzibF , Reyes-GonzalezL , et al. Dose response and efficacy of a live, attenuated human rotavirus vaccine in Mexican infants. Pediatrics2007;120(2):e253-61. [Not available for review]Ruiz-PalaciosGM . Impact of maternal antibodies on the immune response to an oral human rotavirus (HRV) vaccine in Mexican infants [presentation]. In: 3rd World Congress of Pediatric Infectious Diseases; 2002 November 19-23; Santiago, Chile. 2002. [Not available for review]SalinasB , Perez SchaelI , LinharesAC , Ruiz PalaciosGM , GuerreroML , YarzabalJP , et al. Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: a randomized, placebo-controlled trial in Latin American infants. Pediatric Infectious Disease Journal2005;24(9):807-16. ">RIX Salinas 2005‐LA</a>). We have reported on cases and episodes separately. </p> <section id="CD008521-sec-0130"> <p><b>Low‐mortality countries</b></p> <p><b>Safety trials (up to two months follow‐up):</b> Rotarix was not better than placebo in reducing the number of cases of all‐cause diarrhoea at two months follow‐up (RR 0.80, 95% CI 0.59 to 1.08; 1906 participants, 3 trials; <a href="./references#CD008521-fig-0021" title="">Analysis 1.17</a>). </p> <p><b>Efficacy trials (two years follow‐up):</b> Rotarix was not better than placebo in reducing the number of cases of all‐cause diarrhoea at two years follow‐up (RR 0.81, 95% CI 0.65 to 1.00; 2789 participants, 2 trials, <a href="./references#CD008521-fig-0023" title="">Analysis 1.19</a>). One trial reported the number of episodes, with little or no difference with Rotarix when compared to placebo at up to two years follow‐up (rate ratio 1.02, 95% CI 0.78 to 1.33; 736 participants, 1 trial; <a href="./references#CD008521-fig-0025" title="">Analysis 1.21</a>). </p> </section> <section id="CD008521-sec-0131"> <p><b>Medium‐mortality countries</b></p> <p><b>Safety trials (up to two months follow‐up):</b> Rotarix was not better than placebo in reducing the number of cases of all‐cause diarrhoea at two months follow‐up (RR 0.97, 95% CI 0.46 to 2.02; 444 participants, 1 trial; <a href="./references#CD008521-fig-0021" title="">Analysis 1.17</a>). </p> <p><b>Efficacy trials (one to two years follow‐up):</b> Rotarix was slightly better than placebo in reducing the number of cases of all‐cause diarrhoea at one‐year follow‐up (RR 0.89, 95% CI 0.80 to 0.98; 2244 participants, 2 trials, <a href="./references#CD008521-fig-0022" title="">Analysis 1.18</a>), and there was little or no difference at up to two years follow‐up (RR 0.95, 95% CI 0.90 to 1.01; 3665 participants, 2 trials; <a href="./references#CD008521-fig-0023" title="">Analysis 1.19</a>). Two trials reported the number of episodes, with little or no difference with Rotarix when compared to placebo at one year (rate ratio 0.98, 95% CI 0.88 to 1.10; 2204 participants, 2 trials; <a href="./references#CD008521-fig-0024" title="">Analysis 1.20</a>). </p> </section> <section id="CD008521-sec-0132"> <p><b>High‐mortality countries</b></p> <p><b>Safety trials (up to two months follow‐up):</b> Rotarix was not better than placebo in reducing the number of cases of all‐cause diarrhoea at two months follow‐up (RR 1.01, 95% CI 0.74 to 1.38; 3132 participants, 3 trials; <a href="./references#CD008521-fig-0021" title="">Analysis 1.17</a>). </p> <p><b>Efficacy trials (one‐year follow‐up):</b> Rotarix was not better than no intervention in reducing the number of cases of all‐cause diarrhoea at one‐year follow‐up (RR 0.99, 95% CI 0.93 to 1.05; 700 participants, 1 trial; <a href="./references#CD008521-fig-0022" title="">Analysis 1.18</a>). </p> </section> </section> <section id="CD008521-sec-0133"> <h6 class="title">1.2.5. All‐cause hospitalizations</h6> <p>Two trials (<a href="./references#CD008521-bbs2-0023" title="EmmanuelB , et al. Immunogenicity of an acellular pertussis combination vaccine co-administered with a novel rotavirus vaccine in Singaporean infants. Asian Congress on Pediatric Infectious Diseases (ACPID); 2-4 September 2004; Kota Kinabula, Malaysia2004. [Not available for review]PhuaKB , et al. Immunogenicity and reactogenicity of two doses of an oral human rotavirus (HRV) vaccine at different concentrations in healthy infants from Singapore. In: 11th Asia Pacific Congress of Pediatrics and the 3rd Asia Pacific Congress of Pediatric Nursing; 2003; Bangkok, Thailand. 2003. [Not available for review]PhuaKB , et al. Intussusception in children: a seven-year experience in Singapore. In: 24th International Congress of Pediatrics (ICP); 2004 August 15-20; Cancun, Mexico. 2004. [Not available for review]VesikariT , et al. High efficacy of two doses of Rotarix™ (RIX4414) against rotavirus disease in Europe, Latin-America and Asia. In: Asian Congress on Pediatric Infectious Diseases (ACPID); 2006 March 07-10; Cebu, Philippines. 2006. [Not available for review]De VosB , GillardP , CheuvartB . RIX4414 vaccine efficacy against rotavirus gastroenteritis due to G2P[4] strain. In: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2006 September 27-30; San Francisco, USA. 2006. [Not available for review]De VosB , VesikariT , LinharesAC , SalinasB , Perez-SchaelI , Ruiz-PalaciosGM , et al. A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis. Pediatric Infectious Disease Journal2004;23(10 Suppl):179-82. [No data for review]EmmanuelS , PhuaKB , GohP , QuakSH , DattaSK , HanHH , et al. Immunogenicity of an acellular pertussis combination vaccine co-administered with a novel rotavirus vaccine in Singaporean infants. In: 23rd Annual Meeting of European Society for Paediatric Infectious Diseases (ESPID); 2005 May 18-20; Valencia, Spain. 2005. [Not available for review]GlaxoSmithKline[444563-007]. A phase IIb, double-blind, randomized, placebo-controlled study to assess the efficacy, immunogenicity, reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine at different viral concentrations (104.7, 105.2 and 106.1 foci forming units (ffu)) in healthy infants previously uninfected with human rotavirus and approximately three months of age, when administered concurrently with DTPa-IPV/Hib and HBV vaccines. www.gsk-studyregister.com/study/6785 (accessed 12 December 2018). NCT00429481. A study to assess the efficacy, immunogenicity and safety of 2 doses of oral live attenuated human rotavirus vaccine (Rotarix) at different viral concentrations in healthy infants. clinicaltrials.gov/ct2/show/record/NCT00429481 (first received 31 January 2007). PhuaKB , EmmanuelSC , GohP , QuakSH , LeeBW , HanHH , et al. A rotavirus vaccine for prophylaxis of infant rotavirus gastroenteritis: the Asian experience. Annals of the Academy of Medicine, Singapore2006;35(1):38-44. PhuaKB , QuakSH , EmmanuelS , GohPS , HanHH , HardtK , et al. A short report on highlights of worldwide development of RIX4414: a Singaporean experience. Vaccine2006;24(18):3782-3. PhuaKB , QuakSH , EmmanuelS , GohPSC , HanHH , HardtK , et al. Highlights of world-wide development: a Singapore experience. In: 3rd International Conference on Vaccines for Enteric Diseases (VED) 28-30 April 2004; Montego Bay, Jamaica. 2004. [Not available for review]PhuaKB , QuakSH , LeeBW , EmmanuelSC , GohP , HanHH , et al. Evaluation of RIX4414, a live, attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled phase 2 trial involving 2464 Singaporean infants. Journal of Infectious Diseases2005;192(Suppl 1):6-16. PhuaKB , QuakSH , LimFS , GohP , TeohYL , DattaSK , et al. Immunogenicity, reactogenicity and safety of a diphtheria-tetanus-acellular pertussis-inactivated polio and Haemophilus influenzae type b combination vaccine in a placebo-controlled rotavirus vaccine study. Annals of the Academy of Medicine, Singapore2008;37(7):546-53. VesikariT . RIX4414: a new attenuated human rotavirus vaccine. In: 23rd Annual Meeting of European Society for Paediatric Infectious Diseases (ESPID); 2005 May 18-20; Valencia, Spain. 2005. [Not available for review]">RIX Phua 2005‐SGP</a>; <a href="./references#CD008521-bbs2-0026" title="Costa ClemensSA , et al. Operational organization of a large scale phase III clinical trial of rotavirus vaccine in multiple sites and countries in Latin America. In: International Congress of Pediatrics (ICP); 2004 August 15-20; Cancun, Mexico. 2004. [Not available for review]De VosB , et al. Rotarix™: an effective way to prevent rotavirus diarrhoea and vomiting. In: 9th Congress of the Asian Pan Pacific Society of Paediatric Gastroenterology, Hepatology and Nutrition &amp; 27th Annual Congress of the Malaysian Paediatric Association; 2005 June 16-19; Kuala Lumpur, Malaysia. 2005. [Not available for review]BaayM , BollaertsK , StruchinerC , VerstraetenT . Background rates of disease in Latin American children from a rotavirus vaccine study. Human Vaccines and Immunotherapeutics2017;13(8):1916-20. GlaxoSmithKline[444563-023-pt1]. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants (efficacy data from visit 1 to visit 4). www.gsk-studyregister.com/study/6791 (accessed 12 December 2018). GlaxoSmithKline[444563-023-pt2]. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants (2nd year efficacy from visit 4 to visit 6). www.gsk-studyregister.com/study/6791 (accessed 12 December 2018). GlaxoSmithKline[444563-023-pt3]. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants (safety for the period between visit 1 and visit 3). www.gsk-studyregister.com/study/6791 (accessed 12 December 2018). JustinoMC , AraújoEC , Van DoornLJ , OliveiraCS , GabbayYB , MascarenhasJD , et al. Oral live attenuated human rotavirus vaccine (Rotarix) offers sustained high protection against severe G9P[8] rotavirus gastroenteritis during the first two years of life in Brazilian children. Memorias do Instituto Oswaldo Cruz2012;107(7):846-53. LinharesAC , VelazquezFR , Perez-SchaelI , Saez-LlorensX , AbateH , EspinozaF , et al. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet2008;371(9619):1181-9. LopezP , LinharesA , Pérez-SchaelI , Ruiz-PalaciosG , Costa ClemensS , SanchezN . Early protection against severe rotavirus gastroenteritis - RIX4414 experience in Latin America. In: 24th Annual Meeting of European Society for Paediatric Infectious Diseases (ESPID); 2006 May 03-05; Basel, Switzerland. 2006. [Not available for review]MaciasM , LopezP , VelazquezFR , VergaraRF , SalmeronJ , TavaresJL . The rotavirus vaccine RIX4414 (Rotarix) is not associated with intussusception in one year old infants. In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2005 December 16-19; Washington DC, USA. 2005. [Not available for review]NCT00139347. A multi-country &amp; multi-center study to assess the efficacy, immunogenicity &amp; safety of two doses of GSK Biologicals' oral live attenuated HRV vaccine given concomitantly with routine EPI vaccinations including OPV in healthy infants. clinicaltrials.gov/ct2/show/NCT00139347 (first received 31 August 2005). [Trial registration document (no data for review)]NCT00140673. Placebo-controlled, multi-country &amp; multi-center study to assess the efficacy, safety &amp; immunogenicity of 2 doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants. clinicaltrials.gov/ct2/show/NCT00140673 (first received 1 September 2005). [Trial registration document (no data for review)]Perez-SchaelI , LinharesAC , VesikariT . Two doses of the human attenuated rotavirus vaccine RIX4414 (Rotarix) show heterotypic protection in Latin America and Europe. In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2005 December 16-19; Washington DC, USA. 2005. [Not available for review]PikeM . New rotavirus vaccine is effective and appears to have no increased risk of intussusception. Clinical Research Abstracts For Pediatricians2006;149(1):143. Ruiz-PalaciosG , AranzaC , VelazquezFR , RichardsonV , NandiE , MaciasM . Two doses of the human-attenuated monovalent G1P[8] rotavirus vaccine, Rotarix show high efficacy in Mexican children against severe rotavirus gastroenteritis and severe overall gastroenteritis. In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2005 December 16-19; Washington DC, USA. 2005. [Not available for review]Ruiz-PalaciosGM , Perez-SchaelI , VelazquezFR , AbateH , BreuerT , ClemensSC , et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. New England Journal of Medicine2006;354(1):11-22. VelázquezFR , AbatH , Costa ClemensSA , EspinozaF , GillardP , LinharesAC , et al. The human monovalent G1P[8] rotavirus vaccine, Rotarix is highly efficacious and provides crossprotection against G1 and non-G1 serotypes. In: 23rd Annual meeting of European Society for Paediatric Infectious Diseases (ESPID); 2005 May 18-20; Valencia, Spain. 2005. VelázquezRF , AbateH , BouckenoogheA . RIX4414, the human G1P[8] rotavirus vaccine is highly efficacious during the second year of life. In: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2006 September 27-30; San Francisco, USA. 2006. [Not available for review]VesikariT , O’RyanM , AbateH , Costa ClemensSA , EspinozaF , GillardP . Overcoming the safety hurdle: the rotavirus vaccine RIX4414 is not associated with intussusception. In: 23rd Annual Meeting of European Society for Paediatric Infectious Diseases (ESPID); 2005 May 18-20; Valencia, Spain. 2005. [Not available for review]">RIX Ruiz‐Palac 06‐LA/EU</a>) provided data for the efficacy of Rotarix to prevent all‐cause hospitalizations. </p> <section id="CD008521-sec-0134"> <p><b>Low‐mortality countries</b></p> <p>Rotarix reduced the number of all‐cause hospitalizations by 64% at up to two years of follow‐up (RR 0.36, 95% CI 0.15 to 0.86; 2421 participants, 1 trial; <a href="./references#CD008521-fig-0026" title="">Analysis 1.22</a>). </p> </section> <section id="CD008521-sec-0135"> <p><b>Medium‐mortality countries</b></p> <p>Rotarix slightly reduced the number of all‐cause hospitalizations at up to two years of follow‐up (RR 0.88, 95% CI 0.81 to 0.96; 63,225 participants, 1 trial; <a href="./references#CD008521-fig-0026" title="">Analysis 1.22</a>). </p> </section> </section> <section id="CD008521-sec-0136"> <h6 class="title">1.2.6. Rotavirus diarrhoea: requiring hospitalization or medical attention</h6> <p>Rotavirus‐related hospitalizations were reduced by 82% after one year (RR 0.18, 95% CI 0.09 to 0.33; 48,718 participants, 8 trials), 85% at two years (RR 0.15, 95% CI 0.11 to 0.22; 35,331 participants, 7 trials), and 95% at three years (RR 0.05, 95% CI 0.02 to 0.16; 10,519 participants, 1 trial (<a href="./references#CD008521-bbs2-0024" title="LauYL , NelsonEA , PoonKH , ChanPK , ChiuS , SungR , et al. Efficacy, safety and immunogenicity of a human rotavirus vaccine (RIX4414) in Hong Kong children up to three years of age: a randomized, controlled trial. Vaccine2013;31(18):2253-9. NCT00197210. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy and safety of two doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine in healthy infants. clinicaltrials.gov/show/NCT00197210 (first received 20 September 2005). NCT00329745. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy and safety of two doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine in healthy infants. clinicaltrials.gov/show/NCT00329745 (first received 25 May 2006). PhuaKB , LimFS , LauYL , NelsonEA , HuangLM , QuakSH , et al. Rotavirus vaccine RIX4414 efficacy sustained during the third year of life: a randomized clinical trial in an Asian population. Vaccine2012;30(30):4552-7. PhuaKB , LimFS , LauYL , NelsonEA , HuangLM , QuakSH , et al. Safety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: randomised, double-blind, controlled study. Vaccine2009;27(43):5936-41. PhuaKB , LimFS , QuakSH , LeeBW , TeohYL , SuryakiranPV , et al. Efficacy, immunogenicity and safety of a human rotavirus vaccine RIX4414 in Singaporean infants. Annals of the Academy of Medicine, Singapore2016;45(2):44-50. ">RIX Phua 2009‐AS</a>, data not shown); pooled results showed statistical heterogeneity at one year of follow‐up (I<sup>2</sup> = 55%); see <a href="./references#CD008521-fig-0027" title="">Analysis 1.23</a>. </p> <p>Rotarix reduced rotavirus‐related medical visits by 92% at one year (RR 0.08, 95% CI 0.04 to 0.16; 3874 participants, 1 trial) and 78% at two years (RR 0.22, 95% CI 0.16 to 0.31; 7017 participants, 3 trials); see <a href="./references#CD008521-fig-0028" title="">Analysis 1.24</a>. </p> </section> <section id="CD008521-sec-0137"> <h6 class="title">1.2.7. All‐cause diarrhoea: requiring hospitalization</h6> <p>Rotarix reduced cases of hospitalization for all‐cause diarrhoea at one‐year follow‐up by 46% (RR 0.54, 95% CI 0.35 to 0.83; 20,703 participants, 3 trials; <a href="./references#CD008521-fig-0029" title="">Analysis 1.25</a>). At two years follow‐up, Rotarix reduced cases by 48% (RR 0.52, 95% CI 0.27 to 0.99; 14,367 participants, 2 trials; <a href="./references#CD008521-fig-0029" title="">Analysis 1.25</a>). <a href="./references#CD008521-bbs2-0024" title="LauYL , NelsonEA , PoonKH , ChanPK , ChiuS , SungR , et al. Efficacy, safety and immunogenicity of a human rotavirus vaccine (RIX4414) in Hong Kong children up to three years of age: a randomized, controlled trial. Vaccine2013;31(18):2253-9. NCT00197210. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy and safety of two doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine in healthy infants. clinicaltrials.gov/show/NCT00197210 (first received 20 September 2005). NCT00329745. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy and safety of two doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine in healthy infants. clinicaltrials.gov/show/NCT00329745 (first received 25 May 2006). PhuaKB , LimFS , LauYL , NelsonEA , HuangLM , QuakSH , et al. Rotavirus vaccine RIX4414 efficacy sustained during the third year of life: a randomized clinical trial in an Asian population. Vaccine2012;30(30):4552-7. PhuaKB , LimFS , LauYL , NelsonEA , HuangLM , QuakSH , et al. Safety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: randomised, double-blind, controlled study. Vaccine2009;27(43):5936-41. PhuaKB , LimFS , QuakSH , LeeBW , TeohYL , SuryakiranPV , et al. Efficacy, immunogenicity and safety of a human rotavirus vaccine RIX4414 in Singaporean infants. Annals of the Academy of Medicine, Singapore2016;45(2):44-50. ">RIX Phua 2009‐AS</a> reported that for hospitalizations due to all‐cause diarrhoea at three years of follow‐up, Rotarix reduced hospitalizations by 28% (RR 0.72, 95% CI 0.59 to 0.86; 10,519 participants, data not shown). Pooled results showed statistical heterogeneity at one‐year (I<sup>2</sup> = 68%) and at two years follow‐up (I<sup>2</sup> = 77%). </p> <p><a href="./references#CD008521-bbs2-0026" title="Costa ClemensSA , et al. Operational organization of a large scale phase III clinical trial of rotavirus vaccine in multiple sites and countries in Latin America. In: International Congress of Pediatrics (ICP); 2004 August 15-20; Cancun, Mexico. 2004. [Not available for review]De VosB , et al. Rotarix™: an effective way to prevent rotavirus diarrhoea and vomiting. In: 9th Congress of the Asian Pan Pacific Society of Paediatric Gastroenterology, Hepatology and Nutrition &amp; 27th Annual Congress of the Malaysian Paediatric Association; 2005 June 16-19; Kuala Lumpur, Malaysia. 2005. [Not available for review]BaayM , BollaertsK , StruchinerC , VerstraetenT . Background rates of disease in Latin American children from a rotavirus vaccine study. Human Vaccines and Immunotherapeutics2017;13(8):1916-20. GlaxoSmithKline[444563-023-pt1]. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants (efficacy data from visit 1 to visit 4). www.gsk-studyregister.com/study/6791 (accessed 12 December 2018). GlaxoSmithKline[444563-023-pt2]. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants (2nd year efficacy from visit 4 to visit 6). www.gsk-studyregister.com/study/6791 (accessed 12 December 2018). GlaxoSmithKline[444563-023-pt3]. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants (safety for the period between visit 1 and visit 3). www.gsk-studyregister.com/study/6791 (accessed 12 December 2018). JustinoMC , AraújoEC , Van DoornLJ , OliveiraCS , GabbayYB , MascarenhasJD , et al. Oral live attenuated human rotavirus vaccine (Rotarix) offers sustained high protection against severe G9P[8] rotavirus gastroenteritis during the first two years of life in Brazilian children. Memorias do Instituto Oswaldo Cruz2012;107(7):846-53. LinharesAC , VelazquezFR , Perez-SchaelI , Saez-LlorensX , AbateH , EspinozaF , et al. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet2008;371(9619):1181-9. LopezP , LinharesA , Pérez-SchaelI , Ruiz-PalaciosG , Costa ClemensS , SanchezN . Early protection against severe rotavirus gastroenteritis - RIX4414 experience in Latin America. In: 24th Annual Meeting of European Society for Paediatric Infectious Diseases (ESPID); 2006 May 03-05; Basel, Switzerland. 2006. [Not available for review]MaciasM , LopezP , VelazquezFR , VergaraRF , SalmeronJ , TavaresJL . The rotavirus vaccine RIX4414 (Rotarix) is not associated with intussusception in one year old infants. In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2005 December 16-19; Washington DC, USA. 2005. [Not available for review]NCT00139347. A multi-country &amp; multi-center study to assess the efficacy, immunogenicity &amp; safety of two doses of GSK Biologicals' oral live attenuated HRV vaccine given concomitantly with routine EPI vaccinations including OPV in healthy infants. clinicaltrials.gov/ct2/show/NCT00139347 (first received 31 August 2005). [Trial registration document (no data for review)]NCT00140673. Placebo-controlled, multi-country &amp; multi-center study to assess the efficacy, safety &amp; immunogenicity of 2 doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants. clinicaltrials.gov/ct2/show/NCT00140673 (first received 1 September 2005). [Trial registration document (no data for review)]Perez-SchaelI , LinharesAC , VesikariT . Two doses of the human attenuated rotavirus vaccine RIX4414 (Rotarix) show heterotypic protection in Latin America and Europe. In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2005 December 16-19; Washington DC, USA. 2005. [Not available for review]PikeM . New rotavirus vaccine is effective and appears to have no increased risk of intussusception. Clinical Research Abstracts For Pediatricians2006;149(1):143. Ruiz-PalaciosG , AranzaC , VelazquezFR , RichardsonV , NandiE , MaciasM . Two doses of the human-attenuated monovalent G1P[8] rotavirus vaccine, Rotarix show high efficacy in Mexican children against severe rotavirus gastroenteritis and severe overall gastroenteritis. In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2005 December 16-19; Washington DC, USA. 2005. [Not available for review]Ruiz-PalaciosGM , Perez-SchaelI , VelazquezFR , AbateH , BreuerT , ClemensSC , et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. New England Journal of Medicine2006;354(1):11-22. VelázquezFR , AbatH , Costa ClemensSA , EspinozaF , GillardP , LinharesAC , et al. The human monovalent G1P[8] rotavirus vaccine, Rotarix is highly efficacious and provides crossprotection against G1 and non-G1 serotypes. In: 23rd Annual meeting of European Society for Paediatric Infectious Diseases (ESPID); 2005 May 18-20; Valencia, Spain. 2005. VelázquezRF , AbateH , BouckenoogheA . RIX4414, the human G1P[8] rotavirus vaccine is highly efficacious during the second year of life. In: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2006 September 27-30; San Francisco, USA. 2006. [Not available for review]VesikariT , O’RyanM , AbateH , Costa ClemensSA , EspinozaF , GillardP . Overcoming the safety hurdle: the rotavirus vaccine RIX4414 is not associated with intussusception. In: 23rd Annual Meeting of European Society for Paediatric Infectious Diseases (ESPID); 2005 May 18-20; Valencia, Spain. 2005. [Not available for review]">RIX Ruiz‐Palac 06‐LA/EU</a> presented data on the number of episodes (<a href="./references#CD008521-fig-0030" title="">Analysis 1.26</a>); Rotarix reduced hospitalization all‐cause diarrhoea episodes by 42% at one year (rate ratio 0.58, 95% CI 0.47 to 0.71; 17,867 participants, 1 trial) and 47% at two years (rate ratio 0.53, 95% CI 0.46 to 0.61; 14,286 participants, 1 trial). </p> </section> <section id="CD008521-sec-0138"> <h6 class="title">1.2.8. Reactogenicity</h6> <p>The occurrence of fever (<a href="./references#CD008521-fig-0031" title="">Analysis 1.27</a>), diarrhoea (<a href="./references#CD008521-fig-0032" title="">Analysis 1.28</a>), and vomiting (<a href="./references#CD008521-fig-0033" title="">Analysis 1.29</a>) were evaluated at several time points: after the first dose, after the second dose, after the third dose, and at the end of the follow‐up period. Most trials contributed data to these outcomes. There were similar results for Rotarix and placebo for each outcome and time point. </p> </section> <section id="CD008521-sec-0139"> <h6 class="title">1.2.9. Adverse events that require discontinuation of vaccination schedule</h6> <p>There was little or no difference detected between Rotarix and placebo in the number of adverse events leading to discontinuation of the vaccination schedule (RR 1.01, 95% CI 0.82 to 1.25; 94,980 participants, 26 trials; <a href="./references#CD008521-fig-0034" title="">Analysis 1.30</a>). </p> </section> </section> <section id="CD008521-sec-0140"> <h5 class="title">1.3. Dropouts before the end of trial</h5> <p>Twenty‐eight trials reported on the number of participants who dropped out of the trial before it ended. Overall, there were slightly fewer dropouts from the Rotarix compared with the placebo or no‐intervention groups (RR 0.94, 95% CI 0.90 to 0.99; 93,106 participants, 28 trials; <a href="./references#CD008521-fig-0035" title="">Analysis 1.31</a>). </p> </section> <section id="CD008521-sec-0141"> <h5 class="title">1.4. Subgroup analyses</h5> <section id="CD008521-sec-0142"> <h6 class="title">1.4.1. Rotavirus serotype (G‐ or P‐type)</h6> <section id="CD008521-sec-0143"> <p><b>Rotavirus diarrhoea: of any severity</b></p> <p>Seven trials reported on rotavirus diarrhoea of any severity by different G types. There were fewer cases of rotavirus diarrhoea of any severity in the group receiving Rotarix when compared to placebo, regardless of G type (G1, G2, G3, G4, G9, G12); however, the pooled data for G1 (I<sup>2</sup> = 81%) and G9 (I<sup>2</sup> = 25%) types showed statistical heterogeneity, see <a href="./references#CD008521-fig-0036" title="">Analysis 1.32</a>.  </p> <p>Three trials reported on rotavirus diarrhoea of any severity by different P types. There were fewer cases of rotavirus diarrhoea of any severity in the group receiving Rotarix when compared to placebo for P8. The results were inconclusive for P4 and P6 due to very few events leading to a very wide 95% CI. The pooled data for P8 type showed statistical heterogeneity (I<sup>2</sup> = 67%), see <a href="./references#CD008521-fig-0036" title="">Analysis 1.32</a>. </p> </section> <section id="CD008521-sec-0144"> <p><b>Rotavirus diarrhoea: severe</b></p> <p>There were fewer severe cases of rotavirus diarrhoea in the Rotarix groups compared with placebo in cases attributed to the G1, G2, G3, G4, G9, G12, P4, P6, and P8 types; see <a href="./references#CD008521-fig-0037" title="">Analysis 1.33</a>. Results were inconclusive for G8 types due to few reported cases leading to a very wide 95% CI. The pooled data for G1, G4, G8 and P8 types showed statistical heterogeneity (I<sup>2</sup> = 65% (G1), 51% (G4), 63% (G8), 65% (P8)). </p> </section> </section> <section id="CD008521-sec-0145"> <h6 class="title">1.4.2. Malnourished children</h6> <section id="CD008521-sec-0146"> <p><b>Rotavirus diarrhoea: of any severity</b></p> <p>One trial provided data separately as the number of cases of rotavirus diarrhoea of any severity in a subgroup of malnourished children (<a href="./references#CD008521-bbs2-0027" title="Ruiz-PalaciosG , GuerreroL , LinharesAC , et al. Efficacy of an oral human rotavirus (HRV) vaccine in preventing diarrhoea due to G1 and non-G1 rotavirus [Presentation]. In: 3rd World Congress of Pediatric Infectious Diseases; 2002 November 19-23; Santiago, Chile. 2002. [Not available for review]Ruiz-PalaciosG , GuerreroML , LinharesAC , et al. Two-year efficacy of GlaxoSmithKline Biologicals' live attenuated rotavirus vaccine in Latin American children [poster]. In: 24th International Congress of Pediatrics; 2004 August 15-20; Cancun, Mexico. 2004. [Not available for review]SalinasB , Perez-SchaelI , Ruiz-PalaciosG , et al. Early protection by GlaxoSmithKline Biologicals' live attenuated rotavirus vaccine in Latin American children [poster]. In: 24th International Congress of Pediatrics; 2004 August 15-20; Cancun, Mexico. 2004. [Not available for review]SalinasB , TomatMA , YarzabalJP , et al. Efficacy of the rotavirus vaccine (RIX4414) among infants in Carabobo State, Venezuela [poster]. In: Asocación Venezolana para el Avance de la Cienca (AsoVAC); 2004; Venezuela. 2004. [Not available for review]AraujoEC , ClemensSA , OliveiraCS , JustinoMC , RubioP , GabbayYB , et al. Safety, immunogenicity, and protective efficacy of two doses of RIX4414 live attenuated human rotavirus vaccine in healthy infants. Jornal de Pediatria2007;83(3):217-24. De VosB , HardtK , LinharesAC , Ruiz-PalaciosG , GuerreroL , SalinasB . Efficacy of two doses of a human monovalent rotavirus vaccine, Rotarix™ in preventing gastro-enteritis due to G1 and Non-G1 rotavirus in Brazil, Mexico and Venezuela [presentation]. In: 8th International Symposium on Double-Stranded RNA Viruses; 2003 September 13-18; Lucca, Italy. 2003. [Not available for review]De VosB , VesikariT , LinharesAC , SalinasB , Perez-SchaelI , Ruiz-PalaciosGM , et al. A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis. Pediatric Infectious Disease Journal2004;23(10 Suppl):179-82. GlaxoSmithKline[444563-006]. A phase IIb, double-blind, randomized, placebo-controlled study to assess the efficacy, immunogenicity, reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals' live attenuated human rotavirus (HRV) vaccine at different virus concentrations (104.7, 105.2 and 105.8 foci forming units [ffu]) in healthy infants (approximately 2 months of age at first dose) following a 0, 2 month schedule and previously uninfected with HRV, when administered concurrently with DTPw-HBV and Hib vaccines. www.gsk-studyregister.com/study/6784 (accessed 12 December 2018). GlaxoSmithKline[444563-006-Annex]. A phase IIb, double-blind, randomized, placebo-controlled study to assess the efficacy, immunogenicity, reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals' live attenuated human rotavirus (HRV) vaccine at different virus concentrations (104.7, 105.2 and 105.8 foci forming units [ffu]) in healthy infants (approximately 2 months of age at first dose) following a 0, 2 month schedule and previously uninfected with HRV, when administered concurrently with DTPw-HBV and Hib vaccines [This summary presents results for the second and combined efficacy periods and results from the 3-Dose subset. Results from the first efficacy period are presented in 444563/006 (Rota-006) summary]. www.gsk-studyregister.com/study/6784 (accessed 12 December 2018). LinharesA , Perez-SchaelI , Ruiz-PalaciosM , PernambucoE , JacquetJ , De VosB . Immunogenicity and reactogenicity of an oral human rotavirus (HRV) vaccine in Latin American infants [poster]. In: 3rd World Congress of Pediatric Infectious Diseases; 2002 November 19-23; Santiago, Chile. 2002. [Not available for review]LinharesAC , Ruiz-PalaciosGM , GuerreroML , SalinasB , Perez-SchaelI , ClemensSA , et al. A short report on highlights of world-wide development of RIX4414: a Latin American experience. Vaccine2006;24(18):3784-5. LinharesAC , VerstraetenT , Wolleswinkel-Van den BoschJ , ClemensR , BreuerT . Rotavirus serotype G9 is associated with more-severe disease in Latin America. Clinical Infectious Diseases2006;43(3):312-4. [Not available for review]NCT00385320. To assess the efficacy, immuno &amp; safety of 2 doses of GSK HRV vaccine at different virus concentrations in healthy infants aged 2 months &amp; previously uninfected with HRV, concurrently given with DTPw-HBV, Hib. clinicaltrials.gov/show/NCT00385320 (first received 9 October 2006). Perez-SchaelI , SalinasB , LinharesA , GuerreroM , Ruiz-PalaciosG , ClemensS , et al. Protective efficacy of an oral human rotavirus (HRV) vaccine in Latin American infants [poster]. In: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy ( ICAAC); San Diego, 27-30 September 2002. 2002:18, LB-23. [Not available for review]Perez-SchaelI , SalinasB , TomatM , LinharesAC , GuerreroML , Ruiz-PalaciosGM , et al. Efficacy of the human rotavirus vaccine RIX4414 in malnourished children. Journal of Infectious Diseases2007;196(4):537-40. Ruiz-PalaciosGM , GuerreroML , Bautista-MarquezA , Ortega-GallegosH , Tuz-DzibF , Reyes-GonzalezL , et al. Dose response and efficacy of a live, attenuated human rotavirus vaccine in Mexican infants. Pediatrics2007;120(2):e253-61. [Not available for review]Ruiz-PalaciosGM . Impact of maternal antibodies on the immune response to an oral human rotavirus (HRV) vaccine in Mexican infants [presentation]. In: 3rd World Congress of Pediatric Infectious Diseases; 2002 November 19-23; Santiago, Chile. 2002. [Not available for review]SalinasB , Perez SchaelI , LinharesAC , Ruiz PalaciosGM , GuerreroML , YarzabalJP , et al. Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: a randomized, placebo-controlled trial in Latin American infants. Pediatric Infectious Disease Journal2005;24(9):807-16. ">RIX Salinas 2005‐LA</a>). Rotarix was significantly better than placebo in preventing rotavirus diarrhoea for this subgroup at one year of follow‐up (RR 0.39, 95% CI 0.19 to 0.79; 287 participants, 1 trial, <a href="./references#CD008521-fig-0038" title="">Analysis 1.34</a>). </p> </section> </section> <section id="CD008521-sec-0147"> <h6 class="title">1.4.3. Children infected with HIV</h6> <section id="CD008521-sec-0148"> <p><b>Rotavirus diarrhoea: of any severity</b></p> <p>One safety trial included only confirmed HIV‐positive, asymptomatic or mildly symptomatic children (<a href="./references#CD008521-bbs2-0029" title="EUCTR2015-001484-39. A phase II study to assess the safety and immunogenicity of GlaxoSmithKline Biologicals rotavirus vaccine, RIX4414 when administered to HIV infected infants in South Africa. www.clinicaltrialsregister.eu/ctr-search/trial/2015-001484-39/results (first received 11 June 2015). GlaxoSmithKline[444563-022]. A phase II, double-blind, randomized, placebo-controlled study to assess the safety, reactogenicity and immunogenicity of three doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine. www.gsk-studyregister.com/study/6790 (accessed 12 December 2018). ISRCTN11877362. A phase II, double-blind, randomised, placebo-controlled study to assess the safety, reactogenicity and immunogenicity of three doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine (RIX4414 at 106.5 CCID50) administered to human immunodeficiency virus (HIV) infected infants at 6, 10 and 14 weeks of age in South Africa. www.controlled-trials.com/ISRCTN11877362 (first received 25 November 2005). NCT00263666. A study of safety, reactogenicity and immunogenicity of HRV vaccine in HIV infected infants in South Africa. clinicaltrials.gov/ct2/show/results/NCT00263666 (first received on 9 December 2005). SteeleAD ,  MadhiSA ,  LouwCE ,  BosP ,  TumboJM ,  WernerCM ,  et al. Safety, reactogenicity, and immunogenicity of human rotavirus vaccine RIX4414 in human immunodeficiency virus-positive infants in South Africa. Pediatric Infectious Diseases Journal2011;30(2):125-30. ">RIX Steele 2010a‐ZAF</a>). At one‐month follow‐up, little or no difference between the Rotarix and placebo arms for rotavirus diarrhoea was reported (RR 1.00, 95% CI 0.26 to 3.78; 100 participants, 1 trial; <a href="./references#CD008521-fig-0039" title="">Analysis 1.35</a>). </p> <p>One efficacy trial included children who were infected with HIV or children that had been exposed to HIV, as long as they were not clinically immunosuppressed (e.g. AIDS) at the age of vaccination (six weeks) (<a href="./references#CD008521-bbs2-0017" title="CunliffeNA , WitteD , NgwiraBM , ToddS , BostockNJ , TurnerAM , et al. Efficacy of human rotavirus vaccine against severe gastroenteritis in Malawian children in the first two years of life: a randomized, double-blind, placebo controlled trial. Vaccine2012;30(Suppl 1):A36-43. MadhiSA , CunliffeNA , SteeleD , WitteD , KirstenM , LouwC , et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. New England Journal of Medicine2010;362(4):289-98. MadhiSA , KirstenM , LouwC , BosP , AspinallS , BouckenoogheA , et al. Efficacy and immunogenicity of two or three dose rotavirus-vaccine regimen in South African children over two consecutive rotavirus seasons: a randomized, double-blind, placebo-controlled trial. Vaccine2012;30(Suppl 1):A44-51. NCT00241644. Multi-center study to assess the efficacy, safety and immunogenicity of 2 or 3 doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations in healthy infants. clinicaltrials.gov/show/NCT00241644 (first received 19 October 2005). NCT00598468. Multi-center study to assess efficacy, safety &amp; immunogenicity of 2 or 3 doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations in healthy infants. clinicaltrials.gov/show/NCT00598468 (first received 19 October 2005). SteeleAD , NeuzilKM , CunliffeNA , MadhiSA , BosP , NgwiraB , et al. Human rotavirus vaccine Rotarix provides protection against diverse circulating rotavirus strains in African infants: a randomized controlled trial. BMC Infectious Diseases2012;12:213. ">RIX Madhi 2010‐AF</a>). HIV tests were performed on approximately 46% of children from Malawi and 23% of children from South Africa. We did not conduct a specific analysis for this population, but the authors stated that demographic characteristics and the proportion of children who were infected with HIV were similar across the study groups. </p> </section> </section> </section> <section id="CD008521-sec-0149"> <h5 class="title">1.5 Sensitivity analysis</h5> <section id="CD008521-sec-0150"> <h6 class="title">1.5.1 Primary outcomes with high heterogeneity according to allocation concealment</h6> <p>To investigate heterogeneity for primary outcomes with pooled results where I<sup>2</sup> &gt; 75%, we planned to pool data only from studies with low risk of bias for allocation concealment in a sensitivity analysis. We rated all trials at low risk of bias for allocation concealment for the two outcomes where heterogeneity was high (I<sup>2</sup> &gt; 75%); see <a href="./references#CD008521-fig-0008" title="">Analysis 1.4</a> (I<sup>2</sup> = 75%) and <a href="./references#CD008521-fig-0009" title="">Analysis 1.5</a> (I<sup>2</sup> = 92%). </p> </section> <section id="CD008521-sec-0151"> <h6 class="title">1.5.2 Cluster‐randomized trials</h6> <p>Three outcomes (serious adverse events: intussusception, rotavirus severe diarrhoea, and rotavirus diarrhoea of any severity at one and two years follow‐up) included one cluster‐randomized trial carried out in a high‐mortality country (<a href="./references#CD008521-bbs2-0038" title="ZamanK , SackDA , NeuzilKM , YunusM , MoultonLH , SugimotoJD , et al. Effectiveness of a live oral human rotavirus vaccine after programmatic introduction in Bangladesh: a cluster-randomized trial. PLOS Medicine2017;14(4):e1002282. ">RIX Zaman 2017‐BGD</a>). When we excluded data from this trial, there was a small but non‐significant change to the effect estimate and 95% CI for rotavirus diarrhoea: severe at up to one‐year follow‐up (from RR 0.42, 95% CI 0.28 to 0.61; 9951 participants, 5 comparisons from 4 trials (<a href="./references#CD008521-fig-0005" title="">Analysis 1.1</a>) to RR 0.37, 95% CI 0.23 to 0.60, 6114 participants, 4 comparisons in 3 trials (analysis not shown)); in the second year of life (from RR 0.82, 95% CI 0.52 to 1.29; 6049 participants, 3 comparisons from 2 trials (<a href="./references#CD008521-fig-0006" title="">Analysis 1.2</a>) to RR 0.78, 95% CI 0.46 to 1.33, 2212 participants, 2 comparisons in 1 trial (analysis not shown)); and at up to 2 years follow‐up (from RR 0.65, 95% CI 0.51 to 0.83; 7113 participants, 3 comparisons from 2 trials (<a href="./references#CD008521-fig-0007" title="">Analysis 1.3</a>) to RR 0.58, 95% CI 0.42 to 0.79, 2764 participants, 2 comparisons in 1 trial (analysis not shown)). There was also a small but non‐significant change to the effect estimate and 95% CI for rotavirus diarrhoea of any severity at up to one‐year follow‐up (from RR 0.51, 95% CI 0.39 to 0.68; 9951 participants, 5 comparisons from 4 trials (<a href="./references#CD008521-fig-0018" title="">Analysis 1.14</a>) to RR 0.49, 95% CI 0.35 to 0.68, 6114 participants, 4 comparisons in 3 trials (analysis not shown)); in the second year of life (from RR 0.66, 95% CI 0.36 to 1.18, 4855 participants, 2 trials (<a href="./references#CD008521-fig-0019" title="">Analysis 1.15</a>) to RR 0.48, 95% CI 0.19 to 1.21, 1018 participants, 1 trial (analysis not shown)); and at up to 2 years follow‐up (from RR 0.55, 95% CI 0.32 to 0.93; 5600 participants, 2 trials (<a href="./references#CD008521-fig-0020" title="">Analysis 1.16</a>) to RR 0.41, 95% CI 0.28 to 0.62, 1251 participants, 1 trial (analysis not shown)). There were no changes to effect estimates or 95% CIs for serious adverse events: intussusception. </p> </section> </section> </section> <section id="CD008521-sec-0152"> <h4 class="title">2. RotaTeq</h4> <section id="CD008521-sec-0153"> <h5 class="title">2.1. Primary outcomes</h5> <p>Summary of findings of primary outcomes according to country mortality rate are presented in <a href="./full#CD008521-tbl-0004">summary of findings Table 4</a> (RotaTeq, low‐mortality countries), <a href="./full#CD008521-tbl-0005">summary of findings Table 5</a> (RotaTeq, medium‐mortality countries), and in <a href="./full#CD008521-tbl-0006">summary of findings Table 6</a> (RotaTeq, high‐mortality countries). </p> <section id="CD008521-sec-0154"> <h6 class="title">2.1.1. Rotavirus diarrhoea: severe</h6> <p>Seven trials provided data for the efficacy of RotaTeq to prevent severe rotavirus diarrhoea in children; see <a href="./references#CD008521-fig-0040" title="">Analysis 2.1</a> for up to one‐year follow‐up, <a href="./references#CD008521-fig-0041" title="">Analysis 2.2</a> for second year of life data, and <a href="./references#CD008521-fig-0042" title="">Analysis 2.3</a> for two years follow‐up. Trials were performed in low‐mortality countries (<a href="./references#CD008521-bbs2-0051" title="ClarkH , WhiteC , OffitP , StinsonD , EidenJ , WeaverS , et al. Preliminary evaluation of safety and efficacy of quadrivalent human-bovine reassortant rotavirus vaccine [abstract]. Pediatric Research1995;37:172A. [No data for review]ClarkHF , BernsteinDI , DennehyPH , OffitP , PichicheroM , TreanorJ , et al. Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants. Journal of Pediatrics2004;144(2):184-90. ClarkHF , OffitPA , EllisRW , EidenJJ , KrahD , ShawAR , et al. The development of multivalent bovine rotavirus (strain WC3) reassortant vaccine for infants. Journal of Infectious Diseases1996;174(Suppl 1):73-80. [No data for review]WardRL , BernsteinDI , SmithVE , SanderDS , ShawA , EidenJJ , et al. Rotavirus immunoglobulin a responses stimulated by each of 3 doses of a quadrivalent human/bovine reassortant rotavirus vaccine. Journal of Infectious Diseases2004;189(12):2290-3. ">TEQ Clark 2004‐USA</a>; <a href="./references#CD008521-bbs2-0059" title="VesikariT , ClarkHF , OffitP , SchodelF , DallasM , HeatonP , et al. The effect of dose and composition of a pentavalent rotavirus reassortant vaccine [RotaTeq (R)] in safety, efficacy, and immunogenicity in healthy infants. Pediatric Research2003;53(4 Suppl):307A. VesikariT , ClarkHF , OffitPA , DallasMJ , DiStefanoDJ , GoveiaMG , et al. Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants. Vaccine2006;24(22):4821-9. ">TEQ Vesikari 2006a‐FIN</a>; <a href="./references#CD008521-bbs2-0060" title="ChangCC , ChangMH , LinTY , LeeHC , HsiehWS , LeePI . Experience of pentavalent human-bovine reassortant rotavirus vaccine among healthy infants in Taiwan. Journal of the Formosan Medical Association2009;108(4):280-5. ChristieCD , DuncanND , ThameKA , OnoratoMT , SmithHD , MalcolmLG , et al. Pentavalent rotavirus vaccine in developing countries: safety and health care resource utilization. Pediatrics2010;126(6):e1499-506. DennehyPH , GoveiaMG , DallasMJ , HeatonPM . The integrated phase III safety profile of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine. International Journal of Infectious Diseases2007;11(Suppl 2):36-42. [No data available for review]GoveiaMG , DiNubileMJ , DallasMJ , HeatonPM , KuterBJ , REST Study Team. Efficacy of pentavalent human-bovine (WC3) reassortant rotavirus vaccine based on breastfeeding frequency. Pediatric Infectious Disease Journal2008;27(7):656-8. GoveiaMG , RodriguezZM , DallasMJ , ItzlerRF , BoslegoJW , HeatonPM , et al. Safety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infants. Pediatric Infectious Disease Journal2007;26(12):1099-104. [No data available for review]GoveiaMG , SuprunL , ItzlerRF , McFetridgeR , DallasMJ , KuterBJ . Efficacy and safety of pentavalent human-bovine reassortant rotavirus vaccine when administered with greater than 10 weeks between doses. Pediatric Infectious Disease Journal2010;29(3):263-5. GrantL , WattJ , MoultonL , WeatherholtzR , ReidR , SantoshamM , et al. Lack of nonspecific protection against all-cause nonrotavirus gastroenteritis by vaccination with orally administered rotavirus vaccine. Journal of Pediatric Gastroenterology and Nutrition2013;56(6):635-40. GrantLR , WattJP , WeatherholtzRC , MoultonLH , ReidR , SantoshamM , et al. Efficacy of a pentavalent human-bovine reassortant rotavirus vaccine against rotavirus gastroenteritis among American Indian children. Pediatric Infectious Disease Journal2012;31(2):184-8. ItzlerR , KochG , MatsonDO , GotheforsL , Van DammeP , DinubileMJ , et al. Robustness of the healthcare utilization results from the Rotavirus Efficacy and Safety Trial (REST) evaluating the human-bovine (WC3) reassortant pentavalent rotavirus vaccine (RV5). BMC Pediatrics2010;10:42. Merck[PN-006]. Safety and efficacy of pentavalent (G1, G2, G3, G4, and P1) human-bovine reassortant rotavirus vaccine in healthy infants NCT00090233 (PN 006). clinicalstudyresults.org/drugdetails/?indication_id=523&amp;sort=c.company_name&amp;page=1&amp;drug_id=1144 (accessed prior to 19 October 2021). [No data available for review]NCT00090233. Safety and efficacy of pentavalent (G1, G2, G3, G4, and P1) human-bovine reassortant rotavirus vaccine in healthy infants. clinicaltrials.gov/ct2/show/record/NCT00090233 (first received 27 August 2004). [Trial registration document]RodriguezZM , GoveiaMG , StekJE , DallasMJ , BoslegoJW , DiNubileMJ , et al. Concomitant use of an oral live pentavalent human-bovine reassortant rotavirus vaccine with licensed parenteral pediatric vaccines in the United States. Pediatric Infectious Disease Journal2007;26(3):221-7. VesikariT ,  KarvonenA ,  FerranteSA ,  KuterBJ ,  CiarletM . Sustained efficacy of the pentavalent rotavirus vaccine, RV5, up to 3.1 years following the last dose of vaccine. Pediatric Infectious Disease Journal2010;29(10):957-63. VesikariT , ItzlerR , KarvonenA , KorhonenT , Van DammeP , BehreU , et al. RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe. Vaccine2009;28(2):345-51. VesikariT , ItzlerR , MatsonDO , SantoshamM , ChristieCD , CoiaM , et al. Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across three regions (11 countries). International Journal of Infectious Diseases2007;11(Suppl 2):29-35. VesikariT , KarvonenA , FerranteSA , CiarletM . Efficacy of the pentavalent rotavirus vaccine, RotaTeq(R), in Finnish infants up to 3 years of age: the Finnish Extension Study. European Journal of Pediatrics2010;169(11):1379-86. VesikariT , MatsonDO , DennehyP , Van DammeP , SantoshamM , RodriguezZ , et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. New England Journal of Medicine2006;354(1):23-33. ">TEQ Vesikari 2006b‐INT</a>; <a href="./references#CD008521-bbs2-0048" title="BlockSL , VesikariT , GoveiaMG , RiversSB , AdeyiBA , DallasMJ , et al. Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life. Pediatrics2007;119(1):11-8. Merck[PN-007]. Study of the efficacy, safety, and immunogenicity of RotaTeq™ at expiry potency NCT00092443 (PN 007). www.clinicalstudyresults.org/drugdetails/?indication_id=523&amp;sort=c.company_name&amp;page=1&amp;drug_id=900 (accessed prior to 19 October 2021). NCT00092443. Study of the efficacy, safety, and immunogenicity of V260 at expiry. clinicaltrials.gov/ct2/show/NCT00092443 (first received 27 September 2004). [Trial registration document]">TEQ Block 2007‐EU/USA</a>; <a href="./references#CD008521-bbs2-0053" title="IwataS , NakataS , UkaeS , KoizumiY , MoritaY , KurokiH , et al. Efficacy and safety of pentavalent rotavirus vaccine in Japan: a randomized, double-blind, placebo-controlled, multicenter trial. Human Vaccines and Immunotherapeutics2013;9(8):1626-33. NCT00718237. A phase III randomized, placebo-controlled clinical trial to study the efficacy and safety of V260 in healthy infants in Japan. clinicaltrials.gov/ct2/show/record/NCT00718237 (first received 16 July 2008). ">TEQ Iwata 2013‐JPN</a>), one trial in a medium‐mortality country (<a href="./references#CD008521-bbs2-0058" title="MoZ , MoY , LiM , TaoJ , YangX , KongJ , et al. Efficacy and safety of a pentavalent live human-bovine reassortant rotavirus vaccine (RV5) in healthy Chinese infants: a randomized, double-blind, placebo-controlled trial. Vaccine2017;35(43):5897-904. NCT02062385. Efficacy, safety, and immunogenicity of V260 in healthy Chinese infants (V260-024). clinicaltrials.gov/show/NCT02062385 (first received 13 February 2014). ">TEQ Mo 2017‐CHN</a>), and two trials were split between five high‐mortality countries (<a href="./references#CD008521-bbs2-0063" title="ZamanK ,  DangDA ,  VictorJC ,  ShinS ,  YunusM ,  DallasMJ ,  et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet2010;376(9741):615-23. ">TEQ Zaman 2010‐VNM</a>; <a href="./references#CD008521-bbs2-0062" title="FellerAJ , ZamanK , LewisKD , HossainI , YunusM , SackDA . Malnutrition levels among vaccinated and unvaccinated children between 2 and 3 years of age following enrollment in a randomized clinical trial with the pentavalent rotavirus vaccine (PRV) in Bangladesh. Vaccine2012;30(Suppl 1):A101-5. ZamanK ,  DangDA ,  VictorJC ,  ShinS ,  YunusM ,  DallasMJ ,  et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet2010;376(9741):615-23. ZamanK , YunusM , ArifeenSE , AzimT , FaruqueAS , HuqE , et al. Methodology and lessons-learned from the efficacy clinical trial of the pentavalent rotavirus vaccine in Bangladesh. Vaccine2012;30(Suppl 1):A94-100. ">TEQ Zaman 2010‐BGD</a>; <a href="./references#CD008521-bbs2-0045" title="ArmahGE ,  SowSO ,  BreimanRF ,  DallasMJ ,  TapiaMD ,  FeikinDR ,  et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet2010;376(9741):606-14. TapiaMD , ArmahG , BreimanRF , DallasMJ , LewisKD , SowSO , et al. Secondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africa. Vaccine2012;30(Suppl 1):A79-85. ">TEQ Armah 2010‐GHA</a>; <a href="./references#CD008521-bbs2-0047" title="ArmahGE ,  SowSO ,  BreimanRF ,  DallasMJ ,  TapiaMD ,  FeikinDR ,  et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet2010;376(9741):606-14. SowSO , TapiaM , HaidaraFC , CiarletM , DialloF , KodioM , et al. Efficacy of the oral pentavalent rotavirus vaccine in Mali. Vaccine2012;30(Suppl 1):A71-8. TapiaMD , ArmahG , BreimanRF , DallasMJ , LewisKD , SowSO , et al. Secondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africa. Vaccine2012;30(Suppl 1):A79-85. ">TEQ Armah 2010‐MLI</a>; <a href="./references#CD008521-bbs2-0046" title="ArmahGE ,  SowSO ,  BreimanRF ,  DallasMJ ,  TapiaMD ,  FeikinDR ,  et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet2010;376(9741):606-14. FeikinDR , LasersonKF , OjwandoJ , NyambaneG , SsempijjaV , AudiA , et al. Efficacy of pentavalent rotavirus vaccine in a high HIV prevalence population in Kenya. Vaccine2012;30(Suppl 1):A52-60. LasersonKF , NyakundiD , FeikinDR , NyambaneG , CookE , OyiekoJ , et al. Safety of the pentavalent rotavirus vaccine (PRV), RotaTeq((R)), in Kenya, including among HIV-infected and HIV-exposed infants. Vaccine2012;30(Suppl 1):A61-70. TapiaMD , ArmahG , BreimanRF , DallasMJ , LewisKD , SowSO , et al. Secondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africa. Vaccine2012;30(Suppl 1):A79-85. ">TEQ Armah 2010‐KEN</a>). Data below are grouped accordingly. </p> <section id="CD008521-sec-0155"> <p><b>Low‐mortality countries</b></p> <p>RotaTeq reduced the number of severe rotavirus diarrhoea cases by 97% at one year (RR 0.03, 95% CI 0.01 to 0.11; 7688 participants, 5 trials), by 91% in the second year of life (RR 0.09, 95% CI 0.02 to 0.33; 2596 participants, 2 trials), and by 96% by two years (RR 0.04, 95% CI 0.01 to 0.11; 5442 participants, 2 trials).  </p> </section> <section id="CD008521-sec-0156"> <p><b>Medium‐mortality countries</b></p> <p>RotaTeq reduced the number of severe rotavirus diarrhoea cases by 79% at two years (RR 0.21, 95% CI 0.11 to 0.41; 1937 participants, 1 trial). </p> </section> <section id="CD008521-sec-0157"> <p><b>High‐mortality countries</b></p> <p>RotaTeq reduced the number of severe rotavirus diarrhoea cases by 57% at one year (RR 0.43, 95% CI 0.29 to 0.64; 6775 participants, 5 comparisons from 2 trials), by 26% in the second year of life (RR 0.74, 95% CI 0.55 to 0.99; 6081 participants, 5 comparisons from 2 trials), and by 44% at two years (RR 0.56, 95% CI 0.41 to 0.77; 6744 participants, 5 comparisons from 2 trials). Pooled results showed statistical heterogeneity at two‐year follow‐up (I<sup>2</sup> = 41%); see <a href="./references#CD008521-fig-0042" title="">Analysis 2.3</a>. </p> </section> </section> <section id="CD008521-sec-0158"> <h6 class="title">2.1.2. All‐cause diarrhoea: severe</h6> <p>Only two trials provided data for the efficacy of RotaTeq to prevent severe all‐cause diarrhoea in children; see <a href="./references#CD008521-fig-0043" title="">Analysis 2.4</a> for one‐year follow‐up and <a href="./references#CD008521-fig-0044" title="">Analysis 2.5</a> for two‐year follow‐up. Trials were performed in high‐mortality countries and one trial was split by country (<a href="./references#CD008521-bbs2-0045" title="ArmahGE ,  SowSO ,  BreimanRF ,  DallasMJ ,  TapiaMD ,  FeikinDR ,  et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet2010;376(9741):606-14. TapiaMD , ArmahG , BreimanRF , DallasMJ , LewisKD , SowSO , et al. Secondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africa. Vaccine2012;30(Suppl 1):A79-85. ">TEQ Armah 2010‐GHA</a>; <a href="./references#CD008521-bbs2-0046" title="ArmahGE ,  SowSO ,  BreimanRF ,  DallasMJ ,  TapiaMD ,  FeikinDR ,  et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet2010;376(9741):606-14. FeikinDR , LasersonKF , OjwandoJ , NyambaneG , SsempijjaV , AudiA , et al. Efficacy of pentavalent rotavirus vaccine in a high HIV prevalence population in Kenya. Vaccine2012;30(Suppl 1):A52-60. LasersonKF , NyakundiD , FeikinDR , NyambaneG , CookE , OyiekoJ , et al. Safety of the pentavalent rotavirus vaccine (PRV), RotaTeq((R)), in Kenya, including among HIV-infected and HIV-exposed infants. Vaccine2012;30(Suppl 1):A61-70. TapiaMD , ArmahG , BreimanRF , DallasMJ , LewisKD , SowSO , et al. Secondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africa. Vaccine2012;30(Suppl 1):A79-85. ">TEQ Armah 2010‐KEN</a>; <a href="./references#CD008521-bbs2-0047" title="ArmahGE ,  SowSO ,  BreimanRF ,  DallasMJ ,  TapiaMD ,  FeikinDR ,  et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet2010;376(9741):606-14. SowSO , TapiaM , HaidaraFC , CiarletM , DialloF , KodioM , et al. Efficacy of the oral pentavalent rotavirus vaccine in Mali. Vaccine2012;30(Suppl 1):A71-8. TapiaMD , ArmahG , BreimanRF , DallasMJ , LewisKD , SowSO , et al. Secondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africa. Vaccine2012;30(Suppl 1):A79-85. ">TEQ Armah 2010‐MLI</a>; <a href="./references#CD008521-bbs2-0061" title="BreimanRF , ZamanK , ArmahG , SowSO , AnhDD , VictorJC , et al. Analyses of health outcomes from the 5 sites participating in the Africa and Asia clinical efficacy trials of the oral pentavalent rotavirus vaccine. Vaccine2012;30(Suppl 1):A24-9. GruberJF , HilleDA , LiuGF , KaplanSS , NelsonM , GoveiaMG , et al. Heterogeneity of rotavirus vaccine efficacy among infants in developing countries. Pediatric Infectious Disease Journal2017;36(1):72-8. NCT00362648. Efficacy, safety, and immunogenicity of RotaTeqTM among infants in Asia and Africa. clinicaltrials.gov/ct2/show/record/NCT00362648 (first received 8 August 2006). ShinS , AnhDD , ZamanK , YunusM , Mai leTP , ThiemVD , et al. Immunogenicity of the pentavalent rotavirus vaccine among infants in two developing countries in Asia, Bangladesh and Vietnam. Vaccine2012;30(Suppl 1):A106-13. ZamanK ,  DangDA ,  VictorJC ,  ShinS ,  YunusM ,  DallasMJ ,  et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet2010;376(9741):615-23. ">TEQ Zaman 2010‐AS</a>). We did not identify any trial that reported on this outcome that was performed in a low‐ or medium‐mortality country. </p> <section id="CD008521-sec-0159"> <p><b>High‐mortality countries</b></p> <p>There was little or no difference between RotaTeq and placebo for all‐cause severe diarrhoea at one‐year follow‐up (RR 0.80, 95% CI 0.58 to 1.11; 4085 participants, 3 comparisons from 1 trial). At two‐year follow‐up, RotaTeq reduced severe cases by 15% (RR 0.85, 95% CI 0.74 to 0.99; 5977 participants, 4 comparisons from 2 trials). Pooled results showed statistical heterogeneity at one‐year follow‐up (I<sup>2</sup> = 46%); see <a href="./references#CD008521-fig-0043" title="">Analysis 2.4</a>. </p> </section> </section> <section id="CD008521-sec-0160"> <h6 class="title">2.1.3. All‐cause death</h6> <p>Eleven trials reported on all‐cause death, in most trials as the number of deaths (<a href="./references#CD008521-bbs2-0044" title="ArmahGE ,  SowSO ,  BreimanRF ,  DallasMJ ,  TapiaMD ,  FeikinDR ,  et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet2010;376(9741):606-14. ArmahGE , BreimanRF , TapiaMD , DallasMJ , NeuzilKM , BinkaFN , et al. Immunogenicity of the pentavalent rotavirus vaccine in African infants. Vaccine2012;30(Suppl 1):A86-93. BreimanRF , ZamanK , ArmahG , SowSO , AnhDD , VictorJC , et al. Analyses of health outcomes from the 5 sites participating in the Africa and Asia clinical efficacy trials of the oral pentavalent rotavirus vaccine. Vaccine2012;30(Suppl 1):A24-9. GruberJF , HilleDA , LiuGF , KaplanSS , NelsonM , GoveiaMG , et al. Heterogeneity of rotavirus vaccine efficacy among infants in developing countries. Pediatric Infectious Disease Journal2017;36(1):72-8. HeylenE , ZellerM , CiarletM , LawrenceJ , SteeleD , Van RanstM , et al. Comparative analysis of pentavalent rotavirus vaccine strains and G8 rotaviruses identified during vaccine trial in Africa. Science Reports2015;5:14658. NCT00362648. Efficacy, safety, and immunogenicity of RotaTeqTM among infants in Asia and Africa. clinicaltrials.gov/ct2/show/record/NCT00362648 (first received 10 August 2006). TapiaMD , ArmahG , BreimanRF , DallasMJ , LewisKD , SowSO , et al. Secondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africa. Vaccine2012;30(Suppl 1):A79-85. ">TEQ Armah 2010‐AF</a>; <a href="./references#CD008521-bbs2-0053" title="IwataS , NakataS , UkaeS , KoizumiY , MoritaY , KurokiH , et al. Efficacy and safety of pentavalent rotavirus vaccine in Japan: a randomized, double-blind, placebo-controlled, multicenter trial. Human Vaccines and Immunotherapeutics2013;9(8):1626-33. NCT00718237. A phase III randomized, placebo-controlled clinical trial to study the efficacy and safety of V260 in healthy infants in Japan. clinicaltrials.gov/ct2/show/record/NCT00718237 (first received 16 July 2008). ">TEQ Iwata 2013‐JPN</a>; <a href="./references#CD008521-bbs2-0055" title="LawrenceJ , HeS , HilleD , ShenC , KuterB , SchodelF , et al. A study of RotaTeqTM (pentavalent rotavirus vaccine) in Chinese healthy adults, children and infants. International Journal of Infectious Diseases2012;16(1):e307. NCT00953056. A study of V260 in healthy Chinese adults, children and infants. clinicaltrials.gov/ct2/show/study/NCT00953056 (first received 4 August 2009). ">TEQ Lawrence 2012‐CHN</a>; <a href="./references#CD008521-bbs2-0056" title="LevinMJ , LindseyJC , KaplanSS , SchimanaW , LawrenceJ , McNealMM , et al. Safety and immunogenicity of a live attenuated pentavalent rotavirus vaccine in HIV-exposed infants with or without HIV infection in Africa. AIDS2017;31(1):49-59. NCT00880698. Safety and immunogenicity of a live, attenuated rotavirus (RotaTeqTM) in HIV-1 infected and uninfected children born to HIV-1-infected mothers. clinicaltrials.gov/ct2/show/study/NCT00880698 (first received 14 April 2009). UpretyP , LindseyJ , LevinM , Rainwater-LovettK , ZiemniakC , KaplanS , et al. Enhanced inflammation and rotavirus vaccine responses in perinatal HIV-1 infection. In: Topics in Antiviral Medicine; 23rd Conference on Retroviruses and Opportunistic Infections, CROI; 2016, USA. Vol. 24(E-1). 2016:347. ">TEQ Levin 2017‐AF</a>; <a href="./references#CD008521-bbs2-0057" title="Merck[PN-009]. Protocol 009 - Comparison of the immunogenicity and safety of three consistency lots of RotaTeq™ in healthy infants (NCT00092456). clinicalstudyresults.org/drugdetails/?indication_id=523&amp;sort=c.company_name&amp;page=1&amp;drug_id=1357 (accessed prior to 19 October 2021). NCT00092456. Comparison of the immunogenicity and safety of three consistency lots of V260 in healthy infants. clinicaltrials.gov/ct2/show/record/NCT00092456 (first received 27 September 2004). [Trial registration document (no data for review)]">TEQ Merck[009] 2005‐USA</a>; <a href="./references#CD008521-bbs2-0058" title="MoZ , MoY , LiM , TaoJ , YangX , KongJ , et al. Efficacy and safety of a pentavalent live human-bovine reassortant rotavirus vaccine (RV5) in healthy Chinese infants: a randomized, double-blind, placebo-controlled trial. Vaccine2017;35(43):5897-904. NCT02062385. Efficacy, safety, and immunogenicity of V260 in healthy Chinese infants (V260-024). clinicaltrials.gov/show/NCT02062385 (first received 13 February 2014). ">TEQ Mo 2017‐CHN</a>; <a href="./references#CD008521-bbs2-0059" title="VesikariT , ClarkHF , OffitP , SchodelF , DallasM , HeatonP , et al. The effect of dose and composition of a pentavalent rotavirus reassortant vaccine [RotaTeq (R)] in safety, efficacy, and immunogenicity in healthy infants. Pediatric Research2003;53(4 Suppl):307A. VesikariT , ClarkHF , OffitPA , DallasMJ , DiStefanoDJ , GoveiaMG , et al. Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants. Vaccine2006;24(22):4821-9. ">TEQ Vesikari 2006a‐FIN</a>; <a href="./references#CD008521-bbs2-0060" title="ChangCC , ChangMH , LinTY , LeeHC , HsiehWS , LeePI . Experience of pentavalent human-bovine reassortant rotavirus vaccine among healthy infants in Taiwan. Journal of the Formosan Medical Association2009;108(4):280-5. ChristieCD , DuncanND , ThameKA , OnoratoMT , SmithHD , MalcolmLG , et al. Pentavalent rotavirus vaccine in developing countries: safety and health care resource utilization. Pediatrics2010;126(6):e1499-506. DennehyPH , GoveiaMG , DallasMJ , HeatonPM . The integrated phase III safety profile of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine. International Journal of Infectious Diseases2007;11(Suppl 2):36-42. [No data available for review]GoveiaMG , DiNubileMJ , DallasMJ , HeatonPM , KuterBJ , REST Study Team. Efficacy of pentavalent human-bovine (WC3) reassortant rotavirus vaccine based on breastfeeding frequency. Pediatric Infectious Disease Journal2008;27(7):656-8. GoveiaMG , RodriguezZM , DallasMJ , ItzlerRF , BoslegoJW , HeatonPM , et al. Safety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infants. Pediatric Infectious Disease Journal2007;26(12):1099-104. [No data available for review]GoveiaMG , SuprunL , ItzlerRF , McFetridgeR , DallasMJ , KuterBJ . Efficacy and safety of pentavalent human-bovine reassortant rotavirus vaccine when administered with greater than 10 weeks between doses. Pediatric Infectious Disease Journal2010;29(3):263-5. GrantL , WattJ , MoultonL , WeatherholtzR , ReidR , SantoshamM , et al. Lack of nonspecific protection against all-cause nonrotavirus gastroenteritis by vaccination with orally administered rotavirus vaccine. Journal of Pediatric Gastroenterology and Nutrition2013;56(6):635-40. GrantLR , WattJP , WeatherholtzRC , MoultonLH , ReidR , SantoshamM , et al. Efficacy of a pentavalent human-bovine reassortant rotavirus vaccine against rotavirus gastroenteritis among American Indian children. Pediatric Infectious Disease Journal2012;31(2):184-8. ItzlerR , KochG , MatsonDO , GotheforsL , Van DammeP , DinubileMJ , et al. Robustness of the healthcare utilization results from the Rotavirus Efficacy and Safety Trial (REST) evaluating the human-bovine (WC3) reassortant pentavalent rotavirus vaccine (RV5). BMC Pediatrics2010;10:42. Merck[PN-006]. Safety and efficacy of pentavalent (G1, G2, G3, G4, and P1) human-bovine reassortant rotavirus vaccine in healthy infants NCT00090233 (PN 006). clinicalstudyresults.org/drugdetails/?indication_id=523&amp;sort=c.company_name&amp;page=1&amp;drug_id=1144 (accessed prior to 19 October 2021). [No data available for review]NCT00090233. Safety and efficacy of pentavalent (G1, G2, G3, G4, and P1) human-bovine reassortant rotavirus vaccine in healthy infants. clinicaltrials.gov/ct2/show/record/NCT00090233 (first received 27 August 2004). [Trial registration document]RodriguezZM , GoveiaMG , StekJE , DallasMJ , BoslegoJW , DiNubileMJ , et al. Concomitant use of an oral live pentavalent human-bovine reassortant rotavirus vaccine with licensed parenteral pediatric vaccines in the United States. Pediatric Infectious Disease Journal2007;26(3):221-7. VesikariT ,  KarvonenA ,  FerranteSA ,  KuterBJ ,  CiarletM . Sustained efficacy of the pentavalent rotavirus vaccine, RV5, up to 3.1 years following the last dose of vaccine. Pediatric Infectious Disease Journal2010;29(10):957-63. VesikariT , ItzlerR , KarvonenA , KorhonenT , Van DammeP , BehreU , et al. RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe. Vaccine2009;28(2):345-51. VesikariT , ItzlerR , MatsonDO , SantoshamM , ChristieCD , CoiaM , et al. Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across three regions (11 countries). International Journal of Infectious Diseases2007;11(Suppl 2):29-35. VesikariT , KarvonenA , FerranteSA , CiarletM . Efficacy of the pentavalent rotavirus vaccine, RotaTeq(R), in Finnish infants up to 3 years of age: the Finnish Extension Study. European Journal of Pediatrics2010;169(11):1379-86. VesikariT , MatsonDO , DennehyP , Van DammeP , SantoshamM , RodriguezZ , et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. New England Journal of Medicine2006;354(1):23-33. ">TEQ Vesikari 2006b‐INT</a>; <a href="./references#CD008521-bbs2-0061" title="BreimanRF , ZamanK , ArmahG , SowSO , AnhDD , VictorJC , et al. Analyses of health outcomes from the 5 sites participating in the Africa and Asia clinical efficacy trials of the oral pentavalent rotavirus vaccine. Vaccine2012;30(Suppl 1):A24-9. GruberJF , HilleDA , LiuGF , KaplanSS , NelsonM , GoveiaMG , et al. Heterogeneity of rotavirus vaccine efficacy among infants in developing countries. Pediatric Infectious Disease Journal2017;36(1):72-8. NCT00362648. Efficacy, safety, and immunogenicity of RotaTeqTM among infants in Asia and Africa. clinicaltrials.gov/ct2/show/record/NCT00362648 (first received 8 August 2006). ShinS , AnhDD , ZamanK , YunusM , Mai leTP , ThiemVD , et al. Immunogenicity of the pentavalent rotavirus vaccine among infants in two developing countries in Asia, Bangladesh and Vietnam. Vaccine2012;30(Suppl 1):A106-13. ZamanK ,  DangDA ,  VictorJC ,  ShinS ,  YunusM ,  DallasMJ ,  et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet2010;376(9741):615-23. ">TEQ Zaman 2010‐AS</a>), and in two trials as fatal serious adverse events (<a href="./references#CD008521-bbs2-0048" title="BlockSL , VesikariT , GoveiaMG , RiversSB , AdeyiBA , DallasMJ , et al. Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life. Pediatrics2007;119(1):11-8. Merck[PN-007]. Study of the efficacy, safety, and immunogenicity of RotaTeq™ at expiry potency NCT00092443 (PN 007). www.clinicalstudyresults.org/drugdetails/?indication_id=523&amp;sort=c.company_name&amp;page=1&amp;drug_id=900 (accessed prior to 19 October 2021). NCT00092443. Study of the efficacy, safety, and immunogenicity of V260 at expiry. clinicaltrials.gov/ct2/show/NCT00092443 (first received 27 September 2004). [Trial registration document]">TEQ Block 2007‐EU/USA</a>; <a href="./references#CD008521-bbs2-0049" title="CiarletM , HeS , LaiS , PetreczM , YuanG , LiuGF , et al. Concomitant use of the 3-dose oral pentavalent rotavirus vaccine with a 3-dose primary vaccination course of a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b vaccine: immunogenicity and reactogenicity. Pediatric Infectious Disease Journal2009;28(3):177-81. Merck[PN-010]. Safety and immunogenicity of concomitant use of RotaTeq™ and INFANRIX™ hexa in healthy infants NCT00258154 (PN 010) [Merck &amp; Co. Inc. Study Synopsis]. clinicalstudyresults.org/drugdetails/?indication_id=1101&amp;sort=c.company_name&amp;page=1&amp;drug_id=2823 (accessed prior to 19 October 2021). NCT00258154. Safety and immunogenicity of concomitant use of V260 and INFANRIX(Tm) hexa in healthy infants. clinicaltrials.gov/show/NCT00258154 (first received 24 November 2005). [Trial registration document (no data for review)]">TEQ Ciarlet 2009‐EU</a>). We pooled the number of deaths and fatal serious adverse events; see <a href="./references#CD008521-fig-0045" title="">Analysis 2.6</a>. We present details of causes of death for each trial in <a href="./appendices#CD008521-sec-0276">Appendix 7</a>. Six trials were performed in low‐mortality countries (<a href="./references#CD008521-bbs2-0048" title="BlockSL , VesikariT , GoveiaMG , RiversSB , AdeyiBA , DallasMJ , et al. Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life. Pediatrics2007;119(1):11-8. Merck[PN-007]. Study of the efficacy, safety, and immunogenicity of RotaTeq™ at expiry potency NCT00092443 (PN 007). www.clinicalstudyresults.org/drugdetails/?indication_id=523&amp;sort=c.company_name&amp;page=1&amp;drug_id=900 (accessed prior to 19 October 2021). NCT00092443. Study of the efficacy, safety, and immunogenicity of V260 at expiry. clinicaltrials.gov/ct2/show/NCT00092443 (first received 27 September 2004). [Trial registration document]">TEQ Block 2007‐EU/USA</a>; <a href="./references#CD008521-bbs2-0049" title="CiarletM , HeS , LaiS , PetreczM , YuanG , LiuGF , et al. Concomitant use of the 3-dose oral pentavalent rotavirus vaccine with a 3-dose primary vaccination course of a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b vaccine: immunogenicity and reactogenicity. Pediatric Infectious Disease Journal2009;28(3):177-81. Merck[PN-010]. Safety and immunogenicity of concomitant use of RotaTeq™ and INFANRIX™ hexa in healthy infants NCT00258154 (PN 010) [Merck &amp; Co. Inc. Study Synopsis]. clinicalstudyresults.org/drugdetails/?indication_id=1101&amp;sort=c.company_name&amp;page=1&amp;drug_id=2823 (accessed prior to 19 October 2021). NCT00258154. Safety and immunogenicity of concomitant use of V260 and INFANRIX(Tm) hexa in healthy infants. clinicaltrials.gov/show/NCT00258154 (first received 24 November 2005). [Trial registration document (no data for review)]">TEQ Ciarlet 2009‐EU</a>; <a href="./references#CD008521-bbs2-0053" title="IwataS , NakataS , UkaeS , KoizumiY , MoritaY , KurokiH , et al. Efficacy and safety of pentavalent rotavirus vaccine in Japan: a randomized, double-blind, placebo-controlled, multicenter trial. Human Vaccines and Immunotherapeutics2013;9(8):1626-33. NCT00718237. A phase III randomized, placebo-controlled clinical trial to study the efficacy and safety of V260 in healthy infants in Japan. clinicaltrials.gov/ct2/show/record/NCT00718237 (first received 16 July 2008). ">TEQ Iwata 2013‐JPN</a>; <a href="./references#CD008521-bbs2-0057" title="Merck[PN-009]. Protocol 009 - Comparison of the immunogenicity and safety of three consistency lots of RotaTeq™ in healthy infants (NCT00092456). clinicalstudyresults.org/drugdetails/?indication_id=523&amp;sort=c.company_name&amp;page=1&amp;drug_id=1357 (accessed prior to 19 October 2021). NCT00092456. Comparison of the immunogenicity and safety of three consistency lots of V260 in healthy infants. clinicaltrials.gov/ct2/show/record/NCT00092456 (first received 27 September 2004). [Trial registration document (no data for review)]">TEQ Merck[009] 2005‐USA</a>; <a href="./references#CD008521-bbs2-0059" title="VesikariT , ClarkHF , OffitP , SchodelF , DallasM , HeatonP , et al. The effect of dose and composition of a pentavalent rotavirus reassortant vaccine [RotaTeq (R)] in safety, efficacy, and immunogenicity in healthy infants. Pediatric Research2003;53(4 Suppl):307A. VesikariT , ClarkHF , OffitPA , DallasMJ , DiStefanoDJ , GoveiaMG , et al. Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants. Vaccine2006;24(22):4821-9. ">TEQ Vesikari 2006a‐FIN</a>, <a href="./references#CD008521-bbs2-0060" title="ChangCC , ChangMH , LinTY , LeeHC , HsiehWS , LeePI . Experience of pentavalent human-bovine reassortant rotavirus vaccine among healthy infants in Taiwan. Journal of the Formosan Medical Association2009;108(4):280-5. ChristieCD , DuncanND , ThameKA , OnoratoMT , SmithHD , MalcolmLG , et al. Pentavalent rotavirus vaccine in developing countries: safety and health care resource utilization. Pediatrics2010;126(6):e1499-506. DennehyPH , GoveiaMG , DallasMJ , HeatonPM . The integrated phase III safety profile of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine. International Journal of Infectious Diseases2007;11(Suppl 2):36-42. [No data available for review]GoveiaMG , DiNubileMJ , DallasMJ , HeatonPM , KuterBJ , REST Study Team. Efficacy of pentavalent human-bovine (WC3) reassortant rotavirus vaccine based on breastfeeding frequency. Pediatric Infectious Disease Journal2008;27(7):656-8. GoveiaMG , RodriguezZM , DallasMJ , ItzlerRF , BoslegoJW , HeatonPM , et al. Safety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infants. Pediatric Infectious Disease Journal2007;26(12):1099-104. [No data available for review]GoveiaMG , SuprunL , ItzlerRF , McFetridgeR , DallasMJ , KuterBJ . Efficacy and safety of pentavalent human-bovine reassortant rotavirus vaccine when administered with greater than 10 weeks between doses. Pediatric Infectious Disease Journal2010;29(3):263-5. GrantL , WattJ , MoultonL , WeatherholtzR , ReidR , SantoshamM , et al. Lack of nonspecific protection against all-cause nonrotavirus gastroenteritis by vaccination with orally administered rotavirus vaccine. Journal of Pediatric Gastroenterology and Nutrition2013;56(6):635-40. GrantLR , WattJP , WeatherholtzRC , MoultonLH , ReidR , SantoshamM , et al. Efficacy of a pentavalent human-bovine reassortant rotavirus vaccine against rotavirus gastroenteritis among American Indian children. Pediatric Infectious Disease Journal2012;31(2):184-8. ItzlerR , KochG , MatsonDO , GotheforsL , Van DammeP , DinubileMJ , et al. Robustness of the healthcare utilization results from the Rotavirus Efficacy and Safety Trial (REST) evaluating the human-bovine (WC3) reassortant pentavalent rotavirus vaccine (RV5). BMC Pediatrics2010;10:42. Merck[PN-006]. Safety and efficacy of pentavalent (G1, G2, G3, G4, and P1) human-bovine reassortant rotavirus vaccine in healthy infants NCT00090233 (PN 006). clinicalstudyresults.org/drugdetails/?indication_id=523&amp;sort=c.company_name&amp;page=1&amp;drug_id=1144 (accessed prior to 19 October 2021). [No data available for review]NCT00090233. Safety and efficacy of pentavalent (G1, G2, G3, G4, and P1) human-bovine reassortant rotavirus vaccine in healthy infants. clinicaltrials.gov/ct2/show/record/NCT00090233 (first received 27 August 2004). [Trial registration document]RodriguezZM , GoveiaMG , StekJE , DallasMJ , BoslegoJW , DiNubileMJ , et al. Concomitant use of an oral live pentavalent human-bovine reassortant rotavirus vaccine with licensed parenteral pediatric vaccines in the United States. Pediatric Infectious Disease Journal2007;26(3):221-7. VesikariT ,  KarvonenA ,  FerranteSA ,  KuterBJ ,  CiarletM . Sustained efficacy of the pentavalent rotavirus vaccine, RV5, up to 3.1 years following the last dose of vaccine. Pediatric Infectious Disease Journal2010;29(10):957-63. VesikariT , ItzlerR , KarvonenA , KorhonenT , Van DammeP , BehreU , et al. RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe. Vaccine2009;28(2):345-51. VesikariT , ItzlerR , MatsonDO , SantoshamM , ChristieCD , CoiaM , et al. Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across three regions (11 countries). International Journal of Infectious Diseases2007;11(Suppl 2):29-35. VesikariT , KarvonenA , FerranteSA , CiarletM . Efficacy of the pentavalent rotavirus vaccine, RotaTeq(R), in Finnish infants up to 3 years of age: the Finnish Extension Study. European Journal of Pediatrics2010;169(11):1379-86. VesikariT , MatsonDO , DennehyP , Van DammeP , SantoshamM , RodriguezZ , et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. New England Journal of Medicine2006;354(1):23-33. ">TEQ Vesikari 2006b‐INT</a>), two trials in medium‐mortality countries (<a href="./references#CD008521-bbs2-0055" title="LawrenceJ , HeS , HilleD , ShenC , KuterB , SchodelF , et al. A study of RotaTeqTM (pentavalent rotavirus vaccine) in Chinese healthy adults, children and infants. International Journal of Infectious Diseases2012;16(1):e307. NCT00953056. A study of V260 in healthy Chinese adults, children and infants. clinicaltrials.gov/ct2/show/study/NCT00953056 (first received 4 August 2009). ">TEQ Lawrence 2012‐CHN</a>; <a href="./references#CD008521-bbs2-0058" title="MoZ , MoY , LiM , TaoJ , YangX , KongJ , et al. Efficacy and safety of a pentavalent live human-bovine reassortant rotavirus vaccine (RV5) in healthy Chinese infants: a randomized, double-blind, placebo-controlled trial. Vaccine2017;35(43):5897-904. NCT02062385. Efficacy, safety, and immunogenicity of V260 in healthy Chinese infants (V260-024). clinicaltrials.gov/show/NCT02062385 (first received 13 February 2014). ">TEQ Mo 2017‐CHN</a>), and three trials were split between six high‐mortality countries (<a href="./references#CD008521-bbs2-0045" title="ArmahGE ,  SowSO ,  BreimanRF ,  DallasMJ ,  TapiaMD ,  FeikinDR ,  et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet2010;376(9741):606-14. TapiaMD , ArmahG , BreimanRF , DallasMJ , LewisKD , SowSO , et al. Secondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africa. Vaccine2012;30(Suppl 1):A79-85. ">TEQ Armah 2010‐GHA</a>; <a href="./references#CD008521-bbs2-0046" title="ArmahGE ,  SowSO ,  BreimanRF ,  DallasMJ ,  TapiaMD ,  FeikinDR ,  et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet2010;376(9741):606-14. FeikinDR , LasersonKF , OjwandoJ , NyambaneG , SsempijjaV , AudiA , et al. Efficacy of pentavalent rotavirus vaccine in a high HIV prevalence population in Kenya. Vaccine2012;30(Suppl 1):A52-60. LasersonKF , NyakundiD , FeikinDR , NyambaneG , CookE , OyiekoJ , et al. Safety of the pentavalent rotavirus vaccine (PRV), RotaTeq((R)), in Kenya, including among HIV-infected and HIV-exposed infants. Vaccine2012;30(Suppl 1):A61-70. TapiaMD , ArmahG , BreimanRF , DallasMJ , LewisKD , SowSO , et al. Secondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africa. Vaccine2012;30(Suppl 1):A79-85. ">TEQ Armah 2010‐KEN</a>; <a href="./references#CD008521-bbs2-0047" title="ArmahGE ,  SowSO ,  BreimanRF ,  DallasMJ ,  TapiaMD ,  FeikinDR ,  et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet2010;376(9741):606-14. SowSO , TapiaM , HaidaraFC , CiarletM , DialloF , KodioM , et al. Efficacy of the oral pentavalent rotavirus vaccine in Mali. Vaccine2012;30(Suppl 1):A71-8. TapiaMD , ArmahG , BreimanRF , DallasMJ , LewisKD , SowSO , et al. Secondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africa. Vaccine2012;30(Suppl 1):A79-85. ">TEQ Armah 2010‐MLI</a>; <a href="./references#CD008521-bbs2-0056" title="LevinMJ , LindseyJC , KaplanSS , SchimanaW , LawrenceJ , McNealMM , et al. Safety and immunogenicity of a live attenuated pentavalent rotavirus vaccine in HIV-exposed infants with or without HIV infection in Africa. AIDS2017;31(1):49-59. NCT00880698. Safety and immunogenicity of a live, attenuated rotavirus (RotaTeqTM) in HIV-1 infected and uninfected children born to HIV-1-infected mothers. clinicaltrials.gov/ct2/show/study/NCT00880698 (first received 14 April 2009). UpretyP , LindseyJ , LevinM , Rainwater-LovettK , ZiemniakC , KaplanS , et al. Enhanced inflammation and rotavirus vaccine responses in perinatal HIV-1 infection. In: Topics in Antiviral Medicine; 23rd Conference on Retroviruses and Opportunistic Infections, CROI; 2016, USA. Vol. 24(E-1). 2016:347. ">TEQ Levin 2017‐AF</a>; <a href="./references#CD008521-bbs2-0062" title="FellerAJ , ZamanK , LewisKD , HossainI , YunusM , SackDA . Malnutrition levels among vaccinated and unvaccinated children between 2 and 3 years of age following enrollment in a randomized clinical trial with the pentavalent rotavirus vaccine (PRV) in Bangladesh. Vaccine2012;30(Suppl 1):A101-5. ZamanK ,  DangDA ,  VictorJC ,  ShinS ,  YunusM ,  DallasMJ ,  et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet2010;376(9741):615-23. ZamanK , YunusM , ArifeenSE , AzimT , FaruqueAS , HuqE , et al. Methodology and lessons-learned from the efficacy clinical trial of the pentavalent rotavirus vaccine in Bangladesh. Vaccine2012;30(Suppl 1):A94-100. ">TEQ Zaman 2010‐BGD</a>; <a href="./references#CD008521-bbs2-0063" title="ZamanK ,  DangDA ,  VictorJC ,  ShinS ,  YunusM ,  DallasMJ ,  et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet2010;376(9741):615-23. ">TEQ Zaman 2010‐VNM</a>). </p> <section id="CD008521-sec-0161"> <p><b>Low‐mortality countries</b></p> <p>There was little or no difference in all‐cause death between RotaTeq and placebo arms (RR 1.24, 95% CI 0.69 to 2.22; 72,654 participants, 6 trials). Twenty‐five deaths occurred among 36,973 participants in the RotaTeq arms and 20 deaths occurred among 34,003 participants in the placebo arms. This corresponds to a risk difference of 13 more deaths with RotaTeq per 100,000 with the 95% CI indicating from 17 fewer to 68 more per 100,000 (data not shown). </p> </section> <section id="CD008521-sec-0162"> <p><b>Medium‐mortality countries</b></p> <p>The results for all‐cause death in medium‐mortality countries was inconclusive due to only one reported event leading to wide 95% CIs (RR 0.33, 95% CI 0.01 to 8.18; 4088 participants, 2 trials). No deaths occurred among 2044 participants in the RotaTeq arm and one death occurred among 2044 participants in the placebo arm. This corresponds to a risk difference of 33 fewer deaths with RotaTeq per 100,000 with the 95% CI indicating from 48 fewer to 351 more per 100,000 (data not shown). </p> </section> <section id="CD008521-sec-0163"> <p><b>High‐mortality countries</b></p> <p>There was little or no difference in all‐cause death between the two arms (RR 0.91, 95% CI 0.68 to 1.23; 7706 participants, 6 comparisons from 4 trials). Eighty‐eight deaths occurred among 42,867 participants in the RotaTeq arms and 88 deaths occurred among 41,581 participants in the placebo arms. This corresponds to a risk difference of 205 fewer deaths with RotaTeq per 100,000 with the 95% CI indicating from 730 fewer to 525 more per 100,000 (data not shown). </p> </section> </section> <section id="CD008521-sec-0164"> <h6 class="title">2.1.4. All serious adverse events</h6> <p>Serious adverse events were reported in 11 trials: in five trials in low‐mortality countries (<a href="./references#CD008521-bbs2-0048" title="BlockSL , VesikariT , GoveiaMG , RiversSB , AdeyiBA , DallasMJ , et al. Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life. Pediatrics2007;119(1):11-8. Merck[PN-007]. Study of the efficacy, safety, and immunogenicity of RotaTeq™ at expiry potency NCT00092443 (PN 007). www.clinicalstudyresults.org/drugdetails/?indication_id=523&amp;sort=c.company_name&amp;page=1&amp;drug_id=900 (accessed prior to 19 October 2021). NCT00092443. Study of the efficacy, safety, and immunogenicity of V260 at expiry. clinicaltrials.gov/ct2/show/NCT00092443 (first received 27 September 2004). [Trial registration document]">TEQ Block 2007‐EU/USA</a>; <a href="./references#CD008521-bbs2-0049" title="CiarletM , HeS , LaiS , PetreczM , YuanG , LiuGF , et al. Concomitant use of the 3-dose oral pentavalent rotavirus vaccine with a 3-dose primary vaccination course of a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b vaccine: immunogenicity and reactogenicity. Pediatric Infectious Disease Journal2009;28(3):177-81. Merck[PN-010]. Safety and immunogenicity of concomitant use of RotaTeq™ and INFANRIX™ hexa in healthy infants NCT00258154 (PN 010) [Merck &amp; Co. Inc. Study Synopsis]. clinicalstudyresults.org/drugdetails/?indication_id=1101&amp;sort=c.company_name&amp;page=1&amp;drug_id=2823 (accessed prior to 19 October 2021). NCT00258154. Safety and immunogenicity of concomitant use of V260 and INFANRIX(Tm) hexa in healthy infants. clinicaltrials.gov/show/NCT00258154 (first received 24 November 2005). [Trial registration document (no data for review)]">TEQ Ciarlet 2009‐EU</a>; <a href="./references#CD008521-bbs2-0053" title="IwataS , NakataS , UkaeS , KoizumiY , MoritaY , KurokiH , et al. Efficacy and safety of pentavalent rotavirus vaccine in Japan: a randomized, double-blind, placebo-controlled, multicenter trial. Human Vaccines and Immunotherapeutics2013;9(8):1626-33. NCT00718237. A phase III randomized, placebo-controlled clinical trial to study the efficacy and safety of V260 in healthy infants in Japan. clinicaltrials.gov/ct2/show/record/NCT00718237 (first received 16 July 2008). ">TEQ Iwata 2013‐JPN</a>; <a href="./references#CD008521-bbs2-0054" title="KimDS , LeeTJ , KangJH , KimJH , LeeJH , MaSH , et al. Immunogenicity and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy infants in Korea. Pediatric Infectious Disease Journal2008;27(2):177-8. Merck[PN-013]. Immunogenicity and safety of RotaTeq® in healthy infants in Korea - NCT00166517 (PN 013). clinicalstudyresults.org/drugdetails/?indication_id=523&amp;sort=c.company_name&amp;page=1&amp;drug_id=2148 (accessed prior to 19 October 2021). NCT00166517. Immunogenicity and safety of V260 in healthy infants in Korea. clinicaltrials.gov/show/NCT00166517 (first received 14 September 2005). [Trial registration document (no data for review)]">TEQ Kim 2008‐KOR</a>; <a href="./references#CD008521-bbs2-0060" title="ChangCC , ChangMH , LinTY , LeeHC , HsiehWS , LeePI . Experience of pentavalent human-bovine reassortant rotavirus vaccine among healthy infants in Taiwan. Journal of the Formosan Medical Association2009;108(4):280-5. ChristieCD , DuncanND , ThameKA , OnoratoMT , SmithHD , MalcolmLG , et al. Pentavalent rotavirus vaccine in developing countries: safety and health care resource utilization. Pediatrics2010;126(6):e1499-506. DennehyPH , GoveiaMG , DallasMJ , HeatonPM . The integrated phase III safety profile of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine. International Journal of Infectious Diseases2007;11(Suppl 2):36-42. [No data available for review]GoveiaMG , DiNubileMJ , DallasMJ , HeatonPM , KuterBJ , REST Study Team. Efficacy of pentavalent human-bovine (WC3) reassortant rotavirus vaccine based on breastfeeding frequency. Pediatric Infectious Disease Journal2008;27(7):656-8. GoveiaMG , RodriguezZM , DallasMJ , ItzlerRF , BoslegoJW , HeatonPM , et al. Safety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infants. Pediatric Infectious Disease Journal2007;26(12):1099-104. [No data available for review]GoveiaMG , SuprunL , ItzlerRF , McFetridgeR , DallasMJ , KuterBJ . Efficacy and safety of pentavalent human-bovine reassortant rotavirus vaccine when administered with greater than 10 weeks between doses. Pediatric Infectious Disease Journal2010;29(3):263-5. GrantL , WattJ , MoultonL , WeatherholtzR , ReidR , SantoshamM , et al. Lack of nonspecific protection against all-cause nonrotavirus gastroenteritis by vaccination with orally administered rotavirus vaccine. Journal of Pediatric Gastroenterology and Nutrition2013;56(6):635-40. GrantLR , WattJP , WeatherholtzRC , MoultonLH , ReidR , SantoshamM , et al. Efficacy of a pentavalent human-bovine reassortant rotavirus vaccine against rotavirus gastroenteritis among American Indian children. Pediatric Infectious Disease Journal2012;31(2):184-8. ItzlerR , KochG , MatsonDO , GotheforsL , Van DammeP , DinubileMJ , et al. Robustness of the healthcare utilization results from the Rotavirus Efficacy and Safety Trial (REST) evaluating the human-bovine (WC3) reassortant pentavalent rotavirus vaccine (RV5). BMC Pediatrics2010;10:42. Merck[PN-006]. Safety and efficacy of pentavalent (G1, G2, G3, G4, and P1) human-bovine reassortant rotavirus vaccine in healthy infants NCT00090233 (PN 006). clinicalstudyresults.org/drugdetails/?indication_id=523&amp;sort=c.company_name&amp;page=1&amp;drug_id=1144 (accessed prior to 19 October 2021). [No data available for review]NCT00090233. Safety and efficacy of pentavalent (G1, G2, G3, G4, and P1) human-bovine reassortant rotavirus vaccine in healthy infants. clinicaltrials.gov/ct2/show/record/NCT00090233 (first received 27 August 2004). [Trial registration document]RodriguezZM , GoveiaMG , StekJE , DallasMJ , BoslegoJW , DiNubileMJ , et al. Concomitant use of an oral live pentavalent human-bovine reassortant rotavirus vaccine with licensed parenteral pediatric vaccines in the United States. Pediatric Infectious Disease Journal2007;26(3):221-7. VesikariT ,  KarvonenA ,  FerranteSA ,  KuterBJ ,  CiarletM . Sustained efficacy of the pentavalent rotavirus vaccine, RV5, up to 3.1 years following the last dose of vaccine. Pediatric Infectious Disease Journal2010;29(10):957-63. VesikariT , ItzlerR , KarvonenA , KorhonenT , Van DammeP , BehreU , et al. RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe. Vaccine2009;28(2):345-51. VesikariT , ItzlerR , MatsonDO , SantoshamM , ChristieCD , CoiaM , et al. Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across three regions (11 countries). International Journal of Infectious Diseases2007;11(Suppl 2):29-35. VesikariT , KarvonenA , FerranteSA , CiarletM . Efficacy of the pentavalent rotavirus vaccine, RotaTeq(R), in Finnish infants up to 3 years of age: the Finnish Extension Study. European Journal of Pediatrics2010;169(11):1379-86. VesikariT , MatsonDO , DennehyP , Van DammeP , SantoshamM , RodriguezZ , et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. New England Journal of Medicine2006;354(1):23-33. ">TEQ Vesikari 2006b‐INT</a>), in two trials in medium‐mortality countries (<a href="./references#CD008521-bbs2-0055" title="LawrenceJ , HeS , HilleD , ShenC , KuterB , SchodelF , et al. A study of RotaTeqTM (pentavalent rotavirus vaccine) in Chinese healthy adults, children and infants. International Journal of Infectious Diseases2012;16(1):e307. NCT00953056. A study of V260 in healthy Chinese adults, children and infants. clinicaltrials.gov/ct2/show/study/NCT00953056 (first received 4 August 2009). ">TEQ Lawrence 2012‐CHN</a>; <a href="./references#CD008521-bbs2-0058" title="MoZ , MoY , LiM , TaoJ , YangX , KongJ , et al. Efficacy and safety of a pentavalent live human-bovine reassortant rotavirus vaccine (RV5) in healthy Chinese infants: a randomized, double-blind, placebo-controlled trial. Vaccine2017;35(43):5897-904. NCT02062385. Efficacy, safety, and immunogenicity of V260 in healthy Chinese infants (V260-024). clinicaltrials.gov/show/NCT02062385 (first received 13 February 2014). ">TEQ Mo 2017‐CHN</a>), and in four trials split into seven country‐level comparisons in high‐mortality countries (<a href="./references#CD008521-bbs2-0045" title="ArmahGE ,  SowSO ,  BreimanRF ,  DallasMJ ,  TapiaMD ,  FeikinDR ,  et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet2010;376(9741):606-14. TapiaMD , ArmahG , BreimanRF , DallasMJ , LewisKD , SowSO , et al. Secondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africa. Vaccine2012;30(Suppl 1):A79-85. ">TEQ Armah 2010‐GHA</a>; <a href="./references#CD008521-bbs2-0046" title="ArmahGE ,  SowSO ,  BreimanRF ,  DallasMJ ,  TapiaMD ,  FeikinDR ,  et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet2010;376(9741):606-14. FeikinDR , LasersonKF , OjwandoJ , NyambaneG , SsempijjaV , AudiA , et al. Efficacy of pentavalent rotavirus vaccine in a high HIV prevalence population in Kenya. Vaccine2012;30(Suppl 1):A52-60. LasersonKF , NyakundiD , FeikinDR , NyambaneG , CookE , OyiekoJ , et al. Safety of the pentavalent rotavirus vaccine (PRV), RotaTeq((R)), in Kenya, including among HIV-infected and HIV-exposed infants. Vaccine2012;30(Suppl 1):A61-70. TapiaMD , ArmahG , BreimanRF , DallasMJ , LewisKD , SowSO , et al. Secondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africa. Vaccine2012;30(Suppl 1):A79-85. ">TEQ Armah 2010‐KEN</a>; <a href="./references#CD008521-bbs2-0047" title="ArmahGE ,  SowSO ,  BreimanRF ,  DallasMJ ,  TapiaMD ,  FeikinDR ,  et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet2010;376(9741):606-14. SowSO , TapiaM , HaidaraFC , CiarletM , DialloF , KodioM , et al. Efficacy of the oral pentavalent rotavirus vaccine in Mali. Vaccine2012;30(Suppl 1):A71-8. TapiaMD , ArmahG , BreimanRF , DallasMJ , LewisKD , SowSO , et al. Secondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africa. Vaccine2012;30(Suppl 1):A79-85. ">TEQ Armah 2010‐MLI</a>; <a href="./references#CD008521-bbs2-0052" title="CTRI/2012/07/002820. A study to evaluate safety of Rotavirus vaccine in healthy adult volunteers followed by safety, tolerability and immunogenicity evaluation in healthy infants. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=4929&amp;EncHid=&amp;userName=CTRI/2012/07/002820 (first received 23 July 2012). DhingraMS , KunduR , GuptaM , KanungoS , GangulyN , SinghMP , et al. Evaluation of safety and immunogenicity of a live attenuated tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus vaccine (BRV-TV) in healthy Indian adults and infants. Vaccine2014;32(Suppl 1):A117-23. ">TEQ Dhingra 2014‐IND</a>; <a href="./references#CD008521-bbs2-0056" title="LevinMJ , LindseyJC , KaplanSS , SchimanaW , LawrenceJ , McNealMM , et al. Safety and immunogenicity of a live attenuated pentavalent rotavirus vaccine in HIV-exposed infants with or without HIV infection in Africa. AIDS2017;31(1):49-59. NCT00880698. Safety and immunogenicity of a live, attenuated rotavirus (RotaTeqTM) in HIV-1 infected and uninfected children born to HIV-1-infected mothers. clinicaltrials.gov/ct2/show/study/NCT00880698 (first received 14 April 2009). UpretyP , LindseyJ , LevinM , Rainwater-LovettK , ZiemniakC , KaplanS , et al. Enhanced inflammation and rotavirus vaccine responses in perinatal HIV-1 infection. In: Topics in Antiviral Medicine; 23rd Conference on Retroviruses and Opportunistic Infections, CROI; 2016, USA. Vol. 24(E-1). 2016:347. ">TEQ Levin 2017‐AF</a>; <a href="./references#CD008521-bbs2-0062" title="FellerAJ , ZamanK , LewisKD , HossainI , YunusM , SackDA . Malnutrition levels among vaccinated and unvaccinated children between 2 and 3 years of age following enrollment in a randomized clinical trial with the pentavalent rotavirus vaccine (PRV) in Bangladesh. Vaccine2012;30(Suppl 1):A101-5. ZamanK ,  DangDA ,  VictorJC ,  ShinS ,  YunusM ,  DallasMJ ,  et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet2010;376(9741):615-23. ZamanK , YunusM , ArifeenSE , AzimT , FaruqueAS , HuqE , et al. Methodology and lessons-learned from the efficacy clinical trial of the pentavalent rotavirus vaccine in Bangladesh. Vaccine2012;30(Suppl 1):A94-100. ">TEQ Zaman 2010‐BGD</a>; <a href="./references#CD008521-bbs2-0063" title="ZamanK ,  DangDA ,  VictorJC ,  ShinS ,  YunusM ,  DallasMJ ,  et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet2010;376(9741):615-23. ">TEQ Zaman 2010‐VNM</a>); see <a href="./references#CD008521-fig-0046" title="">Analysis 2.7</a>. </p> <section id="CD008521-sec-0165"> <p><b>Low‐mortality countries</b></p> <p>There was little or no difference between children allocated to RotaTeq compared with placebo in serious adverse events (RR 0.92, 95% CI 0.84 to 1.01; 70,690 participants, 5 trials; <a href="./references#CD008521-fig-0046" title="">Analysis 2.7</a>).  </p> </section> <section id="CD008521-sec-0166"> <p><b>Medium‐mortality countries</b></p> <p>Pooled results showed little or no difference in the number of serious adverse events in the RotaTeq group compared with the placebo group (RR 0.66, 95% CI 0.14 to 3.17; 4082 participants, 2 trials; <a href="./references#CD008521-fig-0046" title="">Analysis 2.7</a>) with statistical heterogeneity (I<sup>2</sup> = 42%). In addition, in a separate cohort of <a href="./references#CD008521-bbs2-0055" title="LawrenceJ , HeS , HilleD , ShenC , KuterB , SchodelF , et al. A study of RotaTeqTM (pentavalent rotavirus vaccine) in Chinese healthy adults, children and infants. International Journal of Infectious Diseases2012;16(1):e307. NCT00953056. A study of V260 in healthy Chinese adults, children and infants. clinicaltrials.gov/ct2/show/study/NCT00953056 (first received 4 August 2009). ">TEQ Lawrence 2012‐CHN</a> that vaccinated 24 older children (aged two to six years) with one‐dose RotaTeq, there were no serious adverse events reported. </p> </section> <section id="CD008521-sec-0167"> <p><b>High‐mortality countries</b></p> <p>Pooled results showed little or no difference in the number of serious adverse events in the RotaTeq group compared with the placebo group (RR 0.99, 95% CI 0.72 to 1.36; 7730 participants, 7 comparisons from 4 trials; <a href="./references#CD008521-fig-0046" title="">Analysis 2.7</a>). </p> </section> </section> <section id="CD008521-sec-0168"> <h6 class="title">2.1.5. Serious adverse events: intussusception</h6> <p>Thirteen trials reported cases of intussusception. Trials were performed in nine low‐mortality countries (<a href="./references#CD008521-bbs2-0048" title="BlockSL , VesikariT , GoveiaMG , RiversSB , AdeyiBA , DallasMJ , et al. Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life. Pediatrics2007;119(1):11-8. Merck[PN-007]. Study of the efficacy, safety, and immunogenicity of RotaTeq™ at expiry potency NCT00092443 (PN 007). www.clinicalstudyresults.org/drugdetails/?indication_id=523&amp;sort=c.company_name&amp;page=1&amp;drug_id=900 (accessed prior to 19 October 2021). NCT00092443. Study of the efficacy, safety, and immunogenicity of V260 at expiry. clinicaltrials.gov/ct2/show/NCT00092443 (first received 27 September 2004). [Trial registration document]">TEQ Block 2007‐EU/USA</a>; <a href="./references#CD008521-bbs2-0049" title="CiarletM , HeS , LaiS , PetreczM , YuanG , LiuGF , et al. Concomitant use of the 3-dose oral pentavalent rotavirus vaccine with a 3-dose primary vaccination course of a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b vaccine: immunogenicity and reactogenicity. Pediatric Infectious Disease Journal2009;28(3):177-81. Merck[PN-010]. Safety and immunogenicity of concomitant use of RotaTeq™ and INFANRIX™ hexa in healthy infants NCT00258154 (PN 010) [Merck &amp; Co. Inc. Study Synopsis]. clinicalstudyresults.org/drugdetails/?indication_id=1101&amp;sort=c.company_name&amp;page=1&amp;drug_id=2823 (accessed prior to 19 October 2021). NCT00258154. Safety and immunogenicity of concomitant use of V260 and INFANRIX(Tm) hexa in healthy infants. clinicaltrials.gov/show/NCT00258154 (first received 24 November 2005). [Trial registration document (no data for review)]">TEQ Ciarlet 2009‐EU</a>; <a href="./references#CD008521-bbs2-0050" title="ClarkHF , BurkeCJ , VolkinDB , OffitP , WardRL , BreseeJS , et al. Safety, immunogenicity and efficacy in healthy infants of G1 and G2 human reassortant rotavirus vaccine in a new stabilizer/buffer liquid formulation. Pediatric Infectious Disease Journal2003;22(10):914-20. ">TEQ Clark 2003‐USA</a>; <a href="./references#CD008521-bbs2-0051" title="ClarkH , WhiteC , OffitP , StinsonD , EidenJ , WeaverS , et al. Preliminary evaluation of safety and efficacy of quadrivalent human-bovine reassortant rotavirus vaccine [abstract]. Pediatric Research1995;37:172A. [No data for review]ClarkHF , BernsteinDI , DennehyPH , OffitP , PichicheroM , TreanorJ , et al. Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants. Journal of Pediatrics2004;144(2):184-90. ClarkHF , OffitPA , EllisRW , EidenJJ , KrahD , ShawAR , et al. The development of multivalent bovine rotavirus (strain WC3) reassortant vaccine for infants. Journal of Infectious Diseases1996;174(Suppl 1):73-80. [No data for review]WardRL , BernsteinDI , SmithVE , SanderDS , ShawA , EidenJJ , et al. Rotavirus immunoglobulin a responses stimulated by each of 3 doses of a quadrivalent human/bovine reassortant rotavirus vaccine. Journal of Infectious Diseases2004;189(12):2290-3. ">TEQ Clark 2004‐USA</a>; <a href="./references#CD008521-bbs2-0053" title="IwataS , NakataS , UkaeS , KoizumiY , MoritaY , KurokiH , et al. Efficacy and safety of pentavalent rotavirus vaccine in Japan: a randomized, double-blind, placebo-controlled, multicenter trial. Human Vaccines and Immunotherapeutics2013;9(8):1626-33. NCT00718237. A phase III randomized, placebo-controlled clinical trial to study the efficacy and safety of V260 in healthy infants in Japan. clinicaltrials.gov/ct2/show/record/NCT00718237 (first received 16 July 2008). ">TEQ Iwata 2013‐JPN</a>; <a href="./references#CD008521-bbs2-0054" title="KimDS , LeeTJ , KangJH , KimJH , LeeJH , MaSH , et al. Immunogenicity and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy infants in Korea. Pediatric Infectious Disease Journal2008;27(2):177-8. Merck[PN-013]. Immunogenicity and safety of RotaTeq® in healthy infants in Korea - NCT00166517 (PN 013). clinicalstudyresults.org/drugdetails/?indication_id=523&amp;sort=c.company_name&amp;page=1&amp;drug_id=2148 (accessed prior to 19 October 2021). NCT00166517. Immunogenicity and safety of V260 in healthy infants in Korea. clinicaltrials.gov/show/NCT00166517 (first received 14 September 2005). [Trial registration document (no data for review)]">TEQ Kim 2008‐KOR</a>; <a href="./references#CD008521-bbs2-0057" title="Merck[PN-009]. Protocol 009 - Comparison of the immunogenicity and safety of three consistency lots of RotaTeq™ in healthy infants (NCT00092456). clinicalstudyresults.org/drugdetails/?indication_id=523&amp;sort=c.company_name&amp;page=1&amp;drug_id=1357 (accessed prior to 19 October 2021). NCT00092456. Comparison of the immunogenicity and safety of three consistency lots of V260 in healthy infants. clinicaltrials.gov/ct2/show/record/NCT00092456 (first received 27 September 2004). [Trial registration document (no data for review)]">TEQ Merck[009] 2005‐USA</a>; <a href="./references#CD008521-bbs2-0059" title="VesikariT , ClarkHF , OffitP , SchodelF , DallasM , HeatonP , et al. The effect of dose and composition of a pentavalent rotavirus reassortant vaccine [RotaTeq (R)] in safety, efficacy, and immunogenicity in healthy infants. Pediatric Research2003;53(4 Suppl):307A. VesikariT , ClarkHF , OffitPA , DallasMJ , DiStefanoDJ , GoveiaMG , et al. Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants. Vaccine2006;24(22):4821-9. ">TEQ Vesikari 2006a‐FIN</a>; <a href="./references#CD008521-bbs2-0060" title="ChangCC , ChangMH , LinTY , LeeHC , HsiehWS , LeePI . Experience of pentavalent human-bovine reassortant rotavirus vaccine among healthy infants in Taiwan. Journal of the Formosan Medical Association2009;108(4):280-5. ChristieCD , DuncanND , ThameKA , OnoratoMT , SmithHD , MalcolmLG , et al. Pentavalent rotavirus vaccine in developing countries: safety and health care resource utilization. Pediatrics2010;126(6):e1499-506. DennehyPH , GoveiaMG , DallasMJ , HeatonPM . The integrated phase III safety profile of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine. International Journal of Infectious Diseases2007;11(Suppl 2):36-42. [No data available for review]GoveiaMG , DiNubileMJ , DallasMJ , HeatonPM , KuterBJ , REST Study Team. Efficacy of pentavalent human-bovine (WC3) reassortant rotavirus vaccine based on breastfeeding frequency. Pediatric Infectious Disease Journal2008;27(7):656-8. GoveiaMG , RodriguezZM , DallasMJ , ItzlerRF , BoslegoJW , HeatonPM , et al. Safety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infants. Pediatric Infectious Disease Journal2007;26(12):1099-104. [No data available for review]GoveiaMG , SuprunL , ItzlerRF , McFetridgeR , DallasMJ , KuterBJ . Efficacy and safety of pentavalent human-bovine reassortant rotavirus vaccine when administered with greater than 10 weeks between doses. Pediatric Infectious Disease Journal2010;29(3):263-5. GrantL , WattJ , MoultonL , WeatherholtzR , ReidR , SantoshamM , et al. Lack of nonspecific protection against all-cause nonrotavirus gastroenteritis by vaccination with orally administered rotavirus vaccine. Journal of Pediatric Gastroenterology and Nutrition2013;56(6):635-40. GrantLR , WattJP , WeatherholtzRC , MoultonLH , ReidR , SantoshamM , et al. Efficacy of a pentavalent human-bovine reassortant rotavirus vaccine against rotavirus gastroenteritis among American Indian children. Pediatric Infectious Disease Journal2012;31(2):184-8. ItzlerR , KochG , MatsonDO , GotheforsL , Van DammeP , DinubileMJ , et al. Robustness of the healthcare utilization results from the Rotavirus Efficacy and Safety Trial (REST) evaluating the human-bovine (WC3) reassortant pentavalent rotavirus vaccine (RV5). BMC Pediatrics2010;10:42. Merck[PN-006]. Safety and efficacy of pentavalent (G1, G2, G3, G4, and P1) human-bovine reassortant rotavirus vaccine in healthy infants NCT00090233 (PN 006). clinicalstudyresults.org/drugdetails/?indication_id=523&amp;sort=c.company_name&amp;page=1&amp;drug_id=1144 (accessed prior to 19 October 2021). [No data available for review]NCT00090233. Safety and efficacy of pentavalent (G1, G2, G3, G4, and P1) human-bovine reassortant rotavirus vaccine in healthy infants. clinicaltrials.gov/ct2/show/record/NCT00090233 (first received 27 August 2004). [Trial registration document]RodriguezZM , GoveiaMG , StekJE , DallasMJ , BoslegoJW , DiNubileMJ , et al. Concomitant use of an oral live pentavalent human-bovine reassortant rotavirus vaccine with licensed parenteral pediatric vaccines in the United States. Pediatric Infectious Disease Journal2007;26(3):221-7. VesikariT ,  KarvonenA ,  FerranteSA ,  KuterBJ ,  CiarletM . Sustained efficacy of the pentavalent rotavirus vaccine, RV5, up to 3.1 years following the last dose of vaccine. Pediatric Infectious Disease Journal2010;29(10):957-63. VesikariT , ItzlerR , KarvonenA , KorhonenT , Van DammeP , BehreU , et al. RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe. Vaccine2009;28(2):345-51. VesikariT , ItzlerR , MatsonDO , SantoshamM , ChristieCD , CoiaM , et al. Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across three regions (11 countries). International Journal of Infectious Diseases2007;11(Suppl 2):29-35. VesikariT , KarvonenA , FerranteSA , CiarletM . Efficacy of the pentavalent rotavirus vaccine, RotaTeq(R), in Finnish infants up to 3 years of age: the Finnish Extension Study. European Journal of Pediatrics2010;169(11):1379-86. VesikariT , MatsonDO , DennehyP , Van DammeP , SantoshamM , RodriguezZ , et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. New England Journal of Medicine2006;354(1):23-33. ">TEQ Vesikari 2006b‐INT</a>), two trials in medium‐mortality countries (<a href="./references#CD008521-bbs2-0055" title="LawrenceJ , HeS , HilleD , ShenC , KuterB , SchodelF , et al. A study of RotaTeqTM (pentavalent rotavirus vaccine) in Chinese healthy adults, children and infants. International Journal of Infectious Diseases2012;16(1):e307. NCT00953056. A study of V260 in healthy Chinese adults, children and infants. clinicaltrials.gov/ct2/show/study/NCT00953056 (first received 4 August 2009). ">TEQ Lawrence 2012‐CHN</a>; <a href="./references#CD008521-bbs2-0058" title="MoZ , MoY , LiM , TaoJ , YangX , KongJ , et al. Efficacy and safety of a pentavalent live human-bovine reassortant rotavirus vaccine (RV5) in healthy Chinese infants: a randomized, double-blind, placebo-controlled trial. Vaccine2017;35(43):5897-904. NCT02062385. Efficacy, safety, and immunogenicity of V260 in healthy Chinese infants (V260-024). clinicaltrials.gov/show/NCT02062385 (first received 13 February 2014). ">TEQ Mo 2017‐CHN</a>), and two trials split into five country‐level comparisons in high‐mortality countries (<a href="./references#CD008521-bbs2-0045" title="ArmahGE ,  SowSO ,  BreimanRF ,  DallasMJ ,  TapiaMD ,  FeikinDR ,  et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet2010;376(9741):606-14. TapiaMD , ArmahG , BreimanRF , DallasMJ , LewisKD , SowSO , et al. Secondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africa. Vaccine2012;30(Suppl 1):A79-85. ">TEQ Armah 2010‐GHA</a>; <a href="./references#CD008521-bbs2-0046" title="ArmahGE ,  SowSO ,  BreimanRF ,  DallasMJ ,  TapiaMD ,  FeikinDR ,  et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet2010;376(9741):606-14. FeikinDR , LasersonKF , OjwandoJ , NyambaneG , SsempijjaV , AudiA , et al. Efficacy of pentavalent rotavirus vaccine in a high HIV prevalence population in Kenya. Vaccine2012;30(Suppl 1):A52-60. LasersonKF , NyakundiD , FeikinDR , NyambaneG , CookE , OyiekoJ , et al. Safety of the pentavalent rotavirus vaccine (PRV), RotaTeq((R)), in Kenya, including among HIV-infected and HIV-exposed infants. Vaccine2012;30(Suppl 1):A61-70. TapiaMD , ArmahG , BreimanRF , DallasMJ , LewisKD , SowSO , et al. Secondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africa. Vaccine2012;30(Suppl 1):A79-85. ">TEQ Armah 2010‐KEN</a>; <a href="./references#CD008521-bbs2-0047" title="ArmahGE ,  SowSO ,  BreimanRF ,  DallasMJ ,  TapiaMD ,  FeikinDR ,  et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet2010;376(9741):606-14. SowSO , TapiaM , HaidaraFC , CiarletM , DialloF , KodioM , et al. Efficacy of the oral pentavalent rotavirus vaccine in Mali. Vaccine2012;30(Suppl 1):A71-8. TapiaMD , ArmahG , BreimanRF , DallasMJ , LewisKD , SowSO , et al. Secondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africa. Vaccine2012;30(Suppl 1):A79-85. ">TEQ Armah 2010‐MLI</a>; <a href="./references#CD008521-bbs2-0062" title="FellerAJ , ZamanK , LewisKD , HossainI , YunusM , SackDA . Malnutrition levels among vaccinated and unvaccinated children between 2 and 3 years of age following enrollment in a randomized clinical trial with the pentavalent rotavirus vaccine (PRV) in Bangladesh. Vaccine2012;30(Suppl 1):A101-5. ZamanK ,  DangDA ,  VictorJC ,  ShinS ,  YunusM ,  DallasMJ ,  et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet2010;376(9741):615-23. ZamanK , YunusM , ArifeenSE , AzimT , FaruqueAS , HuqE , et al. Methodology and lessons-learned from the efficacy clinical trial of the pentavalent rotavirus vaccine in Bangladesh. Vaccine2012;30(Suppl 1):A94-100. ">TEQ Zaman 2010‐BGD</a>; <a href="./references#CD008521-bbs2-0063" title="ZamanK ,  DangDA ,  VictorJC ,  ShinS ,  YunusM ,  DallasMJ ,  et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet2010;376(9741):615-23. ">TEQ Zaman 2010‐VNM</a>); see <a href="./references#CD008521-fig-0047" title="">Analysis 2.8</a>. </p> <section id="CD008521-sec-0169"> <p><b>Low‐mortality countries</b></p> <p>Fourteen cases of intussusception were reported in a total of 37,846 children in the RotaTeq arms compared with 19 cases of intussusception in 36,079 children in the placebo arms. This corresponds to a risk difference of 16 fewer cases of intussusception with RotaTeq per 100,000 children with the 95% CI indicating from 34 fewer to 20 more per 100,000 (data not shown). Pooled results showed no increased risk of intussusception in children receiving RotaTeq when compared to placebo (RR 0.69, 95% CI 0.35 to 1.38; 73,925 participants, 9 trials; <a href="./references#CD008521-fig-0047" title="">Analysis 2.8</a>). </p> </section> <section id="CD008521-sec-0170"> <p><b>Medium‐mortality countries</b></p> <p>Two cases of intussusception were reported in a total of 2039 children in the RotaTeq arms compared with no cases of intussusception in 2043 children in the placebo arms. Risk difference could not be estimated due to no events in the placebo arms. Pooled results showed no increased risk of intussusception in children receiving RotaTeq when compared to placebo (RR 5.01, 95% CI 0.24 to 104.29; 4082 participants, 2 trials; <a href="./references#CD008521-fig-0047" title="">Analysis 2.8</a>). </p> </section> <section id="CD008521-sec-0171"> <p><b>High‐mortality countries</b></p> <p>No cases of intussusception were reported in a total of 3744 children in the RotaTeq arms compared with one case of intussusception in 3744 children in the placebo arms. This corresponds to a risk difference of 18 fewer cases of intussusception with RotaTeq per 100,000 children with the 95% CI indicating from 26 fewer to 191 more per 100,000 (data not shown). Pooled results showed no increased risk of intussusception in children receiving RotaTeq when compared to placebo (RR 0.33, 95% CI 0.01 to 8.16; 7488 participants, 5 comparisons in 2 trials; <a href="./references#CD008521-fig-0047" title="">Analysis 2.8</a>). </p> </section> </section> </section> <section id="CD008521-sec-0172"> <h5 class="title">2.2. Secondary outcomes</h5> <section id="CD008521-sec-0173"> <h6 class="title">2.2.1. Rotavirus diarrhoea: of any severity</h6> <p>Nine trials provided data for the efficacy of RotaTeq to prevent rotavirus diarrhoea of any severity in children; see <a href="./references#CD008521-fig-0048" title="">Analysis 2.9</a> for one‐year follow‐up and <a href="./references#CD008521-fig-0050" title="">Analysis 2.11</a> for two‐year follow‐up. Six trials were performed in low‐mortality countries (<a href="./references#CD008521-bbs2-0048" title="BlockSL , VesikariT , GoveiaMG , RiversSB , AdeyiBA , DallasMJ , et al. Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life. Pediatrics2007;119(1):11-8. Merck[PN-007]. Study of the efficacy, safety, and immunogenicity of RotaTeq™ at expiry potency NCT00092443 (PN 007). www.clinicalstudyresults.org/drugdetails/?indication_id=523&amp;sort=c.company_name&amp;page=1&amp;drug_id=900 (accessed prior to 19 October 2021). NCT00092443. Study of the efficacy, safety, and immunogenicity of V260 at expiry. clinicaltrials.gov/ct2/show/NCT00092443 (first received 27 September 2004). [Trial registration document]">TEQ Block 2007‐EU/USA</a>; <a href="./references#CD008521-bbs2-0050" title="ClarkHF , BurkeCJ , VolkinDB , OffitP , WardRL , BreseeJS , et al. Safety, immunogenicity and efficacy in healthy infants of G1 and G2 human reassortant rotavirus vaccine in a new stabilizer/buffer liquid formulation. Pediatric Infectious Disease Journal2003;22(10):914-20. ">TEQ Clark 2003‐USA</a>; <a href="./references#CD008521-bbs2-0051" title="ClarkH , WhiteC , OffitP , StinsonD , EidenJ , WeaverS , et al. Preliminary evaluation of safety and efficacy of quadrivalent human-bovine reassortant rotavirus vaccine [abstract]. Pediatric Research1995;37:172A. [No data for review]ClarkHF , BernsteinDI , DennehyPH , OffitP , PichicheroM , TreanorJ , et al. Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants. Journal of Pediatrics2004;144(2):184-90. ClarkHF , OffitPA , EllisRW , EidenJJ , KrahD , ShawAR , et al. The development of multivalent bovine rotavirus (strain WC3) reassortant vaccine for infants. Journal of Infectious Diseases1996;174(Suppl 1):73-80. [No data for review]WardRL , BernsteinDI , SmithVE , SanderDS , ShawA , EidenJJ , et al. Rotavirus immunoglobulin a responses stimulated by each of 3 doses of a quadrivalent human/bovine reassortant rotavirus vaccine. Journal of Infectious Diseases2004;189(12):2290-3. ">TEQ Clark 2004‐USA</a>; <a href="./references#CD008521-bbs2-0053" title="IwataS , NakataS , UkaeS , KoizumiY , MoritaY , KurokiH , et al. Efficacy and safety of pentavalent rotavirus vaccine in Japan: a randomized, double-blind, placebo-controlled, multicenter trial. Human Vaccines and Immunotherapeutics2013;9(8):1626-33. NCT00718237. A phase III randomized, placebo-controlled clinical trial to study the efficacy and safety of V260 in healthy infants in Japan. clinicaltrials.gov/ct2/show/record/NCT00718237 (first received 16 July 2008). ">TEQ Iwata 2013‐JPN</a>; <a href="./references#CD008521-bbs2-0059" title="VesikariT , ClarkHF , OffitP , SchodelF , DallasM , HeatonP , et al. The effect of dose and composition of a pentavalent rotavirus reassortant vaccine [RotaTeq (R)] in safety, efficacy, and immunogenicity in healthy infants. Pediatric Research2003;53(4 Suppl):307A. VesikariT , ClarkHF , OffitPA , DallasMJ , DiStefanoDJ , GoveiaMG , et al. Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants. Vaccine2006;24(22):4821-9. ">TEQ Vesikari 2006a‐FIN</a>; <a href="./references#CD008521-bbs2-0060" title="ChangCC , ChangMH , LinTY , LeeHC , HsiehWS , LeePI . Experience of pentavalent human-bovine reassortant rotavirus vaccine among healthy infants in Taiwan. Journal of the Formosan Medical Association2009;108(4):280-5. ChristieCD , DuncanND , ThameKA , OnoratoMT , SmithHD , MalcolmLG , et al. Pentavalent rotavirus vaccine in developing countries: safety and health care resource utilization. Pediatrics2010;126(6):e1499-506. DennehyPH , GoveiaMG , DallasMJ , HeatonPM . The integrated phase III safety profile of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine. International Journal of Infectious Diseases2007;11(Suppl 2):36-42. [No data available for review]GoveiaMG , DiNubileMJ , DallasMJ , HeatonPM , KuterBJ , REST Study Team. Efficacy of pentavalent human-bovine (WC3) reassortant rotavirus vaccine based on breastfeeding frequency. Pediatric Infectious Disease Journal2008;27(7):656-8. GoveiaMG , RodriguezZM , DallasMJ , ItzlerRF , BoslegoJW , HeatonPM , et al. Safety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infants. Pediatric Infectious Disease Journal2007;26(12):1099-104. [No data available for review]GoveiaMG , SuprunL , ItzlerRF , McFetridgeR , DallasMJ , KuterBJ . Efficacy and safety of pentavalent human-bovine reassortant rotavirus vaccine when administered with greater than 10 weeks between doses. Pediatric Infectious Disease Journal2010;29(3):263-5. GrantL , WattJ , MoultonL , WeatherholtzR , ReidR , SantoshamM , et al. Lack of nonspecific protection against all-cause nonrotavirus gastroenteritis by vaccination with orally administered rotavirus vaccine. Journal of Pediatric Gastroenterology and Nutrition2013;56(6):635-40. GrantLR , WattJP , WeatherholtzRC , MoultonLH , ReidR , SantoshamM , et al. Efficacy of a pentavalent human-bovine reassortant rotavirus vaccine against rotavirus gastroenteritis among American Indian children. Pediatric Infectious Disease Journal2012;31(2):184-8. ItzlerR , KochG , MatsonDO , GotheforsL , Van DammeP , DinubileMJ , et al. Robustness of the healthcare utilization results from the Rotavirus Efficacy and Safety Trial (REST) evaluating the human-bovine (WC3) reassortant pentavalent rotavirus vaccine (RV5). BMC Pediatrics2010;10:42. Merck[PN-006]. Safety and efficacy of pentavalent (G1, G2, G3, G4, and P1) human-bovine reassortant rotavirus vaccine in healthy infants NCT00090233 (PN 006). clinicalstudyresults.org/drugdetails/?indication_id=523&amp;sort=c.company_name&amp;page=1&amp;drug_id=1144 (accessed prior to 19 October 2021). [No data available for review]NCT00090233. Safety and efficacy of pentavalent (G1, G2, G3, G4, and P1) human-bovine reassortant rotavirus vaccine in healthy infants. clinicaltrials.gov/ct2/show/record/NCT00090233 (first received 27 August 2004). [Trial registration document]RodriguezZM , GoveiaMG , StekJE , DallasMJ , BoslegoJW , DiNubileMJ , et al. Concomitant use of an oral live pentavalent human-bovine reassortant rotavirus vaccine with licensed parenteral pediatric vaccines in the United States. Pediatric Infectious Disease Journal2007;26(3):221-7. VesikariT ,  KarvonenA ,  FerranteSA ,  KuterBJ ,  CiarletM . Sustained efficacy of the pentavalent rotavirus vaccine, RV5, up to 3.1 years following the last dose of vaccine. Pediatric Infectious Disease Journal2010;29(10):957-63. VesikariT , ItzlerR , KarvonenA , KorhonenT , Van DammeP , BehreU , et al. RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe. Vaccine2009;28(2):345-51. VesikariT , ItzlerR , MatsonDO , SantoshamM , ChristieCD , CoiaM , et al. Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across three regions (11 countries). International Journal of Infectious Diseases2007;11(Suppl 2):29-35. VesikariT , KarvonenA , FerranteSA , CiarletM . Efficacy of the pentavalent rotavirus vaccine, RotaTeq(R), in Finnish infants up to 3 years of age: the Finnish Extension Study. European Journal of Pediatrics2010;169(11):1379-86. VesikariT , MatsonDO , DennehyP , Van DammeP , SantoshamM , RodriguezZ , et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. New England Journal of Medicine2006;354(1):23-33. ">TEQ Vesikari 2006b‐INT</a>), one trial in a medium‐mortality country (<a href="./references#CD008521-bbs2-0058" title="MoZ , MoY , LiM , TaoJ , YangX , KongJ , et al. Efficacy and safety of a pentavalent live human-bovine reassortant rotavirus vaccine (RV5) in healthy Chinese infants: a randomized, double-blind, placebo-controlled trial. Vaccine2017;35(43):5897-904. NCT02062385. Efficacy, safety, and immunogenicity of V260 in healthy Chinese infants (V260-024). clinicaltrials.gov/show/NCT02062385 (first received 13 February 2014). ">TEQ Mo 2017‐CHN</a>), and two trials split into four country‐level comparisons in high‐mortality countries (<a href="./references#CD008521-bbs2-0045" title="ArmahGE ,  SowSO ,  BreimanRF ,  DallasMJ ,  TapiaMD ,  FeikinDR ,  et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet2010;376(9741):606-14. TapiaMD , ArmahG , BreimanRF , DallasMJ , LewisKD , SowSO , et al. Secondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africa. Vaccine2012;30(Suppl 1):A79-85. ">TEQ Armah 2010‐GHA</a>; <a href="./references#CD008521-bbs2-0046" title="ArmahGE ,  SowSO ,  BreimanRF ,  DallasMJ ,  TapiaMD ,  FeikinDR ,  et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet2010;376(9741):606-14. FeikinDR , LasersonKF , OjwandoJ , NyambaneG , SsempijjaV , AudiA , et al. Efficacy of pentavalent rotavirus vaccine in a high HIV prevalence population in Kenya. Vaccine2012;30(Suppl 1):A52-60. LasersonKF , NyakundiD , FeikinDR , NyambaneG , CookE , OyiekoJ , et al. Safety of the pentavalent rotavirus vaccine (PRV), RotaTeq((R)), in Kenya, including among HIV-infected and HIV-exposed infants. Vaccine2012;30(Suppl 1):A61-70. TapiaMD , ArmahG , BreimanRF , DallasMJ , LewisKD , SowSO , et al. Secondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africa. Vaccine2012;30(Suppl 1):A79-85. ">TEQ Armah 2010‐KEN</a>; <a href="./references#CD008521-bbs2-0047" title="ArmahGE ,  SowSO ,  BreimanRF ,  DallasMJ ,  TapiaMD ,  FeikinDR ,  et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet2010;376(9741):606-14. SowSO , TapiaM , HaidaraFC , CiarletM , DialloF , KodioM , et al. Efficacy of the oral pentavalent rotavirus vaccine in Mali. Vaccine2012;30(Suppl 1):A71-8. TapiaMD , ArmahG , BreimanRF , DallasMJ , LewisKD , SowSO , et al. Secondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africa. Vaccine2012;30(Suppl 1):A79-85. ">TEQ Armah 2010‐MLI</a>; <a href="./references#CD008521-bbs2-0061" title="BreimanRF , ZamanK , ArmahG , SowSO , AnhDD , VictorJC , et al. Analyses of health outcomes from the 5 sites participating in the Africa and Asia clinical efficacy trials of the oral pentavalent rotavirus vaccine. Vaccine2012;30(Suppl 1):A24-9. GruberJF , HilleDA , LiuGF , KaplanSS , NelsonM , GoveiaMG , et al. Heterogeneity of rotavirus vaccine efficacy among infants in developing countries. Pediatric Infectious Disease Journal2017;36(1):72-8. NCT00362648. Efficacy, safety, and immunogenicity of RotaTeqTM among infants in Asia and Africa. clinicaltrials.gov/ct2/show/record/NCT00362648 (first received 8 August 2006). ShinS , AnhDD , ZamanK , YunusM , Mai leTP , ThiemVD , et al. Immunogenicity of the pentavalent rotavirus vaccine among infants in two developing countries in Asia, Bangladesh and Vietnam. Vaccine2012;30(Suppl 1):A106-13. ZamanK ,  DangDA ,  VictorJC ,  ShinS ,  YunusM ,  DallasMJ ,  et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet2010;376(9741):615-23. ">TEQ Zaman 2010‐AS</a>). Data below are grouped accordingly. </p> <section id="CD008521-sec-0174"> <p><b>Low‐mortality countries</b></p> <p>RotaTeq reduced the number of cases of rotavirus diarrhoea by 70% at both one‐year (RR 0.30, 95% CI 0.25 to 0.37; 8644 participants, 5 trials; <a href="./references#CD008521-fig-0048" title="">Analysis 2.9</a>) and two years follow‐up (RR 0.30, 95% CI 0.25 to 0.37; 5223 participants, 2 trials; <a href="./references#CD008521-fig-0050" title="">Analysis 2.11</a>). </p> </section> <section id="CD008521-sec-0175"> <p><b>Medium‐mortality countries</b></p> <p>RotaTeq reduced the number of cases of rotavirus diarrhoea by 69% at two years follow‐up (RR 0.31, 95% CI 0.21 to 0.46; 3864 participants, 1 trial; <a href="./references#CD008521-fig-0048" title="">Analysis 2.9</a>). </p> </section> <section id="CD008521-sec-0176"> <p><b>High‐mortality countries</b></p> <p>RotaTeq reduced the number of cases of rotavirus diarrhoea by 48% at one year (RR 0.52, 95% CI 0.28 to 0.94; 4806 participants, 3 comparisons from 1 trial; <a href="./references#CD008521-fig-0048" title="">Analysis 2.9</a>) and by 39% at two years (RR 0.61, 95% CI 0.45 to 0.83; 6744 participants, 4 comparisons from 2 trials; <a href="./references#CD008521-fig-0050" title="">Analysis 2.11</a>). Pooled results had significant heterogeneity at one‐year (I<sup>2</sup> = 67%; see <a href="./references#CD008521-fig-0048" title="">Analysis 2.9</a>) and at two‐year (I<sup>2</sup> = 69%; see <a href="./references#CD008521-fig-0050" title="">Analysis 2.11</a>) follow‐up. </p> </section> </section> <section id="CD008521-sec-0177"> <h6 class="title">2.2.2. All‐cause diarrhoea: of any severity</h6> <p>One trial performed in high‐mortality Kenya (<a href="./references#CD008521-bbs2-0046" title="ArmahGE ,  SowSO ,  BreimanRF ,  DallasMJ ,  TapiaMD ,  FeikinDR ,  et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet2010;376(9741):606-14. FeikinDR , LasersonKF , OjwandoJ , NyambaneG , SsempijjaV , AudiA , et al. Efficacy of pentavalent rotavirus vaccine in a high HIV prevalence population in Kenya. Vaccine2012;30(Suppl 1):A52-60. LasersonKF , NyakundiD , FeikinDR , NyambaneG , CookE , OyiekoJ , et al. Safety of the pentavalent rotavirus vaccine (PRV), RotaTeq((R)), in Kenya, including among HIV-infected and HIV-exposed infants. Vaccine2012;30(Suppl 1):A61-70. TapiaMD , ArmahG , BreimanRF , DallasMJ , LewisKD , SowSO , et al. Secondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africa. Vaccine2012;30(Suppl 1):A79-85. ">TEQ Armah 2010‐KEN</a>) provided data for the efficacy of RotaTeq to prevent all‐cause diarrhoea of any severity; see <a href="./references#CD008521-fig-0051" title="">Analysis 2.12</a> for one‐year and <a href="./references#CD008521-fig-0052" title="">Analysis 2.13</a> for two‐year follow‐up. </p> <section id="CD008521-sec-0178"> <p><b>High‐mortality countries</b></p> <p>There was little or no difference between RotaTeq and placebo for any severity all‐cause diarrhoea at one‐year (RR 0.82, 95% CI 0.61 to 1.11; 1059 participants, 1 trial; <a href="./references#CD008521-fig-0051" title="">Analysis 2.12</a>) or at two‐year follow‐up (RR 0.89, 95% CI 0.68 to 1.16; 1059 participants, 1 trial; <a href="./references#CD008521-fig-0052" title="">Analysis 2.13</a>). </p> </section> </section> <section id="CD008521-sec-0179"> <h6 class="title">All‐cause hospitalization</h6> <p>Data on all‐cause hospitalization were provided from one trial carried out in Botswana, Tanzania, Zambia, and Zimbabwe (high‐mortality countries) (<a href="./references#CD008521-bbs2-0056" title="LevinMJ , LindseyJC , KaplanSS , SchimanaW , LawrenceJ , McNealMM , et al. Safety and immunogenicity of a live attenuated pentavalent rotavirus vaccine in HIV-exposed infants with or without HIV infection in Africa. AIDS2017;31(1):49-59. NCT00880698. Safety and immunogenicity of a live, attenuated rotavirus (RotaTeqTM) in HIV-1 infected and uninfected children born to HIV-1-infected mothers. clinicaltrials.gov/ct2/show/study/NCT00880698 (first received 14 April 2009). UpretyP , LindseyJ , LevinM , Rainwater-LovettK , ZiemniakC , KaplanS , et al. Enhanced inflammation and rotavirus vaccine responses in perinatal HIV-1 infection. In: Topics in Antiviral Medicine; 23rd Conference on Retroviruses and Opportunistic Infections, CROI; 2016, USA. Vol. 24(E-1). 2016:347. ">TEQ Levin 2017‐AF</a>). </p> <p>There was little or no difference between RotaTeq and placebo for all‐cause hospitalization at two‐year follow‐up (RR 1.21, 95% CI 0.42 to 3.49; 202 participants, 1 trial; <a href="./references#CD008521-fig-0053" title="">Analysis 2.14</a>). </p> </section> <section id="CD008521-sec-0180"> <h6 class="title">2.2.3. Rotavirus diarrhoea: requiring hospitalization or medical attention</h6> <p>RotaTeq reduced hospitalizations due to rotavirus diarrhoea episodes by 96% at one year of follow‐up (RR 0.04, 95% CI 0.02 to 0.10; 57,134 participants, 1 trial; <a href="./references#CD008521-fig-0054" title="">Analysis 2.15</a>). </p> <p>RotaTeq reduced the number of children requiring medical attention at one year of follow‐up by 93% compared to placebo (RR 0.07, 95% CI 0.04 to 0.12; 57,134 participants, 1 trial; <a href="./references#CD008521-fig-0055" title="">Analysis 2.16</a>). </p> <p>Data for medical attention and hospitalization rates due to all‐cause diarrhoea were not estimable. </p> </section> <section id="CD008521-sec-0181"> <h6 class="title">2.2.4. Reactogenicity</h6> <p>The incidence of fever (<a href="./references#CD008521-fig-0056" title="">Analysis 2.17</a>), diarrhoea (<a href="./references#CD008521-fig-0057" title="">Analysis 2.18</a>), and vomiting (<a href="./references#CD008521-fig-0058" title="">Analysis 2.19</a>) were evaluated after the first dose, second dose, and third dose, and at the end of the follow‐up period. We found little or no differences between the RotaTeq and placebo groups for any of the reactogenicity outcomes and time points. We noted significant heterogeneity for the pooled post‐first dose data on fever (I<sup>2</sup> = 61%). </p> </section> <section id="CD008521-sec-0182"> <h6 class="title">2.2.5. Adverse events that require discontinuation of vaccination schedule</h6> <p>Ten trials reported the number of adverse events leading to discontinuation of the vaccination schedule, with little or no difference between RotaTeq and placebo (RR 0.84, 95% CI 0.46 to 1.56; 15,471 participants, 10 trials; <a href="./references#CD008521-fig-0059" title="">Analysis 2.20</a>). </p> </section> </section> <section id="CD008521-sec-0183"> <h5 class="title">2.3. Dropouts before the end of trial</h5> <p>Similar numbers of children taking RotaTeq and placebo dropped out from trials before they ended (RR 0.98, 95% CI 0.90 to 1.08; 85,855 participants, 13 trials; <a href="./references#CD008521-fig-0060" title="">Analysis 2.21</a>). </p> </section> <section id="CD008521-sec-0184"> <h5 class="title">2.4. Subgroup analyses</h5> <section id="CD008521-sec-0185"> <h6 class="title">2.4.1. Rotavirus serotype (G‐ or P‐type)</h6> <section id="CD008521-sec-0186"> <p><b>Rotavirus diarrhoea: of any severity</b></p> <p>Four trials reported on serotype specific rotavirus diarrhoea of any severity (<a href="./references#CD008521-fig-0061" title="">Analysis 2.22</a>). There were fewer cases of G1, G2, G9, and P8 rotavirus diarrhoea in the RotaTeq group compared to the placebo group. Results were inconclusive for G3 and G4‐specific rotavirus diarrhoea due to few events leading to wide 95% CIs. The pooled data for type G3 showed statistical heterogeneity (I<sup>2</sup> = 50%). </p> </section> <section id="CD008521-sec-0187"> <p><b>Rotavirus diarrhoea: severe</b></p> <p>Three trials reported on serotype‐specific severe rotavirus diarrhoea (<a href="./references#CD008521-fig-0062" title="">Analysis 2.23</a>). There were fewer severe cases of G4, G8, G9, and P6 rotavirus diarrhoea in the RotaTeq groups.  Results were inconclusive for G1, G2, G3, P4, and P8 rotavirus diarrhoea due to few events or inconsistent results between trials leading to wide 95% CIs. The pooled data for G1 (I<sup>2</sup> = 97%), G3 (I<sup>2</sup> = 64%) and P8 (I<sup>2</sup> = 87%) types showed statistical heterogeneity. </p> </section> </section> <section id="CD008521-sec-0188"> <h6 class="title">2.4.2. HIV‐infected children</h6> <p>One trial (<a href="./references#CD008521-bbs2-0044" title="ArmahGE ,  SowSO ,  BreimanRF ,  DallasMJ ,  TapiaMD ,  FeikinDR ,  et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet2010;376(9741):606-14. ArmahGE , BreimanRF , TapiaMD , DallasMJ , NeuzilKM , BinkaFN , et al. Immunogenicity of the pentavalent rotavirus vaccine in African infants. Vaccine2012;30(Suppl 1):A86-93. BreimanRF , ZamanK , ArmahG , SowSO , AnhDD , VictorJC , et al. Analyses of health outcomes from the 5 sites participating in the Africa and Asia clinical efficacy trials of the oral pentavalent rotavirus vaccine. Vaccine2012;30(Suppl 1):A24-9. GruberJF , HilleDA , LiuGF , KaplanSS , NelsonM , GoveiaMG , et al. Heterogeneity of rotavirus vaccine efficacy among infants in developing countries. Pediatric Infectious Disease Journal2017;36(1):72-8. HeylenE , ZellerM , CiarletM , LawrenceJ , SteeleD , Van RanstM , et al. Comparative analysis of pentavalent rotavirus vaccine strains and G8 rotaviruses identified during vaccine trial in Africa. Science Reports2015;5:14658. NCT00362648. Efficacy, safety, and immunogenicity of RotaTeqTM among infants in Asia and Africa. clinicaltrials.gov/ct2/show/record/NCT00362648 (first received 10 August 2006). TapiaMD , ArmahG , BreimanRF , DallasMJ , LewisKD , SowSO , et al. Secondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africa. Vaccine2012;30(Suppl 1):A79-85. ">TEQ Armah 2010‐AF</a>) performed HIV tests for 89% of participants and reported outcomes for HIV‐infected children (38/1158); another trial (<a href="./references#CD008521-bbs2-0056" title="LevinMJ , LindseyJC , KaplanSS , SchimanaW , LawrenceJ , McNealMM , et al. Safety and immunogenicity of a live attenuated pentavalent rotavirus vaccine in HIV-exposed infants with or without HIV infection in Africa. AIDS2017;31(1):49-59. NCT00880698. Safety and immunogenicity of a live, attenuated rotavirus (RotaTeqTM) in HIV-1 infected and uninfected children born to HIV-1-infected mothers. clinicaltrials.gov/ct2/show/study/NCT00880698 (first received 14 April 2009). UpretyP , LindseyJ , LevinM , Rainwater-LovettK , ZiemniakC , KaplanS , et al. Enhanced inflammation and rotavirus vaccine responses in perinatal HIV-1 infection. In: Topics in Antiviral Medicine; 23rd Conference on Retroviruses and Opportunistic Infections, CROI; 2016, USA. Vol. 24(E-1). 2016:347. ">TEQ Levin 2017‐AF</a>) included and reported outcomes for HIV‐exposed but uninfected and HIV‐infected children. We included only HIV‐infected children from this study in this subgroup analysis (<a href="./references#CD008521-fig-0063" title="">Analysis 2.24</a>). </p> <section id="CD008521-sec-0189"> <p><b>Rotavirus diarrhoea: severe (up to two years of follow‐up)</b></p> <p>One of 21 children in the vaccine arm, and 0/17 children in the placebo arm had severe rotavirus diarrhoea at two‐year follow‐up; the result was inconclusive due to imprecision from the very wide 95% CI around the risk ratio (RR 2.45, 95% CI 0.11 to 56.68, 1 trial). </p> </section> <section id="CD008521-sec-0190"> <p><b>All‐cause diarrhoea: severe (up to two years of follow‐up)</b></p> <p>Five of 21 children in the vaccine arm, and 1/17 children in the placebo arm had severe all‐cause diarrhoea at two‐year follow‐up; the result was inconclusive due to imprecision from the very wide 95% CI around the risk ratio (RR 4.05, 95% CI 0.52 to 31.43, 1 trial). </p> </section> <section id="CD008521-sec-0191"> <p><b>All‐cause death</b></p> <p>Nine of 58 children in the vaccine arm, and 6/56 children in the placebo arm died; the result was inconclusive due to imprecision from the very wide 95% CI around the risk ratio (RR 1.36, 95% CI 0.53 to 3.45, 2 trials). </p> </section> <section id="CD008521-sec-0192"> <p><b>Serious adverse events (1‐14 days after any dose)</b></p> <p>Ten of 58 children in the vaccine arm, and 6/55 children in the placebo arm had a serious adverse event; the result was inconclusive due to imprecision from the very wide 95% CI around the risk ratio (RR 1.53, 95% CI 0.59 to 3.97, 2 trials). </p> </section> </section> </section> <section id="CD008521-sec-0193"> <h5 class="title">2.5 Sensitivity analysis</h5> <section id="CD008521-sec-0194"> <h6 class="title">2.5.1 Primary outcomes with high heterogeneity according to allocation concealment</h6> <p>There were no primary outcomes with high heterogeneity (I<sup>2</sup> &gt; 75%). </p> </section> </section> </section> <section id="CD008521-sec-0195"> <h4 class="title">3. Rotasiil</h4> <section id="CD008521-sec-0196"> <h5 class="title">3.1. Primary outcomes</h5> <p>Summary of findings of primary outcomes are presented in <a href="./full#CD008521-tbl-0007">summary of findings Table 7</a> (Rotasiil, high‐mortality countries). </p> <section id="CD008521-sec-0197"> <h6 class="title">3.1.1. Rotavirus diarrhoea: severe</h6> <section id="CD008521-sec-0198"> <p><b>High‐mortality countries</b></p> <p>Two trials conducted in India and Niger provided data for the efficacy of Rotasiil to prevent severe rotavirus diarrhoea in children. Rotasiil reduced severe rotavirus diarrhoea cases by 48% at one year (RR 0.52, 95% CI 0.33 to 0.81; 11,008 participants; <a href="./references#CD008521-fig-0064" title="">Analysis 3.1</a>) and by 44% by two years (RR 0.56, 95% CI 0.42 to 0.74; 11,008 participants; <a href="./references#CD008521-fig-0065" title="">Analysis 3.2</a>). The pooled data at one year (I<sup>2</sup> = 77%) and at two years (I<sup>2</sup> = 62%) showed statistical heterogeneity. </p> </section> </section> <section id="CD008521-sec-0199"> <h6 class="title">3.1.2. All‐cause diarrhoea: severe</h6> <section id="CD008521-sec-0200"> <p><b>High‐mortality countries</b></p> <p>Two trials conducted in India and Niger provided data for the efficacy of Rotasiil to prevent severe all‐cause diarrhoea in children. The trials showed little or no difference in the number of severe cases of diarrhoea with Rotasiil compared to placebo at one‐year (RR 0.92, 95% CI 0.84 to 1.01; 11,008 participants; <a href="./references#CD008521-fig-0066" title="">Analysis 3.3</a>) and at two years (RR 0.94, 95% CI 0.88 to 1.01; 11,008 participants; <a href="./references#CD008521-fig-0067" title="">Analysis 3.4</a>) follow‐up. </p> </section> </section> <section id="CD008521-sec-0201"> <h6 class="title">3.1.3. All‐cause death</h6> <section id="CD008521-sec-0202"> <p><b>High‐mortality countries</b></p> <p>Two trials conducted in India and Niger reported on all‐cause death. There was little or no difference in all‐cause death between Rotasiil and placebo (RR 1.14, 95% CI 0.82 to 1.59; 11,586 participants; <a href="./references#CD008521-fig-0068" title="">Analysis 3.5</a>). Seventy‐four deaths occurred among 5791 participants in the Rotasiil arms and 65 deaths occurred among 5795 participants in the placebo arms. This corresponds to a risk difference of 157 more deaths with Rotasiil per 100,000 children with the 95% CI indicating from 202 fewer to 662 more per 100,000 (data not shown). We present details of causes of death for each trial in <a href="./appendices#CD008521-sec-0276">Appendix 7</a>. </p> </section> </section> <section id="CD008521-sec-0203"> <h6 class="title">3.1.4. All serious adverse events</h6> <section id="CD008521-sec-0204"> <p><b>High‐mortality countries</b></p> <p>Serious adverse events were reported in three trials conducted in India and Niger. Pooled results showed no statistically significant difference in the number of serious adverse events in the Rotasiil group compared with the placebo group (RR 0.98, 95% CI 0.92 to 1.04; 11,646 participants, 3 trials; <a href="./references#CD008521-fig-0069" title="">Analysis 3.6</a>). </p> <p>In addition, another two trials conducted in India reported narrative results on serious adverse events: <a href="./references#CD008521-bbs2-0042" title="CTRI/2009/091/000821. A randomized, double-blind, placebo controlled study to assess the safety and tolerability of RotaVac vaccine (live attenuated bovine-human (UK) reassortant pentavalent rotavirus vaccine). ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=987&amp;EncHid=&amp;modid=&amp;compid=%27,%27987det%27 (first received 15 October 2009). Zade JK,  KulkarniPS ,  Desai SA,  Sabale RN,  Naik SP,  Dhere RM. Bovine rotavirus pentavalent vaccine development in India. Vaccine2014;32(Suppl 1):A124-8. [DOI: 10.1016/j.vaccine.2014.03.003]">SIIL Zade 2014‐INDb</a> reported that "Two SAEs (urinary tract infections and septicaemia) unrelated to study vaccines were reported and both recovered uneventfully", but it was not clear in which group the events took place. No SAEs were reported among 18 infants and 18 toddlers in <a href="./references#CD008521-bbs2-0041" title="CTRI/2009/091/000821. A randomized, double-blind, placebo controlled study to assess the safety and tolerability of rotaVac vaccine (live attenuated bovine-human (UK) reassortant pentavalent rotavirus vaccine). ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=987&amp;EncHid=&amp;modid=&amp;compid=%27,%27987det%27 (first received 15 October 2009). Zade JK,  KulkarniPS ,  Desai SA,  Sabale RN,  Naik SP,  Dhere RM. Bovine rotavirus pentavalent vaccine development in India. Vaccine2014;32(Suppl 1):A124-8. [DOI: 10.1016/j.vaccine.2014.03.003]">SIIL Zade 2014‐INDa</a>, but the total number of participants per group were not reported. </p> </section> </section> <section id="CD008521-sec-0205"> <h6 class="title">3.1.5. Serious adverse events: intussusception</h6> <section id="CD008521-sec-0206"> <p><b>High‐mortality countries</b></p> <p>Two trials conducted in India and Niger reported on cases of intussusception. Seven cases of intussusception were reported in a total of 5791 children in the Rotasiil arms compared with seven cases of intussusception in 5795 children in the placebo arms. This corresponds to a risk difference of two fewer cases of intussusception with Rotasiil per 100,000 children with the 95% CI indicating from 79 fewer to 210 more per 100,000 (data not shown). Pooled results showed no increased risk of intussusception in children receiving Rotasiil when compared to placebo (RR 0.98, 95% CI 0.35 to 2.74; 11,586 participants; <a href="./references#CD008521-fig-0070" title="">Analysis 3.7</a>). </p> </section> </section> </section> <section id="CD008521-sec-0207"> <h5 class="title">3.2. Secondary outcomes</h5> <section id="CD008521-sec-0208"> <h6 class="title">3.2.1. Rotavirus diarrhoea: of any severity</h6> <p>Two trials provided data for the efficacy of Rotasiil to prevent rotavirus diarrhoea of any severity in children. Rotasiil reduced the number of cases of rotavirus diarrhoea of any severity by 33% at one‐year (RR 0.67, 95% CI 0.59 to 0.76; 11,008 participants; <a href="./references#CD008521-fig-0071" title="">Analysis 3.8</a>) and by 23% at two‐year follow‐up (RR 0.77, 95% CI 0.71 to 0.84; 11,008 participants; <a href="./references#CD008521-fig-0072" title="">Analysis 3.9</a>). </p> </section> <section id="CD008521-sec-0209"> <h6 class="title">3.2.2. Rotavirus diarrhoea: requiring hospitalization</h6> <p>Rotasiil reduced the number of children requiring hospitalization due to rotavirus diarrhoea by 41% at one‐year (RR 0.59, 95% CI 0.39 to 0.88; 7500 participants, 1 trial) and at two years (RR 0.66, 95% CI 0.52 to 0.85, 7500 participants, 1 trial) follow‐up compared to placebo (<a href="./references#CD008521-fig-0073" title="">Analysis 3.10</a>). </p> </section> <section id="CD008521-sec-0210"> <h6 class="title">3.2.3. All‐cause diarrhoea of any severity</h6> <p>There was little or no difference between Rotasiil and placebo for any severity all‐cause diarrhoea at one‐year (RR 0.97, 95% CI 0.90 to 1.04; 3508 participants, 1 trial; <a href="./references#CD008521-fig-0074" title="">Analysis 3.11</a>) and at two years follow‐up (RR 0.96, 95% CI 0.90 to 1.02; 3508 participants, 1 trial; <a href="./references#CD008521-fig-0075" title="">Analysis 3.12</a>). </p> </section> <section id="CD008521-sec-0211"> <h6 class="title">3.2.4. Reactogenicity</h6> <p>The incidence of fever (<a href="./references#CD008521-fig-0076" title="">Analysis 3.13</a>), diarrhoea (<a href="./references#CD008521-fig-0077" title="">Analysis 3.14</a>), and vomiting (<a href="./references#CD008521-fig-0078" title="">Analysis 3.15</a>) were evaluated after any dose in four trials. We found little or no difference between the Rotasiil and placebo groups for any of the reactogenicity outcomes. </p> </section> <section id="CD008521-sec-0212"> <h6 class="title">3.2.5. Adverse events requiring discontinuation</h6> <p>One trial reported no adverse events leading to discontinuation of the vaccination schedule (RR not estimable, 7500 participants; <a href="./references#CD008521-fig-0079" title="">Analysis 3.16</a>). </p> </section> <section id="CD008521-sec-0213"> <h6 class="title">3.2.6. Dropouts before the end of trial</h6> <p>Similar numbers of children taking Rotasiil or placebo dropped out from trials before they ended (RR 0.93, 95% CI 0.66 to 1.32; 11,591 participants, 2 trials; <a href="./references#CD008521-fig-0080" title="">Analysis 3.17</a>). </p> </section> </section> <section id="CD008521-sec-0214"> <h5 class="title">3.3. Subgroup analyses</h5> <section id="CD008521-sec-0215"> <h6 class="title">3.3.1. Rotavirus serotype (G‐ or P‐type)</h6> <section id="CD008521-sec-0216"> <p><b>Rotavirus diarrhoea: severe</b></p> <p>Two trials (<a href="./references#CD008521-bbs2-0039" title="ColdironME , GuindoO , MakarimiR , SoumanaI , Matar SeckA , GarbaS , et al. Safety of a heat-stable rotavirus vaccine among children in Niger: data from a phase 3, randomized, double-blind, placebo-controlled trial. Vaccine2018;36(25):3674-80. IsanakaS , DjiboA , GraisRF . Heat-stable oral rotavirus vaccine. New England Journal of Medicine2017;377(3):302. IsanakaS , GuindoO , LangendorfC , GraisR , ROSE Trial Study Team. Efficacy and safety of a low-cost, heat-stable oral roatvirus vaccine agains severe rotavirus gastroenteritis in Niger. American Journal of Tropical Medicine and Hygiene2017;95(Suppl 5):242. IsanakaS , GuindoO , LangendorfC , Matar SeckA , PlikaytisBD , Sayinzoga-MakombeN , et al. Efficacy of a low-cost, heat-stable oral Rotavirus vaccine in Niger. New England Journal of Medicine2017;376(12):1121-30. IsanakaS , LangendorfC , McNealMM , MeyerN , PlikaytisB , GarbaS , et al. Rotavirus vaccine efficacy up to 2 years of age and against diverse circulating rotavirus strains in Niger: a randomized controlled clinical trial (unpublished manuscript received via email correspondence from Rebecca Grais to Nicholas Henschke on 19 August 2020). data on file. NCT02145000. Efficacy and safety of a pentavalent Rotavirus vaccine (BRV-PV) against severe rotavirus gastroenteritis in Niger (ROSE). clinicaltrials.gov/ct2/show/NCT02145000 (first received 20 May 2014). ">SIIL Isanaka 2017‐NER</a>; <a href="./references#CD008521-bbs2-0040" title="CTRI/2013/05/003667. A clinical trial to study the effect and safety of Rotavirus vaccine against severe Rotavirus gastroenteritis in healthy Indian Infants. www.ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=5518&amp;EncHid=&amp;modid=&amp;compid=%27,%275518det%27 (first received 23 May 2013). KulkarniPS , DesaiS , TewariT , KawadeA , GoyalN , GargBS , et al. A randomized phase III clinical trial to assess the efficacy of a bovine-human reassortant pentavalent rotavirus vaccine in Indian infants. Vaccine2017;35(45):6228-37. NCT02133690. A clinical trial to study the effect and safety of Rotavirus vaccine against severe rotavirus gastroenteritis in healthy Indian infants. clinicaltrials.gov/ct2/show/NCT02133690 (first received 6 May 2014). ">SIIL Kulkarni 2017‐IND</a>) reported on G‐ and P‐type specific severe cases of rotavirus diarrhoea (<a href="./references#CD008521-fig-0081" title="">Analysis 3.18</a>). </p> <p>There were fewer severe cases of rotavirus diarrhoea in the Rotasiil groups for G1, G2, Gp, P4, P6; results were inconclusive due to inconsistency in the results or few events leading to wide 95% CIs for G3, G4, G8, G12, and P8. The pooled data showed statistical heterogeneity for G1 (I<sup>2</sup> = 49%), G2 (I<sup>2</sup> = 47%), and G3‐specific severe rotavirus diarrhoea (I<sup>2</sup> = 73%). </p> </section> <section id="CD008521-sec-0217"> <p><b>Rotavirus diarrhoea: any severity</b></p> <p>One trial (<a href="./references#CD008521-bbs2-0039" title="ColdironME , GuindoO , MakarimiR , SoumanaI , Matar SeckA , GarbaS , et al. Safety of a heat-stable rotavirus vaccine among children in Niger: data from a phase 3, randomized, double-blind, placebo-controlled trial. Vaccine2018;36(25):3674-80. IsanakaS , DjiboA , GraisRF . Heat-stable oral rotavirus vaccine. New England Journal of Medicine2017;377(3):302. IsanakaS , GuindoO , LangendorfC , GraisR , ROSE Trial Study Team. Efficacy and safety of a low-cost, heat-stable oral roatvirus vaccine agains severe rotavirus gastroenteritis in Niger. American Journal of Tropical Medicine and Hygiene2017;95(Suppl 5):242. IsanakaS , GuindoO , LangendorfC , Matar SeckA , PlikaytisBD , Sayinzoga-MakombeN , et al. Efficacy of a low-cost, heat-stable oral Rotavirus vaccine in Niger. New England Journal of Medicine2017;376(12):1121-30. IsanakaS , LangendorfC , McNealMM , MeyerN , PlikaytisB , GarbaS , et al. Rotavirus vaccine efficacy up to 2 years of age and against diverse circulating rotavirus strains in Niger: a randomized controlled clinical trial (unpublished manuscript received via email correspondence from Rebecca Grais to Nicholas Henschke on 19 August 2020). data on file. NCT02145000. Efficacy and safety of a pentavalent Rotavirus vaccine (BRV-PV) against severe rotavirus gastroenteritis in Niger (ROSE). clinicaltrials.gov/ct2/show/NCT02145000 (first received 20 May 2014). ">SIIL Isanaka 2017‐NER</a>) reported on G‐ and P‐type specific cases of rotavirus diarrhoea of any severity (<a href="./references#CD008521-fig-0082" title="">Analysis 3.19</a>). </p> <p>There were fewer cases of rotavirus diarrhoea in the Rotasiil groups for G1, G2, P4, P6; results were inconclusive due to few events leading to wide 95% CIs for G3, G4, G8, G9, G12, and P8. </p> <p>The included Rotasiil trials did not report separate data on immunocompromised or malnourished subgroups. </p> </section> </section> </section> <section id="CD008521-sec-0218"> <h5 class="title">3.4 Sensitivity analyses</h5> <section id="CD008521-sec-0219"> <h6 class="title">3.4.1 Primary outcomes with high heterogeneity according to allocation concealment</h6> <p>We rated all trials at low risk of bias for allocation concealment for the outcome where heterogeneity was high (I<sup>2</sup> &gt; 75%); see <a href="./references#CD008521-fig-0064" title="">Analysis 3.1</a> (I<sup>2</sup> = 77%). </p> </section> </section> </section> <section id="CD008521-sec-0220"> <h4 class="title">4. Rotavac</h4> <section id="CD008521-sec-0221"> <h5 class="title">4.1. Primary outcomes</h5> <p>Summary of findings of primary outcomes are presented in <a href="./full#CD008521-tbl-0008">summary of findings Table 8</a> (Rotavac, high‐mortality countries). </p> <section id="CD008521-sec-0222"> <h6 class="title">4.1.1. Rotavirus diarrhoea: severe</h6> <section id="CD008521-sec-0223"> <p><b>High‐mortality countries</b></p> <p>One trial conducted in India provided data for the efficacy of Rotavac to prevent severe rotavirus diarrhoea in children. Rotavac reduced severe rotavirus diarrhoea cases by 57% at one year (RR 0.43, 95% CI 0.30 to 0.60; 6799 participants; <a href="./references#CD008521-fig-0083" title="">Analysis 4.1</a>), by 48% in the second year of life (RR 0.52, 95% CI 0.33 to 0.81; 6516 participants; <a href="./references#CD008521-fig-0084" title="">Analysis 4.2</a>), and by 54% by up to two years follow‐up (RR 0.46, 95% CI 0.35 to 0.60; 6541 participants; <a href="./references#CD008521-fig-0085" title="">Analysis 4.3</a>). </p> </section> </section> <section id="CD008521-sec-0224"> <h6 class="title">4.1.2. All‐cause diarrhoea: severe</h6> <section id="CD008521-sec-0225"> <p><b>High‐mortality countries</b></p> <p>One trial conducted in India provided data for the efficacy of Rotavac to prevent severe all‐cause diarrhoea in children. The trial showed a reduction in the number of severe cases of diarrhoea with Rotavac compared to placebo at one year by 16% (RR 0.84, 95% CI 0.71 to 0.98; 6799 participants; <a href="./references#CD008521-fig-0086" title="">Analysis 4.4</a>). </p> </section> </section> <section id="CD008521-sec-0226"> <h6 class="title">4.1.3. All‐cause death</h6> <section id="CD008521-sec-0227"> <p><b>High‐mortality countries</b></p> <p>Two trials conducted in India reported on all‐cause death. There was little or no difference in all‐cause death between Rotavac and placebo (RR 0.88, 95% CI 0.50 to 1.56; 8155 participants, <a href="./references#CD008521-fig-0087" title="">Analysis 4.5</a>). Thirty‐five deaths occurred among 5549 participants in the Rotavac arms and 18 deaths occurred among 2606 participants in the placebo arms. This corresponds to a risk difference of 83 fewer deaths with Rotavac per 100,000 children with the 95% CI indicating from 345 fewer to 387 more per 100,000 (data not shown). We present details of causes of death for each trial in <a href="./appendices#CD008521-sec-0276">Appendix 7</a>. </p> </section> </section> <section id="CD008521-sec-0228"> <h6 class="title">4.1.4. All serious adverse events</h6> <section id="CD008521-sec-0229"> <p><b>High‐mortality countries</b></p> <p>Serious adverse events were reported in three trials conducted in India. Pooled results showed no statistically significant difference in the number of serious adverse events in the Rotavac group compared with the placebo group (RR 0.93, 95% CI 0.85 to 1.02; 8210 participants, 3 trials; <a href="./references#CD008521-fig-0088" title="">Analysis 4.6</a>). </p> </section> </section> <section id="CD008521-sec-0230"> <h6 class="title">4.1.5. Serious adverse events: intussusception</h6> <section id="CD008521-sec-0231"> <p><b>High‐mortality countries</b></p> <p>Four trials conducted in India reported on cases of intussusception. Eight cases of intussusception were reported in a total of 5764 children in the Rotavac arm compared with three cases of intussusception in 2818 children in the placebo arm. This corresponds to a risk difference of 35 more cases of intussusception with Rotavac per 100,000 children with the 95% CI indicating from 69 fewer to 428 more per 100,000 (data not shown). Pooled results were inconclusive due to few events leading to wide 95% CIs (RR 1.33, 95% CI 0.35 to 5.02; 8582 participants; <a href="./references#CD008521-fig-0089" title="">Analysis 4.7</a>). </p> </section> </section> </section> <section id="CD008521-sec-0232"> <h5 class="title">4.2. Secondary outcomes</h5> <section id="CD008521-sec-0233"> <h6 class="title">4.2.1. Rotavirus diarrhoea: of any severity</h6> <p>One trial provided data for the efficacy of Rotavac to prevent rotavirus diarrhoea of any severity in children. Rotavac reduced the number of cases of rotavirus diarrhoea of any severity by 34% at both one‐year (RR 0.66, 95% CI 0.56 to 0.78; 6799 participants, 1 trial; <a href="./references#CD008521-fig-0090" title="">Analysis 4.8</a>) and two‐year follow‐up (RR 0.66, 95% CI 0.57 to 0.76; 6541 participants, 1 trial; <a href="./references#CD008521-fig-0084" title="">Analysis 4.2</a>). </p> </section> <section id="CD008521-sec-0234"> <h6 class="title">4.2.2. Rotavirus diarrhoea: requiring medical attention</h6> <p>Rotavac reduced the number of children requiring medical attention due to rotavirus diarrhoea at one year of follow‐up by 31% compared to placebo (RR 0.69, 95% CI 0.58 to 0.81; 6799 participants, 1 trial; <a href="./references#CD008521-fig-0093" title="">Analysis 4.11</a>). </p> </section> <section id="CD008521-sec-0235"> <h6 class="title">4.2.3. Reactogenicity</h6> <p>The incidence of fever (<a href="./references#CD008521-fig-0094" title="">Analysis 4.12</a>), diarrhoea (<a href="./references#CD008521-fig-0095" title="">Analysis 4.13</a>), and vomiting (<a href="./references#CD008521-fig-0096" title="">Analysis 4.14</a>) were evaluated after the first dose in two trials, second dose in one trial, and third dose in one trial. We found little or no difference between the Rotavac and placebo groups for most of the reactogenicity outcomes and time points, except for diarrhoea, which demonstrated an increase with Rotavac compared to placebo after the second dose (RR 1.55, 95% CI 1.00 to 2.41; 356 participants) and third dose (RR 4.09, 95% CI 2.11 to 7.92; 358 participants). </p> </section> <section id="CD008521-sec-0236"> <h6 class="title">4.2.4. Dropouts before the end of trial</h6> <p>Similar numbers of children taking Rotavac or placebo dropped out from trials before they ended (RR 0.85, 95% CI 0.57 to 1.29; 8215 participants, 3 trials; <a href="./references#CD008521-fig-0097" title="">Analysis 4.15</a>). </p> </section> </section> <section id="CD008521-sec-0237"> <h5 class="title">4.3. Subgroup analyses</h5> <section id="CD008521-sec-0238"> <h6 class="title">4.3.1. Rotavirus serotype (G‐ or P‐type)</h6> <section id="CD008521-sec-0239"> <p><b>Rotavirus diarrhoea: severe</b></p> <p>One trial reported severe cases of rotavirus diarrhoea by G and P type (<a href="./references#CD008521-bbs2-0066" title="BhandariN , Rongsen-ChandolaT , BavdekarA , JohnJ , AntonyK , TanejaS , et al. Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian children in the second year of life. Vaccine2014;32(Suppl 1):A110-6. BhandariN , Rongsen-ChandolaT , BavdekarA , JohnJ , AntonyK , TanejaS , et al. Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo-controlled trial. Lancet2014;383(9935):2136-43. CTRI/2010/091/000102. A phase III clinical trial to evaluate the protective efficacy of three doses of oral rotavirus vaccine (ORV) 116E. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=1317 (first received 22 November 2010). JohnJ , KawadeA , Rongsen-ChandolaT , BavdekarA , BhandariN , TanejaS , et al. Active surveillance for intussusception in a phase III efficacy trial of an oral monovalent rotavirus vaccine in India. Vaccine2014;32(Suppl 1):A104-9. JohnTJ . Why was there no vaccine-associated intussusception in Indian rotavirus vaccine trial?Indian Pediatrics2015;52(10):906. NCT01305109. A phase III, randomized, double blind, placebo controlled trial to evaluate the protective efficacy of three doses of oral rotavirus vaccine (ORV) 116E, against severe rotavirus gastroenteritis in infants. clinicaltrials.gov/show/NCT01305109 (first received 28 February 2011). ">VAC Bhandari 2014‐IND</a>). </p> <p>At one‐year follow‐up (<a href="./references#CD008521-fig-0098" title="">Analysis 4.16</a>), there were significantly fewer severe episodes of rotavirus diarrhoea in the Rotavac groups for G2P[4] (RR 0.39, 95% CI 0.22 to 0.69; 6541 participants) and G12P[6] (RR 0.31, 95% CI 0.13 to 0.74; 6541 participants); results were not significantly different between Rotavac and placebo for G1P[8] (RR 0.66, 95% CI 0.36 to 1.20; 6541 participants) and G12P[8] (RR 0.30, 95% CI 0.07 to 1.26; 6541 participants). </p> <p>At two‐year follow‐up (<a href="./references#CD008521-fig-0099" title="">Analysis 4.17</a>) there were significantly fewer severe episodes of rotavirus diarrhoea in the Rotavac groups for G1P[8] (RR 0.59, 95% CI 0.38 to 0.93; 6541 participants), G2P[4] (RR 0.37, 95% CI 0.23 to 0.62; 6541 participants), G12P[6] (RR 0.31, 95% CI 0.13 to 0.74; 6541 participants), and G12P[8] (RR 0.31, 95% CI 0.10 to 0.96; 6541 participants). </p> <p>The included Rotavac trials did not report separate data on immunocompromised or malnourished subgroups. </p> </section> </section> </section> <section id="CD008521-sec-0240"> <h5 class="title">4.4 Sensitivity analyses</h5> <section id="CD008521-sec-0241"> <h6 class="title">4.4.1 Primary outcomes with high heterogeneity according to allocation concealment</h6> <p>There were no primary outcomes with high heterogeneity (I<sup>2</sup> &gt; 75%). </p> </section> </section> </section> <section id="CD008521-sec-0242"> <h4 class="title">5 Post hoc subgroup analysis: Intussusception combining all vaccines</h4> <p>The risk of intussusception with any rotavirus vaccine compared with placebo was 1 fewer case per 10,000 children (95% CI from 2 fewer to 1 more case per 10,000) with a RR of 0.87 (95% CI 0.61 to 1.25, 43 trials, 212,636 participants, <a href="#CD008521-tbl-0010">Table 2</a>). The risk difference was similar in all mortality settings. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD008521-sec-0243" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD008521-sec-0243"></div> <p>Rotavirus vaccines have been under development since the 1980s and, to date, four vaccines have been prequalified by the WHO (Rotarix, RotaTeq, Rotasiil, and Rotavac). A further two rotavirus vaccines are licensed for use in individual countries (LLR in China and Rotavin in Vietnam, see <a href="./appendices#CD008521-sec-0277">Appendix 8</a>). RRV‐TV (RotaShield) has not been used since 1999. The four vaccines currently in use and prequalified by the WHO (Rotarix, RotaTeq, Rotasiil, and Rotavac) are the focus of this review. </p> <section id="CD008521-sec-0244"> <h3 class="title" id="CD008521-sec-0244">Summary of main results</h3> <p>We included 60 trials with a total of 228,233 participants, that evaluated Rotarix (36 trials), RotaTeq (15 trials), Rotasiil (5 trials), and Rotavac (4 trials). Our analysis stratified the primary outcomes by country under‐five child mortality strata (high‐mortality countries, medium‐mortality countries, and low‐mortality countries; <a href="./references#CD008521-bbs2-0179" title="United Nations Inter-agency Group for Child Mortality Estimation (UN IGME). Levels &amp; trends in child mortality: report 2019, estimates developed by the United Nations Inter-agency Group for child mortality estimation. Available from unicef.org/reports/levels-and-trends-child-mortality-report-2019 (accessed prior to 12 October 2021).">UNICEF 2019</a>). </p> <p>The trials were not designed or powered to detect an effect on preventing death or on the occurrence of possible rare serious adverse events, such as intussusception. </p> <section id="CD008521-sec-0245"> <h4 class="title">1. Rotarix</h4> <p>Fourteen Rotarix trials were conducted in low‐mortality countries; five in Asia, five in Europe, and four in North America. See <a href="./full#CD008521-tbl-0001">summary of findings Table 1</a> for main results. Briefly, in infants under one year, Rotarix vaccination prevented 93% of cases of severe rotavirus diarrhoea (high‐certainty evidence) and 52% of cases of severe all‐cause diarrhoea (moderate‐certainty evidence). In children up to two years, 90% of cases of severe rotavirus diarrhoea (high‐certainty evidence) and  51% of cases of severe all‐cause diarrhoea (moderate‐certainty evidence) were prevented with Rotarix. For serious adverse events, children receiving Rotarix had 11% fewer events than those receiving placebo (high‐certainty evidence). </p> <p>Ten Rotarix trials were conducted in medium‐mortality countries; five in Latin America, four in Asia, and one in Europe. See <a href="./full#CD008521-tbl-0002">summary of findings Table 2</a> for main results. Briefly, in infants under one year, Rotarix prevented 79% of cases of severe rotavirus diarrhoea (high‐certainty evidence) and 36% of cases of severe all‐cause diarrhoea (high‐certainty evidence). In children up to two years, 77% of cases of severe rotavirus diarrhoea (high‐certainty evidence) and 26% of severe all‐cause diarrhoea cases (low‐certainty evidence) were prevented with Rotarix. For serious adverse events, children receiving Rotarix had 15% fewer events than those receiving placebo (high‐certainty evidence). </p> <p>Twelve Rotarix trials were conducted in high‐mortality countries; seven in Asia, four in Africa, and one in Latin America. See <a href="./full#CD008521-tbl-0003">summary of findings Table 3</a> for main results. Briefly, in infants under one year, Rotarix prevented 58% of cases of severe rotavirus diarrhoea (high‐certainty evidence) and 27% of cases of severe all‐cause diarrhoea (high‐certainty evidence). In children up to two years, 35% of cases of severe rotavirus diarrhoea (moderate‐certainty evidence) and 17% of cases of severe all‐cause diarrhoea (high‐certainty evidence) were prevented with Rotarix. Rotarix had little or no effect on serious adverse events in this setting (high‐certainty evidence). </p> <p>An effect of Rotarix on all‐cause mortality (low‐ to moderate‐certainty evidence) or on intussusception (low‐certainty evidence) has not been shown in any of the settings. </p> </section> <section id="CD008521-sec-0246"> <h4 class="title">2. RotaTeq</h4> <p>Nine RotaTeq trials were conducted in low‐mortality countries;  three in North America, two in Asia, two in Europe, one in Europe and the USA, and one in North America, Europe, Asia, and Latin America. See <a href="./full#CD008521-tbl-0004">summary of findings Table 4</a> for main results. Briefly, RotaTeq vaccination prevented 97% of cases of severe rotavirus diarrhoea in infants under one year (high‐certainty evidence) and 96% of cases in children up to two years (high‐certainty evidence). We found no RotaTeq trials that reported on severe all‐cause diarrhoea. RotaTeq had little or no effect on serious adverse events in this setting (high‐certainty evidence). </p> <p>Two RotaTeq trials were conducted in medium‐mortality countries; both in Asia. In addition, a large multicentre trial that was conducted on several continents included centres in a few medium‐mortality countries, but was analysed in the low‐mortality stratum since most centres were in low‐mortality countries (see <a href="./references#CD008521-bbs2-0060" title="ChangCC , ChangMH , LinTY , LeeHC , HsiehWS , LeePI . Experience of pentavalent human-bovine reassortant rotavirus vaccine among healthy infants in Taiwan. Journal of the Formosan Medical Association2009;108(4):280-5. ChristieCD , DuncanND , ThameKA , OnoratoMT , SmithHD , MalcolmLG , et al. Pentavalent rotavirus vaccine in developing countries: safety and health care resource utilization. Pediatrics2010;126(6):e1499-506. DennehyPH , GoveiaMG , DallasMJ , HeatonPM . The integrated phase III safety profile of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine. International Journal of Infectious Diseases2007;11(Suppl 2):36-42. [No data available for review]GoveiaMG , DiNubileMJ , DallasMJ , HeatonPM , KuterBJ , REST Study Team. Efficacy of pentavalent human-bovine (WC3) reassortant rotavirus vaccine based on breastfeeding frequency. Pediatric Infectious Disease Journal2008;27(7):656-8. GoveiaMG , RodriguezZM , DallasMJ , ItzlerRF , BoslegoJW , HeatonPM , et al. Safety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infants. Pediatric Infectious Disease Journal2007;26(12):1099-104. [No data available for review]GoveiaMG , SuprunL , ItzlerRF , McFetridgeR , DallasMJ , KuterBJ . Efficacy and safety of pentavalent human-bovine reassortant rotavirus vaccine when administered with greater than 10 weeks between doses. Pediatric Infectious Disease Journal2010;29(3):263-5. GrantL , WattJ , MoultonL , WeatherholtzR , ReidR , SantoshamM , et al. Lack of nonspecific protection against all-cause nonrotavirus gastroenteritis by vaccination with orally administered rotavirus vaccine. Journal of Pediatric Gastroenterology and Nutrition2013;56(6):635-40. GrantLR , WattJP , WeatherholtzRC , MoultonLH , ReidR , SantoshamM , et al. Efficacy of a pentavalent human-bovine reassortant rotavirus vaccine against rotavirus gastroenteritis among American Indian children. Pediatric Infectious Disease Journal2012;31(2):184-8. ItzlerR , KochG , MatsonDO , GotheforsL , Van DammeP , DinubileMJ , et al. Robustness of the healthcare utilization results from the Rotavirus Efficacy and Safety Trial (REST) evaluating the human-bovine (WC3) reassortant pentavalent rotavirus vaccine (RV5). BMC Pediatrics2010;10:42. Merck[PN-006]. Safety and efficacy of pentavalent (G1, G2, G3, G4, and P1) human-bovine reassortant rotavirus vaccine in healthy infants NCT00090233 (PN 006). clinicalstudyresults.org/drugdetails/?indication_id=523&amp;sort=c.company_name&amp;page=1&amp;drug_id=1144 (accessed prior to 19 October 2021). [No data available for review]NCT00090233. Safety and efficacy of pentavalent (G1, G2, G3, G4, and P1) human-bovine reassortant rotavirus vaccine in healthy infants. clinicaltrials.gov/ct2/show/record/NCT00090233 (first received 27 August 2004). [Trial registration document]RodriguezZM , GoveiaMG , StekJE , DallasMJ , BoslegoJW , DiNubileMJ , et al. Concomitant use of an oral live pentavalent human-bovine reassortant rotavirus vaccine with licensed parenteral pediatric vaccines in the United States. Pediatric Infectious Disease Journal2007;26(3):221-7. VesikariT ,  KarvonenA ,  FerranteSA ,  KuterBJ ,  CiarletM . Sustained efficacy of the pentavalent rotavirus vaccine, RV5, up to 3.1 years following the last dose of vaccine. Pediatric Infectious Disease Journal2010;29(10):957-63. VesikariT , ItzlerR , KarvonenA , KorhonenT , Van DammeP , BehreU , et al. RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe. Vaccine2009;28(2):345-51. VesikariT , ItzlerR , MatsonDO , SantoshamM , ChristieCD , CoiaM , et al. Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across three regions (11 countries). International Journal of Infectious Diseases2007;11(Suppl 2):29-35. VesikariT , KarvonenA , FerranteSA , CiarletM . Efficacy of the pentavalent rotavirus vaccine, RotaTeq(R), in Finnish infants up to 3 years of age: the Finnish Extension Study. European Journal of Pediatrics2010;169(11):1379-86. VesikariT , MatsonDO , DennehyP , Van DammeP , SantoshamM , RodriguezZ , et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. New England Journal of Medicine2006;354(1):23-33. ">TEQ Vesikari 2006b‐INT</a>). See <a href="./full#CD008521-tbl-0005">summary of findings Table 5</a> for main results. Briefly, no medium‐mortality stratum RotaTeq trials reported on severe rotavirus diarrhoea or on severe all‐cause diarrhoea in infants under one year. In children up to two years, RotaTeq prevented 79% of cases of severe rotavirus diarrhoea (low‐certainty evidence). For serious adverse events, an effect of the vaccine has not been shown (very low‐certainty evidence). </p> <p>Three RotaTeq trials were conducted in high‐mortality countries; two in Asia and one in Africa. See <a href="./full#CD008521-tbl-0006">summary of findings Table 6</a> for main results. Briefly, in infants under one year, RotaTeq prevented 57% of cases of severe rotavirus diarrhoea (high‐certainty evidence) and 20% of cases of severe all‐cause diarrhoea (moderate‐certainty evidence). In children up to two years, RotaTeq prevented 44% of cases of severe rotavirus diarrhoea (high‐certainty evidence) and 15% of cases of severe all‐cause diarrhoea (high‐certainty evidence). RotaTeq had little or no effect on serious adverse events in this setting (moderate‐certainty evidence). </p> <p>An effect of RotaTeq on all‐cause mortality (very low‐ to moderate‐certainty evidence) or on intussusception (very low‐ to low‐certainty evidence) has not been shown in any of the settings. </p> </section> <section id="CD008521-sec-0247"> <h4 class="title">3. Rotasiil</h4> <p>No Rotasiil trials have been carried out in low‐ or medium‐mortality countries. Five Rotasiil trials were conducted in high‐mortality countries; four in India and one in Niger. See <a href="./full#CD008521-tbl-0007">summary of findings Table 7</a> for main results. Briefly, in infants under one year, Rotasiil vaccination prevented 48% of cases of severe rotavirus diarrhoea (high‐certainty evidence) and resulted in little to no difference in severe all‐cause diarrhoea (high‐certainty evidence). In children up to two years, Rotasiil vaccination prevented 44% of cases of severe rotavirus diarrhoea (high‐certainty evidence), but resulted in little to no difference in severe all‐cause diarrhoea (high‐certainty evidence). Rotasiil had little or no effect on serious adverse events in this setting (high‐certainty evidence). An effect of Rotasiil on all‐cause mortality (moderate‐certainty evidence) or on intussusception (low‐certainty evidence) has not been shown. </p> </section> <section id="CD008521-sec-0248"> <h4 class="title">4. Rotavac </h4> <p>No Rotavac trials have been carried out in low‐ or medium‐mortality countries. All four Rotavac trials were conducted in India, a high‐mortality country. See <a href="./full#CD008521-tbl-0008">summary of findings Table 8</a> for main results. Briefly, in infants under one year, Rotavac prevented 57% of cases of severe rotavirus diarrhoea (moderate‐certainty evidence) and 16% of cases of severe all‐cause diarrhoea (moderate‐certainty evidence). In children up to two years, Rotavac prevented 54% of cases of severe rotavirus diarrhoea (moderate‐certainty evidence). Rotavac had little or no effect on serious adverse events in this setting (moderate‐certainty evidence). An effect of Rotavac on all‐cause mortality (very low‐certainty evidence) or on intussusception (very low‐certainty evidence) has not been shown. </p> </section> </section> <section id="CD008521-sec-0249"> <h3 class="title" id="CD008521-sec-0249">Overall completeness and applicability of evidence</h3> <p>We carried out this systematic review using RCTs. All the included trials were placebo‐controlled, except for two Rotarix trials that compared vaccine to no intervention (<a href="./references#CD008521-bbs2-0005" title='ColgateER , HaqueR , DicksonDM , CarmolliMP , MychaleckyjJC , NayakU , et al. Delayed dosing of oral rotavirus vaccine demonstrates decreased risk of rotavirus gastroenteritis associated with serum zinc: a randomized controlled trial. Clinical Infectious Diseases2016;63(5):634-41. KirkpatrickBD , ColgateER , MychaleckyjJC , HaqueR , DicksonDM , CarmolliMP , et al. The "Performance of Rotavirus and Oral Polio Vaccines in Developing Countries" (PROVIDE) study: description of methods of an interventional study designed to explore complex biologic problems. American Journal of Tropical Medicine and Hygiene2015;92(4):744-51. LeeB , DicksonDM , DeCampAC , ColgateER , DiehlSA , UddinMI , et al. Histo-blood group antigen phenotype determines susceptibility to genotype-specific rotavirus infections and impacts measures of rotavirus vaccine efficacy. Journal of Infectious Diseases2018;217(9):1399-407. LeeB , DiehlSA , ColgateER , DicksonDM , UddinMI , SharminS , et al. Lewis antigen and secretor status mediate susceptibility to p-genotype specific rotavirus infections but do not affect rotavirus vaccine performance among infants in Bangladesh. American Journal of Tropical Medicine and Hygiene2017;97:226. NCT01375647. Exploration of the biologic basis for underperformance of oral polio and rotavirus vaccines in Bangladesh PROVIDE. clinicaltrials.gov/show/NCT01375647 (first received 17 June 2011). RogawskiET , Platts-MillsJA , ColgateER , HaqueR , ZamanK , PetriWA , et al. Quantifying the impact of natural immunity on rotavirus vaccine efficacy estimates: a clinical trial in Dhaka, Bangladesh (PROVIDE) and a simulation study. Journal of Infectious Diseases2018;217(6):861-8. '>RIX Colgate 2016‐BGD</a>; <a href="./references#CD008521-bbs2-0038" title="ZamanK , SackDA , NeuzilKM , YunusM , MoultonLH , SugimotoJD , et al. Effectiveness of a live oral human rotavirus vaccine after programmatic introduction in Bangladesh: a cluster-randomized trial. PLOS Medicine2017;14(4):e1002282. ">RIX Zaman 2017‐BGD</a>). The trials provided only limited data for special groups of children, such as malnourished or immunocompromised children. </p> <section id="CD008521-sec-0250"> <h4 class="title">Efficacy by setting</h4> <p>Rotarix and RotaTeq were highly efficacious in reducing severe rotavirus diarrhoea in low‐mortality countries; widespread roll‐out of rotavirus vaccines has led to major reductions in rotavirus hospitalizations in such settings (<a href="./references#CD008521-bbs2-0144" title="HungerfordD , SmithK , TuckerA , Iturriza-GómaraM , VivancosR , McLeonardC , et al. Population effectiveness of the pentavalent and monovalent rotavirus vaccines: a systematic review and meta-analysis of observational studies. BMC Infectious Diseases2017;17(1):569.">Hungerford 2017</a>; <a href="./references#CD008521-bbs2-0146" title="JonestellerCL , BurnettE , YenC , TateJE , ParasharUD . Effectiveness of rotavirus vaccination: a systematic review of the first decade of global postlicensure data, 2006-2016. Clinical Infectious Diseases2017;65(5):840-50.">Jonesteller 2017</a>). In contrast, trials of Rotarix, RotaTeq, Rotasiil and Rotavac in high‐mortality countries in Africa and Asia demonstrated a relatively lower vaccine efficacy. However, because of the higher burden of rotavirus disease in such countries, the absolute number of events prevented by vaccination is greater than in low‐mortality countries (<a href="./references#CD008521-bbs2-0017" title="CunliffeNA , WitteD , NgwiraBM , ToddS , BostockNJ , TurnerAM , et al. Efficacy of human rotavirus vaccine against severe gastroenteritis in Malawian children in the first two years of life: a randomized, double-blind, placebo controlled trial. Vaccine2012;30(Suppl 1):A36-43. MadhiSA , CunliffeNA , SteeleD , WitteD , KirstenM , LouwC , et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. New England Journal of Medicine2010;362(4):289-98. MadhiSA , KirstenM , LouwC , BosP , AspinallS , BouckenoogheA , et al. Efficacy and immunogenicity of two or three dose rotavirus-vaccine regimen in South African children over two consecutive rotavirus seasons: a randomized, double-blind, placebo-controlled trial. Vaccine2012;30(Suppl 1):A44-51. NCT00241644. Multi-center study to assess the efficacy, safety and immunogenicity of 2 or 3 doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations in healthy infants. clinicaltrials.gov/show/NCT00241644 (first received 19 October 2005). NCT00598468. Multi-center study to assess efficacy, safety &amp; immunogenicity of 2 or 3 doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations in healthy infants. clinicaltrials.gov/show/NCT00598468 (first received 19 October 2005). SteeleAD , NeuzilKM , CunliffeNA , MadhiSA , BosP , NgwiraB , et al. Human rotavirus vaccine Rotarix provides protection against diverse circulating rotavirus strains in African infants: a randomized controlled trial. BMC Infectious Diseases2012;12:213. ">RIX Madhi 2010‐AF</a>). </p> <p>A recent meta‐analysis of observational studies (<a href="./references#CD008521-bbs2-0119" title="BurnettE , ParasharUD , TateJE . Real-world effectiveness of rotavirus vaccines, 2006-19: a literature review and meta-analysis. Lancet Global Health2020;8(9):e1195-202.">Burnett 2020a</a>) documented that effectiveness of rotavirus vaccination against severe rotavirus gastroenteritis in children age &lt; 12 months was 86%, 77% and 63‐66% in low‐, medium‐ and high‐mortality countries, respectively. </p> <p>The global impact of rotavirus vaccination on rotavirus hospitalizations, all‐cause diarrhoea hospitalizations, and diarrhoea mortality, has recently been reviewed across a range of child mortality strata (<a href="./references#CD008521-bbs2-0120" title="BurnettE , ParasharUD , TateJE . Global impact of rotavirus vaccination on diarrhea hospitalizations and deaths among children &lt;5 years old: 2006–2019. Journal of Infectious Diseases2020;222(10):1731-9.">Burnett 2020b</a>). </p> </section> <section id="CD008521-sec-0251"> <h4 class="title">Efficacy by age</h4> <p>Results from RCTs of Rotarix and RotaTeq found higher vaccine efficacy against severe rotavirus diarrhoea in the first year compared to the cumulative efficacy for the first and second years. Vaccine efficacy was lower in the second year of life to a degree that varied by setting; the difference in efficacy between the first and second years was greater in high‐mortality (Rotarix: 63% up to one year versus 54% up to two years; RotaTeq: 57% versus 41%) compared to low‐mortality countries (Rotarix: 84% up to one year versus 82% up to two years; RotaTeq: 92% versus 82%). Trials with Rotavac and Rotasiil were not carried out in any low‐mortality country. </p> <p>Reduced vaccine efficacy in high‐mortality countries in trials reporting two years of follow‐up could be explained either by waning of vaccine‐induced immunity, or some protection in the placebo group resulting from more frequent exposure to natural rotavirus infection (<a href="./references#CD008521-bbs2-0017" title="CunliffeNA , WitteD , NgwiraBM , ToddS , BostockNJ , TurnerAM , et al. Efficacy of human rotavirus vaccine against severe gastroenteritis in Malawian children in the first two years of life: a randomized, double-blind, placebo controlled trial. Vaccine2012;30(Suppl 1):A36-43. MadhiSA , CunliffeNA , SteeleD , WitteD , KirstenM , LouwC , et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. New England Journal of Medicine2010;362(4):289-98. MadhiSA , KirstenM , LouwC , BosP , AspinallS , BouckenoogheA , et al. Efficacy and immunogenicity of two or three dose rotavirus-vaccine regimen in South African children over two consecutive rotavirus seasons: a randomized, double-blind, placebo-controlled trial. Vaccine2012;30(Suppl 1):A44-51. NCT00241644. Multi-center study to assess the efficacy, safety and immunogenicity of 2 or 3 doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations in healthy infants. clinicaltrials.gov/show/NCT00241644 (first received 19 October 2005). NCT00598468. Multi-center study to assess efficacy, safety &amp; immunogenicity of 2 or 3 doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations in healthy infants. clinicaltrials.gov/show/NCT00598468 (first received 19 October 2005). SteeleAD , NeuzilKM , CunliffeNA , MadhiSA , BosP , NgwiraB , et al. Human rotavirus vaccine Rotarix provides protection against diverse circulating rotavirus strains in African infants: a randomized controlled trial. BMC Infectious Diseases2012;12:213. ">RIX Madhi 2010‐AF</a>). A modelling study in Malawi concluded that reduced protection could be predicted in the absence of waning immunity (<a href="./references#CD008521-bbs2-0162" title="PitzerVE , BennettA , Bar-ZeevN , JereKC , LopmanBA , LewnardJA , et al. Evaluating strategies to improve rotavirus vaccine impact during the second year of life in Malawi. Science Translational Medicine2019;11(505):eaav6419.">Pitzer 2019</a>). In real‐world vaccine effectiveness studies among children age 12‐23 months, effectiveness was 84‐86%, 54% and 58% in low‐, medium‐ and high‐mortality countries, respectively (<a href="./references#CD008521-bbs2-0119" title="BurnettE , ParasharUD , TateJE . Real-world effectiveness of rotavirus vaccines, 2006-19: a literature review and meta-analysis. Lancet Global Health2020;8(9):e1195-202.">Burnett 2020a</a>). Additional vaccine doses have been explored in an attempt to extend the duration of protection in settings with a high burden of disease (<a href="./references#CD008521-bbs2-0129" title="CunliffeNA , KangG . Can changes to scheduling enhance the performance of rotavirus vaccines in low-income countries?Journal of Infectious Diseases2016;213(11):1673-5.">Cunliffe 2016</a>), although the predicted impact of one such strategy, an additional vaccine dose at nine months of age in a high‐mortality setting (Malawi) was modest (<a href="./references#CD008521-bbs2-0162" title="PitzerVE , BennettA , Bar-ZeevN , JereKC , LopmanBA , LewnardJA , et al. Evaluating strategies to improve rotavirus vaccine impact during the second year of life in Malawi. Science Translational Medicine2019;11(505):eaav6419.">Pitzer 2019</a>). </p> </section> <section id="CD008521-sec-0252"> <h4 class="title">Efficacy by schedule</h4> <p>Children who were enrolled in trials performed in low‐mortality countries received the vaccines according to the country's immunization schedule. Trials performed in high‐mortality countries examined the efficacy of Rotarix when administered at 10 to 14 weeks of age, a later age than is recommended in the Expanded Programme on Immunization (EPI) schedule. However, the 6‐ and 10‐week Rotarix schedule used in EPI programmes has now been extensively evaluated following vaccine roll‐out in high‐mortality countries in Africa, with effectiveness comparable to efficacy trial estimates (<a href="./references#CD008521-bbs2-0120" title="BurnettE , ParasharUD , TateJE . Global impact of rotavirus vaccination on diarrhea hospitalizations and deaths among children &lt;5 years old: 2006–2019. Journal of Infectious Diseases2020;222(10):1731-9.">Burnett 2020b</a>). </p> </section> <section id="CD008521-sec-0253"> <h4 class="title">All‐cause diarrhoea</h4> <p>The impact of rotavirus vaccination on severe all‐cause diarrhoea from a public health perspective is important, as laboratories in low‐income countries may not routinely test for rotavirus infection. The effect on all‐cause diarrhoea is a function of the contribution of rotavirus to all diarrhoea; the efficacy of the vaccine against rotavirus; and potential nonspecific effects of vaccination on gut health. Surprisingly, few trials reported vaccine efficacy against all‐cause diarrhoea. Vaccine efficacy against all‐cause diarrhoea of any severity was lower, meaning that vaccination may not have such a noticeable impact on milder episodes of diarrhoea occurring in the community (<a href="./references#CD008521-bbs2-0145" title="HungerfordD , VivancosR , ReadJM , Iturriza-GόmaraM , FrenchN , CunliffeNA . Rotavirus vaccine impact and socioeconomic deprivation: an interrupted time-series analysis of gastrointestinal disease outcomes across primary and secondary care in the UK. BMC Medicine2018;16(1):10.">Hungerford 2018</a>). </p> </section> <section id="CD008521-sec-0254"> <h4 class="title">Mortality data</h4> <p>The included trials were not individually powered to detect a mortality effect. This review did not detect a difference in the number of deaths for children receiving any of the vaccines or placebo. Two post‐vaccine implementation national surveillance studies from Mexico and Brazil reported that the introduction of Rotarix into the national immunization programme was associated with a decline in the number of diarrhoea‐related deaths (<a href="./references#CD008521-bbs2-0133" title="Do CarmoGM ,  YenC ,  CortesJ ,  SiqueiraAA ,  De OliveiraWK ,  Cortez-EscalanteJJ ,  et al. Decline in diarrhea mortality and admissions after routine childhood rotavirus immunization in Brazil: a time-series analysis. PLOS Medicine2011;8(4):e1001024.">Do Carmo 2011</a>; <a href="./references#CD008521-bbs2-0166" title="RichardsonV ,  Hernandez-PichardoJ ,  Quintanar-SolaresM ,  Esparza-AguilarM ,  JohnsonB ,  Gomez-AltamiranoCM ,  et al. Effect of rotavirus vaccination on death from childhood diarrhea in Mexico. New England Journal of Medicine2010;362(4):299-305.">Richardson 2010</a>) in comparison with historical controls. A study from rural Malawi showed that diarrhoea deaths reduced by a third following Rotarix introduction (<a href="./references#CD008521-bbs2-0118" title="Bar-ZeevN , KingC , PhiriT , BeardJ , MvulaH , CrampinAC , et al. Impact of monovalent rotavirus vaccine on diarrhoea-associated post-neonatal infant mortality in rural communities in Malawi: a population-based birth cohort study. Lancet Global Health2018;6(9):e1036-44.">Bar‐Zeev 2018</a>). </p> </section> <section id="CD008521-sec-0255"> <h4 class="title">Safety data</h4> <p>There was no detectable difference in the number of cases of intussusception for children receiving vaccine or placebo. While both Rotarix and RotaTeq have been associated with a low risk of intussusception in post‐marketing studies in Europe, Americas and Australia, the benefits of vaccination are considered to outweigh the risk of vaccine‐associated intussusception (<a href="./references#CD008521-bbs2-0189" title="YenC , HealyK , TateJE , ParasharUD , BinesJ , NeuzilK , et al. Rotavirus vaccination and intussusception – science, surveillance, and safety: a review of evidence and recommendations for future research priorities in low and middle income countries. Human Vaccines and Immunotherapeutics2016;12(10):2580-9.">Yen 2016</a>). However, the risk of intussusception after administration of Rotarix was not higher than the background risk of intussusception in seven lower‐income sub‐Saharan African countries (<a href="./references#CD008521-bbs2-0178" title="TateJE , MwendaJM , ArmahG , JaniB , OmoreR , AdemeA , et al. Evaluation of intussusception after monovalent rotavirus vaccination in Africa. New England Journal of Medicine2018;378(16):1521-8.">Tate 2018</a>). </p> </section> <section id="CD008521-sec-0256"> <h4 class="title">Subgroup analyses</h4> <section id="CD008521-sec-0257"> <h5 class="title">Rotavirus G‐ and P‐types</h5> <p>All four rotavirus vaccines demonstrated efficacy against most of the  rotavirus G‐ and P‐types that were assessed (G1, G2, G3, G4, G8, G9, G12, P4, P6, P8), although results were often inconsistent between different countries and were imprecise due to few events. </p> </section> <section id="CD008521-sec-0258"> <h5 class="title">Immunocompromised children</h5> <p>One Rotarix trial and two RotaTeq trials reported on immunocompromised children exposed to, or infected with, HIV.  No differences were identified for efficacy or safety, but studies were not sufficiently powered for these endpoints. It is  recommended that all HIV‐infected or HIV‐exposed infants be vaccinated with oral rotavirus vaccine, unless severely immunocompromised (<a href="./references#CD008521-bbs2-0123" title="CallesNR , SchutzeGE . Immunizations for children with HIV. Module for HIV Curriculum available from: bipai.org/sites/bipai/files/20-Immunizations.pdf (accessed 25 Oct 2018).">Calles 2010</a>). While specific information on rotavirus vaccination in many immunodeficiency conditions is lacking, infants with known severe combined immunodeficiency should not receive live rotavirus vaccine (<a href="./references#CD008521-bbs2-0161" title="PintoMV , BihariS , SnapeMD . Immunisation of the immunocompromised child. Journal of Infection2016;72(Suppl):S13-22.">Pinto 2016</a>; <a href="./references#CD008521-bbs2-0183" title="VesikariT , Van DammeP , GiaquintoC , DaganR , GuarinoA , SzajewskaH , et al. European Society for Paediatric Infectious Diseases consensus recommendations for rotavirus vaccination in Europe. Pediatric Infectious Disease Journal2015;34(6):635-43.">Vesikari 2015</a>). </p> </section> <section id="CD008521-sec-0259"> <h5 class="title">Children with malnutrition</h5> <p>One Rotarix trial (<a href="./references#CD008521-bbs2-0027" title="Ruiz-PalaciosG , GuerreroL , LinharesAC , et al. Efficacy of an oral human rotavirus (HRV) vaccine in preventing diarrhoea due to G1 and non-G1 rotavirus [Presentation]. In: 3rd World Congress of Pediatric Infectious Diseases; 2002 November 19-23; Santiago, Chile. 2002. [Not available for review]Ruiz-PalaciosG , GuerreroML , LinharesAC , et al. Two-year efficacy of GlaxoSmithKline Biologicals' live attenuated rotavirus vaccine in Latin American children [poster]. In: 24th International Congress of Pediatrics; 2004 August 15-20; Cancun, Mexico. 2004. [Not available for review]SalinasB , Perez-SchaelI , Ruiz-PalaciosG , et al. Early protection by GlaxoSmithKline Biologicals' live attenuated rotavirus vaccine in Latin American children [poster]. In: 24th International Congress of Pediatrics; 2004 August 15-20; Cancun, Mexico. 2004. [Not available for review]SalinasB , TomatMA , YarzabalJP , et al. Efficacy of the rotavirus vaccine (RIX4414) among infants in Carabobo State, Venezuela [poster]. In: Asocación Venezolana para el Avance de la Cienca (AsoVAC); 2004; Venezuela. 2004. [Not available for review]AraujoEC , ClemensSA , OliveiraCS , JustinoMC , RubioP , GabbayYB , et al. Safety, immunogenicity, and protective efficacy of two doses of RIX4414 live attenuated human rotavirus vaccine in healthy infants. Jornal de Pediatria2007;83(3):217-24. De VosB , HardtK , LinharesAC , Ruiz-PalaciosG , GuerreroL , SalinasB . Efficacy of two doses of a human monovalent rotavirus vaccine, Rotarix™ in preventing gastro-enteritis due to G1 and Non-G1 rotavirus in Brazil, Mexico and Venezuela [presentation]. In: 8th International Symposium on Double-Stranded RNA Viruses; 2003 September 13-18; Lucca, Italy. 2003. [Not available for review]De VosB , VesikariT , LinharesAC , SalinasB , Perez-SchaelI , Ruiz-PalaciosGM , et al. A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis. Pediatric Infectious Disease Journal2004;23(10 Suppl):179-82. GlaxoSmithKline[444563-006]. A phase IIb, double-blind, randomized, placebo-controlled study to assess the efficacy, immunogenicity, reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals' live attenuated human rotavirus (HRV) vaccine at different virus concentrations (104.7, 105.2 and 105.8 foci forming units [ffu]) in healthy infants (approximately 2 months of age at first dose) following a 0, 2 month schedule and previously uninfected with HRV, when administered concurrently with DTPw-HBV and Hib vaccines. www.gsk-studyregister.com/study/6784 (accessed 12 December 2018). GlaxoSmithKline[444563-006-Annex]. A phase IIb, double-blind, randomized, placebo-controlled study to assess the efficacy, immunogenicity, reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals' live attenuated human rotavirus (HRV) vaccine at different virus concentrations (104.7, 105.2 and 105.8 foci forming units [ffu]) in healthy infants (approximately 2 months of age at first dose) following a 0, 2 month schedule and previously uninfected with HRV, when administered concurrently with DTPw-HBV and Hib vaccines [This summary presents results for the second and combined efficacy periods and results from the 3-Dose subset. Results from the first efficacy period are presented in 444563/006 (Rota-006) summary]. www.gsk-studyregister.com/study/6784 (accessed 12 December 2018). LinharesA , Perez-SchaelI , Ruiz-PalaciosM , PernambucoE , JacquetJ , De VosB . Immunogenicity and reactogenicity of an oral human rotavirus (HRV) vaccine in Latin American infants [poster]. In: 3rd World Congress of Pediatric Infectious Diseases; 2002 November 19-23; Santiago, Chile. 2002. [Not available for review]LinharesAC , Ruiz-PalaciosGM , GuerreroML , SalinasB , Perez-SchaelI , ClemensSA , et al. A short report on highlights of world-wide development of RIX4414: a Latin American experience. Vaccine2006;24(18):3784-5. LinharesAC , VerstraetenT , Wolleswinkel-Van den BoschJ , ClemensR , BreuerT . Rotavirus serotype G9 is associated with more-severe disease in Latin America. Clinical Infectious Diseases2006;43(3):312-4. [Not available for review]NCT00385320. To assess the efficacy, immuno &amp; safety of 2 doses of GSK HRV vaccine at different virus concentrations in healthy infants aged 2 months &amp; previously uninfected with HRV, concurrently given with DTPw-HBV, Hib. clinicaltrials.gov/show/NCT00385320 (first received 9 October 2006). Perez-SchaelI , SalinasB , LinharesA , GuerreroM , Ruiz-PalaciosG , ClemensS , et al. Protective efficacy of an oral human rotavirus (HRV) vaccine in Latin American infants [poster]. In: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy ( ICAAC); San Diego, 27-30 September 2002. 2002:18, LB-23. [Not available for review]Perez-SchaelI , SalinasB , TomatM , LinharesAC , GuerreroML , Ruiz-PalaciosGM , et al. Efficacy of the human rotavirus vaccine RIX4414 in malnourished children. Journal of Infectious Diseases2007;196(4):537-40. Ruiz-PalaciosGM , GuerreroML , Bautista-MarquezA , Ortega-GallegosH , Tuz-DzibF , Reyes-GonzalezL , et al. Dose response and efficacy of a live, attenuated human rotavirus vaccine in Mexican infants. Pediatrics2007;120(2):e253-61. [Not available for review]Ruiz-PalaciosGM . Impact of maternal antibodies on the immune response to an oral human rotavirus (HRV) vaccine in Mexican infants [presentation]. In: 3rd World Congress of Pediatric Infectious Diseases; 2002 November 19-23; Santiago, Chile. 2002. [Not available for review]SalinasB , Perez SchaelI , LinharesAC , Ruiz PalaciosGM , GuerreroML , YarzabalJP , et al. Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: a randomized, placebo-controlled trial in Latin American infants. Pediatric Infectious Disease Journal2005;24(9):807-16. ">RIX Salinas 2005‐LA</a>) found that Rotarix was significantly superior to placebo in preventing rotavirus diarrhoea in a subgroup of malnourished children. </p> </section> </section> </section> <section id="CD008521-sec-0260"> <h3 class="title" id="CD008521-sec-0260">Quality of the evidence</h3> <p>The trials included in this updated review were placebo‐controlled (53 trials) or compared vaccine to no intervention (<a href="./references#CD008521-bbs2-0005" title='ColgateER , HaqueR , DicksonDM , CarmolliMP , MychaleckyjJC , NayakU , et al. Delayed dosing of oral rotavirus vaccine demonstrates decreased risk of rotavirus gastroenteritis associated with serum zinc: a randomized controlled trial. Clinical Infectious Diseases2016;63(5):634-41. KirkpatrickBD , ColgateER , MychaleckyjJC , HaqueR , DicksonDM , CarmolliMP , et al. The "Performance of Rotavirus and Oral Polio Vaccines in Developing Countries" (PROVIDE) study: description of methods of an interventional study designed to explore complex biologic problems. American Journal of Tropical Medicine and Hygiene2015;92(4):744-51. LeeB , DicksonDM , DeCampAC , ColgateER , DiehlSA , UddinMI , et al. Histo-blood group antigen phenotype determines susceptibility to genotype-specific rotavirus infections and impacts measures of rotavirus vaccine efficacy. Journal of Infectious Diseases2018;217(9):1399-407. LeeB , DiehlSA , ColgateER , DicksonDM , UddinMI , SharminS , et al. Lewis antigen and secretor status mediate susceptibility to p-genotype specific rotavirus infections but do not affect rotavirus vaccine performance among infants in Bangladesh. American Journal of Tropical Medicine and Hygiene2017;97:226. NCT01375647. Exploration of the biologic basis for underperformance of oral polio and rotavirus vaccines in Bangladesh PROVIDE. clinicaltrials.gov/show/NCT01375647 (first received 17 June 2011). RogawskiET , Platts-MillsJA , ColgateER , HaqueR , ZamanK , PetriWA , et al. Quantifying the impact of natural immunity on rotavirus vaccine efficacy estimates: a clinical trial in Dhaka, Bangladesh (PROVIDE) and a simulation study. Journal of Infectious Diseases2018;217(6):861-8. '>RIX Colgate 2016‐BGD</a>; <a href="./references#CD008521-bbs2-0038" title="ZamanK , SackDA , NeuzilKM , YunusM , MoultonLH , SugimotoJD , et al. Effectiveness of a live oral human rotavirus vaccine after programmatic introduction in Bangladesh: a cluster-randomized trial. PLOS Medicine2017;14(4):e1002282. ">RIX Zaman 2017‐BGD</a>); were conducted in Latin America, North America, Europe, Asia, and Africa; and the largest included over 60,000 children (<a href="./references#CD008521-bbs2-0026" title="Costa ClemensSA , et al. Operational organization of a large scale phase III clinical trial of rotavirus vaccine in multiple sites and countries in Latin America. In: International Congress of Pediatrics (ICP); 2004 August 15-20; Cancun, Mexico. 2004. [Not available for review]De VosB , et al. Rotarix™: an effective way to prevent rotavirus diarrhoea and vomiting. In: 9th Congress of the Asian Pan Pacific Society of Paediatric Gastroenterology, Hepatology and Nutrition &amp; 27th Annual Congress of the Malaysian Paediatric Association; 2005 June 16-19; Kuala Lumpur, Malaysia. 2005. [Not available for review]BaayM , BollaertsK , StruchinerC , VerstraetenT . Background rates of disease in Latin American children from a rotavirus vaccine study. Human Vaccines and Immunotherapeutics2017;13(8):1916-20. GlaxoSmithKline[444563-023-pt1]. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants (efficacy data from visit 1 to visit 4). www.gsk-studyregister.com/study/6791 (accessed 12 December 2018). GlaxoSmithKline[444563-023-pt2]. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants (2nd year efficacy from visit 4 to visit 6). www.gsk-studyregister.com/study/6791 (accessed 12 December 2018). GlaxoSmithKline[444563-023-pt3]. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants (safety for the period between visit 1 and visit 3). www.gsk-studyregister.com/study/6791 (accessed 12 December 2018). JustinoMC , AraújoEC , Van DoornLJ , OliveiraCS , GabbayYB , MascarenhasJD , et al. Oral live attenuated human rotavirus vaccine (Rotarix) offers sustained high protection against severe G9P[8] rotavirus gastroenteritis during the first two years of life in Brazilian children. Memorias do Instituto Oswaldo Cruz2012;107(7):846-53. LinharesAC , VelazquezFR , Perez-SchaelI , Saez-LlorensX , AbateH , EspinozaF , et al. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet2008;371(9619):1181-9. LopezP , LinharesA , Pérez-SchaelI , Ruiz-PalaciosG , Costa ClemensS , SanchezN . Early protection against severe rotavirus gastroenteritis - RIX4414 experience in Latin America. In: 24th Annual Meeting of European Society for Paediatric Infectious Diseases (ESPID); 2006 May 03-05; Basel, Switzerland. 2006. [Not available for review]MaciasM , LopezP , VelazquezFR , VergaraRF , SalmeronJ , TavaresJL . The rotavirus vaccine RIX4414 (Rotarix) is not associated with intussusception in one year old infants. In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2005 December 16-19; Washington DC, USA. 2005. [Not available for review]NCT00139347. A multi-country &amp; multi-center study to assess the efficacy, immunogenicity &amp; safety of two doses of GSK Biologicals' oral live attenuated HRV vaccine given concomitantly with routine EPI vaccinations including OPV in healthy infants. clinicaltrials.gov/ct2/show/NCT00139347 (first received 31 August 2005). [Trial registration document (no data for review)]NCT00140673. Placebo-controlled, multi-country &amp; multi-center study to assess the efficacy, safety &amp; immunogenicity of 2 doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants. clinicaltrials.gov/ct2/show/NCT00140673 (first received 1 September 2005). [Trial registration document (no data for review)]Perez-SchaelI , LinharesAC , VesikariT . Two doses of the human attenuated rotavirus vaccine RIX4414 (Rotarix) show heterotypic protection in Latin America and Europe. In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2005 December 16-19; Washington DC, USA. 2005. [Not available for review]PikeM . New rotavirus vaccine is effective and appears to have no increased risk of intussusception. Clinical Research Abstracts For Pediatricians2006;149(1):143. Ruiz-PalaciosG , AranzaC , VelazquezFR , RichardsonV , NandiE , MaciasM . Two doses of the human-attenuated monovalent G1P[8] rotavirus vaccine, Rotarix show high efficacy in Mexican children against severe rotavirus gastroenteritis and severe overall gastroenteritis. In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2005 December 16-19; Washington DC, USA. 2005. [Not available for review]Ruiz-PalaciosGM , Perez-SchaelI , VelazquezFR , AbateH , BreuerT , ClemensSC , et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. New England Journal of Medicine2006;354(1):11-22. VelázquezFR , AbatH , Costa ClemensSA , EspinozaF , GillardP , LinharesAC , et al. The human monovalent G1P[8] rotavirus vaccine, Rotarix is highly efficacious and provides crossprotection against G1 and non-G1 serotypes. In: 23rd Annual meeting of European Society for Paediatric Infectious Diseases (ESPID); 2005 May 18-20; Valencia, Spain. 2005. VelázquezRF , AbateH , BouckenoogheA . RIX4414, the human G1P[8] rotavirus vaccine is highly efficacious during the second year of life. In: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2006 September 27-30; San Francisco, USA. 2006. [Not available for review]VesikariT , O’RyanM , AbateH , Costa ClemensSA , EspinozaF , GillardP . Overcoming the safety hurdle: the rotavirus vaccine RIX4414 is not associated with intussusception. In: 23rd Annual Meeting of European Society for Paediatric Infectious Diseases (ESPID); 2005 May 18-20; Valencia, Spain. 2005. [Not available for review]">RIX Ruiz‐Palac 06‐LA/EU</a>; <a href="./references#CD008521-bbs2-0060" title="ChangCC , ChangMH , LinTY , LeeHC , HsiehWS , LeePI . Experience of pentavalent human-bovine reassortant rotavirus vaccine among healthy infants in Taiwan. Journal of the Formosan Medical Association2009;108(4):280-5. ChristieCD , DuncanND , ThameKA , OnoratoMT , SmithHD , MalcolmLG , et al. Pentavalent rotavirus vaccine in developing countries: safety and health care resource utilization. Pediatrics2010;126(6):e1499-506. DennehyPH , GoveiaMG , DallasMJ , HeatonPM . The integrated phase III safety profile of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine. International Journal of Infectious Diseases2007;11(Suppl 2):36-42. [No data available for review]GoveiaMG , DiNubileMJ , DallasMJ , HeatonPM , KuterBJ , REST Study Team. Efficacy of pentavalent human-bovine (WC3) reassortant rotavirus vaccine based on breastfeeding frequency. Pediatric Infectious Disease Journal2008;27(7):656-8. GoveiaMG , RodriguezZM , DallasMJ , ItzlerRF , BoslegoJW , HeatonPM , et al. Safety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infants. Pediatric Infectious Disease Journal2007;26(12):1099-104. [No data available for review]GoveiaMG , SuprunL , ItzlerRF , McFetridgeR , DallasMJ , KuterBJ . Efficacy and safety of pentavalent human-bovine reassortant rotavirus vaccine when administered with greater than 10 weeks between doses. Pediatric Infectious Disease Journal2010;29(3):263-5. GrantL , WattJ , MoultonL , WeatherholtzR , ReidR , SantoshamM , et al. Lack of nonspecific protection against all-cause nonrotavirus gastroenteritis by vaccination with orally administered rotavirus vaccine. Journal of Pediatric Gastroenterology and Nutrition2013;56(6):635-40. GrantLR , WattJP , WeatherholtzRC , MoultonLH , ReidR , SantoshamM , et al. Efficacy of a pentavalent human-bovine reassortant rotavirus vaccine against rotavirus gastroenteritis among American Indian children. Pediatric Infectious Disease Journal2012;31(2):184-8. ItzlerR , KochG , MatsonDO , GotheforsL , Van DammeP , DinubileMJ , et al. Robustness of the healthcare utilization results from the Rotavirus Efficacy and Safety Trial (REST) evaluating the human-bovine (WC3) reassortant pentavalent rotavirus vaccine (RV5). BMC Pediatrics2010;10:42. Merck[PN-006]. Safety and efficacy of pentavalent (G1, G2, G3, G4, and P1) human-bovine reassortant rotavirus vaccine in healthy infants NCT00090233 (PN 006). clinicalstudyresults.org/drugdetails/?indication_id=523&amp;sort=c.company_name&amp;page=1&amp;drug_id=1144 (accessed prior to 19 October 2021). [No data available for review]NCT00090233. Safety and efficacy of pentavalent (G1, G2, G3, G4, and P1) human-bovine reassortant rotavirus vaccine in healthy infants. clinicaltrials.gov/ct2/show/record/NCT00090233 (first received 27 August 2004). [Trial registration document]RodriguezZM , GoveiaMG , StekJE , DallasMJ , BoslegoJW , DiNubileMJ , et al. Concomitant use of an oral live pentavalent human-bovine reassortant rotavirus vaccine with licensed parenteral pediatric vaccines in the United States. Pediatric Infectious Disease Journal2007;26(3):221-7. VesikariT ,  KarvonenA ,  FerranteSA ,  KuterBJ ,  CiarletM . Sustained efficacy of the pentavalent rotavirus vaccine, RV5, up to 3.1 years following the last dose of vaccine. Pediatric Infectious Disease Journal2010;29(10):957-63. VesikariT , ItzlerR , KarvonenA , KorhonenT , Van DammeP , BehreU , et al. RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe. Vaccine2009;28(2):345-51. VesikariT , ItzlerR , MatsonDO , SantoshamM , ChristieCD , CoiaM , et al. Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across three regions (11 countries). International Journal of Infectious Diseases2007;11(Suppl 2):29-35. VesikariT , KarvonenA , FerranteSA , CiarletM . Efficacy of the pentavalent rotavirus vaccine, RotaTeq(R), in Finnish infants up to 3 years of age: the Finnish Extension Study. European Journal of Pediatrics2010;169(11):1379-86. VesikariT , MatsonDO , DennehyP , Van DammeP , SantoshamM , RodriguezZ , et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. New England Journal of Medicine2006;354(1):23-33. ">TEQ Vesikari 2006b‐INT</a>); we identified the need for such trials in the original version of the review (<a href="./references#CD008521-bbs2-0191" title="Soares-WeiserK , GoldbergE , TamimiG , PitanOC , LeiboviciL . Rotavirus vaccine for preventing diarrhoea. Cochrane Database of Systematic Reviews2004, Issue 1. Art. No: CD002848. [DOI: 10.1002/14651858.CD002848.pub2]">Soares‐Weiser 2004</a>). However, most children were followed for safety outcomes only. </p> <p>The certainty of the evidence for efficacy outcomes (rotavirus diarrhoea of any severity and severe, and all‐cause diarrhoea of any severity and severe) was either high or moderate. This was because most trials were assessed as being at low risk of bias, especially more recent trials, and pooled samples were usually large enough to generate precise estimates. When we downgraded efficacy outcomes to moderate certainty, this was due to selective reporting bias (only half of the studies reporting on severe rotavirus diarrhoea reported on severe all‐cause diarrhoea), imprecision (low number of events), risk of bias (unclear selection bias or risk of performance and detection bias), or indirectness (only one study carried out in one high‐mortality country makes it difficult to generalize to any high‐mortality country). </p> <p>The certainty of the evidence for all‐cause mortality was low because the trials were not powered to detect an effect on mortality, and results were consequently imprecise with wide 95% CIs. </p> <p>The certainty of the evidence for all serious adverse events was mostly high but was downgraded to moderate for RotaTeq in high‐mortality countries due to imprecise results, and for Rotavac due to indirectness (all trials were carried out in India). For the rare serious adverse event intussusception, evidence was of low certainty for Rotarix, RotaTeq and Rotasiil due to imprecision with very wide 95% CIs. For Rotavac, evidence on intussusception was of very low certainty, due to imprecision and indirectness, as previously described. </p> </section> <section id="CD008521-sec-0261"> <h3 class="title" id="CD008521-sec-0261">Potential biases in the review process</h3> <p>We stratified all analyses by under‐five child mortality rates (<a href="./references#CD008521-bbs2-0179" title="United Nations Inter-agency Group for Child Mortality Estimation (UN IGME). Levels &amp; trends in child mortality: report 2019, estimates developed by the United Nations Inter-agency Group for child mortality estimation. Available from unicef.org/reports/levels-and-trends-child-mortality-report-2019 (accessed prior to 12 October 2021).">UNICEF 2019</a>) to highlight the previously noted differences in rotavirus vaccine efficacy across countries. However, the use of stratified analyses can introduce bias when interpreting the implications of the review. The strata used may not reflect the current mortality rate in some of the countries, or the mortality rate when the trials were conducted. Alternatively, analyses could be stratified by prevalence or burden of rotavirus disease across different countries; however, this will likely result in similar problems. </p> <p>The use of broad strata (i.e. low, medium, high) based on infant mortality are also unlikely to show differences at the country level. However, the stratified analysis provides indirect efficacy and safety results to countries that are not represented within the included trials. The largest RotaTeq trial (<a href="./references#CD008521-bbs2-0060" title="ChangCC , ChangMH , LinTY , LeeHC , HsiehWS , LeePI . Experience of pentavalent human-bovine reassortant rotavirus vaccine among healthy infants in Taiwan. Journal of the Formosan Medical Association2009;108(4):280-5. ChristieCD , DuncanND , ThameKA , OnoratoMT , SmithHD , MalcolmLG , et al. Pentavalent rotavirus vaccine in developing countries: safety and health care resource utilization. Pediatrics2010;126(6):e1499-506. DennehyPH , GoveiaMG , DallasMJ , HeatonPM . The integrated phase III safety profile of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine. International Journal of Infectious Diseases2007;11(Suppl 2):36-42. [No data available for review]GoveiaMG , DiNubileMJ , DallasMJ , HeatonPM , KuterBJ , REST Study Team. Efficacy of pentavalent human-bovine (WC3) reassortant rotavirus vaccine based on breastfeeding frequency. Pediatric Infectious Disease Journal2008;27(7):656-8. GoveiaMG , RodriguezZM , DallasMJ , ItzlerRF , BoslegoJW , HeatonPM , et al. Safety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infants. Pediatric Infectious Disease Journal2007;26(12):1099-104. [No data available for review]GoveiaMG , SuprunL , ItzlerRF , McFetridgeR , DallasMJ , KuterBJ . Efficacy and safety of pentavalent human-bovine reassortant rotavirus vaccine when administered with greater than 10 weeks between doses. Pediatric Infectious Disease Journal2010;29(3):263-5. GrantL , WattJ , MoultonL , WeatherholtzR , ReidR , SantoshamM , et al. Lack of nonspecific protection against all-cause nonrotavirus gastroenteritis by vaccination with orally administered rotavirus vaccine. Journal of Pediatric Gastroenterology and Nutrition2013;56(6):635-40. GrantLR , WattJP , WeatherholtzRC , MoultonLH , ReidR , SantoshamM , et al. Efficacy of a pentavalent human-bovine reassortant rotavirus vaccine against rotavirus gastroenteritis among American Indian children. Pediatric Infectious Disease Journal2012;31(2):184-8. ItzlerR , KochG , MatsonDO , GotheforsL , Van DammeP , DinubileMJ , et al. Robustness of the healthcare utilization results from the Rotavirus Efficacy and Safety Trial (REST) evaluating the human-bovine (WC3) reassortant pentavalent rotavirus vaccine (RV5). BMC Pediatrics2010;10:42. Merck[PN-006]. Safety and efficacy of pentavalent (G1, G2, G3, G4, and P1) human-bovine reassortant rotavirus vaccine in healthy infants NCT00090233 (PN 006). clinicalstudyresults.org/drugdetails/?indication_id=523&amp;sort=c.company_name&amp;page=1&amp;drug_id=1144 (accessed prior to 19 October 2021). [No data available for review]NCT00090233. Safety and efficacy of pentavalent (G1, G2, G3, G4, and P1) human-bovine reassortant rotavirus vaccine in healthy infants. clinicaltrials.gov/ct2/show/record/NCT00090233 (first received 27 August 2004). [Trial registration document]RodriguezZM , GoveiaMG , StekJE , DallasMJ , BoslegoJW , DiNubileMJ , et al. Concomitant use of an oral live pentavalent human-bovine reassortant rotavirus vaccine with licensed parenteral pediatric vaccines in the United States. Pediatric Infectious Disease Journal2007;26(3):221-7. VesikariT ,  KarvonenA ,  FerranteSA ,  KuterBJ ,  CiarletM . Sustained efficacy of the pentavalent rotavirus vaccine, RV5, up to 3.1 years following the last dose of vaccine. Pediatric Infectious Disease Journal2010;29(10):957-63. VesikariT , ItzlerR , KarvonenA , KorhonenT , Van DammeP , BehreU , et al. RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe. Vaccine2009;28(2):345-51. VesikariT , ItzlerR , MatsonDO , SantoshamM , ChristieCD , CoiaM , et al. Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across three regions (11 countries). International Journal of Infectious Diseases2007;11(Suppl 2):29-35. VesikariT , KarvonenA , FerranteSA , CiarletM . Efficacy of the pentavalent rotavirus vaccine, RotaTeq(R), in Finnish infants up to 3 years of age: the Finnish Extension Study. European Journal of Pediatrics2010;169(11):1379-86. VesikariT , MatsonDO , DennehyP , Van DammeP , SantoshamM , RodriguezZ , et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. New England Journal of Medicine2006;354(1):23-33. ">TEQ Vesikari 2006b‐INT</a>) was carried out mostly in low‐mortality countries (Belgium, Finland, Germany, Italy, Puerto Rico, Sweden, Taiwan, USA), but also in some medium‐mortality countries (Costa Rica, Jamaica, Mexico) and in one high‐mortality country (Guatemala). Disaggregated data, split by country, were not available for this trial. The data were placed in the low‐mortality stratum and potentially resulted in under‐representation in the medium‐mortality stratum for RotaTeq. </p> </section> <section id="CD008521-sec-0262"> <h3 class="title" id="CD008521-sec-0262">Agreements and disagreements with other studies or reviews</h3> <p>We identified three systematic reviews of RCTs evaluating the efficacy or safety of rotavirus vaccines that have been conducted since the 2012 update of this Cochrane Review: </p> <p> <ul id="CD008521-list-0005"> <li> <p><a href="./references#CD008521-bbs2-0147" title="LambertiLM , AshrafS , WalkerCL , BlackRE . A systematic review of the effect of rotavirus vaccination on diarrhea outcomes among children younger than 5 years. Pediatric Infectious Disease Journal2016;35(9):992-8.">Lamberti 2016</a> included RCTs and observational studies and evaluated region‐specific effectiveness of Rotarix, RotaTeq and Rotavac. The systematic review found that rotavirus vaccination was both efficacious and effective in preventing rotavirus diarrhoea, severe rotavirus diarrhoea and rotavirus hospitalizations among children under five across all regions, with higher efficacy in more developed regions. </p> </li> <li> <p><a href="./references#CD008521-bbs2-0181" title="VelázquezRF , LinharesAC , MuñozS , SeronP , Lorca P3, DeAntonioR , et al. Efficacy, safety and effectiveness of licensed rotavirus vaccines: a systematic review and meta-analysis for Latin America and the Caribbean. BMC Pediatrics2017;17(1):14.">Velázquez 2017</a> included RCTs and post‐licensure observational studies from Latin America and the Caribbean, and found that Rotarix reduced the risk of any‐severity rotavirus‐related gastroenteritis by 65% and of severe gastroenteritis by 82% versus placebo. Both Rotarix and RotaTeq vaccines significantly reduced the risk of hospitalization and emergency visits by 85% for Rotarix and by 90% for RotaTeq. Vaccination with RotaTeq or Rotarix did not increase the risk of death, intussusception, or other severe adverse events. </p> </li> <li> <p><a href="./references#CD008521-bbs2-0122" title="BuyseH , VinalsC , KarkadaN , HanHH . The human rotavirus vaccine Rotarix™ in infants: an integrated analysis of safety and reactogenicity. Human Vaccines and Immunotherapeutics2014;10(1):19-24.">Buyse 2014</a> presented an integrated meta‐analysis of safety and reactogenicity data of 28 Rotarix RCTs and found that Rotarix has a reactogenicity and safety profile similar to placebo. </p> </li> <li> <p><a href="./references#CD008521-bbs2-0127" title="ClarkAC , Van ZandvoortK , FlascheS , SandersonC , BinesJ , TateJ , et al. Efficacy of live oral rotavirus vaccines by duration of follow-up: a meta-regression of randomised controlled trials. Lancet Infectious Diseases2019;19(7):P717-27.">Clark 2019</a> conducted a meta‐regression analysis of RCTs of rotavirus vaccines and demonstrated that efficacy fell more rapidly, to 44% by 12 months of age, in high‐mortality settings. </p> </li> <li> <p><a href="./references#CD008521-bbs2-0175" title="SkansbergA , SauerM , TanM , SantoshamM , JenningsMC . Product review of the rotavirus vaccines ROTASIIL, ROTAVAC, and Rotavin-M1. Human Vaccines &amp; Immunotherapeutics2021;17(4):1223-34.">Skansberg 2021</a> summarized the available clinical trial and post‐introduction evidence for the newer vaccines Rotasiil, Rotavac, and Rotavin, and concluded that all three vaccines had demonstrated safety and efficacy against rotavirus diarrhoea. </p> </li> <li> <p><a href="./references#CD008521-bbs2-0150" title="LuHL , DingY , GoyalH , XuHG . Association between rotavirus vaccination and risk of intussusception among neonates and infants: a systematic review and meta-analysis. JAMA Network Open2019;2(10):e1912458.">Lu 2019</a> assessed the risk of intussusception in RCTs of Rotarix, RotaTeq, Rotasiil, Rotavac, and RV3‐BB and found that the vaccines were not associated with an elevated risk of intussusception among neonates or infants. </p> </li> </ul> </p> <p>The findings of these systematic reviews agree with the findings of our review, although the scope of these reviews was narrower; they reviewed efficacy or safety only, or were limited to a specific geographical region, or reviewed only one of the vaccines. Consequently, we included more trials in our review. Finally, the major findings of this review update, including new evidence from five trials of Rotasiil, are not significantly different from the previous <a href="./references#CD008521-bbs2-0195" title="Soares-WeiserK , BergmanH , HenschkeN , PitanF , CunliffeN . Vaccines for preventing rotavirus diarrhoea: vaccines in use. Cochrane Database of Systematic Reviews2019, Issue 10. Art. No: CD008521. [DOI: 10.1002/14651858.CD008521.pub4]">Soares‐Weiser 2019</a> review. </p> <section id="CD008521-sec-0263"> <h4 class="title">Relationship to current policies</h4> <p>The data in this review support the WHO's Strategic Advisory Group of Experts (SAGE) on Immunization’s recommendation for "the inclusion of rotavirus vaccination of infants into all national immunization programmes" with a stronger recommendation for countries where "diarrhoeal deaths account for ≥ 10% of mortality among children aged &lt; 5 years" (<a href="./references#CD008521-bbs2-0169" title="SAGE. Meeting of the immunization Strategic Advisory Group of Experts, April 2009 - conclusions and recommendations. Weekly Epidemiological Record2009;84(23):220-36.">SAGE 2009</a>; <a href="./references#CD008521-bbs2-0185" title="World Health Organization. Meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization 5 -7 October 2020. www.who.int/docs/default-source/mca-documents/stage/2-4-nov-2020-meeting/stage-2-4-nov-2020-sage-oct-2020-meeting_short-summary_.pdf?sfvrsn=1ca0e652_5 (accessed 20 May 2021).">WHO 2020</a>). </p> </section> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD008521-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-FIG-01" target="_blank"><b></b></a></p> </div><img alt="A simplified diagram of the location of rotavirus structural proteins (source: Graham Cohn, Wikipedia (public domain image)): Rotaviruses are segmented, double‐stranded RNA viruses. The mature, triple‐layered virus particle comprises a core (which contains the viral genome), a middle layer (comprised of viral protein (VP)6, and an outer layer (comprised of VP7 and VP4) as shown in the figure. VP6 defines rotavirus group, and most rotaviruses that infect humans are of group A. The two outer capsid proteins independently induce neutralizing antibodies: VP7, a glycoprotein, defines G‐serotype; and the protease‐sensitive VP4 protein defines P‐serotype. G‐serotype determined by serological methods correlates precisely with G‐genotype obtained through molecular assays, whereas there is an imperfect correlation of P‐serotype and P‐genotype; P‐genotype is thus included in square brackets." data-id="CD008521-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p><b>A simplified diagram of the location of rotavirus structural proteins (source: Graham Cohn, Wikipedia (public domain image)):</b> Rotaviruses are segmented, double‐stranded RNA viruses. The mature, triple‐layered virus particle comprises a core (which contains the viral genome), a middle layer (comprised of viral protein (VP)6, and an outer layer (comprised of VP7 and VP4) as shown in the figure. VP6 defines rotavirus group, and most rotaviruses that infect humans are of group A. The two outer capsid proteins independently induce neutralizing antibodies: VP7, a glycoprotein, defines G‐serotype; and the protease‐sensitive VP4 protein defines P‐serotype. G‐serotype determined by serological methods correlates precisely with G‐genotype obtained through molecular assays, whereas there is an imperfect correlation of P‐serotype and P‐genotype; P‐genotype is thus included in square brackets. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/full#CD008521-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-FIG-02" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD008521-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-FIG-02.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/full#CD008521-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-FIG-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD008521-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/full#CD008521-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study." data-id="CD008521-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/full#CD008521-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Rotarix versus placebo, Outcome 1: Rotavirus diarrhoea: severe (up to 1 year follow‐up)" data-id="CD008521-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Rotarix versus placebo, Outcome 1: Rotavirus diarrhoea: severe (up to 1 year follow‐up) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Rotarix versus placebo, Outcome 2: Rotavirus diarrhoea: severe (2nd year of life)" data-id="CD008521-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Rotarix versus placebo, Outcome 2: Rotavirus diarrhoea: severe (2nd year of life) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Rotarix versus placebo, Outcome 3: Rotavirus diarrhoea: severe (up to 2 years follow‐up)" data-id="CD008521-fig-0007" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Rotarix versus placebo, Outcome 3: Rotavirus diarrhoea: severe (up to 2 years follow‐up) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Rotarix versus placebo, Outcome 4: All‐cause diarrhoea: severe cases (up to 1 year follow‐up)" data-id="CD008521-fig-0008" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Rotarix versus placebo, Outcome 4: All‐cause diarrhoea: severe cases (up to 1 year follow‐up) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Rotarix versus placebo, Outcome 5: All‐cause diarrhoea: severe cases (up to 2 years follow‐up)" data-id="CD008521-fig-0009" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Rotarix versus placebo, Outcome 5: All‐cause diarrhoea: severe cases (up to 2 years follow‐up) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Rotarix versus placebo, Outcome 6: All‐cause diarrhoea: severe episodes (up to 1 year follow‐up)" data-id="CD008521-fig-0010" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Rotarix versus placebo, Outcome 6: All‐cause diarrhoea: severe episodes (up to 1 year follow‐up) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Rotarix versus placebo, Outcome 7: All‐cause diarrhoea: severe episodes (up to 2 years follow‐up)" data-id="CD008521-fig-0011" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Rotarix versus placebo, Outcome 7: All‐cause diarrhoea: severe episodes (up to 2 years follow‐up) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Rotarix versus placebo, Outcome 8: All‐cause death" data-id="CD008521-fig-0012" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Rotarix versus placebo, Outcome 8: All‐cause death</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Rotarix versus placebo, Outcome 9: All serious adverse events" data-id="CD008521-fig-0013" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Rotarix versus placebo, Outcome 9: All serious adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Rotarix versus placebo, Outcome 10: Serious adverse events: intussusception" data-id="CD008521-fig-0014" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Rotarix versus placebo, Outcome 10: Serious adverse events: intussusception</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Rotarix versus placebo, Outcome 11: Serious adverse events: Kawasaki disease" data-id="CD008521-fig-0015" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Rotarix versus placebo, Outcome 11: Serious adverse events: Kawasaki disease </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Rotarix versus placebo, Outcome 12: Serious adverse events requiring hospitalization" data-id="CD008521-fig-0016" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Rotarix versus placebo, Outcome 12: Serious adverse events requiring hospitalization </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Rotarix versus placebo, Outcome 13: Rotavirus diarrhoea: of any severity (up to 2 months follow‐up)" data-id="CD008521-fig-0017" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: Rotarix versus placebo, Outcome 13: Rotavirus diarrhoea: of any severity (up to 2 months follow‐up) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-001.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Rotarix versus placebo, Outcome 14: Rotavirus diarrhoea: of any severity (up to 1 year follow‐up)" data-id="CD008521-fig-0018" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-001.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-001.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1: Rotarix versus placebo, Outcome 14: Rotavirus diarrhoea: of any severity (up to 1 year follow‐up) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-001.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-001.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Rotarix versus placebo, Outcome 15: Rotavirus diarrhoea: of any severity (2nd year of life)" data-id="CD008521-fig-0019" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-001.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-001.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1: Rotarix versus placebo, Outcome 15: Rotavirus diarrhoea: of any severity (2nd year of life) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-001.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-001.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Rotarix versus placebo, Outcome 16: Rotavirus diarrhoea: of any severity (up to 2 years follow‐up)" data-id="CD008521-fig-0020" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-001.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-001.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1: Rotarix versus placebo, Outcome 16: Rotavirus diarrhoea: of any severity (up to 2 years follow‐up) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-001.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-001.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Rotarix versus placebo, Outcome 17: All‐cause diarrhoea: all cases (up to 2 months follow‐up)" data-id="CD008521-fig-0021" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-001.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-001.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1: Rotarix versus placebo, Outcome 17: All‐cause diarrhoea: all cases (up to 2 months follow‐up) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-001.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-001.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Rotarix versus placebo, Outcome 18: All‐cause diarrhoea: all cases (up to 1 year follow‐up)" data-id="CD008521-fig-0022" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-001.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-001.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1: Rotarix versus placebo, Outcome 18: All‐cause diarrhoea: all cases (up to 1 year follow‐up) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-001.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-001.19" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Rotarix versus placebo, Outcome 19: All‐cause diarrhoea: all cases (up to 2 years follow‐up)" data-id="CD008521-fig-0023" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-001.19.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-001.19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1: Rotarix versus placebo, Outcome 19: All‐cause diarrhoea: all cases (up to 2 years follow‐up) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-001.19.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-001.20" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Rotarix versus placebo, Outcome 20: All‐cause diarrhoea: all episodes (up to 1 year follow‐up)" data-id="CD008521-fig-0024" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-001.20.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-001.20.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1: Rotarix versus placebo, Outcome 20: All‐cause diarrhoea: all episodes (up to 1 year follow‐up) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-001.20.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-001.21" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Rotarix versus placebo, Outcome 21: All‐cause diarrhoea: all episodes (up to 2 years follow‐up)" data-id="CD008521-fig-0025" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-001.21.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-001.21.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.21</div> <div class="figure-caption"> <p>Comparison 1: Rotarix versus placebo, Outcome 21: All‐cause diarrhoea: all episodes (up to 2 years follow‐up) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-001.21.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-001.22" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Rotarix versus placebo, Outcome 22: All‐cause hospitalizations (up to 2 years follow‐up)" data-id="CD008521-fig-0026" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-001.22.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-001.22.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.22</div> <div class="figure-caption"> <p>Comparison 1: Rotarix versus placebo, Outcome 22: All‐cause hospitalizations (up to 2 years follow‐up) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-001.22.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-001.23" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Rotarix versus placebo, Outcome 23: Rotavirus diarrhoea: requiring hospitalization" data-id="CD008521-fig-0027" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-001.23.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-001.23.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.23</div> <div class="figure-caption"> <p>Comparison 1: Rotarix versus placebo, Outcome 23: Rotavirus diarrhoea: requiring hospitalization</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-001.23.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-001.24" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Rotarix versus placebo, Outcome 24: Rotavirus diarrhoea: requiring medical attention" data-id="CD008521-fig-0028" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-001.24.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-001.24.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.24</div> <div class="figure-caption"> <p>Comparison 1: Rotarix versus placebo, Outcome 24: Rotavirus diarrhoea: requiring medical attention </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-001.24.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-001.25" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Rotarix versus placebo, Outcome 25: All‐cause diarrhoea: cases requiring hospitalization" data-id="CD008521-fig-0029" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-001.25.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-001.25.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.25</div> <div class="figure-caption"> <p>Comparison 1: Rotarix versus placebo, Outcome 25: All‐cause diarrhoea: cases requiring hospitalization </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-001.25.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-001.26" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Rotarix versus placebo, Outcome 26: All‐cause diarrhoea: episodes requiring hospitalization" data-id="CD008521-fig-0030" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-001.26.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-001.26.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.26</div> <div class="figure-caption"> <p>Comparison 1: Rotarix versus placebo, Outcome 26: All‐cause diarrhoea: episodes requiring hospitalization </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-001.26.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-001.27" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Rotarix versus placebo, Outcome 27: Reactogenicity: fever" data-id="CD008521-fig-0031" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-001.27.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-001.27.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.27</div> <div class="figure-caption"> <p>Comparison 1: Rotarix versus placebo, Outcome 27: Reactogenicity: fever</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-001.27.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-001.28" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Rotarix versus placebo, Outcome 28: Reactogenicity: diarrhoea" data-id="CD008521-fig-0032" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-001.28.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-001.28.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.28</div> <div class="figure-caption"> <p>Comparison 1: Rotarix versus placebo, Outcome 28: Reactogenicity: diarrhoea</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-001.28.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-001.29" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Rotarix versus placebo, Outcome 29: Reactogenicity: vomiting" data-id="CD008521-fig-0033" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-001.29.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-001.29.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.29</div> <div class="figure-caption"> <p>Comparison 1: Rotarix versus placebo, Outcome 29: Reactogenicity: vomiting</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-001.29.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-001.30" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Rotarix versus placebo, Outcome 30: Adverse events requiring discontinuation (end of follow‐up)" data-id="CD008521-fig-0034" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-001.30.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-001.30.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.30</div> <div class="figure-caption"> <p>Comparison 1: Rotarix versus placebo, Outcome 30: Adverse events requiring discontinuation (end of follow‐up) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-001.30.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-001.31" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Rotarix versus placebo, Outcome 31: Dropouts before the end of the trial" data-id="CD008521-fig-0035" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-001.31.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-001.31.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.31</div> <div class="figure-caption"> <p>Comparison 1: Rotarix versus placebo, Outcome 31: Dropouts before the end of the trial</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-001.31.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-001.32" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Rotarix versus placebo, Outcome 32: Subgroup analysis: rotavirus diarrhoea of any severity (by G‐ or P‐type)" data-id="CD008521-fig-0036" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-001.32.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-001.32.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.32</div> <div class="figure-caption"> <p>Comparison 1: Rotarix versus placebo, Outcome 32: Subgroup analysis: rotavirus diarrhoea of any severity (by G‐ or P‐type) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-001.32.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-001.33" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Rotarix versus placebo, Outcome 33: Subgroup analysis: severe cases of rotavirus diarrhoea (by G‐ or P‐type)" data-id="CD008521-fig-0037" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-001.33.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-001.33.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.33</div> <div class="figure-caption"> <p>Comparison 1: Rotarix versus placebo, Outcome 33: Subgroup analysis: severe cases of rotavirus diarrhoea (by G‐ or P‐type) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-001.33.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-001.34" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Rotarix versus placebo, Outcome 34: Subgroup analysis: rotavirus diarrhoea in malnourished children" data-id="CD008521-fig-0038" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-001.34.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-001.34.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.34</div> <div class="figure-caption"> <p>Comparison 1: Rotarix versus placebo, Outcome 34: Subgroup analysis: rotavirus diarrhoea in malnourished children </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-001.34.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-001.35" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Rotarix versus placebo, Outcome 35: Subgroup analysis: rotavirus diarrhoea in HIV‐infected children" data-id="CD008521-fig-0039" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-001.35.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-001.35.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.35</div> <div class="figure-caption"> <p>Comparison 1: Rotarix versus placebo, Outcome 35: Subgroup analysis: rotavirus diarrhoea in HIV‐infected children </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-001.35.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: RotaTeq versus placebo, Outcome 1: Rotavirus diarrhoea: severe (up to 1 year follow‐up)" data-id="CD008521-fig-0040" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: RotaTeq versus placebo, Outcome 1: Rotavirus diarrhoea: severe (up to 1 year follow‐up) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: RotaTeq versus placebo, Outcome 2: Rotavirus diarrhoea: severe (in 2nd year)" data-id="CD008521-fig-0041" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: RotaTeq versus placebo, Outcome 2: Rotavirus diarrhoea: severe (in 2nd year) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: RotaTeq versus placebo, Outcome 3: Rotavirus diarrhoea: severe (up to 2 years follow‐up)" data-id="CD008521-fig-0042" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: RotaTeq versus placebo, Outcome 3: Rotavirus diarrhoea: severe (up to 2 years follow‐up) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: RotaTeq versus placebo, Outcome 4: All‐cause diarrhoea: severe cases (up to 1 year follow‐up)" data-id="CD008521-fig-0043" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: RotaTeq versus placebo, Outcome 4: All‐cause diarrhoea: severe cases (up to 1 year follow‐up) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: RotaTeq versus placebo, Outcome 5: All‐cause diarrhoea: severe cases (up to 2 years follow‐up)" data-id="CD008521-fig-0044" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: RotaTeq versus placebo, Outcome 5: All‐cause diarrhoea: severe cases (up to 2 years follow‐up) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: RotaTeq versus placebo, Outcome 6: All‐cause death" data-id="CD008521-fig-0045" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: RotaTeq versus placebo, Outcome 6: All‐cause death</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: RotaTeq versus placebo, Outcome 7: All serious adverse events" data-id="CD008521-fig-0046" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: RotaTeq versus placebo, Outcome 7: All serious adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-002.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: RotaTeq versus placebo, Outcome 8: Serious adverse events: intussusception" data-id="CD008521-fig-0047" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-002.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-002.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2: RotaTeq versus placebo, Outcome 8: Serious adverse events: intussusception</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-002.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-002.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: RotaTeq versus placebo, Outcome 9: Rotavirus diarrhoea: of any severity (up to 1 year follow‐up)" data-id="CD008521-fig-0048" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-002.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-002.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2: RotaTeq versus placebo, Outcome 9: Rotavirus diarrhoea: of any severity (up to 1 year follow‐up) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-002.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-002.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: RotaTeq versus placebo, Outcome 10: Rotavirus diarrhoea: of any severity (2nd year of life)" data-id="CD008521-fig-0049" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-002.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-002.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2: RotaTeq versus placebo, Outcome 10: Rotavirus diarrhoea: of any severity (2nd year of life) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-002.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-002.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: RotaTeq versus placebo, Outcome 11: Rotavirus diarrhoea: of any severity (up to 2 years follow‐up)" data-id="CD008521-fig-0050" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-002.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-002.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2: RotaTeq versus placebo, Outcome 11: Rotavirus diarrhoea: of any severity (up to 2 years follow‐up) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-002.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-002.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: RotaTeq versus placebo, Outcome 12: All‐cause diarrhoea: of any severity (up to 1 year follow‐up)" data-id="CD008521-fig-0051" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-002.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-002.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2: RotaTeq versus placebo, Outcome 12: All‐cause diarrhoea: of any severity (up to 1 year follow‐up) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-002.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-002.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: RotaTeq versus placebo, Outcome 13: All‐cause diarrhoea: of any severity (up to 2 years follow‐up)" data-id="CD008521-fig-0052" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-002.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-002.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2: RotaTeq versus placebo, Outcome 13: All‐cause diarrhoea: of any severity (up to 2 years follow‐up) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-002.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-002.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: RotaTeq versus placebo, Outcome 14: All‐cause hospitalizations (up to 2 years follow‐up)" data-id="CD008521-fig-0053" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-002.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-002.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2: RotaTeq versus placebo, Outcome 14: All‐cause hospitalizations (up to 2 years follow‐up) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-002.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-002.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: RotaTeq versus placebo, Outcome 15: Rotavirus diarrhoea: requiring hospitalization" data-id="CD008521-fig-0054" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-002.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-002.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.15</div> <div class="figure-caption"> <p>Comparison 2: RotaTeq versus placebo, Outcome 15: Rotavirus diarrhoea: requiring hospitalization</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-002.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-002.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: RotaTeq versus placebo, Outcome 16: Rotavirus diarrhoea: requiring medical attention" data-id="CD008521-fig-0055" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-002.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-002.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.16</div> <div class="figure-caption"> <p>Comparison 2: RotaTeq versus placebo, Outcome 16: Rotavirus diarrhoea: requiring medical attention </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-002.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-002.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: RotaTeq versus placebo, Outcome 17: Reactogenicity: fever" data-id="CD008521-fig-0056" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-002.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-002.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.17</div> <div class="figure-caption"> <p>Comparison 2: RotaTeq versus placebo, Outcome 17: Reactogenicity: fever</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-002.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-002.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: RotaTeq versus placebo, Outcome 18: Reactogenicity: diarrhoea" data-id="CD008521-fig-0057" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-002.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-002.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.18</div> <div class="figure-caption"> <p>Comparison 2: RotaTeq versus placebo, Outcome 18: Reactogenicity: diarrhoea</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-002.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-002.19" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: RotaTeq versus placebo, Outcome 19: Reactogenicity: vomiting" data-id="CD008521-fig-0058" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-002.19.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-002.19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.19</div> <div class="figure-caption"> <p>Comparison 2: RotaTeq versus placebo, Outcome 19: Reactogenicity: vomiting</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-002.19.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-002.20" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: RotaTeq versus placebo, Outcome 20: Adverse events requiring discontinuation (end of follow‐up)" data-id="CD008521-fig-0059" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-002.20.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-002.20.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.20</div> <div class="figure-caption"> <p>Comparison 2: RotaTeq versus placebo, Outcome 20: Adverse events requiring discontinuation (end of follow‐up) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-002.20.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-002.21" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: RotaTeq versus placebo, Outcome 21: Dropouts before the end of the trial" data-id="CD008521-fig-0060" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-002.21.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-002.21.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.21</div> <div class="figure-caption"> <p>Comparison 2: RotaTeq versus placebo, Outcome 21: Dropouts before the end of the trial</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-002.21.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-002.22" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: RotaTeq versus placebo, Outcome 22: Subgroup analysis: rotavirus diarrhoea of any severity (by G‐ or P‐type)" data-id="CD008521-fig-0061" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-002.22.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-002.22.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.22</div> <div class="figure-caption"> <p>Comparison 2: RotaTeq versus placebo, Outcome 22: Subgroup analysis: rotavirus diarrhoea of any severity (by G‐ or P‐type) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-002.22.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-002.23" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: RotaTeq versus placebo, Outcome 23: Subgroup analysis: severe cases of rotavirus diarrhoea (by G‐ or P‐type)" data-id="CD008521-fig-0062" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-002.23.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-002.23.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.23</div> <div class="figure-caption"> <p>Comparison 2: RotaTeq versus placebo, Outcome 23: Subgroup analysis: severe cases of rotavirus diarrhoea (by G‐ or P‐type) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-002.23.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-002.24" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: RotaTeq versus placebo, Outcome 24: Subgroup analysis: HIV‐infected children" data-id="CD008521-fig-0063" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-002.24.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-002.24.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.24</div> <div class="figure-caption"> <p>Comparison 2: RotaTeq versus placebo, Outcome 24: Subgroup analysis: HIV‐infected children </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-002.24.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Rotasiil versus placebo, Outcome 1: Rotavirus diarrhoea: severe (up to 1 year follow‐up)" data-id="CD008521-fig-0064" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Rotasiil versus placebo, Outcome 1: Rotavirus diarrhoea: severe (up to 1 year follow‐up) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Rotasiil versus placebo, Outcome 2: Rotavirus diarrhoea: severe (up to 2 years follow‐up)" data-id="CD008521-fig-0065" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Rotasiil versus placebo, Outcome 2: Rotavirus diarrhoea: severe (up to 2 years follow‐up) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Rotasiil versus placebo, Outcome 3: All‐cause diarrhoea: severe cases (up to 1 year follow‐up)" data-id="CD008521-fig-0066" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Rotasiil versus placebo, Outcome 3: All‐cause diarrhoea: severe cases (up to 1 year follow‐up) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Rotasiil versus placebo, Outcome 4: All‐cause diarrhoea: severe cases (up to 2 years follow‐up)" data-id="CD008521-fig-0067" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Rotasiil versus placebo, Outcome 4: All‐cause diarrhoea: severe cases (up to 2 years follow‐up) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Rotasiil versus placebo, Outcome 5: All‐cause death" data-id="CD008521-fig-0068" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Rotasiil versus placebo, Outcome 5: All‐cause death</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Rotasiil versus placebo, Outcome 6: All serious adverse events" data-id="CD008521-fig-0069" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: Rotasiil versus placebo, Outcome 6: All serious adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-003.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Rotasiil versus placebo, Outcome 7: Serious adverse events: intussusception" data-id="CD008521-fig-0070" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-003.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-003.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3: Rotasiil versus placebo, Outcome 7: Serious adverse events: intussusception</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-003.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-003.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Rotasiil versus placebo, Outcome 8: Rotavirus diarrhoea: of any severity (up to 1 year follow‐up)" data-id="CD008521-fig-0071" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-003.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-003.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3: Rotasiil versus placebo, Outcome 8: Rotavirus diarrhoea: of any severity (up to 1 year follow‐up) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-003.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-003.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Rotasiil versus placebo, Outcome 9: Rotavirus diarrhoea: of any severity (up to 2 years follow‐up)" data-id="CD008521-fig-0072" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-003.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-003.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3: Rotasiil versus placebo, Outcome 9: Rotavirus diarrhoea: of any severity (up to 2 years follow‐up) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-003.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-003.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Rotasiil versus placebo, Outcome 10: Rotavirus diarrhoea: requiring hospitalization" data-id="CD008521-fig-0073" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-003.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-003.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3: Rotasiil versus placebo, Outcome 10: Rotavirus diarrhoea: requiring hospitalization </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-003.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-003.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Rotasiil versus placebo, Outcome 11: All‐cause diarrhoea: of any severity (up to 1 year follow‐up)" data-id="CD008521-fig-0074" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-003.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-003.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3: Rotasiil versus placebo, Outcome 11: All‐cause diarrhoea: of any severity (up to 1 year follow‐up) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-003.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-003.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Rotasiil versus placebo, Outcome 12: All‐cause diarrhoea: of any severity (up to 2 years follow‐up)" data-id="CD008521-fig-0075" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-003.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-003.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.12</div> <div class="figure-caption"> <p>Comparison 3: Rotasiil versus placebo, Outcome 12: All‐cause diarrhoea: of any severity (up to 2 years follow‐up) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-003.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-003.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Rotasiil versus placebo, Outcome 13: Reactogenicity: fever" data-id="CD008521-fig-0076" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-003.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-003.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.13</div> <div class="figure-caption"> <p>Comparison 3: Rotasiil versus placebo, Outcome 13: Reactogenicity: fever</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-003.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-003.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Rotasiil versus placebo, Outcome 14: Reactogenicity: diarrhoea" data-id="CD008521-fig-0077" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-003.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-003.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.14</div> <div class="figure-caption"> <p>Comparison 3: Rotasiil versus placebo, Outcome 14: Reactogenicity: diarrhoea</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-003.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-003.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Rotasiil versus placebo, Outcome 15: Reactogenicity: vomiting" data-id="CD008521-fig-0078" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-003.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-003.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.15</div> <div class="figure-caption"> <p>Comparison 3: Rotasiil versus placebo, Outcome 15: Reactogenicity: vomiting</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-003.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-003.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Rotasiil versus placebo, Outcome 16: Adverse events requiring discontinuation" data-id="CD008521-fig-0079" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-003.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-003.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.16</div> <div class="figure-caption"> <p>Comparison 3: Rotasiil versus placebo, Outcome 16: Adverse events requiring discontinuation</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-003.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-003.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Rotasiil versus placebo, Outcome 17: Dropouts before the end of the trial" data-id="CD008521-fig-0080" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-003.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-003.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.17</div> <div class="figure-caption"> <p>Comparison 3: Rotasiil versus placebo, Outcome 17: Dropouts before the end of the trial </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-003.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-003.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Rotasiil versus placebo, Outcome 18: Subgroup analysis: severe cases of rotavirus diarrhoea by G and P types (up to 2 years follow‐up)" data-id="CD008521-fig-0081" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-003.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-003.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.18</div> <div class="figure-caption"> <p>Comparison 3: Rotasiil versus placebo, Outcome 18: Subgroup analysis: severe cases of rotavirus diarrhoea by G and P types (up to 2 years follow‐up) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-003.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-003.19" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Rotasiil versus placebo, Outcome 19: Subgroup analysis: rotavirus diarrhoea of any severity by G and P types (up to 2 years follow‐up)" data-id="CD008521-fig-0082" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-003.19.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-003.19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.19</div> <div class="figure-caption"> <p>Comparison 3: Rotasiil versus placebo, Outcome 19: Subgroup analysis: rotavirus diarrhoea of any severity by G and P types (up to 2 years follow‐up) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-003.19.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0083"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Rotavac versus placebo, Outcome 1: Rotavirus diarrhoea: severe (up to 1 year follow‐up)" data-id="CD008521-fig-0083" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Rotavac versus placebo, Outcome 1: Rotavirus diarrhoea: severe (up to 1 year follow‐up) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0083">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0084"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Rotavac versus placebo, Outcome 2: Rotavirus diarrhoea: severe (2nd year of life)" data-id="CD008521-fig-0084" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Rotavac versus placebo, Outcome 2: Rotavirus diarrhoea: severe (2nd year of life) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0084">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0085"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Rotavac versus placebo, Outcome 3: Rotavirus diarrhoea: severe (up to 2 years follow‐up)" data-id="CD008521-fig-0085" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Rotavac versus placebo, Outcome 3: Rotavirus diarrhoea: severe (up to 2 years follow‐up) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0085">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0086"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Rotavac versus placebo, Outcome 4: All‐cause diarrhoea: severe cases (up to 1 year follow‐up)" data-id="CD008521-fig-0086" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: Rotavac versus placebo, Outcome 4: All‐cause diarrhoea: severe cases (up to 1 year follow‐up) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0086">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0087"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-004.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Rotavac versus placebo, Outcome 5: All‐cause death" data-id="CD008521-fig-0087" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-004.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-004.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4: Rotavac versus placebo, Outcome 5: All‐cause death</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0087">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-004.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0088"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-004.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Rotavac versus placebo, Outcome 6: All serious adverse events" data-id="CD008521-fig-0088" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-004.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-004.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4: Rotavac versus placebo, Outcome 6: All serious adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0088">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-004.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0089"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-004.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Rotavac versus placebo, Outcome 7: Serious adverse events: intussusception" data-id="CD008521-fig-0089" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-004.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-004.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4: Rotavac versus placebo, Outcome 7: Serious adverse events: intussusception</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0089">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-004.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0090"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-004.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Rotavac versus placebo, Outcome 8: Rotavirus diarrhoea: of any severity (up to 1 year follow‐up)" data-id="CD008521-fig-0090" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-004.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-004.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4: Rotavac versus placebo, Outcome 8: Rotavirus diarrhoea: of any severity (up to 1 year follow‐up) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0090">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-004.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0091"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-004.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Rotavac versus placebo, Outcome 9: Rotavirus diarrhoea: of any severity (2nd year of life)" data-id="CD008521-fig-0091" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-004.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-004.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.9</div> <div class="figure-caption"> <p>Comparison 4: Rotavac versus placebo, Outcome 9: Rotavirus diarrhoea: of any severity (2nd year of life) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0091">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-004.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0092"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-004.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Rotavac versus placebo, Outcome 10: Rotavirus diarrhoea: of any severity (up to 2 years follow‐up)" data-id="CD008521-fig-0092" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-004.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-004.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.10</div> <div class="figure-caption"> <p>Comparison 4: Rotavac versus placebo, Outcome 10: Rotavirus diarrhoea: of any severity (up to 2 years follow‐up) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0092">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-004.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0093"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-004.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Rotavac versus placebo, Outcome 11: Rotavirus diarrhoea: requiring medical attention" data-id="CD008521-fig-0093" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-004.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-004.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.11</div> <div class="figure-caption"> <p>Comparison 4: Rotavac versus placebo, Outcome 11: Rotavirus diarrhoea: requiring medical attention </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0093">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-004.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0094"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-004.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Rotavac versus placebo, Outcome 12: Reactogenicity: fever" data-id="CD008521-fig-0094" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-004.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-004.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.12</div> <div class="figure-caption"> <p>Comparison 4: Rotavac versus placebo, Outcome 12: Reactogenicity: fever</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0094">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-004.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0095"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-004.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Rotavac versus placebo, Outcome 13: Reactogenicity: diarrhoea" data-id="CD008521-fig-0095" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-004.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-004.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.13</div> <div class="figure-caption"> <p>Comparison 4: Rotavac versus placebo, Outcome 13: Reactogenicity: diarrhoea</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0095">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-004.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0096"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-004.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Rotavac versus placebo, Outcome 14: Reactogenicity: vomiting" data-id="CD008521-fig-0096" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-004.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-004.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.14</div> <div class="figure-caption"> <p>Comparison 4: Rotavac versus placebo, Outcome 14: Reactogenicity: vomiting</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0096">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-004.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0097"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-004.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Rotavac versus placebo, Outcome 15: Dropouts before the end of the trial" data-id="CD008521-fig-0097" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-004.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-004.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.15</div> <div class="figure-caption"> <p>Comparison 4: Rotavac versus placebo, Outcome 15: Dropouts before the end of the trial</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0097">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-004.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0098"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-004.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Rotavac versus placebo, Outcome 16: Subgroup analysis: severe cases of rotavirus diarrhoea by G and P types (up to 1 year follow‐up)" data-id="CD008521-fig-0098" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-004.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-004.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.16</div> <div class="figure-caption"> <p>Comparison 4: Rotavac versus placebo, Outcome 16: Subgroup analysis: severe cases of rotavirus diarrhoea by G and P types (up to 1 year follow‐up) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0098">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-004.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008521-fig-0099"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/urn:x-wiley:14651858:media:CD008521:CD008521-CMP-004.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Rotavac versus placebo, Outcome 17: Subgroup analysis: severe cases of rotavirus diarrhoea by G and P types (up to 2 years follow‐up)" data-id="CD008521-fig-0099" src="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-004.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_t/tCD008521-CMP-004.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.17</div> <div class="figure-caption"> <p>Comparison 4: Rotavac versus placebo, Outcome 17: Subgroup analysis: severe cases of rotavirus diarrhoea by G and P types (up to 2 years follow‐up) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-fig-0099">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/media/CDSR/CD008521/image_n/nCD008521-CMP-004.17.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD008521-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Rotarix compared with placebo for preventing rotavirus diarrhoea in low‐mortality countries</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children<br/><b>Setting:</b> low‐mortality countries<br/><b>Intervention:</b> Rotarix, 2 doses<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Rotarix</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe cases of rotavirus diarrhoea</b><br/>Follow‐up: up to 1 year </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>13 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1 per 1000</b><br/>(0 to 2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.07</b><br/>(0.03 to 0.18) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14,976<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/><b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rotarix reduces severe rotavirus diarrhoea compared with placebo at up to one‐year follow‐up. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe cases of rotavirus diarrhoea</b><br/>Follow‐up: up to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>29 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>3 per 1000</b><br/>(2 to 4) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.10</b><br/>(0.07 to 0.14) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18,145<br/>(6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/><b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rotarix reduces severe rotavirus diarrhoea compared with placebo at up to two years follow‐up. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe cases of all‐cause diarrhoea</b><br/>Follow‐up: up to 1 year </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>94 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>45 per 1000 </b><br/>(35 to 58) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.48</b><br/>(0.37 to 0.61) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3874<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>a</sup> </p> <p><i>due to reporting bias</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rotarix probably reduces severe all‐cause diarrhoea compared with placebo at up to one‐year follow‐up. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe cases of all‐cause diarrhoea</b><br/>Follow‐up: up to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>84 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>41 per 1000 </b><br/>(34 to 51) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.49</b><br/>(0.40 to 0.60) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6269<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>b</sup> </p> <p><i>due to reporting bias</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rotarix probably reduces severe all‐cause diarrhoea compared with placebo at up to two years follow‐up. </p> <p>One additional study reported on <i>episodes </i> of children with severe all‐cause diarrhoea (rate ratio 0.70, 95% CI 0.56 to 0.86; n = 10,519); these data could not be pooled with the studies reporting on number of <i>cases.</i> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause death</b><br/>Follow‐up: 2 months to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.71</b><br/>(0.17 to 2.88) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20,361<br/>(10 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>c</sup> </p> <p><i>due to serious imprecision</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rotarix may result in little to no difference in all‐cause death compared with placebo.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All serious adverse events</b><br/>Follow‐up: 2 months to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>44 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>39 per 1000</b><br/>(32 to 48) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.89</b><br/>(0.72 to 1.10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18,971<br/>(12 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/><b>high</b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rotarix results in little to no difference in serious adverse events compared with placebo. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events: intussusception</b><br/>Follow‐up: 2 months to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1 per 1000</b><br/>(0 to 3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.42</b><br/>(0.52 to 3.87) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20,773<br/>(10 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>d</sup> </p> <p><i>due to serious imprecision</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rotarix may result in little to no difference in intussusception compared with placebo.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the control group risk across studies included in the meta‐analysis. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RCT</b> : randomized controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one level for risk of selective reporting bias. Only one of the four studies reporting on severe rotavirus diarrhoea provided data for this outcome.<br/><sup>b</sup>Downgraded by one level for risk of selective reporting bias. Only three of the six studies reporting on severe rotavirus diarrhoea provided data for this outcome.<br/><sup>c</sup>Downgraded by two levels for serious imprecision. These trials were not powered to detect an effect on mortality.<br/><sup>d</sup>Downgraded by two levels for serious imprecision: very few events with wide 95% CIs that included no effect. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Rotarix compared with placebo for preventing rotavirus diarrhoea in low‐mortality countries</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/full#CD008521-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008521-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Rotarix compared with placebo for preventing rotavirus diarrhoea in medium‐mortality countries</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children<br/><b>Setting:</b> medium‐mortality countries<br/><b>Intervention:</b> Rotarix, 2 doses<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Rotarix</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe cases of rotavirus diarrhoea</b><br/>Follow‐up: up to 1 year </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>13 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>3 per 1000</b><br/>(2 to 4) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.21</b><br/>(0.16 to 0.29) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31,671<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/><b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rotarix reduces severe rotavirus diarrhoea compared with placebo at up to one‐year follow‐up. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe cases of rotavirus diarrhoea</b><br/>Follow‐up: up to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>25 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 1000</b><br/>(4 to 7) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.23</b><br/>(0.17 to 0.29) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23,834</p> <p>(3 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/><b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rotarix reduces severe rotavirus diarrhoea compared with placebo at up to two years follow‐up. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe cases of all‐cause diarrhoea</b><br/>Follow‐up: up to 1 year </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>38 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>25 per 1000 </b><br/>(20 to 30) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.64</b> (0.52 to 0.79) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26,479<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rotarix reduces severe all‐cause diarrhoea compared with placebo at up to one‐year follow‐up. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe cases of all‐cause diarrhoea</b><br/>Follow‐up: up to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>78 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>58 per 1000 </b><br/>(39 to 85) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.74</b><br/>(0.50 to 1.09) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23,317<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a,b</sup> </p> <p><i>due to serious inconsistency</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rotarix may reduce severe all‐cause diarrhoea compared with placebo at up to two years follow‐up. </p> <p>Serious inconsistency (I<sup>2</sup> = 92%) in the pooled data: <a href="./references#CD008521-bbs2-0016" title="GlaxoSmithKline[113808-075]. Efficacy, immunogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals' oral live attenuated liquid Human Rotavirus (HRV) vaccine (444563), in healthy infants. www.gsk-studyregister.com/study/4036 (accessed 12 December 2018). LiRC , HuangT , LiY , LuoD , TaoJ , FuB , et al. Human rotavirus vaccine (RIX4414) efficacy in the first two years of life: a randomized, placebo-controlled trial in China. Human Vaccines and Immunotherapeutics2014;10(1):11-8. LiRC , HuangT , LiY , WangLH , TaoJ , FuB , et al. Immunogenicity and reactogenicity of the human rotavirus vaccine, RIX4414 oral suspension, when co-administered with routine childhood vaccines in Chinese infants. Human Vaccines and Immunotherapeutics2016;12(3):785-93. NCT01171963. Efficacy, immunogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals' oral live attenuated liquid human rotavirus (HRV) vaccine (444563), in healthy infants. clinicaltrials.gov/show/NCT01171963 (first received 29 July 2010). ">RIX Li 2014‐CHN</a>: RR 0.91 (0.75 to 1.09), n = 3148; <a href="./references#CD008521-bbs2-0026" title="Costa ClemensSA , et al. Operational organization of a large scale phase III clinical trial of rotavirus vaccine in multiple sites and countries in Latin America. In: International Congress of Pediatrics (ICP); 2004 August 15-20; Cancun, Mexico. 2004. [Not available for review]De VosB , et al. Rotarix™: an effective way to prevent rotavirus diarrhoea and vomiting. In: 9th Congress of the Asian Pan Pacific Society of Paediatric Gastroenterology, Hepatology and Nutrition &amp; 27th Annual Congress of the Malaysian Paediatric Association; 2005 June 16-19; Kuala Lumpur, Malaysia. 2005. [Not available for review]BaayM , BollaertsK , StruchinerC , VerstraetenT . Background rates of disease in Latin American children from a rotavirus vaccine study. Human Vaccines and Immunotherapeutics2017;13(8):1916-20. GlaxoSmithKline[444563-023-pt1]. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants (efficacy data from visit 1 to visit 4). www.gsk-studyregister.com/study/6791 (accessed 12 December 2018). GlaxoSmithKline[444563-023-pt2]. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants (2nd year efficacy from visit 4 to visit 6). www.gsk-studyregister.com/study/6791 (accessed 12 December 2018). GlaxoSmithKline[444563-023-pt3]. A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants (safety for the period between visit 1 and visit 3). www.gsk-studyregister.com/study/6791 (accessed 12 December 2018). JustinoMC , AraújoEC , Van DoornLJ , OliveiraCS , GabbayYB , MascarenhasJD , et al. Oral live attenuated human rotavirus vaccine (Rotarix) offers sustained high protection against severe G9P[8] rotavirus gastroenteritis during the first two years of life in Brazilian children. Memorias do Instituto Oswaldo Cruz2012;107(7):846-53. LinharesAC , VelazquezFR , Perez-SchaelI , Saez-LlorensX , AbateH , EspinozaF , et al. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet2008;371(9619):1181-9. LopezP , LinharesA , Pérez-SchaelI , Ruiz-PalaciosG , Costa ClemensS , SanchezN . Early protection against severe rotavirus gastroenteritis - RIX4414 experience in Latin America. In: 24th Annual Meeting of European Society for Paediatric Infectious Diseases (ESPID); 2006 May 03-05; Basel, Switzerland. 2006. [Not available for review]MaciasM , LopezP , VelazquezFR , VergaraRF , SalmeronJ , TavaresJL . The rotavirus vaccine RIX4414 (Rotarix) is not associated with intussusception in one year old infants. In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2005 December 16-19; Washington DC, USA. 2005. [Not available for review]NCT00139347. A multi-country &amp; multi-center study to assess the efficacy, immunogenicity &amp; safety of two doses of GSK Biologicals' oral live attenuated HRV vaccine given concomitantly with routine EPI vaccinations including OPV in healthy infants. clinicaltrials.gov/ct2/show/NCT00139347 (first received 31 August 2005). [Trial registration document (no data for review)]NCT00140673. Placebo-controlled, multi-country &amp; multi-center study to assess the efficacy, safety &amp; immunogenicity of 2 doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants. clinicaltrials.gov/ct2/show/NCT00140673 (first received 1 September 2005). [Trial registration document (no data for review)]Perez-SchaelI , LinharesAC , VesikariT . Two doses of the human attenuated rotavirus vaccine RIX4414 (Rotarix) show heterotypic protection in Latin America and Europe. In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2005 December 16-19; Washington DC, USA. 2005. [Not available for review]PikeM . New rotavirus vaccine is effective and appears to have no increased risk of intussusception. Clinical Research Abstracts For Pediatricians2006;149(1):143. Ruiz-PalaciosG , AranzaC , VelazquezFR , RichardsonV , NandiE , MaciasM . Two doses of the human-attenuated monovalent G1P[8] rotavirus vaccine, Rotarix show high efficacy in Mexican children against severe rotavirus gastroenteritis and severe overall gastroenteritis. In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2005 December 16-19; Washington DC, USA. 2005. [Not available for review]Ruiz-PalaciosGM , Perez-SchaelI , VelazquezFR , AbateH , BreuerT , ClemensSC , et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. New England Journal of Medicine2006;354(1):11-22. VelázquezFR , AbatH , Costa ClemensSA , EspinozaF , GillardP , LinharesAC , et al. The human monovalent G1P[8] rotavirus vaccine, Rotarix is highly efficacious and provides crossprotection against G1 and non-G1 serotypes. In: 23rd Annual meeting of European Society for Paediatric Infectious Diseases (ESPID); 2005 May 18-20; Valencia, Spain. 2005. VelázquezRF , AbateH , BouckenoogheA . RIX4414, the human G1P[8] rotavirus vaccine is highly efficacious during the second year of life. In: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2006 September 27-30; San Francisco, USA. 2006. [Not available for review]VesikariT , O’RyanM , AbateH , Costa ClemensSA , EspinozaF , GillardP . Overcoming the safety hurdle: the rotavirus vaccine RIX4414 is not associated with intussusception. In: 23rd Annual Meeting of European Society for Paediatric Infectious Diseases (ESPID); 2005 May 18-20; Valencia, Spain. 2005. [Not available for review]">RIX Ruiz‐Palac 06‐LA/EU</a>: RR 0.61 (0.55 to 0.69), n = 20,169. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause death</b><br/>Follow‐up: 2 months to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 1000</b><br/>(1 to 3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.27</b><br/>(0.89 to 1.81) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77,043<br/>(9 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>c</sup> </p> <p><i>due to imprecision</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rotarix probably results in little to no difference in all‐cause death compared with placebo. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All serious adverse events</b><br/>Follow‐up: 2 months to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>45 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>38 per 1000</b><br/>(34 to 43) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.85</b><br/>(0.76 to 0.95) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77,069<br/>(9 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/><b>high</b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rotarix reduces serious adverse events compared with placebo.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events: intussusception</b><br/>Follow‐up: 2 months to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.72</b> (0.39 to 1.32) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75,540<br/>(6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>d</sup> </p> <p><i>due to imprecision</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rotarix may result in little to no difference in intussusception compared with placebo.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the control group risk across studies included in the meta‐analysis. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded by two levels for serious inconsistency in the pooled data: I<sup>2</sup> = 92%.<br/><sup>b</sup>Although the 95% CI included both no effect and appreciable benefit, we did not downgrade for imprecision since it arose due to inconsistency between two precise estimates which was accounted for by downgrading for inconsistency.<br/><sup>c</sup>Downgraded by one level for imprecision. The 95% CI was wide and included both no effect and appreciable harm.<br/><sup>d</sup>Downgraded by two levels for serious imprecision: very few events with wide 95% CIs that included no effect. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Rotarix compared with placebo for preventing rotavirus diarrhoea in medium‐mortality countries</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/full#CD008521-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008521-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Rotarix compared with placebo for preventing rotavirus diarrhoea in high‐mortality countries</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children<br/><b>Settings:</b> high‐mortality countries<br/><b>Intervention:</b> Rotarix, 2 doses<br/><b>Comparison:</b> placebo or no intervention </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty</b> of the evidence<br/>(GRADE) </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Placebo or no intervention</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Rotarix</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe cases of rotavirus diarrhoea</b><br/>Follow‐up: up to 1 year </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>40 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>17 per 1000</b><br/>(11 to 25) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.42</b><br/>(0.28 to 0.61) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15,822**<br/>(5 comparisons from 4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/><b>high</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rotarix reduces severe rotavirus diarrhoea compared with placebo or no intervention at up to one‐year follow‐up. </p> <p>Sensitivity analysis excluding the cluster‐RCT (<a href="./references#CD008521-bbs2-0038" title="ZamanK , SackDA , NeuzilKM , YunusM , MoultonLH , SugimotoJD , et al. Effectiveness of a live oral human rotavirus vaccine after programmatic introduction in Bangladesh: a cluster-randomized trial. PLOS Medicine2017;14(4):e1002282. ">RIX Zaman 2017‐BGD</a>) that contributed data to this outcome showed no important change in the effect estimate or 95% CI (RR 0.37, 95% CI 0.23 to 0.60, n = 6114, 3 RCTs with 4 comparisons). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe cases of rotavirus diarrhoea</b><br/>Follow‐up: up to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>43 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>28 per 1000</b><br/>(22 to 35) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.65 </b><br/>(0.51 to 0.83) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13,768**<br/>(3 comparisons from 2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>c</sup> </p> <p><i>due to risk of bias</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rotarix probably reduces severe rotavirus diarrhoea compared with placebo or no intervention at up to two years follow‐up. </p> <p>Sensitivity analysis excluding the cluster‐RCT (<a href="./references#CD008521-bbs2-0038" title="ZamanK , SackDA , NeuzilKM , YunusM , MoultonLH , SugimotoJD , et al. Effectiveness of a live oral human rotavirus vaccine after programmatic introduction in Bangladesh: a cluster-randomized trial. PLOS Medicine2017;14(4):e1002282. ">RIX Zaman 2017‐BGD</a>) that contributed data to this outcome showed no important change in the effect estimate or 95% CI (RR 0.58, 95% CI 0.42 to 0.79, n = 2764, 1 RCT with 2 comparisons). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe cases of all‐cause diarrhoea</b><br/>Follow‐up: up to 1 year </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>176 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>129 per 1000</b><br/>(99 to 167) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.73 </b><br/>(0.56 to 0.95) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5639<br/>(3 comparisons from 2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/><b>high</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rotarix reduces severe all‐cause diarrhoea compared with placebo or no intervention at up to one‐year follow‐up. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe cases of all‐cause diarrhoea</b><br/>Follow‐up: up to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>233 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>194 per 1000</b><br/>(168 to 224) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.83</b><br/>(0.72 to 0.96) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2764<br/>(2 comparisons from 1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/><b>high</b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rotarix reduces severe all‐cause diarrhoea compared with placebo at up to two years follow‐up. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause death</b><br/>Follow‐up: 2 months to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>20 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>18 per 1000</b><br/>(13 to 25) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.88 </b><br/>(0.63 to 1.21) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8374<br/>(11 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>e</sup> </p> <p><i>due to imprecision</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rotarix probably results in little to no difference in all‐cause death compared with placebo or no intervention. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All serious adverse events</b><br/>Follow‐up: 2 months to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>92 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>83 per 1000</b><br/>(71 to 96) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.90</b><br/>(0.77 to 1.05) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7674<br/>(10 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/><b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rotarix results in little to no difference in serious adverse events compared with placebo or no intervention. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events: intussusception</b><br/>Follow‐up: 2 months to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>not estimable</b>, no events in control group, 1 event in intervention group </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>not estimable</b>, no events in control group, 1 event in intervention group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.49 </b><br/>(0.06 to 36.63) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17,068**<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>f</sup> </p> <p><i>due to serious imprecision</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rotarix may result in little to no difference in intussusception compared with placebo or no intervention. </p> <p>Sensitivity analysis excluding the cluster‐RCT (<a href="./references#CD008521-bbs2-0038" title="ZamanK , SackDA , NeuzilKM , YunusM , MoultonLH , SugimotoJD , et al. Effectiveness of a live oral human rotavirus vaccine after programmatic introduction in Bangladesh: a cluster-randomized trial. PLOS Medicine2017;14(4):e1002282. ">RIX Zaman 2017‐BGD</a>) that contributed data to this outcome showed no change in the effect estimate or 95% CI. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the control group risk across studies included in the meta‐analysis. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p>**Number of participants in this table shows the true number of participants for this outcome; the number of events and the number of participants in the analysis has been adjusted for the included cluster trial <a href="./references#CD008521-bbs2-0038" title="ZamanK , SackDA , NeuzilKM , YunusM , MoultonLH , SugimotoJD , et al. Effectiveness of a live oral human rotavirus vaccine after programmatic introduction in Bangladesh: a cluster-randomized trial. PLOS Medicine2017;14(4):e1002282. ">RIX Zaman 2017‐BGD</a> using a design effect of 2.53.<br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>We did not downgrade for inconsistency as the heterogeneity observed in the pooled data (I<sup>2</sup> = 52%) was due to within‐study heterogeneity (<a href="./references#CD008521-bbs2-0017" title="CunliffeNA , WitteD , NgwiraBM , ToddS , BostockNJ , TurnerAM , et al. Efficacy of human rotavirus vaccine against severe gastroenteritis in Malawian children in the first two years of life: a randomized, double-blind, placebo controlled trial. Vaccine2012;30(Suppl 1):A36-43. MadhiSA , CunliffeNA , SteeleD , WitteD , KirstenM , LouwC , et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. New England Journal of Medicine2010;362(4):289-98. MadhiSA , KirstenM , LouwC , BosP , AspinallS , BouckenoogheA , et al. Efficacy and immunogenicity of two or three dose rotavirus-vaccine regimen in South African children over two consecutive rotavirus seasons: a randomized, double-blind, placebo-controlled trial. Vaccine2012;30(Suppl 1):A44-51. NCT00241644. Multi-center study to assess the efficacy, safety and immunogenicity of 2 or 3 doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations in healthy infants. clinicaltrials.gov/show/NCT00241644 (first received 19 October 2005). NCT00598468. Multi-center study to assess efficacy, safety &amp; immunogenicity of 2 or 3 doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations in healthy infants. clinicaltrials.gov/show/NCT00598468 (first received 19 October 2005). SteeleAD , NeuzilKM , CunliffeNA , MadhiSA , BosP , NgwiraB , et al. Human rotavirus vaccine Rotarix provides protection against diverse circulating rotavirus strains in African infants: a randomized controlled trial. BMC Infectious Diseases2012;12:213. ">RIX Madhi 2010‐AF</a> results split by country).<br/><sup>b</sup>Downgraded by two levels for serious imprecision; wide 95% CIs that included both appreciable benefit and appreciable harm.<br/><sup>c</sup>Downgraded by one for risk of bias: the largest trial contributing data (<a href="./references#CD008521-bbs2-0038" title="ZamanK , SackDA , NeuzilKM , YunusM , MoultonLH , SugimotoJD , et al. Effectiveness of a live oral human rotavirus vaccine after programmatic introduction in Bangladesh: a cluster-randomized trial. PLOS Medicine2017;14(4):e1002282. ">RIX Zaman 2017‐BGD</a>) was a cluster‐RCT where participants, carers and investigators were aware of treatment allocation.<br/><sup>d</sup>We did not downgrade for inconsistency as the heterogeneity observed in the pooled data (I<sup>2</sup> = 75%) was due to within‐study heterogeneity (<a href="./references#CD008521-bbs2-0017" title="CunliffeNA , WitteD , NgwiraBM , ToddS , BostockNJ , TurnerAM , et al. Efficacy of human rotavirus vaccine against severe gastroenteritis in Malawian children in the first two years of life: a randomized, double-blind, placebo controlled trial. Vaccine2012;30(Suppl 1):A36-43. MadhiSA , CunliffeNA , SteeleD , WitteD , KirstenM , LouwC , et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. New England Journal of Medicine2010;362(4):289-98. MadhiSA , KirstenM , LouwC , BosP , AspinallS , BouckenoogheA , et al. Efficacy and immunogenicity of two or three dose rotavirus-vaccine regimen in South African children over two consecutive rotavirus seasons: a randomized, double-blind, placebo-controlled trial. Vaccine2012;30(Suppl 1):A44-51. NCT00241644. Multi-center study to assess the efficacy, safety and immunogenicity of 2 or 3 doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations in healthy infants. clinicaltrials.gov/show/NCT00241644 (first received 19 October 2005). NCT00598468. Multi-center study to assess efficacy, safety &amp; immunogenicity of 2 or 3 doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations in healthy infants. clinicaltrials.gov/show/NCT00598468 (first received 19 October 2005). SteeleAD , NeuzilKM , CunliffeNA , MadhiSA , BosP , NgwiraB , et al. Human rotavirus vaccine Rotarix provides protection against diverse circulating rotavirus strains in African infants: a randomized controlled trial. BMC Infectious Diseases2012;12:213. ">RIX Madhi 2010‐AF</a> results split by country).<br/><sup>e</sup>Downgraded by one level for imprecision; wide 95% CIs that included both appreciable benefit and no effect.<br/><sup>f</sup>Downgraded by two levels for serious imprecision: very few events with wide 95% CIs that included no effect. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Rotarix compared with placebo for preventing rotavirus diarrhoea in high‐mortality countries</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/full#CD008521-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008521-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">RotaTeq compared with placebo for preventing rotavirus diarrhoea in low‐mortality countries</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children<br/><b>Settings:</b> low‐mortality countries<br/><b>Intervention:</b> RotaTeq, 3 doses<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty</b> of the evidence<br/>(GRADE) </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>RotaTeq</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe cases of rotavirus diarrhoea</b><br/>Follow‐up: up to 1 year </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>23 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1 per 1000</b><br/>(0 to 3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.03 </b><br/>(0.01 to 0.11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7688<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RotaTeq reduces severe rotavirus diarrhoea compared with placebo at up to one‐year follow‐up. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe cases of rotavirus diarrhoea</b><br/>Follow‐up: up to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>32 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1 per 1000</b><br/>(0 to 4) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.04</b><br/>(0.01 to 0.11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5442<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RotaTeq reduces severe rotavirus diarrhoea compared with placebo at up to two years follow‐up. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe all‐cause diarrhoea</b><br/>Follow‐up: up to 1 year </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We found no studies that reported on this outcome in this setting.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe all‐cause diarrhoea</b><br/>Follow‐up: up to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We found no studies that reported on this outcome in this setting.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause death</b><br/>Follow‐up: 2 months to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1 per 1000</b><br/>(0 to 1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.24</b><br/>(0.69 to 2.22) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72,654<br/>(6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a</sup> </p> <p><i>due to serious imprecision</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RotaTeq may result in little to no difference in all‐cause death compared with placebo.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All serious adverse events</b><br/>Follow‐up: 2 months to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>26 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>24 per 1000</b><br/>(22 to 26) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.92</b><br/>(0.84 to 1.01) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70,690<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/><b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RotaTeq results in little to no difference in serious adverse events compared with placebo. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events: intussusception</b><br/>Follow‐up: 2 months to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.69</b><br/>(0.35 to 1.38) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73,925<br/>(9 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>b</sup> </p> <p><i>due to serious imprecision</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RotaTeq may result in little to no difference in intussusception compared with placebo.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the control group risk across studies included in the meta‐analysis. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by two levels for serious imprecision. These trials were not powered to detect an effect on mortality.<br/><sup>b</sup>Downgraded by two levels for serious imprecision: very few events with wide 95% CIs that included no effect. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">RotaTeq compared with placebo for preventing rotavirus diarrhoea in low‐mortality countries</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/full#CD008521-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008521-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">RotaTeq compared with placebo for preventing rotavirus diarrhoea in medium‐mortality countries</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children<br/><b>Settings:</b> medium‐mortality countries<br/><b>Intervention:</b> RotaTeq, 3 doses<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty</b> of the evidence<br/>(GRADE) </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>RotaTeq</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe cases of rotavirus diarrhoea</b><br/>Follow‐up: up to 1 year </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We found no studies that reported on this outcome in this setting.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe cases of rotavirus diarrhoea</b><br/>Follow‐up: up to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>27 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 1000</b><br/>(3 to 11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.21</b> (0.11 to 0.41) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3863<br/>(1 RCT)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a,b</sup> </p> <p><i>due to risk of bias and indirectness</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RotaTeq may reduce severe rotavirus diarrhoea compared with placebo at up to two years follow‐up. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe all‐cause diarrhoea</b><br/>Follow‐up: up to 1 year </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We found no studies that reported on this outcome in this setting.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe all‐cause diarrhoea</b><br/>Follow‐up: up to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We found no studies that reported on this outcome in this setting.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause death</b><br/>Follow‐up: 2 months to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 4) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.33</b> (0.01 to 8.18) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4088<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>very low</b><sup>a,c,d</sup> </p> <p><i>due to risk of bias, indirectness, and serious imprecision</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effect of RotaTeq on all‐cause death.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All serious adverse events</b><br/>Follow‐up: 2 months to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>58 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>38 per 1000</b><br/>(8 to 185) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.66</b> (0.14 to 3.17) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4082<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a,e</sup> </p> <p><i>due to risk of bias and imprecision</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effect of RotaTeq on serious adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events: intussusception</b><br/>Follow‐up: 2 months to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 5.01</b> (0.24 to 104.29) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4082<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a,e</sup> </p> <p><i>due to risk of bias and serious imprecision</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effect of RotaTeq on intussusception.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the control group risk across studies included in the meta‐analysis. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one level for risk of bias; unclear risk of selection bias.<br/><sup>b</sup>Downgraded by one level for indirectness; single study carried out in China; difficult to apply results to any medium‐mortality settings.<br/><sup>c</sup>Downgraded by one level for indirectness; two studies carried out in China; difficult to apply results to any medium‐mortality settings.<br/><sup>d</sup>Downgraded by two levels for serious imprecision. These trials were not powered to detect an effect on mortality.<br/><sup>e</sup>Downgraded by two levels for serious imprecision: very few events with wide 95% CIs that included no effect. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">RotaTeq compared with placebo for preventing rotavirus diarrhoea in medium‐mortality countries</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/full#CD008521-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008521-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">RotaTeq compared with placebo for preventing rotavirus diarrhoea in high‐mortality countries</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children<br/><b>Settings:</b> high‐mortality countries<br/><b>Intervention:</b> RotaTeq, 3 doses<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty</b> of the evidence<br/>(GRADE) </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>RotaTeq</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe cases of rotavirus diarrhoea</b><br/>Follow‐up: up to 1 year </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>28 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>12 per 1000</b><br/>(8 to 18) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.43</b><br/>(0.29 to 0.64) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6775<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/><b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RotaTeq reduces severe rotavirus diarrhoea compared with placebo at up to one‐year follow‐up. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe cases of rotavirus diarrhoea</b><br/>Follow‐up: up to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>59 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>33 per 1000</b><br/>(27 to 51) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.56</b><br/>(0.41 to 0.77) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6744<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/><b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RotaTeq reduces severe rotavirus diarrhoea compared with placebo at up to two years follow‐up. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe cases of all‐cause diarrhoea </b><br/>Follow‐up: up to 1 year </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>77 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>62 per 1000</b><br/>(45 to 85) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.80</b><br/>(0.58 to 1.11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4085<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>a</sup> </p> <p><i>due to imprecision</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RotaTeq probably results in little to no difference in severe all‐cause diarrhoea compared with placebo at up to one‐year follow‐up. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe cases of all‐cause diarrhoea</b><br/>Follow‐up: up to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>130 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>110 per 1000</b><br/>(96 to 128) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.85 </b><br/>(0.74 to 0.99) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5977<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/><b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RotaTeq slightly reduces severe all‐cause diarrhoea compared with placebo at up to two years follow‐up. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause death</b><br/>Follow‐up: 2 months to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>23 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>21 per 1000</b><br/>(16 to 28) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.91</b><br/>(0.68 to 1.23) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7706<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>a</sup> </p> <p><i>due to imprecision</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RotaTeq probably results in little to no difference in all‐cause death compared with placebo. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All serious adverse events</b><br/>Follow‐up: 2 months to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>19 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>19 per 1000</b><br/>(14 to 26) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.99</b><br/>(0.72 to 1.36) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7730<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>b</sup> </p> <p><i>due to imprecision</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RotaTeq probably results in little to no difference in serious adverse events compared with placebo. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events: intussusception</b><br/>Follow‐up: 2 months to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.33</b> (0.01 to 8.16) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7488<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>c</sup> </p> <p><i>due to serious imprecision</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RotaTeq may result in little to no difference in intussusception compared with placebo.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the control group risk across studies included in the meta‐analysis. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one level for imprecision. The 95% CI included both no effect and appreciable benefit.<br/><sup>b</sup>Downgraded by one level for imprecision. The 95% CI included both no effect and appreciable harm.<br/><sup>c</sup>Downgraded by two levels for serious imprecision: very few events with wide 95% CIs that included no effect. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">RotaTeq compared with placebo for preventing rotavirus diarrhoea in high‐mortality countries</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/full#CD008521-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008521-tbl-0007"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Rotasiil compared with placebo for preventing rotavirus diarrhoea in high‐mortality countries</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children </p> <p><b>Settings:</b> high‐mortality countries (Niger, India) </p> <p><b>Intervention:</b> Rotasiil, 3 doses </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Illustrative comparative risks*<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign=""> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign=""> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign=""> <p><b>Certainty of the evidence<br/>(GRADE)<br/> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign=""> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Rotasiil</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Severe cases of rotavirus diarrhoea </b> </p> <p>follow‐up: up to 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>45 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>23 per 1000</b><br/>(15 to 36)  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.52</b><br/>(0.33 to 0.81) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11,008<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/><b>high</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rotasiil reduces severe rotavirus diarrhoea compared with placebo at up to one‐year follow‐up. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Severe cases of rotavirus diarrhoea</b> follow‐up: up to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>76 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>43 per 1000</b><br/>(32 to 56) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.56</b> </p> <p>(0.42 to 0.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11,008<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/><b>high</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rotasiil reduces severe rotavirus diarrhoea compared with placebo at up to two years follow‐up.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Severe cases of all‐cause diarrhoea</b> </p> <p>follow‐up: up to 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>145 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p> <br/> <b>133 per 1000</b><br/>(121 to 146) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.92</b> </p> <p>(0.84 to 1.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11,008<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/><b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rotasiil results in little to no difference in severe all‐cause diarrhoea compared with placebo at up to one‐year follow‐up. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Severe cases of all‐cause diarrhoea</b> </p> <p>follow‐up: up to 2 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>239 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p> <b>225 per 1000</b><br/>(211 to 242) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.94</b> </p> <p>(0.88 to 1.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11,008<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/><b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rotasiil results in little to no difference in severe all‐cause diarrhoea compared with placebo at up to two years follow‐up. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All‐cause death</b> </p> <p>follow‐up: up to 2 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>11 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p> <b>13 per 1000</b><br/>(9 to 18) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.14</b> </p> <p>(0.82 to 1.59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11,586</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>b</sup> </p> <p><i>due to imprecision</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rotasiil probably results in little to no difference in all‐cause death compared with placebo at up to two years follow‐up. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All serious adverse events</b> </p> <p>follow‐up: up to 2 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>264 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p> <b>258 per 1000</b><br/>(242 to 274) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.98</b> </p> <p>(0.92 to 1.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11,646</p> <p>(3 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/><b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rotasiil results in little to no difference in serious adverse events compared with placebo at up to two years follow‐up.<br/>In addition: <a href="./references#CD008521-bbs2-0042" title="CTRI/2009/091/000821. A randomized, double-blind, placebo controlled study to assess the safety and tolerability of RotaVac vaccine (live attenuated bovine-human (UK) reassortant pentavalent rotavirus vaccine). ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=987&amp;EncHid=&amp;modid=&amp;compid=%27,%27987det%27 (first received 15 October 2009). Zade JK,  KulkarniPS ,  Desai SA,  Sabale RN,  Naik SP,  Dhere RM. Bovine rotavirus pentavalent vaccine development in India. Vaccine2014;32(Suppl 1):A124-8. [DOI: 10.1016/j.vaccine.2014.03.003]">SIIL Zade 2014‐INDb</a> reported that "Two SAEs (urinary tract infections and septicaemia) unrelated to study vaccines were reported and both recovered uneventfully". No SAEs were reported among 18 infants and 18 toddlers in <a href="./references#CD008521-bbs2-0041" title="CTRI/2009/091/000821. A randomized, double-blind, placebo controlled study to assess the safety and tolerability of rotaVac vaccine (live attenuated bovine-human (UK) reassortant pentavalent rotavirus vaccine). ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=987&amp;EncHid=&amp;modid=&amp;compid=%27,%27987det%27 (first received 15 October 2009). Zade JK,  KulkarniPS ,  Desai SA,  Sabale RN,  Naik SP,  Dhere RM. Bovine rotavirus pentavalent vaccine development in India. Vaccine2014;32(Suppl 1):A124-8. [DOI: 10.1016/j.vaccine.2014.03.003]">SIIL Zade 2014‐INDa</a>. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events: intussusception</b> </p> <p>follow‐up: up to 2 years</p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>1 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>1 per 1000</b><br/>(0 to 3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.98</b> </p> <p>(0.35 to 2.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11,586</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/><b>low</b><sup>c</sup> </p> <p><i>due to serious imprecision</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rotasiil may result in little to no difference in intussusception compared with placebo at up to two years follow‐up. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the control group risk across studies included in the meta‐analysis. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>There was unexplained statistical heterogeneity in this analysis (I<sup>2</sup> &gt; 50%), however, we did not downgrade for inconsistency since all estimates were in the same direction showing appreciable benefit.<br/><sup>b</sup>Downgraded by one level for imprecision: wide 95% CIs that included no effect as well as appreciable harm.<br/><sup>c</sup>Downgraded by two levels for serious imprecision: very few events with wide 95% CIs that included no effect. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Rotasiil compared with placebo for preventing rotavirus diarrhoea in high‐mortality countries</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/full#CD008521-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008521-tbl-0008"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Rotavac compared with placebo for preventing rotavirus diarrhoea in high‐mortality countries</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children </p> <p><b>Settings:</b> one high‐mortality country (India) </p> <p><b>Intervention:</b> Rotavac, 3 doses </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty</b> of the evidence<br/>(GRADE) </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Rotavac</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe cases of rotavirus diarrhoea</b> </p> <p>follow‐up: up to 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>31 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>13 per 1000</b><br/>(9 to 19) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.43</b><br/>(0.30 to 0.60) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6799<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>a</sup> </p> <p><i>due to indirectness</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rotavac probably reduces severe rotavirus diarrhoea compared with placebo at up to one‐year follow‐up. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe cases of rotavirus diarrhoea </b><br/>follow‐up: up to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>47 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>21 per 1000</b><br/>(16 to 28) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.46</b><br/>(0.35 to 0.60) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6541<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>a</sup> </p> <p><i>due to indirectness</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rotavac probably reduces severe rotavirus diarrhoea compared with placebo at up to two years follow‐up. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe cases of all‐cause diarrhoea</b> </p> <p>follow‐up: up to 1 year</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>93 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>78 per 1000</b><br/>(66 to 91) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.84</b><br/>(0.71 to 0.98) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6799<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>a</sup> </p> <p><i>due to indirectness</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rotavac probably slightly reduces severe all‐cause diarrhoea compared with placebo at up to one‐year follow‐up. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe cases of all‐cause diarrhoea</b> </p> <p>follow‐up: up to 2 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We found no studies that reported on this outcome in this setting.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause death</b> </p> <p>follow‐up: up to 2 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>7 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 1000</b><br/>(3 to 11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.88</b><br/>(0.50 to 1.56) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8155<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>b,c</sup> </p> <p><i>due to indirectness and serious imprecision</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effect of Rotavac on all‐cause death.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All serious adverse events</b> </p> <p>follow‐up: up to 2 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>204 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>189 per 1000</b><br/>(173 to 208) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.93</b><br/>(0.85 to 1.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8210<br/>(3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>b</sup> </p> <p><i>due to indirectness</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rotavac probably results in little to no difference in serious adverse events compared with placebo. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events: intussusception</b> </p> <p>follow‐up: up to 2 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1 per 1000</b><br/>(0 to 5) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.33</b><br/>(0.35 to 5.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8582<br/>(4 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>b,d</sup> </p> <p><i>due to indirectness and serious imprecision</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events were reported in three of the four studies.</p> <p>The evidence is very uncertain about the effect of Rotavac on intussusception.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the control group risk across studies included in the meta‐analysis. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one level for indirectness; single trial conducted in India, so generalization to any high‐mortality country is difficult.<br/><sup>b</sup>Downgraded by one level for indirectness. All trials were conducted in India, so generalization to any high‐mortality country is difficult.<br/><sup>c</sup>Downgraded by two levels for serious imprecision. These trials were not powered to detect an effect on mortality.<br/><sup>d</sup>Downgraded by two levels for serious imprecision: very few events with wide 95% CIs that included no effect. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Rotavac compared with placebo for preventing rotavirus diarrhoea in high‐mortality countries</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/full#CD008521-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008521-tbl-0009"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Prespecified changes for review update</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Protocol section</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Appraisal points</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Address here </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Background and research question</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>• Review and update background section, including supporting references to take account of any changes that may have occurred. This should include updating any new information and current policy debates on the topic. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Authors plan to update the Background section with any new relevant background information and references, but this will not have changed much since October 2019. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Inclusion criteria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>• Review current PICO(s) and amend in light of new knowledge.<br/>• Identify any changes in usual care standards.<br/>• Check for standardized core outcome sets, such as those developed in collaboration with the core outcome measures in effectiveness trials (COMET) initiative (<a href="http://www.comet-initiative.org/" target="_blank">www.comet-initiative.org</a>) or by guideline groups since the original review.<br/>• Check for any relevant patient reported outcomes to include subsequent to the original review.<br/>• Consider any new studies with less risk of bias that might warrant a stricter study design inclusion criteria (where the older version, when there was a dearth of evidence, included observational or quasi‐randomized comparisons). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Authors plan to amend the types of outcome measures list: </p> <p>1) remove immunogenicity outcomes because there is plenty of high‐certainty efficacy data, also for the new vaccines, and therefore no need to include immunogenicity outcomes for the objective of this review.  </p> <p>2) include 2<sup>nd</sup> year of life as a time point for primary efficacy outcomes (in addition to first year of life and up to two years).  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Methods</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>• Appraise and update the methods pending relevant methodological advancements or developments. For example, if there are new tools for assessing the risk of bias of individual studies or appraising the quality of a body of evidence (e.g. GRADE). </p> <p>• Update or include a summary of findings table, which is recommended for all systematic reviews, because it improves the clarity, understanding, and interpretation of the findings of a systematic review, and rapidly reduces the amount of time readers require to find key information. </p> <p>• Any new subanalysis needed.</p> <p>• Any substantive change in the review structure.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1) Authors plan to update the country mortality stratification using the 2019 UNICEF report on levels and trends in child mortality <a href="https://reliefweb.int/sites/reliefweb.int/files/resources/UN-IGME-Child-Mortality-Report-2019.pdf" target="_blank">https://reliefweb.int/sites/reliefweb.int/files/resources/UN-IGME-Child-Mortality-Report-2019.pdf</a>. Data and summary of findings tables will be stratified based on country under‐5 mortality: low‐mortality countries are those in the lowest quartile of under‐5 child mortality rates, medium‐mortality countries are those in the second quartile, and high‐mortality countries are those in the highest two quartiles. </p> <p>2) Authors plan to carry out subgroup analyses for virus P‐types (in addition to G‐types that have been assessed in the current review). </p> <p>3) Authors plan to use vaccine brand names (Rotarix, Rotasiil, RotaTeq, Rotavac with abbreviations rix, siil, teq, vac) since the previous way of naming the vaccines, based on number of strains, is no longer possible because the new vaccines have the same number of strains (one or five) as the old. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>Submitted by the author team, and approved by the CIDG Editors 23 November 2020.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Prespecified changes for review update</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/full#CD008521-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008521-tbl-0010"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Post hoc subgroup analysis: Intussusception combining all vaccines</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Setting</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Illustrative comparable risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Number of participants</b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>RR (95% CI)</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Assumed risk</b> <br/><b>Placebo</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Corresponding risk </b> <br/><b>Rotavirus vaccine</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Low‐mortality countries</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 per 10,000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 per 10,000<br/>(3 to 9) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>94,698 <br/>(19 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.87 (0.50 to 1.54)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>1 fewer per 10,000<br/>(from 3 fewer to 3 more) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Medium‐mortality countries</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 per 10,000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 per 10,000<br/>(3 to 8) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>79,622<br/>(8 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.77 (0.43 to 1.40)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>1 fewer per 10,000<br/>(from 3 fewer to 2 more) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>High‐mortality countries</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 per 10,000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 per 10,000<br/>(3 to 15) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>38,316<br/>(16 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>1.04 (0.49 to 2.25)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>0 fewer per 10,000<br/>(from 3 fewer to 8 more) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>All settings</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 per 10,000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 per 10,000<br/>(4 to 7) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>212,636<br/>(43 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.87 (0.61 to 1.25)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>1 fewer per 10,000<br/>(from 2 fewer to 1 more) </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>*The basis for the <b>assumed risk</b> is the control group risk across studies included in the meta‐analysis. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RCT</b> : randomized controlled trial; <b>RR:</b> risk ratio </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Post hoc subgroup analysis: Intussusception combining all vaccines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/full#CD008521-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008521-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Rotarix versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Rotavirus diarrhoea: severe (up to 1 year follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56598</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.16, 0.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Low‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14976</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [0.03, 0.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 Medium‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31671</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.16, 0.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.3 High‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9951</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.28, 0.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Rotavirus diarrhoea: severe (2nd year of life) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38590</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.16, 0.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Low‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14808</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.08, 0.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 Medium‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17733</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.17, 0.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.3 High‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6049</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.52, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Rotavirus diarrhoea: severe (up to 2 years follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49092</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [0.13, 0.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Low‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [0.07, 0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Medium‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23834</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [0.17, 0.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.3 High‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.51, 0.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 All‐cause diarrhoea: severe cases (up to 1 year follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35992</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.54, 0.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 Low‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3874</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.37, 0.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 Medium‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26479</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.52, 0.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.3 High‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5639</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.56, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 All‐cause diarrhoea: severe cases (up to 2 years follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32350</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.55, 0.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 Low‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6269</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.40, 0.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 Medium‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23317</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.50, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.3 High‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2764</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.72, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 All‐cause diarrhoea: severe episodes (up to 1 year follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 Medium‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 All‐cause diarrhoea: severe episodes (up to 2 years follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 Low‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10519</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.56, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.2 Medium‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28572</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.53, 0.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 All‐cause death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105778</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.81, 1.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.1 Low‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20361</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.17, 2.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.2 Medium‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77043</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.89, 1.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.3 High‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8374</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.63, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 All serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>103714</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.81, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.1 Low‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18971</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.72, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.2 Medium‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77069</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.76, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.3 High‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7674</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.77, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Serious adverse events: intussusception <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106973</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.52, 1.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.1 Low‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20773</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [0.52, 3.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.2 Medium‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75540</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.39, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.3 High‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10660</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.49 [0.06, 36.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Serious adverse events: Kawasaki disease <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.75 [0.29, 10.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Serious adverse events requiring hospitalization <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63675</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.81, 0.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 Rotavirus diarrhoea: of any severity (up to 2 months follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4294</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.66, 1.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.1 Low‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2061</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.23, 3.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.2 Medium‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>444</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.07, 22.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.3 High‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1789</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.65, 2.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.14 Rotavirus diarrhoea: of any severity (up to 1 year follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19600</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.26, 0.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.1 Low‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.10, 0.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.2 Medium‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5192</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.26, 0.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.3 High‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9951</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.39, 0.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.15 Rotavirus diarrhoea: of any severity (2nd year of life) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12744</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.32, 0.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.1 Low‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4393</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.22, 0.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.2 Medium‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3496</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.38, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.3 High‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4855</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.36, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.16 Rotavirus diarrhoea: of any severity (up to 2 years follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.25, 0.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.1 Low‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6878</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [0.18, 0.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.2 Medium‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3665</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.35, 0.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.3 High‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5600</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.32, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.17 All‐cause diarrhoea: all cases (up to 2 months follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.73, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.17.1 Low‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1906</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.59, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.17.2 Medium‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>444</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.46, 2.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.17.3 High‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>782</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.74, 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.18 All‐cause diarrhoea: all cases (up to 1 year follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2944</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.84, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.18.1 Medium‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2244</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.80, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.18.2 High‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>700</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.93, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.19 All‐cause diarrhoea: all cases (up to 2 years follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6454</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.88, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.19.1 Low‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2789</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.65, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.19.2 Medium‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3665</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.90, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.20 All‐cause diarrhoea: all episodes (up to 1 year follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.88, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.1 Medium‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.88, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.21 All‐cause diarrhoea: all episodes (up to 2 years follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.78, 1.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.21.1 Low‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.78, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.22 All‐cause hospitalizations (up to 2 years follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65646</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.27, 1.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.22.1 Low‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2421</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.15, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.22.2 Medium‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.81, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.23 Rotavirus diarrhoea: requiring hospitalization <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.23.1 Up to 1 year follow‐up (at least 1 rotavirus season)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48718</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.09, 0.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.23.2 Up to 2 years follow‐up (at least 2 rotavirus seasons)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35331</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.11, 0.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.24 Rotavirus diarrhoea: requiring medical attention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.24.1 Up to 1 year follow‐up (at least 1 rotavirus season)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3874</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.04, 0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.24.2 Up to 2 years follow‐up (at least 2 rotavirus seasons)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7017</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [0.16, 0.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.25 All‐cause diarrhoea: cases requiring hospitalization <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.25.1 Up to one year of follow‐up (at least 1 rotavirus season)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20703</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.35, 0.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.25.2 Second year of follow‐up (at least 2 rotavirus seasons)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14367</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.27, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.26 All‐cause diarrhoea: episodes requiring hospitalization <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.26.1 Up to 1 year of follow‐up (at least 1 rotavirus season)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.47, 0.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.26.2 Second year of follow‐up (at least 2 rotavirus seasons)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.46, 0.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.27 Reactogenicity: fever <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.27.1 After dose 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16192</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.97, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.27.2 After dose 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15630</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.92, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.27.3 After dose 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1390</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.86, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.27.4 End of follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11926</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.93, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.28 Reactogenicity: diarrhoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.28.1 After dose 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18732</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.88, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.28.2 After dose 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15630</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.86, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.28.3 After dose 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1390</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.35, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.28.4 End of follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14305</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.84, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.29 Reactogenicity: vomiting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.29.1 After dose 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18732</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.94, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.29.2 After dose 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15630</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.81, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.29.3 After dose 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1390</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [0.71, 2.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.29.4 End of follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14305</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.84, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.30 Adverse events requiring discontinuation (end of follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.82, 1.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.31 Dropouts before the end of the trial <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>93106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.90, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.32 Subgroup analysis: rotavirus diarrhoea of any severity (by G‐ or P‐type) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.32.1 G1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31618</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.13, 0.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.32.2 G2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31618</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.32, 0.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.32.3 G3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9914</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.06, 0.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.32.4 G4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6666</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.09, 0.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.32.5 G9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13651</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.26, 0.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.32.6 G12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3837</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.28, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.32.7 P4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4685</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.17, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.32.8 P6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3937</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.28, 2.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.32.9 P8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4685</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.16, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.33 Subgroup analysis: severe cases of rotavirus diarrhoea (by G‐ or P‐type) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.33.1 G1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51229</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.10, 0.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.33.2 G2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.18, 0.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.33.3 G3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45296</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.09, 0.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.33.4 G4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26464</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [0.04, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.33.5 G8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4417</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [0.02, 2.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.33.6 G9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53740</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.13, 0.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.33.7 G12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4417</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.23, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.33.8 P4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.20, 0.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.33.9 P6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24586</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.20, 0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.33.10 P8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31644</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.14, 0.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.34 Subgroup analysis: rotavirus diarrhoea in malnourished children <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.34.1 Up to 1 year of follow‐up (at least 1 rotavirus season)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.35 Subgroup analysis: rotavirus diarrhoea in HIV‐infected children <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.26, 3.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Rotarix versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008521-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">RotaTeq versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Rotavirus diarrhoea: severe (up to 1 year follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14463</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.09, 0.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 Low‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7688</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [0.01, 0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 High‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6775</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.29, 0.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Rotavirus diarrhoea: severe (in 2nd year) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8677</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.32, 0.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 Low‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2596</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.02, 0.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.2 High‐mortality countries </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6081</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.55, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Rotavirus diarrhoea: severe (up to 2 years follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16049</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.17, 0.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 Low‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5442</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [0.01, 0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.2 Medium‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3863</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.11, 0.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.3 High‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6744</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.41, 0.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 All‐cause diarrhoea: severe cases (up to 1 year follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4085</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.58, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.1 High‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4085</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.58, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 All‐cause diarrhoea: severe cases (up to 2 years follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5977</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.74, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.1 High‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5977</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.74, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 All‐cause death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84448</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.74, 1.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.1 Low‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72654</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.69, 2.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.2 Medium‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4088</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 8.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.3 High‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7706</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.68, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 All serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>82502</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.86, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.1 Low‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70690</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.84, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.2 Medium‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4082</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.14, 3.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.3 High‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7730</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.72, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.8 Serious adverse events: intussusception <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85495</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.38, 1.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8.1 Low‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>73925</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.35, 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8.2 Medium‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4082</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.01 [0.24, 104.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8.3 High‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7488</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 8.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.9 Rotavirus diarrhoea: of any severity (up to 1 year follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13450</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.28, 0.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.1 Low‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8644</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.25, 0.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.2 High‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4806</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.28, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.10 Rotavirus diarrhoea: of any severity (2nd year of life) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2396</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.22, 0.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10.1 Low‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1569</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.26, 0.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10.2 High‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>827</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.20, 4.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.11 Rotavirus diarrhoea: of any severity (up to 2 years follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15831</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.30, 0.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11.1 Low‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5223</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.25, 0.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11.2 Medium‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3864</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.21, 0.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11.3 High‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6744</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.45, 0.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.12 All‐cause diarrhoea: of any severity (up to 1 year follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1059</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.61, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12.1 High‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1059</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.61, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.13 All‐cause diarrhoea: of any severity (up to 2 years follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1059</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.68, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.13.1 High‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1059</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.68, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.14 All‐cause hospitalizations (up to 2 years follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.42, 3.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.14.1 High‐mortality countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.42, 3.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.15 Rotavirus diarrhoea: requiring hospitalization <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [0.02, 0.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.15.1 Up to 1 year of follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [0.02, 0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.16 Rotavirus diarrhoea: requiring medical attention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [0.04, 0.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.16.1 Up to 1 year of follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [0.04, 0.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.17 Reactogenicity: fever <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17.1 After dose 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.91, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17.2 After dose 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4322</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.69, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17.3 After dose 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4294</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.90, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17.4 End of follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18391</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.94, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.18 Reactogenicity: diarrhoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.18.1 After dose 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4745</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.95, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.18.2 After dose 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3905</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.72, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.18.3 End of follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17087</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.99, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.19 Reactogenicity: vomiting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.19.1 After dose 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4745</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.64, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.19.2 After dose 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3905</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.32, 1.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.19.3 After dose 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3878</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.16, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.19.4 End of follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16294</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.91, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.20 Adverse events requiring discontinuation (end of follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15471</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.46, 1.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.21 Dropouts before the end of the trial <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85855</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.90, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.22 Subgroup analysis: rotavirus diarrhoea of any severity (by G‐ or P‐type) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.22.1 G1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11022</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.21, 0.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.22.2 G2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9907</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.16, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.22.3 G3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11022</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.08, 2.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.22.4 G4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9907</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.13, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.22.5 G9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9537</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.20, 0.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.22.6 P8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3864</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.21, 0.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.23 Subgroup analysis: severe cases of rotavirus diarrhoea (by G‐ or P‐type) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.23.1 G1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75909</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [0.03, 1.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.23.2 G2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75909</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.13, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.23.3 G3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75909</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.05, 2.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.23.4 G4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75909</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [0.03, 0.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.23.5 G8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [0.02, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.23.6 G9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75909</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.05, 0.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.23.7 P4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.39, 1.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.23.8 P6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.31, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.23.9 P8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7872</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.13, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.24 Subgroup analysis: HIV‐infected children <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.24.1 Rotavirus diarrhoea: severe (up to two years follow‐up)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.45 [0.11, 56.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.24.2 All‐cause diarrhoea: severe (up to two years follow‐up)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.05 [0.52, 31.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.24.3 All‐cause death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [0.53, 3.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.24.4 Serious adverse events (up to 24 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [0.59, 3.97]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">RotaTeq versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008521-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Rotasiil versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Rotavirus diarrhoea: severe (up to 1 year follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.33, 0.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Rotavirus diarrhoea: severe (up to 2 years follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.42, 0.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 All‐cause diarrhoea: severe cases (up to 1 year follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.84, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 All‐cause diarrhoea: severe cases (up to 2 years follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.88, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 All‐cause death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11586</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.82, 1.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 All serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11646</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.92, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.7 Serious adverse events: intussusception <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11586</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.35, 2.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.8 Rotavirus diarrhoea: of any severity (up to 1 year follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.59, 0.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.9 Rotavirus diarrhoea: of any severity (up to 2 years follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.71, 0.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.10 Rotavirus diarrhoea: requiring hospitalization <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.52, 0.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.10.1 Up to 1 year follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.39, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.10.2 Up to 2 years follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.52, 0.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.11 All‐cause diarrhoea: of any severity (up to 1 year follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3508</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.90, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.12 All‐cause diarrhoea: of any severity (up to 2 years follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3508</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.90, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.13 Reactogenicity: fever <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.93, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.13.1 After any dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.93, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.14 Reactogenicity: diarrhoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.58, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.14.1 After any dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.58, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.15 Reactogenicity: vomiting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.76, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.15.1 After any dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.76, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.16 Adverse events requiring discontinuation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.17 Dropouts before the end of the trial <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11591</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.66, 1.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.18 Subgroup analysis: severe cases of rotavirus diarrhoea by G and P types (up to 2 years follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.18.1 G1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.24, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.18.2 G2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.34, 0.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.18.3 G3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.11, 2.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.18.4 G4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3508</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.18.5 G8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3508</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.01, 7.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.18.6 G9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.53, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.18.7 G12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.45, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.18.8 P4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3508</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.28, 0.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.18.9 P6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3508</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.08, 0.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.18.10 P8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3508</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.45, 1.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.19 Subgroup analysis: rotavirus diarrhoea of any severity by G and P types (up to 2 years follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.19.1 G1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3508</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.39, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.19.2 G2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3508</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.52, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.19.3 G3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3508</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.31, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.19.4 G4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3508</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.91 [0.12, 71.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.19.5 G8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3508</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.01, 7.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.19.6 G9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3508</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.67, 1.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.19.7 G12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3508</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.57, 1.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.19.8 P4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3508</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.53, 0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.19.9 P6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3508</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.44, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.19.10 P8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3508</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.61, 1.20]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Rotasiil versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008521-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Rotavac versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Rotavirus diarrhoea: severe (up to 1 year follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6799</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.30, 0.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Rotavirus diarrhoea: severe (2nd year of life) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6516</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.33, 0.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Rotavirus diarrhoea: severe (up to 2 years follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6541</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.35, 0.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 All‐cause diarrhoea: severe cases (up to 1 year follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6799</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.71, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.5 All‐cause death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.50, 1.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.6 All serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.85, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.7 Serious adverse events: intussusception <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8582</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.35, 5.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.8 Rotavirus diarrhoea: of any severity (up to 1 year follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6799</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.56, 0.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.9 Rotavirus diarrhoea: of any severity (2nd year of life) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6516</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.53, 0.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.10 Rotavirus diarrhoea: of any severity (up to 2 years follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6541</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.57, 0.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.11 Rotavirus diarrhoea: requiring medical attention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6799</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.58, 0.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.11.1 Up to 1 year follow‐up (at least 1 rotavirus season)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6799</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.58, 0.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.12 Reactogenicity: fever <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.12.1 After dose 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>427</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.34, 1.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.12.2 After dose 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>356</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.33, 1.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.12.3 After dose 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.52, 2.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.13 Reactogenicity: diarrhoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.13.1 After dose 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>427</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.61, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.13.2 After dose 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>356</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.55 [1.00, 2.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.13.3 After dose 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.09 [2.11, 7.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.14 Reactogenicity: vomiting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.14.1 After dose 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>427</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [0.70, 2.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.14.2 After dose 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>356</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [0.64, 3.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.14.3 After dose 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.39, 2.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.15 Dropouts before the end of the trial <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8215</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.57, 1.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.16 Subgroup analysis: severe cases of rotavirus diarrhoea by G and P types (up to 1 year follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.16.1 G1P[8]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6541</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.36, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.16.2 G2P[4]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6541</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.22, 0.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.16.3 G12P[6]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6541</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.13, 0.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.16.4 G12P[8]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6541</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.07, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.17 Subgroup analysis: severe cases of rotavirus diarrhoea by G and P types (up to 2 years follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.17.1 G1P[8]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6541</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.38, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.17.2 G2P[4]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6541</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.23, 0.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.17.3 G9P[4]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6541</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.52 [0.57, 35.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.17.4 G12P[6]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6541</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.13, 0.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.17.5 G12P[8]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6541</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.10, 0.96]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Rotavac versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008521.pub6/references#CD008521-tbl-0014">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD008521.pub6&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD008521-note-0013">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD008521-note-0021">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD008521-note-0018">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD008521-note-0019">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD008521-note-0017">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD008521-note-0020">Polski</a> </li> <li class="section-language"> <a class="" href="th#CD008521-note-0016">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD008521-note-0014">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD008521-note-0015">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008521\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008521\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008521\x2epub6\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008521\x2epub6"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008521\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008521\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008521\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008521\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008521\x2epub6\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008521\x2epub6"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008521\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008521\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008521\x2epub6\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008521\x2epub6"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008521\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008521\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008521\x2epub6\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008521\x2epub6"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=zCmos3jT&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008521.pub6&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008521.pub6';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD008521.pub6/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD008521.pub6/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008521.pub6%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740725399650"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008521.pub6/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740725399654"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008521.pub6/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e7a438f1ef4b8',t:'MTc0MDcyNTQwMC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 